{"daf33a68848e97ccce919dd77c627fccc1daee9b": [["IntroductionPorcine circovirus (PCV), a member of the Circoviridae family, is a small, non-enveloped, spherical single-stranded DNA virus.", [["IntroductionPorcine circovirus", "ORGANISM", 0, 30], ["PCV", "GENE_OR_GENE_PRODUCT", 32, 35], ["Circoviridae", "GENE_OR_GENE_PRODUCT", 54, 66], ["DNA", "CELLULAR_COMPONENT", 128, 131], ["IntroductionPorcine circovirus", "SPECIES", 0, 30], ["IntroductionPorcine circovirus (PCV", "TREATMENT", 0, 35], ["a small, non-enveloped, spherical single-stranded DNA virus", "PROBLEM", 78, 137], ["small", "OBSERVATION_MODIFIER", 80, 85]]], ["There are two types of PCVs, namely PCV1 and PCV2.", [["PCVs", "PATHOLOGICAL_FORMATION", 23, 27], ["PCV2", "ORGANISM", 45, 49], ["PCV1", "SPECIES", 36, 40], ["PCVs", "TREATMENT", 23, 27], ["PCV1", "TREATMENT", 36, 40], ["PCV2", "TREATMENT", 45, 49], ["two", "OBSERVATION_MODIFIER", 10, 13], ["types", "OBSERVATION_MODIFIER", 14, 19], ["PCVs", "OBSERVATION", 23, 27]]], ["Both of them are presumed to be widespread in the swine population.", [["swine", "ORGANISM", 50, 55], ["swine", "SPECIES", 50, 55], ["swine", "SPECIES", 50, 55], ["presumed to be", "UNCERTAINTY", 17, 31], ["widespread", "OBSERVATION_MODIFIER", 32, 42], ["swine", "OBSERVATION_MODIFIER", 50, 55], ["population", "OBSERVATION", 56, 66]]], ["Though PCV1 is considered to be nonpathogenic (Allan et al., 1995) , it can infect human leukocytes in vitro, and is now considered to be a potential risk for viral transmission when porcine tissues and organs are used for xenotransplantation (Arteaga-Troncoso et al., 2005) .", [["leukocytes", "ANATOMY", 89, 99], ["tissues", "ANATOMY", 191, 198], ["organs", "ANATOMY", 203, 209], ["PCV1", "GENE_OR_GENE_PRODUCT", 7, 11], ["human", "ORGANISM", 83, 88], ["leukocytes", "CELL", 89, 99], ["porcine", "ORGANISM", 183, 190], ["tissues", "TISSUE", 191, 198], ["organs", "ORGAN", 203, 209], ["human leukocytes", "CELL_TYPE", 83, 99], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 83, 88], ["porcine", "SPECIES", 183, 190], ["xenotransplantation", "TREATMENT", 223, 242]]], ["PCV2 is associated www.elsevier.com/locate/vetmic Veterinary Microbiology 123 (2007) [203] [204] [205] [206] [207] [208] [209] with postweaning multisystemic wasting syndrome (PMWS) (Clark, 1997; Harding and Clark, 1997) , porcine dermatitis, nephropathy syndrome (PDNS) (Rosell et al., 2000) .", [["multisystemic wasting syndrome", "DISEASE", 144, 174], ["PMWS", "DISEASE", 176, 180], ["porcine dermatitis", "DISEASE", 223, 241], ["nephropathy syndrome", "DISEASE", 243, 263], ["PDNS", "DISEASE", 265, 269], ["PCV2", "ORGANISM", 0, 4], ["porcine", "SPECIES", 223, 230], ["PCV2", "SPECIES", 0, 4], ["PCV2", "PROBLEM", 0, 4], ["postweaning multisystemic wasting syndrome", "PROBLEM", 132, 174], ["PMWS", "PROBLEM", 176, 180], ["Clark", "TEST", 183, 188], ["Clark", "TEST", 208, 213], ["porcine dermatitis", "PROBLEM", 223, 241], ["nephropathy syndrome", "PROBLEM", 243, 263], ["multisystemic", "OBSERVATION_MODIFIER", 144, 157], ["wasting syndrome", "OBSERVATION", 158, 174], ["porcine dermatitis", "OBSERVATION", 223, 241], ["nephropathy syndrome", "OBSERVATION", 243, 263]]], ["Furthermore, PCV2 may damage the immune system and induce immunosuppression, which results in other pathogenyes coinfection (Segales et al., 2004) .", [["immune system", "ANATOMY", 33, 46], ["coinfection", "DISEASE", 112, 123], ["PCV2", "ORGANISM", 13, 17], ["PCV2", "SPECIES", 13, 17], ["PCV2", "PROBLEM", 13, 17], ["immunosuppression", "TREATMENT", 58, 75], ["other pathogenyes coinfection", "PROBLEM", 94, 123]]], ["Although, vaccine for PCV2 has been developed recently, the efficiency still needs to be tested in the field trials.", [["PCV2", "ORGANISM", 22, 26], ["PCV2", "SPECIES", 22, 26], ["vaccine", "TREATMENT", 10, 17], ["PCV2", "PROBLEM", 22, 26]]], ["Thus, new method development for controlling PCV2 infection is urgently necessary.IntroductionThe RNAs of PCV synthesized during productive infection in porcine kidney cells were recently characterized.", [["kidney cells", "ANATOMY", 161, 173], ["PCV2 infection", "DISEASE", 45, 59], ["infection", "DISEASE", 140, 149], ["PCV2", "ORGANISM", 45, 49], ["PCV", "GENE_OR_GENE_PRODUCT", 106, 109], ["porcine", "ORGANISM", 153, 160], ["kidney cells", "CELL", 161, 173], ["porcine kidney cells", "CELL_TYPE", 153, 173], ["porcine", "SPECIES", 153, 160], ["PCV2", "SPECIES", 45, 49], ["porcine", "SPECIES", 153, 160], ["new method development", "TREATMENT", 6, 28], ["PCV2 infection", "PROBLEM", 45, 59], ["The RNAs of PCV", "TREATMENT", 94, 109], ["productive infection in porcine kidney cells", "PROBLEM", 129, 173], ["infection", "OBSERVATION", 50, 59], ["productive", "OBSERVATION_MODIFIER", 129, 139], ["infection", "OBSERVATION", 140, 149], ["kidney", "ANATOMY", 161, 167]]], ["During PCV1 replication, 12 species of RNAs are synthesized.", [["RNAs", "RNA", 39, 43], ["PCV1", "SPECIES", 7, 11], ["PCV1 replication", "TREATMENT", 7, 23]]], ["These include capsid protein RNA (CR), eight Rep-associated RNAs (Rep, Rep 0 , Rep3a, Rep3b, Rep3c-1, Rep3c-2, Rep3c-3, Rep3c-4), and three NS-associated RNAs (NS462, NS642 and NS0).", [["capsid protein RNA (CR)", "GENE_OR_GENE_PRODUCT", 14, 37], ["Rep-", "GENE_OR_GENE_PRODUCT", 45, 49], ["Rep", "GENE_OR_GENE_PRODUCT", 66, 69], ["Rep 0", "GENE_OR_GENE_PRODUCT", 71, 76], ["Rep3a", "GENE_OR_GENE_PRODUCT", 79, 84], ["Rep3b", "GENE_OR_GENE_PRODUCT", 86, 91], ["Rep3c-1", "GENE_OR_GENE_PRODUCT", 93, 100], ["Rep3c-2", "GENE_OR_GENE_PRODUCT", 102, 109], ["Rep3c-3", "GENE_OR_GENE_PRODUCT", 111, 118], ["Rep3c-4", "GENE_OR_GENE_PRODUCT", 120, 127], ["capsid protein RNA", "RNA", 14, 32], ["CR", "PROTEIN", 34, 36], ["Rep-associated RNAs", "DNA", 45, 64], ["Rep", "PROTEIN", 66, 69], ["Rep 0", "PROTEIN", 71, 76], ["Rep3a", "PROTEIN", 79, 84], ["Rep3b", "PROTEIN", 86, 91], ["Rep3c", "PROTEIN", 93, 98], ["Rep3c", "DNA", 102, 107], ["Rep3c", "DNA", 111, 116], ["Rep3c", "DNA", 120, 125], ["NS-associated RNAs", "DNA", 140, 158], ["NS462", "DNA", 160, 165], ["NS642", "DNA", 167, 172], ["NS0", "DNA", 177, 180], ["capsid protein RNA", "TEST", 14, 32], ["CR", "TEST", 34, 36], ["Rep3a", "TEST", 79, 84], ["Rep3b", "TEST", 86, 91], ["Rep3c", "TEST", 93, 98], ["Rep3c", "TEST", 102, 107], ["Rep3c", "TEST", 111, 116], ["Rep3c", "TEST", 120, 125], ["NS642", "TREATMENT", 167, 172], ["NS0", "TREATMENT", 177, 180], ["protein RNA", "OBSERVATION", 21, 32]]], ["For PCV2, five Rep-associated RNAs (Rep, Rep 0 , Rep3a, Rep3b and Rep3c), and three NSassociated RNAs (NS515, NS672 and NS0), are synthesized during replication in PK-15 cells (Cheung, 2003a) .", [["PK-15 cells", "ANATOMY", 164, 175], ["PCV2", "ORGANISM", 4, 8], ["Rep-", "GENE_OR_GENE_PRODUCT", 15, 19], ["Rep", "GENE_OR_GENE_PRODUCT", 36, 39], ["Rep 0", "GENE_OR_GENE_PRODUCT", 41, 46], ["Rep3a", "GENE_OR_GENE_PRODUCT", 49, 54], ["Rep3b", "GENE_OR_GENE_PRODUCT", 56, 61], ["Rep3c", "GENE_OR_GENE_PRODUCT", 66, 71], ["NS515", "GENE_OR_GENE_PRODUCT", 103, 108], ["NS672", "GENE_OR_GENE_PRODUCT", 110, 115], ["NS0", "GENE_OR_GENE_PRODUCT", 120, 123], ["PK-15 cells", "CELL", 164, 175], ["Rep-associated RNAs", "RNA", 15, 34], ["Rep", "PROTEIN", 36, 39], ["Rep 0", "PROTEIN", 41, 46], ["Rep3a", "PROTEIN", 49, 54], ["Rep3b", "PROTEIN", 56, 61], ["Rep3c", "PROTEIN", 66, 71], ["NSassociated RNAs", "RNA", 84, 101], ["NS515", "DNA", 103, 108], ["NS672", "DNA", 110, 115], ["NS0", "DNA", 120, 123], ["PK-15 cells", "CELL_LINE", 164, 175], ["PCV2", "PROBLEM", 4, 8], ["PK", "TEST", 164, 166]]], ["Two proteins derived from ORF1, the full-length (Rep) and the spliced (Rep 0 ), are essential for PCV DNA replication (Mankertz and Hillenbrand, 2001) .", [["ORF1", "GENE_OR_GENE_PRODUCT", 26, 30], ["Rep", "GENE_OR_GENE_PRODUCT", 49, 52], ["Rep 0", "GENE_OR_GENE_PRODUCT", 71, 76], ["DNA", "CELLULAR_COMPONENT", 102, 105], ["ORF1", "DNA", 26, 30], ["full-length", "DNA", 36, 47], ["Rep", "DNA", 49, 52], ["Rep 0", "DNA", 71, 76], ["PCV DNA replication", "TREATMENT", 98, 117]]], ["It has been reported that muta-tions in Rep or truncated Rep 0 proteins of PCV2 can cause more than a 99% reduction in viral protein synthesis and completely shut down viral DNA replication (Cheung, 2003b) .", [["Rep", "GENE_OR_GENE_PRODUCT", 40, 43], ["Rep 0", "GENE_OR_GENE_PRODUCT", 57, 62], ["PCV2", "ORGANISM", 75, 79], ["DNA", "CELLULAR_COMPONENT", 174, 177], ["Rep", "PROTEIN", 40, 43], ["truncated Rep 0 proteins", "PROTEIN", 47, 71], ["viral protein", "PROTEIN", 119, 132], ["PCV2", "PROBLEM", 75, 79], ["viral protein synthesis", "TREATMENT", 119, 142], ["viral DNA replication", "TREATMENT", 168, 189], ["viral protein synthesis", "OBSERVATION", 119, 142]]], ["It is, therefore, suggested that Rep or Rep 0 could be a target for inhibition of PCV replication.IntroductionRNA interference (RNAi) was first discovered by plant biologists in the late 1980s.", [["Rep", "GENE_OR_GENE_PRODUCT", 33, 36], ["Rep 0", "GENE_OR_GENE_PRODUCT", 40, 45], ["PCV", "SIMPLE_CHEMICAL", 82, 85], ["Rep", "PROTEIN", 33, 36], ["Rep 0", "PROTEIN", 40, 45], ["PCV replication", "TREATMENT", 82, 97]]], ["However, its molecular mechanism remained unclear until the 1990s, when an elegant work in the nematode Caenorhabditis elegans showed that RNAi is an evolutionarily conserved gene-silencing mechanism (Fire et al., 1998) .", [["nematode Caenorhabditis elegans", "ORGANISM", 95, 126], ["Caenorhabditis elegans", "SPECIES", 104, 126], ["Caenorhabditis elegans", "SPECIES", 104, 126]]], ["The post-translational silencing of gene expression occurs in response to the introduction of homologous double-stranded RNA (dsRNA) into a cell.", [["cell", "ANATOMY", 140, 144], ["cell", "CELL", 140, 144], ["homologous double-stranded RNA", "RNA", 94, 124], ["homologous double-stranded RNA (dsRNA", "TREATMENT", 94, 131]]], ["This phenomenon can result in highly specific suppression of gene expression.", [["gene expression", "OBSERVATION", 61, 76]]], ["In the past few years, RNAi has become widely used as an experimental tool to analyze the function of genes and it represents a new feasible approach to develop effective antiviral treatments.", [["RNAi", "PROBLEM", 23, 27], ["effective antiviral treatments", "TREATMENT", 161, 191]]], ["RNAi antiviral therapy has been shown to inhibit the replication of human immunodeficiency virus (Capodici et al., 2002) , severe acute respiratory syndrome virus (Wang et al., 2004) , influenza virus (Ge et al., 2004) and foot-and-mouth disease virus .", [["human immunodeficiency virus", "DISEASE", 68, 96], ["acute respiratory syndrome virus", "DISEASE", 130, 162], ["influenza virus", "DISEASE", 185, 200], ["foot-and-mouth disease", "DISEASE", 223, 245], ["human immunodeficiency virus", "ORGANISM", 68, 96], ["severe acute respiratory syndrome virus", "ORGANISM", 123, 162], ["influenza virus", "ORGANISM", 185, 200], ["foot-and-mouth disease virus", "ORGANISM", 223, 251], ["human immunodeficiency virus", "SPECIES", 68, 96], ["influenza virus", "SPECIES", 185, 200], ["foot-and-mouth disease virus", "SPECIES", 223, 251], ["human immunodeficiency virus", "SPECIES", 68, 96], ["severe acute respiratory syndrome virus", "SPECIES", 123, 162], ["foot-and-mouth disease virus", "SPECIES", 223, 251], ["RNAi antiviral therapy", "TREATMENT", 0, 22], ["human immunodeficiency virus", "PROBLEM", 68, 96], ["severe acute respiratory syndrome virus", "PROBLEM", 123, 162], ["influenza virus", "PROBLEM", 185, 200], ["foot", "TEST", 223, 227], ["mouth disease virus", "PROBLEM", 232, 251], ["severe", "OBSERVATION_MODIFIER", 123, 129], ["acute", "OBSERVATION_MODIFIER", 130, 135], ["respiratory syndrome", "OBSERVATION", 136, 156], ["foot", "ANATOMY", 223, 227], ["mouth", "ANATOMY", 232, 237], ["disease", "OBSERVATION", 238, 245]]], ["Therefore, RNAi would accord- ingly serve as a new strategy for battling viral infections.IntroductionIn this study, three siRNAs, specifically targeting the Rep gene RNA of both PCV1 and PCV2, were designed and used to inhibit the production of both viruses.", [["viral infections", "DISEASE", 73, 89], ["Rep", "GENE_OR_GENE_PRODUCT", 158, 161], ["PCV1", "GENE_OR_GENE_PRODUCT", 179, 183], ["PCV2", "ORGANISM", 188, 192], ["Rep gene RNA", "DNA", 158, 170], ["PCV1", "DNA", 179, 183], ["a new strategy", "TREATMENT", 45, 59], ["battling viral infections", "PROBLEM", 64, 89], ["this study", "TEST", 105, 115], ["PCV2", "TREATMENT", 188, 192], ["viruses", "OBSERVATION", 251, 258]]], ["Our results suggest that RNAi technology might serve as a potential molecular strategy for PCV therapy.Target sequence selection and vector constructionThree same target sequences (nts 130-150, 500-520 and 819-839 of PCV1; nts 143-163, 832-852 and 513-533 of PCV2) in the coding region of the Rep gene were selected and served as a basis for the design of the two complementary 55-mer siRNA template oligonucleotides (Fig. 1A) .", [["Rep", "GENE_OR_GENE_PRODUCT", 293, 296], ["target sequences", "DNA", 163, 179], ["nts 130-150", "DNA", 181, 192], ["PCV1", "DNA", 217, 221], ["Rep gene", "DNA", 293, 301], ["complementary 55-mer siRNA template oligonucleotides", "DNA", 364, 416], ["RNAi technology", "TREATMENT", 25, 40], ["PCV therapy", "TREATMENT", 91, 102], ["nts", "TEST", 181, 184], ["PCV1", "TEST", 217, 221], ["nts", "TEST", 223, 226], ["PCV2", "TEST", 259, 263], ["mer siRNA template oligonucleotides", "TREATMENT", 381, 416]]], ["They were synthesized, annealed and inserted into the BamHI and HindIII sites of the siRNA expression vector pSilencer4.1cytomegalovirus (CMV) neo (Ambion).", [["BamHI", "GENE_OR_GENE_PRODUCT", 54, 59], ["HindIII", "GENE_OR_GENE_PRODUCT", 64, 71], ["pSilencer4.1cytomegalovirus", "ORGANISM", 109, 136], ["CMV", "ORGANISM", 138, 141], ["neo", "ORGANISM", 143, 146], ["Ambion", "ORGANISM", 148, 154], ["BamHI and HindIII sites", "DNA", 54, 77], ["siRNA expression vector pSilencer4.1cytomegalovirus (CMV) neo", "DNA", 85, 146], ["CMV", "SPECIES", 138, 141], ["the BamHI and HindIII sites", "TREATMENT", 50, 77], ["the siRNA expression vector", "TREATMENT", 81, 108], ["cytomegalovirus (CMV", "TREATMENT", 121, 141], ["neo (Ambion)", "TREATMENT", 143, 155], ["BamHI", "ANATOMY", 54, 59], ["siRNA", "ANATOMY", 85, 90]]], ["The resulting recombinant plasmids were designated as pS-RepA, pS-RepB and pS-RepC.", [["plasmids", "ANATOMY", 26, 34], ["pS-RepA", "GENE_OR_GENE_PRODUCT", 54, 61], ["pS-RepB", "GENE_OR_GENE_PRODUCT", 63, 70], ["pS-RepC", "GENE_OR_GENE_PRODUCT", 75, 82], ["recombinant plasmids", "DNA", 14, 34], ["pS", "DNA", 54, 56], ["RepA", "DNA", 57, 61], ["pS", "DNA", 63, 65], ["RepB", "DNA", 66, 70], ["pS", "DNA", 75, 77], ["RepC", "DNA", 78, 82], ["The resulting recombinant plasmids", "TREATMENT", 0, 34], ["pS", "TEST", 54, 56], ["pS", "TREATMENT", 63, 65], ["RepB", "TREATMENT", 66, 70], ["pS", "TREATMENT", 75, 77], ["RepC", "TREATMENT", 78, 82]]], ["The pSilencer4.1-CMV neo Negative Control (Ambion) is a negative control plasmid (pS-Negative) encoding a hairpin siRNA whose sequence is not found in the mouse, human or PCV genome databases.Target sequence selection and vector constructionThe Rep gene of PCV1 (Rep1) and the Rep gene of PCV2 (Rep2) were amplified and subcloned into the vector pCD-EGFP, respectively, and then fused to the N terminus of the enhanced green fluorescent protein (EGFP) under the control of the immediate early promoter of human cytomegalovirus.", [["plasmid", "ANATOMY", 73, 80], ["CMV", "ORGANISM", 17, 20], ["Ambion", "ORGANISM", 43, 49], ["mouse", "ORGANISM", 155, 160], ["human", "ORGANISM", 162, 167], ["Rep", "GENE_OR_GENE_PRODUCT", 245, 248], ["PCV1", "GENE_OR_GENE_PRODUCT", 257, 261], ["Rep1", "GENE_OR_GENE_PRODUCT", 263, 267], ["Rep", "GENE_OR_GENE_PRODUCT", 277, 280], ["PCV2", "ORGANISM", 289, 293], ["Rep2", "GENE_OR_GENE_PRODUCT", 295, 299], ["pCD-EGFP", "GENE_OR_GENE_PRODUCT", 346, 354], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 419, 444], ["EGFP", "GENE_OR_GENE_PRODUCT", 446, 450], ["human", "ORGANISM", 505, 510], ["cytomegalovirus", "ORGANISM", 511, 526], ["negative control plasmid", "DNA", 56, 80], ["pS", "DNA", 82, 84], ["mouse, human or PCV genome databases", "DNA", 155, 191], ["Rep gene", "DNA", 245, 253], ["PCV1", "DNA", 257, 261], ["Rep1", "DNA", 263, 267], ["Rep gene", "DNA", 277, 285], ["PCV2", "DNA", 289, 293], ["Rep2", "DNA", 295, 299], ["pCD", "DNA", 346, 349], ["EGFP", "DNA", 350, 354], ["N terminus", "PROTEIN", 392, 402], ["enhanced green fluorescent protein", "PROTEIN", 410, 444], ["EGFP", "PROTEIN", 446, 450], ["immediate early promoter", "DNA", 477, 501], ["mouse", "SPECIES", 155, 160], ["human", "SPECIES", 162, 167], ["human", "SPECIES", 505, 510], ["mouse", "SPECIES", 155, 160], ["human", "SPECIES", 162, 167], ["human cytomegalovirus", "SPECIES", 505, 526], ["The pSilencer4.1", "TEST", 0, 16], ["CMV neo", "TREATMENT", 17, 24], ["a hairpin siRNA", "TREATMENT", 104, 119], ["Target sequence selection", "TEST", 192, 217], ["PCV1 (Rep1)", "TREATMENT", 257, 268], ["the Rep gene of PCV2 (Rep2)", "TREATMENT", 273, 300], ["human cytomegalovirus", "PROBLEM", 505, 526], ["human cytomegalovirus", "OBSERVATION", 505, 526]]], ["The eukaryotic expression vectors were named pRep1-EGFP and pRep2-EGFP (Fig. 1B) .Cell culture and transfectionPCV-free PK-15 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated foetal bovine serum (FBS) (Shijiqing, China) at 37 8C and 5% CO 2 .", [["Cell", "ANATOMY", 82, 86], ["PK-15 cells", "ANATOMY", 120, 131], ["serum", "ANATOMY", 244, 249], ["FBS", "ANATOMY", 251, 254], ["CO", "CHEMICAL", 291, 293], ["pRep1-EGFP", "GENE_OR_GENE_PRODUCT", 45, 55], ["pRep2-EGFP", "GENE_OR_GENE_PRODUCT", 60, 70], ["Cell", "CELL", 82, 86], ["PK-15 cells", "CELL", 120, 131], ["foetal", "ORGANISM", 230, 236], ["bovine", "ORGANISM", 237, 243], ["serum", "ORGANISM_SUBSTANCE", 244, 249], ["FBS", "ORGANISM_SUBSTANCE", 251, 254], ["eukaryotic expression vectors", "DNA", 4, 33], ["pRep1", "DNA", 45, 50], ["EGFP", "DNA", 51, 55], ["pRep2", "DNA", 60, 65], ["EGFP", "DNA", 66, 70], ["PK-15 cells", "CELL_LINE", 120, 131], ["bovine", "SPECIES", 237, 243], ["bovine", "SPECIES", 237, 243], ["The eukaryotic expression vectors", "TREATMENT", 0, 33], ["pRep2", "TEST", 60, 65], ["Cell culture", "TEST", 82, 94], ["transfectionPCV", "TEST", 99, 114], ["free PK", "TEST", 115, 122], ["cells", "TEST", 126, 131], ["Dulbecco", "TEST", 149, 157], ["foetal bovine serum", "TEST", 230, 249]]], ["PK-15 cells were plated onto 6-well plates and cultured overnight.", [["PK-15 cells", "ANATOMY", 0, 11], ["PK-15 cells", "CELL", 0, 11], ["PK-15 cells", "CELL_LINE", 0, 11], ["PK", "TEST", 0, 2]]], ["When cells reached 70-80% confluency, they were transfected separately with 6 mg of pS-RepA, pS-RepB, pS-RepC and pS-Negative in combination with 6 mg of pRep1-EGFP/ pRep2-EGFP using LipofectamineTM 2000 (invitrogen) according to the manufacturer's recommendation.", [["cells", "ANATOMY", 5, 10], ["LipofectamineTM 2000", "CHEMICAL", 183, 203], ["invitrogen", "CHEMICAL", 205, 215], ["invitrogen", "CHEMICAL", 205, 215], ["cells", "CELL", 5, 10], ["RepA", "GENE_OR_GENE_PRODUCT", 87, 91], ["pS-RepB", "GENE_OR_GENE_PRODUCT", 93, 100], ["pS-RepC", "GENE_OR_GENE_PRODUCT", 102, 109], ["pRep1-EGFP", "GENE_OR_GENE_PRODUCT", 154, 164], ["pRep2-EGFP", "GENE_OR_GENE_PRODUCT", 166, 176], ["LipofectamineTM", "SIMPLE_CHEMICAL", 183, 198], ["invitrogen", "SIMPLE_CHEMICAL", 205, 215], ["RepA", "PROTEIN", 87, 91], ["pS", "PROTEIN", 93, 95], ["RepB", "PROTEIN", 96, 100], ["pS", "PROTEIN", 102, 104], ["RepC", "PROTEIN", 105, 109], ["pS", "DNA", 114, 116], ["pRep1", "PROTEIN", 154, 159], ["EGFP", "PROTEIN", 160, 164], ["pRep2", "PROTEIN", 166, 171], ["EGFP", "DNA", 172, 176], ["pS", "TREATMENT", 84, 86], ["RepA", "TREATMENT", 87, 91], ["pS", "TREATMENT", 93, 95], ["RepB", "TREATMENT", 96, 100], ["pS", "TREATMENT", 102, 104], ["RepC", "TREATMENT", 105, 109], ["pS", "TEST", 114, 116], ["pRep1", "TREATMENT", 154, 159], ["EGFP", "TREATMENT", 160, 164], ["pRep2", "TREATMENT", 166, 171], ["LipofectamineTM", "TREATMENT", 183, 198]]], ["Non-transfected cells were used as negative controls.Analysis of Rep and EGFP expression in PK-15 cellsForty-eight hours after transfection, EGFP expression in the transfected cells was examined with the Olympus fluorescence microscope (Olympus, Japan).", [["cells", "ANATOMY", 16, 21], ["PK-15 cells", "ANATOMY", 92, 103], ["cells", "ANATOMY", 176, 181], ["cells", "CELL", 16, 21], ["Rep", "GENE_OR_GENE_PRODUCT", 65, 68], ["EGFP", "GENE_OR_GENE_PRODUCT", 73, 77], ["PK-15 cells", "CELL", 92, 103], ["EGFP", "GENE_OR_GENE_PRODUCT", 141, 145], ["cells", "CELL", 176, 181], ["Non-transfected cells", "CELL_LINE", 0, 21], ["Rep", "PROTEIN", 65, 68], ["EGFP", "PROTEIN", 73, 77], ["PK-15 cells", "CELL_LINE", 92, 103], ["EGFP", "DNA", 141, 145], ["transfected cells", "CELL_LINE", 164, 181], ["Non-transfected cells", "PROBLEM", 0, 21], ["Rep", "TEST", 65, 68], ["EGFP expression", "TEST", 73, 88], ["PK", "TEST", 92, 94], ["transfection", "TREATMENT", 127, 139], ["EGFP expression in the transfected cells", "PROBLEM", 141, 181], ["the Olympus fluorescence microscope", "TEST", 200, 235], ["transfected cells", "OBSERVATION", 164, 181]]], ["EGFP positive cells and EGFP expression signal were then evaluated by flow cytometry using the FACSCalibur Flow Cytometry System (BD, USA).Virus titration by indirect immunofluorescence assay (IFA)PCV2 (YU A strain) originally isolated from a lymph node tissue sample from a pig with naturally occurring PMWS (Cao et al., 2005) and PCV1 isolated from the IBRS-2 cell line were used in this study.", [["cells", "ANATOMY", 14, 19], ["lymph node tissue sample", "ANATOMY", 243, 267], ["IBRS-2 cell line", "ANATOMY", 355, 371], ["PMWS", "DISEASE", 304, 308], ["EGFP", "GENE_OR_GENE_PRODUCT", 0, 4], ["EGFP", "GENE_OR_GENE_PRODUCT", 24, 28], ["Virus", "ORGANISM", 139, 144], ["PCV2", "ORGANISM", 197, 201], ["YU A", "GENE_OR_GENE_PRODUCT", 203, 207], ["lymph node tissue", "TISSUE", 243, 260], ["pig", "ORGANISM", 275, 278], ["IBRS-2 cell line", "CELL", 355, 371], ["EGFP positive cells", "CELL_LINE", 0, 19], ["EGFP", "PROTEIN", 24, 28], ["IBRS-2 cell line", "CELL_LINE", 355, 371], ["pig", "SPECIES", 275, 278], ["pig", "SPECIES", 275, 278], ["EGFP expression signal", "TEST", 24, 46], ["flow cytometry", "TEST", 70, 84], ["Virus titration", "TREATMENT", 139, 154], ["indirect immunofluorescence assay", "TEST", 158, 191], ["PCV2", "PROBLEM", 197, 201], ["a lymph node tissue sample", "TREATMENT", 241, 267], ["a pig", "TREATMENT", 273, 278], ["PCV1", "TREATMENT", 332, 336], ["the IBRS", "TREATMENT", 351, 359], ["2 cell line", "TREATMENT", 360, 371], ["this study", "TEST", 385, 395], ["positive cells", "OBSERVATION", 5, 19], ["lymph node tissue", "OBSERVATION", 243, 260], ["cell line", "OBSERVATION", 362, 371]]], ["The TCID 50 of PCV was determined by IFA as previously described (Fenaux et al., 2002) .Viral challenge assay in PK-15 cellsTwenty-four hours after transfection with siRNA expression plasmids, the PK-15 cells were challenged with 500 TCID 50 of PCV1/PCV2 per 0.1 ml.", [["PK-15 cells", "ANATOMY", 113, 124], ["plasmids", "ANATOMY", 183, 191], ["PK-15 cells", "ANATOMY", 197, 208], ["PK-15 cells", "CELL", 113, 124], ["PK-15 cells", "CELL", 197, 208], ["PCV1", "ORGANISM", 245, 249], ["PCV2", "ORGANISM", 250, 254], ["PK-15 cells", "CELL_LINE", 113, 124], ["siRNA expression plasmids", "DNA", 166, 191], ["PK-15 cells", "CELL_LINE", 197, 208], ["PCV", "TREATMENT", 15, 18], ["Viral challenge assay", "TEST", 88, 109], ["PK", "TEST", 113, 115], ["transfection with siRNA expression plasmids", "TREATMENT", 148, 191], ["the PK", "TEST", 193, 199], ["PCV1", "TREATMENT", 245, 249], ["PCV2", "TREATMENT", 250, 254]]], ["After 1 h of adsorption, the inoculum was removed and cells were washed twice with DMEM.", [["cells", "ANATOMY", 54, 59], ["cells", "CELL", 54, 59], ["the inoculum", "TREATMENT", 25, 37], ["inoculum", "OBSERVATION", 29, 37]]], ["The infection was then performed in DMEM supplemented with 10% FBS.", [["FBS", "ANATOMY", 63, 66], ["infection", "DISEASE", 4, 13], ["FBS", "ORGANISM_SUBSTANCE", 63, 66], ["The infection", "PROBLEM", 0, 13], ["10% FBS", "TREATMENT", 59, 66], ["infection", "OBSERVATION", 4, 13]]], ["Seventy two hours after viral challenge, virus titer was detected by IFA.", [["viral challenge", "TREATMENT", 24, 39], ["virus titer", "TEST", 41, 52]]], ["On the other hand, Rep mRNA level in the cells 48 h postvirus challenge and protein level of the capsid protein (Cap) in the cells 72 h post-virus challenge were evaluated by real-time RT-PCR and Western blotting, respectively.Statistical analysisStandard deviation of the mean and Student's t-test were determined using Microsoft Excel for all experiments, and each experiment was repeated at least three times.siRNA expression plasmids specifically inhibit Rep expression in PK-15 cellsWe first examined the EGFP expression in the cotransfected cells using the Olympus fluorescence microscope (Olympus, Japan).", [["cells", "ANATOMY", 41, 46], ["cells", "ANATOMY", 125, 130], ["plasmids", "ANATOMY", 429, 437], ["PK-15 cells", "ANATOMY", 477, 488], ["cells", "ANATOMY", 547, 552], ["Rep", "GENE_OR_GENE_PRODUCT", 19, 22], ["cells", "CELL", 41, 46], ["Cap", "GENE_OR_GENE_PRODUCT", 113, 116], ["cells", "CELL", 125, 130], ["Rep", "GENE_OR_GENE_PRODUCT", 459, 462], ["PK-15 cells", "CELL", 477, 488], ["EGFP", "GENE_OR_GENE_PRODUCT", 510, 514], ["cells", "CELL", 547, 552], ["Rep mRNA", "RNA", 19, 27], ["capsid protein", "PROTEIN", 97, 111], ["Cap", "PROTEIN", 113, 116], [".siRNA expression plasmids", "DNA", 411, 437], ["Rep", "PROTEIN", 459, 462], ["PK-15 cells", "CELL_LINE", 477, 488], ["EGFP", "DNA", 510, 514], ["cotransfected cells", "CELL_LINE", 533, 552], ["Rep mRNA level", "TEST", 19, 33], ["the cells", "TEST", 37, 46], ["postvirus challenge", "TEST", 52, 71], ["protein level", "TEST", 76, 89], ["the capsid protein", "TEST", 93, 111], ["Cap", "TEST", 113, 116], ["the cells", "TEST", 121, 130], ["virus challenge", "TEST", 141, 156], ["Student's t-test", "TEST", 282, 298], ["expression plasmids", "TREATMENT", 418, 437], ["Rep expression", "TEST", 459, 473], ["PK", "TEST", 477, 479], ["the Olympus fluorescence microscope", "TEST", 559, 594]]], ["Compared to the negative controls (cells cotransfected with pRep1-EGFP/pRep2-EGFP and pS-Negative), the green fluorescence signals were reduced in the cells cotransfected with pRep1-EGFP/pRep2-EGFP and pS-RepA, pS-RepB and pS-RepC, respectively.", [["cells", "ANATOMY", 35, 40], ["cells", "ANATOMY", 151, 156], ["cells", "CELL", 35, 40], ["pRep1-EGFP", "GENE_OR_GENE_PRODUCT", 60, 70], ["pRep2-EGFP", "GENE_OR_GENE_PRODUCT", 71, 81], ["pS-Negative", "GENE_OR_GENE_PRODUCT", 86, 97], ["cells", "CELL", 151, 156], ["pRep1", "GENE_OR_GENE_PRODUCT", 176, 181], ["EGFP", "GENE_OR_GENE_PRODUCT", 182, 186], ["pRep2", "GENE_OR_GENE_PRODUCT", 187, 192], ["EGFP", "GENE_OR_GENE_PRODUCT", 193, 197], ["pS-RepA", "GENE_OR_GENE_PRODUCT", 202, 209], ["pS-RepB", "GENE_OR_GENE_PRODUCT", 211, 218], ["pS-RepC", "GENE_OR_GENE_PRODUCT", 223, 230], ["pRep1", "PROTEIN", 60, 65], ["EGFP", "PROTEIN", 66, 70], ["pRep2", "PROTEIN", 71, 76], ["EGFP", "PROTEIN", 77, 81], ["pS", "PROTEIN", 86, 88], ["pRep1", "PROTEIN", 176, 181], ["EGFP", "PROTEIN", 182, 186], ["pRep2", "PROTEIN", 187, 192], ["EGFP", "DNA", 193, 197], ["pS", "DNA", 202, 204], ["RepA", "DNA", 205, 209], ["pS", "DNA", 211, 213], ["RepB", "DNA", 214, 218], ["pS", "DNA", 223, 225], ["RepC", "DNA", 226, 230], ["pRep1", "TEST", 60, 65], ["EGFP", "TEST", 66, 70], ["pRep2", "TEST", 71, 76], ["EGFP", "TEST", 77, 81], ["pS", "TEST", 86, 88], ["the green fluorescence signals", "TEST", 100, 130], ["pRep1", "TEST", 176, 181], ["pRep2", "TREATMENT", 187, 192], ["pS", "TREATMENT", 202, 204], ["RepA", "TREATMENT", 205, 209], ["pS", "TEST", 211, 213], ["RepB", "TREATMENT", 214, 218], ["pS", "TREATMENT", 223, 225], ["RepC", "TREATMENT", 226, 230]]], ["No EGFP signal was detected in the control cells ( Fig. 2A) .", [["cells", "ANATOMY", 43, 48], ["EGFP", "GENE_OR_GENE_PRODUCT", 3, 7], ["cells", "CELL", 43, 48], ["EGFP", "PROTEIN", 3, 7], ["control cells", "CELL_TYPE", 35, 48], ["EGFP signal", "PROBLEM", 3, 14], ["EGFP signal", "OBSERVATION", 3, 14]]], ["Furthermore, the inhibitory effects of the siRNAs on the expression of EGFP were quantitatively validated by flow cytometry analysis 48 h after transfection.", [["EGFP", "GENE_OR_GENE_PRODUCT", 71, 75], ["EGFP", "DNA", 71, 75], ["the siRNAs", "PROBLEM", 39, 49], ["EGFP", "TEST", 71, 75], ["flow cytometry analysis", "TEST", 109, 132]]], ["The extent of EGFP down regulation was quantitated by assessing the mean fluorescence of the positive cells and the percentage of EGFP positive cells.", [["cells", "ANATOMY", 102, 107], ["cells", "ANATOMY", 144, 149], ["EGFP", "GENE_OR_GENE_PRODUCT", 14, 18], ["cells", "CELL", 102, 107], ["EGFP", "GENE_OR_GENE_PRODUCT", 130, 134], ["cells", "CELL", 144, 149], ["EGFP", "DNA", 14, 18], ["positive cells", "CELL_TYPE", 93, 107], ["EGFP positive cells", "CELL_LINE", 130, 149], ["EGFP down regulation", "TEST", 14, 34], ["the positive cells", "PROBLEM", 89, 107], ["EGFP positive cells", "PROBLEM", 130, 149], ["extent", "OBSERVATION_MODIFIER", 4, 10], ["EGFP down", "OBSERVATION", 14, 23], ["positive cells", "OBSERVATION", 93, 107], ["EGFP positive cells", "OBSERVATION", 130, 149]]], ["As shown in Fig. 2B and C, for Rep1, the mean intensity of EGFP signal in the cells transfected with pS-RepC decreased about 87.9% (P < 0.01) (Fig. 2B) , and the percentage of EGFP positive cells was reduced about 87.4% compared to that of negative controls (P < 0.01) (Fig. 2C ).", [["cells", "ANATOMY", 78, 83], ["cells", "ANATOMY", 190, 195], ["C", "GENE_OR_GENE_PRODUCT", 24, 25], ["Rep1", "GENE_OR_GENE_PRODUCT", 31, 35], ["EGFP", "GENE_OR_GENE_PRODUCT", 59, 63], ["cells", "CELL", 78, 83], ["pS-RepC", "GENE_OR_GENE_PRODUCT", 101, 108], ["EGFP", "GENE_OR_GENE_PRODUCT", 176, 180], ["cells", "CELL", 190, 195], ["Rep1", "PROTEIN", 31, 35], ["EGFP", "PROTEIN", 59, 63], ["pS", "PROTEIN", 101, 103], ["RepC", "PROTEIN", 104, 108], ["EGFP positive cells", "CELL_LINE", 176, 195], ["Rep1", "TEST", 31, 35], ["EGFP signal", "TEST", 59, 70], ["pS", "TEST", 101, 103], ["RepC", "TEST", 104, 108], ["P", "TEST", 132, 133], ["EGFP positive cells", "PROBLEM", 176, 195]]], ["For Rep2, the mean intensity of the EGFP signal in the cells transfected with pS-RepC decreased about 84.5% (P < 0.01) (Fig. 2B) , and the percentage of EGFP positive cells was reduced about 83.1% compare to that of the negative controls (P < 0.01) (Fig. 2C) .", [["cells", "ANATOMY", 55, 60], ["cells", "ANATOMY", 167, 172], ["Rep2", "GENE_OR_GENE_PRODUCT", 4, 8], ["EGFP", "GENE_OR_GENE_PRODUCT", 36, 40], ["cells", "CELL", 55, 60], ["pS-RepC", "GENE_OR_GENE_PRODUCT", 78, 85], ["EGFP", "GENE_OR_GENE_PRODUCT", 153, 157], ["cells", "CELL", 167, 172], ["Rep2", "PROTEIN", 4, 8], ["pS", "PROTEIN", 78, 80], ["RepC", "PROTEIN", 81, 85], ["EGFP positive cells", "CELL_LINE", 153, 172], ["the EGFP signal", "TEST", 32, 47], ["pS", "TEST", 78, 80], ["RepC", "TEST", 81, 85], ["P", "TEST", 109, 110], ["EGFP positive cells", "PROBLEM", 153, 172]]], ["For both Rep1 and Rep2, pS-RepA and pS-RepB resulted in a weak reduction in the mean intensity of EGFP signal (11.3 and 25.2% for Rep1; 20.7 and 37.1% for Rep2, P < 0.05) and the percentage of EGFP positive cells (43.1 and 49.8% for Rep1; 43.7 and 50.4% for Rep2, P < 0.05).siRNA expression plasmids inhibit PCV viral production and Cap protein expression in PK-15 cellsTo study the effect of siRNAs on viral transcription, mRNA levels of Rep1 and Rep2 in infected cells were The results showed that both PCV1 and PCV2 production were inhibited significantly by pS-RepC; P < 0.01. detected by real-time RT-PCR (Fig. 3) .", [["EGFP positive cells", "ANATOMY", 193, 212], ["plasmids", "ANATOMY", 291, 299], ["PK-15 cells", "ANATOMY", 359, 370], ["cells", "ANATOMY", 465, 470], ["Rep1", "GENE_OR_GENE_PRODUCT", 9, 13], ["Rep2", "GENE_OR_GENE_PRODUCT", 18, 22], ["pS-RepA", "GENE_OR_GENE_PRODUCT", 24, 31], ["pS-RepB", "GENE_OR_GENE_PRODUCT", 36, 43], ["EGFP", "GENE_OR_GENE_PRODUCT", 98, 102], ["EGFP", "GENE_OR_GENE_PRODUCT", 193, 197], ["cells", "CELL", 207, 212], ["PCV viral", "ORGANISM", 308, 317], ["Cap", "GENE_OR_GENE_PRODUCT", 333, 336], ["PK-15 cells", "CELL", 359, 370], ["Rep1", "GENE_OR_GENE_PRODUCT", 439, 443], ["Rep2", "GENE_OR_GENE_PRODUCT", 448, 452], ["cells", "CELL", 465, 470], ["PCV1", "GENE_OR_GENE_PRODUCT", 505, 509], ["PCV2", "ORGANISM", 514, 518], ["Rep1", "PROTEIN", 9, 13], ["Rep2", "PROTEIN", 18, 22], ["pS", "PROTEIN", 24, 26], ["RepA", "PROTEIN", 27, 31], ["pS", "PROTEIN", 36, 38], ["RepB", "PROTEIN", 39, 43], ["EGFP", "PROTEIN", 98, 102], ["Rep1", "PROTEIN", 130, 134], ["Rep2", "PROTEIN", 155, 159], ["EGFP positive cells", "CELL_TYPE", 193, 212], ["Rep1", "PROTEIN", 233, 237], ["Rep2", "PROTEIN", 258, 262], ["siRNA expression plasmids", "DNA", 274, 299], ["Cap protein", "PROTEIN", 333, 344], ["PK-15 cells", "CELL_LINE", 359, 370], ["Rep1", "PROTEIN", 439, 443], ["Rep2", "PROTEIN", 448, 452], ["infected cells", "CELL_TYPE", 456, 470], ["pS", "TREATMENT", 24, 26], ["RepA", "TREATMENT", 27, 31], ["pS", "TREATMENT", 36, 38], ["a weak reduction", "PROBLEM", 56, 72], ["EGFP signal", "TEST", 98, 109], ["Rep1", "TEST", 130, 134], ["Rep2", "TEST", 155, 159], ["P", "TEST", 161, 162], ["EGFP positive cells", "PROBLEM", 193, 212], ["Rep1", "TEST", 233, 237], ["Rep2", "TEST", 258, 262], ["P", "TEST", 264, 265], ["siRNA expression plasmids", "TREATMENT", 274, 299], ["PCV viral production", "PROBLEM", 308, 328], ["Cap protein expression", "TEST", 333, 355], ["PK", "TEST", 359, 361], ["siRNAs", "PROBLEM", 393, 399], ["viral transcription", "TREATMENT", 403, 422], ["mRNA levels", "TEST", 424, 435], ["Rep1", "TEST", 439, 443], ["infected cells", "PROBLEM", 456, 470], ["PCV1", "TEST", 505, 509], ["PCV2 production", "PROBLEM", 514, 529], ["pS", "TEST", 562, 564], ["RepC", "TEST", 565, 569], ["P", "TEST", 571, 572], ["weak", "OBSERVATION_MODIFIER", 58, 62], ["reduction", "OBSERVATION_MODIFIER", 63, 72], ["PCV2 production", "OBSERVATION", 514, 529]]], ["The results showed that both Rep1 and Rep2 mRNA levels were reduced significantly in the cells transfected with pS-RepC (P < 0.01), a slight decrease was found in the cells transfected with pS-RepA and pS-RepB (P < 0.05).", [["cells", "ANATOMY", 89, 94], ["cells", "ANATOMY", 167, 172], ["Rep1", "GENE_OR_GENE_PRODUCT", 29, 33], ["Rep2", "GENE_OR_GENE_PRODUCT", 38, 42], ["cells", "CELL", 89, 94], ["pS-RepC", "GENE_OR_GENE_PRODUCT", 112, 119], ["cells", "CELL", 167, 172], ["pS-RepA", "GENE_OR_GENE_PRODUCT", 190, 197], ["pS-RepB", "GENE_OR_GENE_PRODUCT", 202, 209], ["pS", "PROTEIN", 112, 114], ["RepC", "PROTEIN", 115, 119], ["pS", "PROTEIN", 190, 192], ["RepA", "PROTEIN", 193, 197], ["pS", "PROTEIN", 202, 204], ["RepB", "PROTEIN", 205, 209], ["both Rep1 and Rep2 mRNA levels", "TEST", 24, 54], ["pS", "TEST", 112, 114], ["RepC", "TEST", 115, 119], ["a slight decrease", "PROBLEM", 132, 149], ["pS", "TEST", 190, 192], ["RepA", "TEST", 193, 197], ["pS", "TEST", 202, 204], ["slight", "OBSERVATION_MODIFIER", 134, 140], ["decrease", "OBSERVATION_MODIFIER", 141, 149]]], ["Interestingly, the expression of the Cap protein of PCV was also inhibited in the transfected samples.", [["samples", "ANATOMY", 94, 101], ["Cap", "GENE_OR_GENE_PRODUCT", 37, 40], ["PCV", "GENE_OR_GENE_PRODUCT", 52, 55], ["Cap protein", "PROTEIN", 37, 48], ["the Cap protein of PCV", "TREATMENT", 33, 55], ["Cap", "OBSERVATION_MODIFIER", 37, 40]]], ["(Fig. 4) . pS-RepC was the most efficient siRNA plasmid for inhibition of Cap expression suggesting that the inhibitory effects occur at both the transcriptional and post-transcriptional levels.siRNA expression plasmids inhibit PCV viral production and Cap protein expression in PK-15 cellsSeventy-two hours post-virus infection, virus titers in siRNA transfected cells and control cells were evaluated by IFA.", [["PK-15 cells", "ANATOMY", 279, 290], ["cells", "ANATOMY", 364, 369], ["cells", "ANATOMY", 382, 387], ["infection", "DISEASE", 319, 328], ["pS-RepC", "GENE_OR_GENE_PRODUCT", 11, 18], ["Cap", "GENE_OR_GENE_PRODUCT", 74, 77], [".siRNA", "GENE_OR_GENE_PRODUCT", 193, 199], ["PCV viral", "ORGANISM", 228, 237], ["Cap", "GENE_OR_GENE_PRODUCT", 253, 256], ["PK-15 cells", "CELL", 279, 290], ["cells", "CELL", 364, 369], ["cells", "CELL", 382, 387], ["pS", "DNA", 11, 13], ["RepC", "DNA", 14, 18], ["siRNA plasmid", "DNA", 42, 55], ["Cap", "DNA", 74, 77], [".siRNA expression plasmids", "DNA", 193, 219], ["Cap protein", "PROTEIN", 253, 264], ["PK-15 cells", "CELL_LINE", 279, 290], ["siRNA transfected cells", "CELL_LINE", 346, 369], ["control cells", "CELL_TYPE", 374, 387], ["pS", "TREATMENT", 11, 13], ["RepC", "TREATMENT", 14, 18], ["siRNA plasmid", "TREATMENT", 42, 55], ["inhibition of Cap expression", "TREATMENT", 60, 88], ["the inhibitory effects", "PROBLEM", 105, 127], ["post-transcriptional levels", "TEST", 166, 193], ["expression plasmids", "TREATMENT", 200, 219], ["PCV viral production", "PROBLEM", 228, 248], ["Cap protein expression", "TEST", 253, 275], ["PK", "TEST", 279, 281], ["cells", "TEST", 285, 290], ["post-virus infection", "PROBLEM", 308, 328], ["virus titers in siRNA transfected cells", "PROBLEM", 330, 369], ["control cells", "PROBLEM", 374, 387], ["infection", "OBSERVATION", 319, 328]]], ["In PCV1 infection, the mean virus TCID 50 in the cells transfected with pS-Negative, pS-RepA, pS-RepB and pS-RepC were 10 5.3 , 10 4.1 , 10 3.9 and 10 2.5 , respectively, and in the cells without transfection, the TCID 50 was 10 5.5 (Fig. 5) .", [["cells", "ANATOMY", 49, 54], ["cells", "ANATOMY", 182, 187], ["infection", "DISEASE", 8, 17], ["PCV1", "ORGANISM", 3, 7], ["cells", "CELL", 49, 54], ["pS-RepA", "GENE_OR_GENE_PRODUCT", 85, 92], ["pS-RepB", "GENE_OR_GENE_PRODUCT", 94, 101], ["pS-RepC", "GENE_OR_GENE_PRODUCT", 106, 113], ["cells", "CELL", 182, 187], ["pS", "PROTEIN", 72, 74], ["pS", "PROTEIN", 85, 87], ["RepA", "PROTEIN", 88, 92], ["pS", "DNA", 94, 96], ["RepB", "DNA", 97, 101], ["pS", "DNA", 106, 108], ["RepC", "DNA", 109, 113], ["PCV1", "SPECIES", 3, 7], ["PCV1 infection", "PROBLEM", 3, 17], ["the mean virus TCID", "TEST", 19, 38], ["pS", "TEST", 72, 74], ["pS", "TEST", 85, 87], ["RepA", "TEST", 88, 92], ["pS", "TEST", 94, 96], ["RepB", "TEST", 97, 101], ["pS", "TEST", 106, 108], ["RepC", "TEST", 109, 113], ["the TCID", "TEST", 210, 218], ["infection", "OBSERVATION", 8, 17]]], ["In PCV2 infection, the mean virus TCID 50 in the cells transfected with pS-Negative, pS-RepA, pS-RepB and pS-RepC were 10 4.8 , 10 3.9 , 10 3.3 and 10 2.1 , respectively, and in the cells without transfection, the TCID 50 was 10 4.9 (Fig. 5) .", [["cells", "ANATOMY", 49, 54], ["cells", "ANATOMY", 182, 187], ["PCV2 infection", "DISEASE", 3, 17], ["PCV2", "ORGANISM", 3, 7], ["cells", "CELL", 49, 54], ["pS-RepA", "GENE_OR_GENE_PRODUCT", 85, 92], ["pS-RepB", "GENE_OR_GENE_PRODUCT", 94, 101], ["pS-RepC", "GENE_OR_GENE_PRODUCT", 106, 113], ["cells", "CELL", 182, 187], ["pS", "PROTEIN", 72, 74], ["pS", "PROTEIN", 85, 87], ["RepA", "PROTEIN", 88, 92], ["pS", "PROTEIN", 94, 96], ["RepB", "DNA", 97, 101], ["pS", "DNA", 106, 108], ["RepC", "DNA", 109, 113], ["PCV2", "SPECIES", 3, 7], ["PCV2 infection", "PROBLEM", 3, 17], ["the mean virus TCID", "TEST", 19, 38], ["pS", "TEST", 72, 74], ["pS", "TEST", 85, 87], ["RepA", "TEST", 88, 92], ["pS", "TEST", 94, 96], ["RepB", "TEST", 97, 101], ["pS", "TEST", 106, 108], ["RepC", "TEST", 109, 113], ["the TCID", "TEST", 210, 218], ["PCV2 infection", "OBSERVATION", 3, 17]]], ["The viral titers of cell lysates transfected with pS-RepC were reduced by approximately 1000-fold compared to that of the control group (P < 0.01).", [["cell lysates", "ANATOMY", 20, 32], ["cell lysates", "CELL", 20, 32], ["pS-RepC", "GENE_OR_GENE_PRODUCT", 50, 57], ["pS", "PROTEIN", 50, 52], ["RepC", "PROTEIN", 53, 57], ["The viral titers", "TEST", 0, 16], ["cell lysates", "TEST", 20, 32], ["pS", "TEST", 50, 52], ["RepC", "TREATMENT", 53, 57], ["viral titers", "OBSERVATION", 4, 16], ["cell lysates", "OBSERVATION", 20, 32]]], ["However, for both PCV1 and PCV2, the viral titers of cells transfected with pS-RepA and pS-RepB were reduced 10-and 100-fold (P < 0.05), respectively.DiscussionPCV2 had been related to PMWS and other diseases, and PCV1 has been considered to be a potential risk for viral transmission when porcine tissues and organs are used for xenotransplantation (Arteaga-Troncoso et al., 2005) .", [["cells", "ANATOMY", 53, 58], ["tissues", "ANATOMY", 298, 305], ["organs", "ANATOMY", 310, 316], ["DiscussionPCV2", "CHEMICAL", 150, 164], ["PMWS", "DISEASE", 185, 189], ["PCV1", "CHEMICAL", 214, 218], ["PCV2", "ORGANISM", 27, 31], ["cells", "CELL", 53, 58], ["pS-RepA", "GENE_OR_GENE_PRODUCT", 76, 83], ["pS-RepB", "GENE_OR_GENE_PRODUCT", 88, 95], ["PCV1", "GENE_OR_GENE_PRODUCT", 214, 218], ["porcine", "ORGANISM", 290, 297], ["tissues", "TISSUE", 298, 305], ["organs", "ORGAN", 310, 316], ["pS", "PROTEIN", 76, 78], ["RepA", "PROTEIN", 79, 83], ["pS", "PROTEIN", 88, 90], ["RepB", "PROTEIN", 91, 95], ["PCV1", "SPECIES", 18, 22], ["PCV2", "SPECIES", 27, 31], ["PCV1", "SPECIES", 214, 218], ["porcine", "SPECIES", 290, 297], ["PCV1", "TEST", 18, 22], ["PCV2", "TREATMENT", 27, 31], ["the viral titers", "TEST", 33, 49], ["pS", "TEST", 76, 78], ["RepA", "TEST", 79, 83], ["pS", "TEST", 88, 90], ["RepB", "TEST", 91, 95], ["PMWS", "PROBLEM", 185, 189], ["other diseases", "PROBLEM", 194, 208], ["PCV1", "TREATMENT", 214, 218], ["xenotransplantation", "TREATMENT", 330, 349], ["PMWS", "OBSERVATION", 185, 189], ["diseases", "OBSERVATION", 200, 208]]], ["It is necessary to find an efficient method for PCV treatment.", [["an efficient method", "TREATMENT", 24, 43], ["PCV treatment", "TREATMENT", 48, 61]]], ["In this study, we used the eukaryotic expression vector pRep1-EGFP/pRep2-EGFP as a reporting system to monitor the function of the siRNAs.", [["pRep1", "GENE_OR_GENE_PRODUCT", 56, 61], ["EGFP", "GENE_OR_GENE_PRODUCT", 62, 66], ["pRep2", "GENE_OR_GENE_PRODUCT", 67, 72], ["EGFP", "GENE_OR_GENE_PRODUCT", 73, 77], ["eukaryotic expression vector", "DNA", 27, 55], ["pRep1", "DNA", 56, 61], ["EGFP", "DNA", 62, 66], ["pRep2", "PROTEIN", 67, 72], ["EGFP", "DNA", 73, 77], ["this study", "TEST", 3, 13], ["siRNAs", "ANATOMY", 131, 137]]], ["Rep1 and Rep2 expression were evaluated by fluorescence microscopy and flow cytometry.", [["Rep1", "GENE_OR_GENE_PRODUCT", 0, 4], ["Rep2", "GENE_OR_GENE_PRODUCT", 9, 13], ["Rep1", "PROTEIN", 0, 4], ["Rep2", "PROTEIN", 9, 13], ["fluorescence microscopy", "TEST", 43, 66], ["flow cytometry", "TEST", 71, 85], ["flow cytometry", "OBSERVATION", 71, 85]]], ["Our results revealed that pS-RepA, pS-RepB and pS-RepC specifically inhibited Rep expression and PCV production in PK-15 cells.", [["PK-15 cells", "ANATOMY", 115, 126], ["pS-RepA", "GENE_OR_GENE_PRODUCT", 26, 33], ["pS-RepB", "GENE_OR_GENE_PRODUCT", 35, 42], ["pS-RepC", "GENE_OR_GENE_PRODUCT", 47, 54], ["Rep", "GENE_OR_GENE_PRODUCT", 78, 81], ["PCV", "SIMPLE_CHEMICAL", 97, 100], ["PK-15 cells", "CELL", 115, 126], ["pS", "PROTEIN", 26, 28], ["RepA", "PROTEIN", 29, 33], ["pS", "PROTEIN", 35, 37], ["RepB", "PROTEIN", 38, 42], ["pS", "PROTEIN", 47, 49], ["RepC", "PROTEIN", 50, 54], ["Rep", "PROTEIN", 78, 81], ["PK-15 cells", "CELL_LINE", 115, 126], ["pS", "TEST", 26, 28], ["RepA", "TREATMENT", 29, 33], ["pS", "TEST", 35, 37], ["RepB", "TREATMENT", 38, 42], ["pS", "TREATMENT", 47, 49], ["RepC", "TREATMENT", 50, 54], ["Rep expression", "TEST", 78, 92], ["PCV production", "TEST", 97, 111], ["PK", "TEST", 115, 117]]], ["Furthermore, we found that siRNAs which inhibited Rep expression can also decrease Cap protein expression in PCV infected cells.", [["cells", "ANATOMY", 122, 127], ["Rep", "GENE_OR_GENE_PRODUCT", 50, 53], ["Cap", "GENE_OR_GENE_PRODUCT", 83, 86], ["cells", "CELL", 122, 127], ["Rep", "PROTEIN", 50, 53], ["Cap protein", "PROTEIN", 83, 94], ["PCV infected cells", "CELL_TYPE", 109, 127], ["siRNAs", "PROBLEM", 27, 33], ["Cap protein expression in PCV infected cells", "PROBLEM", 83, 127], ["siRNAs", "OBSERVATION", 27, 33], ["protein expression", "OBSERVATION", 87, 105], ["infected cells", "OBSERVATION", 113, 127]]], ["These results were in agreement with a recent study that found that shRNA could not only significantly reduce its corresponding mRNA level but inhibited other viral gene transcription as well (J. .", [["a recent study", "TEST", 37, 51], ["shRNA", "PROBLEM", 68, 73]]], ["It is, therefore, assumed that siRNAs initiate the degradation of Rep mRNA, which then results in blockage of PCV replication and protein synthesis.DiscussionAccording to our data, pS-RepC, which targeting the middle site of the Rep gene RNA appeared much more efficient than pS-RepA and pS-RepB, which target the 5 0 end and 3 0 end of the Rep gene RNA, respectively.", [["Rep", "GENE_OR_GENE_PRODUCT", 66, 69], ["PCV", "SIMPLE_CHEMICAL", 110, 113], ["pS-RepC", "GENE_OR_GENE_PRODUCT", 181, 188], ["Rep", "GENE_OR_GENE_PRODUCT", 229, 232], ["pS-RepA", "GENE_OR_GENE_PRODUCT", 276, 283], ["pS-RepB", "GENE_OR_GENE_PRODUCT", 288, 295], ["Rep", "GENE_OR_GENE_PRODUCT", 341, 344], ["Rep mRNA", "RNA", 66, 74], ["pS", "DNA", 181, 183], ["RepC", "DNA", 184, 188], ["middle site", "DNA", 210, 221], ["Rep gene RNA", "RNA", 229, 241], ["pS", "DNA", 276, 278], ["RepA", "DNA", 279, 283], ["pS", "DNA", 288, 290], ["RepB", "DNA", 291, 295], ["5 0 end", "DNA", 314, 321], ["3 0 end", "DNA", 326, 333], ["Rep gene RNA", "RNA", 341, 353], ["siRNAs", "PROBLEM", 31, 37], ["Rep mRNA", "TEST", 66, 74], ["PCV replication", "TREATMENT", 110, 125], ["protein synthesis", "PROBLEM", 130, 147], ["pS", "TEST", 181, 183], ["RepC", "TREATMENT", 184, 188], ["pS", "TEST", 276, 278], ["pS", "TEST", 288, 290], ["RepB", "TREATMENT", 291, 295], ["siRNAs", "OBSERVATION", 31, 37], ["PCV replication", "OBSERVATION", 110, 125], ["protein synthesis", "OBSERVATION", 130, 147], ["middle", "ANATOMY_MODIFIER", 210, 216]]], ["Recently, siRNAs targeted against PCV2 infection in cells and mouse models were reported.", [["cells", "ANATOMY", 52, 57], ["PCV2 infection", "DISEASE", 34, 48], ["PCV2", "ORGANISM", 34, 38], ["cells", "CELL", 52, 57], ["mouse", "ORGANISM", 62, 67], ["mouse", "SPECIES", 62, 67], ["PCV2", "SPECIES", 34, 38], ["mouse", "SPECIES", 62, 67], ["siRNAs", "TREATMENT", 10, 16], ["PCV2 infection in cells", "PROBLEM", 34, 57], ["PCV2 infection", "OBSERVATION", 34, 48]]], ["The authors demonstrated that the siRNAs targeting the Rep gene of PCV2 at nts 624-642 was most effective (J. .", [["nts 624-642", "CHEMICAL", 75, 86], ["Rep", "GENE_OR_GENE_PRODUCT", 55, 58], ["PCV2", "ORGANISM", 67, 71], ["Rep gene", "DNA", 55, 63], ["the siRNAs", "TREATMENT", 30, 40], ["PCV2", "PROBLEM", 67, 71], ["siRNAs", "OBSERVATION", 34, 40]]], ["In our previous study, we also found that two siRNAs targeting the middle sequence of NS1 more efficiently inhibited Japanese encephalitis virus replication in BHK-21 cells (X. .", [["BHK-21 cells", "ANATOMY", 160, 172], ["encephalitis", "DISEASE", 126, 138], ["NS1", "GENE_OR_GENE_PRODUCT", 86, 89], ["Japanese encephalitis virus", "ORGANISM", 117, 144], ["BHK-21 cells", "CELL", 160, 172], ["NS1", "PROTEIN", 86, 89], ["BHK-21 cells", "CELL_LINE", 160, 172], ["Japanese encephalitis virus", "SPECIES", 117, 144], ["Japanese encephalitis virus", "SPECIES", 117, 144], ["BHK-21", "SPECIES", 160, 166], ["our previous study", "TEST", 3, 21], ["two siRNAs", "PROBLEM", 42, 52], ["NS1", "PROBLEM", 86, 89], ["Japanese encephalitis virus replication in BHK", "PROBLEM", 117, 163], ["siRNAs", "OBSERVATION", 46, 52], ["middle", "ANATOMY_MODIFIER", 67, 73]]], ["This phenomenon may be due to different positional accessibility caused by steric hindrance by a secondary or tertiary structure and/or protein binding (Yuan et al., 2005) .", [["This phenomenon", "PROBLEM", 0, 15], ["steric hindrance", "PROBLEM", 75, 91], ["a secondary or tertiary structure", "PROBLEM", 95, 128], ["protein binding", "PROBLEM", 136, 151], ["may be due to", "UNCERTAINTY", 16, 29], ["positional accessibility", "OBSERVATION", 40, 64], ["steric hindrance", "OBSERVATION", 75, 91]]], ["In addition, analysis of ORF1 of PCV2 has shown 83% nucleotide and 86% predicted protein homology with PCV1.", [["nucleotide", "CHEMICAL", 52, 62], ["nucleotide", "CHEMICAL", 52, 62], ["ORF1", "GENE_OR_GENE_PRODUCT", 25, 29], ["PCV2", "ORGANISM", 33, 37], ["ORF1", "DNA", 25, 29], ["PCV1", "PROTEIN", 103, 107], ["analysis", "TEST", 13, 21], ["ORF1", "TEST", 25, 29], ["PCV2", "TEST", 33, 37], ["nucleotide", "TEST", 52, 62], ["PCV1", "TREATMENT", 103, 107]]], ["It suggests that siRNAs targeting same sequence of Rep1 and Rep2 may be efficient for both PCV1 and PCV2.", [["Rep1", "GENE_OR_GENE_PRODUCT", 51, 55], ["Rep2", "GENE_OR_GENE_PRODUCT", 60, 64], ["PCV1", "GENE_OR_GENE_PRODUCT", 91, 95], ["PCV2", "ORGANISM", 100, 104], ["Rep1", "PROTEIN", 51, 55], ["Rep2", "PROTEIN", 60, 64], ["PCV1", "SPECIES", 91, 95], ["siRNAs", "PROBLEM", 17, 23], ["Rep1", "TEST", 51, 55], ["PCV2", "TREATMENT", 100, 104], ["siRNAs", "OBSERVATION", 17, 23], ["PCV2", "OBSERVATION", 100, 104]]], ["In this study, we firstly reported that three siRNAs targeting the same sequence of Rep1 and Rep2 can inhibit Rep expression and viral production of PCV1 and PCV2.DiscussionTaken together, our research demonstrated that pS-RepA, pS-RepB and pS-RepC did not only effectively inhibit PCV Rep transcription and expression, but also inhibited PCV production in PK-15 cells. pS-RepC was most efficient for both PCV1 and PCV2.", [["PK-15 cells", "ANATOMY", 357, 368], ["Rep1", "GENE_OR_GENE_PRODUCT", 84, 88], ["Rep2", "GENE_OR_GENE_PRODUCT", 93, 97], ["Rep", "GENE_OR_GENE_PRODUCT", 110, 113], ["PCV1", "GENE_OR_GENE_PRODUCT", 149, 153], ["PCV2", "ORGANISM", 158, 162], ["pS-RepA", "GENE_OR_GENE_PRODUCT", 220, 227], ["pS-RepB", "GENE_OR_GENE_PRODUCT", 229, 236], ["pS-RepC", "GENE_OR_GENE_PRODUCT", 241, 248], ["PCV Rep", "GENE_OR_GENE_PRODUCT", 282, 289], ["PCV", "SIMPLE_CHEMICAL", 339, 342], ["PK-15 cells", "CELL", 357, 368], ["pS-RepC", "GENE_OR_GENE_PRODUCT", 370, 377], ["PCV2", "ORGANISM", 415, 419], ["Rep1", "PROTEIN", 84, 88], ["Rep2", "PROTEIN", 93, 97], ["Rep", "PROTEIN", 110, 113], ["pS", "PROTEIN", 220, 222], ["RepA", "PROTEIN", 223, 227], ["pS", "PROTEIN", 229, 231], ["RepB", "PROTEIN", 232, 236], ["pS", "DNA", 241, 243], ["RepC", "PROTEIN", 244, 248], ["Rep", "PROTEIN", 286, 289], ["PK-15 cells", "CELL_LINE", 357, 368], ["RepC", "PROTEIN", 373, 377], ["PCV1", "SPECIES", 149, 153], ["PCV1", "SPECIES", 406, 410], ["this study", "TEST", 3, 13], ["three siRNAs", "TREATMENT", 40, 52], ["viral production of PCV1", "TREATMENT", 129, 153], ["PCV2", "TREATMENT", 158, 162], ["pS", "TEST", 220, 222], ["pS", "TREATMENT", 229, 231], ["RepB", "TREATMENT", 232, 236], ["pS", "TREATMENT", 241, 243], ["RepC", "TREATMENT", 244, 248], ["PCV Rep transcription", "TREATMENT", 282, 303], ["PCV production", "TEST", 339, 353], ["PK", "TEST", 357, 359], ["pS", "TREATMENT", 370, 372], ["RepC", "TREATMENT", 373, 377], ["both PCV1", "TREATMENT", 401, 410], ["PCV2", "TREATMENT", 415, 419], ["PCV2", "OBSERVATION", 415, 419]]]], "PMC7163997": [], "188e368c531cafb73a066f52db629d62c23e6088": [], "PMC7324688": [["Special communicationThe coronavirus SARS-CoV-2, which causes the severe acute respiratory disease COVID-19, has currently spread to almost every country and is causing increasing morbidity and mortality around the world with as yet an unknown conclusion.", [["respiratory", "ANATOMY", 79, 90], ["acute respiratory disease", "DISEASE", 73, 98], ["coronavirus SARS-CoV-2", "ORGANISM", 25, 47], ["coronavirus SARS-CoV", "SPECIES", 25, 45], ["SARS-CoV-2", "SPECIES", 37, 47], ["The coronavirus SARS", "TEST", 21, 41], ["the severe acute respiratory disease COVID", "PROBLEM", 62, 104], ["increasing morbidity", "PROBLEM", 169, 189], ["coronavirus SARS", "OBSERVATION", 25, 41], ["severe", "OBSERVATION_MODIFIER", 66, 72], ["acute", "OBSERVATION_MODIFIER", 73, 78], ["respiratory disease", "OBSERVATION", 79, 98], ["increasing", "OBSERVATION_MODIFIER", 169, 179], ["morbidity", "OBSERVATION", 180, 189]]], ["It is causing huge strains on our health systems and devastating world economies.", [["huge strains on our health systems", "PROBLEM", 14, 48], ["huge", "OBSERVATION_MODIFIER", 14, 18], ["strains", "OBSERVATION", 19, 26]]], ["As countries and states/provinces in middle- and high-income countries wrangle for effective personal protective equipment and ventilators, lower-income countries are contemplating what will happen when the \u201cCOVID-19 wave\u201d becomes their reality which they will face without many of these critical tools.", [["ventilators", "TREATMENT", 127, 138]]], ["This further drives the urgency to identify and repurpose pharmaceuticals for use in these countries for both prophylaxis and treatment.", [["the urgency", "PROBLEM", 20, 31], ["pharmaceuticals", "TREATMENT", 58, 73], ["both prophylaxis", "TREATMENT", 105, 121], ["treatment", "TREATMENT", 126, 135]]], ["An unprecedented number of clinical trials have been registered for COVID-191, yet no therapy has been recognized by the scientific community to be efficacious and have an appropriate benefit-risk profile.Special communicationCOVID-19 studies will need to evaluate the efficacy of interventions against different aspects of the disease (for example pre- or post-exposure prophylaxis, mild/moderate, or preventing severe disease; therapeutics, vaccines or diagnostics).", [["COVID-191", "CHEMICAL", 68, 77], ["COVID-191", "CHEMICAL", 68, 77], ["COVID-191", "SIMPLE_CHEMICAL", 68, 77], ["COVID", "TEST", 68, 73], ["therapy", "TREATMENT", 86, 93], ["Special communicationCOVID-19 studies", "TEST", 205, 242], ["interventions", "TREATMENT", 281, 294], ["the disease", "PROBLEM", 324, 335], ["post-exposure prophylaxis", "TREATMENT", 357, 382], ["mild/moderate", "PROBLEM", 384, 397], ["severe disease", "PROBLEM", 413, 427], ["vaccines", "TREATMENT", 443, 451], ["diagnostics", "TEST", 455, 466], ["disease", "OBSERVATION", 328, 335], ["moderate", "OBSERVATION_MODIFIER", 389, 397], ["severe", "OBSERVATION_MODIFIER", 413, 419], ["disease", "OBSERVATION", 420, 427]]], ["It is critical to ensure these studies provide clear and timely answers to the scientific questions most needed to guide us not only through the initial wave of this pandemic but towards scalable solutions that help re-establish day-to-day healthy living and economic well-being2.", [["these studies", "TEST", 25, 38]]], ["There are significant challenges in operationalizing trials during a pandemic and with SARS-CoV-2, a novel virus, we are learning its natural history in real time.", [["SARS", "DISEASE", 87, 91], ["SARS-CoV-2", "ORGANISM", 87, 97], ["SARS-CoV", "SPECIES", 87, 95], ["operationalizing trials", "TREATMENT", 36, 59], ["a pandemic", "PROBLEM", 67, 77], ["SARS", "PROBLEM", 87, 91], ["a novel virus", "PROBLEM", 99, 112], ["significant", "OBSERVATION_MODIFIER", 10, 21], ["challenges", "OBSERVATION", 22, 32]]], ["Factors including public policies for managing the pandemic, public health and clinical capacity, travel and migration, and availability of tests and infrastructure all lead to spikes and troughs in patient count by location.", [["patient", "ORGANISM", 199, 206], ["patient", "SPECIES", 199, 206], ["public policies", "TREATMENT", 18, 33], ["clinical capacity", "PROBLEM", 79, 96], ["tests", "TEST", 140, 145], ["infrastructure", "TREATMENT", 150, 164], ["spikes", "PROBLEM", 177, 183]]], ["For example, trial suspensions have begun to appear due to a lack of available patients in some locales3.", [["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["trial suspensions", "TREATMENT", 13, 30]]], ["It may be that only a centralized multi-trial monitoring platform, powered by widely adopted and validated COVID-19 epidemic prediction algorithms4, could effectively predict recruitment success across the globe as a pandemic progresses.Special communicationThe rapid identification of effective COVID-19 therapies and vaccines requires informative trial outcomes derived from robustly designed studies using standardized approaches with high-quality data.", [["a centralized multi-trial monitoring platform", "TEST", 20, 65], ["COVID", "TEST", 107, 112], ["effective COVID-19 therapies", "TREATMENT", 286, 314], ["vaccines", "TREATMENT", 319, 327], ["standardized approaches", "TREATMENT", 409, 432], ["globe", "ANATOMY", 206, 211], ["rapid", "OBSERVATION_MODIFIER", 262, 267]]], ["Particularly in a pandemic setting, stakeholders should be able to have rapid access to de-identified patient-level data, through managed or open access, and to results of related trials, to inform the design of new and ongoing studies, whether interventional or observational in nature.", [["patient", "ORGANISM", 102, 109], ["patient", "SPECIES", 102, 109], ["de-identified patient-level data", "TEST", 88, 120], ["ongoing studies", "TEST", 220, 235]]], ["Rapid access to high-quality data and results is also critical to help build and support new policy approaches as well as in maintaining and strengthening trust between participants, the public and the research community5.", [["participants", "SPECIES", 169, 181]]], ["Using standard platform-based approaches enables stakeholders to harmonize, clean, analyze and use data insights much faster, whilst maintaining scientific rigour.", [["clean", "OBSERVATION", 76, 81]]], ["Adopting this type of pandemic-centric fit-for-purpose set of best practices, study quality assessments, and data approaches makes sense when there is no time for errors.Special communicationThe many trials being established will place demands for access to COVID-19 patients and in some cases may exceed the capacity for clinical research, particularly recognizing the challenges of running clinical research in the middle of a pandemic, with cases peaking at different times around the globe.", [["patients", "ORGANISM", 267, 275], ["patients", "SPECIES", 267, 275], ["study quality assessments", "TEST", 78, 103], ["middle", "ANATOMY_MODIFIER", 417, 423], ["globe", "ANATOMY", 488, 493]]], ["A new paradigm for conducting clinical trials is needed in which pandemic predictive models are used to direct clinical trial site preparation in future hot zones, further enabled through a pre-approved master protocol or smaller studies with aligned endpoints.", [["A new paradigm", "TREATMENT", 0, 14], ["conducting clinical trials", "TREATMENT", 19, 45], ["clinical trial site preparation", "TREATMENT", 111, 142], ["a pre-approved master protocol", "TREATMENT", 188, 218], ["new", "OBSERVATION_MODIFIER", 2, 5]]], ["This approach would sync clinical trials with the pandemic.", [["the pandemic", "PROBLEM", 46, 58]]], ["As waves of the COVID-19 pandemic surge around the globe and impact health systems and populations, so too do waves of frenetic effort to save lives.", [["the COVID", "TEST", 12, 21], ["globe", "ANATOMY", 51, 56]]], ["In this context, physicians, study participants and their families may feel there is insufficient time and confusing information on which studies to join.", [["participants", "SPECIES", 35, 47]]], ["In one study, statisticians found that across 171 COVID-19 clinical trials, there were over 300 distinct primary endpoints registered by principle investigators6.", [["COVID", "TEST", 50, 55]]], ["This fragmentation makes it very challenging to aggregate findings systematically toward impacting policy decisions.", [["This fragmentation", "PROBLEM", 0, 18]]], ["Standardized, open, high-quality endpoints and master protocols can resolve much of the confusion.Special communicationFurthermore, such a standardized approach with tools such as clinical trial management dashboards and remote monitoring will facilitate rapid initiation of the protocol throughout the world which may prove necessary as the pandemic wanes in some regions, but infections increases in others.", [["confusion", "DISEASE", 88, 97], ["infections", "DISEASE", 378, 388], ["master protocols", "TREATMENT", 47, 63], ["the confusion", "PROBLEM", 84, 97], ["a standardized approach", "TREATMENT", 137, 160], ["clinical trial management", "TREATMENT", 180, 205], ["remote monitoring", "TEST", 221, 238], ["the protocol", "TREATMENT", 275, 287], ["the pandemic wanes", "PROBLEM", 338, 356], ["infections", "PROBLEM", 378, 388], ["infections", "OBSERVATION", 378, 388]]], ["If we employ sound science with efficient study designs, we will help get the right products, to the right people at the right dose (in the case of therapeutics) and the right time.", [["people", "ORGANISM", 107, 113], ["people", "SPECIES", 107, 113], ["the right products", "TREATMENT", 74, 92], ["right", "ANATOMY_MODIFIER", 78, 83], ["right", "ANATOMY_MODIFIER", 101, 106], ["right", "ANATOMY_MODIFIER", 121, 126], ["right", "ANATOMY_MODIFIER", 170, 175]]], ["These include both pre-specified interim and final data outputs, as well as protocols and standards used to collect the data where possible7.", [["final data outputs", "TEST", 45, 63], ["the data", "TEST", 116, 124]]], ["The focus must be on delivering robust and timely answers to scientific questions that demonstrate the safety and efficacy characteristics of the intervention.Special communicationThe focus must also be on understanding how to provide equitable access to these interventions ensuring that interventions reach those who need them the most, be it patients in low resource settings or vulnerable groups.", [["patients", "ORGANISM", 345, 353], ["patients", "SPECIES", 345, 353], ["the intervention", "TREATMENT", 142, 158], ["these interventions", "TREATMENT", 255, 274], ["interventions", "TREATMENT", 289, 302]]], ["Solid answers can quickly result in policy and practice changes that benefit the health of the public and subsequently world economies and the many other aspects of our lives that have been upended by this pandemic.Special communicationThe COVID-19 pandemic and simultaneous flood of observational studies and clinical trials comes at an interesting time.", [["The COVID", "TEST", 236, 245], ["observational studies", "TEST", 284, 305], ["clinical trials", "TREATMENT", 310, 325]]], ["There is increasing interest in why so many studies end with stakeholders and participants expecting greater impact.", [["participants", "SPECIES", 78, 90], ["increasing", "OBSERVATION_MODIFIER", 9, 19], ["interest", "OBSERVATION_MODIFIER", 20, 28]]], ["This is not a new problem, nor one specifically related to COVID-19.", [["COVID-19", "CHEMICAL", 59, 67], ["COVID-19", "DNA", 59, 67], ["a new problem", "PROBLEM", 12, 25], ["COVID", "TEST", 59, 64], ["new", "OBSERVATION_MODIFIER", 14, 17], ["problem", "OBSERVATION", 18, 25]]], ["The failure rate for a drug progressing from a phase 1 study to launch hovers around 90%, and evidence abounds that poor trial design and/or data quality are significant contributing factors8,9.", [["The failure rate", "PROBLEM", 0, 16], ["poor trial design and/or data quality", "PROBLEM", 116, 153], ["significant contributing factors", "PROBLEM", 158, 190], ["failure", "OBSERVATION", 4, 11]]], ["Informative studies provide robust clinical insight, a solid on-ramp to the next phase of development or a change in policy or standard of care, or to the decision not to progress.", [["Informative studies", "TEST", 0, 19]]], ["\u201cAn uninformative trial is \u201cone that provides results that are not of meaningful use for a patient, clinician, researcher, or policy maker.\u201d10 In the supplement to their paper in JAMA, they identified twelve \u2018red flags\u2019: qualities of clinical trials associated with uninformative trials.", [["patient", "ORGANISM", 91, 98], ["patient", "SPECIES", 91, 98], ["uninformative trials", "TREATMENT", 266, 286]]], ["Studies that failed to influence policy change or a confident next step in a go/no-go decision were commonly associated with factors such as lack of use of common endpoints, lack of conservatism in effect estimates, not using biostatistical simulation to derive proper sample sizes, using unduly restrictive inclusion criteria, and avoiding use of innovative trial designs.Special communicationClinical trials are not the only source of data.", [["innovative trial designs", "TREATMENT", 348, 372]]], ["Real-world data, largescale epidemiological studies, health systems research and social sciences all play an integral part in building a comprehensive evidence base.", [["base", "ANATOMY_MODIFIER", 160, 164]]], ["To help establish standardized clinical endpoints and case definitions that help regulators and policy makers evaluate data and make decisions, current efforts have accelerated to develop a standard approach to convert clinical trial data to the most commonly used observational, real world evidence data models.", [["clinical trial data", "TEST", 219, 238]]], ["Global experts and implementers abound, and sustainability is strong\u2014these are the most widely used standards globally for formatting trial data and storing observational data18\u201320.", [["formatting trial data", "TEST", 123, 144]]], ["Wide adoption of one of these standards enabled one study to compile a virtual real-world evidence dataset with over 300,000 users of hydroxychloroquine in combination with azithromycin21.", [["hydroxychloroquine", "CHEMICAL", 134, 152], ["azithromycin21", "CHEMICAL", 173, 187], ["hydroxychloroquine", "CHEMICAL", 134, 152], ["azithromycin21", "CHEMICAL", 173, 187], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 134, 152], ["azithromycin21", "SIMPLE_CHEMICAL", 173, 187], ["one study", "TEST", 48, 57], ["hydroxychloroquine", "TREATMENT", 134, 152], ["azithromycin21", "TREATMENT", 173, 187]]], ["Likewise, wide adoption of, for example, the same inclusion/exclusion criteria and primary endpoints could enable clinical or implementation science researchers to compile a systematic review with compelling evidence.Special communicationA robust understanding of risk factors and best practices for informative trial design creates a need for a diagnostic guide to help relevant stakeholders assess whether a proposed study is likely to provide definitive answers and lead to implementable results.", [["a proposed study", "TEST", 408, 424], ["wide", "OBSERVATION_MODIFIER", 10, 14]]], ["This guide can quickly identify studies that lack basic components, \u2018flag\u2019 studies that could be predicted to end uninformatively and guide these stakeholders towards studies designed to address questions in more definitive ways.", [["flag\u2019 studies", "TEST", 69, 82]]], ["One guide that is free and publicly available for COVID-19 studies is located athttps://bit.ly/dat-covid-19, and we encourage all researchers to use this when designing COVID-19 related clinical studies.", [["COVID", "TEST", 50, 55], ["clinical studies", "TEST", 186, 202], ["free", "OBSERVATION_MODIFIER", 18, 22]]], ["The guide will be used to screen and help applicants design their clinical trials for the recently announced COVID-19 Therapeutic Accelerator, (seehttps://www.therapeuticsaccelerator.org/).", [["Therapeutic Accelerator", "TREATMENT", 118, 141]]], ["Faced with an influx of COVID-19 clinical research approval requests, researchers and funders could use such an assessment tool to help select the most appropriate studies, those more likely to definitively answer clinical questions.Special communicationThese still early days of COVID-19 are an ideal time to implement trial assessment guides.", [["COVID", "TEST", 24, 29], ["an assessment tool", "TEST", 109, 127], ["trial assessment", "TEST", 320, 336]]], ["Best practice methods can include striving toward both informative results as well as data that is findable, accessible, interoperable and reusable.", [["Best practice methods", "TREATMENT", 0, 21]]], ["A level of rigor will help route sick patients into studies most likely to be informative and ultimately to therapies more likely to be part of an at-scale response.Special communicationThe COVID-19 pandemic calls for fit-for-purpose solutions that will surely challenge business as usual practices.", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["A level of rigor", "PROBLEM", 0, 16], ["therapies", "TREATMENT", 108, 117], ["purpose solutions", "TREATMENT", 226, 243]]], ["Considerations around study design, real-world evidence to optimize the study, research methods, centralized recruitment and quality monitoring, use of common endpoints and established protocols and availability of interim and final data output for secondary analysis all depend on a variety of variables, including the purpose of the study and the data involved.", [["the study", "TEST", 68, 77], ["research methods", "TEST", 79, 95], ["quality monitoring", "TEST", 125, 143], ["established protocols", "TREATMENT", 173, 194], ["final data output", "TEST", 227, 244], ["secondary analysis", "TEST", 249, 267], ["the study", "TEST", 331, 340]]], ["As such, there is no one-size-fits-all rule of thumb.", [["thumb", "ORGANISM_SUBDIVISION", 47, 52], ["no", "UNCERTAINTY", 18, 20], ["size", "OBSERVATION_MODIFIER", 25, 29], ["thumb", "ANATOMY", 47, 52]]], ["With multiple vaccine candidates currently being developed and tested, the same considerations and best practices apply to therapeutic as to vaccine trials.", [["multiple vaccine candidates", "TREATMENT", 5, 32], ["vaccine trials", "TREATMENT", 141, 155]]], ["Tools for evaluating designs and protocols as well as guiding toward best practice interoperable data platforms are urgently needed now to help identify appropriate therapies for COVID-19.", [["protocols", "TREATMENT", 33, 42], ["COVID", "TEST", 179, 184]]], ["In the process, such tools could teach the next generation of researchers how to design studies and generate data that will affect policy and practice change by integrating best practices for implementation research, health systems strengthening, biostatistics, epidemiology, participant engagement, and model-informed drug development.", [["design studies", "TEST", 81, 95]]], ["Adoption of well-governed, global master protocols and participation in consortia that could develop lasting standards will help now and in the future1,22.", [["global master protocols", "TREATMENT", 27, 50]]], ["Our commonality of purpose in this moment of crisis can be transformative, not only for therapies rapidly identified to save lives but for research and business innovations that accelerate health and equity for those around the world needing it the most.Data availabilityNo data are associated with this article.", [["crisis", "PROBLEM", 45, 51], ["therapies", "TREATMENT", 88, 97]]]], "3a68b79bd192af03c65de40574c22b18b0fa5c53": [["PerspectiveDuring the COVID-19 pandemic, as well as other recent emergencies brought on by climate change and other disasters, persons with disabilities (PWDs) [1] living in cities may be four times more likely to be injured or die than non-disabled persons, not because of their \"vulnerable\" position but because urban health policy, planning, and practice have not considered their needs [2] .", [["PWDs", "DISEASE", 154, 158], ["persons", "SPECIES", 127, 134], ["persons", "SPECIES", 250, 257]]], ["We suggest in this perspective that the adverse health impacts on PWDs during the COVID-19 pandemic reveal the \"everyday emergencies\" in cities for PWDs and that these can be avoided through more inclusive community planning, a whole-of-government commitment to equal access, and implementation of universal design strategies [3] .", [["PWDs", "TREATMENT", 66, 70], ["the COVID", "TEST", 78, 87], ["PWDs", "TREATMENT", 148, 152], ["universal design strategies", "TREATMENT", 298, 325]]], ["Importantly, COVID-19 can place PWDs at a higher risk of infection since some may already have compromised immune and respiratory systems, and policy responses, such as social distancing, can lead to life-threatening disruptions in care for those that rely on home health or personal assistants [4] .", [["COVID-19", "CHEMICAL", 13, 21], ["infection", "DISEASE", 57, 66], ["COVID-19", "GENE_OR_GENE_PRODUCT", 13, 21], ["PWDs", "PATHOLOGICAL_FORMATION", 32, 36], ["PWDs", "TREATMENT", 32, 36], ["infection", "PROBLEM", 57, 66], ["compromised immune and respiratory systems", "PROBLEM", 95, 137], ["infection", "OBSERVATION", 57, 66]]], ["Living in cities may already present health-damaging challenges for PWDs, such as lack of access to services and employment, physical barriers on streets and transportation, and smart city technologies that are not made universally accessible.", [["PWDs", "DISEASE", 68, 72], ["PWDs", "TREATMENT", 68, 72]]], ["This perspective offers insights for ensuring the twenty-first-century response to COVID-19 focuses on promoting more inclusive and healthy cities for all.Disability, Emergencies, and the Urban Health ChallengeThe WHO and World Bank reported that \"more than one billion people in the world live with some form of disability, of whom nearly 200 million experience considerable difficulties in functioning,\", and by 2050, 940 million people in cities may be living with a disability [5] .", [["disability", "DISEASE", 313, 323], ["disability", "DISEASE", 470, 480], ["people", "ORGANISM", 270, 276], ["people", "ORGANISM", 432, 438], ["people", "SPECIES", 270, 276], ["people", "SPECIES", 432, 438], ["COVID", "TEST", 83, 88]]], ["For example, in the USA, 62% of PWDs (including physical, intellectual, and developmental; sensory; and other disability categories) are unemployed, 27% live below the poverty line [6] , and over 45% rated their health as \"fair or poor\" in 2018, making PWDs an often unrecognized health disparity population [7] .", [["PWDs", "DISEASE", 32, 36], ["physical, intellectual, and developmental; sensory; and other disability", "DISEASE", 48, 120], ["PWDs", "TEST", 32, 36]]], ["Urban health equity for PWDs means recognizing the immediate, acute care needs that they face but also reversing the social, physical, and often place-based determinants of poor health that have gone unaddressed in cities [8] .Disability, Emergencies, and the Urban Health ChallengeThe WHO states that disability is an intersecting issue of public health, human rights, and development, noting that poverty, combined with the high prevalence of PWDs in low-income countries, makes this a global health and urban development issue [9] .", [["disability", "DISEASE", 302, 312], ["poverty", "DISEASE", 399, 406], ["PWDs", "DISEASE", 445, 449], ["human", "ORGANISM", 356, 361], ["human", "SPECIES", 356, 361], ["human", "SPECIES", 356, 361]]], ["Part of the urban health equity challenge raised by the COVID-19 crisis and acknowledged by the UN is confronting the all too common medical model of disability, which defines people as disabled due to their impairments or differences [10] .", [["disability", "DISEASE", 150, 160], ["people", "ORGANISM", 176, 182], ["people", "SPECIES", 176, 182], ["their impairments", "PROBLEM", 202, 219]]], ["Moving toward urban health equity in cities means implementing the social model of disability in all policies.", [["disability", "DISEASE", 83, 93]]], ["The social model of disability views impairments as limitations of public policy, not people.", [["disability", "DISEASE", 20, 30], ["people", "ORGANISM", 86, 92], ["people", "SPECIES", 86, 92]]], ["For example, in urban health planning, a street intersection without a curb cut that limits a person in a wheelchair from crossing is a limitation and failure of urban design, policy, and planning, not the person.", [["person", "SPECIES", 94, 100], ["person", "SPECIES", 206, 212]]], ["Further, in low-income countries around the world where 50-75% of the urban population lives in slums or informal settlements, the difficulties of social distancing for those with a disability should not be viewed as an individual challenge but rather a failure of land use, shelter, and infrastructure planning.Disability, Emergencies, and the Urban Health ChallengeLessons from previous disasters and emergencies offer some guidance for inclusive, urban health planning for the COVID-19 pandemic.", [["disability", "DISEASE", 182, 192], ["the COVID", "TEST", 476, 485], ["pandemic", "PROBLEM", 489, 497]]], ["A 2006 post-Hurricane Katrina and Rita report by the US National Council on Disabilities (NCD) noted that in New Orleans, \"people with disabilities were disproportionately affected by the Hurricanes because their needs were often overlooked or completely disregarded.", [["people", "ORGANISM", 123, 129], ["people", "SPECIES", 123, 129]]], ["Their evacuation, shelter, and recovery experiences differed vastly from the experiences of people without disabilities\" [11] .", [["people", "ORGANISM", 92, 98], ["people", "SPECIES", 92, 98], ["Their evacuation", "TREATMENT", 0, 16]]], ["In the West African Ebola outbreak of 2014, Marais et al. noted the importance of including community knowledge, including that of PWDs, in educating different groups and in preventing transmission [13] .", [["Ebola", "DISEASE", 20, 25], ["PWDs", "TREATMENT", 131, 135]]], ["Wars in the Middle East, West and Central Africa, and other regions have left tens of thousands disabled, many of whom migrate to cities seeking care but are then denied access to schools, employment, and face stigma [14] .", [["Middle", "ANATOMY_MODIFIER", 12, 18], ["Central", "ANATOMY_MODIFIER", 34, 41], ["left", "ANATOMY_MODIFIER", 73, 77]]], ["Armed conflict continues to increase the number of disabled children and has made girls and women especially susceptible to exploitation and infections, including HIV and other diseases [15] .Disability, Emergencies, and the Urban Health ChallengeAn unaddressed key issue during this pandemic, which also applies to the human rights of PWD, is how to ensure PWDs continue to receive the support required to ensure their well-being, independence, and self-determination when their regular caregivers/ personal assistants are quarantined, fall ill, and/or are unable to continue providing support [16] ?", [["infections", "DISEASE", 141, 151], ["HIV and other diseases", "DISEASE", 163, 185], ["children", "ORGANISM", 60, 68], ["women", "ORGANISM", 92, 97], ["human", "ORGANISM", 320, 325], ["children", "SPECIES", 60, 68], ["girls", "SPECIES", 82, 87], ["women", "SPECIES", 92, 97], ["HIV", "SPECIES", 163, 166], ["human", "SPECIES", 320, 325], ["HIV", "SPECIES", 163, 166], ["human", "SPECIES", 320, 325], ["infections", "PROBLEM", 141, 151], ["HIV and other diseases", "PROBLEM", 163, 185], ["the support", "TREATMENT", 383, 394], ["infections", "OBSERVATION", 141, 151]]], ["In Italy and other European countries, there were few messages communicated in accessible formats, and no specific measures were taken early in the crises for PWDs [18] .", [["PWDs", "DISEASE", 159, 163]]], ["An early lesson is that cities must ensure that all public health messaging, technologies, and communications are accessible to all.", [["early", "OBSERVATION_MODIFIER", 3, 8], ["lesson", "OBSERVATION", 9, 15]]], ["For instance, during COVID-19, very few public announcements include sign language interpretation, and the ubiquity of face masks can further frustrate the ability of those who rely on lip-reading to understand and communicate.Disability, Emergencies, and the Urban Health ChallengeThe livelihoods of persons with disabilities are also at serious risk due to the economic downturn brought about by the pandemic.", [["lip", "ANATOMY", 185, 188], ["lip", "ORGAN", 185, 188], ["persons", "ORGANISM", 301, 308], ["persons", "SPECIES", 301, 308], ["COVID", "TEST", 21, 26], ["face masks", "TREATMENT", 119, 129]]], ["Yet, PWDs have not been included in economic responses to the COVID-19 pandemic nor involved in planning to prevent future crises [19] .", [["future crises", "PROBLEM", 116, 129]]], ["As the UN Special Rapporteur on the rights of persons with disabilities, Catalina Devandas, noted on 20 March 2020: \"People with disabilities feel they have been left behind.", [["persons", "ORGANISM", 46, 53], ["persons", "SPECIES", 46, 53], ["People", "SPECIES", 117, 123], ["left", "ANATOMY_MODIFIER", 162, 166]]], ["Containment measures, such as social distancing and self-isolation, may be impossible for those who rely on the support of others to eat, dress and bathe.\"", [["Containment measures", "TREATMENT", 0, 20], ["self-isolation", "TREATMENT", 52, 66]]], ["We suggest that people with disabilities bring a unique expertise to framing and implementing public health activities [20] .The Cities for All Response to Epidemics and Health EquityBelow we offer some brief recommendations for how the COVID-19 pandemic response can best support PWDs and why these practices will also ensure cities are made more inclusive and healthier for all.", [["people", "ORGANISM", 16, 22], ["people", "SPECIES", 16, 22], ["the COVID", "TREATMENT", 233, 242]]], ["For example, the Standard Rules on the Equalization of Opportunity for Persons with Disabilities (1994) (A/RES/48/96) identify \"accessibility\" of the physical environment and of information and communication as two \"target areas\" to ensure equalization of opportunities.", [["Persons", "SPECIES", 71, 78]]], ["The Article 25 of the UN Convention on the Rights of Persons with Disabilities (CRPD) reinforces the right of PWDs to attain the highest standard of health and health care, without discrimination [21] .", [["CRPD", "DISEASE", 80, 84], ["Persons", "SPECIES", 53, 60], ["right", "ANATOMY_MODIFIER", 101, 106]]], ["Cities have been slow to comply with these directives, as they have \"left behind\" those with physical impairments by not adopting universal design principles in urban development, by ignoring the needs of PWDs in the adoption of new, smart city technologies, and through other forms of physical and social exclusion [22] .The Cities for All Response to Epidemics and Health EquityWe offer the following recommendations for inclusive cities in response to COVID-19:The Cities for All Response to Epidemics and Health Equity(1) Accessible Information Access Cities must disseminate public information in accessible formats, including sign language and realtime captioning at all press conferences and public service announcements.", [["physical impairments", "DISEASE", 93, 113], ["PWDs", "DISEASE", 205, 209], ["physical impairments", "PROBLEM", 93, 113], ["COVID", "TEST", 455, 460]]], ["In the crafting of COVID-19 messages, cities should also take extra care in ensuring that all public communications do not discriminate against or reinforce harmful stereotypes of any population group, including persons with disabilities.The Cities for All Response to Epidemics and Health Equity(2) Inclusive decision-making PWDs and disabled persons' organizations (DPOs) must be at the center of the program and policy decisions and implementation.", [["persons", "ORGANISM", 212, 219], ["persons", "SPECIES", 212, 219], ["persons", "SPECIES", 344, 351]]], ["This can ensure that the needs of persons with diverse disabilities are adequately met and their rights and dignity respectfully upheld.", [["persons", "ORGANISM", 34, 41], ["persons", "SPECIES", 34, 41], ["diverse disabilities", "TREATMENT", 47, 67]]], ["COVID-19 responses should be inclusive by prioritizing the principles of Universal Design and Access as well as the Convention on the Rights of Persons with Disabilities.", [["Persons", "SPECIES", 144, 151], ["COVID", "TEST", 0, 5], ["Universal Design and Access", "TREATMENT", 73, 100]]], ["Indeed, persons with disabilities hold a privileged vantage point in understanding and dealing with crises and are a special asset in the current pandemic.", [["persons", "ORGANISM", 8, 15], ["persons", "SPECIES", 8, 15], ["crises", "PROBLEM", 100, 106]]], ["Therefore, governments and local authorities should establish Pandemic Responses Task Forces that include PWDs to make sure that the latter are consulted, and accessibility, inclusivity, and universal design are mainstreamed into risk reduction responses.The Cities for All Response to Epidemics and Health Equity(3) Accessibility through continuity of care and social supportsThe Cities for All Response to Epidemics and Health EquityCities should ensure that persons with disabilities have continued access to essential services, including healthcare and personal assistants.", [["persons", "ORGANISM", 461, 468], ["persons", "SPECIES", 461, 468], ["PWDs", "TREATMENT", 106, 110], ["continuity of care", "TREATMENT", 339, 357], ["Epidemics", "PROBLEM", 408, 417]]], ["During any closure or minimization of services, PWDs must be supported to meet their daily living requirements, including access to food (as needed with specific dietary requirements), housing, healthcare, and in-home school and community supports [24] .", [["any closure", "TREATMENT", 7, 18], ["PWDs", "TREATMENT", 48, 52]]], ["Further, there is an opportunity for cities to invest in existing DPOs by providing them financial support to offer culturally competent continuity of care training and service delivery, especially when there are human resource shortages.(4) Economic SupportsPWDs in many cities are living in poverty, may be informal day laborers or are homeless, and expenditures used to arrest the COVID-19 pandemic must also be used to improve the immediate and long-term economic status of PWDs.", [["PWDs", "DISEASE", 478, 482], ["human", "ORGANISM", 213, 218], ["human", "SPECIES", 213, 218], ["human", "SPECIES", 213, 218], ["financial support", "TREATMENT", 89, 106], ["care training", "TREATMENT", 151, 164], ["service delivery", "TREATMENT", 169, 185]]], ["A 2019 study in the UK by John et al., called the \"Disability Price Tag,\" found that PWDs spent about 700 USD more a month than others, due to higher costs for transportation, utilities, care, and such things as accessible hotel rooms.", [["Tag", "GENE_OR_GENE_PRODUCT", 68, 71]]], ["These costs make it much harder for PWDs to build savings and plan for the future and make them extremely vulnerable to economic shocks, like the current coronavirus pandemic [26] .", [["coronavirus pandemic", "DISEASE", 154, 174]]], ["One policy response could be eliminating any restrictions governments may have on hiring family members to ensure continuity of care for PWDs.(4) Economic Supports(5) Non-discrimination PWDs are frequently subject to discrimination and stigma, which can impact their access to care, employment, and other life supports.", [["PWDs", "DISEASE", 137, 141], ["PWDs", "TREATMENT", 137, 141], ["Non-discrimination PWDs", "TREATMENT", 167, 190], ["stigma", "PROBLEM", 236, 242]]], ["Cities should adopt more strict anti-discrimination and labor protection laws for PWDs and strengthen enforcement of such laws during this crisis to safeguard against unfair or discriminatory dismissal from work and/or needed care services.", [["PWDs", "DISEASE", 82, 86], ["labor protection laws", "TREATMENT", 56, 77], ["PWDs", "TREATMENT", 82, 86]]], ["PWDs may also be receiving disability benefits, and these must not only continue on time but also may need to be enhanced to buffer the increased costs of living for PWDs stemming from the pandemic, such as the extra costs of home deliveries and/or hiring of private support due to the suspension of public services.Toward Disability Justice and Global Healthy Cities for AllWe have offered a few recommendations to ensure persons with disabilities living in cities are not disproportionately harmed during the COVID-19 crisis.", [["PWDs", "DISEASE", 0, 4], ["PWDs", "DISEASE", 166, 170], ["persons", "ORGANISM", 423, 430], ["persons", "SPECIES", 423, 430], ["private support", "TREATMENT", 259, 274], ["increased", "OBSERVATION_MODIFIER", 136, 145]]], ["Clearly, many of these suggestions should continue beyond the crisis and form an \"urban disability justice\" strategy, which can address systemic ableism in urban health research, policy, and planning [27] .", [["ableism", "DISEASE", 145, 152]]], ["The COVID-19 crisis can highlight and hopefully reveal policies to reverse the everyday crises and structural exclusion that PWDs face in cities [28] .", [["PWDs", "DISEASE", 125, 129], ["The COVID", "TEST", 0, 9], ["the everyday crises", "PROBLEM", 75, 94]]], ["The global pandemic must be viewed by global urban health advocates much like the urban epidemics of the nineteenth century, where urban sanitary and governance reforms helped improve population health [29] .", [["governance reforms", "TREATMENT", 150, 168], ["global", "OBSERVATION_MODIFIER", 4, 10], ["pandemic", "OBSERVATION", 11, 19]]], ["However, some responses to the urban epidemics of the nineteenth and early twentieth century enhanced exclusion and segregation in cities, while others challenged colonialist, racist, and discriminatory urban health practices [30] .", [["segregation", "OBSERVATION_MODIFIER", 116, 127]]], ["The COVID-19 crisis presents urban health practitioners with an opportunity to maintain the status quo, perpetuate even greater spatial segregation and exclusion, or to offer a vision for (re)building our cities to be more inclusive and healthier for all.", [["The COVID", "TEST", 0, 9]]]], "f0975ba62de933eb2c424b9d8fc5916049e444c6": [["INTRODUCTIONProtein products are the basis of life on Earth and serve nearly all the functions in the essential biochemistry of life science.", [["INTRODUCTIONProtein products", "TREATMENT", 0, 28]]], ["Each nascent protein exists as an unfolded polypeptide or random coil when translated from a sequence of mRNA to a linear chain of residues by a ribosome.", [["ribosome", "CELLULAR_COMPONENT", 145, 153], ["nascent protein", "PROTEIN", 5, 20], ["mRNA", "RNA", 105, 109], ["an unfolded polypeptide", "PROBLEM", 31, 54], ["random coil", "TREATMENT", 58, 69], ["protein", "OBSERVATION", 13, 20], ["unfolded", "OBSERVATION_MODIFIER", 34, 42]]], ["The intrinsic biological functions of a protein are expressed and determined by its native three-dimensional (3D) structure that derives from the physical process of protein folding 1 , by which a polypeptide folds into its native characteristic and functional three-dimensional structure, in an expeditious and reproducible manner.", [["protein folding 1", "PROTEIN", 166, 183], ["a polypeptide folds", "TEST", 195, 214], ["intrinsic", "OBSERVATION_MODIFIER", 4, 13], ["biological functions", "OBSERVATION", 14, 34], ["protein folding", "OBSERVATION", 166, 181], ["native characteristic", "OBSERVATION_MODIFIER", 224, 245], ["functional", "OBSERVATION_MODIFIER", 250, 260], ["three", "OBSERVATION_MODIFIER", 261, 266], ["expeditious", "OBSERVATION", 296, 307], ["reproducible", "OBSERVATION_MODIFIER", 312, 324]]], ["Protein folding can thereby be considered the most important mechanism, principle, and motivation of biological existence, functionalization, diversity, and evolution [2] [3] [4] .INTRODUCTIONBased on the complexity of protein folding, the protein-folding problem has been summarized in three unanswered questions 1 : (i) What is the physical folding code in the amino acid sequence that dictates the particular native 3D structure? (ii) What is the folding mechanism that enables proteins to fold so quickly? (iii) Is it possible to devise a computer algorithm to effectively predict a protein's native structure from its amino acid sequence?", [["amino acid", "CHEMICAL", 363, 373], ["amino acid", "CHEMICAL", 623, 633], ["amino acid", "CHEMICAL", 363, 373], ["(iii)", "CHEMICAL", 510, 515], ["amino acid", "CHEMICAL", 623, 633], ["[2] [3] [4]", "SIMPLE_CHEMICAL", 167, 178], ["amino acid", "AMINO_ACID", 363, 373], ["amino acid", "AMINO_ACID", 623, 633], ["amino acid sequence", "PROTEIN", 363, 382], ["amino acid sequence", "PROTEIN", 623, 642], ["Protein folding", "PROBLEM", 0, 15], ["protein folding", "TREATMENT", 219, 234], ["the protein-folding problem", "PROBLEM", 236, 263], ["the amino acid sequence", "TEST", 359, 382], ["the folding mechanism", "PROBLEM", 446, 467], ["a computer algorithm", "TEST", 541, 561], ["a protein's native structure", "PROBLEM", 585, 613], ["its amino acid sequence", "TEST", 619, 642]]], ["Moreover, another essential question is why protein folding highly depends on the solvent (water or lipid bilayer) 5 and the temperature 6 ?", [["water", "SIMPLE_CHEMICAL", 91, 96], ["protein folding", "PROBLEM", 44, 59], ["the solvent (water or lipid bilayer)", "TREATMENT", 78, 114], ["the temperature", "TEST", 121, 136]]], ["The protein folding problem was brought to light over 60 years ago.", [["The protein folding problem", "PROBLEM", 0, 27], ["protein folding", "OBSERVATION", 4, 19]]], ["In particular, since Anfinsen shared a 1972 Nobel Prize in Chemistry for his work revealing the connection between the amino acid sequence and the native conformation 7 , understanding of protein sequence-structure relationships has become the most fundamental task in molecular and structural biology 8 .INTRODUCTIONProtein folding is one of the miracles of nature that human technology finds quite difficult to follow, due to the very large number of degrees of rotational freedom in an unfolded polypeptide chain.", [["amino acid", "CHEMICAL", 119, 129], ["amino acid", "CHEMICAL", 119, 129], ["amino acid", "AMINO_ACID", 119, 129], ["human", "ORGANISM", 371, 376], ["amino acid sequence", "PROTEIN", 119, 138], ["unfolded polypeptide chain", "PROTEIN", 489, 515], ["human", "SPECIES", 371, 376], ["human", "SPECIES", 371, 376], ["his work", "TEST", 73, 81], ["the amino acid sequence", "TEST", 115, 138], ["protein sequence", "TEST", 188, 204], ["rotational freedom in an unfolded polypeptide chain", "PROBLEM", 464, 515], ["very", "OBSERVATION_MODIFIER", 432, 436], ["large", "OBSERVATION_MODIFIER", 437, 442], ["number", "OBSERVATION_MODIFIER", 443, 449], ["rotational freedom", "OBSERVATION", 464, 482], ["unfolded", "OBSERVATION_MODIFIER", 489, 497], ["polypeptide chain", "OBSERVATION", 498, 515]]], ["In the 1960s, Cyrus Levinthal pointed out that the apparent contradiction between the astronomical number of possible conformations for a protein chain and the fact that proteins can fold quickly into their native structures should be regarded as a paradox (Levinthal's paradox) 9 , so there must be mechanisms that allow polypeptide chains to find the native states encoded in their sequence.", [["protein chain", "PROTEIN", 138, 151], ["a protein chain", "PROBLEM", 136, 151], ["a paradox (Levinthal's paradox", "TREATMENT", 247, 277], ["polypeptide chains", "TREATMENT", 322, 340]]], ["As stated in Anfinsen's Dogma, the well-defined native 3D structures of small globular proteins are uniquely encoded in their primary structures (the amino acid sequences), is kinetically reproducible and stable under a range of physiological conditions, and can therefore be considered as an issue of the certainty.INTRODUCTIONMany proteins or protein domains, relatively rapid and efficient refolding can be observed in vitro, thus proteins may be regarded as \"folding themselves\" following explicit folding pathways 1 .", [["primary structures", "ANATOMY", 126, 144], ["amino acid", "CHEMICAL", 150, 160], ["amino acid", "CHEMICAL", 150, 160], ["amino acid", "AMINO_ACID", 150, 160], ["small globular proteins", "PROTEIN", 72, 95], ["amino acid sequences", "PROTEIN", 150, 170], ["protein domains", "PROTEIN", 345, 360], ["small globular proteins", "PROBLEM", 72, 95], ["the amino acid sequences", "TEST", 146, 170], ["INTRODUCTIONMany proteins or protein domains", "PROBLEM", 316, 360], ["small", "OBSERVATION_MODIFIER", 72, 77], ["globular proteins", "OBSERVATION", 78, 95], ["kinetically", "OBSERVATION_MODIFIER", 176, 187], ["reproducible", "OBSERVATION_MODIFIER", 188, 200], ["stable", "OBSERVATION_MODIFIER", 205, 211]]], ["Protein folding is considered a free energy minimization or a relaxation process that is guided mainly by the following physical forces: (i) formation of intramolecular hydrogen bonds, (ii) van der Waals interactions, (iii) electrostatic interactions, (iv) hydrophobic interactions, (v) chain entropy of protein, (vi) thermal motions 1, 10 .", [["hydrogen", "CHEMICAL", 169, 177], ["Protein folding", "PROBLEM", 0, 15], ["a relaxation process", "PROBLEM", 60, 80], ["intramolecular hydrogen bonds", "PROBLEM", 154, 183], ["relaxation process", "OBSERVATION", 62, 80], ["intramolecular", "OBSERVATION", 154, 168], ["hydrogen bonds", "OBSERVATION", 169, 183]]], ["Among them, hydrophobic effect is normally thought to play a decisive role 11 .", [["hydrophobic effect", "OBSERVATION", 12, 30]]], ["Currently, the generally accepted hypothesis in the field is to conceive of protein folding in a funnel-shaped energy landscape, where every possible conformation is represented by a free energy value.", [["protein folding", "PROBLEM", 76, 91], ["a funnel-shaped energy landscape", "PROBLEM", 95, 127], ["hypothesis", "OBSERVATION", 34, 44], ["protein folding", "OBSERVATION", 76, 91], ["shaped", "OBSERVATION_MODIFIER", 104, 110], ["energy landscape", "OBSERVATION", 111, 127]]], ["The rapid folding of proteins has been attributed to random thermal motions that cause conformational changes leading energetically downhill toward the native structure corresponds to its free energy minimum under the solution conditions 1, 10 .", [["The rapid folding of proteins", "PROBLEM", 0, 29], ["random thermal motions", "PROBLEM", 53, 75], ["conformational changes", "PROBLEM", 87, 109], ["rapid", "OBSERVATION_MODIFIER", 4, 9], ["folding", "OBSERVATION", 10, 17], ["random thermal", "OBSERVATION_MODIFIER", 53, 67]]], ["However, there are both enthalpic and entropic contributions to free energy of protein that change with temperature and so give rise to heat denaturation and, in some cases, cold denaturation 12 .", [["heat denaturation", "PROBLEM", 136, 153], ["cold denaturation", "PROBLEM", 174, 191], ["both", "OBSERVATION_MODIFIER", 19, 23], ["enthalpic", "OBSERVATION", 24, 33], ["entropic contributions", "OBSERVATION", 38, 60], ["denaturation", "OBSERVATION", 141, 153]]], ["So far the hypothesis haven't been able to decipher the folding code and therefore aren't generally able to read a sequence and predict what shape it will adopt.INTRODUCTIONThe interaction of protein surface with the surrounding water is often referred to as protein hydration layer (also sometimes called hydration shell) and is fundamental to structural stability of protein, because non-aqueous solvents in general denature proteins 13 .", [["surface", "ANATOMY", 200, 207], ["general denature proteins 13", "PROTEIN", 410, 438], ["protein surface", "TREATMENT", 192, 207], ["protein hydration layer", "TREATMENT", 259, 282], ["hydration shell", "TREATMENT", 306, 321], ["non-aqueous solvents in general denature proteins", "PROBLEM", 386, 435], ["surface", "OBSERVATION_MODIFIER", 200, 207]]], ["The hydration layer around a protein has been found to have dynamics distinct from the bulk water to a distance of 1 nm and water molecules slow down greatly when they encounter a protein 14 .", [["protein 14", "PROTEIN", 180, 190], ["The hydration layer", "TREATMENT", 0, 19], ["a protein", "TEST", 178, 187], ["hydration", "OBSERVATION_MODIFIER", 4, 13], ["layer", "OBSERVATION_MODIFIER", 14, 19]]], ["Thus, hydrophilic side chains of proteins are normally hydrogen bonded with surrounding water molecules in aqueous environments, thereby preventing the surface hydrophilic side-chains of proteins from randomly hydrogen bonding together 14,15 16 .", [["surface", "ANATOMY", 152, 159], ["hydrogen", "CHEMICAL", 55, 63], ["hydrogen", "CHEMICAL", 210, 218], ["hydrophilic side chains of proteins", "PROBLEM", 6, 41], ["normally hydrogen bonded", "PROBLEM", 46, 70], ["hydrophilic", "OBSERVATION_MODIFIER", 6, 17], ["hydrogen bonded", "OBSERVATION", 55, 70], ["water molecules", "OBSERVATION", 88, 103], ["aqueous environments", "OBSERVATION", 107, 127], ["surface", "OBSERVATION_MODIFIER", 152, 159], ["hydrophilic", "OBSERVATION_MODIFIER", 160, 171], ["hydrogen bonding", "OBSERVATION", 210, 226]]], ["This is the reason why proteins usually do not aggregate or crystallize in unsaturated aqueous solutions 17 , even though the solvent-facing surface of the proteins is usually composed of predominantly hydrophilic regions.", [["predominantly hydrophilic regions", "PROTEIN", 188, 221], ["proteins", "OBSERVATION", 156, 164], ["predominantly", "OBSERVATION_MODIFIER", 188, 201], ["hydrophilic", "OBSERVATION_MODIFIER", 202, 213]]], ["Experiments have also shown that secondary structures of protein (such as \uf061-helices and \uf062-sheets) are stabilized by hydrogen bonds between the N-H groups and C=O groups of the main chain 18, 19 .", [["N-H", "CHEMICAL", 143, 146], ["hydrogen", "CHEMICAL", 116, 124], ["N-H", "CHEMICAL", 143, 146], ["C=O", "CHEMICAL", 158, 161], ["N-H", "SIMPLE_CHEMICAL", 143, 146], ["C=O", "SIMPLE_CHEMICAL", 158, 161], ["\uf061-helices", "PROTEIN", 74, 83], ["secondary structures of protein", "PROBLEM", 33, 64], ["\uf061-helices and \uf062-sheets", "TREATMENT", 74, 96], ["hydrogen bonds", "OBSERVATION", 116, 130], ["main chain", "ANATOMY", 176, 186]]], ["This also indicates that the shielding effect of surrounding water molecules prevent hydrophilic side-chains from interfering with the formation of secondary structures during protein folding.", [["the shielding effect", "PROBLEM", 25, 45], ["surrounding water molecules", "TREATMENT", 49, 76], ["hydrophilic side-chains", "TREATMENT", 85, 108], ["secondary structures during protein folding", "PROBLEM", 148, 191], ["hydrophilic", "OBSERVATION_MODIFIER", 85, 96], ["secondary structures", "OBSERVATION", 148, 168], ["protein folding", "OBSERVATION", 176, 191]]], ["Thus, water molecules should be able to saturate the hydrogen bond formations of hydrophilic side-chains and the main chain before the protein folding 14-16 , due to water molecules have very strong polarity 20,21 .", [["hydrogen", "CHEMICAL", 53, 61], ["hydrophilic side-chains", "PROTEIN", 81, 104], ["water molecules", "PROTEIN", 166, 181], ["the protein folding", "TEST", 131, 150], ["water molecules", "PROBLEM", 166, 181], ["hydrogen bond", "OBSERVATION", 53, 66], ["hydrophilic", "OBSERVATION_MODIFIER", 81, 92], ["chains", "ANATOMY_MODIFIER", 98, 104], ["main", "ANATOMY_MODIFIER", 113, 117], ["chain", "ANATOMY_MODIFIER", 118, 123]]], ["This is the reason why intrinsically disordered proteins (IDPs) and regions (IDRs) can make up a significant part of the proteome 22 .", [["IDRs", "GENE_OR_GENE_PRODUCT", 77, 81], ["intrinsically disordered proteins", "PROTEIN", 23, 56], ["IDPs", "PROTEIN", 58, 62], ["IDRs", "PROTEIN", 77, 81], ["intrinsically disordered proteins", "PROBLEM", 23, 56]]], ["Before the folding of secondary structures, the early steps of protein folding may be not directly dominated by the formation of intramolecular hydrogen bonds, due to the shielding effect of surrounding water molecules.", [["hydrogen", "CHEMICAL", 144, 152], ["secondary structures", "PROBLEM", 22, 42], ["protein folding", "PROBLEM", 63, 78], ["intramolecular hydrogen bonds", "PROBLEM", 129, 158], ["the shielding effect", "PROBLEM", 167, 187], ["surrounding water molecules", "PROBLEM", 191, 218], ["secondary structures", "OBSERVATION", 22, 42], ["early", "OBSERVATION_MODIFIER", 48, 53], ["protein folding", "OBSERVATION", 63, 78], ["intramolecular hydrogen bonds", "OBSERVATION", 129, 158], ["water molecules", "OBSERVATION", 203, 218]]], ["Thus, this problem may lie in our lack of understanding of the hydrophobic interaction among neighbored side-chains of unfolded proteins at early steps of the folding, given the lack of awareness of the importance of the shielding effect of water.INTRODUCTIONAlmost all experimentally determined native tertiary structures of water-soluble proteins have a hydrophobic core in which hydrophobic side-chains are buried from water 23-25 .", [["water", "SIMPLE_CHEMICAL", 241, 246], ["neighbored side-chains", "PROTEIN", 93, 115], ["unfolded proteins", "PROTEIN", 119, 136], ["water-soluble proteins", "PROTEIN", 326, 348], ["unfolded proteins", "PROBLEM", 119, 136], ["the shielding effect of water", "TREATMENT", 217, 246], ["tertiary", "OBSERVATION_MODIFIER", 303, 311]]], ["Incidentally, polar residues interact favorably with water, thus the solvent-facing surface of the peptide is usually composed of predominantly hydrophilic regions 26 .", [["water", "SIMPLE_CHEMICAL", 53, 58], ["polar residues", "OBSERVATION", 14, 28], ["predominantly", "OBSERVATION_MODIFIER", 130, 143], ["hydrophilic", "OBSERVATION_MODIFIER", 144, 155]]], ["Minimizing the number of hydrophobic side-chains exposed to water, namely, hydrophobic collapse thus has been regarded as one of the most important driving force for protein folding processs 27 .", [["water", "SIMPLE_CHEMICAL", 60, 65], ["hydrophobic collapse", "PROBLEM", 75, 95], ["protein folding processs", "PROBLEM", 166, 190], ["collapse", "OBSERVATION", 87, 95]]], ["Experimental methods such as laser temperature jumping technology and single molecule experimental techniques have revealed that protein folding first leads to the formation of secondary structures (\u03b1-helices and \u03b2-strands), and the tertiary structure is formed by the folding of secondary structures 28 .", [["\u03b1-helices", "PROTEIN", 199, 208], ["\u03b2-strands", "PROTEIN", 213, 222], ["Experimental methods", "TREATMENT", 0, 20], ["laser temperature jumping technology", "TREATMENT", 29, 65], ["single molecule experimental techniques", "TEST", 70, 109], ["protein folding", "PROBLEM", 129, 144], ["protein folding", "OBSERVATION", 129, 144], ["secondary", "OBSERVATION_MODIFIER", 177, 186], ["tertiary", "OBSERVATION_MODIFIER", 233, 241], ["secondary", "OBSERVATION_MODIFIER", 280, 289]]], ["It is likely that the nascent polypeptide forms initial secondary structure through creating localized regions of predominantly hydrophobic residues due to hydrophobic effect 29 .", [["the nascent polypeptide forms", "PROBLEM", 18, 47], ["predominantly hydrophobic residues", "PROBLEM", 114, 148], ["hydrophobic effect", "PROBLEM", 156, 174], ["is likely", "UNCERTAINTY", 3, 12], ["secondary structure", "OBSERVATION", 56, 75], ["predominantly", "OBSERVATION_MODIFIER", 114, 127], ["hydrophobic residues", "OBSERVATION", 128, 148], ["hydrophobic effect", "OBSERVATION", 156, 174]]], ["The secondary structures interacts with water, thus placing thermodynamic pressures on these regions which then aggregate or \"collapse\" into a tertiary conformation with a hydrophobic core 26 .", [["water", "SIMPLE_CHEMICAL", 40, 45], ["thermodynamic pressures", "TEST", 60, 83], ["\"collapse\"", "PROBLEM", 125, 135], ["a hydrophobic core", "TREATMENT", 170, 188], ["pressures", "OBSERVATION_MODIFIER", 74, 83], ["collapse", "OBSERVATION", 126, 134]]], ["Therefore, protein folding is highly dependent on folding of secondary structures as the way to hierarchically pave a native folding pathway that lead to formation of correct tertiary structures and cause conformational changes leading energetically downhill toward the native globular structure that possesses the minimum free energy.", [["native globular structure", "PROTEIN", 270, 295], ["protein folding", "PROBLEM", 11, 26], ["secondary structures", "PROBLEM", 61, 81], ["correct tertiary structures", "PROBLEM", 167, 194], ["conformational changes", "PROBLEM", 205, 227], ["protein folding", "OBSERVATION", 11, 26], ["highly dependent", "OBSERVATION_MODIFIER", 30, 46], ["globular structure", "OBSERVATION", 277, 295], ["minimum", "OBSERVATION_MODIFIER", 315, 322], ["free energy", "OBSERVATION", 323, 334]]], ["Thus, decipher of the folding codes in amino acid sequence that dictate the secondary structures formation should be regarded as a key to crack the protein folding problem.", [["amino acid", "CHEMICAL", 39, 49], ["amino acid", "CHEMICAL", 39, 49], ["amino acid", "AMINO_ACID", 39, 49], ["amino acid sequence", "PROTEIN", 39, 58], ["amino acid sequence", "TEST", 39, 58], ["the secondary structures formation", "PROBLEM", 72, 106], ["the protein folding problem", "PROBLEM", 144, 171], ["protein folding", "OBSERVATION", 148, 163]]], ["Among types of secondary structure in proteins, the \u03b2-sheet is the most prevalent.", [["\u03b2-sheet", "PROTEIN", 52, 59], ["secondary structure in proteins", "PROBLEM", 15, 46], ["secondary structure", "OBSERVATION", 15, 34], ["most prevalent", "OBSERVATION_MODIFIER", 67, 81]]], ["If the controlling mechanism for \u03b2-sheet folding can be revealed, it would remarkably promote solution of the protein folding problem.INTRODUCTIONCurrently, several hypotheses has been proposed for explaining the folding mechanism of \u03b2-sheet.", [["\u03b2-sheet", "SIMPLE_CHEMICAL", 33, 40], ["\u03b2-sheet folding", "PROBLEM", 33, 48], ["the protein folding problem", "PROBLEM", 106, 133]]], ["The hydrophobic zipper hypothesis indicates that a hairpin is first formed before hydrophobic contacts act as constraints which bring other contacts into spatial proximity 30 .", [["The hydrophobic zipper hypothesis", "PROBLEM", 0, 33], ["a hairpin", "PROBLEM", 49, 58], ["hydrophobic zipper", "OBSERVATION", 4, 22], ["hairpin", "OBSERVATION", 51, 58]]], ["Munoz et al proposed that the folding of a \u03b2-hairpin initiates at the turn and propagates towards the tails 31 .", [["\u03b2-hairpin", "GENE_OR_GENE_PRODUCT", 43, 52], ["\u03b2-hairpin", "PROTEIN", 43, 52], ["tails 31", "PROTEIN", 102, 110], ["a \u03b2-hairpin", "TREATMENT", 41, 52]]], ["In particular, they found that stabilization through hydrophobic contacts between residues and hydrogen bonding interaction are important for the formation of the \u03b2hairpin.", [["hydrogen", "CHEMICAL", 95, 103], ["\u03b2hairpin", "CHEMICAL", 163, 171], ["hydrogen", "SIMPLE_CHEMICAL", 95, 103], ["\u03b2hairpin", "SIMPLE_CHEMICAL", 163, 171], ["\u03b2hairpin", "PROTEIN", 163, 171], ["hydrophobic contacts between residues", "PROBLEM", 53, 90], ["hydrogen bonding interaction", "TREATMENT", 95, 123], ["the \u03b2hairpin", "TREATMENT", 159, 171], ["stabilization", "OBSERVATION", 31, 44], ["hydrogen bonding", "OBSERVATION", 95, 111]]], ["Petrovich et al. 32 studied a 37-residue triple-stranded \u03b2-sheet protein via MD simulations.", [["37-residue triple-stranded \u03b2-sheet protein", "PROTEIN", 30, 72]]], ["Their results indicate that a \u03b2-hairpin first appears before the third strand joins in to complete the \u03b2-sheet at the end of the folding process.", [["\u03b2-hairpin", "CHEMICAL", 30, 39], ["\u03b2-hairpin", "PROTEIN", 30, 39], ["\u03b2-sheet", "DNA", 103, 110], ["a \u03b2-hairpin", "TREATMENT", 28, 39]]], ["They ascribe the folding mechanism of the \u03b2-sheet to a combination of initial hydrophobic collapse and zipper mechanism, which serve to nucleate the hairpin formation.", [["hairpin", "CELLULAR_COMPONENT", 149, 156], ["\u03b2-sheet", "PROTEIN", 42, 49], ["initial hydrophobic collapse and zipper mechanism", "PROBLEM", 70, 119], ["hydrophobic collapse", "OBSERVATION", 78, 98], ["zipper mechanism", "OBSERVATION", 103, 119], ["hairpin formation", "OBSERVATION", 149, 166]]], ["Notably, all the three mechanisms above suggest that the folding of a \u03b2-sheet is necessarily preceded by the occurrence of a \u03b2-turn.", [["\u03b2-turn", "PROTEIN", 125, 131], ["a \u03b2-sheet", "TREATMENT", 68, 77]]], ["By mechanism, we mean a narrative that explains how the time evolution of a \u03b2-sheet folding development derives from its amino acid sequence and solution conditions.Results\u03b2-sheet folding highly depends on the temperature 5 , where \u03b2-sheets can form in as little as 1 microsecond after the temperature jumping 33-35 . \u03b2-sheets consist of \u03b2-strands connected laterally by at least three backbone hydrogen bonds, forming a generally pleated sheet.", [["\u03b2-sheets", "ANATOMY", 318, 326], ["amino acid", "CHEMICAL", 121, 131], ["amino acid", "CHEMICAL", 121, 131], ["hydrogen", "CHEMICAL", 395, 403], ["amino acid", "AMINO_ACID", 121, 131], ["\u03b2-strands", "PROTEIN", 338, 347], ["a \u03b2-sheet folding development", "TREATMENT", 74, 103], ["its amino acid sequence and solution conditions", "TREATMENT", 117, 164], ["the temperature", "TEST", 286, 301], ["hydrogen bonds", "OBSERVATION", 395, 409]]], ["A \u03b2-strand is a stretch of polypeptide chain typically 3 or more amino acids long with backbone in an extended conformation.", [["amino acids", "CHEMICAL", 65, 76], ["amino acids", "CHEMICAL", 65, 76], ["amino acids", "AMINO_ACID", 65, 76], ["a stretch of polypeptide chain", "TREATMENT", 14, 44], ["amino acids", "TREATMENT", 65, 76], ["backbone", "TREATMENT", 87, 95]]], ["Because it is difficult to explain how the folding process of a \u03b2-sheet (i.e., laterally hydrogen bonding process of segments of unfolded polypeptide) is accompanied by stretching process of the segments of polypeptide into \u03b2-strands.", [["hydrogen", "CHEMICAL", 89, 97], ["unfolded polypeptide", "PROTEIN", 129, 149], ["\u03b2-strands", "PROTEIN", 224, 233], ["a \u03b2-sheet", "TREATMENT", 62, 71], ["laterally hydrogen bonding process", "TREATMENT", 79, 113], ["unfolded polypeptide", "TREATMENT", 129, 149], ["stretching", "OBSERVATION", 169, 179]]], ["There must be mechanisms that allow polypeptide chain segments to find the states of \u03b2-strands encoded in their sequence.", [["polypeptide chain segments", "PROTEIN", 36, 62], ["\u03b2-strands", "PROTEIN", 85, 94], ["polypeptide chain segments", "TREATMENT", 36, 62]]], ["There also must be some physical effects providing the long-range attractive force among \u03b2strands for the \u03b2-sheets formation.ResultsExperimental evidences of the folding of unfolded proteins provide corroboration for a hypothesis that folding initiation sites arise from hydrophobic interactions 11,36 .", [["\u03b2-sheets", "ANATOMY", 106, 114], ["\u03b2strands", "SIMPLE_CHEMICAL", 89, 97], ["\u03b2-sheets", "TISSUE", 106, 114], ["unfolded proteins", "PROTEIN", 173, 190], ["the long-range attractive force", "TREATMENT", 51, 82], ["the \u03b2-sheets formation", "TREATMENT", 102, 124], ["unfolded proteins", "PROBLEM", 173, 190], ["a hypothesis", "PROBLEM", 217, 229]]], ["The folding of \u03b2-strands and \u03b2-sheets may be driven by hydrophobic interactions, as the nascent polypeptide may form initial primary structure through creating localized regions of predominantly hydrophobic residues 29 .", [["\u03b2-sheets", "SIMPLE_CHEMICAL", 29, 37], ["\u03b2-strands", "PROTEIN", 15, 24], ["hydrophobic residues 29", "PROTEIN", 195, 218], ["\u03b2-strands and \u03b2-sheets", "TREATMENT", 15, 37], ["the nascent polypeptide", "TREATMENT", 84, 107], ["predominantly hydrophobic residues", "PROBLEM", 181, 215], ["predominantly", "OBSERVATION_MODIFIER", 181, 194], ["hydrophobic residues", "OBSERVATION", 195, 215]]], ["Hydrophobic effect most likely can contribute to the formation of \u03b2-sheets through multistage aggregations of neighbored hydrophobic groups of unfolded polypeptides, which lead to the formation of \u03b2-strands, and consequently fold into \u03b2-sheets.", [["\u03b2-strands", "PROTEIN", 197, 206], ["Hydrophobic effect", "PROBLEM", 0, 18], ["\u03b2-sheets", "PROBLEM", 66, 74], ["unfolded polypeptides", "PROBLEM", 143, 164], ["\u03b2-strands", "PROBLEM", 197, 206], ["most likely", "UNCERTAINTY", 19, 30], ["unfolded polypeptides", "OBSERVATION", 143, 164]]], ["A \u03b2-sheet always is amphipathic in nature, namely, contain hydrophilic surface areas and hydrophobic surface areas.", [["surface", "ANATOMY", 71, 78], ["amphipathic", "OBSERVATION", 20, 31], ["hydrophilic", "OBSERVATION_MODIFIER", 59, 70], ["surface", "OBSERVATION_MODIFIER", 71, 78], ["hydrophobic", "OBSERVATION_MODIFIER", 89, 100], ["surface", "OBSERVATION_MODIFIER", 101, 108]]], ["Note that the hydrophobic attraction (due to the hydrophobic effect) among adjacent side-chains on one side or the other side of a \u03b2-strand may be common in experimentally determined protein structures, which should be considered as an evidence for hydrophobic effect dominating the formation of \u03b2-strands.ResultsIt has previously been noted that many amino acid side chains contain considerable nonpolar sections, even if they also contain polar or charged groups 36 .", [["sections", "ANATOMY", 405, 413], ["amino acid", "CHEMICAL", 352, 362], ["amino acid", "CHEMICAL", 352, 362], ["amino acid", "AMINO_ACID", 352, 362], ["\u03b2-strands", "PROTEIN", 296, 305], ["the hydrophobic attraction", "PROBLEM", 10, 36], ["the hydrophobic effect", "PROBLEM", 45, 67], ["hydrophobic effect", "PROBLEM", 249, 267], ["\u03b2-strands", "PROBLEM", 296, 305], ["many amino acid side chains", "TREATMENT", 347, 374], ["considerable nonpolar sections", "TREATMENT", 383, 413], ["hydrophobic effect", "OBSERVATION", 249, 267], ["considerable", "OBSERVATION_MODIFIER", 383, 395], ["nonpolar sections", "OBSERVATION", 396, 413], ["polar", "OBSERVATION_MODIFIER", 441, 446]]], ["Namely, hydrophilic side-chains are not completely hydrophilic.", [["completely hydrophilic", "PROBLEM", 40, 62], ["hydrophilic", "OBSERVATION_MODIFIER", 8, 19], ["not", "UNCERTAINTY", 36, 39], ["completely", "OBSERVATION_MODIFIER", 40, 50], ["hydrophilic", "OBSERVATION", 51, 62]]], ["The hydrophilicity of hydrophilic side-chains is normally expressed by C=O or N-H2 groups at their ends, and the other portions of hydrophilic side-chains are hydrophobic, because the molecular structures of these portions are basically alkyl and benzene ring structures, as shown in Figure 1 .", [["N-H2", "CHEMICAL", 78, 82], ["alkyl", "CHEMICAL", 237, 242], ["benzene", "CHEMICAL", 247, 254], ["C=O", "CHEMICAL", 71, 74], ["N-H2", "CHEMICAL", 78, 82], ["benzene", "CHEMICAL", 247, 254], ["C=O", "SIMPLE_CHEMICAL", 71, 74], ["N-H2", "SIMPLE_CHEMICAL", 78, 82], ["alkyl", "SIMPLE_CHEMICAL", 237, 242], ["benzene", "SIMPLE_CHEMICAL", 247, 254], ["hydrophobic", "PROBLEM", 159, 170], ["basically alkyl and benzene ring structures", "PROBLEM", 227, 270], ["hydrophilicity", "OBSERVATION_MODIFIER", 4, 18], ["hydrophilic", "OBSERVATION_MODIFIER", 22, 33], ["chains", "ANATOMY_MODIFIER", 39, 45], ["hydrophilic", "OBSERVATION_MODIFIER", 131, 142], ["hydrophobic", "OBSERVATION_MODIFIER", 159, 170], ["alkyl", "OBSERVATION_MODIFIER", 237, 242], ["benzene ring", "OBSERVATION", 247, 259]]], ["Folding initiation sites of \u03b2-brands might therefore contain not only accepted \"hydrophobic\" amino acids, but also larger hydrophilic side-chains 36 .", [["amino acids", "CHEMICAL", 93, 104], ["amino acids", "CHEMICAL", 93, 104], ["\u03b2-brands", "GENE_OR_GENE_PRODUCT", 28, 36], ["amino acids", "AMINO_ACID", 93, 104], ["\u03b2-brands", "PROTEIN", 28, 36], ["Folding initiation sites of \u03b2-brands", "PROBLEM", 0, 36], ["hydrophobic\" amino acids", "TREATMENT", 80, 104], ["larger", "OBSERVATION_MODIFIER", 115, 121], ["hydrophilic", "OBSERVATION_MODIFIER", 122, 133]]], ["If formation of \u03b2-brands is driven by hydrophobic interactions among neighbored side-chains of unfolded polypeptide, we should be able to find experimental evidence of the hydrophobic interaction in the Protein Data Bank (PDB) achieves, due to hundreds of thousands of \u03b2-sheet structures have been experimentally determined.", [["\u03b2-brands", "PROTEIN", 16, 24], ["neighbored side-chains", "PROTEIN", 69, 91], ["\u03b2-brands", "PROBLEM", 16, 24], ["unfolded polypeptide", "PROBLEM", 95, 115], ["the hydrophobic interaction", "PROBLEM", 168, 195]]], ["In an aqueous environment, the water molecules tend to segregate around the \"hydrophobic\" side chains of the nascent protein, creating hydration shells of ordered water molecules 37 .", [["nascent protein", "PROTEIN", 109, 124], ["ordered water molecules 37", "PROTEIN", 155, 181], ["the water molecules", "TREATMENT", 27, 46], ["the \"hydrophobic\" side chains", "TREATMENT", 72, 101], ["creating hydration shells of ordered water molecules", "TREATMENT", 126, 178]]], ["An ordering of water molecules around a hydrophobic region increases order in a system and therefore contributes a negative change in entropy (less entropy in the system) 38 .", [["water molecules", "PROTEIN", 15, 30], ["hydrophobic region", "PROTEIN", 40, 58], ["An ordering of water molecules", "TREATMENT", 0, 30], ["a hydrophobic region", "PROBLEM", 38, 58], ["a negative change in entropy", "PROBLEM", 113, 141], ["negative", "OBSERVATION", 115, 123], ["change", "OBSERVATION_MODIFIER", 124, 130]]], ["The water molecules are fixed in these water cages which drives the hydrophobic collapse, or the aggregation of the hydrophobic groups.", [["The water molecules", "TREATMENT", 0, 19], ["these water cages", "TREATMENT", 33, 50], ["the hydrophobic collapse", "PROBLEM", 64, 88], ["water molecules", "OBSERVATION", 4, 19], ["hydrophobic collapse", "OBSERVATION", 68, 88]]], ["Thus, the hydrophobic interaction among neighbored side-chains in sequence can introduce entropy back to the system via the breaking of their water cages which frees the ordered water molecules 39 .", [["neighbored side-chains", "PROTEIN", 40, 62], ["ordered water molecules 39", "PROTEIN", 170, 196], ["their water cages", "TREATMENT", 136, 153], ["the ordered water molecules", "TREATMENT", 166, 193]]], ["If hydrophobic interactions among neighbor sidechains in amino acid sequences provide the structural stability for \u03b2-brands formation, we must can find out that the phenomenon of a large hydrophobic surface area covering on one side or the other side of a \u03b2-strand is prevail in almost all experimentally determined \u03b2-sheets.", [["surface area", "ANATOMY", 199, 211], ["amino acid", "CHEMICAL", 57, 67], ["amino acid", "CHEMICAL", 57, 67], ["amino acid", "AMINO_ACID", 57, 67], ["\u03b2-brands", "SIMPLE_CHEMICAL", 115, 123], ["hydrophobic interactions", "PROBLEM", 3, 27], ["amino acid sequences", "TEST", 57, 77], ["\u03b2-brands formation", "PROBLEM", 115, 133], ["the phenomenon", "PROBLEM", 161, 175], ["a large hydrophobic surface area", "TREATMENT", 179, 211], ["large", "OBSERVATION_MODIFIER", 181, 186], ["hydrophobic", "OBSERVATION_MODIFIER", 187, 198], ["surface", "OBSERVATION_MODIFIER", 199, 206]]], ["If the phenomenon of hydrophobic side-chains tend to cluster together on one side of adjacent \u03b2-strands of a \u03b2-sheet is prevail in almost all experimentally determined \u03b2-sheets, we may demonstrate that the hydrophobic interaction among the neighbored side-chains responsible for \u03b2-sheet-folding initiation.ResultsThe capability of an amino acid residue to get involved in the hydrophobic attraction with neighbored residues in sequence can be evaluated by the exposed alkyl and benzene ring structures of the side-chain, as shown in Fig.1 , in which 20 kinds of amino acid residue are divided into four groups 40 .", [["amino acid", "CHEMICAL", 334, 344], ["alkyl", "CHEMICAL", 468, 473], ["benzene", "CHEMICAL", 478, 485], ["amino acid", "CHEMICAL", 562, 572], ["amino acid", "CHEMICAL", 334, 344], ["benzene", "CHEMICAL", 478, 485], ["amino acid", "CHEMICAL", 562, 572], ["amino acid", "AMINO_ACID", 334, 344], ["alkyl", "SIMPLE_CHEMICAL", 468, 473], ["benzene", "SIMPLE_CHEMICAL", 478, 485], ["amino acid", "AMINO_ACID", 562, 572], ["residue", "AMINO_ACID", 573, 580], ["\u03b2-sheet", "PROTEIN", 109, 116], ["neighbored side-chains", "PROTEIN", 240, 262], ["the hydrophobic interaction", "PROBLEM", 202, 229], ["\u03b2-sheet-folding initiation", "TREATMENT", 279, 305], ["an amino acid residue", "PROBLEM", 331, 352], ["neighbored residues in sequence", "PROBLEM", 404, 435], ["the exposed alkyl and benzene ring structures", "TREATMENT", 456, 501], ["amino acid residue", "TREATMENT", 562, 580], ["benzene ring", "OBSERVATION", 478, 490], ["chain", "ANATOMY_MODIFIER", 514, 519], ["amino acid residue", "OBSERVATION", 562, 580]]], ["Arginine-R, Histidine-H, and Lysine-K can involve in hydrophobic interaction with adjacent hydrophobic side-chains in sequence due to their long hydrophilic side chains contain long nonpolar alkyl structures, see Fig. 2C and 2D.", [["Arginine", "CHEMICAL", 0, 8], ["Histidine-H", "CHEMICAL", 12, 23], ["Lysine-K", "CHEMICAL", 29, 37], ["Arginine", "CHEMICAL", 0, 8], ["Histidine", "CHEMICAL", 12, 21], ["H", "CHEMICAL", 22, 23], ["Lysine-K", "CHEMICAL", 29, 37], ["Arginine-R", "SIMPLE_CHEMICAL", 0, 10], ["Histidine-H", "SIMPLE_CHEMICAL", 12, 23], ["Lysine-K", "SIMPLE_CHEMICAL", 29, 37], ["hydrophobic side-chains", "PROTEIN", 91, 114], ["Arginine", "TEST", 0, 8], ["Histidine-H", "TREATMENT", 12, 23], ["Lysine", "TREATMENT", 29, 35], ["adjacent hydrophobic side-chains", "TREATMENT", 82, 114], ["their long hydrophilic side chains", "PROBLEM", 134, 168], ["long nonpolar alkyl structures", "PROBLEM", 177, 207], ["long", "OBSERVATION_MODIFIER", 177, 181], ["nonpolar alkyl", "OBSERVATION", 182, 196]]], ["Noting that every \u03b2-strand is characterized by a large hydrophobic surface fully covering one side of the \u03b2-brand (the inner side), and caused each side-chains is parallel to every other side-chain of each strands due to the hydrophobic interaction.", [["surface", "ANATOMY", 67, 74], ["\u03b2-brand", "PROTEIN", 106, 113], ["a large hydrophobic surface", "TREATMENT", 47, 74], ["the hydrophobic interaction", "PROBLEM", 221, 248], ["large", "OBSERVATION_MODIFIER", 49, 54], ["hydrophobic", "OBSERVATION_MODIFIER", 55, 66], ["surface", "OBSERVATION_MODIFIER", 67, 74]]], ["Parallel distribution of adjacent peptide planes of these \u03b2-strands also causes adjacent sidechains to distribute on opposite sides of the main chain and each carbonyl oxygen atom in a peptide plane tends to hydrogen bond with an amide hydrogen atom in an adjacent peptide plane due to the electrostatic attractions between them, except the Proline-P 15 .", [["oxygen", "CHEMICAL", 168, 174], ["Proline", "CHEMICAL", 341, 348], ["carbonyl", "CHEMICAL", 159, 167], ["oxygen", "CHEMICAL", 168, 174], ["hydrogen", "CHEMICAL", 208, 216], ["amide", "CHEMICAL", 230, 235], ["hydrogen", "CHEMICAL", 236, 244], ["Proline-P", "CHEMICAL", 341, 350], ["carbonyl oxygen atom", "SIMPLE_CHEMICAL", 159, 179], ["amide hydrogen atom", "SIMPLE_CHEMICAL", 230, 249], ["Proline-P 15", "PROTEIN", 341, 353], ["these \u03b2-strands", "PROBLEM", 52, 67], ["adjacent sidechains", "PROBLEM", 80, 99], ["each carbonyl oxygen atom", "TREATMENT", 154, 179], ["an amide hydrogen atom", "TREATMENT", 227, 249], ["an adjacent peptide plane", "TREATMENT", 253, 278], ["peptide planes", "OBSERVATION", 34, 48], ["strands", "OBSERVATION", 60, 67], ["sidechains", "OBSERVATION_MODIFIER", 89, 99], ["main", "ANATOMY_MODIFIER", 139, 143], ["chain", "ANATOMY_MODIFIER", 144, 149], ["carbonyl", "OBSERVATION", 159, 167], ["oxygen atom", "OBSERVATION", 168, 179], ["hydrogen bond", "OBSERVATION", 208, 221], ["electrostatic attractions", "OBSERVATION", 290, 315]]], ["Parallel distribution of neighbored \"hydrophobic\" sidechains in a \u03b2-strand can effectively introduce entropy back to the system via the merging of the water cages of the side-chains which frees the ordered water molecules, see Fig.2D .", [["ordered water molecules", "PROTEIN", 198, 221], [".2D", "PROTEIN", 230, 233], ["neighbored \"hydrophobic\" sidechains", "PROBLEM", 25, 60], ["the water cages", "TREATMENT", 147, 162], ["distribution", "OBSERVATION_MODIFIER", 9, 21]]], ["Thus, \u03b2-strand should be considered as a metastable state for unfolded polypeptides corresponds to its free energy minimum under the solution conditions, creating localized regions of predominantly hydrophobic side-chains 15 .ResultsWe use another small-molecule protein (PBDID:1OUR) as the example to demonstrate the role of hydrophobic interactions among neighbored side-chains played in formation of \u03b2-strands, \u03b2-turns and \u03b2sheets, see Fig.3 .", [["\u03b2-strands", "SIMPLE_CHEMICAL", 403, 412], ["\u03b2-turns", "SIMPLE_CHEMICAL", 414, 421], ["\u03b2sheets", "SIMPLE_CHEMICAL", 426, 433], ["hydrophobic side-chains 15", "PROTEIN", 198, 224], ["small-molecule protein", "PROTEIN", 248, 270], ["PBDID", "PROTEIN", 272, 277], ["1OUR", "PROTEIN", 278, 282], ["neighbored side-chains", "PROTEIN", 357, 379], ["\u03b2-strands", "PROTEIN", 403, 412], ["\u03b2-turns", "PROTEIN", 414, 421], ["\u03b2sheets", "PROTEIN", 426, 433], ["Fig.3", "PROTEIN", 439, 444], ["unfolded polypeptides", "PROBLEM", 62, 83], ["the solution conditions", "TREATMENT", 129, 152], ["predominantly", "OBSERVATION_MODIFIER", 184, 197], ["hydrophobic", "OBSERVATION_MODIFIER", 198, 209]]], ["The protein is mainly composed with \u03b2-strands and 10 \u03b2-turns.", [["\u03b2-strands", "PROTEIN", 36, 45], ["\u03b2", "PROTEIN", 53, 54], ["\u03b2-strands", "TREATMENT", 36, 45]]], ["Every \u03b2-strand of the protein is also characterized by a large hydrophobic surface fully covering one side or the other side of the \u03b2-brand, see Fig.3A .", [["surface", "ANATOMY", 75, 82], ["\u03b2-brand", "PROTEIN", 132, 139], [".3A", "PROTEIN", 148, 151], ["a large hydrophobic surface", "TREATMENT", 55, 82], ["large", "OBSERVATION_MODIFIER", 57, 62], ["hydrophobic", "OBSERVATION_MODIFIER", 63, 74], ["surface", "OBSERVATION_MODIFIER", 75, 82]]], ["Aspartate-D, Asparagine-N, Serine-S, Proline-P, Glycine-G most likely contribute to formation of \u03b2-turns in protein folding, due to the other neighbored side-chains in amino acid sequence tend to hydrophobic attract with each other through bypassing these residues (see Fig.1d ).ResultsThereby, Aspartate-D, Asparagine-N, Serine-S, Proline-P, Glycine-G can be classified as a hydrophobic blocking (RB) group.", [["Aspartate", "CHEMICAL", 0, 9], ["Asparagine", "CHEMICAL", 13, 23], ["Proline", "CHEMICAL", 37, 44], ["amino acid", "CHEMICAL", 168, 178], ["Aspartate", "CHEMICAL", 295, 304], ["Asparagine-N, Serine-S, Proline-P, Glycine-G", "CHEMICAL", 308, 352], ["Aspartate", "CHEMICAL", 0, 9], ["Asparagine", "CHEMICAL", 13, 23], ["N", "CHEMICAL", 24, 25], ["Serine", "CHEMICAL", 27, 33], ["S", "CHEMICAL", 34, 35], ["Proline", "CHEMICAL", 37, 44], ["Glycine-G", "CHEMICAL", 48, 57], ["amino acid", "CHEMICAL", 168, 178], ["Aspartate", "CHEMICAL", 295, 304], ["Asparagine", "CHEMICAL", 308, 318], ["N", "CHEMICAL", 319, 320], ["Serine", "CHEMICAL", 322, 328], ["S", "CHEMICAL", 329, 330], ["Proline", "CHEMICAL", 332, 339], ["Glycine-G", "CHEMICAL", 343, 352], ["Aspartate-D", "SIMPLE_CHEMICAL", 0, 11], ["Asparagine-N", "SIMPLE_CHEMICAL", 13, 25], ["Serine-S", "SIMPLE_CHEMICAL", 27, 35], ["Proline-P", "SIMPLE_CHEMICAL", 37, 46], ["Glycine-G", "SIMPLE_CHEMICAL", 48, 57], ["\u03b2-turns", "SIMPLE_CHEMICAL", 97, 104], ["amino acid", "AMINO_ACID", 168, 178], ["Aspartate-D", "SIMPLE_CHEMICAL", 295, 306], ["Asparagine-N", "SIMPLE_CHEMICAL", 308, 320], ["Serine-S", "SIMPLE_CHEMICAL", 322, 330], ["Proline-P", "SIMPLE_CHEMICAL", 332, 341], ["Glycine-G", "SIMPLE_CHEMICAL", 343, 352], ["\u03b2-turns", "PROTEIN", 97, 104], ["neighbored side-chains", "PROTEIN", 142, 164], ["Aspartate", "TEST", 0, 9], ["Asparagine", "TEST", 13, 23], ["Serine", "TREATMENT", 27, 33], ["Proline-P, Glycine-G", "TREATMENT", 37, 57], ["\u03b2-turns in protein folding", "PROBLEM", 97, 123], ["amino acid sequence", "TREATMENT", 168, 187], ["Aspartate", "TEST", 295, 304], ["Asparagine", "TEST", 308, 318], ["Serine-S", "TREATMENT", 322, 330], ["Proline-P, Glycine-G", "TREATMENT", 332, 352], ["a hydrophobic blocking (RB) group", "TREATMENT", 374, 407]]], ["It is worth noting that almost all the 10 \u03b2-turns of the protein are composed with two or more residues of Aspartate-D, Asparagine-N, Serine-S, Proline-P, Glycine-G, see Fig.3A and 3B.", [["Aspartate", "CHEMICAL", 107, 116], ["Asparagine", "CHEMICAL", 120, 130], ["Aspartate", "CHEMICAL", 107, 116], ["Asparagine", "CHEMICAL", 120, 130], ["N", "CHEMICAL", 131, 132], ["Serine", "CHEMICAL", 134, 140], ["S", "CHEMICAL", 141, 142], ["Proline", "CHEMICAL", 144, 151], ["Glycine-G", "CHEMICAL", 155, 164], ["Aspartate-D", "SIMPLE_CHEMICAL", 107, 118], ["Asparagine-N", "SIMPLE_CHEMICAL", 120, 132], ["Serine-S", "SIMPLE_CHEMICAL", 134, 142], ["Proline-P", "SIMPLE_CHEMICAL", 144, 153], ["Glycine-G", "SIMPLE_CHEMICAL", 155, 164], ["\u03b2", "PROTEIN", 42, 43], ["the protein", "TREATMENT", 53, 64], ["Aspartate", "TEST", 107, 116], ["Asparagine", "TEST", 120, 130], ["Proline", "TREATMENT", 144, 151], ["Glycine", "TREATMENT", 155, 162]]], ["This indicates that two or more adjacent RB residues can effectively block hydrophobic attraction among neighbored side-chains in sequence at both side of a strand.", [["RB residues", "PROTEIN", 41, 52], ["neighbored side-chains", "PROTEIN", 104, 126], ["more adjacent RB residues", "PROBLEM", 27, 52], ["RB residues", "OBSERVATION", 41, 52], ["strand", "OBSERVATION", 157, 163]]], ["We plot the protein structure into three parts according to three segments of the amino acid sequence to illustrate the hydrophobic collapse among neighbored \u03b2-strands in sequence, see Fig.3B and 3C.", [["amino acid", "CHEMICAL", 82, 92], ["amino acid", "CHEMICAL", 82, 92], ["amino acid", "AMINO_ACID", 82, 92], ["amino acid sequence", "PROTEIN", 82, 101], ["neighbored \u03b2-strands", "PROTEIN", 147, 167], ["Fig.3B", "PROTEIN", 185, 191], ["the amino acid sequence", "TEST", 78, 101], ["the hydrophobic collapse", "PROBLEM", 116, 140], ["protein structure", "OBSERVATION", 12, 29], ["hydrophobic collapse", "OBSERVATION", 120, 140]]], ["Hydrophobic interactions among these \u03b2-strands may drive them collapse together through bending the unfolded polypeptide at the location of these RB residues, namely, bypassing these RB residues at the turns to achieve the hydrophobic collapse.", [["RB residues", "PROTEIN", 146, 157], ["RB", "PROTEIN", 183, 185], ["Hydrophobic interactions", "PROBLEM", 0, 24], ["them collapse", "PROBLEM", 57, 70], ["the unfolded polypeptide", "PROBLEM", 96, 120], ["the hydrophobic collapse", "PROBLEM", 219, 243], ["collapse", "OBSERVATION", 62, 70], ["RB residues", "OBSERVATION", 146, 157], ["RB residues", "OBSERVATION", 183, 194], ["hydrophobic", "OBSERVATION_MODIFIER", 223, 234], ["collapse", "OBSERVATION", 235, 243]]], ["This also indicates that hydrophobic attraction among neighbored side-chains drive the \u03b2-strands formation and then cause hydrophobic attraction among the neighbored \u03b2-strands and formation of the \u03b2-sheets, due to \u03b2-strands formation create localized regions of predominantly hydrophobic residues and place thermodynamic pressures on these regions under the solution conditions.", [["\u03b2-strands", "SIMPLE_CHEMICAL", 87, 96], ["\u03b2-strands", "SIMPLE_CHEMICAL", 214, 223], ["neighbored side-chains", "PROTEIN", 54, 76], ["neighbored \u03b2-strands", "PROTEIN", 155, 175], ["\u03b2-sheets", "PROTEIN", 197, 205], ["hydrophobic attraction", "PROBLEM", 25, 47], ["hydrophobic attraction", "PROBLEM", 122, 144], ["\u03b2-strands formation", "PROBLEM", 214, 233], ["predominantly hydrophobic residues", "PROBLEM", 262, 296], ["thermodynamic pressures", "TREATMENT", 307, 330], ["the solution conditions", "TREATMENT", 354, 377], ["hydrophobic attraction", "OBSERVATION", 25, 47], ["predominantly", "OBSERVATION_MODIFIER", 262, 275], ["hydrophobic residues", "OBSERVATION", 276, 296], ["thermodynamic pressures", "OBSERVATION", 307, 330]]], ["Formation of \u03b2-sheets also make \u03b2-strands aggregate or \"collapse\" into a tertiary conformation with a hydrophobic core.ResultsThereby, we speculate that folding of \u03b2-sheets is triggered by multistage hydrophobic interactions among neighbored side-chains of unfolded polypeptides, enable \u03b2-sheets fold reproducibly following explicit physical folding codes in aqueous environments.ResultsWe use 1000 experimentally determined small protein structures to further demonstrate the hydrophobiceffect-based folding mechanism for \u03b2-sheets.", [["\u03b2-sheets", "SIMPLE_CHEMICAL", 13, 21], ["\u03b2-strands", "SIMPLE_CHEMICAL", 32, 41], ["\u03b2-sheets", "SIMPLE_CHEMICAL", 523, 531], ["\u03b2-sheets", "PROTEIN", 164, 172], ["neighbored side-chains", "PROTEIN", 231, 253], ["strands aggregate", "PROBLEM", 34, 51], ["\"collapse", "PROBLEM", 55, 64], ["a hydrophobic core", "TREATMENT", 100, 118], ["unfolded polypeptides", "PROBLEM", 257, 278], ["small protein structures", "PROBLEM", 425, 449], ["the hydrophobiceffect", "PROBLEM", 473, 494], ["collapse", "OBSERVATION", 56, 64]]], ["All the 1000 small proteins were randomly selected from the PDB.", [["small", "OBSERVATION_MODIFIER", 13, 18], ["proteins", "OBSERVATION", 19, 27], ["PDB", "ANATOMY", 60, 63]]], ["3235 \u03b2-strands can be identified in the 1000 protein structures by using the PDB archive and the STRIDE software 42 .", [["the STRIDE software", "TEST", 93, 112]]], ["From analysis of all the 3235 \u03b2-strands of the 1000 proteins in PDB, we find out that the feature of hydrophobic attraction (due to the hydrophobic effect) among adjacent side-chains on one side or the other side of a \u03b2-strand covering the length of the \u03b2-strand is prevail in all the experimentally determined \u03b2-strands (see Supplementary S5 ).", [["3235 \u03b2-strands", "DNA", 25, 39], ["1000 proteins", "PROTEIN", 47, 60], ["S5", "PROTEIN", 340, 342], ["the 1000 proteins in PDB", "TREATMENT", 43, 67], ["hydrophobic attraction", "PROBLEM", 101, 123], ["the hydrophobic effect", "PROBLEM", 132, 154], ["hydrophobic attraction", "OBSERVATION", 101, 123]]], ["This indicates that the hydrophobic interaction among the neighbored side-chains responsible for the formation of \u03b2-strands.ResultsAspartate-D, Asparagine-N, Serine-S, Proline-P, Glycine-G can't effectively hydrophobic attract with neighbored side-chains in sequence, see Fig.1D .", [["ResultsAspartate-D", "CHEMICAL", 124, 142], ["Asparagine", "CHEMICAL", 144, 154], ["Proline", "CHEMICAL", 168, 175], ["ResultsAspartate-D", "CHEMICAL", 124, 142], ["Asparagine-N", "CHEMICAL", 144, 156], ["Serine", "CHEMICAL", 158, 164], ["S", "CHEMICAL", 165, 166], ["Proline-P", "CHEMICAL", 168, 177], ["Glycine-G", "CHEMICAL", 179, 188], ["ResultsAspartate-D", "SIMPLE_CHEMICAL", 124, 142], ["Asparagine-N", "SIMPLE_CHEMICAL", 144, 156], ["Serine-S", "SIMPLE_CHEMICAL", 158, 166], ["Proline-P", "SIMPLE_CHEMICAL", 168, 177], ["Glycine-G ca", "SIMPLE_CHEMICAL", 179, 191], ["neighbored side-chains", "PROTEIN", 58, 80], ["\u03b2-strands", "PROTEIN", 114, 123], ["neighbored side-chains", "PROTEIN", 232, 254], ["the hydrophobic interaction", "PROBLEM", 20, 47], ["\u03b2-strands", "PROBLEM", 114, 123], ["ResultsAspartate", "TEST", 124, 140], ["Asparagine", "TEST", 144, 154], ["Serine", "TREATMENT", 158, 164], ["Proline", "TREATMENT", 168, 175], ["Glycine", "TREATMENT", 179, 186], ["hydrophobic", "OBSERVATION_MODIFIER", 24, 35]]], ["Thus, Aspartate-D, Asparagine-N, Serine-S, Proline-P, Glycine-G most likely lead to \u03b2-turns formation in protein folding, due to the other neighbored sidechains in amino acid sequence tend to hydrophobic attract with each other through bypassing these residues.", [["Aspartate", "CHEMICAL", 6, 15], ["Asparagine", "CHEMICAL", 19, 29], ["Proline", "CHEMICAL", 43, 50], ["amino acid", "CHEMICAL", 164, 174], ["Aspartate", "CHEMICAL", 6, 15], ["Asparagine", "CHEMICAL", 19, 29], ["N", "CHEMICAL", 30, 31], ["Serine", "CHEMICAL", 33, 39], ["S", "CHEMICAL", 40, 41], ["Proline", "CHEMICAL", 43, 50], ["Glycine-G", "CHEMICAL", 54, 63], ["amino acid", "CHEMICAL", 164, 174], ["Aspartate-D", "SIMPLE_CHEMICAL", 6, 17], ["Asparagine-N", "SIMPLE_CHEMICAL", 19, 31], ["Serine-S", "SIMPLE_CHEMICAL", 33, 41], ["Proline-P", "SIMPLE_CHEMICAL", 43, 52], ["Glycine-G", "SIMPLE_CHEMICAL", 54, 63], ["\u03b2-turns", "SIMPLE_CHEMICAL", 84, 91], ["amino acid", "AMINO_ACID", 164, 174], ["amino acid sequence", "PROTEIN", 164, 183], ["Aspartate", "TEST", 6, 15], ["Asparagine", "TEST", 19, 29], ["Serine-S, Proline-P, Glycine-G", "TREATMENT", 33, 63], ["protein folding", "PROBLEM", 105, 120], ["the other neighbored sidechains", "PROBLEM", 129, 160], ["amino acid sequence", "TREATMENT", 164, 183]]], ["The \u03b2-turn is the third most important secondary structure after helices and \u03b2-strands. \u03b2-turns have been classified according to the values of the dihedral angles \u03c6 and \u03c8 of the central residue. \u03b2-turns can be easily identified in between \u03b2-strands or \u03b1-helices of the protein structures using the PDB archive and the STRIDE software 42 .", [["\u03b2-turn", "GENE_OR_GENE_PRODUCT", 4, 10], ["\u03b2-turn", "PROTEIN", 4, 10], ["\u03b2-strands", "PROTEIN", 77, 86], ["the central residue", "PROBLEM", 175, 194], ["the STRIDE software", "TEST", 315, 334], ["secondary structure", "OBSERVATION", 39, 58], ["central residue", "OBSERVATION", 179, 194]]], ["We find out that about 97.4% of the \u03b2-turns contain at least one Aspartate-D, Asparagine-N, Serine-S, Proline-P or Glycine-G residue 43 , as illustrated in Supplementary 2.ResultsWhereas, most of the rest no-RB \u03b2-turns contain at least one Glutamate-E, Glutamine-Q, Threonine-T, and Alanine-A residue.", [["Asparagine", "CHEMICAL", 78, 88], ["Glutamate", "CHEMICAL", 240, 249], ["Glutamine", "CHEMICAL", 253, 262], ["Threonine-T", "CHEMICAL", 266, 277], ["Alanine-A", "CHEMICAL", 283, 292], ["Aspartate", "CHEMICAL", 65, 74], ["Asparagine", "CHEMICAL", 78, 88], ["N", "CHEMICAL", 89, 90], ["Serine", "CHEMICAL", 92, 98], ["S", "CHEMICAL", 99, 100], ["Proline", "CHEMICAL", 102, 109], ["Glycine-G", "CHEMICAL", 115, 124], ["Glutamate", "CHEMICAL", 240, 249], ["Glutamine", "CHEMICAL", 253, 262], ["Threonine", "CHEMICAL", 266, 275], ["Alanine", "CHEMICAL", 283, 290], ["Aspartate-D", "SIMPLE_CHEMICAL", 65, 76], ["Asparagine-N", "SIMPLE_CHEMICAL", 78, 90], ["Serine-S", "SIMPLE_CHEMICAL", 92, 100], ["Proline-P", "SIMPLE_CHEMICAL", 102, 111], ["Glycine-G residue 43", "AMINO_ACID", 115, 135], ["Glutamate-E", "SIMPLE_CHEMICAL", 240, 251], ["Glutamine-Q", "SIMPLE_CHEMICAL", 253, 264], ["Threonine-T", "SIMPLE_CHEMICAL", 266, 277], ["Alanine-A", "SIMPLE_CHEMICAL", 283, 292], ["\u03b2-turns", "PROTEIN", 36, 43], ["no-RB \u03b2-turns", "PROTEIN", 205, 218], ["Aspartate", "TEST", 65, 74], ["Asparagine", "TREATMENT", 78, 88], ["Serine", "TREATMENT", 92, 98], ["Proline", "TREATMENT", 102, 109], ["Glycine-G residue", "TREATMENT", 115, 132], ["Glutamate", "TEST", 240, 249], ["Glutamine", "TREATMENT", 253, 262], ["Threonine", "TREATMENT", 266, 275], ["Alanine", "TREATMENT", 283, 290]]], ["This indicates that Glutamate-E, Glutamine-Q, Threonine-T, and Alanine-A may contribute to the formation of \u03b2-turns due to their exposed hydrophobic proportions is relatively small.ResultsMoreover, about 99.3% \u03b2-hairpin turns contain at least one Aspartate-D, Asparagine-N, Serine-S, Proline-P or Glycine-G residue, see Supplementary 2.", [["Glutamate", "CHEMICAL", 20, 29], ["Glutamine", "CHEMICAL", 33, 42], ["Threonine-T", "CHEMICAL", 46, 57], ["Alanine-A", "CHEMICAL", 63, 72], ["\u03b2-turns", "DISEASE", 108, 115], ["Asparagine", "CHEMICAL", 260, 270], ["Proline", "CHEMICAL", 284, 291], ["Glutamate", "CHEMICAL", 20, 29], ["Glutamine", "CHEMICAL", 33, 42], ["Threonine", "CHEMICAL", 46, 55], ["Alanine", "CHEMICAL", 63, 70], ["Aspartate", "CHEMICAL", 247, 256], ["Asparagine", "CHEMICAL", 260, 270], ["N", "CHEMICAL", 271, 272], ["Serine", "CHEMICAL", 274, 280], ["S", "CHEMICAL", 281, 282], ["Proline-P", "CHEMICAL", 284, 293], ["Glycine-G", "CHEMICAL", 297, 306], ["Glutamate-E", "SIMPLE_CHEMICAL", 20, 31], ["Glutamine-Q", "SIMPLE_CHEMICAL", 33, 44], ["Threonine-T", "SIMPLE_CHEMICAL", 46, 57], ["Alanine-A", "SIMPLE_CHEMICAL", 63, 72], ["\u03b2-turns", "SIMPLE_CHEMICAL", 108, 115], ["Aspartate-D", "SIMPLE_CHEMICAL", 247, 258], ["Asparagine-N", "SIMPLE_CHEMICAL", 260, 272], ["Serine-S", "SIMPLE_CHEMICAL", 274, 282], ["Proline-P", "SIMPLE_CHEMICAL", 284, 293], ["Glycine-G residue", "SIMPLE_CHEMICAL", 297, 314], ["Glutamate-E", "TREATMENT", 20, 31], ["Glutamine", "TREATMENT", 33, 42], ["Threonine-T", "TREATMENT", 46, 57], ["Alanine-A", "TREATMENT", 63, 72], ["\u03b2-turns", "TREATMENT", 108, 115], ["Aspartate", "TEST", 247, 256], ["Asparagine", "TEST", 260, 270], ["Serine", "TREATMENT", 274, 280], ["Proline", "TREATMENT", 284, 291], ["Glycine-G residue", "TREATMENT", 297, 314], ["relatively", "OBSERVATION_MODIFIER", 164, 174], ["small", "OBSERVATION_MODIFIER", 175, 180]]], ["Two RB residues coded together normally shouldn't be able to present at the middle of a long straight \u03b2strand.", [["RB residues", "PROTEIN", 4, 15], ["long straight \u03b2strand", "PROTEIN", 88, 109], ["RB residues", "OBSERVATION", 4, 15]]], ["Because the other residues of the strand at both sides of the two RB residues tend to hydrophobic aggregate together and thus would bend the strand at the two RB residues to achieve the hydrophobic interaction.", [["strand", "CELLULAR_COMPONENT", 34, 40], ["RB residues", "PROTEIN", 66, 77], ["RB residues", "PROTEIN", 159, 170], ["the strand", "PROBLEM", 30, 40], ["the two RB residues", "PROBLEM", 58, 77], ["RB residues", "OBSERVATION", 66, 77], ["RB residues", "OBSERVATION", 159, 170]]], ["However, we can still identified 29 long \u03b2-strands (each \u03b2-strands contain more than 12 residues), which are characterized by two adjacent RB residues locating at the middle of the \u03b2-strands through scanning the 1000 protein structures by using the STRIDE software 42 .", [["29 long \u03b2-strands", "DNA", 33, 50], ["RB residues", "PROTEIN", 139, 150], ["\u03b2-strands", "PROTEIN", 181, 190], ["29 long \u03b2-strands (each \u03b2-strands", "PROBLEM", 33, 66], ["two adjacent RB residues", "PROBLEM", 126, 150], ["the STRIDE software", "TEST", 245, 264], ["RB residues", "OBSERVATION", 139, 150], ["middle", "ANATOMY_MODIFIER", 167, 173]]], ["By checking these long \u03b2-strands using PyMOL software, we find out that 24 of these long \u03b2-strands actually curved exactly at their two RB residues in the amino acid sequences, demonstrating the capability of RB residues to cause \u03b2-turns formation, see Fig. 4 .", [["amino acid", "CHEMICAL", 155, 165], ["amino acid", "CHEMICAL", 155, 165], ["amino acid", "AMINO_ACID", 155, 165], ["\u03b2-turns", "SIMPLE_CHEMICAL", 230, 237], ["long \u03b2-strands", "DNA", 18, 32], ["long \u03b2-strands", "DNA", 84, 98], ["RB residues", "PROTEIN", 136, 147], ["amino acid sequences", "PROTEIN", 155, 175], ["RB", "PROTEIN", 209, 211], ["the amino acid sequences", "TEST", 151, 175], ["RB residues", "PROBLEM", 209, 220], ["\u03b2-turns formation", "PROBLEM", 230, 247], ["RB residues", "OBSERVATION", 136, 147], ["RB residues", "OBSERVATION", 209, 220]]], ["The other 5 long \u03b2-strands either have three or more RB residues coded together or have RB residues located at one end of the strands that make the hydrophobic blocking region extend to the ends of these \u03b2-strands, thus undermining the hydrophobic interaction between the both ends of these \u03b2-strands, see Supplementary S3.", [["5 long \u03b2-strands", "DNA", 10, 26], ["RB residues", "PROTEIN", 53, 64], ["RB", "PROTEIN", 88, 90], ["hydrophobic blocking region", "PROTEIN", 148, 175], ["\u03b2-strands", "PROTEIN", 204, 213], ["RB residues", "PROBLEM", 88, 99], ["the hydrophobic blocking region", "PROBLEM", 144, 175], ["RB residues", "OBSERVATION", 53, 64], ["RB residues", "OBSERVATION", 88, 99], ["hydrophobic interaction", "OBSERVATION", 236, 259]]], ["The long \u03b2-strand of the 1YV7 protein curved at a sequence segment of threonine-threonine-terine-glutamate (TTSE), see Supplementary S3.", [["threonine-threonine-terine-glutamate", "CHEMICAL", 70, 106], ["threonine", "CHEMICAL", 70, 79], ["threonine", "CHEMICAL", 80, 89], ["glutamate", "CHEMICAL", 97, 106], ["TTSE", "CHEMICAL", 108, 112], ["1YV7", "GENE_OR_GENE_PRODUCT", 25, 29], ["threonine-threonine-terine-glutamate", "SIMPLE_CHEMICAL", 70, 106], ["1YV7 protein", "PROTEIN", 25, 37], ["threonine", "TEST", 70, 79]]], ["This indicates that Glutamate-E, Glutamine-Q, Threonine-T, and Alanine-A may also contribute to the formation of \u03b2-turns due to their exposed hydrophobic proportions is relatively small.ResultsThe spike (S) protein of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Resultsis of great concern due to the coronavirus disease 2019 (COVID-19) pandemic.", [["Glutamate", "CHEMICAL", 20, 29], ["Glutamine", "CHEMICAL", 33, 42], ["Threonine-T", "CHEMICAL", 46, 57], ["Alanine-A", "CHEMICAL", 63, 72], ["\u03b2-turns", "DISEASE", 113, 120], ["acute respiratory syndrome coronavirus", "DISEASE", 231, 269], ["coronavirus disease", "DISEASE", 322, 341], ["Glutamate", "CHEMICAL", 20, 29], ["Glutamine", "CHEMICAL", 33, 42], ["Threonine", "CHEMICAL", 46, 55], ["Alanine", "CHEMICAL", 63, 70], ["Glutamate-E", "SIMPLE_CHEMICAL", 20, 31], ["Glutamine-Q", "SIMPLE_CHEMICAL", 33, 44], ["Threonine-T", "SIMPLE_CHEMICAL", 46, 57], ["Alanine-A", "SIMPLE_CHEMICAL", 63, 72], ["spike (S) protein", "PROTEIN", 197, 214], ["severe acute respiratory syndrome coronavirus", "SPECIES", 224, 269], ["SARS-CoV", "SPECIES", 273, 281], ["Glutamate-E", "TREATMENT", 20, 31], ["Glutamine", "TREATMENT", 33, 42], ["Threonine-T", "TREATMENT", 46, 57], ["Alanine", "TREATMENT", 63, 70], ["The spike (S) protein", "TEST", 193, 214], ["novel severe acute respiratory syndrome coronavirus", "PROBLEM", 218, 269], ["SARS", "TEST", 273, 277], ["CoV", "TEST", 278, 281], ["the coronavirus disease", "PROBLEM", 318, 341], ["COVID", "TEST", 348, 353], ["pandemic", "PROBLEM", 358, 366], ["relatively", "OBSERVATION_MODIFIER", 169, 179], ["small", "OBSERVATION_MODIFIER", 180, 185], ["severe", "OBSERVATION_MODIFIER", 224, 230], ["acute", "OBSERVATION_MODIFIER", 231, 236], ["respiratory syndrome", "OBSERVATION", 237, 257], ["coronavirus", "OBSERVATION", 322, 333]]], ["The D614G mutation in SARS-CoV-2 begin to receive widespread attention for its rising dominance worldwide.", [["SARS", "DISEASE", 22, 26], ["D614G", "GENE_OR_GENE_PRODUCT", 4, 9], ["SARS-CoV-2", "ORGANISM", 22, 32], ["SARS-CoV", "SPECIES", 22, 30], ["The D614G mutation", "PROBLEM", 0, 18], ["SARS", "PROBLEM", 22, 26], ["widespread attention", "TREATMENT", 50, 70]]], ["This mutation changes the amino acid at position 614, from D (aspartic acid) to G (glycine), the initial D614 is now the G614 variant.", [["amino acid", "CHEMICAL", 26, 36], ["aspartic acid", "CHEMICAL", 62, 75], ["glycine", "CHEMICAL", 83, 90], ["amino acid", "CHEMICAL", 26, 36], ["aspartic acid", "CHEMICAL", 62, 75], ["glycine", "CHEMICAL", 83, 90], ["amino acid", "AMINO_ACID", 26, 36], ["position 614", "AMINO_ACID", 40, 52], ["aspartic acid", "AMINO_ACID", 62, 75], ["G", "AMINO_ACID", 80, 81], ["glycine", "AMINO_ACID", 83, 90], ["G614 variant", "PROTEIN", 121, 133], ["This mutation changes", "PROBLEM", 0, 21], ["the amino acid", "TEST", 22, 36], ["D (aspartic acid)", "TREATMENT", 59, 76]]], ["It is worth noting that the amino acid at position 614 is located at a \u03b2-turn in a tertiary structure of the spike.", [["amino acid", "CHEMICAL", 28, 38], ["amino acid", "CHEMICAL", 28, 38], ["amino acid", "AMINO_ACID", 28, 38], ["position 614", "AMINO_ACID", 42, 54], ["\u03b2-turn", "PROTEIN", 71, 77], ["the amino acid at position", "PROBLEM", 24, 50], ["spike", "OBSERVATION_MODIFIER", 109, 114]]], ["This is consistent with our new theory that both D (aspartic acid) to G (glycine) can result in the \u03b2-turn formation.", [["D (aspartic acid", "CHEMICAL", 49, 65], ["glycine", "CHEMICAL", 73, 80], ["D (aspartic acid", "CHEMICAL", 49, 65], ["glycine", "CHEMICAL", 73, 80], ["D (aspartic acid", "SIMPLE_CHEMICAL", 49, 65], ["G", "SIMPLE_CHEMICAL", 70, 71], ["glycine", "AMINO_ACID", 73, 80], ["\u03b2-turn", "SIMPLE_CHEMICAL", 100, 106], ["D (aspartic acid) to G (glycine)", "TREATMENT", 49, 81], ["the \u03b2-turn formation", "PROBLEM", 96, 116], ["consistent with", "UNCERTAINTY", 8, 23]]], ["The D-614-G nutation may accelerate the folding of the quaternary structure of the spike due to G614 most likely can contribute to the hydrophobic effect between two tertiary structures of the protein rather than the D614 (see Fig.1D ), due to the position 614 located at the docking site in between them.ResultsA typical \u03b2-hairpin structure contains two \u03b2-strands with hydrophobic attraction between each side-chain and every other side-chain on the strands.", [["D-614-G", "CHEMICAL", 4, 11], ["G614", "CHEMICAL", 96, 100], ["G614", "GENE_OR_GENE_PRODUCT", 96, 100], ["\u03b2-hairpin", "CANCER", 322, 331], ["D-614-G nutation", "DNA", 4, 20], ["G614", "PROTEIN", 96, 100], ["D614", "PROTEIN", 217, 221], ["Fig.1D", "PROTEIN", 227, 233], ["position 614", "PROTEIN", 248, 260], ["docking site", "PROTEIN", 276, 288], ["\u03b2-hairpin structure", "PROTEIN", 322, 341], ["The D-614-G nutation", "TREATMENT", 0, 20], ["the spike", "PROBLEM", 79, 88], ["the hydrophobic effect", "PROBLEM", 131, 153], ["hydrophobic effect", "OBSERVATION", 135, 153], ["docking site", "OBSERVATION", 276, 288], ["two", "OBSERVATION_MODIFIER", 351, 354], ["hydrophobic attraction", "OBSERVATION", 370, 392], ["chain", "OBSERVATION_MODIFIER", 411, 416]]], ["We may can predict \u03b2-hairpin through identifying two neighbored sequences of residues in the polypeptide chain both characterized by hydrophobic attraction between each side-chain to every other side-chain, and have two RB in between them.", [["\u03b2-hairpin", "SIMPLE_CHEMICAL", 19, 28], ["\u03b2-hairpin", "PROTEIN", 19, 28], ["polypeptide chain", "PROTEIN", 93, 110], ["RB", "PROTEIN", 220, 222], ["the polypeptide chain", "TREATMENT", 89, 110], ["hydrophobic attraction", "OBSERVATION", 133, 155]]], ["By using this method, we identified 553 samples in terms of the characteristics above from the 1000 proteins.", [["samples", "ANATOMY", 40, 47], ["1000 proteins", "PROTEIN", 95, 108]]], ["We find that 158 of the samples are \u03b2-hairpins, 36 of the samples are structures of strand-turn-strand, 296 of the samples are structures of strand-turn-helix, 23 of the samples are structures of coil-turn-strand, 23 of the samples are coil-turncoil and 6 of the samples are \u03b1-helices.", [["samples", "ANATOMY", 24, 31], ["samples", "ANATOMY", 58, 65], ["samples", "ANATOMY", 115, 122], ["samples", "ANATOMY", 170, 177], ["samples", "ANATOMY", 224, 231], ["samples", "ANATOMY", 263, 270], ["\u03b2-hairpins", "CANCER", 36, 46], ["\u03b1-helices", "PROTEIN", 275, 284], ["the samples", "TEST", 20, 31], ["\u03b2-hairpins", "TEST", 36, 46], ["the samples", "TEST", 54, 65], ["the samples", "TEST", 111, 122]]], ["Thus, physical folding codes for \u03b2-hairpins and strand-turn-strand can be deciphered through evaluating hydrophobic interaction among side-chains of an unfolded polypeptide.", [["\u03b2-hairpins", "GENE_OR_GENE_PRODUCT", 33, 43], ["\u03b2-hairpins", "PROTEIN", 33, 43], ["side-chains", "PROTEIN", 134, 145], ["\u03b2-hairpins", "TREATMENT", 33, 43], ["strand-turn-strand", "TREATMENT", 48, 66], ["an unfolded polypeptide", "TREATMENT", 149, 172]]], ["The results show that strand-turn-helix also can be predict by the method.", [["strand-turn-helix", "PROBLEM", 22, 39]]], ["This indicates that folding of \u03b1-helix may be initiated from a \u03b2-strand-like thermodynamic metastable state 15 .ConclusionMany amino acid residues contain considerable nonpolar sections in their side-chains, even if they also contain polar or charged groups.", [["sections", "ANATOMY", 177, 185], ["amino acid", "CHEMICAL", 127, 137], ["amino acid", "CHEMICAL", 127, 137], ["\u03b1-helix", "GENE_OR_GENE_PRODUCT", 31, 38], ["amino acid", "AMINO_ACID", 127, 137], ["\u03b1-helix", "PROTEIN", 31, 38], ["folding of \u03b1-helix", "PROBLEM", 20, 38], ["a \u03b2-strand-like thermodynamic metastable state", "PROBLEM", 61, 107], ["Many amino acid residues", "TREATMENT", 122, 146], ["considerable", "OBSERVATION_MODIFIER", 155, 167], ["nonpolar sections", "OBSERVATION", 168, 185], ["polar", "OBSERVATION_MODIFIER", 234, 239], ["charged", "OBSERVATION", 243, 250]]], ["This make hydrophobic interaction among neighbored amino acid sidechains in amino acid sequence of polypeptides becomes an important driving force for the stabilization of initial thermodynamic state of unfolded Proteins.", [["amino acid", "CHEMICAL", 51, 61], ["amino acid", "CHEMICAL", 76, 86], ["amino acid", "CHEMICAL", 51, 61], ["amino acid", "CHEMICAL", 76, 86], ["amino acid", "AMINO_ACID", 51, 61], ["amino acid", "AMINO_ACID", 76, 86], ["amino acid sequence", "PROTEIN", 76, 95], ["unfolded Proteins", "PROTEIN", 203, 220], ["hydrophobic interaction", "PROBLEM", 10, 33], ["neighbored amino acid sidechains", "TREATMENT", 40, 72], ["amino acid sequence of polypeptides", "TREATMENT", 76, 111], ["unfolded Proteins", "PROBLEM", 203, 220], ["unfolded Proteins", "OBSERVATION", 203, 220]]], ["The feature of a large hydrophobic surface area covering most side-chains on one side or the other side of adjacent \u03b2-strands of a \u03b2-sheet is prevail in almost all experimentally determined \u03b2-sheets.", [["surface area", "ANATOMY", 35, 47], ["a large hydrophobic surface area", "TREATMENT", 15, 47], ["a \u03b2-sheet", "TREATMENT", 129, 138], ["large", "OBSERVATION_MODIFIER", 17, 22], ["hydrophobic", "OBSERVATION_MODIFIER", 23, 34], ["surface", "OBSERVATION_MODIFIER", 35, 42], ["area", "OBSERVATION_MODIFIER", 43, 47], ["most side", "OBSERVATION_MODIFIER", 57, 66], ["chains", "OBSERVATION_MODIFIER", 67, 73]]], ["Minimizing the exposed hydrophobic portions of adjacent side-chains to water should be regarded as the most important driving force for the \u03b2-strands formation and caused each side-chains is parallel to every other side-chain on strands. \u03b2-turns often contain residues of Aspartate-D, Asparagine-N, Serine-S, Proline-P, Glycine-G which characterized with their sidechains having very small hydrophobic proportions exposure, that is explained as these residues can block hydrophobic effect among neighbored side-chains in sequence, thereby contribute to turns formation.ConclusionThe folding of \u03b2-sheets are most likely triggered by multistage hydrophobic interactions among neighbored side-chains of unfolded polypeptides, enable \u03b2-sheets fold reproducibly following explicit physical folding codes in aqueous environments.", [["\u03b2-sheets", "ANATOMY", 594, 602], ["Aspartate", "CHEMICAL", 272, 281], ["Asparagine", "CHEMICAL", 285, 295], ["Proline", "CHEMICAL", 309, 316], ["Aspartate", "CHEMICAL", 272, 281], ["Asparagine", "CHEMICAL", 285, 295], ["N", "CHEMICAL", 296, 297], ["Serine", "CHEMICAL", 299, 305], ["S", "CHEMICAL", 306, 307], ["Proline", "CHEMICAL", 309, 316], ["Glycine-G", "CHEMICAL", 320, 329], ["water", "SIMPLE_CHEMICAL", 71, 76], ["\u03b2-strands", "SIMPLE_CHEMICAL", 140, 149], ["Aspartate-D", "SIMPLE_CHEMICAL", 272, 283], ["Asparagine-N", "SIMPLE_CHEMICAL", 285, 297], ["Serine-S", "SIMPLE_CHEMICAL", 299, 307], ["Proline-P", "SIMPLE_CHEMICAL", 309, 318], ["Glycine-G", "SIMPLE_CHEMICAL", 320, 329], ["neighbored side-chains", "PROTEIN", 495, 517], ["neighbored side-chains", "PROTEIN", 674, 696], ["the \u03b2-strands formation", "TREATMENT", 136, 159], ["Aspartate", "TEST", 272, 281], ["Asparagine", "TEST", 285, 295], ["Proline", "TREATMENT", 309, 316], ["Glycine-G", "TREATMENT", 320, 329], ["turns formation", "PROBLEM", 553, 568], ["multistage hydrophobic interactions", "PROBLEM", 632, 667], ["unfolded polypeptides", "PROBLEM", 700, 721], ["hydrophobic", "OBSERVATION_MODIFIER", 23, 34], ["most likely", "UNCERTAINTY", 607, 618]]], ["Temperature dependence of the folding of \u03b2-sheet is thus attributed to temperature dependence of the strength of the hydrophobicity.", [["\u03b2-sheet", "PROTEIN", 41, 48], ["Temperature dependence", "PROBLEM", 0, 22], ["temperature dependence", "PROBLEM", 71, 93], ["the hydrophobicity", "PROBLEM", 113, 131], ["thus attributed to", "UNCERTAINTY", 52, 70], ["temperature dependence", "OBSERVATION", 71, 93], ["hydrophobicity", "OBSERVATION_MODIFIER", 117, 131]]], ["The hydrophobic collapse of \u03b2-strands into \u03b2-sheets most likely trigger enthalpy-entropy compensation of unfolded polypeptides, enable the main-chain of \u03b2-strands to get rid of the hydrogen-bonded water molecules and laterally hydrogen bonding with each other.", [["hydrogen", "CHEMICAL", 181, 189], ["hydrogen", "CHEMICAL", 227, 235], ["water molecules", "SIMPLE_CHEMICAL", 197, 212], ["\u03b2-strands", "PROTEIN", 153, 162], ["hydrogen-bonded water molecules", "PROTEIN", 181, 212], ["The hydrophobic collapse of \u03b2-strands into \u03b2-sheets", "PROBLEM", 0, 51], ["unfolded polypeptides", "PROBLEM", 105, 126], ["the hydrogen-bonded water molecules", "TREATMENT", 177, 212], ["laterally hydrogen bonding", "PROBLEM", 217, 243], ["hydrophobic", "OBSERVATION_MODIFIER", 4, 15], ["collapse", "OBSERVATION", 16, 24], ["most likely", "UNCERTAINTY", 52, 63], ["entropy compensation", "OBSERVATION", 81, 101], ["unfolded polypeptides", "OBSERVATION", 105, 126], ["main", "OBSERVATION_MODIFIER", 139, 143]]], ["The folding codes in amino acid sequence that dictate the formation of a \u03b2-hairpin can thus be deciphered through evaluating hydrophobic interaction among sidechains of an unfolded polypeptide from a \u03b2-strand-like thermodynamic metastable state.Protein structuresIn this study, many experimentally determined native structures of proteins are used to study the folding mechanism of \u03b2-sheets.", [["amino acid", "CHEMICAL", 21, 31], ["amino acid", "CHEMICAL", 21, 31], ["amino acid", "AMINO_ACID", 21, 31], ["\u03b2-hairpin", "SIMPLE_CHEMICAL", 73, 82], ["amino acid sequence", "PROTEIN", 21, 40], ["\u03b2-hairpin", "PROTEIN", 73, 82], ["amino acid sequence", "TEST", 21, 40], ["an unfolded polypeptide", "PROBLEM", 169, 192], ["a \u03b2-strand-like thermodynamic metastable state", "PROBLEM", 198, 244], ["Protein structures", "TEST", 245, 263], ["this study", "TEST", 266, 276], ["thermodynamic metastable", "OBSERVATION", 214, 238]]], ["All the three-dimensional (3D) structure data of protein molecules are resourced from the PDB database.", [["protein molecules", "PROTEIN", 49, 66], ["protein molecules", "PROBLEM", 49, 66], ["the PDB database", "TEST", 86, 102], ["PDB", "ANATOMY", 90, 93]]], ["IDs of these proteins according to PDB database are marked in the Fig.2, Fig.3 , and Fig.4 .", [["Fig.3", "GENE_OR_GENE_PRODUCT", 73, 78], ["Fig.2", "PROTEIN", 66, 71], ["Fig.3", "PROTEIN", 73, 78], ["Fig.4", "PROTEIN", 85, 90], ["these proteins", "TEST", 7, 21], ["PDB database", "TEST", 35, 47], ["marked", "OBSERVATION_MODIFIER", 52, 58]]], ["In order to show the distribution of hydrophobic areas on the surface of \u03b2-strands and \u03b2-sheets in these figures, we used the structural biology visualization software PyMOL to display the hydrophobic surface areas of these secondary structures.Identification of secondary structures of proteinsSecondary structures of \u03b2-strands, \u03b2-turns, \u03b2-sheets and \u03b1-helices were identified in the 1000 proteins by using the STRIDE software 42 .", [["surface", "ANATOMY", 62, 69], ["surface", "CELLULAR_COMPONENT", 62, 69], ["\u03b2-turns", "SIMPLE_CHEMICAL", 330, 337], ["\u03b2-sheets", "SIMPLE_CHEMICAL", 339, 347], ["\u03b1-helices", "SIMPLE_CHEMICAL", 352, 361], ["\u03b2-strands", "PROTEIN", 73, 82], ["\u03b2-strands", "PROTEIN", 319, 328], ["\u03b2-turns", "PROTEIN", 330, 337], ["\u03b1-helices", "PROTEIN", 352, 361], ["1000 proteins", "PROTEIN", 385, 398], ["secondary structures of proteins", "PROBLEM", 263, 295], ["\u03b2-strands", "PROBLEM", 319, 328], ["the STRIDE software", "TEST", 408, 427], ["hydrophobic", "OBSERVATION_MODIFIER", 37, 48], ["areas", "OBSERVATION_MODIFIER", 49, 54], ["hydrophobic", "OBSERVATION_MODIFIER", 189, 200], ["surface", "OBSERVATION_MODIFIER", 201, 208], ["secondary structures", "OBSERVATION", 224, 244], ["secondary", "OBSERVATION_MODIFIER", 263, 272], ["strands", "OBSERVATION_MODIFIER", 321, 328]]], ["We also used molecular 3D structure display software PyMOL to confirm the identification of secondary structures of proteins.", [["secondary structures of proteins", "PROBLEM", 92, 124]]], ["Long \u03b2-strands (more than 12 residues) characterized with two adjacent RB residues located at the middle of the \u03b2-strands and curved exactly at their two RB residues in the amino acid sequences.", [["amino acid", "CHEMICAL", 173, 183], ["amino acid", "CHEMICAL", 173, 183], ["amino acid", "AMINO_ACID", 173, 183], ["RB residues", "PROTEIN", 71, 82], ["\u03b2-strands", "PROTEIN", 112, 121], ["RB residues", "PROTEIN", 154, 165], ["amino acid sequences", "PROTEIN", 173, 193], ["Long \u03b2-strands", "PROBLEM", 0, 14], ["two adjacent RB residues", "PROBLEM", 58, 82], ["the amino acid sequences", "TEST", 169, 193], ["strands", "OBSERVATION", 7, 14], ["RB residues", "OBSERVATION", 71, 82], ["middle", "ANATOMY_MODIFIER", 98, 104], ["RB residues", "OBSERVATION", 154, 165]]], ["134L 1KP4 1Z3L 3C3G 4IC9 1FDD 1R75 2OAI 3OZZ 5HBP 155C 1KSM 1Z3M 3C4S 4IDL 1FE3 1R9H 2OJR 3P2X 5HBQ 1A0B 1KTH 1Z3P 3C5K 4IP1 1FE5 1RAQ 2OLI 3PAZ 5HDG 1A18 1KXI 1ZIA 3C7I 4IP6 1FER 1RBI 2ON8 3Q1D 5HJC 1A6F 1KXW 1ZIB 3C97 4IPF 1FES 1RBW 2OPY 3Q4Y 5HKN 1AA2 1KXX 1ZJ7 3CE8 4JHB 1FEV 1RBX 2OQK 3Q7Y 5HMB 1AB0 1KXY 5LAW 1B0T 1LXI 2B4A 3ETW 4LYO 1FOW 1RRI 2P8V 3SGP 5LAZ 1B1E 1LYO 2B8G 3EZM 4MDQ 1FOY 1RRY 2PAL 3STM 5LN2 1B1I 1LZ4 2B9D 3F3Q 4MJJ 1G2S 1RS2 2PK7 3SUL 5M9A 1B1J 1M1S 2BEZ 3F45 4ML2 1GBQ 1RSI 2PKT 3T1X 5MXY 1B1U 1M4A 2BFH 3F8C 4MZ2 1GD6 1RTU 2PNE 3T3J 5NGN 1B2O 1M4B 2BHK 3FAJ 4N0Z 1GDC 1RWJ 2PPI 3T8R 5NWX 1B6E 1M4M 2BHO 3FFY 4N5T 1GHJ 1RZY 2PPN 3T8T 5O3A 1BAS 1MB3 2BO1 3FRV 4N6J 1GKH 1S3P 2PVT 3UAF 5OC4 1BEA 1MG6 2BPP 3FWU 4NEJ 1GMG 1S7I 2PW5 3UB2 5OC8 1BEL 1MH7 2BQQ 3FYR 4NXR 1GOD 1SDZ 2PWS 3UB3 5OMD 1BFE 1MH8 2BRF 3FZ9 4OOH 1GP3 1SF6 2PYK 3UB4 5PAL 1BGI 1MK0 2BS5 3FZA 4OV1 1GS3 1SF7 2PZW 3UMD 5PAZ 1BHF 1MKU 2BTI 3G7C 4OXW 1GSW 1SFB 2Q1M 3UME 5RHN 1BKF 1ML8 2BWK 3GBQ 4OZL 1GV2 1SFG 2QAS 3UNN 5RNT 1BKV 1MLI 2BWL 3GK2 4P15 1GVP 1SKZ 2QDB 3V19 5TAB 1BM2 1N9N 2BZY 3GK4 4P2P 1GXT 1SNP 2QHE 3V1G 5U9U 1BMG 1N9O 2CDS 3GKY 4P7U 1H2P 1SNQ 2QHW 3VXW 5UEP 1BO0 1NEH 2COQ 3GLW 4P9E 1HD0 1SSC 2QIU 3VYA 5UER 1BPQ 1NEQ 2CW4 3GM2 4P9V 1HE7 1SV9 2QNW 3WIT 5UES 1BQK 1NKO 2CXY 3GM3 4PAZ 1HEH 1T00 2QR3 3WRP 5UET 1BQR 1NLO 2D4L 3GQU 4PE7 1HEY 1T1D 2QVT 3WUN 5UEV 1BU3 1NN7 2D4M 3GSP 4PTA 1HFX 1T2J 2R2Y 3WVT 5UEY 1BXY 1NNX 2D58 3H33 4QYW 1HIK 1TAY 2R34 3WW5 5USV 1BYL 1NXT 2DB7 3H9W 4RLM 1HKF 1TCY 2R36 3WX4 5UVS 1C0B 1NXV 2DH1 3HAF 4RLN 1HME 1TDY 2R39 3ZEK 5UVY 1C0C 1O2E 2DP9 3HAK 4RUD 1HQ8 1TEN 2REA 3ZK0 5UVZ 1C76 1O3X 2DRT 3HEY 4TQN 1HQB 1TGJ 2REY 4AHG 5VEA 1C9H 1O41 2DU9 3HFF 4TS8 1HRC 1TNS 2RKN 4AHI 5VR3 1C9V 1O42 2DYQ 3HFN 4UNG 1HRQ 1TS9 2RLN 4AHN 5WOR 1CDP 1O43 6CE8 1DDV 1O4M 2FKL 3IRC 4ZC3 1IOR 1UID 2WOR 4DP2 6CEA 1DDW 1O4N 2FLS 3J4G 5AEF 1IOS 1UIE 2WOS 4DP4 6CEC 1DKJ 1O4O 2FLT 3JTE 5AFG 1IOT 1UIF 2WQ0 4E1P 6CED 1DMM 1O4Q 2FMB 3JZR 5AI2 1IR7 1UIG 2WQ3 4E1R 6CEE 1DMN 1O4R 2FO3 3K0X 5B1F 1IR8 1UKU 2WQH 4EC2 6CEF 1DMQ 1O5J 2FQL 3K63 5B1G 1IR9 1UPJ 2X44 4EES 6DXH 1DPY 1O7Z 2FTB 3K6D 5B3Q 1IRQ 1UPR 2X9C 4ET8 6DXR 1DQ7 1OAP 2GSP 3K9I 5B52 1IRW 1UVY 2XBD 4ET9 6EKB 1DYZ 1OB6 2GV2 3KD0 5B79 1ISU 1UW3 2XCZ 4ETA 6EVL 1DZ0 1OD7 2H2B 3KHQ 5BMH 1IYU 1UW7 2XDY 4ETB 6EVM 1E5B 1ODA 2H36 3KLU 5BPO 1IZA 1UWM 2XFE 4ETD 6FCE 1E6K 1OOI 2H46 3KMJ 5C39 1J2V 1V07 2XKH 4ETE 6FGL 1E6L 1OPY 2H8A 3KQ6 5C4P 1J4H 1V46 2XMU 4EWW 6FGT 1E6M 1OR5 2H8V 3KQI 5C68 1J4I 1VAT 2YHN 4EWZ 6FGU 1E97 1P0R 2H95 3KTP 5C6X 1J73 1VED 2YWZ 4EX0 6FH6 1EA2 1P65 2HB4 3KU7 5CB9 1J7Z 1VER 2YXY 4F1A 6FH7 1ECW 1P9G 2HC8 3KVT 5CO9 1J81 1VHF 2Z44 4F2E 6FXF 1ED1 1PAL 2HPL 3L1M 5CPV 1J82 1VIH 2Z7J 4F68 6GF0 1EFQ 1PAZ 2HWV 3L6W 5CUL 1JC7 1VMG 2ZGD 4F69 6H0K 1EIF 1PBI 2I9V 3LHC 5D53 1JDL 1W2L 2ZHH 4F6D 6H0L 1EIG 1PI8 2IGP 3LJM 5D54 1JER 1W6X 3A0D 4FC1 6HA4 1EMN 1PKS 2IIY 3LLH 5DKN 1JHC 1WAQ 3A0S 4FDX 6I3S 1EN2 1PO8 2INT 3LMF 5DM9 1JKD 1WHI 3A0V 4FE6 6I5A 1ENV 1PZ4 2J5A 3LR0 5DZD 1JOI 1WJG 3A7L 4G3O 6IFH 1EOQ 1PZA 2JIN 3LVE 5E0Z 1JON 1WJX 3ADY 4G4W 6INS 1EOT 1PZB 2JK7 3LYO 5E4P 1JPE 1WRP 3AZ5 4G4X 6IQC 1EOW 1PZC 2JP8 3LZ2 5E4X 1JPO 1WY9 3B7X 4GBC 6JQ4 1EQV 1Q4R 2JVH 3M4T 5EE2 1JZA 1XW3 3B84 4GBN 6MHN 1EV3 1Q4V 2KRI 3MAZ 5EH4 1K1Z 1XW4 3BF2 4GFY 6MPM 1F1W 1Q7O", [["1B1U 1M4A 2BFH 3F8C 4MZ2 1GD6 1RTU 2PNE 3T3J 5NGN 1B2O 1M4B 2BHK 3FAJ 4N0Z 1GDC 1RWJ 2PPI 3T8R 5NWX 1B6E 1M4M 2BHO 3FFY 4N5T 1GHJ 1RZY 2PPN 3T8T 5O3A 1BAS 1MB3 2BO1 3FRV 4N6J 1GKH 1S3P 2PVT", "CHEMICAL", 515, 704], ["3GK2 4P15 1GVP 1SKZ 2QDB 3V19 5TAB 1BM2 1N9N 2BZY 3GK4 4P2P 1GXT 1SNP 2QHE 3V1G 5U9U 1BMG 1N9O 2CDS 3GKY 4P7U 1H2P 1SNQ 2QHW 3VXW 5UEP 1BO0 1NEH 2COQ", "CHEMICAL", 1030, 1179], ["1Q7O", "CHEMICAL", 3235, 3239], ["134L 1KP4 1Z3L 3C3G 4IC9 1FDD 1R75 2OAI 3OZZ 5HBP 155C 1KSM 1Z3M 3C4S 4IDL 1FE3 1R9H 2OJR 3P2X 5HBQ 1A0B 1KTH 1Z3P 3C5K 4IP1 1FE5 1RAQ 2OLI 3PAZ 5HDG 1A18 1KXI 1ZIA 3C7I 4IP6 1FER 1RBI 2ON8 3Q1D 5HJC 1A6F 1KXW 1ZIB 3C97 4IPF 1FES 1RBW 2OPY 3Q4Y 5HKN 1AA2 1KXX 1ZJ7 3CE8 4JHB 1FEV 1RBX 2OQK 3Q7Y 5HMB 1AB0 1KXY 5LAW 1B0T 1LXI 2B4A 3ETW 4LYO 1FOW 1RRI 2P8V 3SGP 5LAZ 1B1E 1LYO 2B8G 3EZM 4MDQ 1FOY 1RRY 2PAL 3STM 5LN2 1B1I 1LZ4 2B9D 3F3Q 4MJJ 1G2S 1RS2 2PK7 3SUL 5M9A 1B1J 1M1S 2BEZ 3F45 4ML2 1GBQ 1RSI 2PKT 3T1X 5MXY 1B1U 1M4A 2BFH 3F8C 4MZ2 1GD6 1RTU 2PNE 3T3J 5NGN 1B2O 1M4B 2BHK 3FAJ 4N0Z 1GDC 1RWJ 2PPI 3T8R 5NWX 1B6E 1M4M 2BHO 3FFY 4N5T 1GHJ 1RZY 2PPN 3T8T 5O3A 1BAS 1MB3 2BO1 3FRV 4N6J 1GKH 1S3P 2PVT 3UAF 5OC4 1BEA 1MG6 2BPP 3FWU 4NEJ 1GMG 1S7I 2PW5 3UB2 5OC8 1BEL 1MH7 2BQQ 3FYR 4NXR 1GOD 1SDZ 2PWS 3UB3 5OMD 1BFE 1MH8 2BRF 3FZ9 4OOH 1GP3 1SF6 2PYK 3UB4 5PAL 1BGI 1MK0 2BS5 3FZA 4OV1 1GS3 1SF7 2PZW 3UMD 5PAZ 1BHF 1MKU 2BTI 3G7C 4OXW 1GSW 1SFB 2Q1M 3UME 5RHN 1BKF 1ML8 2BWK 3GBQ 4OZL 1GV2 1SFG 2QAS 3UNN 5RNT 1BKV 1MLI 2BWL 3GK2 4P15 1GVP 1SKZ 2QDB 3V19 5TAB 1BM2 1N9N 2BZY 3GK4 4P2P 1GXT 1SNP 2QHE 3V1G 5U9U 1BMG 1N9O 2CDS 3GKY 4P7U 1H2P 1SNQ", "DNA", 0, 1149], ["1PAZ 2HWV 3L6W 5CUL 1JC7 1VMG 2ZGD 4F69 6H0K 1EIF 1PBI 2I9V 3LHC 5D53 1JDL 1W2L 2ZHH 4F6D 6H0L 1EIG 1PI8 2IGP 3LJM 5D54 1JER 1W6X 3A0D 4FC1 6HA4 1EMN 1PKS 2IIY 3LLH 5DKN 1JHC 1WAQ 3A0S 4FDX 6I3S 1EN2 1PO8 2INT 3LMF 5DM9 1JKD 1WHI 3A0V 4FE6 6I5A 1ENV 1PZ4 2J5A 3LR0 5DZD 1JOI 1WJG 3A7L 4G3O 6IFH 1EOQ 1PZA 2JIN 3LVE 5E0Z 1JON 1WJX 3ADY 4G4W 6INS 1EOT 1PZB 2JK7 3LYO 5E4P 1JPE 1WRP 3AZ5 4G4X 6IQC 1EOW 1PZC 2JP8 3LZ2 5E4X 1JPO 1WY9 3B7X 4GBC 6JQ4 1EQV 1Q4R 2JVH 3M4T 5EE2 1JZA 1XW3 3B84 4GBN 6MHN 1EV3 1Q4V 2KRI 3MAZ 5EH4 1K1Z 1XW4 3BF2 4GFY 6MPM 1F1W 1Q7O", "DNA", 2685, 3239], ["5HBP", "TEST", 45, 49], ["4IDL", "TEST", 70, 74], ["2OJR", "TEST", 85, 89], ["2OLI", "TEST", 135, 139], ["3PAZ", "TEST", 140, 144], ["1RBI", "TEST", 180, 184], ["5HJC", "TEST", 195, 199], ["1ZIB", "TEST", 210, 214], ["1FES", "TEST", 225, 229], ["2OPY", "TEST", 235, 239], ["5HKN", "TEST", 245, 249], ["1AA2", "TEST", 250, 254], ["1KXX", "TEST", 255, 259], ["1ZJ7", "TEST", 260, 264], ["3CE8", "TEST", 265, 269], ["4JHB", "TEST", 270, 274], ["1FEV", "TEST", 275, 279], ["1RBX", "TEST", 280, 284], ["5HMB", "TEST", 295, 299], ["1AB0", "TEST", 300, 304], ["1KXY", "TEST", 305, 309], ["1B0T", "TEST", 315, 319], ["4LYO", "TEST", 335, 339], ["1RRI", "TEST", 345, 349], ["5LAZ", "TEST", 360, 364], ["2PAL", "TEST", 400, 404], ["3STM", "TEST", 405, 409], ["2BEZ", "TEST", 475, 479], ["3T1X", "TEST", 505, 509], ["2BFH", "TEST", 525, 529], ["4MZ2", "TEST", 535, 539], ["1RTU", "TEST", 545, 549], ["2PNE", "TEST", 550, 554], ["3T3J", "TEST", 555, 559], ["5NGN", "TEST", 560, 564], ["1M4B", "TEST", 570, 574], ["2BHK", "TEST", 575, 579], ["3FAJ", "TEST", 580, 584], ["4N0Z", "TEST", 585, 589], ["1GDC", "TEST", 590, 594], ["1RWJ", "TEST", 595, 599], ["2PPI", "TEST", 600, 604], ["3T8R", "TEST", 605, 609], ["5NWX", "TEST", 610, 614], ["1M4M", "TEST", 620, 624], ["2BHO", "TEST", 625, 629], ["1GHJ", "TEST", 640, 644], ["1RZY", "TEST", 645, 649], ["3T8T", "TEST", 655, 659], ["1BAS", "TEST", 665, 669], ["1MB3", "TEST", 670, 674], ["2BO1", "TEST", 675, 679], ["3FRV", "TEST", 680, 684], ["4N6J", "TEST", 685, 689], ["1GKH", "TEST", 690, 694], ["1S3P", "TEST", 695, 699], ["2PVT", "TEST", 700, 704], ["3UAF", "TEST", 705, 709], ["1BEA", "TEST", 715, 719], ["2BPP", "TEST", 725, 729], ["4NEJ", "TEST", 735, 739], ["1S7I", "TEST", 745, 749], ["1BEL", "TEST", 765, 769], ["1MH7", "TEST", 770, 774], ["3FYR", "TEST", 780, 784], ["4NXR", "TEST", 785, 789], ["1GOD", "TEST", 790, 794], ["1SDZ", "TEST", 795, 799], ["2PWS", "TEST", 800, 804], ["5OMD", "TEST", 810, 814], ["1BFE", "TEST", 815, 819], ["1MH8", "TEST", 820, 824], ["2BRF", "TEST", 825, 829], ["3FZ9", "TEST", 830, 834], ["4OOH", "TEST", 835, 839], ["2PYK", "TEST", 850, 854], ["5PAL", "TEST", 860, 864], ["1BGI", "TEST", 865, 869], ["1MK0", "TEST", 870, 874], ["3FZA", "TEST", 880, 884], ["1GS3", "TEST", 890, 894], ["1SF7", "TEST", 895, 899], ["2PZW", "TEST", 900, 904], ["3UMD", "TEST", 905, 909], ["5PAZ", "TEST", 910, 914], ["1BHF", "TEST", 915, 919], ["1MKU", "TEST", 920, 924], ["2BTI", "TEST", 925, 929], ["4OXW", "TEST", 935, 939], ["1GSW", "TEST", 940, 944], ["2Q1M", "TEST", 950, 954], ["3UME", "TEST", 955, 959], ["5RHN", "TEST", 960, 964], ["1BKF", "TEST", 965, 969], ["1ML8", "TEST", 970, 974], ["2BWK", "TEST", 975, 979], ["4OZL", "TEST", 985, 989], ["1GV2", "TEST", 990, 994], ["2QAS", "TEST", 1000, 1004], ["3UNN", "TEST", 1005, 1009], ["5RNT", "TEST", 1010, 1014], ["1BKV", "TEST", 1015, 1019], ["1MLI", "TEST", 1020, 1024], ["2BWL", "TEST", 1025, 1029], ["3GK2", "TEST", 1030, 1034], ["1SKZ", "TEST", 1045, 1049], ["2QDB", "TEST", 1050, 1054], ["5TAB", "TEST", 1060, 1064], ["1BM2", "TEST", 1065, 1069], ["2BZY", "TEST", 1075, 1079], ["3GK4", "TEST", 1080, 1084], ["1GXT", "TEST", 1090, 1094], ["1SNP", "TEST", 1095, 1099], ["2QHE", "TEST", 1100, 1104], ["3V1G", "TEST", 1105, 1109], ["5U9U", "TEST", 1110, 1114], ["1BMG", "TEST", 1115, 1119], ["2CDS", "TEST", 1125, 1129], ["3GKY", "TEST", 1130, 1134], ["1SNQ", "TEST", 1145, 1149], ["2QHW", "TEST", 1150, 1154], ["3VXW", "TEST", 1155, 1159], ["5UEP", "TEST", 1160, 1164], ["1BO0", "TEST", 1165, 1169], ["2COQ", "TEST", 1175, 1179], ["3GLW", "TEST", 1180, 1184], ["1SSC", "TEST", 1195, 1199], ["3VYA", "TEST", 1205, 1209], ["1BPQ", "TEST", 1215, 1219], ["1NEQ", "TEST", 1220, 1224], ["2CW4", "TEST", 1225, 1229], ["4P9V", "TEST", 1235, 1239], ["1SV9", "TEST", 1245, 1249], ["2QNW", "TEST", 1250, 1254], ["3WIT", "TEST", 1255, 1259], ["5UES", "TEST", 1260, 1264], ["1BQK", "TEST", 1265, 1269], ["1NKO", "TEST", 1270, 1274], ["2CXY", "TEST", 1275, 1279], ["3GM3", "TEST", 1280, 1284], ["4PAZ", "TEST", 1285, 1289], ["1HEH", "TEST", 1290, 1294], ["2QR3", "TEST", 1300, 1304], ["3WRP", "TEST", 1305, 1309], ["5UET", "TEST", 1310, 1314], ["1BQR", "TEST", 1315, 1319], ["2D4L", "TEST", 1325, 1329], ["3GQU", "TEST", 1330, 1334], ["1HEY", "TEST", 1340, 1344], ["2QVT", "TEST", 1350, 1354], ["5UEV", "TEST", 1360, 1364], ["1NN7", "TEST", 1370, 1374], ["2D4M", "TEST", 1375, 1379], ["3GSP", "TEST", 1380, 1384], ["4PTA", "TEST", 1385, 1389], ["1HFX", "TEST", 1390, 1394], ["1T2J", "TEST", 1395, 1399], ["3WVT", "TEST", 1405, 1409], ["5UEY", "TEST", 1410, 1414], ["1BXY", "TEST", 1415, 1419], ["1NNX", "TEST", 1420, 1424], ["4QYW", "TEST", 1435, 1439], ["5USV", "TEST", 1460, 1464], ["1BYL", "TEST", 1465, 1469], ["1NXT", "TEST", 1470, 1474], ["2DB7", "TEST", 1475, 1479], ["4RLM", "TEST", 1485, 1489], ["1TCY", "TEST", 1495, 1499], ["5UVS", "TEST", 1510, 1514], ["1NXV", "TEST", 1520, 1524], ["2DH1", "TEST", 1525, 1529], ["3HAF", "TEST", 1530, 1534], ["4RLN", "TEST", 1535, 1539], ["1HME", "TEST", 1540, 1544], ["1TDY", "TEST", 1545, 1549], ["3ZEK", "TEST", 1555, 1559], ["5UVY", "TEST", 1560, 1564], ["1C0C", "TEST", 1565, 1569], ["3HAK", "TEST", 1580, 1584], ["1TEN", "TEST", 1595, 1599], ["2REA", "TEST", 1600, 1604], ["3ZK0", "TEST", 1605, 1609], ["5UVZ", "TEST", 1610, 1614], ["2DRT", "TEST", 1625, 1629], ["1TGJ", "TEST", 1645, 1649], ["2REY", "TEST", 1650, 1654], ["4AHG", "TEST", 1655, 1659], ["5VEA", "TEST", 1660, 1664], ["2DU9", "TEST", 1675, 1679], ["3HFF", "TEST", 1680, 1684], ["4TS8", "TEST", 1685, 1689], ["1HRC", "TEST", 1690, 1694], ["1TNS", "TEST", 1695, 1699], ["2RKN", "TEST", 1700, 1704], ["4AHI", "TEST", 1705, 1709], ["5VR3", "TEST", 1710, 1714], ["1C9V", "TEST", 1715, 1719], ["2DYQ", "TEST", 1725, 1729], ["3HFN", "TEST", 1730, 1734], ["4UNG", "TEST", 1735, 1739], ["1HRQ", "TEST", 1740, 1744], ["2RLN", "TEST", 1750, 1754], ["4AHN", "TEST", 1755, 1759], ["5WOR", "TEST", 1760, 1764], ["1CDP", "TEST", 1765, 1769], ["6CE8", "TEST", 1775, 1779], ["1DDV", "TEST", 1780, 1784], ["3IRC", "TEST", 1795, 1799], ["4ZC3", "TEST", 1800, 1804], ["1IOR", "TEST", 1805, 1809], ["1UID", "TEST", 1810, 1814], ["2WOR", "TEST", 1815, 1819], ["6CEA", "TEST", 1825, 1829], ["1DDW", "TEST", 1830, 1834], ["2FLS", "TEST", 1840, 1844], ["3J4G", "TEST", 1845, 1849], ["5AEF", "TEST", 1850, 1854], ["1IOS", "TEST", 1855, 1859], ["1UIE", "TEST", 1860, 1864], ["2WOS", "TEST", 1865, 1869], ["6CEC", "TEST", 1875, 1879], ["1DKJ", "TEST", 1880, 1884], ["3JTE", "TEST", 1895, 1899], ["5AFG", "TEST", 1900, 1904], ["1IOT", "TEST", 1905, 1909], ["1UIF", "TEST", 1910, 1914], ["2WQ0", "TEST", 1915, 1919], ["1DMM", "TEST", 1930, 1934], ["2FMB", "TEST", 1940, 1944], ["3JZR", "TEST", 1945, 1949], ["5AI2", "TEST", 1950, 1954], ["1UIG", "TEST", 1960, 1964], ["6CEE", "TEST", 1975, 1979], ["1DMN", "TEST", 1980, 1984], ["3K0X", "TEST", 1995, 1999], ["1UKU", "TEST", 2010, 2014], ["4EC2", "TEST", 2020, 2024], ["6CEF", "TEST", 2025, 2029], ["1DMQ", "TEST", 2030, 2034], ["1O5J", "TEST", 2035, 2039], ["1UPJ", "TEST", 2060, 2064], ["6DXH", "TEST", 2075, 2079], ["2FTB", "TEST", 2090, 2094], ["1UPR", "TEST", 2110, 2114], ["2X9C", "TEST", 2115, 2119], ["6DXR", "TEST", 2125, 2129], ["2GSP", "TEST", 2140, 2144], ["1UVY", "TEST", 2160, 2164], ["2XBD", "TEST", 2165, 2169], ["1DYZ", "TEST", 2180, 2184], ["3KD0", "TEST", 2195, 2199], ["2XCZ", "TEST", 2215, 2219], ["4ETA", "TEST", 2220, 2224], ["6EVL", "TEST", 2225, 2229], ["2H2B", "TEST", 2240, 2244], ["5BMH", "TEST", 2250, 2254], ["1IYU", "TEST", 2255, 2259], ["2XDY", "TEST", 2265, 2269], ["4ETB", "TEST", 2270, 2274], ["6EVM", "TEST", 2275, 2279], ["3KLU", "TEST", 2295, 2299], ["1IZA", "TEST", 2305, 2309], ["2XFE", "TEST", 2315, 2319], ["4ETD", "TEST", 2320, 2324], ["6FCE", "TEST", 2325, 2329], ["1OOI", "TEST", 2335, 2339], ["3KMJ", "TEST", 2345, 2349], ["1J2V", "TEST", 2355, 2359], ["2XKH", "TEST", 2365, 2369], ["4ETE", "TEST", 2370, 2374], ["6FGL", "TEST", 2375, 2379], ["1OPY", "TEST", 2385, 2389], ["2H8A", "TEST", 2390, 2394], ["3KQ6", "TEST", 2395, 2399], ["5C4P", "TEST", 2400, 2404], ["1J4H", "TEST", 2405, 2409], ["2XMU", "TEST", 2415, 2419], ["4EWW", "TEST", 2420, 2424], ["6FGT", "TEST", 2425, 2429], ["1OR5", "TEST", 2435, 2439], ["2H8V", "TEST", 2440, 2444], ["3KQI", "TEST", 2445, 2449], ["1J4I", "TEST", 2455, 2459], ["1VAT", "TEST", 2460, 2464], ["2YHN", "TEST", 2465, 2469], ["4EWZ", "TEST", 2470, 2474], ["6FGU", "TEST", 2475, 2479], ["1P0R", "TEST", 2485, 2489], ["3KTP", "TEST", 2495, 2499], ["5C6X", "TEST", 2500, 2504], ["2YWZ", "TEST", 2515, 2519], ["4EX0", "TEST", 2520, 2524], ["1EA2", "TEST", 2530, 2534], ["2HB4", "TEST", 2540, 2544], ["1J7Z", "TEST", 2555, 2559], ["1VER", "TEST", 2560, 2564], ["2YXY", "TEST", 2565, 2569], ["4F1A", "TEST", 2570, 2574], ["1ECW", "TEST", 2580, 2584], ["2HC8", "TEST", 2590, 2594], ["3KVT", "TEST", 2595, 2599], ["1J81", "TEST", 2605, 2609], ["1VHF", "TEST", 2610, 2614], ["2Z44", "TEST", 2615, 2619], ["4F2E", "TEST", 2620, 2624], ["6FXF", "TEST", 2625, 2629], ["1ED1", "TEST", 2630, 2634], ["1PAL", "TEST", 2635, 2639], ["2HPL", "TEST", 2640, 2644], ["3L1M", "TEST", 2645, 2649], ["5CPV", "TEST", 2650, 2654], ["1J82", "TEST", 2655, 2659], ["1VIH", "TEST", 2660, 2664], ["2Z7J", "TEST", 2665, 2669], ["6GF0", "TEST", 2675, 2679], ["1PAZ", "TEST", 2685, 2689], ["2HWV", "TEST", 2690, 2694], ["5CUL", "TEST", 2700, 2704], ["1JC7", "TEST", 2705, 2709], ["1VMG", "TEST", 2710, 2714], ["2ZGD", "TEST", 2715, 2719], ["1PBI", "TEST", 2735, 2739], ["2I9V", "TEST", 2740, 2744], ["3LHC", "TEST", 2745, 2749], ["1JDL", "TEST", 2755, 2759], ["2ZHH", "TEST", 2765, 2769], ["1EIG", "TEST", 2780, 2784], ["2IGP", "TEST", 2790, 2794], ["3LJM", "TEST", 2795, 2799], ["1JER", "TEST", 2805, 2809], ["1W6X", "TEST", 2810, 2814], ["1EMN", "TEST", 2830, 2834], ["1PKS", "TEST", 2835, 2839], ["2IIY", "TEST", 2840, 2844], ["3LLH", "TEST", 2845, 2849], ["5DKN", "TEST", 2850, 2854], ["1JHC", "TEST", 2855, 2859], ["3A0S", "TEST", 2865, 2869], ["4FDX", "TEST", 2870, 2874], ["6I3S", "TEST", 2875, 2879], ["2INT", "TEST", 2890, 2894], ["3LMF", "TEST", 2895, 2899], ["5DM9", "TEST", 2900, 2904], ["1JKD", "TEST", 2905, 2909], ["1WHI", "TEST", 2910, 2914], ["3A0V", "TEST", 2915, 2919], ["1ENV", "TEST", 2930, 2934], ["1PZ4", "TEST", 2935, 2939], ["2J5A", "TEST", 2940, 2944], ["3LR0", "TEST", 2945, 2949], ["5DZD", "TEST", 2950, 2954], ["1JOI", "TEST", 2955, 2959], ["1WJG", "TEST", 2960, 2964], ["3A7L", "TEST", 2965, 2969], ["6IFH", "TEST", 2975, 2979], ["1EOQ", "TEST", 2980, 2984], ["1PZA", "TEST", 2985, 2989], ["2JIN", "TEST", 2990, 2994], ["3LVE", "TEST", 2995, 2999], ["5E0Z", "TEST", 3000, 3004], ["1JON", "TEST", 3005, 3009], ["1WJX", "TEST", 3010, 3014], ["3ADY", "TEST", 3015, 3019], ["4G4W", "TEST", 3020, 3024], ["6INS", "TEST", 3025, 3029], ["1EOT", "TEST", 3030, 3034], ["1PZB", "TEST", 3035, 3039], ["2JK7", "TEST", 3040, 3044], ["3LYO", "TEST", 3045, 3049], ["1JPE", "TEST", 3055, 3059], ["1WRP", "TEST", 3060, 3064], ["3AZ5", "TEST", 3065, 3069], ["6IQC", "TEST", 3075, 3079], ["1PZC", "TEST", 3085, 3089], ["2JP8", "TEST", 3090, 3094], ["1JPO", "TEST", 3105, 3109], ["3B7X", "TEST", 3115, 3119], ["4GBC", "TEST", 3120, 3124], ["1EQV", "TEST", 3130, 3134], ["2JVH", "TEST", 3140, 3144], ["1JZA", "TEST", 3155, 3159], ["4GBN", "TEST", 3170, 3174], ["6MHN", "TEST", 3175, 3179], ["1EV3", "TEST", 3180, 3184], ["2KRI", "TEST", 3190, 3194], ["3MAZ", "TEST", 3195, 3199]]]], "262216c512be06a11e72b4abe4ec52c38db47d7f": [["INTRODUCTIONViral infections are important causes of disease of the respiratory tract.", [["respiratory tract", "ANATOMY", 68, 85], ["infections", "DISEASE", 18, 28], ["disease of the respiratory tract", "DISEASE", 53, 85], ["respiratory tract", "ORGANISM_SUBDIVISION", 68, 85], ["INTRODUCTIONViral infections", "PROBLEM", 0, 28], ["disease of the respiratory tract", "PROBLEM", 53, 85], ["infections", "OBSERVATION", 18, 28], ["disease", "OBSERVATION", 53, 60], ["respiratory tract", "ANATOMY", 68, 85]]], ["The common cold is the most frequently encountered infectious syndrome of humans, while influenza continues to be a major cause of mortality and serious morbidity worldwide.", [["influenza", "DISEASE", 88, 97], ["humans", "ORGANISM", 74, 80], ["humans", "SPECIES", 74, 80], ["humans", "SPECIES", 74, 80], ["infectious syndrome of humans", "PROBLEM", 51, 80], ["influenza", "PROBLEM", 88, 97], ["serious morbidity worldwide", "PROBLEM", 145, 172], ["most frequently", "OBSERVATION_MODIFIER", 23, 38], ["infectious", "OBSERVATION", 51, 61]]], ["Respiratory viral infections frequently complicate the course of patients with chronic obstructive pulmonary disease (COPD) and asthma.", [["pulmonary", "ANATOMY", 99, 108], ["Respiratory viral infections", "DISEASE", 0, 28], ["chronic obstructive pulmonary disease", "DISEASE", 79, 116], ["COPD", "DISEASE", 118, 122], ["asthma", "DISEASE", 128, 134], ["patients", "ORGANISM", 65, 73], ["pulmonary", "ORGAN", 99, 108], ["patients", "SPECIES", 65, 73], ["Respiratory viral infections", "PROBLEM", 0, 28], ["chronic obstructive pulmonary disease", "PROBLEM", 79, 116], ["COPD)", "PROBLEM", 118, 123], ["asthma", "PROBLEM", 128, 134], ["viral infections", "OBSERVATION", 12, 28], ["chronic", "OBSERVATION_MODIFIER", 79, 86], ["obstructive", "OBSERVATION_MODIFIER", 87, 98], ["pulmonary", "ANATOMY", 99, 108], ["disease", "OBSERVATION", 109, 116], ["COPD", "OBSERVATION", 118, 122], ["asthma", "OBSERVATION", 128, 134]]], ["As the number of immunocompromised persons in the population has increased, infections due to cytomegalovirus and other herpes viruses, adenoviruses, and paramyxoviruses have assumed increasing importance in pulmonary medicine.", [["pulmonary", "ANATOMY", 208, 217], ["infections", "DISEASE", 76, 86], ["cytomegalovirus", "DISEASE", 94, 109], ["herpes viruses", "DISEASE", 120, 134], ["persons", "ORGANISM", 35, 42], ["cytomegalovirus", "ORGANISM", 94, 109], ["herpes viruses", "ORGANISM", 120, 134], ["adenoviruses", "ORGANISM", 136, 148], ["pulmonary", "ORGAN", 208, 217], ["persons", "SPECIES", 35, 42], ["immunocompromised persons", "PROBLEM", 17, 42], ["infections", "PROBLEM", 76, 86], ["cytomegalovirus", "PROBLEM", 94, 109], ["other herpes viruses", "PROBLEM", 114, 134], ["adenoviruses", "PROBLEM", 136, 148], ["paramyxoviruses", "PROBLEM", 154, 169], ["pulmonary medicine", "TREATMENT", 208, 226], ["immunocompromised", "OBSERVATION", 17, 34], ["increased", "OBSERVATION_MODIFIER", 65, 74], ["infections", "OBSERVATION", 76, 86], ["cytomegalovirus", "OBSERVATION", 94, 109], ["herpes viruses", "OBSERVATION", 120, 134], ["increasing", "OBSERVATION_MODIFIER", 183, 193], ["pulmonary", "ANATOMY", 208, 217]]], ["Finally, recent years have seen the emergence of new viral respiratory pathogens, including hantaviruses, human metapneumovirus, avian influenza A viruses, and the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses.", [["viral respiratory pathogens", "DISEASE", 53, 80], ["hantaviruses", "DISEASE", 92, 104], ["human metapneumovirus", "DISEASE", 106, 127], ["avian influenza A viruses", "DISEASE", 129, 154], ["acute respiratory syndrome", "DISEASE", 171, 197], ["SARS", "DISEASE", 199, 203], ["Middle East respiratory syndrome (MERS) coronaviruses", "DISEASE", 209, 262], ["human metapneumovirus", "ORGANISM", 106, 127], ["avian influenza A viruses", "ORGANISM", 129, 154], ["human", "SPECIES", 106, 111], ["metapneumovirus", "SPECIES", 112, 127], ["avian influenza A viruses", "SPECIES", 129, 154], ["human metapneumovirus", "SPECIES", 106, 127], ["avian influenza A viruses", "SPECIES", 129, 154], ["Middle East respiratory syndrome (MERS) coronaviruses", "SPECIES", 209, 262], ["new viral respiratory pathogens", "PROBLEM", 49, 80], ["hantaviruses", "PROBLEM", 92, 104], ["human metapneumovirus", "PROBLEM", 106, 127], ["avian influenza A viruses", "PROBLEM", 129, 154], ["the severe acute respiratory syndrome", "PROBLEM", 160, 197], ["SARS)", "PROBLEM", 199, 204], ["Middle East respiratory syndrome (MERS) coronaviruses", "PROBLEM", 209, 262], ["new", "OBSERVATION_MODIFIER", 49, 52], ["viral", "OBSERVATION_MODIFIER", 53, 58], ["respiratory pathogens", "OBSERVATION", 59, 80], ["severe", "OBSERVATION_MODIFIER", 164, 170], ["acute", "OBSERVATION_MODIFIER", 171, 176], ["respiratory syndrome", "OBSERVATION", 177, 197], ["Middle", "ANATOMY_MODIFIER", 209, 215], ["respiratory syndrome", "OBSERVATION", 221, 241]]], ["This introductory section outlines general concepts of respiratory viral infections and their associated clinical syndromes.", [["respiratory viral infections", "DISEASE", 55, 83], ["This introductory section", "TREATMENT", 0, 25], ["respiratory viral infections", "PROBLEM", 55, 83], ["their associated clinical syndromes", "PROBLEM", 88, 123], ["respiratory", "ANATOMY", 55, 66], ["viral infections", "OBSERVATION", 67, 83]]], ["The following sections then provide a review of the major viral pathogens infecting the respiratory tract.CLASSIFICATIONViruses of importance in the respiratory tract (Table 32-1) include those considered to be principal respiratory viruses, the replication of which is generally restricted to the respiratory tract, and others in which respiratory involvement is part of a generalized infection.", [["sections", "ANATOMY", 14, 22], ["respiratory tract", "ANATOMY", 88, 105], ["respiratory tract", "ANATOMY", 149, 166], ["respiratory tract", "ANATOMY", 298, 315], ["respiratory", "ANATOMY", 337, 348], ["viral pathogens infecting the respiratory tract", "DISEASE", 58, 105], ["respiratory viruses", "DISEASE", 221, 240], ["infection", "DISEASE", 386, 395], ["respiratory tract", "ORGANISM_SUBDIVISION", 88, 105], ["respiratory tract", "ORGANISM_SUBDIVISION", 149, 166], ["respiratory tract", "ORGANISM_SUBDIVISION", 298, 315], ["the major viral pathogens infecting the respiratory tract", "PROBLEM", 48, 105], ["principal respiratory viruses", "PROBLEM", 211, 240], ["a generalized infection", "PROBLEM", 372, 395], ["respiratory tract", "ANATOMY", 88, 105], ["respiratory tract", "ANATOMY", 149, 166], ["respiratory viruses", "OBSERVATION", 221, 240], ["respiratory tract", "ANATOMY", 298, 315], ["generalized", "OBSERVATION_MODIFIER", 374, 385], ["infection", "OBSERVATION", 386, 395]]], ["Virus classification depends in part on the type and configuration of the nucleic acid in the viral genome, the characteristics of the viral structural proteins, and the presence or absence of an envelope surrounding the virus particle.", [["nucleic acid", "CHEMICAL", 74, 86], ["viral genome", "DNA", 94, 106], ["viral structural proteins", "PROTEIN", 135, 160], ["Virus classification", "PROBLEM", 0, 20], ["the nucleic acid", "PROBLEM", 70, 86], ["the viral genome", "PROBLEM", 90, 106], ["the viral structural proteins", "PROBLEM", 131, 160], ["an envelope surrounding the virus particle", "PROBLEM", 193, 235], ["nucleic acid", "OBSERVATION", 74, 86], ["viral genome", "OBSERVATION", 94, 106], ["viral structural proteins", "OBSERVATION", 135, 160], ["virus particle", "OBSERVATION", 221, 235]]], ["The number of distinct antigenic types within each of the virus families also varies.TRANSMISSIONThe routes by which the different respiratory viruses spread from person to person are variable and include combinations of contact, droplet, and aerosol transmission.", [["person", "SPECIES", 163, 169], ["person", "SPECIES", 173, 179], ["the different respiratory viruses spread", "PROBLEM", 117, 157], ["distinct", "OBSERVATION_MODIFIER", 14, 22], ["antigenic types", "OBSERVATION", 23, 38], ["respiratory viruses", "OBSERVATION", 131, 150]]], ["For example, rhinovirus and respiratory syncytial virus (RSV) are primarily spread by direct contact with contaminated skin and environmental surfaces followed by self-inoculation of virus onto the nasal mucosa or conjunctiva.", [["skin", "ANATOMY", 119, 123], ["nasal mucosa", "ANATOMY", 198, 210], ["conjunctiva", "ANATOMY", 214, 225], ["respiratory syncytial virus", "DISEASE", 28, 55], ["rhinovirus", "ORGANISM", 13, 23], ["respiratory syncytial virus", "ORGANISM", 28, 55], ["RSV", "ORGANISM", 57, 60], ["skin", "ORGAN", 119, 123], ["nasal mucosa", "MULTI-TISSUE_STRUCTURE", 198, 210], ["conjunctiva", "ORGAN", 214, 225], ["rhinovirus", "SPECIES", 13, 23], ["respiratory syncytial virus", "SPECIES", 28, 55], ["respiratory syncytial virus", "SPECIES", 28, 55], ["RSV", "SPECIES", 57, 60], ["rhinovirus", "PROBLEM", 13, 23], ["respiratory syncytial virus (RSV)", "PROBLEM", 28, 61], ["contaminated skin and environmental surfaces", "PROBLEM", 106, 150], ["rhinovirus", "OBSERVATION", 13, 23], ["respiratory", "ANATOMY", 28, 39], ["syncytial virus", "OBSERVATION", 40, 55], ["skin", "ANATOMY", 119, 123], ["nasal mucosa", "ANATOMY", 198, 210], ["conjunctiva", "ANATOMY", 214, 225]]], ["Other viruses, such as measles and varicella-zoster viruses, spread as small-particle aerosols.", [["measles", "DISEASE", 23, 30], ["varicella-zoster viruses", "DISEASE", 35, 59], ["measles", "ORGANISM", 23, 30], ["varicella-zoster viruses", "ORGANISM", 35, 59], ["varicella-zoster viruses", "SPECIES", 35, 59], ["varicella-zoster viruses", "SPECIES", 35, 59], ["Other viruses", "PROBLEM", 0, 13], ["measles", "PROBLEM", 23, 30], ["varicella", "PROBLEM", 35, 44], ["zoster viruses", "PROBLEM", 45, 59], ["viruses", "OBSERVATION", 6, 13], ["zoster viruses", "OBSERVATION", 45, 59], ["small", "OBSERVATION_MODIFIER", 71, 76], ["particle aerosols", "OBSERVATION", 77, 94]]], ["Other viruses may spread by means of larger-particle aerosols over short distances (1 m).", [["Other viruses", "PROBLEM", 0, 13], ["viruses", "OBSERVATION", 6, 13], ["larger", "OBSERVATION_MODIFIER", 37, 43]]], ["The relative importance of the various transmission routes under natural conditions for each virus varies and in many cases is unknown.PATHOGENESIS OF INFECTIONThe initial sites of infection and pathogenesis differ for the various virus groups.", [["sites", "ANATOMY", 172, 177], ["infection", "DISEASE", 181, 190], ["each virus varies", "PROBLEM", 88, 105], ["INFECTION", "PROBLEM", 151, 160], ["infection", "PROBLEM", 181, 190], ["pathogenesis", "PROBLEM", 195, 207], ["the various virus groups", "PROBLEM", 219, 243], ["INFECTION", "OBSERVATION", 151, 160], ["infection", "OBSERVATION", 181, 190]]], ["Some, such as rhinovirus, are associated mainly with upper respiratory tract involvement.", [["upper respiratory tract", "ANATOMY", 53, 76], ["rhinovirus", "ORGANISM", 14, 24], ["upper", "ORGANISM_SUBDIVISION", 53, 58], ["respiratory tract", "ORGANISM_SUBDIVISION", 59, 76], ["rhinovirus", "PROBLEM", 14, 24], ["upper respiratory tract involvement", "PROBLEM", 53, 88], ["rhinovirus", "OBSERVATION", 14, 24], ["upper", "ANATOMY_MODIFIER", 53, 58], ["respiratory tract", "ANATOMY", 59, 76]]], ["Others, such as influenza, commonly invade the lower airways and sometimes pulmonary parenchyma in addition to causing upper airway disease.", [["lower airways", "ANATOMY", 47, 60], ["pulmonary parenchyma", "ANATOMY", 75, 95], ["upper airway", "ANATOMY", 119, 131], ["influenza", "DISEASE", 16, 25], ["upper airway disease", "DISEASE", 119, 139], ["airways", "MULTI-TISSUE_STRUCTURE", 53, 60], ["pulmonary parenchyma", "MULTI-TISSUE_STRUCTURE", 75, 95], ["upper airway", "MULTI-TISSUE_STRUCTURE", 119, 131], ["influenza", "PROBLEM", 16, 25], ["upper airway disease", "PROBLEM", 119, 139], ["lower", "ANATOMY_MODIFIER", 47, 52], ["airways", "ANATOMY", 53, 60], ["pulmonary", "ANATOMY", 75, 84], ["parenchyma", "ANATOMY_MODIFIER", 85, 95], ["upper", "ANATOMY_MODIFIER", 119, 124], ["airway", "ANATOMY", 125, 131], ["disease", "OBSERVATION", 132, 139]]], ["The viruses also differ in the relative contributions to the clinical manifestations of disease from damage due to direct viral mechanisms and damage due to host immune responses and inflammation.PATHOGENESIS OF INFECTIONAn additional important feature of respiratory virus infections is their effect on the resident bacterial flora of the upper airways.", [["upper airways", "ANATOMY", 340, 353], ["inflammation", "DISEASE", 183, 195], ["respiratory virus infections", "DISEASE", 256, 284], ["respiratory virus", "ORGANISM", 256, 273], ["upper airways", "MULTI-TISSUE_STRUCTURE", 340, 353], ["The viruses", "PROBLEM", 0, 11], ["disease", "PROBLEM", 88, 95], ["damage", "PROBLEM", 101, 107], ["direct viral mechanisms", "PROBLEM", 115, 138], ["damage", "PROBLEM", 143, 149], ["host immune responses", "PROBLEM", 157, 178], ["inflammation", "PROBLEM", 183, 195], ["respiratory virus infections", "PROBLEM", 256, 284], ["viruses", "OBSERVATION", 4, 11], ["inflammation", "OBSERVATION", 183, 195], ["important feature of", "UNCERTAINTY", 235, 255], ["respiratory virus infections", "OBSERVATION", 256, 284], ["bacterial flora", "OBSERVATION", 317, 332], ["upper", "ANATOMY_MODIFIER", 340, 345], ["airways", "ANATOMY", 346, 353]]], ["Respiratory virus infections alter bacterial colonization patterns, increase bacterial adhesion to respiratory epithelium, and reduce mucociliary clearance and phagocytosis.", [["respiratory epithelium", "ANATOMY", 99, 121], ["mucociliary", "ANATOMY", 134, 145], ["Respiratory virus infections", "DISEASE", 0, 28], ["Respiratory virus", "ORGANISM", 0, 17], ["respiratory epithelium", "TISSUE", 99, 121], ["mucociliary", "MULTI-TISSUE_STRUCTURE", 134, 145], ["Respiratory virus", "SPECIES", 0, 17], ["Respiratory virus infections", "PROBLEM", 0, 28], ["alter bacterial colonization patterns", "PROBLEM", 29, 66], ["bacterial adhesion to respiratory epithelium", "PROBLEM", 77, 121], ["mucociliary clearance", "TEST", 134, 155], ["phagocytosis", "PROBLEM", 160, 172], ["virus infections", "OBSERVATION", 12, 28], ["bacterial colonization", "OBSERVATION", 35, 57], ["increase", "OBSERVATION_MODIFIER", 68, 76], ["bacterial adhesion", "OBSERVATION", 77, 95], ["respiratory epithelium", "OBSERVATION", 99, 121], ["mucociliary clearance", "OBSERVATION", 134, 155]]], ["These impairments of host defenses by viruses allow colonization by pathogenic bacteria and invasion of normally sterile areas, such as the paranasal sinuses, middle ear, and lower respiratory tract, resulting in secondary infection.CLINICAL SYNDROMESAs shown in Table 32COMMON COLDThere is no universally accepted, standard definition of a cold, but the term is usually used to refer to acute rhinitis with variable degrees of pharyngitis.", [["paranasal sinuses", "ANATOMY", 140, 157], ["middle ear", "ANATOMY", 159, 169], ["lower respiratory tract", "ANATOMY", 175, 198], ["infection", "DISEASE", 223, 232], ["rhinitis", "DISEASE", 394, 402], ["pharyngitis", "DISEASE", 428, 439], ["paranasal sinuses", "MULTI-TISSUE_STRUCTURE", 140, 157], ["ear", "ORGAN", 166, 169], ["lower", "ORGANISM_SUBDIVISION", 175, 180], ["respiratory tract", "ORGANISM_SUBDIVISION", 181, 198], ["host defenses", "PROBLEM", 21, 34], ["pathogenic bacteria", "PROBLEM", 68, 87], ["invasion of normally sterile areas", "PROBLEM", 92, 126], ["the paranasal sinuses, middle ear, and lower respiratory tract", "PROBLEM", 136, 198], ["secondary infection", "PROBLEM", 213, 232], ["a cold", "PROBLEM", 339, 345], ["acute rhinitis", "PROBLEM", 388, 402], ["pharyngitis", "PROBLEM", 428, 439], ["host defenses", "OBSERVATION", 21, 34], ["pathogenic", "OBSERVATION_MODIFIER", 68, 78], ["bacteria", "OBSERVATION_MODIFIER", 79, 87], ["invasion", "OBSERVATION_MODIFIER", 92, 100], ["normally", "OBSERVATION_MODIFIER", 104, 112], ["sterile", "OBSERVATION_MODIFIER", 113, 120], ["areas", "OBSERVATION", 121, 126], ["paranasal sinuses", "ANATOMY", 140, 157], ["middle ear", "ANATOMY", 159, 169], ["lower", "ANATOMY_MODIFIER", 175, 180], ["respiratory tract", "ANATOMY", 181, 198], ["secondary", "OBSERVATION_MODIFIER", 213, 222], ["infection", "OBSERVATION", 223, 232], ["no", "UNCERTAINTY", 291, 293], ["acute", "OBSERVATION_MODIFIER", 388, 393], ["rhinitis", "OBSERVATION", 394, 402], ["variable degrees", "OBSERVATION_MODIFIER", 408, 424], ["pharyngitis", "OBSERVATION", 428, 439]]], ["Systemic complaints are absent or modest in severity and fever is unusual.", [["fever", "DISEASE", 57, 62], ["Systemic complaints", "PROBLEM", 0, 19], ["modest in severity", "PROBLEM", 34, 52], ["fever", "PROBLEM", 57, 62], ["modest", "OBSERVATION_MODIFIER", 34, 40], ["fever", "OBSERVATION", 57, 62]]], ["Allergic diseases of the upper airway often have clinical manifestations similar to those of colds.", [["upper airway", "ANATOMY", 25, 37], ["Allergic diseases of the upper airway", "DISEASE", 0, 37], ["colds", "DISEASE", 93, 98], ["upper airway", "ORGANISM_SUBDIVISION", 25, 37], ["Allergic diseases of the upper airway", "PROBLEM", 0, 37], ["clinical manifestations", "PROBLEM", 49, 72], ["colds", "PROBLEM", 93, 98], ["upper", "ANATOMY_MODIFIER", 25, 30], ["airway", "ANATOMY", 31, 37]]], ["Colds are frequently associated with involvement of the middle ear, likely due to viruses that cause colds.", [["middle ear", "ANATOMY", 56, 66], ["colds", "DISEASE", 101, 106], ["middle", "ORGAN", 56, 62], ["ear", "ORGAN", 63, 66], ["Colds", "PROBLEM", 0, 5], ["involvement of the middle ear", "PROBLEM", 37, 66], ["viruses", "PROBLEM", 82, 89], ["colds", "PROBLEM", 101, 106], ["middle ear", "ANATOMY", 56, 66], ["likely due to", "UNCERTAINTY", 68, 81], ["viruses", "OBSERVATION", 82, 89]]], ["In some cases, pharyngeal symptoms predominate to a degree that overshadows other complaints.", [["pharyngeal", "ANATOMY", 15, 25], ["pharyngeal", "ORGAN", 15, 25], ["pharyngeal symptoms", "PROBLEM", 15, 34], ["other complaints", "PROBLEM", 76, 92], ["pharyngeal", "ANATOMY", 15, 25]]], ["The kinins are potent stimulators of pain nerve endings, and high levels of bradykinin and lysylbradykinin are present in nasal secretions of patients with rhinovirusinduced colds.", [["nerve endings", "ANATOMY", 42, 55], ["nasal secretions", "ANATOMY", 122, 138], ["pain", "DISEASE", 37, 41], ["bradykinin", "CHEMICAL", 76, 86], ["lysylbradykinin", "CHEMICAL", 91, 106], ["colds", "DISEASE", 174, 179], ["bradykinin", "CHEMICAL", 76, 86], ["lysylbradykinin", "CHEMICAL", 91, 106], ["kinins", "GENE_OR_GENE_PRODUCT", 4, 10], ["nerve endings", "MULTI-TISSUE_STRUCTURE", 42, 55], ["bradykinin", "GENE_OR_GENE_PRODUCT", 76, 86], ["lysylbradykinin", "SIMPLE_CHEMICAL", 91, 106], ["nasal secretions", "ORGANISM_SUBSTANCE", 122, 138], ["patients", "ORGANISM", 142, 150], ["patients", "SPECIES", 142, 150], ["pain nerve endings", "PROBLEM", 37, 55], ["bradykinin and lysylbradykinin", "TREATMENT", 76, 106], ["nasal secretions", "PROBLEM", 122, 138], ["rhinovirusinduced colds", "PROBLEM", 156, 179], ["potent", "OBSERVATION_MODIFIER", 15, 21], ["pain nerve", "ANATOMY", 37, 47], ["high", "OBSERVATION_MODIFIER", 61, 65], ["nasal", "ANATOMY", 122, 127], ["secretions", "OBSERVATION", 128, 138]]], ["Intranasal application of bradykinin promotes sore throat and nasal symptoms in volunteers, supporting a role for these agents in the pathogenesis of cold symptoms.", [["sore throat", "ANATOMY", 46, 57], ["nasal", "ANATOMY", 62, 67], ["bradykinin", "CHEMICAL", 26, 36], ["sore throat", "DISEASE", 46, 57], ["bradykinin", "CHEMICAL", 26, 36], ["bradykinin", "SIMPLE_CHEMICAL", 26, 36], ["throat", "ORGANISM_SUBDIVISION", 51, 57], ["nasal", "ORGANISM_SUBDIVISION", 62, 67], ["volunteers", "ORGANISM", 80, 90], ["Intranasal application of bradykinin", "TREATMENT", 0, 36], ["sore throat", "PROBLEM", 46, 57], ["nasal symptoms in volunteers", "PROBLEM", 62, 90], ["these agents", "TREATMENT", 114, 126], ["cold symptoms", "PROBLEM", 150, 163], ["nasal", "ANATOMY", 62, 67]]], ["5 The respiratory viruses causing pharyngitis can be divided into two groups: those associated with a pharyngeal or tonsillar exudate and those without such an exudate (Table 32-3) .", [["pharyngeal", "ANATOMY", 102, 112], ["tonsillar exudate", "ANATOMY", 116, 133], ["respiratory viruses", "DISEASE", 6, 25], ["pharyngitis", "DISEASE", 34, 45], ["pharyngeal", "ORGANISM_SUBDIVISION", 102, 112], ["The respiratory viruses", "PROBLEM", 2, 25], ["pharyngitis", "PROBLEM", 34, 45], ["a pharyngeal or tonsillar exudate", "PROBLEM", 100, 133], ["an exudate", "PROBLEM", 157, 167], ["respiratory viruses", "OBSERVATION", 6, 25], ["pharyngitis", "OBSERVATION", 34, 45], ["pharyngeal", "ANATOMY", 102, 112], ["tonsillar", "ANATOMY", 116, 125], ["exudate", "OBSERVATION", 126, 133], ["exudate", "OBSERVATION", 160, 167]]], ["Pharyngitis is often a prominent complaint with adenovirus and influenza virus infection.", [["Pharyngitis", "DISEASE", 0, 11], ["influenza virus infection", "DISEASE", 63, 88], ["adenovirus", "ORGANISM", 48, 58], ["influenza virus", "ORGANISM", 63, 78], ["influenza virus", "SPECIES", 63, 78], ["Pharyngitis", "PROBLEM", 0, 11], ["adenovirus", "PROBLEM", 48, 58], ["influenza virus infection", "PROBLEM", 63, 88], ["prominent", "OBSERVATION_MODIFIER", 23, 32], ["influenza virus", "OBSERVATION", 63, 78]]], ["Also, some eustachian tube dysfunction.", [["eustachian tube", "ANATOMY", 11, 26], ["eustachian tube dysfunction", "DISEASE", 11, 38], ["eustachian tube", "TISSUE", 11, 26], ["some eustachian tube dysfunction", "PROBLEM", 6, 38], ["eustachian", "OBSERVATION", 11, 21], ["tube dysfunction", "OBSERVATION", 22, 38]]], ["Colds are associated with symptomatic otitis media in approximately 2% of cases in adults and in a higher proportion in young children.", [["otitis media", "DISEASE", 38, 50], ["children", "ORGANISM", 126, 134], ["children", "SPECIES", 126, 134], ["Colds", "PROBLEM", 0, 5], ["symptomatic otitis media", "PROBLEM", 26, 50], ["symptomatic", "OBSERVATION_MODIFIER", 26, 37], ["otitis", "OBSERVATION", 38, 44]]], ["Colds are frequently associated with sinus mucosal thickening or secretions on computed tomography scans but rarely result in symptomatic sinusitis.", [["sinus mucosal", "ANATOMY", 37, 50], ["secretions", "ANATOMY", 65, 75], ["sinusitis", "DISEASE", 138, 147], ["sinus mucosal", "PATHOLOGICAL_FORMATION", 37, 50], ["Colds", "PROBLEM", 0, 5], ["sinus mucosal thickening", "PROBLEM", 37, 61], ["secretions", "PROBLEM", 65, 75], ["computed tomography scans", "TEST", 79, 104], ["symptomatic sinusitis", "PROBLEM", 126, 147], ["sinus mucosal", "ANATOMY", 37, 50], ["thickening", "OBSERVATION", 51, 61], ["secretions", "OBSERVATION", 65, 75], ["symptomatic", "OBSERVATION_MODIFIER", 126, 137], ["sinusitis", "OBSERVATION", 138, 147]]], ["Vertigo associated with viral labyrinthitis may also be seen.COMMON COLDThe common cold syndrome is caused by any one of a large number of antigenically distinct viruses found in four principal groups (Table 32-2) .", [["Vertigo", "DISEASE", 0, 7], ["viral labyrinthitis", "DISEASE", 24, 43], ["cold syndrome", "DISEASE", 83, 96], ["Vertigo", "PROBLEM", 0, 7], ["viral labyrinthitis", "PROBLEM", 24, 43], ["COMMON COLDThe common cold syndrome", "PROBLEM", 61, 96], ["antigenically distinct viruses", "PROBLEM", 139, 169], ["viral labyrinthitis", "OBSERVATION", 24, 43], ["may also be seen", "UNCERTAINTY", 44, 60], ["common cold", "ANATOMY", 76, 87], ["syndrome", "OBSERVATION", 88, 96], ["large", "OBSERVATION_MODIFIER", 123, 128], ["number", "OBSERVATION_MODIFIER", 129, 135], ["antigenically", "OBSERVATION_MODIFIER", 139, 152], ["distinct", "OBSERVATION_MODIFIER", 153, 161], ["viruses", "OBSERVATION", 162, 169], ["four", "OBSERVATION_MODIFIER", 179, 183], ["principal", "OBSERVATION_MODIFIER", 184, 193]]], ["Epidemiologic studies have indicated that on an annual basis, any one antigenic type of virus is responsible for less than 1% of all colds.", [["colds", "DISEASE", 133, 138], ["Epidemiologic studies", "TEST", 0, 21], ["virus", "PROBLEM", 88, 93], ["virus", "OBSERVATION", 88, 93], ["colds", "OBSERVATION", 133, 138]]], ["Since the discovery of the respiratory viruses in the 1960s, rhinovirus has emerged as the prototype common cold virus ( Fig. 32-1) .COMMON COLDThe recommended approach to colds is to use individual remedies to treat specific symptoms.", [["respiratory viruses", "DISEASE", 27, 46], ["colds", "DISEASE", 172, 177], ["rhinovirus", "ORGANISM", 61, 71], ["cold virus", "ORGANISM", 108, 118], ["the respiratory viruses", "PROBLEM", 23, 46], ["rhinovirus", "PROBLEM", 61, 71], ["the prototype common cold virus", "PROBLEM", 87, 118], ["individual remedies", "TREATMENT", 188, 207], ["specific symptoms", "PROBLEM", 217, 234], ["respiratory", "ANATOMY", 27, 38], ["viruses", "OBSERVATION", 39, 46], ["rhinovirus", "OBSERVATION", 61, 71]]], ["Nasal sprays containing decongestants should be used for no more than 3 days, to avoid a rebound vasomotor rhinitis.", [["Nasal", "ANATOMY", 0, 5], ["vasomotor rhinitis", "DISEASE", 97, 115], ["Nasal sprays containing decongestants", "TREATMENT", 0, 37], ["a rebound vasomotor rhinitis", "PROBLEM", 87, 115], ["rhinitis", "OBSERVATION", 107, 115]]], ["Cough syrups containing expectorants are of unproven value in common colds.", [["colds", "DISEASE", 69, 74], ["Cough syrups", "PROBLEM", 0, 12], ["unproven value in common colds", "PROBLEM", 44, 74], ["common", "OBSERVATION_MODIFIER", 62, 68], ["colds", "OBSERVATION", 69, 74]]], ["Symptoms of sneezing and rhinorrhea can be alleviated with nonselective antihistamines such as brompheniramine, chlorpheniramine, or clemastine fumarate, 1 but treatment with selective H 1 inhibitors is not effective.", [["sneezing", "DISEASE", 12, 20], ["rhinorrhea", "DISEASE", 25, 35], ["brompheniramine", "CHEMICAL", 95, 110], ["chlorpheniramine", "CHEMICAL", 112, 128], ["clemastine fumarate", "CHEMICAL", 133, 152], ["brompheniramine", "CHEMICAL", 95, 110], ["chlorpheniramine", "CHEMICAL", 112, 128], ["clemastine fumarate", "CHEMICAL", 133, 152], ["brompheniramine", "SIMPLE_CHEMICAL", 95, 110], ["chlorpheniramine", "SIMPLE_CHEMICAL", 112, 128], ["clemastine fumarate", "SIMPLE_CHEMICAL", 133, 152], ["selective H 1", "GENE_OR_GENE_PRODUCT", 175, 188], ["Symptoms", "PROBLEM", 0, 8], ["sneezing", "PROBLEM", 12, 20], ["rhinorrhea", "PROBLEM", 25, 35], ["nonselective antihistamines", "TREATMENT", 59, 86], ["brompheniramine", "TREATMENT", 95, 110], ["chlorpheniramine", "TREATMENT", 112, 128], ["clemastine fumarate", "TREATMENT", 133, 152], ["treatment", "TREATMENT", 160, 169], ["selective H 1 inhibitors", "TREATMENT", 175, 199], ["sneezing", "OBSERVATION", 12, 20], ["rhinorrhea", "OBSERVATION", 25, 35]]], ["Studies of pseudoephedrine have demonstrated measurable improvements in nasal air flow consistent with a decongestant effect.", [["nasal", "ANATOMY", 72, 77], ["pseudoephedrine", "CHEMICAL", 11, 26], ["pseudoephedrine", "CHEMICAL", 11, 26], ["pseudoephedrine", "SIMPLE_CHEMICAL", 11, 26], ["Studies of pseudoephedrine", "TEST", 0, 26], ["nasal air flow", "PROBLEM", 72, 86], ["a decongestant effect", "PROBLEM", 103, 124], ["measurable", "OBSERVATION_MODIFIER", 45, 55], ["improvements", "OBSERVATION_MODIFIER", 56, 68], ["nasal", "ANATOMY", 72, 77], ["air flow", "OBSERVATION", 78, 86], ["consistent with", "UNCERTAINTY", 87, 102], ["decongestant effect", "OBSERVATION", 105, 124]]], ["2 Nonsteroidal anti-inflammatory drugs such as naproxen moderate the systemic symptoms of rhinovirus infection.", [["naproxen", "CHEMICAL", 47, 55], ["rhinovirus infection", "DISEASE", 90, 110], ["naproxen", "CHEMICAL", 47, 55], ["naproxen", "SIMPLE_CHEMICAL", 47, 55], ["rhinovirus", "ORGANISM", 90, 100], ["2 Nonsteroidal anti-inflammatory drugs", "TREATMENT", 0, 38], ["naproxen", "TREATMENT", 47, 55], ["the systemic symptoms", "PROBLEM", 65, 86], ["rhinovirus infection", "PROBLEM", 90, 110], ["anti-inflammatory drugs", "OBSERVATION", 15, 38], ["rhinovirus", "OBSERVATION", 90, 100]]], ["However, the use of the decongestant phenylpropanolamine has been shown to be associated with an increased risk of hemorrhagic stroke.", [["phenylpropanolamine", "CHEMICAL", 37, 56], ["hemorrhagic stroke", "DISEASE", 115, 133], ["phenylpropanolamine", "CHEMICAL", 37, 56], ["phenylpropanolamine", "SIMPLE_CHEMICAL", 37, 56], ["the decongestant phenylpropanolamine", "TREATMENT", 20, 56], ["hemorrhagic stroke", "PROBLEM", 115, 133], ["increased", "OBSERVATION_MODIFIER", 97, 106], ["hemorrhagic", "OBSERVATION_MODIFIER", 115, 126], ["stroke", "OBSERVATION", 127, 133]]], ["3 Topical application of ipratropium, a quaternary anticholinergic agent that is minimally absorbed across biologic membranes, reduces rhinorrhea significantly in naturally occurring colds.", [["membranes", "ANATOMY", 116, 125], ["ipratropium", "CHEMICAL", 25, 36], ["rhinorrhea", "DISEASE", 135, 145], ["colds", "DISEASE", 183, 188], ["ipratropium", "CHEMICAL", 25, 36], ["ipratropium", "SIMPLE_CHEMICAL", 25, 36], ["ipratropium", "TREATMENT", 25, 36], ["a quaternary anticholinergic agent", "TREATMENT", 38, 72], ["minimally absorbed across biologic membranes", "PROBLEM", 81, 125], ["rhinorrhea", "PROBLEM", 135, 145], ["rhinorrhea", "OBSERVATION", 135, 145]]], ["This agent probably exerts its major effect on the parasympathetic regulation of mucous and seromucous glands.", [["mucous", "ANATOMY", 81, 87], ["seromucous glands", "ANATOMY", 92, 109], ["mucous", "MULTI-TISSUE_STRUCTURE", 81, 87], ["seromucous glands", "ORGAN", 92, 109], ["mucous and seromucous glands", "PROBLEM", 81, 109], ["mucous", "ANATOMY", 81, 87], ["seromucous glands", "ANATOMY", 92, 109]]], ["Importantly, most over-the-counter cough and cold remedies have not been studied in pediatric populations, where they may be associated with significant side effects.", [["cough", "DISEASE", 35, 40], ["cough", "PROBLEM", 35, 40], ["cold remedies", "TREATMENT", 45, 58], ["significant side effects", "PROBLEM", 141, 165]]], ["4PHARYNGITISPharyngitis most often presents as part of the common cold syndrome and thus is usually associated with the same as dextromethorphan in suppressing night time coughing, 7 but honey should not be administered to infants younger than 1 (due to risk of infant botulism).INFLUENZA-LIKE ILLNESSThe clinical syndrome of influenza is characterized by the rapid onset of constitutional symptoms, including fever, chills, prostration, muscle ache, and headache, concurrent with or followed by upper and lower respiratory tract symptoms.", [["muscle", "ANATOMY", 438, 444], ["lower respiratory tract", "ANATOMY", 506, 529], ["4PHARYNGITISPharyngitis", "DISEASE", 0, 23], ["cold syndrome", "DISEASE", 66, 79], ["dextromethorphan", "CHEMICAL", 128, 144], ["coughing", "DISEASE", 171, 179], ["botulism", "DISEASE", 269, 277], ["influenza", "DISEASE", 326, 335], ["fever", "DISEASE", 410, 415], ["chills", "DISEASE", 417, 423], ["prostration", "DISEASE", 425, 436], ["muscle ache", "DISEASE", 438, 449], ["headache", "DISEASE", 455, 463], ["dextromethorphan", "CHEMICAL", 128, 144], ["dextromethorphan", "SIMPLE_CHEMICAL", 128, 144], ["infants", "ORGANISM", 223, 230], ["muscle", "ORGAN", 438, 444], ["upper", "ORGANISM_SUBDIVISION", 496, 501], ["lower", "ORGANISM_SUBDIVISION", 506, 511], ["respiratory tract", "ORGANISM_SUBDIVISION", 512, 529], ["infants", "SPECIES", 223, 230], ["infant", "SPECIES", 262, 268], ["4PHARYNGITISPharyngitis", "PROBLEM", 0, 23], ["the common cold syndrome", "PROBLEM", 55, 79], ["dextromethorphan", "TREATMENT", 128, 144], ["infant botulism", "PROBLEM", 262, 277], ["INFLUENZA", "PROBLEM", 279, 288], ["ILLNESSThe clinical syndrome", "PROBLEM", 294, 322], ["influenza", "PROBLEM", 326, 335], ["constitutional symptoms", "PROBLEM", 375, 398], ["fever", "PROBLEM", 410, 415], ["chills", "PROBLEM", 417, 423], ["prostration", "PROBLEM", 425, 436], ["muscle ache", "PROBLEM", 438, 449], ["headache", "PROBLEM", 455, 463], ["upper and lower respiratory tract symptoms", "PROBLEM", 496, 538], ["syndrome", "OBSERVATION", 71, 79], ["influenza", "OBSERVATION", 326, 335], ["muscle ache", "ANATOMY", 438, 449], ["upper", "ANATOMY_MODIFIER", 496, 501], ["lower", "ANATOMY_MODIFIER", 506, 511], ["respiratory tract", "ANATOMY", 512, 529]]], ["Systemic symptoms tend to dominate for the first several days of illness, whereas respiratory complaints, particularly cough, predominate later in the first week of illness.", [["respiratory", "ANATOMY", 82, 93], ["illness", "DISEASE", 65, 72], ["respiratory complaints", "DISEASE", 82, 104], ["cough", "DISEASE", 119, 124], ["Systemic symptoms", "PROBLEM", 0, 17], ["illness", "PROBLEM", 65, 72], ["respiratory complaints", "PROBLEM", 82, 104], ["cough", "PROBLEM", 119, 124], ["illness", "PROBLEM", 165, 172]]], ["Photophobia, excess tearing, and pain with eye movement are common early in the illness.", [["eye", "ANATOMY", 43, 46], ["Photophobia", "DISEASE", 0, 11], ["excess tearing", "DISEASE", 13, 27], ["pain", "DISEASE", 33, 37], ["eye", "ORGAN", 43, 46], ["Photophobia", "PROBLEM", 0, 11], ["excess tearing", "PROBLEM", 13, 27], ["pain with eye movement", "PROBLEM", 33, 55], ["excess tearing", "OBSERVATION", 13, 27]]], ["Mild conjunctivitis, clear nasal discharge without obstruction, pharyngeal injection, and small tender cervical lymph nodes are frequently present.", [["nasal", "ANATOMY", 27, 32], ["pharyngeal", "ANATOMY", 64, 74], ["cervical lymph nodes", "ANATOMY", 103, 123], ["conjunctivitis", "DISEASE", 5, 19], ["obstruction", "DISEASE", 51, 62], ["nasal", "ORGANISM_SUBDIVISION", 27, 32], ["pharyngeal", "ORGAN", 64, 74], ["cervical lymph nodes", "MULTI-TISSUE_STRUCTURE", 103, 123], ["Mild conjunctivitis", "PROBLEM", 0, 19], ["clear nasal discharge", "PROBLEM", 21, 42], ["obstruction", "PROBLEM", 51, 62], ["pharyngeal injection", "TREATMENT", 64, 84], ["small tender cervical lymph nodes", "PROBLEM", 90, 123], ["conjunctivitis", "OBSERVATION", 5, 19], ["clear", "OBSERVATION_MODIFIER", 21, 26], ["nasal", "ANATOMY", 27, 32], ["discharge", "OBSERVATION", 33, 42], ["without", "UNCERTAINTY", 43, 50], ["obstruction", "OBSERVATION", 51, 62], ["pharyngeal", "ANATOMY", 64, 74], ["small", "OBSERVATION_MODIFIER", 90, 95], ["tender", "OBSERVATION_MODIFIER", 96, 102], ["cervical", "ANATOMY", 103, 111], ["lymph nodes", "OBSERVATION", 112, 123]]], ["Fever may peak at 39\u00b0 C to 40\u00b0 C or higher and can last for 1 to 5 days.", [["Fever", "DISEASE", 0, 5], ["C", "GENE_OR_GENE_PRODUCT", 31, 32], ["Fever", "PROBLEM", 0, 5]]], ["Persistent nonproductive cough, easy fatigability, and asthenia are common in the second week of illness.", [["cough", "DISEASE", 25, 30], ["fatigability", "DISEASE", 37, 49], ["asthenia", "DISEASE", 55, 63], ["Persistent nonproductive cough", "PROBLEM", 0, 30], ["easy fatigability", "PROBLEM", 32, 49], ["asthenia", "PROBLEM", 55, 63], ["illness", "PROBLEM", 97, 104], ["nonproductive", "OBSERVATION_MODIFIER", 11, 24], ["cough", "OBSERVATION", 25, 30]]], ["Influenza type A and B viruses are the most important causes of the influenza syndrome, particularly when the illness presents in an epidemic form.", [["Influenza type A and B viruses", "DISEASE", 0, 30], ["influenza syndrome", "DISEASE", 68, 86], ["illness", "DISEASE", 110, 117], ["Influenza type A", "ORGANISM", 0, 16], ["B viruses", "ORGANISM", 21, 30], ["Influenza type A", "SPECIES", 0, 16], ["B viruses", "SPECIES", 21, 30], ["Influenza type A and B viruses", "PROBLEM", 0, 30], ["the influenza syndrome", "PROBLEM", 64, 86], ["influenza syndrome", "OBSERVATION", 68, 86]]], ["However, the syndrome can also be seen in association with infection by other viruses, including adenovirus, parainfluenza, and RSV.", [["infection", "DISEASE", 59, 68], ["adenovirus, parainfluenza, and RSV", "DISEASE", 97, 131], ["adenovirus", "ORGANISM", 97, 107], ["parainfluenza", "ORGANISM", 109, 122], ["RSV", "ORGANISM", 128, 131], ["parainfluenza", "SPECIES", 109, 122], ["RSV", "SPECIES", 128, 131], ["the syndrome", "PROBLEM", 9, 21], ["infection", "PROBLEM", 59, 68], ["other viruses", "PROBLEM", 72, 85], ["adenovirus", "PROBLEM", 97, 107], ["parainfluenza", "PROBLEM", 109, 122], ["RSV", "PROBLEM", 128, 131], ["syndrome", "OBSERVATION", 13, 21], ["can also be seen", "UNCERTAINTY", 22, 38], ["infection", "OBSERVATION", 59, 68], ["viruses", "OBSERVATION", 78, 85]]], ["The characteristic clinical features of influenza and its epidemic nature usually permit the practitioner to make an accurate diagnosis during recognized epidemics of influenza virus infection, particularly if cough and fever are present.", [["influenza", "DISEASE", 40, 49], ["influenza virus infection", "DISEASE", 167, 192], ["cough", "DISEASE", 210, 215], ["fever", "DISEASE", 220, 225], ["influenza virus", "ORGANISM", 167, 182], ["influenza virus", "SPECIES", 167, 182], ["influenza virus", "SPECIES", 167, 182], ["influenza", "PROBLEM", 40, 49], ["influenza virus infection", "PROBLEM", 167, 192], ["cough", "PROBLEM", 210, 215], ["fever", "PROBLEM", 220, 225], ["influenza", "OBSERVATION", 40, 49], ["influenza virus infection", "OBSERVATION", 167, 192], ["fever", "OBSERVATION", 220, 225]]], ["8 Specific antiviral therapy is effective if given early in the course of the illness (see the section on influenza virus).", [["influenza virus", "DISEASE", 106, 121], ["influenza virus", "ORGANISM", 106, 121], ["Specific antiviral therapy", "TREATMENT", 2, 28], ["the illness", "PROBLEM", 74, 85], ["influenza virus", "PROBLEM", 106, 121], ["antiviral therapy", "OBSERVATION", 11, 28]]], ["Symptomatic treatment (bed rest, oral hydration, antipyretics, and antitussives) is also beneficial.", [["oral", "ANATOMY", 33, 37], ["oral", "ORGANISM_SUBDIVISION", 33, 37], ["Symptomatic treatment", "TREATMENT", 0, 21], ["bed rest", "TREATMENT", 23, 31], ["oral hydration", "TREATMENT", 33, 47], ["antipyretics", "TREATMENT", 49, 61], ["antitussives", "TREATMENT", 67, 79]]], ["Fever should be treated in certain clinical situations, such as in children with previous febrile convulsions or patients with preexisting cardiac disease.", [["cardiac", "ANATOMY", 139, 146], ["Fever", "DISEASE", 0, 5], ["febrile convulsions", "DISEASE", 90, 109], ["cardiac disease", "DISEASE", 139, 154], ["children", "ORGANISM", 67, 75], ["patients", "ORGANISM", 113, 121], ["cardiac", "ORGAN", 139, 146], ["children", "SPECIES", 67, 75], ["patients", "SPECIES", 113, 121], ["Fever", "PROBLEM", 0, 5], ["previous febrile convulsions", "PROBLEM", 81, 109], ["preexisting cardiac disease", "PROBLEM", 127, 154], ["cardiac", "ANATOMY", 139, 146], ["disease", "OBSERVATION", 147, 154]]], ["Because of its possible association with Reye's syndrome, aspirin must be avoided in pediatric patients.CROUPThe croup syndrome of children is characterized by an unusual brassy or barking cough (see Audio 30-3) that may be accompanied by inspiratory stridor, dyspnea, and hoarseness.", [["brassy", "ANATOMY", 171, 177], ["Reye's syndrome", "DISEASE", 41, 56], ["aspirin", "CHEMICAL", 58, 65], ["croup syndrome", "DISEASE", 113, 127], ["cough", "DISEASE", 189, 194], ["stridor", "DISEASE", 251, 258], ["dyspnea", "DISEASE", 260, 267], ["hoarseness", "DISEASE", 273, 283], ["aspirin", "CHEMICAL", 58, 65], ["aspirin", "SIMPLE_CHEMICAL", 58, 65], ["patients", "ORGANISM", 95, 103], ["children", "ORGANISM", 131, 139], ["patients", "SPECIES", 95, 103], ["children", "SPECIES", 131, 139], ["Reye's syndrome", "PROBLEM", 41, 56], ["aspirin", "TREATMENT", 58, 65], ["an unusual brassy", "PROBLEM", 160, 177], ["barking cough", "PROBLEM", 181, 194], ["inspiratory stridor", "PROBLEM", 239, 258], ["dyspnea", "PROBLEM", 260, 267], ["hoarseness", "PROBLEM", 273, 283], ["inspiratory", "ANATOMY", 239, 250], ["stridor", "OBSERVATION", 251, 258], ["dyspnea", "OBSERVATION", 260, 267], ["hoarseness", "OBSERVATION", 273, 283]]], ["8a The symptoms are often preceded by several days of upper respiratory illness and are typically worse at night.", [["respiratory", "ANATOMY", 60, 71], ["8a", "CHEMICAL", 0, 2], ["respiratory illness", "DISEASE", 60, 79], ["The symptoms", "PROBLEM", 3, 15], ["upper respiratory illness", "PROBLEM", 54, 79], ["upper", "ANATOMY_MODIFIER", 54, 59], ["respiratory", "ANATOMY", 60, 71], ["illness", "OBSERVATION", 72, 79]]], ["Croup is seen primarily in children younger than 6.", [["children", "ORGANISM", 27, 35], ["children", "SPECIES", 27, 35]]], ["The term acute infectious croup or laryngotracheobronchitis is applied to a contagious disease that affects otherwise healthy children, often associated with a respiratory illness in the family.", [["respiratory", "ANATOMY", 160, 171], ["croup", "DISEASE", 26, 31], ["laryngotracheobronchitis", "DISEASE", 35, 59], ["respiratory illness", "DISEASE", 160, 179], ["children", "ORGANISM", 126, 134], ["children", "SPECIES", 126, 134], ["The term acute infectious croup", "PROBLEM", 0, 31], ["laryngotracheobronchitis", "PROBLEM", 35, 59], ["a contagious disease", "PROBLEM", 74, 94], ["a respiratory illness", "PROBLEM", 158, 179], ["term", "OBSERVATION_MODIFIER", 4, 8], ["acute", "OBSERVATION_MODIFIER", 9, 14], ["infectious", "OBSERVATION", 15, 25]]], ["The term acute spasmodic croup is applied to a similar syndrome that is most common in young children prone to recurrent attacks precipitated by respiratory viral infections and possibly allergic or other factors.", [["spasmodic croup", "DISEASE", 15, 30], ["respiratory viral infections", "DISEASE", 145, 173], ["allergic", "DISEASE", 187, 195], ["children", "ORGANISM", 93, 101], ["children", "SPECIES", 93, 101], ["The term acute spasmodic croup", "PROBLEM", 0, 30], ["a similar syndrome", "PROBLEM", 45, 63], ["recurrent attacks", "PROBLEM", 111, 128], ["respiratory viral infections", "PROBLEM", 145, 173], ["allergic", "PROBLEM", 187, 195], ["other factors", "PROBLEM", 199, 212], ["term", "OBSERVATION_MODIFIER", 4, 8], ["acute", "OBSERVATION_MODIFIER", 9, 14], ["spasmodic", "OBSERVATION_MODIFIER", 15, 24], ["croup", "OBSERVATION", 25, 30], ["respiratory", "ANATOMY", 145, 156], ["viral infections", "OBSERVATION", 157, 173], ["possibly", "UNCERTAINTY", 178, 186], ["allergic", "OBSERVATION", 187, 195]]], ["In these children, fever is frequently absent and symptoms often abate within several hours.CROUPMost children with acute laryngotracheobronchitis have symptoms of decreasing intensity over several days and can be managed at home.", [["fever", "DISEASE", 19, 24], ["laryngotracheobronchitis", "DISEASE", 122, 146], ["children", "ORGANISM", 9, 17], ["children", "ORGANISM", 102, 110], ["children", "SPECIES", 9, 17], ["children", "SPECIES", 102, 110], ["fever", "PROBLEM", 19, 24], ["symptoms", "PROBLEM", 50, 58], ["acute laryngotracheobronchitis", "PROBLEM", 116, 146], ["symptoms", "PROBLEM", 152, 160], ["decreasing intensity", "PROBLEM", 164, 184], ["fever", "OBSERVATION", 19, 24], ["acute", "OBSERVATION_MODIFIER", 116, 121], ["laryngotracheobronchitis", "OBSERVATION", 122, 146], ["decreasing", "OBSERVATION_MODIFIER", 164, 174], ["intensity", "OBSERVATION_MODIFIER", 175, 184]]], ["However, increasing laryngeal obstruction can be associated with respiratory insufficiency.", [["laryngeal", "ANATOMY", 20, 29], ["respiratory", "ANATOMY", 65, 76], ["laryngeal obstruction", "DISEASE", 20, 41], ["respiratory insufficiency", "DISEASE", 65, 90], ["laryngeal", "ORGAN", 20, 29], ["increasing laryngeal obstruction", "PROBLEM", 9, 41], ["respiratory insufficiency", "PROBLEM", 65, 90], ["increasing", "OBSERVATION_MODIFIER", 9, 19], ["laryngeal", "ANATOMY", 20, 29], ["obstruction", "OBSERVATION", 30, 41], ["can be associated with", "UNCERTAINTY", 42, 64], ["respiratory insufficiency", "OBSERVATION", 65, 90]]], ["This is manifested by restlessness, air hunger, stridor viruses are associated with other types of enanthems, meaning lesions on the mucous membranes, such as vesicles and ulcers.", [["lesions", "ANATOMY", 118, 125], ["mucous membranes", "ANATOMY", 133, 149], ["vesicles", "ANATOMY", 159, 167], ["ulcers", "ANATOMY", 172, 178], ["air hunger", "DISEASE", 36, 46], ["stridor viruses", "DISEASE", 48, 63], ["enanthems", "DISEASE", 99, 108], ["ulcers", "DISEASE", 172, 178], ["lesions", "PATHOLOGICAL_FORMATION", 118, 125], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 133, 149], ["vesicles", "CELLULAR_COMPONENT", 159, 167], ["ulcers", "PATHOLOGICAL_FORMATION", 172, 178], ["restlessness", "PROBLEM", 22, 34], ["air hunger", "PROBLEM", 36, 46], ["stridor viruses", "PROBLEM", 48, 63], ["enanthems", "PROBLEM", 99, 108], ["meaning lesions on the mucous membranes", "PROBLEM", 110, 149], ["vesicles", "PROBLEM", 159, 167], ["ulcers", "PROBLEM", 172, 178], ["restlessness", "OBSERVATION_MODIFIER", 22, 34], ["air hunger", "OBSERVATION", 36, 46], ["stridor viruses", "OBSERVATION", 48, 63], ["enanthems", "OBSERVATION", 99, 108], ["lesions", "OBSERVATION", 118, 125], ["mucous membranes", "ANATOMY", 133, 149], ["vesicles", "ANATOMY", 159, 167], ["ulcers", "OBSERVATION", 172, 178]]], ["Coxsackie A viruses are associated with the condition herpangina, a painful, often febrile pharyngitis of children and young adults characterized by vesicular lesions of the soft palate.CROUPViruses in the herpes family cause a small proportion of cases of pharyngitis.", [["vesicular lesions", "ANATOMY", 149, 166], ["soft palate", "ANATOMY", 174, 185], ["Coxsackie A viruses", "DISEASE", 0, 19], ["herpangina", "DISEASE", 54, 64], ["febrile pharyngitis", "DISEASE", 83, 102], ["vesicular lesions of the soft palate", "DISEASE", 149, 185], ["CROUPViruses", "CHEMICAL", 186, 198], ["herpes", "DISEASE", 206, 212], ["pharyngitis", "DISEASE", 257, 268], ["Coxsackie A viruses", "ORGANISM", 0, 19], ["children", "ORGANISM", 106, 114], ["vesicular lesions", "PATHOLOGICAL_FORMATION", 149, 166], ["palate", "ORGAN", 179, 185], ["herpes", "ORGANISM", 206, 212], ["children", "SPECIES", 106, 114], ["Coxsackie A viruses", "SPECIES", 0, 19], ["Coxsackie A viruses", "PROBLEM", 0, 19], ["the condition herpangina", "PROBLEM", 40, 64], ["a painful", "PROBLEM", 66, 75], ["febrile pharyngitis of children", "PROBLEM", 83, 114], ["vesicular lesions of the soft palate", "PROBLEM", 149, 185], ["pharyngitis", "PROBLEM", 257, 268], ["viruses", "OBSERVATION", 12, 19], ["painful", "OBSERVATION_MODIFIER", 68, 75], ["vesicular", "OBSERVATION_MODIFIER", 149, 158], ["lesions", "OBSERVATION", 159, 166], ["soft palate", "ANATOMY", 174, 185], ["herpes", "OBSERVATION", 206, 212], ["small", "OBSERVATION_MODIFIER", 228, 233], ["pharyngitis", "OBSERVATION", 257, 268]]], ["Primary infection with herpes simplex virus manifests as an acute vesiculoulcerative pharyngitis or gingivostomatitis that may have an exudative character.", [["Primary infection", "DISEASE", 0, 17], ["herpes simplex virus", "DISEASE", 23, 43], ["pharyngitis", "DISEASE", 85, 96], ["gingivostomatitis", "DISEASE", 100, 117], ["herpes simplex virus", "ORGANISM", 23, 43], ["herpes simplex virus", "SPECIES", 23, 43], ["herpes simplex virus", "SPECIES", 23, 43], ["Primary infection", "PROBLEM", 0, 17], ["herpes simplex virus", "PROBLEM", 23, 43], ["an acute vesiculoulcerative pharyngitis", "PROBLEM", 57, 96], ["gingivostomatitis", "PROBLEM", 100, 117], ["an exudative character", "PROBLEM", 132, 154], ["infection", "OBSERVATION", 8, 17], ["herpes simplex virus", "OBSERVATION", 23, 43], ["acute", "OBSERVATION_MODIFIER", 60, 65], ["vesiculoulcerative", "OBSERVATION_MODIFIER", 66, 84], ["pharyngitis", "OBSERVATION", 85, 96], ["exudative", "OBSERVATION_MODIFIER", 135, 144]]], ["In immunocompromised patients, herpes simplex virus causes large, shallow ulcers of the mucosa that are chronic and progressive if untreated.", [["mucosa", "ANATOMY", 88, 94], ["herpes simplex virus", "DISEASE", 31, 51], ["ulcers", "DISEASE", 74, 80], ["patients", "ORGANISM", 21, 29], ["herpes simplex virus", "ORGANISM", 31, 51], ["ulcers", "PATHOLOGICAL_FORMATION", 74, 80], ["mucosa", "MULTI-TISSUE_STRUCTURE", 88, 94], ["patients", "SPECIES", 21, 29], ["herpes simplex virus", "SPECIES", 31, 51], ["herpes simplex virus", "SPECIES", 31, 51], ["herpes simplex virus", "PROBLEM", 31, 51], ["large, shallow ulcers of the mucosa", "PROBLEM", 59, 94], ["immunocompromised", "OBSERVATION", 3, 20], ["herpes simplex virus", "OBSERVATION", 31, 51], ["large", "OBSERVATION_MODIFIER", 59, 64], ["shallow", "OBSERVATION_MODIFIER", 66, 73], ["ulcers", "OBSERVATION", 74, 80], ["mucosa", "ANATOMY", 88, 94], ["chronic", "OBSERVATION_MODIFIER", 104, 111], ["progressive", "OBSERVATION_MODIFIER", 116, 127]]], ["Epstein-Barr virus mononucleosis characteristically has an acute exudative pharyngitis.", [["Epstein-Barr virus mononucleosis", "DISEASE", 0, 32], ["pharyngitis", "DISEASE", 75, 86], ["Epstein-Barr virus", "ORGANISM", 0, 18], ["Epstein-Barr virus", "SPECIES", 0, 18], ["Barr virus mononucleosis", "PROBLEM", 8, 32], ["an acute exudative pharyngitis", "PROBLEM", 56, 86], ["Barr virus", "OBSERVATION", 8, 18], ["acute", "OBSERVATION_MODIFIER", 59, 64], ["exudative", "OBSERVATION_MODIFIER", 65, 74], ["pharyngitis", "OBSERVATION", 75, 86]]], ["Mononucleosis due to cytomegalovirus infection may have a nonexudative pharyngitis that is acute or chronic, and rarely, cytomegalovirus causes oral ulcerations in immunosuppressed patients.", [["oral", "ANATOMY", 144, 148], ["Mononucleosis", "DISEASE", 0, 13], ["cytomegalovirus infection", "DISEASE", 21, 46], ["pharyngitis", "DISEASE", 71, 82], ["cytomegalovirus", "DISEASE", 121, 136], ["oral ulcerations", "DISEASE", 144, 160], ["cytomegalovirus", "ORGANISM", 21, 36], ["cytomegalovirus", "ORGANISM", 121, 136], ["oral ulcerations", "PATHOLOGICAL_FORMATION", 144, 160], ["patients", "ORGANISM", 181, 189], ["patients", "SPECIES", 181, 189], ["Mononucleosis", "PROBLEM", 0, 13], ["cytomegalovirus infection", "PROBLEM", 21, 46], ["a nonexudative pharyngitis", "PROBLEM", 56, 82], ["chronic", "PROBLEM", 100, 107], ["cytomegalovirus", "PROBLEM", 121, 136], ["oral ulcerations", "PROBLEM", 144, 160], ["immunosuppressed patients", "TREATMENT", 164, 189], ["cytomegalovirus", "OBSERVATION", 21, 36], ["nonexudative", "OBSERVATION_MODIFIER", 58, 70], ["pharyngitis", "OBSERVATION", 71, 82], ["acute", "OBSERVATION_MODIFIER", 91, 96], ["chronic", "OBSERVATION_MODIFIER", 100, 107], ["cytomegalovirus", "OBSERVATION", 121, 136], ["oral", "OBSERVATION_MODIFIER", 144, 148], ["ulcerations", "OBSERVATION", 149, 160], ["immunosuppressed", "OBSERVATION", 164, 180]]], ["Pharyngitis can arise during primary infection with human immunodeficiency virus (HIV).", [["Pharyngitis", "DISEASE", 0, 11], ["primary infection", "DISEASE", 29, 46], ["human immunodeficiency virus (HIV)", "DISEASE", 52, 86], ["human immunodeficiency virus", "ORGANISM", 52, 80], ["HIV", "ORGANISM", 82, 85], ["human", "SPECIES", 52, 57], ["immunodeficiency virus", "SPECIES", 58, 80], ["human immunodeficiency virus", "SPECIES", 52, 80], ["HIV", "SPECIES", 82, 85], ["Pharyngitis", "PROBLEM", 0, 11], ["primary infection", "PROBLEM", 29, 46], ["human immunodeficiency virus", "PROBLEM", 52, 80]]], ["Viruses in the hemorrhagic fever group produce an acute pharyngitis early in the disease, before skin lesions appear.", [["skin lesions", "ANATOMY", 97, 109], ["hemorrhagic fever", "DISEASE", 15, 32], ["pharyngitis", "DISEASE", 56, 67], ["skin lesions", "PATHOLOGICAL_FORMATION", 97, 109], ["hemorrhagic fever group", "SPECIES", 15, 38], ["Viruses", "PROBLEM", 0, 7], ["the hemorrhagic fever", "PROBLEM", 11, 32], ["an acute pharyngitis", "PROBLEM", 47, 67], ["the disease", "PROBLEM", 77, 88], ["skin lesions", "PROBLEM", 97, 109], ["hemorrhagic", "OBSERVATION_MODIFIER", 15, 26], ["fever", "OBSERVATION", 27, 32], ["acute", "OBSERVATION_MODIFIER", 50, 55], ["pharyngitis", "OBSERVATION", 56, 67], ["disease", "OBSERVATION", 81, 88], ["skin", "ANATOMY", 97, 101], ["lesions", "OBSERVATION", 102, 109]]], ["Exudative pharyngitis is a common clinical manifestation in Lassa fever.CROUPTypically, sore throat accompanied by nasal symptoms is more likely to be viral in nature.", [["nasal", "ANATOMY", 115, 120], ["pharyngitis", "DISEASE", 10, 21], ["Lassa fever", "DISEASE", 60, 71], ["sore throat", "DISEASE", 88, 99], ["Lassa", "ORGANISM", 60, 65], ["throat", "ORGANISM_SUBDIVISION", 93, 99], ["nasal", "ORGANISM_SUBDIVISION", 115, 120], ["Exudative pharyngitis", "PROBLEM", 0, 21], ["Lassa fever", "PROBLEM", 60, 71], ["sore throat", "PROBLEM", 88, 99], ["nasal symptoms", "PROBLEM", 115, 129], ["pharyngitis", "OBSERVATION", 10, 21], ["Lassa", "OBSERVATION_MODIFIER", 60, 65], ["sore throat", "ANATOMY", 88, 99], ["nasal", "ANATOMY", 115, 120], ["symptoms", "OBSERVATION", 121, 129], ["more likely to be", "UNCERTAINTY", 133, 150], ["viral", "OBSERVATION", 151, 156]]], ["Infection with mixed anaerobic bacteria (Vincent angina) or Corynebacterium diphtheria is also in the differential diagnosis of exudative pharyngitis.", [["Vincent angina", "DISEASE", 41, 55], ["Corynebacterium diphtheria", "DISEASE", 60, 86], ["exudative pharyngitis", "DISEASE", 128, 149], ["Corynebacterium diphtheria", "ORGANISM", 60, 86], ["Corynebacterium diphtheria", "SPECIES", 60, 86], ["Corynebacterium diphtheria", "SPECIES", 60, 86], ["Infection", "PROBLEM", 0, 9], ["mixed anaerobic bacteria", "PROBLEM", 15, 39], ["Vincent angina)", "PROBLEM", 41, 56], ["Corynebacterium diphtheria", "PROBLEM", 60, 86], ["exudative pharyngitis", "PROBLEM", 128, 149], ["mixed", "OBSERVATION_MODIFIER", 15, 20], ["anaerobic bacteria", "OBSERVATION", 21, 39], ["exudative", "OBSERVATION_MODIFIER", 128, 137], ["pharyngitis", "OBSERVATION", 138, 149]]], ["The treatment of most cases of viral pharyngitis is symptomatic.ACUTE BRONCHITISThe diagnosis of acute bronchitis is usually applied to cases of acute respiratory disease with severe and prolonged cough that continues after other signs and symptoms of the acute infection have subsided.", [["respiratory", "ANATOMY", 151, 162], ["viral pharyngitis", "DISEASE", 31, 48], ["bronchitis", "DISEASE", 103, 113], ["respiratory disease", "DISEASE", 151, 170], ["cough", "DISEASE", 197, 202], ["infection", "DISEASE", 262, 271], ["viral pharyngitis", "PROBLEM", 31, 48], ["symptomatic", "PROBLEM", 52, 63], ["acute bronchitis", "PROBLEM", 97, 113], ["acute respiratory disease", "PROBLEM", 145, 170], ["severe and prolonged cough", "PROBLEM", 176, 202], ["other signs and symptoms", "PROBLEM", 224, 248], ["the acute infection", "PROBLEM", 252, 271], ["viral", "OBSERVATION_MODIFIER", 31, 36], ["pharyngitis", "OBSERVATION", 37, 48], ["symptomatic", "OBSERVATION_MODIFIER", 52, 63], ["acute", "OBSERVATION_MODIFIER", 97, 102], ["bronchitis", "OBSERVATION", 103, 113], ["acute", "OBSERVATION_MODIFIER", 145, 150], ["respiratory", "ANATOMY", 151, 162], ["disease", "OBSERVATION", 163, 170], ["severe", "OBSERVATION_MODIFIER", 176, 182], ["prolonged", "OBSERVATION_MODIFIER", 187, 196], ["cough", "OBSERVATION", 197, 202], ["acute", "OBSERVATION_MODIFIER", 256, 261], ["infection", "OBSERVATION", 262, 271]]], ["Cough appears during the first week of illness in 30% of rhinovirus colds in young adults and in 80% or more of cases of influenza A virus infection, in which it is often prolonged.", [["Cough", "DISEASE", 0, 5], ["illness", "DISEASE", 39, 46], ["rhinovirus colds", "DISEASE", 57, 73], ["influenza A virus infection", "DISEASE", 121, 148], ["rhinovirus", "ORGANISM", 57, 67], ["influenza A virus", "ORGANISM", 121, 138], ["influenza A virus", "SPECIES", 121, 138], ["influenza A virus", "SPECIES", 121, 138], ["Cough", "PROBLEM", 0, 5], ["illness", "PROBLEM", 39, 46], ["rhinovirus colds", "PROBLEM", 57, 73], ["influenza A virus infection", "PROBLEM", 121, 148], ["influenza", "OBSERVATION", 121, 130], ["virus infection", "OBSERVATION", 133, 148], ["prolonged", "OBSERVATION_MODIFIER", 171, 180]]], ["Adenovirus infections characteristically involve the tracheobronchial tree, with resultant bronchitis that, in military populations, is part of the syndrome of acute respiratory disease.ACUTE BRONCHITISThe mechanisms of cough production in viral infection are not well understood but may include direct damage to the respiratory mucosa, release of inflammatory substances in response to the infection, increased production and/or decreased clearance of respiratory secretions, and stimulation of airway irritant receptors.", [["tracheobronchial tree", "ANATOMY", 53, 74], ["respiratory", "ANATOMY", 166, 177], ["respiratory mucosa", "ANATOMY", 317, 335], ["respiratory secretions", "ANATOMY", 453, 475], ["airway", "ANATOMY", 496, 502], ["Adenovirus infections", "DISEASE", 0, 21], ["bronchitis", "DISEASE", 91, 101], ["acute respiratory disease", "DISEASE", 160, 185], ["cough", "DISEASE", 220, 225], ["viral infection", "DISEASE", 240, 255], ["infection", "DISEASE", 391, 400], ["Adenovirus", "ORGANISM", 0, 10], ["tracheobronchial tree", "MULTI-TISSUE_STRUCTURE", 53, 74], ["mucosa", "MULTI-TISSUE_STRUCTURE", 329, 335], ["airway", "MULTI-TISSUE_STRUCTURE", 496, 502], ["airway irritant receptors", "PROTEIN", 496, 521], ["Adenovirus", "SPECIES", 0, 10], ["Adenovirus infections", "PROBLEM", 0, 21], ["resultant bronchitis", "PROBLEM", 81, 101], ["the syndrome", "PROBLEM", 144, 156], ["acute respiratory disease", "PROBLEM", 160, 185], ["ACUTE BRONCHITISThe mechanisms", "PROBLEM", 186, 216], ["cough production", "PROBLEM", 220, 236], ["viral infection", "PROBLEM", 240, 255], ["direct damage to the respiratory mucosa", "PROBLEM", 296, 335], ["inflammatory substances", "PROBLEM", 348, 371], ["the infection", "PROBLEM", 387, 400], ["increased production", "PROBLEM", 402, 422], ["decreased clearance of respiratory secretions", "PROBLEM", 430, 475], ["stimulation of airway irritant receptors", "TREATMENT", 481, 521], ["infections", "OBSERVATION", 11, 21], ["tracheobronchial", "ANATOMY", 53, 69], ["tree", "ANATOMY_MODIFIER", 70, 74], ["resultant", "OBSERVATION_MODIFIER", 81, 90], ["bronchitis", "OBSERVATION", 91, 101], ["military", "OBSERVATION_MODIFIER", 111, 119], ["populations", "OBSERVATION_MODIFIER", 120, 131], ["syndrome", "OBSERVATION", 148, 156], ["acute", "OBSERVATION_MODIFIER", 160, 165], ["respiratory disease", "OBSERVATION", 166, 185], ["cough", "OBSERVATION", 220, 225], ["viral", "OBSERVATION_MODIFIER", 240, 245], ["infection", "OBSERVATION", 246, 255], ["respiratory mucosa", "ANATOMY", 317, 335], ["inflammatory substances", "OBSERVATION", 348, 371], ["infection", "OBSERVATION", 391, 400], ["increased", "OBSERVATION_MODIFIER", 402, 411], ["decreased", "OBSERVATION_MODIFIER", 430, 439], ["respiratory secretions", "OBSERVATION", 453, 475], ["airway", "ANATOMY", 496, 502]]], ["Intranasal application of several prostaglandins also produces cough in uninfected volunteers.", [["prostaglandins", "CHEMICAL", 34, 48], ["cough", "DISEASE", 63, 68], ["prostaglandins", "CHEMICAL", 34, 48], ["prostaglandins", "SIMPLE_CHEMICAL", 34, 48], ["volunteers", "ORGANISM", 83, 93], ["Intranasal application", "TREATMENT", 0, 22], ["several prostaglandins", "TREATMENT", 26, 48], ["cough in uninfected volunteers", "PROBLEM", 63, 93], ["cough", "OBSERVATION", 63, 68], ["uninfected volunteers", "OBSERVATION", 72, 93]]], ["5 Infection may also enhance airway reactivity, leading to increased sensitivity to cold air and pollutants such as smoke.ACUTE BRONCHITISThe differential diagnosis of acute bronchitis includes nonviral infections and noninfectious etiologies such as cough-variant asthma.", [["airway", "ANATOMY", 29, 35], ["bronchitis", "DISEASE", 174, 184], ["nonviral infections", "DISEASE", 194, 213], ["cough-variant asthma", "DISEASE", 251, 271], ["airway", "MULTI-TISSUE_STRUCTURE", 29, 35], ["Infection", "PROBLEM", 2, 11], ["airway reactivity", "PROBLEM", 29, 46], ["increased sensitivity", "PROBLEM", 59, 80], ["cold air", "PROBLEM", 84, 92], ["acute bronchitis", "PROBLEM", 168, 184], ["nonviral infections", "PROBLEM", 194, 213], ["noninfectious etiologies", "PROBLEM", 218, 242], ["cough", "PROBLEM", 251, 256], ["variant asthma", "PROBLEM", 257, 271], ["Infection", "OBSERVATION", 2, 11], ["airway", "ANATOMY", 29, 35], ["increased", "OBSERVATION_MODIFIER", 59, 68], ["acute", "OBSERVATION_MODIFIER", 168, 173], ["bronchitis", "OBSERVATION", 174, 184], ["nonviral", "OBSERVATION_MODIFIER", 194, 202], ["infections", "OBSERVATION", 203, 213], ["noninfectious", "OBSERVATION_MODIFIER", 218, 231], ["asthma", "OBSERVATION", 265, 271]]], ["Bordetella pertussis, Mycoplasma pneumoniae, and Chlamydia pneumoniae infections cause prolonged cough.", [["Bordetella pertussis", "DISEASE", 0, 20], ["Mycoplasma pneumoniae", "DISEASE", 22, 43], ["Chlamydia pneumoniae infections", "DISEASE", 49, 80], ["cough", "DISEASE", 97, 102], ["Bordetella pertussis", "ORGANISM", 0, 20], ["Mycoplasma pneumoniae", "ORGANISM", 22, 43], ["Chlamydia pneumoniae", "ORGANISM", 49, 69], ["Bordetella pertussis", "SPECIES", 0, 20], ["Mycoplasma pneumoniae", "SPECIES", 22, 43], ["Chlamydia pneumoniae", "SPECIES", 49, 69], ["Bordetella pertussis", "SPECIES", 0, 20], ["Mycoplasma pneumoniae", "SPECIES", 22, 43], ["Chlamydia pneumoniae", "SPECIES", 49, 69], ["Bordetella pertussis", "PROBLEM", 0, 20], ["Mycoplasma pneumoniae", "PROBLEM", 22, 43], ["Chlamydia pneumoniae infections", "PROBLEM", 49, 80], ["prolonged cough", "PROBLEM", 87, 102], ["Mycoplasma pneumoniae", "OBSERVATION", 22, 43], ["Chlamydia", "OBSERVATION_MODIFIER", 49, 58], ["pneumoniae", "OBSERVATION", 59, 69], ["prolonged", "OBSERVATION_MODIFIER", 87, 96], ["cough", "OBSERVATION", 97, 102]]], ["In otherwise healthy persons, workup of acute cough should be directed toward determining the presence of pneumonia and, if this is not present, then treatment with antibacterial agents is of no benefit.", [["cough", "DISEASE", 46, 51], ["pneumonia", "DISEASE", 106, 115], ["persons", "ORGANISM", 21, 28], ["persons", "SPECIES", 21, 28], ["workup", "TEST", 30, 36], ["acute cough", "PROBLEM", 40, 51], ["pneumonia", "PROBLEM", 106, 115], ["antibacterial agents", "TREATMENT", 165, 185], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["cough", "OBSERVATION", 46, 51], ["pneumonia", "OBSERVATION", 106, 115]]], ["6 Symptomatic treatment is directed at the suppression of cough.", [["cough", "DISEASE", 58, 63], ["Symptomatic treatment", "TREATMENT", 2, 23], ["cough", "PROBLEM", 58, 63], ["Symptomatic", "OBSERVATION_MODIFIER", 2, 13], ["treatment", "OBSERVATION", 14, 23], ["cough", "OBSERVATION", 58, 63]]], ["In children, a single nocturnal dose of honey is as effective ments in oxygenation.", [["children", "ORGANISM", 3, 11], ["honey", "ORGANISM_SUBDIVISION", 40, 45], ["children", "SPECIES", 3, 11]]], ["Steroids have been shown to confer significant benefits in the management of mild, moderate, and severe croup, including more rapid improvement in symptoms, reduced length of hospital stay, and reduced rates of intubation.", [["croup", "DISEASE", 104, 109], ["Steroids", "CHEMICAL", 0, 8], ["Steroids", "TREATMENT", 0, 8], ["the management", "TREATMENT", 59, 73], ["mild, moderate, and severe croup", "PROBLEM", 77, 109], ["symptoms", "PROBLEM", 147, 155], ["intubation", "TREATMENT", 211, 221], ["mild", "OBSERVATION_MODIFIER", 77, 81], ["moderate", "OBSERVATION_MODIFIER", 83, 91], ["severe", "OBSERVATION_MODIFIER", 97, 103], ["croup", "OBSERVATION", 104, 109], ["rapid", "OBSERVATION_MODIFIER", 126, 131], ["improvement", "OBSERVATION_MODIFIER", 132, 143], ["reduced", "OBSERVATION_MODIFIER", 157, 164], ["length", "OBSERVATION_MODIFIER", 165, 171]]], ["Administration of single-dose steroid therapy in this setting has not been associated with significant side effects and should probably be used in any patient ill enough to require an emergency department or clinic visit.", [["steroid", "CHEMICAL", 30, 37], ["steroid", "CHEMICAL", 30, 37], ["steroid", "SIMPLE_CHEMICAL", 30, 37], ["patient", "ORGANISM", 151, 158], ["patient", "SPECIES", 151, 158], ["single-dose steroid therapy", "TREATMENT", 18, 45], ["significant side effects", "PROBLEM", 91, 115]]], ["9 Antiviral agents have not been tested for efficacy in this situation, although the potential benefit of antiviral therapy in the typical self-limited course of croup would likely be limited.", [["croup", "DISEASE", 162, 167], ["Antiviral agents", "TREATMENT", 2, 18], ["antiviral therapy", "TREATMENT", 106, 123], ["croup", "PROBLEM", 162, 167], ["antiviral therapy", "OBSERVATION", 106, 123]]], ["Since croup is a viral illness, antibiotic therapy is of no benefit.BRONCHIOLITISBronchiolitis is an acute inflammatory disorder of the small airways characterized by obstruction with \"air trapping,\" hyperinflation of the lungs, and atelectasis typically seen in children younger than 2.", [["small airways", "ANATOMY", 136, 149], ["lungs", "ANATOMY", 222, 227], ["croup", "DISEASE", 6, 11], ["viral illness", "DISEASE", 17, 30], ["BRONCHIOLITISBronchiolitis", "CHEMICAL", 68, 94], ["disorder of the small airways", "DISEASE", 120, 149], ["obstruction", "DISEASE", 167, 178], ["hyperinflation of the lungs", "DISEASE", 200, 227], ["atelectasis", "DISEASE", 233, 244], ["airways", "MULTI-TISSUE_STRUCTURE", 142, 149], ["lungs", "ORGAN", 222, 227], ["children", "ORGANISM", 263, 271], ["children", "SPECIES", 263, 271], ["a viral illness", "PROBLEM", 15, 30], ["antibiotic therapy", "TREATMENT", 32, 50], ["BRONCHIOLITISBronchiolitis", "PROBLEM", 68, 94], ["an acute inflammatory disorder of the small airways", "PROBLEM", 98, 149], ["obstruction", "PROBLEM", 167, 178], ["\"air trapping", "PROBLEM", 184, 197], ["hyperinflation of the lungs", "PROBLEM", 200, 227], ["atelectasis", "PROBLEM", 233, 244], ["viral illness", "OBSERVATION", 17, 30], ["acute", "OBSERVATION_MODIFIER", 101, 106], ["inflammatory", "OBSERVATION", 107, 119], ["small airways", "ANATOMY", 136, 149], ["obstruction", "OBSERVATION", 167, 178], ["air trapping", "OBSERVATION", 185, 197], ["hyperinflation", "OBSERVATION", 200, 214], ["lungs", "ANATOMY", 222, 227], ["atelectasis", "OBSERVATION", 233, 244]]], ["After a several-day prodrome of mild upper respiratory tract symptoms, patients typically present with inspiratory and expiratory wheezing.", [["upper respiratory tract", "ANATOMY", 37, 60], ["upper respiratory tract symptoms", "DISEASE", 37, 69], ["inspiratory and expiratory wheezing", "DISEASE", 103, 138], ["upper", "ORGANISM_SUBDIVISION", 37, 42], ["respiratory tract", "ORGANISM_SUBDIVISION", 43, 60], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["mild upper respiratory tract symptoms", "PROBLEM", 32, 69], ["inspiratory and expiratory wheezing", "PROBLEM", 103, 138], ["mild", "OBSERVATION_MODIFIER", 32, 36], ["upper", "ANATOMY_MODIFIER", 37, 42], ["respiratory tract", "ANATOMY", 43, 60], ["inspiratory", "ANATOMY", 103, 114], ["expiratory wheezing", "OBSERVATION", 119, 138]]], ["The clinical features, which include tachypnea, intercostal and suprasternal retractions, nasal flaring, hyperresonant chest, wheezing, and inspiratory rales, usually lead to an accurate clinical diagnosis.", [["intercostal", "ANATOMY", 48, 59], ["suprasternal", "ANATOMY", 64, 76], ["nasal", "ANATOMY", 90, 95], ["chest", "ANATOMY", 119, 124], ["tachypnea", "DISEASE", 37, 46], ["wheezing", "DISEASE", 126, 134], ["intercostal", "MULTI-TISSUE_STRUCTURE", 48, 59], ["nasal", "ORGANISM_SUBDIVISION", 90, 95], ["chest", "ORGANISM_SUBDIVISION", 119, 124], ["tachypnea", "PROBLEM", 37, 46], ["intercostal and suprasternal retractions", "PROBLEM", 48, 88], ["nasal flaring", "PROBLEM", 90, 103], ["hyperresonant chest", "PROBLEM", 105, 124], ["wheezing", "PROBLEM", 126, 134], ["inspiratory rales", "PROBLEM", 140, 157], ["tachypnea", "OBSERVATION", 37, 46], ["intercostal", "ANATOMY", 48, 59], ["suprasternal", "ANATOMY", 64, 76], ["retractions", "OBSERVATION", 77, 88], ["nasal", "ANATOMY", 90, 95], ["flaring", "OBSERVATION", 96, 103], ["chest", "ANATOMY", 119, 124], ["wheezing", "OBSERVATION", 126, 134], ["inspiratory", "ANATOMY", 140, 151], ["rales", "OBSERVATION", 152, 157]]], ["The infant is often afebrile and, in mild cases, symptoms resolve within several days.", [["infant", "ORGANISM", 4, 10], ["infant", "SPECIES", 4, 10], ["afebrile", "PROBLEM", 20, 28], ["mild cases", "PROBLEM", 37, 47], ["symptoms", "PROBLEM", 49, 57], ["often", "OBSERVATION_MODIFIER", 14, 19], ["afebrile", "OBSERVATION", 20, 28], ["mild", "OBSERVATION_MODIFIER", 37, 41]]], ["Chest radiographs show increased lung volumes with flattening of the diaphragms, peribronchial thickening (eFig.", [["lung", "ANATOMY", 33, 37], ["diaphragms", "ANATOMY", 69, 79], ["peribronchial", "ANATOMY", 81, 94], ["lung", "ORGAN", 33, 37], ["diaphragms", "MULTI-TISSUE_STRUCTURE", 69, 79], ["peribronchial", "TISSUE", 81, 94], ["Chest radiographs", "TEST", 0, 17], ["increased lung volumes", "PROBLEM", 23, 45], ["flattening of the diaphragms", "PROBLEM", 51, 79], ["peribronchial thickening", "PROBLEM", 81, 105], ["increased", "OBSERVATION_MODIFIER", 23, 32], ["lung", "ANATOMY", 33, 37], ["volumes", "OBSERVATION", 38, 45], ["flattening", "OBSERVATION_MODIFIER", 51, 61], ["diaphragms", "ANATOMY", 69, 79], ["peribronchial", "ANATOMY", 81, 94], ["thickening", "OBSERVATION", 95, 105]]], ["32-2), and often atelectasis or parenchymal consolidation indicative of concurrent bronchopneumonia (Fig. 32-3 ).", [["parenchymal", "ANATOMY", 32, 43], ["atelectasis", "DISEASE", 17, 28], ["bronchopneumonia", "DISEASE", 83, 99], ["parenchymal", "ORGAN", 32, 43], ["often atelectasis", "PROBLEM", 11, 28], ["parenchymal consolidation", "PROBLEM", 32, 57], ["concurrent bronchopneumonia", "PROBLEM", 72, 99], ["atelectasis", "OBSERVATION", 17, 28], ["parenchymal", "ANATOMY_MODIFIER", 32, 43], ["consolidation", "OBSERVATION", 44, 57], ["indicative of", "UNCERTAINTY", 58, 71], ["concurrent", "OBSERVATION_MODIFIER", 72, 82], ["bronchopneumonia", "OBSERVATION", 83, 99]]], ["Chest computed tomography (CT) may show bronchial wall thickening and areas of increased attenuation representing atelectasis mixed with areas of decreased attenuation due to small airway inflammation and obstruction producing air trapping (eFig. .", [["bronchial wall", "ANATOMY", 40, 54], ["airway", "ANATOMY", 181, 187], ["atelectasis", "DISEASE", 114, 125], ["inflammation", "DISEASE", 188, 200], ["obstruction", "DISEASE", 205, 216], ["bronchial wall", "TISSUE", 40, 54], ["airway", "MULTI-TISSUE_STRUCTURE", 181, 187], ["Chest computed tomography (CT)", "TEST", 0, 30], ["bronchial wall thickening", "PROBLEM", 40, 65], ["increased attenuation", "PROBLEM", 79, 100], ["atelectasis", "PROBLEM", 114, 125], ["decreased attenuation", "PROBLEM", 146, 167], ["small airway inflammation", "PROBLEM", 175, 200], ["obstruction producing air trapping", "PROBLEM", 205, 239], ["bronchial", "ANATOMY", 40, 49], ["wall", "ANATOMY_MODIFIER", 50, 54], ["thickening", "OBSERVATION", 55, 65], ["areas", "OBSERVATION_MODIFIER", 70, 75], ["increased", "OBSERVATION_MODIFIER", 79, 88], ["attenuation", "OBSERVATION_MODIFIER", 89, 100], ["atelectasis", "OBSERVATION", 114, 125], ["decreased attenuation", "OBSERVATION", 146, 167], ["small", "OBSERVATION_MODIFIER", 175, 180], ["airway", "ANATOMY", 181, 187], ["inflammation", "OBSERVATION", 188, 200], ["obstruction", "OBSERVATION", 205, 216], ["air trapping", "OBSERVATION", 227, 239]]], ["The white blood cell count and differential count are usually within normal limits.BRONCHIOLITISat rest, use of accessory muscles, and intercostal retractions and may be followed by development of exhaustion with severe hypoventilation, cyanosis, and cardiovascular collapse.", [["white blood cell", "ANATOMY", 4, 20], ["accessory muscles", "ANATOMY", 112, 129], ["intercostal", "ANATOMY", 135, 146], ["cardiovascular", "ANATOMY", 251, 265], ["intercostal retractions", "DISEASE", 135, 158], ["hypoventilation", "DISEASE", 220, 235], ["cyanosis", "DISEASE", 237, 245], ["cardiovascular collapse", "DISEASE", 251, 274], ["white blood cell", "CELL", 4, 20], ["muscles", "ORGAN", 122, 129], ["intercostal", "MULTI-TISSUE_STRUCTURE", 135, 146], ["The white blood cell count", "TEST", 0, 26], ["differential count", "TEST", 31, 49], ["accessory muscles", "PROBLEM", 112, 129], ["intercostal retractions", "PROBLEM", 135, 158], ["exhaustion", "PROBLEM", 197, 207], ["severe hypoventilation", "PROBLEM", 213, 235], ["cyanosis", "PROBLEM", 237, 245], ["cardiovascular collapse", "PROBLEM", 251, 274], ["within normal limits", "OBSERVATION", 62, 82], ["accessory muscles", "ANATOMY", 112, 129], ["intercostal", "ANATOMY", 135, 146], ["retractions", "OBSERVATION", 147, 158], ["severe", "OBSERVATION_MODIFIER", 213, 219], ["hypoventilation", "OBSERVATION", 220, 235], ["cyanosis", "OBSERVATION", 237, 245], ["cardiovascular", "ANATOMY", 251, 265], ["collapse", "OBSERVATION", 266, 274]]], ["A fluctuating course is typical.BRONCHIOLITISRadiologic examination of the upper airway shows glottic and subglottic edema ( Fig. 32-2 , eFig.", [["upper airway", "ANATOMY", 75, 87], ["glottic", "ANATOMY", 94, 101], ["subglottic edema", "ANATOMY", 106, 122], ["subglottic edema", "DISEASE", 106, 122], ["upper airway", "ORGANISM_SUBDIVISION", 75, 87], ["glottic", "MULTI-TISSUE_STRUCTURE", 94, 101], ["subglottic edema", "PATHOLOGICAL_FORMATION", 106, 122], ["BRONCHIOLITISRadiologic examination of the upper airway", "TEST", 32, 87], ["glottic and subglottic edema", "PROBLEM", 94, 122], ["Fig.", "TEST", 125, 129], ["fluctuating", "OBSERVATION_MODIFIER", 2, 13], ["course", "OBSERVATION_MODIFIER", 14, 20], ["upper", "ANATOMY_MODIFIER", 75, 80], ["airway", "ANATOMY", 81, 87], ["glottic", "ANATOMY", 94, 101], ["subglottic", "ANATOMY", 106, 116], ["edema", "OBSERVATION", 117, 122]]], ["32-1) and helps to differentiate the disorder from acute bacterial epiglottitis.", [["epiglottitis", "DISEASE", 67, 79], ["the disorder", "PROBLEM", 33, 45], ["acute bacterial epiglottitis", "PROBLEM", 51, 79], ["acute", "OBSERVATION_MODIFIER", 51, 56], ["bacterial epiglottitis", "OBSERVATION", 57, 79]]], ["However, radiographs are limited in accuracy and, when the diagnosis is uncertain, radiologic and pharyngeal examination should be avoided because of the risk of cardiorespiratory arrest in acute epiglottitis.", [["pharyngeal", "ANATOMY", 98, 108], ["cardiorespiratory arrest", "DISEASE", 162, 186], ["epiglottitis", "DISEASE", 196, 208], ["pharyngeal", "ORGAN", 98, 108], ["radiographs", "TEST", 9, 20], ["pharyngeal examination", "TEST", 98, 120], ["cardiorespiratory arrest", "PROBLEM", 162, 186], ["acute epiglottitis", "PROBLEM", 190, 208], ["pharyngeal", "ANATOMY", 98, 108], ["cardiorespiratory arrest", "OBSERVATION", 162, 186], ["acute", "OBSERVATION_MODIFIER", 190, 195], ["epiglottitis", "OBSERVATION", 196, 208]]], ["Emergency assessment by an otolaryngologist or an anesthesiologist is indicated in this situation.BRONCHIOLITISThe acute infectious croup syndrome has been associated principally with infection by one of the parainfluenza viruses, as well as RSV, influenza A and B viruses, adenoviruses, and rhinovirus.", [["croup syndrome", "DISEASE", 132, 146], ["infection", "DISEASE", 184, 193], ["parainfluenza viruses", "DISEASE", 208, 229], ["influenza A and B viruses", "DISEASE", 247, 272], ["rhinovirus", "DISEASE", 292, 302], ["parainfluenza viruses", "ORGANISM", 208, 229], ["RSV", "ORGANISM", 242, 245], ["influenza A and B viruses", "ORGANISM", 247, 272], ["adenoviruses", "ORGANISM", 274, 286], ["rhinovirus", "ORGANISM", 292, 302], ["parainfluenza", "SPECIES", 208, 221], ["RSV", "SPECIES", 242, 245], ["influenza A", "SPECIES", 247, 258], ["B viruses", "SPECIES", 263, 272], ["Emergency assessment", "TEST", 0, 20], ["BRONCHIOLITISThe acute infectious croup syndrome", "PROBLEM", 98, 146], ["infection", "PROBLEM", 184, 193], ["the parainfluenza viruses", "PROBLEM", 204, 229], ["RSV", "PROBLEM", 242, 245], ["influenza A and B viruses", "PROBLEM", 247, 272], ["adenoviruses", "PROBLEM", 274, 286], ["rhinovirus", "PROBLEM", 292, 302], ["acute", "OBSERVATION_MODIFIER", 115, 120], ["infectious", "OBSERVATION", 121, 131], ["infection", "OBSERVATION", 184, 193], ["parainfluenza viruses", "OBSERVATION", 208, 229], ["influenza", "OBSERVATION", 247, 256], ["rhinovirus", "OBSERVATION", 292, 302]]], ["Measles is an important cause of severe croup in the developing world, and influenza A epidemics also are associated with severe croup.", [["Measles", "DISEASE", 0, 7], ["croup", "DISEASE", 40, 45], ["influenza A epidemics", "DISEASE", 75, 96], ["croup", "DISEASE", 129, 134], ["influenza A", "ORGANISM", 75, 86], ["severe croup", "PROBLEM", 33, 45], ["influenza A epidemics", "PROBLEM", 75, 96], ["severe croup", "PROBLEM", 122, 134], ["important cause", "UNCERTAINTY", 14, 29], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["croup", "OBSERVATION", 40, 45], ["severe", "OBSERVATION_MODIFIER", 122, 128], ["croup", "OBSERVATION", 129, 134]]], ["The differential diagnosis of croup includes acute bacterial epiglottitis, diphtheritic croup, asthma, and intrinsic or extrinsic upper airway obstruction related to an aspirated foreign body, allergic angioedema, and retropharyngeal abscess.BRONCHIOLITISBecause the majority of hospitalized children are hypoxemic, oxygen is the mainstay of treatment for severe disease.", [["airway", "ANATOMY", 136, 142], ["body", "ANATOMY", 187, 191], ["retropharyngeal abscess", "ANATOMY", 218, 241], ["croup", "DISEASE", 30, 35], ["epiglottitis", "DISEASE", 61, 73], ["croup", "DISEASE", 88, 93], ["asthma", "DISEASE", 95, 101], ["airway obstruction", "DISEASE", 136, 154], ["allergic angioedema", "DISEASE", 193, 212], ["retropharyngeal abscess", "DISEASE", 218, 241], ["hypoxemic", "DISEASE", 305, 314], ["oxygen", "CHEMICAL", 316, 322], ["oxygen", "CHEMICAL", 316, 322], ["upper airway", "ORGANISM_SUBDIVISION", 130, 142], ["retropharyngeal abscess", "PATHOLOGICAL_FORMATION", 218, 241], ["children", "ORGANISM", 292, 300], ["oxygen", "SIMPLE_CHEMICAL", 316, 322], ["children", "SPECIES", 292, 300], ["croup", "PROBLEM", 30, 35], ["acute bacterial epiglottitis", "PROBLEM", 45, 73], ["diphtheritic croup", "PROBLEM", 75, 93], ["asthma", "PROBLEM", 95, 101], ["extrinsic upper airway obstruction", "PROBLEM", 120, 154], ["an aspirated foreign body", "PROBLEM", 166, 191], ["allergic angioedema", "PROBLEM", 193, 212], ["retropharyngeal abscess", "PROBLEM", 218, 241], ["hypoxemic", "PROBLEM", 305, 314], ["oxygen", "TREATMENT", 316, 322], ["treatment", "TREATMENT", 342, 351], ["severe disease", "PROBLEM", 356, 370], ["acute", "OBSERVATION_MODIFIER", 45, 50], ["bacterial", "OBSERVATION_MODIFIER", 51, 60], ["epiglottitis", "OBSERVATION", 61, 73], ["asthma", "OBSERVATION", 95, 101], ["upper", "ANATOMY_MODIFIER", 130, 135], ["airway", "ANATOMY", 136, 142], ["obstruction", "OBSERVATION", 143, 154], ["aspirated", "OBSERVATION", 169, 178], ["foreign body", "OBSERVATION", 179, 191], ["allergic angioedema", "OBSERVATION", 193, 212], ["retropharyngeal", "ANATOMY", 218, 233], ["abscess", "OBSERVATION", 234, 241], ["majority", "OBSERVATION_MODIFIER", 267, 275], ["hypoxemic", "OBSERVATION", 305, 314], ["severe", "OBSERVATION_MODIFIER", 356, 362], ["disease", "OBSERVATION", 363, 370]]], ["Humidified air, or mist therapy, is commonly used, but the value of mist therapy has not been proven, and removal of the child from the parents and placement in a mist tent can be more distressing than beneficial to the child.BRONCHIOLITISAdministration of nebulized racemic epinephrine is commonly used for symptomatic relief in croup.", [["epinephrine", "CHEMICAL", 275, 286], ["croup", "DISEASE", 330, 335], ["epinephrine", "CHEMICAL", 275, 286], ["child", "ORGANISM", 121, 126], ["child", "ORGANISM", 220, 225], ["epinephrine", "SIMPLE_CHEMICAL", 275, 286], ["Humidified air", "TREATMENT", 0, 14], ["mist therapy", "TREATMENT", 19, 31], ["mist therapy", "TREATMENT", 68, 80], ["removal", "TREATMENT", 106, 113], ["placement", "TREATMENT", 148, 157], ["a mist tent", "TREATMENT", 161, 172], ["nebulized racemic epinephrine", "TREATMENT", 257, 286], ["symptomatic relief in croup", "PROBLEM", 308, 335], ["air", "OBSERVATION", 11, 14], ["nebulized", "OBSERVATION_MODIFIER", 257, 266], ["racemic epinephrine", "OBSERVATION", 267, 286], ["croup", "OBSERVATION", 330, 335]]], ["It is believed that \u03b1-adrenergic stimulation by this drug causes mucosal vasoconstriction, leading to decreased subglottic edema.", [["mucosal", "ANATOMY", 65, 72], ["subglottic edema", "ANATOMY", 112, 128], ["subglottic edema", "DISEASE", 112, 128], ["\u03b1-adrenergic", "SIMPLE_CHEMICAL", 20, 32], ["mucosal", "MULTI-TISSUE_STRUCTURE", 65, 72], ["subglottic edema", "PATHOLOGICAL_FORMATION", 112, 128], ["\u03b1-adrenergic stimulation", "TREATMENT", 20, 44], ["mucosal vasoconstriction", "PROBLEM", 65, 89], ["decreased subglottic edema", "PROBLEM", 102, 128], ["mucosal vasoconstriction", "OBSERVATION", 65, 89], ["decreased", "OBSERVATION_MODIFIER", 102, 111], ["subglottic", "ANATOMY", 112, 122], ["edema", "OBSERVATION", 123, 128]]], ["The onset of action is rapid, often within minutes, but the duration of relief is also limited, lasting 2 hours or less.", [["rapid", "OBSERVATION_MODIFIER", 23, 28]]], ["Therefore, treated subjects should be observed closely for clinical deterioration.", [["clinical deterioration", "PROBLEM", 59, 81]]], ["Although symptomatic relief is considerable, use of epinephrine is not associated with improve- B A many patients with acute viral infections.", [["epinephrine", "CHEMICAL", 52, 63], ["acute viral infections", "DISEASE", 119, 141], ["epinephrine", "CHEMICAL", 52, 63], ["epinephrine", "SIMPLE_CHEMICAL", 52, 63], ["patients", "ORGANISM", 105, 113], ["patients", "SPECIES", 105, 113], ["symptomatic relief", "PROBLEM", 9, 27], ["epinephrine", "TREATMENT", 52, 63], ["acute viral infections", "PROBLEM", 119, 141], ["symptomatic", "OBSERVATION_MODIFIER", 9, 20], ["relief", "OBSERVATION", 21, 27], ["acute", "OBSERVATION_MODIFIER", 119, 124], ["viral", "OBSERVATION_MODIFIER", 125, 130], ["infections", "OBSERVATION", 131, 141]]], ["Also, because viral infections may be complicated by secondary bacterial pneumonias, invasive procedures would be necessary to differentiate among pure viral pneumonias, secondary bacterial pneumonias, and mixed viral and bacterial infections.Normal HostThe relative importance of the different viruses as causes of pneumonia depends on the season and the age distribution of the population under study.", [["viral infections", "DISEASE", 14, 30], ["pneumonias", "DISEASE", 73, 83], ["viral pneumonias", "DISEASE", 152, 168], ["bacterial pneumonias", "DISEASE", 180, 200], ["viral and bacterial infections", "DISEASE", 212, 242], ["pneumonia", "DISEASE", 316, 325], ["viral infections", "PROBLEM", 14, 30], ["secondary bacterial pneumonias", "PROBLEM", 53, 83], ["invasive procedures", "TREATMENT", 85, 104], ["pure viral pneumonias", "PROBLEM", 147, 168], ["secondary bacterial pneumonias", "PROBLEM", 170, 200], ["mixed viral and bacterial infections", "PROBLEM", 206, 242], ["the different viruses", "PROBLEM", 281, 302], ["pneumonia", "PROBLEM", 316, 325], ["secondary", "OBSERVATION_MODIFIER", 53, 62], ["bacterial", "OBSERVATION_MODIFIER", 63, 72], ["pneumonias", "OBSERVATION", 73, 83], ["viral", "OBSERVATION_MODIFIER", 152, 157], ["pneumonias", "OBSERVATION", 158, 168], ["bacterial", "OBSERVATION_MODIFIER", 180, 189], ["pneumonias", "OBSERVATION", 190, 200], ["mixed", "OBSERVATION_MODIFIER", 206, 211], ["viral", "OBSERVATION_MODIFIER", 212, 217], ["bacterial", "OBSERVATION_MODIFIER", 222, 231], ["infections", "OBSERVATION", 232, 242], ["Host", "OBSERVATION_MODIFIER", 250, 254], ["different", "OBSERVATION_MODIFIER", 285, 294], ["viruses", "OBSERVATION", 295, 302], ["pneumonia", "OBSERVATION", 316, 325]]], ["During outbreaks, influenza virus accounts for more than 50% of viral pneumonia in adults.", [["influenza virus", "DISEASE", 18, 33], ["pneumonia", "DISEASE", 70, 79], ["influenza virus", "ORGANISM", 18, 33], ["influenza virus", "SPECIES", 18, 33], ["influenza virus", "SPECIES", 18, 33], ["influenza virus", "PROBLEM", 18, 33], ["viral pneumonia in adults", "PROBLEM", 64, 89], ["influenza virus", "OBSERVATION", 18, 33], ["viral", "OBSERVATION_MODIFIER", 64, 69], ["pneumonia", "OBSERVATION", 70, 79]]], ["In addition, RSV, adenovirus, parainfluenza virus, and varicella virus cause pneumonia in normal adults.", [["parainfluenza virus", "DISEASE", 30, 49], ["varicella virus", "DISEASE", 55, 70], ["pneumonia", "DISEASE", 77, 86], ["RSV", "ORGANISM", 13, 16], ["adenovirus", "ORGANISM", 18, 28], ["parainfluenza virus", "ORGANISM", 30, 49], ["varicella virus", "ORGANISM", 55, 70], ["parainfluenza virus", "SPECIES", 30, 49], ["varicella virus", "SPECIES", 55, 70], ["RSV", "SPECIES", 13, 16], ["parainfluenza virus", "SPECIES", 30, 49], ["varicella virus", "SPECIES", 55, 70], ["RSV", "PROBLEM", 13, 16], ["adenovirus", "PROBLEM", 18, 28], ["parainfluenza virus", "PROBLEM", 30, 49], ["varicella virus", "PROBLEM", 55, 70], ["pneumonia", "PROBLEM", 77, 86], ["RSV", "OBSERVATION", 13, 16], ["parainfluenza virus", "OBSERVATION", 30, 49], ["varicella virus", "OBSERVATION", 55, 70], ["normal adults", "OBSERVATION", 90, 103]]], ["Unusual viruses continue to emerge in epidemics of severe acute pneumonitis, including hantavirus, coronavirus (SARS), and avian influenza A viruses.Normal HostIn children, RSV, parainfluenza virus, and adenovirus, in addition to influenza viruses, are the most important causes of pneumonia.", [["pneumonitis", "DISEASE", 64, 75], ["hantavirus, coronavirus", "DISEASE", 87, 110], ["SARS", "DISEASE", 112, 116], ["avian influenza A viruses", "DISEASE", 123, 148], ["RSV, parainfluenza virus", "DISEASE", 173, 197], ["influenza viruses", "DISEASE", 230, 247], ["pneumonia", "DISEASE", 282, 291], ["avian influenza A viruses", "ORGANISM", 123, 148], ["HostIn children", "ORGANISM", 156, 171], ["RSV", "ORGANISM", 173, 176], ["parainfluenza virus", "ORGANISM", 178, 197], ["adenovirus", "ORGANISM", 203, 213], ["influenza viruses", "ORGANISM", 230, 247], ["avian influenza A", "SPECIES", 123, 140], ["children", "SPECIES", 163, 171], ["RSV", "SPECIES", 173, 176], ["parainfluenza virus", "SPECIES", 178, 197], ["avian influenza A viruses", "SPECIES", 123, 148], ["RSV", "SPECIES", 173, 176], ["parainfluenza virus", "SPECIES", 178, 197], ["adenovirus", "SPECIES", 203, 213], ["Unusual viruses", "PROBLEM", 0, 15], ["severe acute pneumonitis", "PROBLEM", 51, 75], ["hantavirus", "PROBLEM", 87, 97], ["coronavirus", "PROBLEM", 99, 110], ["SARS", "PROBLEM", 112, 116], ["avian influenza A viruses", "PROBLEM", 123, 148], ["RSV", "PROBLEM", 173, 176], ["parainfluenza virus", "PROBLEM", 178, 197], ["adenovirus", "PROBLEM", 203, 213], ["influenza viruses", "PROBLEM", 230, 247], ["pneumonia", "PROBLEM", 282, 291], ["viruses", "OBSERVATION", 8, 15], ["severe", "OBSERVATION_MODIFIER", 51, 57], ["acute", "OBSERVATION_MODIFIER", 58, 63], ["pneumonitis", "OBSERVATION", 64, 75], ["hantavirus", "OBSERVATION", 87, 97], ["parainfluenza virus", "OBSERVATION", 178, 197], ["influenza viruses", "OBSERVATION", 230, 247], ["pneumonia", "OBSERVATION", 282, 291]]], ["Measles virus pneumonia affects children and adults during epidemics in susceptible populations.", [["Measles virus pneumonia", "DISEASE", 0, 23], ["Measles virus", "ORGANISM", 0, 13], ["children", "ORGANISM", 32, 40], ["Measles virus pneumonia", "SPECIES", 0, 23], ["children", "SPECIES", 32, 40], ["Measles virus", "SPECIES", 0, 13], ["Measles virus pneumonia", "PROBLEM", 0, 23]]], ["There are reports of cases of pneumonia in adults and children attributable to rhinovirus, but the evidence that these viruses are definite causes of pneumonia is circumstantial.Normal HostThe clinical and radiographic features of sporadic cases of viral pneumonia are usually not sufficiently characteristic to permit specific viral diagnosis or differentiation from bacterial pneumonias on clinical grounds alone.", [["pneumonia", "DISEASE", 30, 39], ["rhinovirus", "DISEASE", 79, 89], ["pneumonia", "DISEASE", 150, 159], ["viral pneumonia", "DISEASE", 249, 264], ["pneumonias", "DISEASE", 378, 388], ["children", "ORGANISM", 54, 62], ["rhinovirus", "ORGANISM", 79, 89], ["children", "SPECIES", 54, 62], ["pneumonia", "PROBLEM", 30, 39], ["rhinovirus", "PROBLEM", 79, 89], ["these viruses", "PROBLEM", 113, 126], ["pneumonia", "PROBLEM", 150, 159], ["viral pneumonia", "PROBLEM", 249, 264], ["bacterial pneumonias", "PROBLEM", 368, 388], ["pneumonia", "OBSERVATION", 30, 39], ["rhinovirus", "OBSERVATION", 79, 89], ["viruses", "OBSERVATION", 119, 126], ["pneumonia", "OBSERVATION", 150, 159], ["Host", "OBSERVATION_MODIFIER", 185, 189], ["sporadic", "OBSERVATION_MODIFIER", 231, 239], ["viral", "OBSERVATION_MODIFIER", 249, 254], ["pneumonia", "OBSERVATION", 255, 264], ["bacterial", "OBSERVATION_MODIFIER", 368, 377], ["pneumonias", "OBSERVATION", 378, 388]]], ["Exceptions include measles (eFig. and varicella pneumonia, in which the associated rash establishes the diagnosis.", [["measles", "DISEASE", 19, 26], ["varicella pneumonia", "DISEASE", 38, 57], ["rash", "DISEASE", 83, 87], ["measles (eFig", "PROBLEM", 19, 32], ["varicella pneumonia", "PROBLEM", 38, 57], ["the associated rash", "PROBLEM", 68, 87], ["measles", "OBSERVATION", 19, 26], ["varicella", "OBSERVATION_MODIFIER", 38, 47], ["pneumonia", "OBSERVATION", 48, 57]]], ["Therefore, attention is first directed at excluding primary or secondary bacterial pneumonia.", [["pneumonia", "DISEASE", 83, 92], ["secondary bacterial pneumonia", "PROBLEM", 63, 92], ["secondary", "OBSERVATION_MODIFIER", 63, 72], ["bacterial", "OBSERVATION_MODIFIER", 73, 82], ["pneumonia", "OBSERVATION", 83, 92]]], ["Tests to detect viral antigens or nucleic acid are increasingly available and are rapidly being adopted as the preferred approaches for establishing the etiologic diagnosis 11a,b (see Chapter 17) .Normal HostTreatment of viral pneumonia in the normal host is supportive in nature and directed at early antimicrobial therapy of secondary bacterial infections, if present.", [["nucleic acid", "CHEMICAL", 34, 46], ["viral pneumonia", "DISEASE", 221, 236], ["bacterial infections", "DISEASE", 337, 357], ["nucleic acid", "SIMPLE_CHEMICAL", 34, 46], ["viral antigens", "PROTEIN", 16, 30], ["Tests", "TEST", 0, 5], ["viral antigens", "TEST", 16, 30], ["nucleic acid", "PROBLEM", 34, 46], ["viral pneumonia", "PROBLEM", 221, 236], ["early antimicrobial therapy", "TREATMENT", 296, 323], ["secondary bacterial infections", "PROBLEM", 327, 357], ["viral", "OBSERVATION_MODIFIER", 221, 226], ["pneumonia", "OBSERVATION", 227, 236], ["normal host", "OBSERVATION_MODIFIER", 244, 255], ["secondary bacterial infections", "OBSERVATION", 327, 357]]], ["Specific antiviral therapy may be beneficial and is discussed with the individual pathogens.", [["Specific antiviral therapy", "TREATMENT", 0, 26], ["antiviral therapy", "OBSERVATION", 9, 26]]], ["Viral pneumonias with extensive involvement of lung tissue may require prolonged ventilatory assistance and pulmonary rehabilitation.", [["lung tissue", "ANATOMY", 47, 58], ["pulmonary", "ANATOMY", 108, 117], ["pneumonias", "DISEASE", 6, 16], ["lung tissue", "TISSUE", 47, 58], ["pulmonary", "ORGAN", 108, 117], ["Viral pneumonias", "PROBLEM", 0, 16], ["lung tissue", "PROBLEM", 47, 58], ["prolonged ventilatory assistance", "TREATMENT", 71, 103], ["pulmonary rehabilitation", "TREATMENT", 108, 132], ["pneumonias", "OBSERVATION", 6, 16], ["extensive", "OBSERVATION_MODIFIER", 22, 31], ["lung", "ANATOMY", 47, 51], ["tissue", "OBSERVATION", 52, 58], ["ventilatory assistance", "OBSERVATION", 81, 103], ["pulmonary", "ANATOMY", 108, 117]]], ["Some cases of viral pneumonia have a rapid and relentless fatal course, with generalized alveolar and interstitial opacities, development of the adult respiratory distress syndrome (ARDS), and progressive respiratory failure.Immunocompromised HostViral pneumonia can be an important problem for the increasing number of persons in the population who have deficiencies in immunity as the result of cytotoxic chemotherapy, organ transplantation, and the acquired immunodeficiency syndrome (AIDS).", [["alveolar", "ANATOMY", 89, 97], ["interstitial", "ANATOMY", 102, 114], ["respiratory", "ANATOMY", 151, 162], ["respiratory", "ANATOMY", 205, 216], ["organ", "ANATOMY", 421, 426], ["viral pneumonia", "DISEASE", 14, 29], ["interstitial opacities", "DISEASE", 102, 124], ["adult respiratory distress syndrome", "DISEASE", 145, 180], ["ARDS", "DISEASE", 182, 186], ["respiratory failure", "DISEASE", 205, 224], ["pneumonia", "DISEASE", 253, 262], ["acquired immunodeficiency syndrome", "DISEASE", 452, 486], ["AIDS", "DISEASE", 488, 492], ["alveolar", "MULTI-TISSUE_STRUCTURE", 89, 97], ["persons", "ORGANISM", 320, 327], ["organ", "ORGAN", 421, 426], ["persons", "SPECIES", 320, 327], ["viral pneumonia", "PROBLEM", 14, 29], ["generalized alveolar and interstitial opacities", "PROBLEM", 77, 124], ["the adult respiratory distress syndrome", "PROBLEM", 141, 180], ["ARDS", "PROBLEM", 182, 186], ["progressive respiratory failure", "PROBLEM", 193, 224], ["Immunocompromised HostViral pneumonia", "PROBLEM", 225, 262], ["deficiencies in immunity", "PROBLEM", 355, 379], ["cytotoxic chemotherapy", "TREATMENT", 397, 419], ["organ transplantation", "TREATMENT", 421, 442], ["the acquired immunodeficiency syndrome", "PROBLEM", 448, 486], ["viral", "OBSERVATION_MODIFIER", 14, 19], ["pneumonia", "OBSERVATION", 20, 29], ["rapid", "OBSERVATION_MODIFIER", 37, 42], ["relentless", "OBSERVATION_MODIFIER", 47, 57], ["generalized", "OBSERVATION_MODIFIER", 77, 88], ["alveolar", "ANATOMY_MODIFIER", 89, 97], ["interstitial", "ANATOMY_MODIFIER", 102, 114], ["opacities", "OBSERVATION", 115, 124], ["adult", "OBSERVATION_MODIFIER", 145, 150], ["respiratory distress syndrome", "OBSERVATION", 151, 180], ["ARDS", "OBSERVATION", 182, 186], ["progressive", "OBSERVATION_MODIFIER", 193, 204], ["respiratory failure", "OBSERVATION", 205, 224], ["pneumonia", "OBSERVATION", 253, 262], ["increasing", "OBSERVATION_MODIFIER", 299, 309], ["number", "OBSERVATION_MODIFIER", 310, 316], ["cytotoxic chemotherapy", "OBSERVATION", 397, 419]]], ["The major respiratory viruses that affect normal persons may also cause pneumonia in impaired hosts; severe and prolonged pneumonias due to adenovirus, respiratory syncytial, influenza, measles, or parainfluenza virus can develop in such patients.", [["respiratory viruses", "DISEASE", 10, 29], ["pneumonia", "DISEASE", 72, 81], ["pneumonias", "DISEASE", 122, 132], ["respiratory syncytial, influenza, measles, or parainfluenza virus", "DISEASE", 152, 217], ["persons", "ORGANISM", 49, 56], ["adenovirus", "ORGANISM", 140, 150], ["respiratory syncytial", "ORGANISM", 152, 173], ["parainfluenza virus", "ORGANISM", 198, 217], ["patients", "ORGANISM", 238, 246], ["persons", "SPECIES", 49, 56], ["parainfluenza virus", "SPECIES", 198, 217], ["patients", "SPECIES", 238, 246], ["parainfluenza virus", "SPECIES", 198, 217], ["The major respiratory viruses", "PROBLEM", 0, 29], ["pneumonia", "PROBLEM", 72, 81], ["impaired hosts", "PROBLEM", 85, 99], ["severe and prolonged pneumonias", "PROBLEM", 101, 132], ["adenovirus", "PROBLEM", 140, 150], ["respiratory syncytial", "PROBLEM", 152, 173], ["influenza", "PROBLEM", 175, 184], ["measles", "PROBLEM", 186, 193], ["parainfluenza virus", "PROBLEM", 198, 217], ["major", "OBSERVATION_MODIFIER", 4, 9], ["respiratory viruses", "OBSERVATION", 10, 29], ["may also cause", "UNCERTAINTY", 57, 71], ["pneumonia", "OBSERVATION", 72, 81], ["severe", "OBSERVATION_MODIFIER", 101, 107], ["prolonged", "OBSERVATION_MODIFIER", 112, 121], ["pneumonias", "OBSERVATION", 122, 132], ["respiratory syncytial", "ANATOMY", 152, 173], ["influenza", "OBSERVATION", 175, 184]]], ["Immunocompromised patients can also shed respiratory viruses for prolonged periods and thus be responsible for extensive transmission of infection to others.", [["respiratory viruses", "DISEASE", 41, 60], ["infection", "DISEASE", 137, 146], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["respiratory viruses", "PROBLEM", 41, 60], ["infection", "PROBLEM", 137, 146], ["respiratory", "ANATOMY", 41, 52], ["viruses", "OBSERVATION", 53, 60], ["infection", "OBSERVATION", 137, 146]]], ["In addition, these individuals may develop pneumonia due to viruses, such as cytomegalovirus, that rarely cause lower respiratory tractImmunocompromised HostThe majority of cases in which an etiologic agent has been identified are associated with RSV.", [["lower respiratory tract", "ANATOMY", 112, 135], ["pneumonia", "DISEASE", 43, 52], ["cytomegalovirus", "DISEASE", 77, 92], ["individuals", "ORGANISM", 19, 30], ["cytomegalovirus", "ORGANISM", 77, 92], ["RSV", "ORGANISM", 247, 250], ["RSV", "SPECIES", 247, 250], ["pneumonia", "PROBLEM", 43, 52], ["viruses", "PROBLEM", 60, 67], ["cytomegalovirus", "PROBLEM", 77, 92], ["lower respiratory tract", "PROBLEM", 112, 135], ["RSV", "PROBLEM", 247, 250], ["pneumonia", "OBSERVATION", 43, 52], ["viruses", "OBSERVATION", 60, 67], ["cytomegalovirus", "OBSERVATION", 77, 92], ["respiratory tract", "ANATOMY", 118, 135]]], ["Other viruses associated with bronchiolitis include human metapneumovirus, bocavirus, parainfluenza virus, influenza A and B viruses, adenovirus, measles, and rhinoviruses.", [["bronchiolitis", "DISEASE", 30, 43], ["human metapneumovirus", "DISEASE", 52, 73], ["parainfluenza virus", "DISEASE", 86, 105], ["influenza A and B viruses", "DISEASE", 107, 132], ["measles, and rhinoviruses", "DISEASE", 146, 171], ["human", "ORGANISM", 52, 57], ["metapneumovirus", "ORGANISM", 58, 73], ["bocavirus", "ORGANISM", 75, 84], ["parainfluenza virus", "ORGANISM", 86, 105], ["influenza A and B viruses", "ORGANISM", 107, 132], ["adenovirus", "ORGANISM", 134, 144], ["rhinoviruses", "ORGANISM", 159, 171], ["human", "SPECIES", 52, 57], ["metapneumovirus", "SPECIES", 58, 73], ["parainfluenza virus", "SPECIES", 86, 105], ["human metapneumovirus", "SPECIES", 52, 73], ["parainfluenza virus", "SPECIES", 86, 105], ["B viruses", "SPECIES", 123, 132], ["adenovirus", "SPECIES", 134, 144], ["Other viruses", "PROBLEM", 0, 13], ["bronchiolitis", "PROBLEM", 30, 43], ["human metapneumovirus", "PROBLEM", 52, 73], ["bocavirus", "PROBLEM", 75, 84], ["parainfluenza virus", "PROBLEM", 86, 105], ["influenza", "PROBLEM", 107, 116], ["B viruses", "PROBLEM", 123, 132], ["adenovirus", "PROBLEM", 134, 144], ["measles", "PROBLEM", 146, 153], ["rhinoviruses", "PROBLEM", 159, 171], ["viruses", "OBSERVATION", 6, 13], ["bronchiolitis", "OBSERVATION", 30, 43], ["metapneumovirus", "OBSERVATION", 58, 73], ["parainfluenza virus", "OBSERVATION", 86, 105], ["rhinoviruses", "OBSERVATION", 159, 171]]], ["The major differential diagnostic consideration is asthma, which is uncommon in children younger than one year old.Immunocompromised HostCorrection of hypoxemia is the most important aspect of managing lower respiratory tract disease.", [["lower respiratory tract", "ANATOMY", 202, 225], ["asthma", "DISEASE", 51, 57], ["hypoxemia", "DISEASE", 151, 160], ["lower respiratory tract disease", "DISEASE", 202, 233], ["children", "ORGANISM", 80, 88], ["lower", "ORGANISM_SUBDIVISION", 202, 207], ["respiratory tract", "ORGANISM_SUBDIVISION", 208, 225], ["children", "SPECIES", 80, 88], ["asthma", "PROBLEM", 51, 57], ["hypoxemia", "PROBLEM", 151, 160], ["managing lower respiratory tract disease", "PROBLEM", 193, 233], ["asthma", "OBSERVATION", 51, 57], ["uncommon", "OBSERVATION_MODIFIER", 68, 76], ["hypoxemia", "OBSERVATION", 151, 160], ["most important", "OBSERVATION_MODIFIER", 168, 182], ["lower", "ANATOMY_MODIFIER", 202, 207], ["respiratory tract", "ANATOMY", 208, 225]]], ["Studies of corticosteroid therapies have found no consistent benefit.", [["corticosteroid", "SIMPLE_CHEMICAL", 11, 25], ["corticosteroid therapies", "TREATMENT", 11, 35], ["no consistent", "UNCERTAINTY", 47, 60]]], ["Studies of bronchodilators have reached conflicting results, and bronchodilating drugs may contribute to increased restlessness and cardiovascular stress, so guidelines do not suggest that bronchodilators be used routinely.", [["cardiovascular", "ANATOMY", 132, 146], ["cardiovascular stress", "DISEASE", 132, 153], ["bronchodilators", "TREATMENT", 11, 26], ["bronchodilating drugs", "TREATMENT", 65, 86], ["increased restlessness", "PROBLEM", 105, 127], ["cardiovascular stress", "PROBLEM", 132, 153], ["bronchodilators", "TREATMENT", 189, 204], ["increased", "OBSERVATION_MODIFIER", 105, 114], ["restlessness", "OBSERVATION", 115, 127]]], ["One recent randomized trial suggests that \"on-demand\" use of inhaled racemic adrenaline may result in decreased length of stay in infants hospitalized with bronchiolitis.", [["adrenaline", "CHEMICAL", 77, 87], ["bronchiolitis", "DISEASE", 156, 169], ["adrenaline", "CHEMICAL", 77, 87], ["adrenaline", "SIMPLE_CHEMICAL", 77, 87], ["infants", "ORGANISM", 130, 137], ["infants", "SPECIES", 130, 137], ["inhaled racemic adrenaline", "TREATMENT", 61, 87], ["bronchiolitis", "PROBLEM", 156, 169], ["decreased", "OBSERVATION_MODIFIER", 102, 111], ["length", "OBSERVATION_MODIFIER", 112, 118], ["bronchiolitis", "OBSERVATION", 156, 169]]], ["10 Because of the dehydrating effect of tachypnea and reduced oral intake in some hospitalized infants, parenteral rehydration is often necessary, but care must be taken to avoid inducing hyponatremia.", [["oral", "ANATOMY", 62, 66], ["parenteral", "ANATOMY", 104, 114], ["tachypnea", "DISEASE", 40, 49], ["hyponatremia", "DISEASE", 188, 200], ["oral", "ORGANISM_SUBDIVISION", 62, 66], ["infants", "ORGANISM", 95, 102], ["infants", "SPECIES", 95, 102], ["the dehydrating effect", "PROBLEM", 14, 36], ["tachypnea", "PROBLEM", 40, 49], ["reduced oral intake", "PROBLEM", 54, 73], ["parenteral rehydration", "TREATMENT", 104, 126], ["hyponatremia", "PROBLEM", 188, 200], ["tachypnea", "OBSERVATION", 40, 49], ["reduced", "OBSERVATION_MODIFIER", 54, 61], ["hyponatremia", "OBSERVATION", 188, 200]]], ["Aerosol treatment with the synthetic nucleoside ribavirin has been associated with reductions in virus titers but inconsistent clinical benefits.", [["nucleoside", "CHEMICAL", 37, 47], ["ribavirin", "CHEMICAL", 48, 57], ["nucleoside ribavirin", "CHEMICAL", 37, 57], ["nucleoside ribavirin", "SIMPLE_CHEMICAL", 37, 57], ["Aerosol treatment", "TREATMENT", 0, 17], ["the synthetic nucleoside ribavirin", "TREATMENT", 23, 57], ["reductions in virus titers", "PROBLEM", 83, 109]]], ["Antibacterial drugs, including azithromycin, are of no benefit.", [["azithromycin", "CHEMICAL", 31, 43], ["azithromycin", "CHEMICAL", 31, 43], ["azithromycin", "SIMPLE_CHEMICAL", 31, 43], ["Antibacterial drugs", "TREATMENT", 0, 19], ["azithromycin", "TREATMENT", 31, 43]]], ["11PNEUMONIAViruses are important causes of pneumonia in both adults and children.", [["pneumonia", "DISEASE", 43, 52], ["children", "ORGANISM", 72, 80], ["children", "SPECIES", 72, 80], ["pneumonia", "PROBLEM", 43, 52], ["important causes of", "UNCERTAINTY", 23, 42], ["pneumonia", "OBSERVATION", 43, 52]]], ["They have been associated with up to 40% of radiographically proven pneumonias in hospitalized adults and are estimated to cause 16% of total pneumonias in pediatric outpatients and up to 49% in hospitalized infants.", [["pneumonias", "DISEASE", 68, 78], ["pneumonias", "DISEASE", 142, 152], ["outpatients", "ORGANISM", 166, 177], ["infants", "ORGANISM", 208, 215], ["outpatients", "SPECIES", 166, 177], ["infants", "SPECIES", 208, 215], ["pneumonias", "PROBLEM", 68, 78], ["total pneumonias", "PROBLEM", 136, 152], ["pneumonias", "OBSERVATION", 68, 78], ["pneumonias", "OBSERVATION", 142, 152]]], ["These figures may underestimate the importance of viral infections as a cause of pneumonia, particularly in outpatients, because of the insensitivity of viral diagnostic methods and because of the lack of chest radiographs in 1 and 2, routinely infect infants and young children, who then have prolonged asymptomatic viral shedding from the respiratory and gastrointestinal (GI) tracts.", [["respiratory", "ANATOMY", 341, 352], ["gastrointestinal (GI) tracts", "ANATOMY", 357, 385], ["viral infections", "DISEASE", 50, 66], ["pneumonia", "DISEASE", 81, 90], ["respiratory and gastrointestinal (GI) tracts", "DISEASE", 341, 385], ["infants", "ORGANISM", 252, 259], ["children", "ORGANISM", 270, 278], ["gastrointestinal", "PATHOLOGICAL_FORMATION", 357, 373], ["infants", "SPECIES", 252, 259], ["children", "SPECIES", 270, 278], ["viral infections", "PROBLEM", 50, 66], ["pneumonia", "PROBLEM", 81, 90], ["chest radiographs", "TEST", 205, 222], ["prolonged asymptomatic viral shedding", "PROBLEM", 294, 331], ["viral", "OBSERVATION_MODIFIER", 50, 55], ["infections", "OBSERVATION", 56, 66], ["pneumonia", "OBSERVATION", 81, 90], ["chest", "ANATOMY", 205, 210], ["respiratory", "ANATOMY", 341, 352], ["gastrointestinal", "ANATOMY", 357, 373]]], ["Other types, including those that have been most often implicated in respiratory disease (e.g., types 3, 4, and 7), are acquired later in life, characteristically in epidemic settings.", [["respiratory", "ANATOMY", 69, 80], ["respiratory disease", "DISEASE", 69, 88], ["respiratory disease", "PROBLEM", 69, 88], ["respiratory disease", "OBSERVATION", 69, 88]]], ["In most instances, viral transmission probably takes place by direct contact with infectious secretions.", [["secretions", "ANATOMY", 93, 103], ["infectious secretions", "PROBLEM", 82, 103], ["most instances", "OBSERVATION_MODIFIER", 3, 17], ["viral", "OBSERVATION", 19, 24]]], ["However, the explosive nature of adenoviral acute respiratory disease in military recruits probably reflects airborne spread.PNEUMONIAMost community adenovirus respiratory disease has been recognized in the summer months in association with outbreaks or sporadic cases of febrile pharyngitis or bronchitis.", [["respiratory", "ANATOMY", 50, 61], ["respiratory", "ANATOMY", 160, 171], ["acute respiratory disease", "DISEASE", 44, 69], ["adenovirus respiratory disease", "DISEASE", 149, 179], ["febrile pharyngitis", "DISEASE", 272, 291], ["bronchitis", "DISEASE", 295, 305], ["adenoviral", "ORGANISM", 33, 43], ["adenovirus", "ORGANISM", 149, 159], ["adenoviral acute respiratory disease", "PROBLEM", 33, 69], ["airborne spread", "PROBLEM", 109, 124], ["PNEUMONIAMost community adenovirus respiratory disease", "PROBLEM", 125, 179], ["febrile pharyngitis", "PROBLEM", 272, 291], ["bronchitis", "PROBLEM", 295, 305], ["explosive", "OBSERVATION_MODIFIER", 13, 22], ["adenoviral", "OBSERVATION_MODIFIER", 33, 43], ["acute", "OBSERVATION_MODIFIER", 44, 49], ["respiratory disease", "OBSERVATION", 50, 69], ["probably reflects", "UNCERTAINTY", 91, 108], ["airborne spread", "OBSERVATION", 109, 124], ["community", "OBSERVATION_MODIFIER", 139, 148], ["adenovirus", "OBSERVATION", 149, 159], ["respiratory disease", "OBSERVATION", 160, 179], ["febrile", "OBSERVATION_MODIFIER", 272, 279], ["pharyngitis", "OBSERVATION", 280, 291], ["bronchitis", "OBSERVATION", 295, 305]]], ["Nosocomial outbreaks of adenovirus infection have arisen in hospital wards, special care units, and psychiatric facilities.", [["adenovirus infection", "DISEASE", 24, 44], ["psychiatric", "DISEASE", 100, 111], ["adenovirus", "ORGANISM", 24, 34], ["adenovirus", "SPECIES", 24, 34], ["Nosocomial outbreaks of adenovirus infection", "PROBLEM", 0, 44], ["adenovirus infection", "OBSERVATION", 24, 44]]], ["New variants of adenovirus have occasionally emerged and have been associated with outbreaks worldwide.", [["adenovirus", "ORGANISM", 16, 26], ["adenovirus", "SPECIES", 16, 26], ["New variants of adenovirus", "PROBLEM", 0, 26], ["adenovirus", "OBSERVATION", 16, 26]]], ["Since 1996, a specific variant of adenovirus type 7 (Ad7d2) has been responsible for several civilian outbreaks and a large military outbreak.", [["adenovirus type 7", "ORGANISM", 34, 51], ["Ad7d2", "GENE_OR_GENE_PRODUCT", 53, 58], ["adenovirus type 7", "SPECIES", 34, 51], ["a large military outbreak", "PROBLEM", 116, 141], ["responsible for", "UNCERTAINTY", 69, 84], ["large", "OBSERVATION_MODIFIER", 118, 123], ["military", "OBSERVATION_MODIFIER", 124, 132], ["outbreak", "OBSERVATION", 133, 141]]], ["13 More recently, adenovirus type 14 (Ad14), a previously rare serotype, has been responsible for outbreaks of disease both in the military and in civilian populations.", [["adenovirus type 14", "ORGANISM", 18, 36], ["Ad14", "GENE_OR_GENE_PRODUCT", 38, 42], ["a previously rare serotype", "PROBLEM", 45, 71], ["disease", "PROBLEM", 111, 118], ["responsible for", "UNCERTAINTY", 82, 97], ["disease", "OBSERVATION", 111, 118]]], ["[14] [15] [16] Most cases have been relatively mild febrile respiratory illnesses, but some cases have been seen with severe pneumonia requiring hospitalization.", [["respiratory", "ANATOMY", 60, 71], ["febrile respiratory illnesses", "DISEASE", 52, 81], ["pneumonia", "DISEASE", 125, 134], ["[14] [15] [16", "SIMPLE_CHEMICAL", 0, 13], ["relatively mild febrile respiratory illnesses", "PROBLEM", 36, 81], ["severe pneumonia", "PROBLEM", 118, 134], ["relatively", "OBSERVATION_MODIFIER", 36, 46], ["mild", "OBSERVATION_MODIFIER", 47, 51], ["febrile", "OBSERVATION_MODIFIER", 52, 59], ["respiratory illnesses", "OBSERVATION", 60, 81], ["severe", "OBSERVATION_MODIFIER", 118, 124], ["pneumonia", "OBSERVATION", 125, 134]]], ["Infection with adenovirus type 36 is associated with weight gain in mice, 17 and serologic positivity for this serotype appears to be more common in adults and children with obesity.", [["weight gain", "DISEASE", 53, 64], ["obesity", "DISEASE", 174, 181], ["adenovirus type 36", "ORGANISM", 15, 33], ["mice", "ORGANISM", 68, 72], ["children", "ORGANISM", 160, 168], ["mice", "SPECIES", 68, 72], ["children", "SPECIES", 160, 168], ["mice", "SPECIES", 68, 72], ["Infection", "PROBLEM", 0, 9], ["adenovirus type", "PROBLEM", 15, 30], ["weight gain", "PROBLEM", 53, 64], ["serologic positivity", "TEST", 81, 101], ["this serotype", "PROBLEM", 106, 119], ["obesity", "PROBLEM", 174, 181], ["obesity", "OBSERVATION", 174, 181]]], ["18PathogenesisAdenoviruses have been isolated from the upper airway, eye, urine, stool, and rarely, blood.", [["upper airway", "ANATOMY", 55, 67], ["eye", "ANATOMY", 69, 72], ["urine", "ANATOMY", 74, 79], ["stool", "ANATOMY", 81, 86], ["blood", "ANATOMY", 100, 105], ["upper airway", "MULTI-TISSUE_STRUCTURE", 55, 67], ["eye", "ORGAN", 69, 72], ["urine", "ORGANISM_SUBSTANCE", 74, 79], ["stool", "ORGANISM_SUBSTANCE", 81, 86], ["blood", "ORGANISM_SUBSTANCE", 100, 105], ["Adenoviruses", "PROBLEM", 14, 26], ["upper", "ANATOMY_MODIFIER", 55, 60], ["airway", "ANATOMY", 61, 67], ["eye", "ANATOMY", 69, 72], ["urine", "ANATOMY", 74, 79], ["stool", "OBSERVATION", 81, 86]]], ["The incubation period for naturally acquired adenovirus disease of the respiratory tract is usually 4 to 7 days but may be up to 2 weeks.PathogenesisCytopathologic changes have also been observed in bronchial epithelial cells, 19 and crystalline arrays of virus particles have been found in alveolar lining cells of infected persons with severe illness.", [["respiratory tract", "ANATOMY", 71, 88], ["bronchial epithelial cells", "ANATOMY", 199, 225], ["alveolar lining cells", "ANATOMY", 291, 312], ["adenovirus disease of the respiratory tract", "DISEASE", 45, 88], ["illness", "DISEASE", 345, 352], ["adenovirus", "ORGANISM", 45, 55], ["respiratory tract", "ORGANISM_SUBDIVISION", 71, 88], ["bronchial epithelial cells", "CELL", 199, 225], ["alveolar lining cells", "CELL", 291, 312], ["persons", "ORGANISM", 325, 332], ["bronchial epithelial cells", "CELL_TYPE", 199, 225], ["alveolar lining cells", "CELL_TYPE", 291, 312], ["persons", "SPECIES", 325, 332], ["naturally acquired adenovirus disease of the respiratory tract", "PROBLEM", 26, 88], ["PathogenesisCytopathologic changes", "PROBLEM", 137, 171], ["bronchial epithelial cells", "TEST", 199, 225], ["crystalline arrays of virus particles", "TREATMENT", 234, 271], ["severe illness", "PROBLEM", 338, 352], ["respiratory tract", "ANATOMY", 71, 88], ["bronchial", "ANATOMY", 199, 208], ["epithelial cells", "OBSERVATION", 209, 225], ["virus particles", "OBSERVATION", 256, 271], ["alveolar lining cells", "OBSERVATION", 291, 312], ["infected", "OBSERVATION_MODIFIER", 316, 324], ["severe", "OBSERVATION_MODIFIER", 338, 344], ["illness", "OBSERVATION", 345, 352]]], ["20 The extent of damage to the respiratory tract in nonfatal adenovirus respiratory disease is not well defined but may result from a combination of direct viral mechanisms and host-related inflammatory responses to infection.", [["respiratory tract", "ANATOMY", 31, 48], ["respiratory", "ANATOMY", 72, 83], ["damage to the respiratory tract", "DISEASE", 17, 48], ["adenovirus respiratory disease", "DISEASE", 61, 91], ["infection", "DISEASE", 216, 225], ["respiratory tract", "ORGANISM_SUBDIVISION", 31, 48], ["adenovirus", "ORGANISM", 61, 71], ["damage to the respiratory tract", "PROBLEM", 17, 48], ["nonfatal adenovirus respiratory disease", "PROBLEM", 52, 91], ["direct viral mechanisms", "PROBLEM", 149, 172], ["host-related inflammatory responses", "PROBLEM", 177, 212], ["infection", "PROBLEM", 216, 225], ["extent", "OBSERVATION_MODIFIER", 7, 13], ["damage", "OBSERVATION", 17, 23], ["respiratory tract", "ANATOMY", 31, 48], ["nonfatal", "OBSERVATION_MODIFIER", 52, 60], ["adenovirus", "OBSERVATION", 61, 71], ["respiratory disease", "OBSERVATION", 72, 91], ["viral", "OBSERVATION", 156, 161], ["inflammatory", "OBSERVATION_MODIFIER", 190, 202], ["infection", "OBSERVATION", 216, 225]]], ["In cases of fatal adenovirus pneumonia, bronchial epithelial necrosis, bronchial obstruction, and interstitial pneumonia have been seen.", [["bronchial epithelial", "ANATOMY", 40, 60], ["bronchial", "ANATOMY", 71, 80], ["interstitial", "ANATOMY", 98, 110], ["pneumonia", "DISEASE", 29, 38], ["bronchial epithelial necrosis", "DISEASE", 40, 69], ["bronchial obstruction", "DISEASE", 71, 92], ["interstitial pneumonia", "DISEASE", 98, 120], ["adenovirus", "ORGANISM", 18, 28], ["bronchial epithelial", "TISSUE", 40, 60], ["fatal adenovirus pneumonia", "PROBLEM", 12, 38], ["bronchial epithelial necrosis", "PROBLEM", 40, 69], ["bronchial obstruction", "PROBLEM", 71, 92], ["interstitial pneumonia", "PROBLEM", 98, 120], ["fatal", "OBSERVATION_MODIFIER", 12, 17], ["adenovirus", "OBSERVATION_MODIFIER", 18, 28], ["pneumonia", "OBSERVATION", 29, 38], ["bronchial", "ANATOMY", 40, 49], ["epithelial", "ANATOMY_MODIFIER", 50, 60], ["necrosis", "OBSERVATION", 61, 69], ["bronchial", "ANATOMY", 71, 80], ["obstruction", "OBSERVATION", 81, 92], ["interstitial", "ANATOMY_MODIFIER", 98, 110], ["pneumonia", "OBSERVATION", 111, 120]]], ["21 Cells containing large basophilic, intranuclear inclusions, so-called \"smudge cells,\" appear to be characteristic .", [["Cells", "ANATOMY", 3, 8], ["basophilic", "ANATOMY", 26, 36], ["intranuclear inclusions", "ANATOMY", 38, 61], ["smudge cells", "ANATOMY", 74, 86], ["Cells", "CELL", 3, 8], ["basophilic", "CELL", 26, 36], ["smudge cells", "CELL", 74, 86], ["smudge cells", "CELL_TYPE", 74, 86], ["large basophilic, intranuclear inclusions", "PROBLEM", 20, 61], ["smudge cells", "PROBLEM", 74, 86], ["large", "OBSERVATION_MODIFIER", 20, 25], ["basophilic", "OBSERVATION_MODIFIER", 26, 36], ["intranuclear inclusions", "OBSERVATION", 38, 61], ["smudge cells", "OBSERVATION", 74, 86], ["appear to be", "UNCERTAINTY", 89, 101]]], ["In lung transplant recipients, necrotizing bronchocentric pneumonia with diffuse alveolar damage has been reported.", [["lung transplant", "ANATOMY", 3, 18], ["bronchocentric", "ANATOMY", 43, 57], ["alveolar", "ANATOMY", 81, 89], ["pneumonia", "DISEASE", 58, 67], ["alveolar damage", "DISEASE", 81, 96], ["lung", "ORGAN", 3, 7], ["alveolar", "MULTI-TISSUE_STRUCTURE", 81, 89], ["lung transplant recipients", "TREATMENT", 3, 29], ["necrotizing bronchocentric pneumonia", "PROBLEM", 31, 67], ["diffuse alveolar damage", "PROBLEM", 73, 96], ["lung", "ANATOMY", 3, 7], ["transplant", "OBSERVATION", 8, 18], ["necrotizing", "OBSERVATION_MODIFIER", 31, 42], ["bronchocentric", "OBSERVATION_MODIFIER", 43, 57], ["pneumonia", "OBSERVATION", 58, 67], ["diffuse", "OBSERVATION_MODIFIER", 73, 80], ["alveolar", "ANATOMY_MODIFIER", 81, 89], ["damage", "OBSERVATION", 90, 96]]], ["22Clinical IllnessAdenovirus Respiratory Disease.", [["Adenovirus Respiratory Disease", "DISEASE", 18, 48], ["22Clinical IllnessAdenovirus Respiratory Disease", "PROBLEM", 0, 48], ["Respiratory Disease", "OBSERVATION", 29, 48]]], ["The nonpneumonic respiratory syndromes associated with adenovirus infection include acute respiratory disease of military recruits and pharyngoconjunctival fever of civilians, which have similar characteristics ( Fig. 32-6 ).", [["respiratory", "ANATOMY", 17, 28], ["respiratory", "ANATOMY", 90, 101], ["respiratory syndromes", "DISEASE", 17, 38], ["adenovirus infection", "DISEASE", 55, 75], ["acute respiratory disease", "DISEASE", 84, 109], ["pharyngoconjunctival fever", "DISEASE", 135, 161], ["adenovirus", "ORGANISM", 55, 65], ["The nonpneumonic respiratory syndromes", "PROBLEM", 0, 38], ["adenovirus infection", "PROBLEM", 55, 75], ["acute respiratory disease", "PROBLEM", 84, 109], ["pharyngoconjunctival fever of civilians", "PROBLEM", 135, 174], ["respiratory syndromes", "OBSERVATION", 17, 38], ["associated with", "UNCERTAINTY", 39, 54], ["adenovirus infection", "OBSERVATION", 55, 75], ["acute", "OBSERVATION_MODIFIER", 84, 89], ["respiratory disease", "OBSERVATION", 90, 109], ["military", "OBSERVATION_MODIFIER", 113, 121], ["pharyngoconjunctival", "OBSERVATION_MODIFIER", 135, 155], ["fever", "OBSERVATION", 156, 161]]], ["Adenovirus respiratory disease typically involves the pharynx as a moderate to severe, sometimes purulent, pharyngitis.", [["respiratory", "ANATOMY", 11, 22], ["pharynx", "ANATOMY", 54, 61], ["Adenovirus respiratory disease", "DISEASE", 0, 30], ["pharyngitis", "DISEASE", 107, 118], ["Adenovirus", "ORGANISM", 0, 10], ["pharynx", "ORGAN", 54, 61], ["Adenovirus respiratory disease", "PROBLEM", 0, 30], ["the pharynx", "PROBLEM", 50, 61], ["a moderate to severe, sometimes purulent", "PROBLEM", 65, 105], ["pharyngitis", "PROBLEM", 107, 118], ["respiratory disease", "OBSERVATION", 11, 30], ["pharynx", "ANATOMY", 54, 61], ["moderate", "OBSERVATION_MODIFIER", 67, 75], ["to severe", "OBSERVATION_MODIFIER", 76, 85], ["sometimes", "OBSERVATION_MODIFIER", 87, 96], ["purulent", "OBSERVATION", 97, 105], ["pharyngitis", "OBSERVATION", 107, 118]]], ["Also characteristic of this disease is marked tracheitis, bronchitis, or tracheobronchitis, as well as rhinitis and conjunctivitis.", [["tracheitis", "DISEASE", 46, 56], ["bronchitis", "DISEASE", 58, 68], ["tracheobronchitis", "DISEASE", 73, 90], ["rhinitis", "DISEASE", 103, 111], ["conjunctivitis", "DISEASE", 116, 130], ["this disease", "PROBLEM", 23, 35], ["marked tracheitis", "PROBLEM", 39, 56], ["bronchitis", "PROBLEM", 58, 68], ["tracheobronchitis", "PROBLEM", 73, 90], ["rhinitis", "PROBLEM", 103, 111], ["conjunctivitis", "PROBLEM", 116, 130], ["disease", "OBSERVATION", 28, 35], ["marked", "OBSERVATION_MODIFIER", 39, 45], ["tracheitis", "OBSERVATION", 46, 56], ["bronchitis", "OBSERVATION", 58, 68], ["tracheobronchitis", "OBSERVATION", 73, 90], ["rhinitis", "OBSERVATION", 103, 111], ["conjunctivitis", "OBSERVATION", 116, 130]]], ["Conjunctivitis is not a feature of infection with the other major respiratory disease in normal hosts.", [["respiratory", "ANATOMY", 66, 77], ["Conjunctivitis", "DISEASE", 0, 14], ["infection", "DISEASE", 35, 44], ["respiratory disease", "DISEASE", 66, 85], ["Conjunctivitis", "PROBLEM", 0, 14], ["infection", "PROBLEM", 35, 44], ["the other major respiratory disease", "PROBLEM", 50, 85], ["not a feature of", "UNCERTAINTY", 18, 34], ["infection", "OBSERVATION", 35, 44], ["respiratory disease", "OBSERVATION", 66, 85], ["normal hosts", "OBSERVATION", 89, 101]]], ["Cytomegalovirus causes severe primary viral pneumonia (see eFigs.", [["Cytomegalovirus", "DISEASE", 0, 15], ["primary viral pneumonia", "DISEASE", 30, 53], ["Cytomegalovirus", "ORGANISM", 0, 15], ["Cytomegalovirus", "PROBLEM", 0, 15], ["severe primary viral pneumonia", "PROBLEM", 23, 53], ["severe", "OBSERVATION_MODIFIER", 23, 29], ["primary", "OBSERVATION_MODIFIER", 30, 37], ["viral", "OBSERVATION_MODIFIER", 38, 43], ["pneumonia", "OBSERVATION", 44, 53]]], ["91-3, 91-4, and 91-5) , as well as predisposing patients to bacterial and fungal superinfections because of its immunosuppressive effects.", [["bacterial and fungal superinfections", "DISEASE", 60, 96], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["bacterial and fungal superinfections", "PROBLEM", 60, 96], ["its immunosuppressive effects", "TREATMENT", 108, 137], ["fungal superinfections", "OBSERVATION", 74, 96], ["immunosuppressive effects", "OBSERVATION", 112, 137]]], ["11c,d Varicella-zoster and herpes simplex virus pneumonias are relatively uncommon but serious infections in immunosuppressed patients.ADENOVIRUSAdenovirus is a medium-sized (65 to 80 nm), nonenveloped virus with a genome composed of linear double-stranded DNA 12 (Fig. 32-4) .", [["Varicella-zoster", "DISEASE", 6, 22], ["herpes simplex virus pneumonias", "DISEASE", 27, 58], ["infections", "DISEASE", 95, 105], ["d", "ORGANISM", 4, 5], ["Varicella-zoster", "ORGANISM", 6, 22], ["herpes simplex virus", "ORGANISM", 27, 47], ["patients", "ORGANISM", 126, 134], ["DNA", "CELLULAR_COMPONENT", 257, 260], ["linear double-stranded DNA 12", "DNA", 234, 263], ["Varicella-zoster", "SPECIES", 6, 22], ["herpes simplex virus", "SPECIES", 27, 47], ["patients", "SPECIES", 126, 134], ["herpes simplex virus", "SPECIES", 27, 47], ["d Varicella", "PROBLEM", 4, 15], ["zoster", "PROBLEM", 16, 22], ["herpes simplex virus pneumonias", "PROBLEM", 27, 58], ["serious infections in immunosuppressed patients", "PROBLEM", 87, 134], ["nonenveloped virus", "PROBLEM", 189, 207], ["linear double-stranded DNA", "TREATMENT", 234, 260], ["Varicella", "ANATOMY", 6, 15], ["zoster", "OBSERVATION", 16, 22], ["herpes simplex virus pneumonias", "OBSERVATION", 27, 58], ["serious", "OBSERVATION_MODIFIER", 87, 94], ["infections", "OBSERVATION", 95, 105], ["immunosuppressed", "OBSERVATION", 109, 125], ["medium-sized", "OBSERVATION_MODIFIER", 161, 173], ["linear", "OBSERVATION_MODIFIER", 234, 240], ["double", "OBSERVATION_MODIFIER", 241, 247]]], ["Currently, 47 antigenic types of adenovirus are associated with human infection, although not all types have been associated with human disease.", [["human infection", "DISEASE", 64, 79], ["adenovirus", "ORGANISM", 33, 43], ["human", "ORGANISM", 64, 69], ["human", "ORGANISM", 130, 135], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 130, 135], ["adenovirus", "SPECIES", 33, 43], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 130, 135], ["adenovirus", "PROBLEM", 33, 43], ["human infection", "PROBLEM", 64, 79], ["human disease", "PROBLEM", 130, 143], ["adenovirus", "OBSERVATION", 33, 43], ["infection", "OBSERVATION", 70, 79], ["associated with", "UNCERTAINTY", 114, 129], ["human disease", "OBSERVATION", 130, 143]]], ["The protein coat of the virus is composed of 252 hexagonal and pentagonal capsomeres in an icosahedral array with long projecting fibers at each vertex.", [["fibers", "ANATOMY", 130, 136], ["fibers", "CELLULAR_COMPONENT", 130, 136], ["The protein coat", "TEST", 0, 16], ["the virus", "PROBLEM", 20, 29], ["an icosahedral array", "TREATMENT", 88, 108], ["protein coat", "OBSERVATION", 4, 16], ["virus", "OBSERVATION", 24, 29], ["pentagonal capsomeres", "OBSERVATION", 63, 84], ["icosahedral array", "OBSERVATION", 91, 108], ["vertex", "ANATOMY_MODIFIER", 145, 151]]], ["These fibers are thought to be the site of host cell attachment.", [["fibers", "ANATOMY", 6, 12], ["cell", "ANATOMY", 48, 52], ["fibers", "CELLULAR_COMPONENT", 6, 12], ["host cell", "CELL", 43, 52], ["host cell attachment", "PROBLEM", 43, 63], ["thought to be", "UNCERTAINTY", 17, 30], ["host cell attachment", "OBSERVATION", 43, 63]]], ["Adenoviruses type 2 and 5 and coxsackie B viruses use the same receptor, designated the coxsackie virus and adenovirus receptor (CAR), whose usual function is to mediate cell interactions with extracellular matrix proteins.", [["cell", "ANATOMY", 170, 174], ["extracellular matrix", "ANATOMY", 193, 213], ["Adenoviruses type 2", "ORGANISM", 0, 19], ["5", "ORGANISM", 24, 25], ["coxsackie B viruses", "ORGANISM", 30, 49], ["coxsackie virus", "ORGANISM", 88, 103], ["adenovirus receptor", "GENE_OR_GENE_PRODUCT", 108, 127], ["CAR", "GENE_OR_GENE_PRODUCT", 129, 132], ["cell", "CELL", 170, 174], ["extracellular matrix", "CELLULAR_COMPONENT", 193, 213], ["adenovirus receptor", "PROTEIN", 108, 127], ["CAR", "PROTEIN", 129, 132], ["extracellular matrix proteins", "PROTEIN", 193, 222], ["coxsackie virus", "SPECIES", 88, 103], ["coxsackie B viruses", "SPECIES", 30, 49], ["coxsackie virus", "SPECIES", 88, 103], ["Adenoviruses type 2", "PROBLEM", 0, 19], ["coxsackie B viruses", "TREATMENT", 30, 49], ["the coxsackie virus", "PROBLEM", 84, 103], ["extracellular matrix proteins", "TREATMENT", 193, 222], ["coxsackie virus", "OBSERVATION", 88, 103]]], ["Some adenoviruses use the complement regulatory protein CD46 as a cellular receptor.", [["cellular", "ANATOMY", 66, 74], ["adenoviruses", "ORGANISM", 5, 17], ["CD46", "GENE_OR_GENE_PRODUCT", 56, 60], ["cellular", "CELL", 66, 74], ["complement regulatory protein", "PROTEIN", 26, 55], ["CD46", "PROTEIN", 56, 60], ["cellular receptor", "PROTEIN", 66, 83], ["Some adenoviruses", "PROBLEM", 0, 17], ["a cellular receptor", "TREATMENT", 64, 83], ["adenoviruses", "OBSERVATION", 5, 17], ["protein CD46", "OBSERVATION", 48, 60]]], ["Virus entry into the cell is also promoted by interaction of the penton base of the virus with alpha-V integrins.", [["cell", "ANATOMY", 21, 25], ["Virus", "ORGANISM", 0, 5], ["cell", "CELL", 21, 25], ["alpha-V integrins", "GENE_OR_GENE_PRODUCT", 95, 112], ["alpha-V integrins", "PROTEIN", 95, 112], ["alpha-V integrins", "TREATMENT", 95, 112], ["cell", "OBSERVATION", 21, 25], ["virus", "OBSERVATION", 84, 89]]], ["Viral typespecific antigens, which give rise to neutralizing antibody, are present on the hexons and fibers of the capsid.", [["hexons", "ANATOMY", 90, 96], ["fibers", "ANATOMY", 101, 107], ["hexons", "GENE_OR_GENE_PRODUCT", 90, 96], ["fibers", "CELLULAR_COMPONENT", 101, 107], ["capsid", "CELLULAR_COMPONENT", 115, 121], ["Viral typespecific antigens", "PROTEIN", 0, 27], ["neutralizing antibody", "PROTEIN", 48, 69], ["Viral typespecific antigens", "PROBLEM", 0, 27], ["neutralizing antibody", "TEST", 48, 69], ["neutralizing antibody", "OBSERVATION", 48, 69], ["capsid", "OBSERVATION", 115, 121]]], ["The hexons also contain a complement-fixation antigen with cross-reactivity among the mammalian adenoviruses.Epidemiology and TransmissionThe adenoviruses that cause human disease do not have nonhuman reservoirs, although nonhuman adenoviruses are found in other species.", [["hexons", "GENE_OR_GENE_PRODUCT", 4, 10], ["adenoviruses", "ORGANISM", 96, 108], ["adenoviruses", "ORGANISM", 142, 154], ["human", "ORGANISM", 166, 171], ["nonhuman adenoviruses", "ORGANISM", 222, 243], ["hexons", "PROTEIN", 4, 10], ["complement-fixation antigen", "PROTEIN", 26, 53], ["human", "SPECIES", 166, 171], ["human", "SPECIES", 166, 171], ["a complement-fixation antigen", "TREATMENT", 24, 53], ["the mammalian adenoviruses", "PROBLEM", 82, 108], ["human disease", "PROBLEM", 166, 179], ["nonhuman reservoirs", "TREATMENT", 192, 211], ["nonhuman adenoviruses", "PROBLEM", 222, 243], ["fixation", "OBSERVATION", 37, 45], ["mammalian adenoviruses", "OBSERVATION", 86, 108]]], ["Some serotypes, especially types populations, both can be seen as sporadic cases.", [["Some serotypes", "PROBLEM", 0, 14], ["serotypes", "OBSERVATION", 5, 14]]], ["In young children, adenovirus infection has been associated with both mild and febrile respiratory illness, with an associated otitis media in approximately 40% of these cases.Adenovirus Pneumonia.Adenovirus was first recognized as a cause of viral pneumonia in military recruits and has since been recognized as a rare cause of pneumonia in civilian adults (eFig.", [["respiratory", "ANATOMY", 87, 98], ["adenovirus infection", "DISEASE", 19, 39], ["febrile respiratory illness", "DISEASE", 79, 106], ["otitis", "DISEASE", 127, 133], ["Adenovirus Pneumonia", "DISEASE", 176, 196], ["viral pneumonia", "DISEASE", 243, 258], ["pneumonia", "DISEASE", 329, 338], ["children", "ORGANISM", 9, 17], ["adenovirus", "ORGANISM", 19, 29], ["Adenovirus", "ORGANISM", 176, 186], ["Adenovirus", "ORGANISM", 197, 207], ["children", "SPECIES", 9, 17], ["Adenovirus", "SPECIES", 176, 186], ["adenovirus", "SPECIES", 19, 29], ["Adenovirus", "SPECIES", 197, 207], ["adenovirus infection", "PROBLEM", 19, 39], ["both mild and febrile respiratory illness", "PROBLEM", 65, 106], ["an associated otitis media", "PROBLEM", 113, 139], ["Adenovirus Pneumonia", "PROBLEM", 176, 196], ["Adenovirus", "PROBLEM", 197, 207], ["viral pneumonia", "PROBLEM", 243, 258], ["pneumonia", "PROBLEM", 329, 338], ["infection", "OBSERVATION", 30, 39], ["mild", "OBSERVATION_MODIFIER", 70, 74], ["febrile", "OBSERVATION_MODIFIER", 79, 86], ["respiratory illness", "OBSERVATION", 87, 106], ["otitis", "OBSERVATION", 127, 133], ["Pneumonia", "OBSERVATION", 187, 196], ["viral", "OBSERVATION_MODIFIER", 243, 248], ["pneumonia", "OBSERVATION", 249, 258], ["pneumonia", "OBSERVATION", 329, 338]]], ["32-5) and children.", [["children", "ORGANISM", 10, 18], ["children", "SPECIES", 10, 18]]], ["The clinical characteristics of adenovirus pneumonia are similar to those of other pneumonias, so it is difficult to make an accurate etiologic diagnosis on the basis of clinical features.", [["adenovirus pneumonia", "DISEASE", 32, 52], ["pneumonias", "DISEASE", 83, 93], ["adenovirus", "ORGANISM", 32, 42], ["adenovirus pneumonia", "PROBLEM", 32, 52], ["other pneumonias", "PROBLEM", 77, 93], ["adenovirus", "OBSERVATION_MODIFIER", 32, 42], ["pneumonia", "OBSERVATION", 43, 52], ["pneumonias", "OBSERVATION", 83, 93]]], ["In fatal cases, there has been extensive pulmonary damage, with death intervening 2 to 3 weeks into the illness.", [["pulmonary", "ANATOMY", 41, 50], ["pulmonary damage", "DISEASE", 41, 57], ["death", "DISEASE", 64, 69], ["pulmonary", "ORGAN", 41, 50], ["extensive pulmonary damage", "PROBLEM", 31, 57], ["death", "PROBLEM", 64, 69], ["extensive", "OBSERVATION_MODIFIER", 31, 40], ["pulmonary", "ANATOMY", 41, 50], ["damage", "OBSERVATION", 51, 57]]], ["Intravascular coagulopathy has also been a late feature of some cases, and a septic shock picture has been described.", [["Intravascular", "ANATOMY", 0, 13], ["Intravascular coagulopathy", "DISEASE", 0, 26], ["shock", "DISEASE", 84, 89], ["Intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 13], ["Intravascular coagulopathy", "PROBLEM", 0, 26], ["a septic shock picture", "PROBLEM", 75, 97], ["coagulopathy", "OBSERVATION", 14, 26], ["late feature", "OBSERVATION_MODIFIER", 43, 55], ["septic", "OBSERVATION_MODIFIER", 77, 83], ["shock", "OBSERVATION", 84, 89]]], ["23 Adenoviruses cause a particularly aggressive form of pneumonia in neonates, characterized by necrotizing bronchiolitis and alveolitis.", [["Adenoviruses", "DISEASE", 3, 15], ["pneumonia", "DISEASE", 56, 65], ["bronchiolitis", "DISEASE", 108, 121], ["alveolitis", "DISEASE", 126, 136], ["neonates", "ORGANISM", 69, 77], ["pneumonia in neonates", "PROBLEM", 56, 77], ["necrotizing bronchiolitis", "PROBLEM", 96, 121], ["alveolitis", "PROBLEM", 126, 136], ["aggressive", "OBSERVATION_MODIFIER", 37, 47], ["pneumonia", "OBSERVATION", 56, 65], ["necrotizing", "OBSERVATION_MODIFIER", 96, 107], ["bronchiolitis", "OBSERVATION", 108, 121], ["alveolitis", "OBSERVATION", 126, 136]]], ["24 The virus may be acquired from the mother, perhaps via the birth canal.", [["canal", "ANATOMY", 68, 73], ["The virus", "PROBLEM", 3, 12], ["virus", "OBSERVATION", 7, 12], ["birth canal", "ANATOMY", 62, 73]]], ["Long-term sequelae of adenovirus infection may include persistent radiographic abnormalities, abnormal pulmonary function tests, bronchiectasis, and bronchiolitis obliterans.Adenovirus Infection in Persons with ImpairedImmunity.", [["pulmonary", "ANATOMY", 103, 112], ["adenovirus infection", "DISEASE", 22, 42], ["abnormal pulmonary function", "DISEASE", 94, 121], ["bronchiectasis", "DISEASE", 129, 143], ["bronchiolitis obliterans", "DISEASE", 149, 173], ["Adenovirus Infection", "DISEASE", 174, 194], ["ImpairedImmunity", "DISEASE", 211, 227], ["adenovirus", "ORGANISM", 22, 32], ["pulmonary", "ORGAN", 103, 112], ["Adenovirus", "ORGANISM", 174, 184], ["Persons", "ORGANISM", 198, 205], ["Persons", "SPECIES", 198, 205], ["adenovirus", "SPECIES", 22, 32], ["Adenovirus", "SPECIES", 174, 184], ["Long-term sequelae", "PROBLEM", 0, 18], ["adenovirus infection", "PROBLEM", 22, 42], ["persistent radiographic abnormalities", "PROBLEM", 55, 92], ["abnormal pulmonary function tests", "PROBLEM", 94, 127], ["bronchiectasis", "PROBLEM", 129, 143], ["bronchiolitis obliterans", "PROBLEM", 149, 173], ["Adenovirus Infection", "PROBLEM", 174, 194], ["-term", "OBSERVATION_MODIFIER", 4, 9], ["sequelae", "OBSERVATION_MODIFIER", 10, 18], ["adenovirus infection", "OBSERVATION", 22, 42], ["may include", "UNCERTAINTY", 43, 54], ["persistent", "OBSERVATION_MODIFIER", 55, 65], ["abnormal", "OBSERVATION_MODIFIER", 94, 102], ["pulmonary", "ANATOMY", 103, 112], ["bronchiectasis", "OBSERVATION", 129, 143], ["bronchiolitis obliterans", "OBSERVATION", 149, 173], ["Infection", "OBSERVATION", 185, 194]]], ["Adenoviruses can cause fatal pneumonia and disseminated infection, with hepatitis, hemorrhagic cystitis, and renal failure, in transplant patients and other immunodeficient persons.", [["renal", "ANATOMY", 109, 114], ["Adenoviruses", "DISEASE", 0, 12], ["pneumonia", "DISEASE", 29, 38], ["disseminated infection", "DISEASE", 43, 65], ["hepatitis", "DISEASE", 72, 81], ["hemorrhagic cystitis", "DISEASE", 83, 103], ["renal failure", "DISEASE", 109, 122], ["renal", "ORGAN", 109, 114], ["patients", "ORGANISM", 138, 146], ["persons", "ORGANISM", 173, 180], ["patients", "SPECIES", 138, 146], ["persons", "SPECIES", 173, 180], ["Adenoviruses", "TREATMENT", 0, 12], ["fatal pneumonia", "PROBLEM", 23, 38], ["disseminated infection", "PROBLEM", 43, 65], ["hepatitis", "PROBLEM", 72, 81], ["hemorrhagic cystitis", "PROBLEM", 83, 103], ["renal failure", "PROBLEM", 109, 122], ["fatal", "OBSERVATION_MODIFIER", 23, 28], ["pneumonia", "OBSERVATION", 29, 38], ["disseminated", "OBSERVATION_MODIFIER", 43, 55], ["infection", "OBSERVATION", 56, 65], ["hepatitis", "OBSERVATION", 72, 81], ["hemorrhagic", "OBSERVATION_MODIFIER", 83, 94], ["cystitis", "OBSERVATION", 95, 103], ["renal", "ANATOMY", 109, 114], ["failure", "OBSERVATION", 115, 122]]], ["25 Various immunotypes have been recovered from these patients (eTable 32-1), including higher numbered serotypes that are only seen in such patients.", [["immunotypes", "CANCER", 11, 22], ["patients", "ORGANISM", 54, 62], ["patients", "ORGANISM", 141, 149], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 141, 149], ["higher numbered serotypes", "PROBLEM", 88, 113], ["serotypes", "OBSERVATION", 104, 113]]], ["The clinical importance of the recovery of an adenovirus from these patients, particularly from stool samples, is often difficult to determine, because immunodeficient patients may shed adenoviruses in the absence of overt disease caused by them.DiagnosisAlthough diagnosis was traditionally achieved by virus culture, viral antigens or nucleic acid can be detected directly from appropriate specimens of respiratory secretions, conjunctival swabs, stool, or urine, depending on the clinical syndrome.", [["stool samples", "ANATOMY", 96, 109], ["specimens", "ANATOMY", 392, 401], ["respiratory secretions", "ANATOMY", 405, 427], ["conjunctival swabs", "ANATOMY", 429, 447], ["stool", "ANATOMY", 449, 454], ["urine", "ANATOMY", 459, 464], ["nucleic acid", "CHEMICAL", 337, 349], ["adenovirus", "ORGANISM", 46, 56], ["patients", "ORGANISM", 68, 76], ["patients", "ORGANISM", 168, 176], ["adenoviruses", "ORGANISM", 186, 198], ["nucleic acid", "SIMPLE_CHEMICAL", 337, 349], ["secretions", "ORGANISM_SUBSTANCE", 417, 427], ["conjunctival swabs", "ORGANISM_SUBSTANCE", 429, 447], ["stool", "ORGANISM_SUBSTANCE", 449, 454], ["urine", "ORGANISM_SUBSTANCE", 459, 464], ["viral antigens", "PROTEIN", 319, 333], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 168, 176], ["adenovirus", "SPECIES", 46, 56], ["an adenovirus", "PROBLEM", 43, 56], ["stool samples", "TEST", 96, 109], ["adenoviruses", "PROBLEM", 186, 198], ["overt disease", "PROBLEM", 217, 230], ["virus culture", "TEST", 304, 317], ["viral antigens", "TEST", 319, 333], ["nucleic acid", "PROBLEM", 337, 349], ["respiratory secretions", "PROBLEM", 405, 427], ["conjunctival swabs, stool, or urine", "TEST", 429, 464], ["the clinical syndrome", "PROBLEM", 479, 500], ["adenovirus", "OBSERVATION", 46, 56], ["disease", "OBSERVATION", 223, 230], ["respiratory secretions", "ANATOMY", 405, 427]]], ["Rapid detection of viral antigens in clinical specimens by ELISA or immunofluorescence and of viral DNA by nucleic acid amplification techniques is increasingly used instead of viral culture because of the fastidiousness of some serotypes and slow rate of isolation 25a (see Chapter 17) .", [["specimens", "ANATOMY", 46, 55], ["nucleic acid", "CHEMICAL", 107, 119], ["specimens", "CANCER", 46, 55], ["DNA", "CELLULAR_COMPONENT", 100, 103], ["viral antigens", "PROTEIN", 19, 33], ["viral DNA", "DNA", 94, 103], ["viral antigens", "PROBLEM", 19, 33], ["clinical specimens", "TEST", 37, 55], ["ELISA", "TEST", 59, 64], ["immunofluorescence", "TEST", 68, 86], ["viral DNA", "PROBLEM", 94, 103], ["nucleic acid amplification techniques", "TREATMENT", 107, 144], ["viral culture", "TEST", 177, 190], ["the fastidiousness", "PROBLEM", 202, 220], ["some serotypes", "PROBLEM", 224, 238], ["slow rate of isolation", "PROBLEM", 243, 265], ["viral", "OBSERVATION_MODIFIER", 19, 24]]], ["Quantitative measurement of adenovirus DNA levels in plasma may be useful for diagnosis and response to therapy.", [["plasma", "ANATOMY", 53, 59], ["adenovirus", "ORGANISM", 28, 38], ["DNA", "CELLULAR_COMPONENT", 39, 42], ["plasma", "ORGANISM_SUBSTANCE", 53, 59], ["adenovirus", "SPECIES", 28, 38], ["Quantitative measurement of adenovirus DNA levels", "TEST", 0, 49], ["therapy", "TREATMENT", 104, 111]]], ["26 Frozen specimens (\u221270\u00b0 C) are satisfactory for testing because of the relative stability of adenoviruses.", [["specimens", "ANATOMY", 10, 19], ["adenoviruses", "ORGANISM", 95, 107], ["Frozen specimens", "TEST", 3, 19], ["testing", "TEST", 50, 57], ["adenoviruses", "PROBLEM", 95, 107], ["stability", "OBSERVATION", 82, 91], ["adenoviruses", "OBSERVATION", 95, 107]]], ["In cell culture, cytopathic effect usually appears in 3 to 7 days but may take several weeks, thus limiting the utility of viral culture in guiding clinical management.", [["cell culture", "ANATOMY", 3, 15], ["cell", "CELL", 3, 7], ["cell culture", "TEST", 3, 15], ["cytopathic effect", "PROBLEM", 17, 34], ["viral culture", "TEST", 123, 136], ["clinical management", "TREATMENT", 148, 167], ["cell culture", "OBSERVATION", 3, 15], ["cytopathic", "OBSERVATION_MODIFIER", 17, 27]]], ["The time required to detect virus in cell culture can be shortened to as little as 2 days by employing centrifugation culture systems.", [["cell culture", "ANATOMY", 37, 49], ["cell", "CELL", 37, 41], ["virus", "PROBLEM", 28, 33], ["cell culture", "TEST", 37, 49], ["centrifugation culture systems", "TEST", 103, 133]]], ["Serodiagnosis has relied primarily on testing for a groupspecific complement-fixation antibody response, using acute and convalescent serum specimens; however, infection with some adenovirus types is not detected by the viruses and therefore, when present, is a useful diagnostic finding in adenovirus respiratory disease.", [["serum specimens", "ANATOMY", 134, 149], ["respiratory", "ANATOMY", 302, 313], ["infection", "DISEASE", 160, 169], ["adenovirus respiratory disease", "DISEASE", 291, 321], ["serum", "ORGANISM_SUBSTANCE", 134, 139], ["adenovirus", "ORGANISM", 180, 190], ["adenovirus", "ORGANISM", 291, 301], ["Serodiagnosis", "TEST", 0, 13], ["testing", "TEST", 38, 45], ["a groupspecific complement", "TEST", 50, 76], ["fixation antibody response", "TEST", 77, 103], ["acute and convalescent serum specimens", "TEST", 111, 149], ["infection", "PROBLEM", 160, 169], ["some adenovirus types", "PROBLEM", 175, 196], ["adenovirus respiratory disease", "PROBLEM", 291, 321], ["infection", "OBSERVATION", 160, 169], ["adenovirus types", "OBSERVATION", 180, 196], ["viruses", "OBSERVATION", 220, 227], ["respiratory disease", "OBSERVATION", 302, 321]]], ["With adenovirus respiratory disease, the conjunctivitis is typically mild and follicular, although some adenovirus types also cause the more severe condition, epidemic keratoconjunctivitis.", [["follicular", "ANATOMY", 78, 88], ["adenovirus respiratory disease", "DISEASE", 5, 35], ["conjunctivitis", "DISEASE", 41, 55], ["keratoconjunctivitis", "DISEASE", 168, 188], ["adenovirus", "ORGANISM", 5, 15], ["adenovirus", "ORGANISM", 104, 114], ["adenovirus respiratory disease", "PROBLEM", 5, 35], ["the conjunctivitis", "PROBLEM", 37, 55], ["typically mild and follicular", "PROBLEM", 59, 88], ["some adenovirus types", "PROBLEM", 99, 120], ["the more severe condition", "PROBLEM", 132, 157], ["epidemic keratoconjunctivitis", "PROBLEM", 159, 188], ["adenovirus", "OBSERVATION", 5, 15], ["respiratory disease", "OBSERVATION", 16, 35], ["conjunctivitis", "OBSERVATION", 41, 55], ["mild", "OBSERVATION_MODIFIER", 69, 73], ["follicular", "OBSERVATION", 78, 88], ["adenovirus", "OBSERVATION", 104, 114], ["more severe", "OBSERVATION_MODIFIER", 136, 147], ["epidemic", "OBSERVATION_MODIFIER", 159, 167], ["keratoconjunctivitis", "OBSERVATION", 168, 188]]], ["Fever, chills, myalgia, and prostration are prominent features of adenovirus infection, so it is often perceived by the patient as a \"flulike\" illness or an unusually severe cold.DiagnosisCases of acute respiratory disease tend to have more tracheobronchitis, perhaps reflecting acquisition of infection by the airborne route.", [["respiratory", "ANATOMY", 203, 214], ["Fever", "DISEASE", 0, 5], ["chills", "DISEASE", 7, 13], ["myalgia", "DISEASE", 15, 22], ["prostration", "DISEASE", 28, 39], ["adenovirus infection", "DISEASE", 66, 86], ["illness", "DISEASE", 143, 150], ["acute respiratory disease", "DISEASE", 197, 222], ["tracheobronchitis", "DISEASE", 241, 258], ["infection", "DISEASE", 294, 303], ["adenovirus", "ORGANISM", 66, 76], ["patient", "ORGANISM", 120, 127], ["patient", "SPECIES", 120, 127], ["adenovirus", "SPECIES", 66, 76], ["Fever", "PROBLEM", 0, 5], ["chills", "PROBLEM", 7, 13], ["myalgia", "PROBLEM", 15, 22], ["prostration", "PROBLEM", 28, 39], ["adenovirus infection", "PROBLEM", 66, 86], ["a \"flulike\" illness", "PROBLEM", 131, 150], ["an unusually severe cold", "PROBLEM", 154, 178], ["acute respiratory disease", "PROBLEM", 197, 222], ["more tracheobronchitis", "PROBLEM", 236, 258], ["infection", "PROBLEM", 294, 303], ["chills", "OBSERVATION", 7, 13], ["myalgia", "OBSERVATION", 15, 22], ["prominent", "OBSERVATION_MODIFIER", 44, 53], ["adenovirus", "OBSERVATION_MODIFIER", 66, 76], ["infection", "OBSERVATION", 77, 86], ["severe", "OBSERVATION_MODIFIER", 167, 173], ["cold", "OBSERVATION", 174, 178], ["acute", "OBSERVATION_MODIFIER", 197, 202], ["respiratory disease", "OBSERVATION", 203, 222], ["more", "OBSERVATION_MODIFIER", 236, 240], ["tracheobronchitis", "OBSERVATION", 241, 258], ["infection", "OBSERVATION", 294, 303]]], ["Conversely, in pharyngoconjunctival fever, the infrequency of cough and other tracheobronchial complaints in some outbreaks may reflect infection contracted by pharyngeal and/or conjunctival inoculation with virus from contaminated water.", [["tracheobronchial", "ANATOMY", 78, 94], ["pharyngeal", "ANATOMY", 160, 170], ["conjunctival", "ANATOMY", 178, 190], ["pharyngoconjunctival fever", "DISEASE", 15, 41], ["cough", "DISEASE", 62, 67], ["tracheobronchial complaints", "DISEASE", 78, 105], ["infection", "DISEASE", 136, 145], ["tracheobronchial", "ORGAN", 78, 94], ["pharyngeal", "ORGANISM_SUBDIVISION", 160, 170], ["conjunctival", "ORGANISM_SUBDIVISION", 178, 190], ["pharyngoconjunctival fever", "PROBLEM", 15, 41], ["cough", "PROBLEM", 62, 67], ["other tracheobronchial complaints", "PROBLEM", 72, 105], ["infection", "PROBLEM", 136, 145], ["conjunctival inoculation", "PROBLEM", 178, 202], ["virus", "PROBLEM", 208, 213], ["cough", "OBSERVATION", 62, 67], ["tracheobronchial", "ANATOMY", 78, 94], ["may reflect", "UNCERTAINTY", 124, 135], ["infection", "OBSERVATION", 136, 145], ["pharyngeal", "ANATOMY", 160, 170], ["conjunctival", "ANATOMY", 178, 190]]], ["The two syndromes are associated with the same viral serotypes and, in civilian viral replicases and proteinases, particularly the 3C-like proteinase, are also antiviral drug targets.Epidemiology and TransmissionHuman coronaviruses OC43 and 229E have been recognized as causes of the common cold for many years and cause frequent reinfections throughout life.", [["3C-like proteinase", "GENE_OR_GENE_PRODUCT", 131, 149], ["TransmissionHuman coronaviruses OC43", "ORGANISM", 200, 236], ["229E", "GENE_OR_GENE_PRODUCT", 241, 245], ["proteinases", "PROTEIN", 101, 112], ["3C-like proteinase", "PROTEIN", 131, 149], ["The two syndromes", "PROBLEM", 0, 17], ["the same viral serotypes", "PROBLEM", 38, 62], ["proteinases", "PROBLEM", 101, 112], ["antiviral drug targets", "TREATMENT", 160, 182], ["frequent reinfections throughout life", "PROBLEM", 321, 358], ["two", "OBSERVATION_MODIFIER", 4, 7], ["syndromes", "OBSERVATION", 8, 17], ["viral serotypes", "OBSERVATION", 47, 62], ["viral replicases", "OBSERVATION", 80, 96], ["frequent", "OBSERVATION_MODIFIER", 321, 329], ["reinfections", "OBSERVATION", 330, 342]]], ["In adults, these viruses account for 4% to 15% of acute respiratory disease annually and up to 35% during peak periods.", [["respiratory", "ANATOMY", 56, 67], ["respiratory disease", "DISEASE", 56, 75], ["acute respiratory disease", "PROBLEM", 50, 75], ["viruses", "OBSERVATION", 17, 24], ["acute", "OBSERVATION_MODIFIER", 50, 55], ["respiratory disease", "OBSERVATION", 56, 75]]], ["Annual illness rates in children reach 8%, with peak rates up to 20%.", [["illness", "DISEASE", 7, 14], ["children", "ORGANISM", 24, 32], ["children", "SPECIES", 24, 32], ["Annual illness rates", "PROBLEM", 0, 20], ["peak rates", "TEST", 48, 58]]], ["34 When polymerase chain reaction (PCR) techniques were applied to samples collected over 20 years from children younger than 5, coronaviruses were associated with 11.4 lower respiratory tract episodes and 67.3 upper respiratory tract illnesses per 1000 person-years.", [["samples", "ANATOMY", 67, 74], ["respiratory tract", "ANATOMY", 175, 192], ["upper respiratory tract", "ANATOMY", 211, 234], ["respiratory tract episodes", "DISEASE", 175, 201], ["respiratory tract illnesses", "DISEASE", 217, 244], ["children", "ORGANISM", 104, 112], ["coronaviruses", "ORGANISM", 129, 142], ["tract", "ORGANISM_SUBDIVISION", 187, 192], ["tract", "ORGANISM_SUBDIVISION", 229, 234], ["children", "SPECIES", 104, 112], ["person", "SPECIES", 254, 260], ["polymerase chain reaction (PCR) techniques", "TREATMENT", 8, 50], ["coronaviruses", "PROBLEM", 129, 142], ["11.4 lower respiratory tract episodes", "PROBLEM", 164, 201], ["upper respiratory tract illnesses", "PROBLEM", 211, 244], ["respiratory tract", "ANATOMY", 175, 192], ["upper", "ANATOMY_MODIFIER", 211, 216], ["respiratory tract", "ANATOMY", 217, 234]]], ["35 The reported frequency of infection in adults for 229E and OC43 viruses has ranged from 15 to 25 per 100 persons per year, with up to 80% of infections seen in persons with prior antibody to the infecting virus.", [["infection", "DISEASE", 29, 38], ["infections", "DISEASE", 144, 154], ["adults", "ORGANISM", 42, 48], ["OC43 viruses", "ORGANISM", 62, 74], ["persons", "ORGANISM", 163, 170], ["persons", "SPECIES", 163, 170], ["infection", "PROBLEM", 29, 38], ["OC43 viruses", "PROBLEM", 62, 74], ["infections", "PROBLEM", 144, 154], ["prior antibody", "PROBLEM", 176, 190], ["the infecting virus", "PROBLEM", 194, 213], ["infection", "OBSERVATION", 29, 38], ["infections", "OBSERVATION", 144, 154], ["infecting virus", "OBSERVATION", 198, 213]]], ["36 Coronaviruses usually circulate during winter and early spring but can be detected year-round.", [["Coronaviruses", "PROBLEM", 3, 16]]], ["37 Novel coronaviruses have recently been associated with severe respiratory disease in outbreaks around the world.", [["respiratory", "ANATOMY", 65, 76], ["respiratory disease", "DISEASE", 65, 84], ["coronaviruses", "ORGANISM", 9, 22], ["Novel coronaviruses", "PROBLEM", 3, 22], ["severe respiratory disease", "PROBLEM", 58, 84], ["coronaviruses", "OBSERVATION", 9, 22], ["associated with", "UNCERTAINTY", 42, 57], ["severe", "OBSERVATION_MODIFIER", 58, 64], ["respiratory disease", "OBSERVATION", 65, 84]]], ["SARS emerged in southern China in 2003 and quickly spread globally.", [["SARS", "DISEASE", 0, 4], ["SARS", "PROBLEM", 0, 4]]], ["38 The causative virus was subsequently named SARS-CoV.", [["SARS-CoV", "ORGANISM", 46, 54], ["SARS-CoV", "SPECIES", 46, 54], ["The causative virus", "PROBLEM", 3, 22], ["virus", "OBSERVATION", 17, 22]]], ["Ultimately, at least 8098 probable cases of severe respiratory disease and 774 deaths in all ages were attributable to SARS worldwide before the outbreak terminated in 2004.", [["respiratory", "ANATOMY", 51, 62], ["respiratory disease", "DISEASE", 51, 70], ["deaths", "DISEASE", 79, 85], ["SARS", "DISEASE", 119, 123], ["severe respiratory disease", "PROBLEM", 44, 70], ["SARS", "PROBLEM", 119, 123], ["severe", "OBSERVATION_MODIFIER", 44, 50], ["respiratory disease", "OBSERVATION", 51, 70]]], ["The source of this outbreak is believed to have been from an animal reservoir, the civet cat.", [["cat", "ORGANISM", 89, 92], ["cat", "SPECIES", 89, 92], ["an animal reservoir", "TREATMENT", 58, 77]]], ["More recently, a second outbreak of coronavirus severe respiratory illness has been recognized, with cases primarily found in Middle Eastern countries.", [["respiratory", "ANATOMY", 55, 66], ["coronavirus", "DISEASE", 36, 47], ["respiratory illness", "DISEASE", 55, 74], ["coronavirus", "ORGANISM", 36, 47], ["coronavirus", "SPECIES", 36, 47], ["coronavirus severe respiratory illness", "PROBLEM", 36, 74], ["coronavirus", "OBSERVATION_MODIFIER", 36, 47], ["severe", "OBSERVATION_MODIFIER", 48, 54], ["respiratory illness", "OBSERVATION", 55, 74], ["Middle", "ANATOMY_MODIFIER", 126, 132]]], ["39,39a,39b In May 2014, the first case of MERS was confirmed in a traveler from Saudi Arabia to the United States.", [["MERS", "DISEASE", 42, 46], ["MERS", "CANCER", 42, 46]]], ["39c The virus responsible for MERS has been named MERS-CoV.", [["39c", "CHEMICAL", 0, 3], ["MERS", "GENE_OR_GENE_PRODUCT", 30, 34], ["MERS-CoV", "ORGANISM", 50, 58], ["MERS", "PROTEIN", 30, 34], ["MERS-CoV", "PROTEIN", 50, 58], ["MERS-CoV", "SPECIES", 50, 58], ["The virus", "PROBLEM", 4, 13], ["MERS", "PROBLEM", 30, 34], ["virus", "OBSERVATION", 8, 13]]], ["It is genetically closely related to coronaviruses found in bats, and evidence indicates that MERS-CoV also infects camels, but the role of each of these in transmission to humans remains to be defined.", [["coronaviruses", "ORGANISM", 37, 50], ["MERS-CoV", "ORGANISM", 94, 102], ["camels", "ORGANISM", 116, 122], ["humans", "ORGANISM", 173, 179], ["humans", "SPECIES", 173, 179], ["MERS-CoV", "SPECIES", 94, 102], ["humans", "SPECIES", 173, 179], ["coronaviruses", "PROBLEM", 37, 50], ["MERS-CoV", "PROBLEM", 94, 102], ["coronaviruses", "OBSERVATION", 37, 50]]], ["40, 41 Information on MERS-CoV is actively evolving; current information can be found at http://www.cdc.gov/coronavirus/mers/.Epidemiology and TransmissionFor all coronaviruses, transmission likely involves close contact and inoculation of the respiratory tract with infectious secretions via large droplets as demonstrated in human challenge experiments for OC43 42 and animal studies for SARS-CoV.", [["respiratory tract", "ANATOMY", 244, 261], ["secretions", "ANATOMY", 278, 288], ["SARS-CoV", "DISEASE", 390, 398], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 22, 30], ["respiratory tract", "ORGANISM_SUBDIVISION", 244, 261], ["human", "ORGANISM", 327, 332], ["SARS-CoV", "ORGANISM", 390, 398], ["human", "SPECIES", 327, 332], ["MERS-CoV", "SPECIES", 22, 30], ["human", "SPECIES", 327, 332], ["SARS-CoV", "SPECIES", 390, 398], ["all coronaviruses", "PROBLEM", 159, 176], ["the respiratory tract", "PROBLEM", 240, 261], ["infectious secretions", "PROBLEM", 267, 288], ["large droplets", "PROBLEM", 293, 307], ["OC43", "TEST", 359, 363], ["animal studies", "TEST", 371, 385], ["SARS", "PROBLEM", 390, 394], ["CoV", "PROBLEM", 395, 398], ["respiratory tract", "ANATOMY", 244, 261]]], ["43 For SARS-CoV, virus shedding peaked at day 10 of symptom onset, which was at the height of disease severity.", [["SARS", "DISEASE", 7, 11], ["SARS-CoV", "ORGANISM", 7, 15], ["virus", "ORGANISM", 17, 22], ["SARS-CoV", "SPECIES", 7, 15], ["SARS", "PROBLEM", 7, 11], ["CoV", "PROBLEM", 12, 15], ["virus shedding", "PROBLEM", 17, 31], ["symptom onset", "PROBLEM", 52, 65], ["disease severity", "PROBLEM", 94, 110], ["disease", "OBSERVATION", 94, 101]]], ["44 This phenomenon accounted for the preponderance of transmission in hospitals, a feature that allowed the outbreak to be controlled with infection control procedures.", [["infection", "DISEASE", 139, 148], ["This phenomenon", "PROBLEM", 3, 18], ["infection control procedures", "TREATMENT", 139, 167]]], ["The incubation period for SARS is estimated from 2 to 10 days, and for conventional human coronaviruses 3 to 4 days.PathogenesisConventional coronavirus antigen has been detected in epithelial cells shed from the nasopharynx of infected volunteers 45 and, during experimental infection, nasal airway resistance, mucosal temperature, and the albumin content of nasal secretions increase.", [["epithelial cells", "ANATOMY", 182, 198], ["nasopharynx", "ANATOMY", 213, 224], ["nasal airway", "ANATOMY", 287, 299], ["mucosal", "ANATOMY", 312, 319], ["nasal secretions", "ANATOMY", 360, 376], ["SARS", "DISEASE", 26, 30], ["infection", "DISEASE", 276, 285], ["human", "ORGANISM", 84, 89], ["coronavirus", "ORGANISM", 141, 152], ["epithelial cells", "CELL", 182, 198], ["nasopharynx", "ORGAN", 213, 224], ["volunteers", "ORGANISM", 237, 247], ["nasal airway", "MULTI-TISSUE_STRUCTURE", 287, 299], ["mucosal", "MULTI-TISSUE_STRUCTURE", 312, 319], ["albumin", "GENE_OR_GENE_PRODUCT", 341, 348], ["nasal secretions", "ORGANISM_SUBSTANCE", 360, 376], ["epithelial cells", "CELL_TYPE", 182, 198], ["human", "SPECIES", 84, 89], ["human coronaviruses", "SPECIES", 84, 103], ["SARS", "PROBLEM", 26, 30], ["Conventional coronavirus antigen", "PROBLEM", 128, 160], ["experimental infection", "PROBLEM", 263, 285], ["nasal airway resistance", "PROBLEM", 287, 310], ["mucosal temperature", "TEST", 312, 331], ["the albumin content", "TEST", 337, 356], ["nasal secretions", "PROBLEM", 360, 376], ["coronavirus", "OBSERVATION", 141, 152], ["epithelial cells", "OBSERVATION", 182, 198], ["nasopharynx", "ANATOMY", 213, 224], ["infected", "OBSERVATION", 228, 236], ["infection", "OBSERVATION", 276, 285], ["nasal", "ANATOMY", 287, 292], ["airway resistance", "OBSERVATION", 293, 310], ["mucosal temperature", "OBSERVATION", 312, 331], ["nasal", "ANATOMY", 360, 365], ["secretions", "OBSERVATION", 366, 376]]], ["46 However, relatively little is complement-fixation test.", [["fixation test", "TEST", 44, 57]]], ["In biopsy specimens, the appearance of characteristic intranuclear basophilic inclusion bodies seen by light microscopy or of crystalline arrays of virus seen by electron microscopy is useful in histopathologic diagnosis.Treatment and PreventionAntiviral treatment of adenovirus infection does not have proven value.", [["biopsy specimens", "ANATOMY", 3, 19], ["intranuclear basophilic inclusion bodies", "ANATOMY", 54, 94], ["adenovirus infection", "DISEASE", 268, 288], ["biopsy specimens", "CANCER", 3, 19], ["adenovirus", "ORGANISM", 268, 278], ["adenovirus", "SPECIES", 268, 278], ["biopsy specimens", "TEST", 3, 19], ["characteristic intranuclear basophilic inclusion bodies", "PROBLEM", 39, 94], ["light microscopy", "TEST", 103, 119], ["crystalline arrays of virus", "PROBLEM", 126, 153], ["electron microscopy", "TEST", 162, 181], ["Treatment", "TREATMENT", 221, 230], ["PreventionAntiviral treatment", "TREATMENT", 235, 264], ["adenovirus infection", "PROBLEM", 268, 288], ["intranuclear basophilic", "OBSERVATION", 54, 77], ["inclusion bodies", "OBSERVATION", 78, 94]]], ["Ganciclovir and cidofovir are active in vitro, and an increasing number of reports indicate that intravenous ganciclovir may be useful in seriously ill patients, although at the expense of significant renal toxicity.", [["intravenous", "ANATOMY", 97, 108], ["renal", "ANATOMY", 201, 206], ["Ganciclovir", "CHEMICAL", 0, 11], ["cidofovir", "CHEMICAL", 16, 25], ["ganciclovir", "CHEMICAL", 109, 120], ["renal toxicity", "DISEASE", 201, 215], ["Ganciclovir", "CHEMICAL", 0, 11], ["cidofovir", "CHEMICAL", 16, 25], ["ganciclovir", "CHEMICAL", 109, 120], ["Ganciclovir", "SIMPLE_CHEMICAL", 0, 11], ["cidofovir", "SIMPLE_CHEMICAL", 16, 25], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 97, 108], ["ganciclovir", "SIMPLE_CHEMICAL", 109, 120], ["patients", "ORGANISM", 152, 160], ["renal", "ORGAN", 201, 206], ["patients", "SPECIES", 152, 160], ["Ganciclovir", "TREATMENT", 0, 11], ["cidofovir", "TREATMENT", 16, 25], ["intravenous ganciclovir", "TREATMENT", 97, 120], ["significant renal toxicity", "PROBLEM", 189, 215], ["active", "OBSERVATION_MODIFIER", 30, 36], ["significant", "OBSERVATION_MODIFIER", 189, 200], ["renal", "ANATOMY", 201, 206], ["toxicity", "OBSERVATION", 207, 215]]], ["27 Cidofovir has also been used for treatment and for presumptive therapy of adenovirus infection in high-risk immunocompromised patients.", [["Cidofovir", "CHEMICAL", 3, 12], ["adenovirus infection", "DISEASE", 77, 97], ["Cidofovir", "CHEMICAL", 3, 12], ["Cidofovir", "SIMPLE_CHEMICAL", 3, 12], ["adenovirus", "ORGANISM", 77, 87], ["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["adenovirus", "SPECIES", 77, 87], ["Cidofovir", "TREATMENT", 3, 12], ["treatment", "TREATMENT", 36, 45], ["adenovirus infection", "PROBLEM", 77, 97], ["adenovirus", "OBSERVATION", 77, 87], ["high-risk", "OBSERVATION_MODIFIER", 101, 110], ["immunocompromised patients", "OBSERVATION", 111, 137]]], ["28 Although intravenous ribavirin (which is active for group C adenoviruses in vitro) 29 or ribavirin combined with immunoglobulin 30 has been used in individual patients, failures are common.", [["intravenous", "ANATOMY", 12, 23], ["ribavirin", "CHEMICAL", 24, 33], ["ribavirin", "CHEMICAL", 92, 101], ["ribavirin", "CHEMICAL", 24, 33], ["ribavirin", "CHEMICAL", 92, 101], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 12, 23], ["ribavirin", "SIMPLE_CHEMICAL", 24, 33], ["adenoviruses", "ORGANISM", 63, 75], ["ribavirin", "SIMPLE_CHEMICAL", 92, 101], ["immunoglobulin 30", "SIMPLE_CHEMICAL", 116, 133], ["patients", "ORGANISM", 162, 170], ["immunoglobulin 30", "PROTEIN", 116, 133], ["patients", "SPECIES", 162, 170], ["intravenous ribavirin", "TREATMENT", 12, 33], ["group C adenoviruses in vitro)", "TREATMENT", 55, 85], ["ribavirin", "TREATMENT", 92, 101], ["immunoglobulin", "TREATMENT", 116, 130], ["failures", "OBSERVATION", 172, 180]]], ["31 Because of the prominent fever and systemic complaints associated with adenovirus respiratory disease, analgesics, such as aspirin and acetaminophen, are needed more often than with a milder coryzal illness such as a rhinovirus cold.", [["respiratory", "ANATOMY", 85, 96], ["fever", "DISEASE", 28, 33], ["systemic complaints", "DISEASE", 38, 57], ["adenovirus respiratory disease", "DISEASE", 74, 104], ["aspirin", "CHEMICAL", 126, 133], ["acetaminophen", "CHEMICAL", 138, 151], ["coryzal illness", "DISEASE", 194, 209], ["aspirin", "CHEMICAL", 126, 133], ["acetaminophen", "CHEMICAL", 138, 151], ["adenovirus", "ORGANISM", 74, 84], ["aspirin", "SIMPLE_CHEMICAL", 126, 133], ["acetaminophen", "SIMPLE_CHEMICAL", 138, 151], ["rhinovirus", "ORGANISM", 220, 230], ["the prominent fever", "PROBLEM", 14, 33], ["systemic complaints", "PROBLEM", 38, 57], ["adenovirus respiratory disease", "PROBLEM", 74, 104], ["analgesics", "TREATMENT", 106, 116], ["aspirin", "TREATMENT", 126, 133], ["acetaminophen", "TREATMENT", 138, 151], ["a milder coryzal illness", "PROBLEM", 185, 209], ["a rhinovirus cold", "PROBLEM", 218, 235], ["prominent", "OBSERVATION_MODIFIER", 18, 27], ["fever", "OBSERVATION", 28, 33], ["respiratory disease", "OBSERVATION", 85, 104], ["rhinovirus", "OBSERVATION", 220, 230]]], ["Warm saline gargles are helpful for relieving throat pain, which does not usually require narcotics.", [["throat", "ANATOMY", 46, 52], ["pain", "DISEASE", 53, 57], ["throat", "ORGANISM_SUBDIVISION", 46, 52], ["Warm saline gargles", "TREATMENT", 0, 19], ["relieving throat pain", "PROBLEM", 36, 57], ["narcotics", "TREATMENT", 90, 99], ["saline gargles", "OBSERVATION", 5, 19]]], ["The presence of pharyngeal exudate may sometimes lead to an incorrect diagnosis of streptococcal pharyngitis, resulting in the initiation of antimicrobial therapy.Treatment and PreventionEffective and safe live oral vaccines for adenovirus types 4 and 7 were developed for military use and, when delivered in enteric-coated capsules, have controlled acute respiratory disease in recruit populations.", [["pharyngeal exudate", "ANATOMY", 16, 34], ["oral", "ANATOMY", 211, 215], ["respiratory", "ANATOMY", 356, 367], ["streptococcal pharyngitis", "DISEASE", 83, 108], ["acute respiratory disease", "DISEASE", 350, 375], ["pharyngeal exudate", "MULTI-TISSUE_STRUCTURE", 16, 34], ["oral", "ORGANISM_SUBDIVISION", 211, 215], ["adenovirus", "ORGANISM", 229, 239], ["pharyngeal exudate", "PROBLEM", 16, 34], ["streptococcal pharyngitis", "PROBLEM", 83, 108], ["antimicrobial therapy", "TREATMENT", 141, 162], ["Treatment", "TREATMENT", 163, 172], ["PreventionEffective", "TREATMENT", 177, 196], ["safe live oral vaccines", "TREATMENT", 201, 224], ["adenovirus types", "TREATMENT", 229, 245], ["enteric-coated capsules", "TREATMENT", 309, 332], ["acute respiratory disease in recruit populations", "PROBLEM", 350, 398], ["pharyngeal", "ANATOMY", 16, 26], ["exudate", "OBSERVATION", 27, 34], ["streptococcal", "OBSERVATION_MODIFIER", 83, 96], ["pharyngitis", "OBSERVATION", 97, 108], ["antimicrobial therapy", "OBSERVATION", 141, 162], ["acute", "OBSERVATION_MODIFIER", 350, 355], ["respiratory disease", "OBSERVATION", 356, 375]]], ["Use of these vaccines was not associated with replacement by nonvaccine serotypes.", [["these vaccines", "TREATMENT", 7, 21], ["replacement by nonvaccine serotypes", "TREATMENT", 46, 81]]], ["When manufacturing of these vaccines was discontinued, adenoviruses reemerged as important causes of acute respiratory disease in this population.", [["respiratory", "ANATOMY", 107, 118], ["acute respiratory disease", "DISEASE", 101, 126], ["adenoviruses", "ORGANISM", 55, 67], ["these vaccines", "TREATMENT", 22, 36], ["adenoviruses", "TREATMENT", 55, 67], ["acute respiratory disease", "PROBLEM", 101, 126], ["acute", "OBSERVATION_MODIFIER", 101, 106], ["respiratory disease", "OBSERVATION", 107, 126]]], ["A new vaccine for Ad4 and Ad7 has subsequently been introduced.", [["Ad4", "CHEMICAL", 18, 21], ["Ad7", "CHEMICAL", 26, 29], ["Ad4", "SIMPLE_CHEMICAL", 18, 21], ["Ad7", "SIMPLE_CHEMICAL", 26, 29], ["Ad7", "PROTEIN", 26, 29], ["Ad4", "SPECIES", 18, 21], ["A new vaccine", "TREATMENT", 0, 13], ["Ad4 and Ad7", "TREATMENT", 18, 29]]], ["32CORONAVIRUSESCoronaviruses are enveloped viruses containing a singlestranded, positive-sense ribonucleic acid (RNA) genome of approximately 29,000 nucleotides.", [["ribonucleic acid", "CHEMICAL", 95, 111], ["nucleotides", "CHEMICAL", 149, 160], ["singlestranded, positive-sense ribonucleic acid", "RNA", 64, 111], ["enveloped viruses", "PROBLEM", 33, 50], ["a singlestranded, positive-sense ribonucleic acid (RNA) genome", "PROBLEM", 62, 124], ["enveloped", "OBSERVATION_MODIFIER", 33, 42], ["viruses", "OBSERVATION", 43, 50], ["positive", "OBSERVATION_MODIFIER", 80, 88], ["ribonucleic acid", "OBSERVATION", 95, 111]]], ["Distinctive club-shaped projections are present on the virus surface, giving the appearance of having a crown or corona, from which it derives its name.", [["surface", "ANATOMY", 61, 68], ["a crown or corona", "PROBLEM", 102, 119], ["club", "OBSERVATION_MODIFIER", 12, 16], ["shaped", "OBSERVATION_MODIFIER", 17, 23], ["crown", "OBSERVATION_MODIFIER", 104, 109], ["corona", "OBSERVATION_MODIFIER", 113, 119]]], ["Coronaviruses are classified into four genera: alpha, beta, gamma, and delta.", [["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["alpha, beta", "GENE_OR_GENE_PRODUCT", 47, 58], ["gamma", "GENE_OR_GENE_PRODUCT", 60, 65], ["delta", "GENE_OR_GENE_PRODUCT", 71, 76], ["alpha, beta, gamma, and delta", "PROTEIN", 47, 76], ["Coronaviruses", "PROBLEM", 0, 13], ["alpha", "TREATMENT", 47, 52], ["delta", "TREATMENT", 71, 76]]], ["The beta genus is further subdivided into four lineages, A-D.", [["beta", "GENE_OR_GENE_PRODUCT", 4, 8], ["The beta genus", "TREATMENT", 0, 14], ["beta genus", "OBSERVATION", 4, 14]]], ["The human coronavirus strains 229E (HCoV 229E) and HCoV NL63 are members of the alpha genus, while the human strains HCoV OC43 and HKU1 are members of the beta genus.", [["human", "ORGANISM", 4, 9], ["coronavirus strains 229E (HCoV 229E", "ORGANISM", 10, 45], ["HCoV NL63", "GENE_OR_GENE_PRODUCT", 51, 60], ["alpha", "GENE_OR_GENE_PRODUCT", 80, 85], ["human", "ORGANISM", 103, 108], ["HCoV OC43", "ORGANISM", 117, 126], ["HKU1", "GENE_OR_GENE_PRODUCT", 131, 135], ["beta", "GENE_OR_GENE_PRODUCT", 155, 159], ["HCoV NL63", "DNA", 51, 60], ["HKU1", "DNA", 131, 135], ["human", "SPECIES", 4, 9], ["coronavirus", "SPECIES", 10, 21], ["human", "SPECIES", 103, 108], ["human coronavirus", "SPECIES", 4, 21], ["HCoV", "SPECIES", 36, 40], ["HCoV", "SPECIES", 51, 55], ["human", "SPECIES", 103, 108], ["HCoV", "SPECIES", 117, 121], ["The human coronavirus strains", "TEST", 0, 29], ["HCoV", "TEST", 36, 40], ["HCoV", "TEST", 51, 55], ["the alpha genus", "TEST", 76, 91], ["the human strains HCoV OC43", "TEST", 99, 126], ["alpha genus", "ANATOMY", 80, 91]]], ["The novel coronaviruses, SARS-CoV and MERS-CoV, are also members of the beta genus, in lineages B and C, respectively.", [["coronaviruses", "ORGANISM", 10, 23], ["SARS-CoV", "ORGANISM", 25, 33], ["MERS-CoV", "ORGANISM", 38, 46], ["beta", "GENE_OR_GENE_PRODUCT", 72, 76], ["B", "CELL", 96, 97], ["C", "CELL", 102, 103], ["SARS-CoV", "SPECIES", 25, 33], ["MERS-CoV", "SPECIES", 38, 46], ["The novel coronaviruses", "PROBLEM", 0, 23], ["SARS", "TEST", 25, 29], ["coronaviruses", "OBSERVATION_MODIFIER", 10, 23]]], ["33 The virus contains five structural proteins: spike or S protein, hemagglutinin-esterase (HE), M (matrix), E (envelope), and N (nucleocapsid).", [["hemagglutinin-esterase", "GENE_OR_GENE_PRODUCT", 68, 90], ["M (matrix)", "GENE_OR_GENE_PRODUCT", 97, 107], ["E (envelope)", "GENE_OR_GENE_PRODUCT", 109, 121], ["structural proteins", "PROTEIN", 27, 46], ["spike or S protein", "PROTEIN", 48, 66], ["hemagglutinin", "PROTEIN", 68, 81], ["esterase", "PROTEIN", 82, 90], ["HE", "PROTEIN", 92, 94], ["M (matrix)", "PROTEIN", 97, 107], ["E", "PROTEIN", 109, 110], ["N", "PROTEIN", 127, 128], ["nucleocapsid", "PROTEIN", 130, 142], ["The virus", "PROBLEM", 3, 12], ["spike", "PROBLEM", 48, 53], ["S protein", "TEST", 57, 66], ["hemagglutinin-esterase", "TEST", 68, 90], ["virus", "OBSERVATION", 7, 12], ["five", "OBSERVATION_MODIFIER", 22, 26], ["structural proteins", "OBSERVATION", 27, 46]]], ["The spike protein is the major envelope glycoprotein and mediates both attachment to cells and fusion with the cell membrane; antibodies to the spike protein are thought to be associated with protection and thus are candidates for therapeutic and vaccine targets.", [["cells", "ANATOMY", 85, 90], ["cell membrane", "ANATOMY", 111, 124], ["cells", "CELL", 85, 90], ["cell membrane", "CELLULAR_COMPONENT", 111, 124], ["antibodies to the spike protein", "GENE_OR_GENE_PRODUCT", 126, 157], ["spike protein", "PROTEIN", 4, 17], ["major envelope glycoprotein", "PROTEIN", 25, 52], ["antibodies", "PROTEIN", 126, 136], ["spike protein", "PROTEIN", 144, 157], ["The spike protein", "PROBLEM", 0, 17], ["the major envelope glycoprotein", "PROBLEM", 21, 52], ["fusion", "TREATMENT", 95, 101], ["the cell membrane", "TREATMENT", 107, 124], ["antibodies", "TREATMENT", 126, 136], ["the spike protein", "PROBLEM", 140, 157], ["therapeutic and vaccine targets", "TREATMENT", 231, 262], ["cell membrane", "OBSERVATION", 111, 124]]], ["The second envelope protein, HE, is only found in some coronavirus strains.", [["HE", "GENE_OR_GENE_PRODUCT", 29, 31], ["coronavirus strains", "ORGANISM", 55, 74], ["envelope protein", "PROTEIN", 11, 27], ["HE", "PROTEIN", 29, 31], ["The second envelope protein", "TEST", 0, 27], ["some coronavirus strains", "PROBLEM", 50, 74], ["coronavirus strains", "OBSERVATION", 55, 74]]], ["Nonstructural proteins such as the effective immunity short-term because rechallenge with homotypic virus, the 229E serotype, resulted in infection and illness.", [["infection", "DISEASE", 138, 147], ["illness", "DISEASE", 152, 159], ["Nonstructural proteins", "PROTEIN", 0, 22], ["Nonstructural proteins", "PROBLEM", 0, 22], ["homotypic virus", "PROBLEM", 90, 105], ["the 229E serotype", "PROBLEM", 107, 124], ["infection", "PROBLEM", 138, 147], ["illness", "PROBLEM", 152, 159], ["infection", "OBSERVATION", 138, 147]]], ["57 In addition, under certain circumstances, vaccines against animal coronaviruses have led to enhanced disease.", [["animal coronaviruses", "ORGANISM", 62, 82], ["vaccines", "TREATMENT", 45, 53], ["animal coronaviruses", "PROBLEM", 62, 82], ["enhanced disease", "PROBLEM", 95, 111]]], ["58 This is being taken into consideration but is not deterring efforts to develop an efficacious SARS-CoV vaccine.", [["SARS-CoV", "ORGANISM", 97, 105], ["SARS-CoV", "SPECIES", 97, 105], ["an efficacious SARS", "PROBLEM", 82, 101], ["CoV vaccine", "TREATMENT", 102, 113]]], ["59 There are no currently available antiviral agents with demonstrated clinical activity against coronaviruses in humans.", [["coronaviruses", "ORGANISM", 97, 110], ["humans", "ORGANISM", 114, 120], ["humans", "SPECIES", 114, 120], ["humans", "SPECIES", 114, 120], ["antiviral agents", "TREATMENT", 36, 52], ["coronaviruses in humans", "PROBLEM", 97, 120], ["no", "UNCERTAINTY", 13, 15]]], ["Agents with potential activity against SARS-CoV include chloroquine, protease inhibitors, ribavirin, type I interferons, niclosamide, and anti-inflammatory agents such as indomethacin.", [["SARS", "DISEASE", 39, 43], ["chloroquine", "CHEMICAL", 56, 67], ["ribavirin", "CHEMICAL", 90, 99], ["type I interferons", "CHEMICAL", 101, 119], ["niclosamide", "CHEMICAL", 121, 132], ["indomethacin", "CHEMICAL", 171, 183], ["chloroquine", "CHEMICAL", 56, 67], ["ribavirin", "CHEMICAL", 90, 99], ["niclosamide", "CHEMICAL", 121, 132], ["indomethacin", "CHEMICAL", 171, 183], ["SARS-CoV", "ORGANISM", 39, 47], ["chloroquine", "SIMPLE_CHEMICAL", 56, 67], ["ribavirin", "SIMPLE_CHEMICAL", 90, 99], ["type I interferons", "GENE_OR_GENE_PRODUCT", 101, 119], ["niclosamide", "SIMPLE_CHEMICAL", 121, 132], ["indomethacin", "SIMPLE_CHEMICAL", 171, 183], ["SARS-CoV", "SPECIES", 39, 47], ["SARS", "PROBLEM", 39, 43], ["chloroquine", "TREATMENT", 56, 67], ["protease inhibitors", "TREATMENT", 69, 88], ["ribavirin", "TREATMENT", 90, 99], ["type I interferons", "TREATMENT", 101, 119], ["niclosamide", "TREATMENT", 121, 132], ["anti-inflammatory agents", "TREATMENT", 138, 162], ["indomethacin", "TREATMENT", 171, 183]]], ["[60] [61] [62] Ribavirin in combination with lopinavir/ritonavir (protease inhibitors used in HIV disease) was associated with a lower incidence of adverse outcomes compared with historical controls of ribavirin alone in one study.", [["[60] [61] [62]", "CHEMICAL", 0, 14], ["Ribavirin", "CHEMICAL", 15, 24], ["lopinavir/ritonavir", "CHEMICAL", 45, 64], ["HIV disease", "DISEASE", 94, 105], ["ribavirin", "CHEMICAL", 202, 211], ["[60] [61] [62] Ribavirin", "CHEMICAL", 0, 24], ["lopinavir", "CHEMICAL", 45, 54], ["ritonavir", "CHEMICAL", 55, 64], ["ribavirin", "CHEMICAL", 202, 211], ["[60] [61] [62] Ribavirin", "SIMPLE_CHEMICAL", 0, 24], ["lopinavir", "SIMPLE_CHEMICAL", 45, 54], ["ritonavir", "SIMPLE_CHEMICAL", 55, 64], ["HIV", "ORGANISM", 94, 97], ["ribavirin", "SIMPLE_CHEMICAL", 202, 211], ["HIV", "SPECIES", 94, 97], ["Ribavirin", "TREATMENT", 15, 24], ["lopinavir", "TREATMENT", 45, 54], ["ritonavir (protease inhibitors", "TREATMENT", 55, 85], ["HIV disease", "PROBLEM", 94, 105], ["adverse outcomes", "PROBLEM", 148, 164], ["ribavirin", "TREATMENT", 202, 211]]], ["Nelfinavir, another protease inhibitor, has also demonstrated in vitro antiviral activity.", [["Nelfinavir", "CHEMICAL", 0, 10], ["Nelfinavir", "CHEMICAL", 0, 10], ["Nelfinavir", "SIMPLE_CHEMICAL", 0, 10], ["Nelfinavir", "TREATMENT", 0, 10], ["another protease inhibitor", "TREATMENT", 12, 38], ["vitro antiviral activity", "TREATMENT", 65, 89], ["antiviral activity", "OBSERVATION", 71, 89]]], ["Other targets for controlling SARS viral replication have included interferons.", [["SARS", "DISEASE", 30, 34], ["interferons", "PROTEIN", 67, 78], ["controlling SARS viral replication", "TREATMENT", 18, 52], ["interferons", "TREATMENT", 67, 78]]], ["Although the mechanisms are unknown, chloroquine, niclosamide, and indomethacin all inhibit SARS-CoV in vitro.", [["chloroquine", "CHEMICAL", 37, 48], ["niclosamide", "CHEMICAL", 50, 61], ["indomethacin", "CHEMICAL", 67, 79], ["chloroquine", "CHEMICAL", 37, 48], ["niclosamide", "CHEMICAL", 50, 61], ["indomethacin", "CHEMICAL", 67, 79], ["chloroquine", "SIMPLE_CHEMICAL", 37, 48], ["niclosamide", "SIMPLE_CHEMICAL", 50, 61], ["indomethacin", "SIMPLE_CHEMICAL", 67, 79], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 92, 100], ["SARS-CoV", "SPECIES", 92, 100], ["chloroquine", "TREATMENT", 37, 48], ["niclosamide", "TREATMENT", 50, 61], ["indomethacin", "TREATMENT", 67, 79]]], ["[63] [64] [65] CYTOMEGALOVIRUS Cytomegalovirus (CMV) is a member of the gammaherpesvirus subfamily of the herpes viruses and has the same structural and biochemical characteristics, which include an internal core containing linear double-stranded DNA, an icosadeltahedral capsid containing 162 capsomeres, and an envelope derived from the host-cell nuclear membrane.", [["cell nuclear membrane", "ANATOMY", 344, 365], ["herpes viruses", "DISEASE", 106, 120], ["Cytomegalovirus", "ORGANISM", 31, 46], ["CMV", "ORGANISM", 48, 51], ["gammaherpesvirus", "ORGANISM", 72, 88], ["herpes viruses", "ORGANISM", 106, 120], ["DNA", "CELLULAR_COMPONENT", 247, 250], ["cell nuclear membrane", "CELLULAR_COMPONENT", 344, 365], ["linear double-stranded DNA", "DNA", 224, 250], ["icosadeltahedral capsid", "PROTEIN", 255, 278], ["162 capsomeres", "PROTEIN", 290, 304], ["CMV", "SPECIES", 48, 51], ["CYTOMEGALOVIRUS Cytomegalovirus (CMV", "TEST", 15, 51], ["the herpes viruses", "PROBLEM", 102, 120], ["linear double-stranded DNA", "TREATMENT", 224, 250], ["an icosadeltahedral capsid", "TREATMENT", 252, 278], ["gammaherpesvirus", "ANATOMY", 72, 88], ["herpes viruses", "OBSERVATION", 106, 120], ["internal", "ANATOMY_MODIFIER", 199, 207], ["linear", "OBSERVATION_MODIFIER", 224, 230], ["double", "OBSERVATION", 231, 237], ["stranded DNA", "OBSERVATION", 238, 250], ["162 capsomeres", "OBSERVATION", 290, 304], ["host", "ANATOMY_MODIFIER", 339, 343], ["cell", "OBSERVATION", 344, 348], ["nuclear membrane", "OBSERVATION", 349, 365]]], ["However, the large size of the CMV virion (200 nm) and larger genome (>200,000 bp) distinguish it from other human herpes viruses.", [["herpes viruses", "DISEASE", 115, 129], ["CMV", "ORGANISM", 31, 34], ["human", "ORGANISM", 109, 114], ["herpes viruses", "ORGANISM", 115, 129], ["human", "SPECIES", 109, 114], ["human herpes viruses", "SPECIES", 109, 129], ["the CMV virion", "PROBLEM", 27, 41], ["larger genome", "PROBLEM", 55, 68], ["other human herpes viruses", "PROBLEM", 103, 129], ["large", "OBSERVATION_MODIFIER", 13, 18], ["size", "OBSERVATION_MODIFIER", 19, 23], ["CMV virion", "OBSERVATION", 31, 41], ["larger", "OBSERVATION_MODIFIER", 55, 61], ["genome", "OBSERVATION_MODIFIER", 62, 68], ["herpes viruses", "OBSERVATION", 115, 129]]], ["There is approximately 80% homology between the genomes of various strains of CMV, but sufficient differences exist to permit strain identification by restriction endonuclease analysis.", [["CMV", "ORGANISM", 78, 81], ["restriction endonuclease", "PROTEIN", 151, 175], ["CMV", "SPECIES", 78, 81], ["CMV", "PROBLEM", 78, 81], ["endonuclease analysis", "TEST", 163, 184], ["CMV", "OBSERVATION", 78, 81]]], ["The CMV genome codes for approximately 33 structural proteins, the functions of many of which are currently unknown.", [["CMV", "ORGANISM", 4, 7], ["CMV genome", "DNA", 4, 14], ["33 structural proteins", "PROTEIN", 39, 61], ["CMV", "SPECIES", 4, 7], ["CMV genome", "OBSERVATION", 4, 14]]], ["In addition, clinical isolates often encode multiple gene products not seen in laboratory strains.", [["multiple gene products", "TREATMENT", 44, 66]]], ["Envelope glycoproteins B and H have been identified as major antigens eliciting neutralizing antibody.", [["Envelope glycoproteins B", "GENE_OR_GENE_PRODUCT", 0, 24], ["H", "GENE_OR_GENE_PRODUCT", 29, 30], ["Envelope glycoproteins B and H", "PROTEIN", 0, 30], ["neutralizing antibody", "PROTEIN", 80, 101], ["neutralizing antibody", "PROBLEM", 80, 101], ["neutralizing antibody", "OBSERVATION", 80, 101]]], ["Glycoprotein B may also be a target for cytotoxic T lymphocyte responses, 66 while multiple proteins also serve as targets for T-cell responses.", [["T lymphocyte", "ANATOMY", 50, 62], ["T-cell", "ANATOMY", 127, 133], ["Glycoprotein B", "GENE_OR_GENE_PRODUCT", 0, 14], ["T lymphocyte", "CELL", 50, 62], ["T-cell", "CELL", 127, 133], ["Glycoprotein B", "PROTEIN", 0, 14], ["Glycoprotein B", "TREATMENT", 0, 14], ["cytotoxic T lymphocyte responses", "TEST", 40, 72], ["multiple proteins", "TEST", 83, 100]]], ["CMV-specific, cytotoxic T-cell responses are an important host defense mechanism that is associated with survival from CMV infection in bone marrow transplant recipients.", [["T-cell", "ANATOMY", 24, 30], ["bone marrow", "ANATOMY", 136, 147], ["CMV infection", "DISEASE", 119, 132], ["CMV", "ORGANISM", 0, 3], ["T-cell", "CELL", 24, 30], ["CMV", "ORGANISM", 119, 122], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 136, 147], ["CMV", "SPECIES", 0, 3], ["CMV", "SPECIES", 119, 122], ["CMV", "TEST", 0, 3], ["CMV infection", "PROBLEM", 119, 132], ["bone marrow transplant recipients", "TREATMENT", 136, 169], ["host defense", "OBSERVATION_MODIFIER", 58, 70], ["associated with", "UNCERTAINTY", 89, 104], ["CMV infection", "OBSERVATION", 119, 132], ["bone", "ANATOMY", 136, 140], ["marrow transplant", "OBSERVATION", 141, 158]]], ["67 However, CMV uses multiple mechanisms, including down-regulation of HLA class I on the cell surface and interference with antigen processing, to evade recognition by the host.Epidemiology and TransmissionInfection with CMV, whether symptomatic or not, is followed by prolonged excretion of virus in urine, saliva, stool, tears, breast milk, vaginal secretions, and semen.", [["cell surface", "ANATOMY", 90, 102], ["urine", "ANATOMY", 302, 307], ["saliva", "ANATOMY", 309, 315], ["stool", "ANATOMY", 317, 322], ["tears", "ANATOMY", 324, 329], ["breast milk", "ANATOMY", 331, 342], ["vaginal secretions", "ANATOMY", 344, 362], ["semen", "ANATOMY", 368, 373], ["CMV", "ORGANISM", 12, 15], ["HLA class I", "GENE_OR_GENE_PRODUCT", 71, 82], ["cell surface", "CELLULAR_COMPONENT", 90, 102], ["CMV", "ORGANISM", 222, 225], ["urine", "ORGANISM_SUBSTANCE", 302, 307], ["saliva", "ORGANISM_SUBSTANCE", 309, 315], ["stool", "ORGANISM_SUBSTANCE", 317, 322], ["tears", "TISSUE", 324, 329], ["breast milk", "ORGANISM_SUBSTANCE", 331, 342], ["vaginal secretions", "ORGANISM_SUBSTANCE", 344, 362], ["semen", "ORGANISM_SUBSTANCE", 368, 373], ["HLA class I", "PROTEIN", 71, 82], ["CMV", "SPECIES", 12, 15], ["CMV", "SPECIES", 222, 225], ["CMV", "PROBLEM", 12, 15], ["the cell surface", "TREATMENT", 86, 102], ["antigen processing", "TREATMENT", 125, 143], ["CMV", "PROBLEM", 222, 225], ["symptomatic", "PROBLEM", 235, 246], ["prolonged excretion of virus in urine", "PROBLEM", 270, 307], ["tears", "PROBLEM", 324, 329], ["breast milk", "TREATMENT", 331, 342], ["vaginal secretions", "PROBLEM", 344, 362], ["CMV", "OBSERVATION", 12, 15], ["CMV", "OBSERVATION", 222, 225], ["virus", "OBSERVATION", 293, 298], ["breast", "ANATOMY", 331, 337], ["vaginal", "ANATOMY", 344, 351], ["secretions", "OBSERVATION", 352, 362]]], ["Thus, the major reservoir for CMV is asymptomatic infected persons.", [["CMV", "ORGANISM", 30, 33], ["persons", "ORGANISM", 59, 66], ["persons", "SPECIES", 59, 66], ["CMV", "SPECIES", 30, 33], ["CMV", "PROBLEM", 30, 33], ["CMV", "OBSERVATION", 30, 33]]], ["Virus shedding persists for years in children with congenital and perinatal CMV infections.", [["CMV infections", "DISEASE", 76, 90], ["Virus", "ORGANISM", 0, 5], ["children", "ORGANISM", 37, 45], ["CMV", "ORGANISM", 76, 79], ["children", "SPECIES", 37, 45], ["CMV", "SPECIES", 76, 79], ["Virus shedding", "PROBLEM", 0, 14], ["congenital and perinatal CMV infections", "PROBLEM", 51, 90], ["congenital", "OBSERVATION", 51, 61], ["CMV infections", "OBSERVATION", 76, 90]]], ["The virus is believed to be transmitted by direct contact, especially under conditions of intimacy such as found in child care centers 68 and the family setting.", [["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9], ["believed to be", "UNCERTAINTY", 13, 27]]], ["Thus, the rate of acquisition of infection is known about the pathogenesis of the common cold induced by conventional human coronaviruses.Epidemiology and TransmissionThe hallmark of pulmonary pathology in fatal cases of SARS was diffuse alveolar damage, 47 type II pneumocyte hyperplasia, squamous metaplasia, and multinucleated giant cells.", [["pulmonary", "ANATOMY", 183, 192], ["alveolar", "ANATOMY", 238, 246], ["squamous metaplasia", "ANATOMY", 290, 309], ["multinucleated giant cells", "ANATOMY", 315, 341], ["infection", "DISEASE", 33, 42], ["pulmonary pathology", "DISEASE", 183, 202], ["SARS", "DISEASE", 221, 225], ["alveolar damage", "DISEASE", 238, 253], ["hyperplasia", "DISEASE", 277, 288], ["squamous metaplasia", "DISEASE", 290, 309], ["human", "ORGANISM", 118, 123], ["pulmonary", "ORGAN", 183, 192], ["alveolar", "TISSUE", 238, 246], ["squamous metaplasia", "CANCER", 290, 309], ["multinucleated giant cells", "CELL", 315, 341], ["multinucleated giant cells", "CELL_TYPE", 315, 341], ["human", "SPECIES", 118, 123], ["human coronaviruses", "SPECIES", 118, 137], ["infection", "PROBLEM", 33, 42], ["conventional human coronaviruses", "PROBLEM", 105, 137], ["SARS", "PROBLEM", 221, 225], ["diffuse alveolar damage", "PROBLEM", 230, 253], ["type II pneumocyte hyperplasia", "PROBLEM", 258, 288], ["squamous metaplasia", "PROBLEM", 290, 309], ["multinucleated giant cells", "PROBLEM", 315, 341], ["infection", "OBSERVATION", 33, 42], ["common cold", "ANATOMY", 82, 93], ["pulmonary", "ANATOMY", 183, 192], ["pathology", "OBSERVATION", 193, 202], ["fatal", "OBSERVATION_MODIFIER", 206, 211], ["diffuse", "OBSERVATION_MODIFIER", 230, 237], ["alveolar damage", "OBSERVATION", 238, 253], ["type II", "OBSERVATION_MODIFIER", 258, 265], ["pneumocyte hyperplasia", "OBSERVATION", 266, 288], ["squamous metaplasia", "OBSERVATION", 290, 309], ["multinucleated", "OBSERVATION_MODIFIER", 315, 329], ["giant cells", "OBSERVATION", 330, 341]]], ["Hemophagocytosis, or the phagocytosis of erythrocytes, leukocytes, and platelets by histiocytes, was reported, potentially as a consequence of cytokine dysregulation.", [["erythrocytes", "ANATOMY", 41, 53], ["leukocytes", "ANATOMY", 55, 65], ["platelets", "ANATOMY", 71, 80], ["histiocytes", "ANATOMY", 84, 95], ["Hemophagocytosis", "DISEASE", 0, 16], ["erythrocytes", "CELL", 41, 53], ["leukocytes", "CELL", 55, 65], ["platelets", "CELL", 71, 80], ["histiocytes", "CELL", 84, 95], ["erythrocytes", "CELL_TYPE", 41, 53], ["leukocytes", "CELL_TYPE", 55, 65], ["platelets", "CELL_TYPE", 71, 80], ["histiocytes", "CELL_TYPE", 84, 95], ["cytokine", "PROTEIN", 143, 151], ["Hemophagocytosis", "PROBLEM", 0, 16], ["the phagocytosis of erythrocytes", "PROBLEM", 21, 53], ["leukocytes", "TEST", 55, 65], ["platelets", "TEST", 71, 80], ["histiocytes", "TEST", 84, 95], ["cytokine dysregulation", "PROBLEM", 143, 165], ["erythrocytes", "ANATOMY", 41, 53], ["leukocytes", "ANATOMY", 55, 65], ["histiocytes", "OBSERVATION", 84, 95], ["cytokine dysregulation", "OBSERVATION", 143, 165]]], ["48 Furthermore, virus was detected within pulmonary epithelial cells.", [["pulmonary epithelial cells", "ANATOMY", 42, 68], ["pulmonary epithelial cells", "CELL", 42, 68], ["pulmonary epithelial cells", "CELL_TYPE", 42, 68], ["virus", "PROBLEM", 16, 21], ["virus", "OBSERVATION", 16, 21], ["pulmonary", "ANATOMY", 42, 51], ["epithelial cells", "OBSERVATION", 52, 68]]], ["49 From these findings, it is postulated that disease pathogenesis involves both direct damage to pulmonary epithelia by the virus in combination with an excessive or dysregulated host immune response.Clinical IllnessConventional human coronaviruses produce a typical coryzal illness that is indistinguishable from colds due to other viruses.", [["pulmonary epithelia", "ANATOMY", 98, 117], ["coryzal", "ANATOMY", 268, 275], ["human coronaviruses", "DISEASE", 230, 249], ["coryzal illness", "DISEASE", 268, 283], ["colds", "DISEASE", 315, 320], ["pulmonary epithelia", "TISSUE", 98, 117], ["human", "ORGANISM", 230, 235], ["coronaviruses", "ORGANISM", 236, 249], ["coryzal", "CANCER", 268, 275], ["human", "SPECIES", 230, 235], ["human coronaviruses", "SPECIES", 230, 249], ["disease pathogenesis", "PROBLEM", 46, 66], ["pulmonary epithelia", "PROBLEM", 98, 117], ["the virus", "PROBLEM", 121, 130], ["an excessive or dysregulated host immune response", "PROBLEM", 151, 200], ["Clinical IllnessConventional human coronaviruses", "PROBLEM", 201, 249], ["a typical coryzal illness", "PROBLEM", 258, 283], ["colds", "PROBLEM", 315, 320], ["other viruses", "PROBLEM", 328, 341], ["disease", "OBSERVATION", 46, 53], ["pulmonary epithelia", "ANATOMY", 98, 117], ["virus", "OBSERVATION", 125, 130], ["dysregulated host immune response", "OBSERVATION", 167, 200], ["viruses", "OBSERVATION", 334, 341]]], ["Coronaviruses have also been linked with acute otitis media, exacerbations of asthma in children, and with exacerbations of chronic bronchitis and pneumonia in adults.Clinical IllnessIn contrast, SARS has a nonspecific presentation that is difficult to distinguish from other viral acute respiratory illnesses, particularly influenza.", [["respiratory", "ANATOMY", 288, 299], ["acute otitis media", "DISEASE", 41, 59], ["asthma", "DISEASE", 78, 84], ["chronic bronchitis", "DISEASE", 124, 142], ["pneumonia", "DISEASE", 147, 156], ["SARS", "DISEASE", 196, 200], ["acute respiratory illnesses", "DISEASE", 282, 309], ["influenza", "DISEASE", 324, 333], ["children", "ORGANISM", 88, 96], ["children", "SPECIES", 88, 96], ["Coronaviruses", "PROBLEM", 0, 13], ["acute otitis media", "PROBLEM", 41, 59], ["asthma", "PROBLEM", 78, 84], ["chronic bronchitis", "PROBLEM", 124, 142], ["pneumonia", "PROBLEM", 147, 156], ["a nonspecific presentation", "PROBLEM", 205, 231], ["other viral acute respiratory illnesses", "PROBLEM", 270, 309], ["influenza", "PROBLEM", 324, 333], ["acute", "OBSERVATION_MODIFIER", 41, 46], ["otitis", "OBSERVATION", 47, 53], ["asthma", "OBSERVATION", 78, 84], ["chronic", "OBSERVATION_MODIFIER", 124, 131], ["bronchitis", "OBSERVATION", 132, 142], ["pneumonia", "OBSERVATION", 147, 156], ["nonspecific", "OBSERVATION_MODIFIER", 207, 218], ["viral", "OBSERVATION_MODIFIER", 276, 281], ["acute", "OBSERVATION_MODIFIER", 282, 287], ["respiratory illnesses", "OBSERVATION", 288, 309]]], ["Common symptoms on presentation are fever, chills and/or rigors, myalgias, and occasionally diarrhea.", [["fever", "DISEASE", 36, 41], ["chills", "DISEASE", 43, 49], ["rigors", "DISEASE", 57, 63], ["myalgias", "DISEASE", 65, 73], ["diarrhea", "DISEASE", 92, 100], ["Common symptoms", "PROBLEM", 0, 15], ["fever", "PROBLEM", 36, 41], ["chills", "PROBLEM", 43, 49], ["rigors", "PROBLEM", 57, 63], ["myalgias", "PROBLEM", 65, 73], ["occasionally diarrhea", "PROBLEM", 79, 100], ["diarrhea", "OBSERVATION", 92, 100]]], ["Cough and dyspnea are the predominant respiratory symptoms but may not be present initially.", [["respiratory", "ANATOMY", 38, 49], ["Cough", "DISEASE", 0, 5], ["dyspnea", "DISEASE", 10, 17], ["Cough", "PROBLEM", 0, 5], ["dyspnea", "PROBLEM", 10, 17], ["the predominant respiratory symptoms", "PROBLEM", 22, 58], ["dyspnea", "OBSERVATION", 10, 17], ["predominant", "OBSERVATION_MODIFIER", 26, 37], ["respiratory symptoms", "OBSERVATION", 38, 58], ["may not be", "UNCERTAINTY", 63, 73]]], ["Respiratory disease becomes more severe over 4 to 7 days, and about 20% of patients require respiratory support.", [["Respiratory", "ANATOMY", 0, 11], ["respiratory", "ANATOMY", 92, 103], ["Respiratory disease", "DISEASE", 0, 19], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["Respiratory disease", "PROBLEM", 0, 19], ["respiratory support", "TREATMENT", 92, 111], ["disease", "OBSERVATION", 12, 19], ["more", "OBSERVATION_MODIFIER", 28, 32], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["respiratory support", "OBSERVATION", 92, 111]]], ["MERS has had a similar presentation, although GI symptoms may be more prominent.", [["GI", "ANATOMY", 46, 48], ["GI symptoms", "PROBLEM", 46, 57], ["more prominent", "OBSERVATION_MODIFIER", 65, 79]]], ["50 SARS fatality rates were 9.6% for all ages but higher in older adults, 51 and children had milder disease.", [["SARS", "DISEASE", 3, 7], ["children", "ORGANISM", 81, 89], ["children", "SPECIES", 81, 89], ["SARS fatality rates", "TEST", 3, 22], ["milder disease", "PROBLEM", 94, 108]]], ["52 Similarly, the majority of recognized cases of MERS to date have been in individuals with comorbidities.", [["MERS", "DISEASE", 50, 54], ["comorbidities", "PROBLEM", 93, 106]]], ["53 SARS laboratory abnormalities include elevations in lactate dehydrogenase, transaminases, and creatine kinase, as well as hematologic abnormalities, particularly lymphopenia (depletion of CD4 and CD8 T cells) and thrombocytopenia.DiagnosisCommon findings on chest CT include unilateral or bilateral areas of ground-glass opacifications and interlobular septal and intralobular interstitial thickening.", [["hematologic", "ANATOMY", 125, 136], ["CD4", "ANATOMY", 191, 194], ["CD8 T cells", "ANATOMY", 199, 210], ["chest", "ANATOMY", 261, 266], ["interlobular septal", "ANATOMY", 343, 362], ["intralobular interstitial", "ANATOMY", 367, 392], ["SARS", "DISEASE", 3, 7], ["lactate", "CHEMICAL", 55, 62], ["creatine", "CHEMICAL", 97, 105], ["hematologic abnormalities", "DISEASE", 125, 150], ["lymphopenia", "DISEASE", 165, 176], ["thrombocytopenia", "DISEASE", 216, 232], ["lactate", "CHEMICAL", 55, 62], ["creatine", "CHEMICAL", 97, 105], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 55, 76], ["transaminases", "SIMPLE_CHEMICAL", 78, 91], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 97, 112], ["CD4", "GENE_OR_GENE_PRODUCT", 191, 194], ["CD8", "GENE_OR_GENE_PRODUCT", 199, 202], ["interlobular septal", "MULTI-TISSUE_STRUCTURE", 343, 362], ["intralobular interstitial", "PATHOLOGICAL_FORMATION", 367, 392], ["lactate dehydrogenase", "PROTEIN", 55, 76], ["transaminases", "PROTEIN", 78, 91], ["creatine kinase", "PROTEIN", 97, 112], ["CD4", "PROTEIN", 191, 194], ["CD8 T cells", "CELL_TYPE", 199, 210], ["SARS laboratory abnormalities", "PROBLEM", 3, 32], ["elevations in lactate dehydrogenase", "PROBLEM", 41, 76], ["transaminases", "TEST", 78, 91], ["creatine kinase", "TEST", 97, 112], ["hematologic abnormalities", "PROBLEM", 125, 150], ["lymphopenia", "PROBLEM", 165, 176], ["CD4", "TEST", 191, 194], ["CD8 T cells", "PROBLEM", 199, 210], ["thrombocytopenia", "PROBLEM", 216, 232], ["chest CT", "TEST", 261, 269], ["unilateral or bilateral areas of ground-glass opacifications", "PROBLEM", 278, 338], ["interlobular septal and intralobular interstitial thickening", "PROBLEM", 343, 403], ["elevations", "OBSERVATION_MODIFIER", 41, 51], ["lactate dehydrogenase", "OBSERVATION", 55, 76], ["lymphopenia", "OBSERVATION", 165, 176], ["thrombocytopenia", "OBSERVATION", 216, 232], ["chest", "ANATOMY", 261, 266], ["unilateral", "ANATOMY_MODIFIER", 278, 288], ["bilateral", "ANATOMY_MODIFIER", 292, 301], ["ground-glass opacifications", "OBSERVATION", 311, 338], ["interlobular", "ANATOMY_MODIFIER", 343, 355], ["septal", "ANATOMY_MODIFIER", 356, 362], ["intralobular", "ANATOMY_MODIFIER", 367, 379], ["interstitial", "ANATOMY_MODIFIER", 380, 392], ["thickening", "OBSERVATION", 393, 403]]], ["In most patients, peripheral involvement in the lower lung zones has been observed.", [["lower lung zones", "ANATOMY", 48, 64], ["patients", "ORGANISM", 8, 16], ["lung zones", "MULTI-TISSUE_STRUCTURE", 54, 64], ["patients", "SPECIES", 8, 16], ["peripheral involvement in the lower lung zones", "PROBLEM", 18, 64], ["peripheral", "ANATOMY_MODIFIER", 18, 28], ["involvement", "OBSERVATION", 29, 40], ["lower", "ANATOMY_MODIFIER", 48, 53], ["lung", "ANATOMY", 54, 58], ["zones", "ANATOMY_MODIFIER", 59, 64]]], ["In some cases, after recovery from acute illness, pulmonary fibrosis has developed.", [["pulmonary", "ANATOMY", 50, 59], ["fibrosis", "DISEASE", 60, 68], ["pulmonary", "ORGAN", 50, 59], ["acute illness", "PROBLEM", 35, 48], ["pulmonary fibrosis", "PROBLEM", 50, 68], ["acute", "OBSERVATION_MODIFIER", 35, 40], ["illness", "OBSERVATION", 41, 48], ["pulmonary", "ANATOMY", 50, 59], ["fibrosis", "OBSERVATION", 60, 68]]], ["54 Clinical features predictive of poor outcomes included the presence of bilateral disease at presentation, markedly elevated lactate dehydrogenase, older age, and other comorbid conditions.DiagnosisThe main site of viral replication of SARS-CoV appears to be the lower respiratory tract.", [["lower respiratory tract", "ANATOMY", 265, 288], ["lactate", "CHEMICAL", 127, 134], ["SARS", "DISEASE", 238, 242], ["lactate", "CHEMICAL", 127, 134], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 127, 148], ["SARS-CoV", "ORGANISM", 238, 246], ["lower", "ORGANISM_SUBDIVISION", 265, 270], ["respiratory tract", "ORGANISM_SUBDIVISION", 271, 288], ["lactate dehydrogenase", "PROTEIN", 127, 148], ["SARS-CoV", "SPECIES", 238, 246], ["bilateral disease", "PROBLEM", 74, 91], ["markedly elevated lactate dehydrogenase", "PROBLEM", 109, 148], ["other comorbid conditions", "PROBLEM", 165, 190], ["viral replication of SARS", "PROBLEM", 217, 242], ["CoV", "PROBLEM", 243, 246], ["bilateral", "ANATOMY_MODIFIER", 74, 83], ["disease", "OBSERVATION", 84, 91], ["markedly", "OBSERVATION_MODIFIER", 109, 117], ["elevated", "OBSERVATION_MODIFIER", 118, 126], ["lactate dehydrogenase", "OBSERVATION", 127, 148], ["main", "OBSERVATION_MODIFIER", 204, 208], ["viral replication", "OBSERVATION", 217, 234], ["SARS", "OBSERVATION", 238, 242], ["lower", "ANATOMY_MODIFIER", 265, 270], ["respiratory tract", "ANATOMY", 271, 288]]], ["49 PCR detection is most reliable in the sputum, but viral RNA can also be detected in the blood and stool.", [["sputum", "ANATOMY", 41, 47], ["blood", "ANATOMY", 91, 96], ["stool", "ANATOMY", 101, 106], ["sputum", "ORGANISM_SUBSTANCE", 41, 47], ["blood", "ORGANISM_SUBSTANCE", 91, 96], ["stool", "ORGANISM_SUBSTANCE", 101, 106], ["viral RNA", "RNA", 53, 62], ["PCR detection", "TEST", 3, 16], ["the sputum", "TEST", 37, 47], ["viral RNA", "PROBLEM", 53, 62], ["sputum", "OBSERVATION", 41, 47], ["viral RNA", "OBSERVATION", 53, 62], ["stool", "OBSERVATION", 101, 106]]], ["55 Serum antibodies rise within 2 to 3 weeks of illness, although measurements at 4 weeks have become the standard to exclude SARS.Treatment and PreventionImmunity against coronaviruses appears to be short-lived.", [["Serum", "ANATOMY", 3, 8], ["illness", "DISEASE", 48, 55], ["SARS", "DISEASE", 126, 130], ["Serum", "ORGANISM_SUBSTANCE", 3, 8], ["coronaviruses", "ORGANISM", 172, 185], ["Serum antibodies", "PROTEIN", 3, 19], ["Serum antibodies", "TEST", 3, 19], ["illness", "PROBLEM", 48, 55], ["SARS", "PROBLEM", 126, 130], ["Treatment", "TREATMENT", 131, 140], ["PreventionImmunity", "TREATMENT", 145, 163], ["coronaviruses", "PROBLEM", 172, 185]]], ["Epidemiologic studies of coronavirus infection have demonstrated high reinfection rates.", [["coronavirus infection", "DISEASE", 25, 46], ["coronavirus", "ORGANISM", 25, 36], ["coronavirus", "SPECIES", 25, 36], ["Epidemiologic studies", "TEST", 0, 21], ["coronavirus infection", "PROBLEM", 25, 46], ["high reinfection rates", "PROBLEM", 65, 87], ["coronavirus infection", "OBSERVATION", 25, 46], ["high", "OBSERVATION_MODIFIER", 65, 69], ["reinfection", "OBSERVATION", 70, 81]]], ["56 In human volunteer experiments, infection with a 229E-like coronavirus only induced nucleosis.", [["infection", "DISEASE", 35, 44], ["nucleosis", "DISEASE", 87, 96], ["human", "ORGANISM", 6, 11], ["229E-like coronavirus", "ORGANISM", 52, 73], ["human", "SPECIES", 6, 11], ["coronavirus", "SPECIES", 62, 73], ["human", "SPECIES", 6, 11], ["infection", "PROBLEM", 35, 44], ["a 229E", "PROBLEM", 50, 56], ["coronavirus", "PROBLEM", 62, 73], ["nucleosis", "PROBLEM", 87, 96], ["infection", "OBSERVATION", 35, 44], ["nucleosis", "OBSERVATION", 87, 96]]], ["In immunocompromised hosts, there may be a variety of clinical syndromes, the severity of which is impacted by whether infection is acquired de novo or represents reactivation of endogenous virus.", [["infection", "DISEASE", 119, 128], ["clinical syndromes", "PROBLEM", 54, 72], ["infection", "PROBLEM", 119, 128], ["endogenous virus", "PROBLEM", 179, 195], ["immunocompromised hosts", "OBSERVATION", 3, 26], ["may be", "UNCERTAINTY", 34, 40], ["variety", "OBSERVATION_MODIFIER", 43, 50], ["infection", "OBSERVATION", 119, 128], ["endogenous virus", "OBSERVATION", 179, 195]]], ["The risk of severe disease is particularly high in transplant patients when a CMV-seronegative recipient receives an organ from a seropositive donor.Treatment and PreventionThe pathogenesis of CMV pneumonia is partly related to viral replication but also thought to have an immunopathologic basis.", [["organ", "ANATOMY", 117, 122], ["CMV pneumonia", "DISEASE", 193, 206], ["patients", "ORGANISM", 62, 70], ["CMV", "ORGANISM", 78, 81], ["organ", "ORGAN", 117, 122], ["CMV", "ORGANISM", 193, 196], ["patients", "SPECIES", 62, 70], ["CMV", "SPECIES", 78, 81], ["CMV", "SPECIES", 193, 196], ["severe disease", "PROBLEM", 12, 26], ["a CMV-seronegative recipient", "TREATMENT", 76, 104], ["a seropositive donor", "TREATMENT", 128, 148], ["Treatment", "TREATMENT", 149, 158], ["CMV pneumonia", "PROBLEM", 193, 206], ["viral replication", "PROBLEM", 228, 245], ["severe", "OBSERVATION_MODIFIER", 12, 18], ["disease", "OBSERVATION", 19, 26], ["high", "OBSERVATION_MODIFIER", 43, 47], ["CMV pneumonia", "OBSERVATION", 193, 206], ["partly related to", "UNCERTAINTY", 210, 227], ["viral replication", "OBSERVATION", 228, 245]]], ["70 The development of CMV pneumonitis reflects a complex interaction between viral infection and graftversus-host disease, particularly in marrow transplant recipients 71,72,72a (see Chapter 91) .", [["marrow", "ANATOMY", 139, 145], ["CMV pneumonitis", "DISEASE", 22, 37], ["viral infection", "DISEASE", 77, 92], ["graftversus-host disease", "DISEASE", 97, 121], ["CMV", "ORGANISM", 22, 25], ["marrow", "ORGAN", 139, 145], ["CMV", "SPECIES", 22, 25], ["CMV pneumonitis", "PROBLEM", 22, 37], ["viral infection", "PROBLEM", 77, 92], ["host disease", "PROBLEM", 109, 121], ["marrow transplant recipients", "TREATMENT", 139, 167], ["CMV pneumonitis", "OBSERVATION", 22, 37], ["complex", "OBSERVATION_MODIFIER", 49, 56], ["viral", "OBSERVATION_MODIFIER", 77, 82], ["infection", "OBSERVATION", 83, 92], ["host disease", "OBSERVATION", 109, 121], ["marrow transplant", "OBSERVATION", 139, 156]]], ["Two patterns of histopathology have been described in the lung tissue of bone marrow transplant patients with serious pneumonia.", [["lung tissue", "ANATOMY", 58, 69], ["bone marrow", "ANATOMY", 73, 84], ["pneumonia", "DISEASE", 118, 127], ["lung tissue", "TISSUE", 58, 69], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 73, 84], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["histopathology", "PROBLEM", 16, 30], ["bone marrow transplant", "TREATMENT", 73, 95], ["serious pneumonia", "PROBLEM", 110, 127], ["histopathology", "OBSERVATION", 16, 30], ["lung", "ANATOMY", 58, 62], ["tissue", "ANATOMY_MODIFIER", 63, 69], ["bone", "ANATOMY", 73, 77], ["marrow transplant", "OBSERVATION", 78, 95], ["serious", "OBSERVATION_MODIFIER", 110, 117], ["pneumonia", "OBSERVATION", 118, 127]]], ["73 One is a miliary pattern, with multiple focal lesions showing extensive cytomegaly with localized necrosis, alveolar hemorrhage, fibrin deposition, and neutrophilic response (see Fig. 32-7) .", [["focal lesions", "ANATOMY", 43, 56], ["cytomegaly", "ANATOMY", 75, 85], ["alveolar", "ANATOMY", 111, 119], ["neutrophilic", "ANATOMY", 155, 167], ["cytomegaly", "DISEASE", 75, 85], ["necrosis", "DISEASE", 101, 109], ["alveolar hemorrhage", "DISEASE", 111, 130], ["focal lesions", "PATHOLOGICAL_FORMATION", 43, 56], ["cytomegaly", "CANCER", 75, 85], ["alveolar", "MULTI-TISSUE_STRUCTURE", 111, 119], ["fibrin", "GENE_OR_GENE_PRODUCT", 132, 138], ["a miliary pattern", "PROBLEM", 10, 27], ["multiple focal lesions", "PROBLEM", 34, 56], ["extensive cytomegaly", "PROBLEM", 65, 85], ["localized necrosis", "PROBLEM", 91, 109], ["alveolar hemorrhage", "PROBLEM", 111, 130], ["fibrin deposition", "PROBLEM", 132, 149], ["neutrophilic response", "PROBLEM", 155, 176], ["miliary", "OBSERVATION_MODIFIER", 12, 19], ["multiple", "OBSERVATION_MODIFIER", 34, 42], ["focal", "OBSERVATION_MODIFIER", 43, 48], ["lesions", "OBSERVATION", 49, 56], ["extensive", "OBSERVATION_MODIFIER", 65, 74], ["cytomegaly", "OBSERVATION", 75, 85], ["localized", "OBSERVATION_MODIFIER", 91, 100], ["necrosis", "OBSERVATION", 101, 109], ["alveolar", "ANATOMY_MODIFIER", 111, 119], ["hemorrhage", "OBSERVATION", 120, 130], ["fibrin deposition", "OBSERVATION", 132, 149], ["neutrophilic response", "OBSERVATION", 155, 176]]], ["The other is an interstitial pattern, with alveolar cell hyperplasia, interstitial edema, lymphoid infiltration, and diffusely distributed cytomegalic cells.Clinical IllnessCytomegalovirus causes a variety of human diseases, including congenital and perinatal infections, infectious mononucleosis, hepatitis, posttransfusion infection, and invasive infection in patients with impaired immunity.", [["interstitial", "ANATOMY", 16, 28], ["alveolar cell", "ANATOMY", 43, 56], ["interstitial edema", "ANATOMY", 70, 88], ["lymphoid", "ANATOMY", 90, 98], ["cytomegalic cells", "ANATOMY", 139, 156], ["alveolar cell hyperplasia", "DISEASE", 43, 68], ["interstitial edema", "DISEASE", 70, 88], ["Cytomegalovirus", "DISEASE", 173, 188], ["congenital and perinatal infections", "DISEASE", 235, 270], ["infectious mononucleosis", "DISEASE", 272, 296], ["hepatitis", "DISEASE", 298, 307], ["posttransfusion infection", "DISEASE", 309, 334], ["invasive infection", "DISEASE", 340, 358], ["impaired immunity", "DISEASE", 376, 393], ["alveolar cell", "CELL", 43, 56], ["interstitial edema", "PATHOLOGICAL_FORMATION", 70, 88], ["lymphoid", "CELL", 90, 98], ["cytomegalic cells", "CELL", 139, 156], ["Cytomegalovirus", "ORGANISM", 173, 188], ["human", "ORGANISM", 209, 214], ["patients", "ORGANISM", 362, 370], ["cytomegalic cells", "CELL_TYPE", 139, 156], ["human", "SPECIES", 209, 214], ["patients", "SPECIES", 362, 370], ["human", "SPECIES", 209, 214], ["an interstitial pattern", "PROBLEM", 13, 36], ["alveolar cell hyperplasia", "PROBLEM", 43, 68], ["interstitial edema", "PROBLEM", 70, 88], ["lymphoid infiltration", "PROBLEM", 90, 111], ["diffusely distributed cytomegalic cells", "PROBLEM", 117, 156], ["Clinical IllnessCytomegalovirus", "PROBLEM", 157, 188], ["human diseases", "PROBLEM", 209, 223], ["congenital and perinatal infections", "PROBLEM", 235, 270], ["infectious mononucleosis", "PROBLEM", 272, 296], ["hepatitis", "PROBLEM", 298, 307], ["posttransfusion infection", "PROBLEM", 309, 334], ["invasive infection", "PROBLEM", 340, 358], ["impaired immunity", "PROBLEM", 376, 393], ["interstitial", "ANATOMY_MODIFIER", 16, 28], ["alveolar cell hyperplasia", "OBSERVATION", 43, 68], ["interstitial", "ANATOMY_MODIFIER", 70, 82], ["edema", "OBSERVATION", 83, 88], ["lymphoid infiltration", "OBSERVATION", 90, 111], ["diffusely", "OBSERVATION_MODIFIER", 117, 126], ["distributed", "OBSERVATION_MODIFIER", 127, 138], ["cytomegalic cells", "OBSERVATION", 139, 156], ["variety", "OBSERVATION_MODIFIER", 198, 205], ["human diseases", "OBSERVATION", 209, 223], ["congenital", "OBSERVATION_MODIFIER", 235, 245], ["perinatal", "OBSERVATION_MODIFIER", 250, 259], ["infections", "OBSERVATION", 260, 270], ["infectious", "OBSERVATION_MODIFIER", 272, 282], ["hepatitis", "OBSERVATION", 298, 307], ["posttransfusion", "OBSERVATION_MODIFIER", 309, 324], ["infection", "OBSERVATION", 325, 334], ["invasive", "OBSERVATION_MODIFIER", 340, 348], ["infection", "OBSERVATION", 349, 358]]], ["In transplant populations, CMV infection often involves multiple organ systems in conjunction with other opportunistic infectious agents.Clinical IllnessBecause the virus rarely causes pneumonia in healthy hosts, the main impact of CMV as a respiratory pathogen is in immunocompromised patients.", [["organ", "ANATOMY", 65, 70], ["respiratory", "ANATOMY", 241, 252], ["CMV infection", "DISEASE", 27, 40], ["pneumonia", "DISEASE", 185, 194], ["respiratory pathogen", "DISEASE", 241, 261], ["CMV", "ORGANISM", 27, 30], ["organ", "ORGAN", 65, 70], ["CMV", "ORGANISM", 232, 235], ["patients", "ORGANISM", 286, 294], ["patients", "SPECIES", 286, 294], ["CMV", "SPECIES", 27, 30], ["CMV", "SPECIES", 232, 235], ["transplant populations", "TREATMENT", 3, 25], ["CMV infection", "PROBLEM", 27, 40], ["multiple organ systems", "PROBLEM", 56, 78], ["opportunistic infectious agents", "TREATMENT", 105, 136], ["Clinical Illness", "PROBLEM", 137, 153], ["the virus", "PROBLEM", 161, 170], ["pneumonia in healthy hosts", "PROBLEM", 185, 211], ["CMV", "TREATMENT", 232, 235], ["a respiratory pathogen", "PROBLEM", 239, 261], ["transplant populations", "OBSERVATION", 3, 25], ["CMV infection", "OBSERVATION", 27, 40], ["pneumonia", "OBSERVATION", 185, 194], ["healthy hosts", "OBSERVATION_MODIFIER", 198, 211], ["main", "OBSERVATION_MODIFIER", 217, 221], ["CMV", "OBSERVATION", 232, 235], ["respiratory pathogen", "OBSERVATION", 241, 261]]], ["In recipients of allogeneic bone marrow transplants, CMV is the most common infectious cause of interstitial pneumonia and, if untreated, is responsible for the highest fatality rate.", [["bone marrow", "ANATOMY", 28, 39], ["interstitial", "ANATOMY", 96, 108], ["interstitial pneumonia", "DISEASE", 96, 118], ["recipients", "ORGANISM", 3, 13], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 28, 39], ["CMV", "ORGANISM", 53, 56], ["interstitial", "IMMATERIAL_ANATOMICAL_ENTITY", 96, 108], ["CMV", "SPECIES", 53, 56], ["allogeneic bone marrow transplants", "TREATMENT", 17, 51], ["CMV", "PROBLEM", 53, 56], ["interstitial pneumonia", "PROBLEM", 96, 118], ["allogeneic bone marrow transplants", "OBSERVATION", 17, 51], ["CMV", "OBSERVATION", 53, 56], ["most common", "OBSERVATION_MODIFIER", 64, 75], ["infectious", "OBSERVATION_MODIFIER", 76, 86], ["interstitial", "ANATOMY_MODIFIER", 96, 108], ["pneumonia", "OBSERVATION", 109, 118]]], ["The risk of CMV pneumonia is greatest between 30 and 90 days after bone marrow transplant.", [["bone marrow", "ANATOMY", 67, 78], ["pneumonia", "DISEASE", 16, 25], ["CMV", "ORGANISM", 12, 15], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 67, 78], ["CMV", "SPECIES", 12, 15], ["CMV pneumonia", "PROBLEM", 12, 25], ["bone marrow transplant", "TREATMENT", 67, 89], ["CMV pneumonia", "OBSERVATION", 12, 25], ["marrow", "ANATOMY", 72, 78], ["transplant", "OBSERVATION", 79, 89]]], ["However, late-onset CMV syndromes, at more than 180 days posttransplantation, have been increasingly recognized with effective control of earlieronset disease.Clinical IllnessRisk factors for the disease include advanced age, the presence of acute graft-versus-host disease, intensive conditioning regimens, and allografts.", [["graft", "ANATOMY", 248, 253], ["allografts", "ANATOMY", 312, 322], ["CMV syndromes", "DISEASE", 20, 33], ["earlieronset disease", "DISEASE", 138, 158], ["acute graft-versus-host disease", "DISEASE", 242, 273], ["CMV", "ORGANISM", 20, 23], ["graft", "TISSUE", 248, 253], ["allografts", "TISSUE", 312, 322], ["CMV", "SPECIES", 20, 23], ["late-onset CMV syndromes", "PROBLEM", 9, 33], ["earlieronset disease", "PROBLEM", 138, 158], ["the disease", "PROBLEM", 192, 203], ["advanced age", "PROBLEM", 212, 224], ["acute graft-versus-host disease", "PROBLEM", 242, 273], ["intensive conditioning regimens", "TREATMENT", 275, 306], ["allografts", "TREATMENT", 312, 322], ["late", "OBSERVATION_MODIFIER", 9, 13], ["-onset", "OBSERVATION_MODIFIER", 13, 19], ["CMV syndromes", "OBSERVATION", 20, 33], ["earlieronset disease", "OBSERVATION", 138, 158], ["acute", "OBSERVATION_MODIFIER", 242, 247], ["graft", "OBSERVATION", 248, 253], ["host disease", "OBSERVATION", 261, 273], ["allografts", "OBSERVATION", 312, 322]]], ["CMV infection and pneumonitis also develop in the majority of lung transplant recipients who are seronegative and, if infection develops in a single-lung recipient, disease is especially marked in the transplanted lung.", [["lung transplant", "ANATOMY", 62, 77], ["lung", "ANATOMY", 149, 153], ["lung", "ANATOMY", 214, 218], ["CMV infection", "DISEASE", 0, 13], ["pneumonitis", "DISEASE", 18, 29], ["infection", "DISEASE", 118, 127], ["CMV", "ORGANISM", 0, 3], ["lung", "ORGAN", 62, 66], ["recipients", "ORGANISM", 78, 88], ["lung", "ORGAN", 149, 153], ["lung", "ORGAN", 214, 218], ["CMV", "SPECIES", 0, 3], ["CMV infection", "PROBLEM", 0, 13], ["pneumonitis", "PROBLEM", 18, 29], ["lung transplant recipients", "TREATMENT", 62, 88], ["seronegative", "PROBLEM", 97, 109], ["infection", "PROBLEM", 118, 127], ["a single-lung recipient", "TREATMENT", 140, 163], ["disease", "PROBLEM", 165, 172], ["infection", "OBSERVATION", 4, 13], ["pneumonitis", "OBSERVATION", 18, 29], ["lung", "ANATOMY", 62, 66], ["transplant", "OBSERVATION", 67, 77], ["lung", "ANATOMY", 149, 153], ["recipient", "OBSERVATION", 154, 163], ["disease", "OBSERVATION", 165, 172], ["marked", "OBSERVATION_MODIFIER", 187, 193], ["transplanted", "ANATOMY_MODIFIER", 201, 213], ["lung", "ANATOMY", 214, 218]]], ["74 In these patients, CMV pneumonitis may be a factor in the development of bronchiolitis obliterans.", [["pneumonitis", "DISEASE", 26, 37], ["bronchiolitis obliterans", "DISEASE", 76, 100], ["patients", "ORGANISM", 12, 20], ["CMV", "ORGANISM", 22, 25], ["patients", "SPECIES", 12, 20], ["CMV", "SPECIES", 22, 25], ["CMV pneumonitis", "PROBLEM", 22, 37], ["bronchiolitis obliterans", "PROBLEM", 76, 100], ["CMV pneumonitis", "OBSERVATION", 22, 37], ["bronchiolitis obliterans", "OBSERVATION", 76, 100]]], ["CMV can also be a primary pathogen in persons with AIDS, although it is more often encountered in conjunction with other pulmonary pathogens 74a (see Chapter 90).", [["pulmonary", "ANATOMY", 121, 130], ["AIDS", "DISEASE", 51, 55], ["CMV", "ORGANISM", 0, 3], ["persons", "ORGANISM", 38, 45], ["pulmonary", "ORGAN", 121, 130], ["persons", "SPECIES", 38, 45], ["CMV", "SPECIES", 0, 3], ["CMV", "PROBLEM", 0, 3], ["AIDS", "PROBLEM", 51, 55], ["other pulmonary pathogens", "PROBLEM", 115, 140], ["pulmonary", "ANATOMY", 121, 130]]], ["Characteristically, patients with CMV pneumonia have sustained fever, nonproductive cough, and dyspnea.", [["CMV pneumonia", "DISEASE", 34, 47], ["fever", "DISEASE", 63, 68], ["nonproductive cough", "DISEASE", 70, 89], ["dyspnea", "DISEASE", 95, 102], ["patients", "ORGANISM", 20, 28], ["CMV", "ORGANISM", 34, 37], ["patients", "SPECIES", 20, 28], ["CMV pneumonia", "PROBLEM", 34, 47], ["sustained fever", "PROBLEM", 53, 68], ["nonproductive cough", "PROBLEM", 70, 89], ["dyspnea", "PROBLEM", 95, 102], ["CMV pneumonia", "OBSERVATION", 34, 47], ["sustained", "OBSERVATION_MODIFIER", 53, 62], ["fever", "OBSERVATION", 63, 68], ["nonproductive", "OBSERVATION_MODIFIER", 70, 83], ["cough", "OBSERVATION", 84, 89], ["dyspnea", "OBSERVATION", 95, 102]]], ["Rales and tachypnea are often present, and marked hypoxemia is an indicator of life-threatening infection.", [["tachypnea", "DISEASE", 10, 19], ["hypoxemia", "DISEASE", 50, 59], ["infection", "DISEASE", 96, 105], ["Rales", "PROBLEM", 0, 5], ["tachypnea", "PROBLEM", 10, 19], ["marked hypoxemia", "PROBLEM", 43, 59], ["life-threatening infection", "PROBLEM", 79, 105], ["tachypnea", "OBSERVATION", 10, 19], ["marked", "OBSERVATION_MODIFIER", 43, 49], ["hypoxemia", "OBSERVATION", 50, 59], ["threatening", "OBSERVATION_MODIFIER", 84, 95], ["infection", "OBSERVATION", 96, 105]]], ["Pneumonitis may be accompanied by mild neutropenia, thrombocytopenia, and elevated liver enzymes, which may be helpful in differential diagnosis.Clinical IllnessRecently, CMV reactivation has been demonstrated to play a role in critically ill, previously immunocompetent patients.", [["liver", "ANATOMY", 83, 88], ["Pneumonitis", "DISEASE", 0, 11], ["neutropenia", "DISEASE", 39, 50], ["thrombocytopenia", "DISEASE", 52, 68], ["elevated liver enzymes", "DISEASE", 74, 96], ["critically ill", "DISEASE", 228, 242], ["liver", "ORGAN", 83, 88], ["CMV", "ORGANISM", 171, 174], ["patients", "ORGANISM", 271, 279], ["liver enzymes", "PROTEIN", 83, 96], ["patients", "SPECIES", 271, 279], ["CMV", "SPECIES", 171, 174], ["Pneumonitis", "PROBLEM", 0, 11], ["mild neutropenia", "PROBLEM", 34, 50], ["thrombocytopenia", "PROBLEM", 52, 68], ["elevated liver enzymes", "PROBLEM", 74, 96], ["CMV reactivation", "PROBLEM", 171, 187], ["mild", "OBSERVATION_MODIFIER", 34, 38], ["neutropenia", "OBSERVATION", 39, 50], ["thrombocytopenia", "OBSERVATION", 52, 68], ["elevated", "OBSERVATION_MODIFIER", 74, 82], ["liver", "ANATOMY", 83, 88], ["CMV reactivation", "OBSERVATION", 171, 187]]], ["During the critical illness, some evidence suggests greater in populations with high density, leading to infection at an early age.", [["infection", "DISEASE", 105, 114], ["the critical illness", "PROBLEM", 7, 27], ["high density", "PROBLEM", 80, 92], ["infection", "PROBLEM", 105, 114], ["evidence suggests", "UNCERTAINTY", 34, 51], ["greater", "OBSERVATION_MODIFIER", 52, 59], ["high density", "OBSERVATION_MODIFIER", 80, 92], ["infection", "OBSERVATION", 105, 114]]], ["In addition to transmission by sexual intercourse, passage through a contaminated birth canal, and ingestion of breast milk, CMV infection can be acquired from transfused blood products and from transplanted organs.", [["canal", "ANATOMY", 88, 93], ["breast milk", "ANATOMY", 112, 123], ["blood", "ANATOMY", 171, 176], ["organs", "ANATOMY", 208, 214], ["breast milk", "DISEASE", 112, 123], ["CMV infection", "DISEASE", 125, 138], ["breast milk", "ORGANISM_SUBSTANCE", 112, 123], ["CMV", "ORGANISM", 125, 128], ["blood", "ORGANISM_SUBSTANCE", 171, 176], ["organs", "ORGAN", 208, 214], ["CMV", "SPECIES", 125, 128], ["a contaminated birth canal", "PROBLEM", 67, 93], ["breast milk", "TREATMENT", 112, 123], ["CMV infection", "PROBLEM", 125, 138], ["transfused blood products", "TREATMENT", 160, 185], ["breast", "ANATOMY", 112, 118], ["CMV infection", "OBSERVATION", 125, 138], ["organs", "ANATOMY", 208, 214]]], ["No seasonal patterns of CMV infection have been observed.PathogenesisIn human fibroblast cell cultures, CMV produces a slowly progressive lytic infection.", [["fibroblast cell cultures", "ANATOMY", 78, 102], ["CMV infection", "DISEASE", 24, 37], ["lytic infection", "DISEASE", 138, 153], ["CMV", "ORGANISM", 24, 27], ["human", "ORGANISM", 72, 77], ["fibroblast cell cultures", "CELL", 78, 102], ["CMV", "ORGANISM", 104, 107], ["PathogenesisIn human fibroblast cell cultures", "CELL_LINE", 57, 102], ["human", "SPECIES", 72, 77], ["CMV", "SPECIES", 24, 27], ["human", "SPECIES", 72, 77], ["CMV", "SPECIES", 104, 107], ["CMV infection", "PROBLEM", 24, 37], ["PathogenesisIn human fibroblast cell cultures", "TEST", 57, 102], ["CMV", "PROBLEM", 104, 107], ["a slowly progressive lytic infection", "PROBLEM", 117, 153], ["seasonal", "OBSERVATION_MODIFIER", 3, 11], ["patterns", "OBSERVATION_MODIFIER", 12, 20], ["CMV infection", "OBSERVATION", 24, 37], ["fibroblast cell cultures", "OBSERVATION", 78, 102], ["slowly", "OBSERVATION_MODIFIER", 119, 125], ["progressive", "OBSERVATION_MODIFIER", 126, 137], ["lytic", "OBSERVATION_MODIFIER", 138, 143], ["infection", "OBSERVATION", 144, 153]]], ["Infected cells contain large irregular basophilic intranuclear inclusions and also eosinophilic inclusions in paranuclear areas.", [["cells", "ANATOMY", 9, 14], ["basophilic intranuclear inclusions", "ANATOMY", 39, 73], ["eosinophilic inclusions", "ANATOMY", 83, 106], ["paranuclear areas", "ANATOMY", 110, 127], ["cells", "CELL", 9, 14], ["eosinophilic inclusions", "CELLULAR_COMPONENT", 83, 106], ["Infected cells", "PROBLEM", 0, 14], ["large irregular basophilic intranuclear inclusions", "PROBLEM", 23, 73], ["eosinophilic inclusions in paranuclear areas", "PROBLEM", 83, 127], ["large", "OBSERVATION_MODIFIER", 23, 28], ["irregular", "OBSERVATION_MODIFIER", 29, 38], ["basophilic intranuclear inclusions", "OBSERVATION", 39, 73], ["eosinophilic inclusions", "OBSERVATION", 83, 106], ["paranuclear areas", "OBSERVATION", 110, 127]]], ["The intranuclear inclusions are a hallmark of CMV infection and have been found in cells of a number of organs, including kidney, liver, and the GI tract, as well as the lung (Fig. 32-7) .", [["intranuclear inclusions", "ANATOMY", 4, 27], ["cells", "ANATOMY", 83, 88], ["organs", "ANATOMY", 104, 110], ["kidney", "ANATOMY", 122, 128], ["liver", "ANATOMY", 130, 135], ["GI tract", "ANATOMY", 145, 153], ["lung", "ANATOMY", 170, 174], ["CMV infection", "DISEASE", 46, 59], ["CMV", "ORGANISM", 46, 49], ["cells", "CELL", 83, 88], ["organs", "ORGAN", 104, 110], ["kidney", "ORGAN", 122, 128], ["liver", "ORGAN", 130, 135], ["GI tract", "ORGAN", 145, 153], ["lung", "ORGAN", 170, 174], ["CMV", "SPECIES", 46, 49], ["The intranuclear inclusions", "PROBLEM", 0, 27], ["CMV infection", "PROBLEM", 46, 59], ["kidney, liver, and the GI tract", "PROBLEM", 122, 153], ["intranuclear", "OBSERVATION_MODIFIER", 4, 16], ["inclusions", "OBSERVATION", 17, 27], ["hallmark", "OBSERVATION_MODIFIER", 34, 42], ["CMV infection", "OBSERVATION", 46, 59], ["organs", "ANATOMY", 104, 110], ["kidney", "ANATOMY", 122, 128], ["liver", "ANATOMY", 130, 135], ["GI tract", "ANATOMY", 145, 153], ["lung", "ANATOMY", 170, 174]]], ["In the lung, fibroblasts, epithelial cells, endothelial cells, and smooth muscle cells are all targets for CMV infection.", [["lung", "ANATOMY", 7, 11], ["fibroblasts", "ANATOMY", 13, 24], ["epithelial cells", "ANATOMY", 26, 42], ["endothelial cells", "ANATOMY", 44, 61], ["smooth muscle cells", "ANATOMY", 67, 86], ["CMV infection", "DISEASE", 107, 120], ["lung", "ORGAN", 7, 11], ["fibroblasts", "CELL", 13, 24], ["epithelial cells", "CELL", 26, 42], ["endothelial cells", "CELL", 44, 61], ["smooth muscle cells", "CELL", 67, 86], ["CMV", "ORGANISM", 107, 110], ["fibroblasts", "CELL_TYPE", 13, 24], ["epithelial cells", "CELL_TYPE", 26, 42], ["endothelial cells", "CELL_TYPE", 44, 61], ["smooth muscle cells", "CELL_TYPE", 67, 86], ["CMV", "SPECIES", 107, 110], ["epithelial cells", "PROBLEM", 26, 42], ["endothelial cells", "PROBLEM", 44, 61], ["smooth muscle cells", "PROBLEM", 67, 86], ["CMV infection", "PROBLEM", 107, 120], ["lung", "ANATOMY", 7, 11], ["fibroblasts", "ANATOMY", 13, 24], ["epithelial cells", "OBSERVATION", 26, 42], ["endothelial cells", "OBSERVATION", 44, 61], ["smooth", "OBSERVATION_MODIFIER", 67, 73], ["muscle cells", "OBSERVATION", 74, 86], ["CMV infection", "OBSERVATION", 107, 120]]], ["69 In immunocompetent persons, most infections are subclinical.", [["infections", "DISEASE", 36, 46], ["persons", "ORGANISM", 22, 29], ["persons", "SPECIES", 22, 29], ["most infections", "PROBLEM", 31, 46], ["infections", "OBSERVATION", 36, 46]]], ["If symptoms arise, the most typical manifestation is that of acute pharyngitis with features similar to mono- marrow/stem cell transplant recipients.", [["marrow", "ANATOMY", 110, 116], ["stem cell", "ANATOMY", 117, 126], ["pharyngitis", "DISEASE", 67, 78], ["stem cell", "CELL", 117, 126], ["recipients", "ORGANISM", 138, 148], ["symptoms", "PROBLEM", 3, 11], ["acute pharyngitis", "PROBLEM", 61, 78], ["mono- marrow/stem cell transplant recipients", "TREATMENT", 104, 148], ["acute", "OBSERVATION_MODIFIER", 61, 66], ["pharyngitis", "OBSERVATION", 67, 78], ["marrow", "ANATOMY", 110, 116], ["stem cell transplant", "OBSERVATION", 117, 137]]], ["The combination of ganciclovir therapy and intravenous CMV immune globulin 81 can reduce mortality from approximately 90% to 50% or lower in these patients.", [["intravenous", "ANATOMY", 43, 54], ["ganciclovir", "CHEMICAL", 19, 30], ["globulin 81", "CHEMICAL", 66, 77], ["ganciclovir", "CHEMICAL", 19, 30], ["ganciclovir", "SIMPLE_CHEMICAL", 19, 30], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 43, 54], ["CMV", "ORGANISM", 55, 58], ["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 147, 155], ["CMV", "SPECIES", 55, 58], ["ganciclovir therapy", "TREATMENT", 19, 38], ["intravenous CMV immune globulin", "TREATMENT", 43, 74], ["ganciclovir therapy", "OBSERVATION", 19, 38]]], ["The effect of the immune globulin in this situation may mostly be to ameliorate graft-versus-host disease.", [["graft", "ANATOMY", 80, 85], ["graft-versus-host disease", "DISEASE", 80, 105], ["immune globulin", "GENE_OR_GENE_PRODUCT", 18, 33], ["graft", "TISSUE", 80, 85], ["immune globulin", "PROTEIN", 18, 33], ["the immune globulin", "TREATMENT", 14, 33], ["host disease", "PROBLEM", 93, 105], ["immune globulin", "OBSERVATION", 18, 33], ["host disease", "OBSERVATION", 93, 105]]], ["Whether combination therapy is required in solid organ transplant recipients with CMV pneumonia is uncertain.", [["solid organ", "ANATOMY", 43, 54], ["CMV pneumonia", "DISEASE", 82, 95], ["organ", "ORGAN", 49, 54], ["CMV", "ORGANISM", 82, 85], ["CMV", "SPECIES", 82, 85], ["combination therapy", "TREATMENT", 8, 27], ["solid organ transplant recipients", "TREATMENT", 43, 76], ["CMV pneumonia", "PROBLEM", 82, 95], ["CMV pneumonia", "OBSERVATION", 82, 95]]], ["Cidofovir and foscarnet are other antiviral drugs with activity against CMV.", [["Cidofovir", "CHEMICAL", 0, 9], ["foscarnet", "CHEMICAL", 14, 23], ["Cidofovir", "CHEMICAL", 0, 9], ["foscarnet", "CHEMICAL", 14, 23], ["Cidofovir", "SIMPLE_CHEMICAL", 0, 9], ["foscarnet", "SIMPLE_CHEMICAL", 14, 23], ["CMV", "ORGANISM", 72, 75], ["CMV", "SPECIES", 72, 75], ["Cidofovir", "TREATMENT", 0, 9], ["foscarnet", "TREATMENT", 14, 23], ["other antiviral drugs", "TREATMENT", 28, 49], ["activity against CMV", "TREATMENT", 55, 75]]], ["Both have been used successfully to treat CMV retinitis, but their effectiveness for treating CMV pneumonia has not been established.", [["CMV retinitis", "DISEASE", 42, 55], ["CMV pneumonia", "DISEASE", 94, 107], ["CMV", "ORGANISM", 42, 45], ["CMV", "ORGANISM", 94, 97], ["CMV", "SPECIES", 42, 45], ["CMV", "SPECIES", 94, 97], ["CMV retinitis", "PROBLEM", 42, 55], ["CMV pneumonia", "PROBLEM", 94, 107], ["CMV retinitis", "OBSERVATION", 42, 55], ["pneumonia", "OBSERVATION", 98, 107]]], ["All of the available CMV antivirals have the potential for serious side effects that require close monitoring.PathogenesisGuidelines for reducing the risk of CMV disease in stem cell transplant recipients have been published.", [["stem cell", "ANATOMY", 173, 182], ["CMV disease", "DISEASE", 158, 169], ["CMV", "ORGANISM", 21, 24], ["CMV", "ORGANISM", 158, 161], ["stem cell", "CELL", 173, 182], ["recipients", "ORGANISM", 194, 204], ["CMV", "SPECIES", 21, 24], ["CMV", "SPECIES", 158, 161], ["CMV antivirals", "TREATMENT", 21, 35], ["serious side effects", "PROBLEM", 59, 79], ["close monitoring", "TEST", 93, 109], ["PathogenesisGuidelines", "TREATMENT", 110, 132], ["CMV disease", "PROBLEM", 158, 169], ["stem cell transplant recipients", "TREATMENT", 173, 204], ["CMV disease", "OBSERVATION", 158, 169], ["stem cell transplant", "OBSERVATION", 173, 193]]], ["82 Transplant candidates should be screened for evidence of CMV immunity, and CMV-seronegative recipients of allogeneic stem cell transplants from CMV-seronegative donors should receive only leukocyte-reduced or CMV-seronegative RBCs and/or leukocyte-reduced platelets.", [["stem cell", "ANATOMY", 120, 129], ["leukocyte", "ANATOMY", 191, 200], ["RBCs", "ANATOMY", 229, 233], ["leukocyte", "ANATOMY", 241, 250], ["platelets", "ANATOMY", 259, 268], ["CMV", "ORGANISM", 60, 63], ["CMV", "ORGANISM", 78, 81], ["recipients", "ORGANISM", 95, 105], ["stem cell", "CELL", 120, 129], ["CMV", "ORGANISM", 147, 150], ["donors", "ORGANISM", 164, 170], ["leukocyte", "CELL", 191, 200], ["CMV", "ORGANISM", 212, 215], ["RBCs", "CELL", 229, 233], ["leukocyte", "CELL", 241, 250], ["platelets", "CELL", 259, 268], ["seronegative RBCs", "CELL_TYPE", 216, 233], ["leukocyte-reduced platelets", "CELL_TYPE", 241, 268], ["CMV", "SPECIES", 60, 63], ["CMV", "SPECIES", 78, 81], ["CMV immunity", "PROBLEM", 60, 72], ["CMV", "PROBLEM", 78, 81], ["allogeneic stem cell transplants", "TREATMENT", 109, 141], ["CMV", "PROBLEM", 147, 150], ["seronegative donors", "PROBLEM", 151, 170], ["leukocyte", "TEST", 191, 200], ["CMV", "TEST", 212, 215], ["seronegative RBCs", "PROBLEM", 216, 233], ["leukocyte", "TEST", 241, 250], ["reduced platelets", "PROBLEM", 251, 268], ["allogeneic stem cell transplants", "OBSERVATION", 109, 141]]], ["In mismatched solid organ transplant recipients (seronegative recipient/ seropositive donor), posttransplant prophylaxis with oral ganciclovir or its prodrug valganciclovir significantly reduces the risk of CMV disease, although late-onset disease still happens.", [["solid organ", "ANATOMY", 14, 25], ["oral", "ANATOMY", 126, 130], ["ganciclovir", "CHEMICAL", 131, 142], ["valganciclovir", "CHEMICAL", 158, 172], ["CMV disease", "DISEASE", 207, 218], ["ganciclovir", "CHEMICAL", 131, 142], ["valganciclovir", "CHEMICAL", 158, 172], ["organ", "ORGAN", 20, 25], ["recipients", "ORGANISM", 37, 47], ["oral", "ORGANISM_SUBDIVISION", 126, 130], ["ganciclovir", "SIMPLE_CHEMICAL", 131, 142], ["valganciclovir", "SIMPLE_CHEMICAL", 158, 172], ["CMV", "ORGANISM", 207, 210], ["CMV", "SPECIES", 207, 210], ["mismatched solid organ transplant recipients", "TREATMENT", 3, 47], ["seronegative recipient/ seropositive donor", "TREATMENT", 49, 91], ["posttransplant prophylaxis", "TREATMENT", 94, 120], ["oral ganciclovir", "TREATMENT", 126, 142], ["its prodrug valganciclovir", "TREATMENT", 146, 172], ["CMV disease", "PROBLEM", 207, 218], ["late-onset disease", "PROBLEM", 229, 247], ["solid organ", "OBSERVATION", 14, 25], ["transplant recipients", "OBSERVATION", 26, 47], ["CMV disease", "OBSERVATION", 207, 218], ["onset", "OBSERVATION_MODIFIER", 234, 239], ["disease", "OBSERVATION", 240, 247]]], ["83 Another strategy is preemptive therapy with ganciclovir or another anti-CMV agent when screening detects infection, but before clinically detectable disease develops.", [["ganciclovir", "CHEMICAL", 47, 58], ["infection", "DISEASE", 108, 117], ["ganciclovir", "CHEMICAL", 47, 58], ["ganciclovir", "SIMPLE_CHEMICAL", 47, 58], ["preemptive therapy", "TREATMENT", 23, 41], ["ganciclovir", "TREATMENT", 47, 58], ["another anti-CMV agent", "TREATMENT", 62, 84], ["infection", "PROBLEM", 108, 117], ["clinically detectable disease", "PROBLEM", 130, 159], ["infection", "OBSERVATION", 108, 117]]], ["This strategy requires the use of rapid, sensitive, and specific laboratory tests for diagnosis.PathogenesisNo vaccines are available for the prevention of CMV infection or disease, although several strategies are being actively pursued, including live attenuated and inactivated subunit vaccines.HANTAVIRUSESHantaviruses are members of the Bunyavirus family and include a number of genetically diverse viruses.", [["CMV infection", "DISEASE", 156, 169], ["CMV", "ORGANISM", 156, 159], ["Bunyavirus", "GENE_OR_GENE_PRODUCT", 341, 351], ["Bunyavirus family", "PROTEIN", 341, 358], ["CMV", "SPECIES", 156, 159], ["specific laboratory tests", "TEST", 56, 81], ["Pathogenesis", "PROBLEM", 96, 108], ["vaccines", "TREATMENT", 111, 119], ["CMV infection", "PROBLEM", 156, 169], ["disease", "PROBLEM", 173, 180], ["inactivated subunit vaccines", "TREATMENT", 268, 296], ["infection", "OBSERVATION", 160, 169], ["viruses", "OBSERVATION", 403, 410]]], ["The hantavirus responsible for an outbreak of severe pulmonary disease in the southwestern United States, Sin Nombre virus, is roughly spherical, with a mean diameter of 112 nm.", [["pulmonary", "ANATOMY", 53, 62], ["hantavirus", "DISEASE", 4, 14], ["pulmonary disease", "DISEASE", 53, 70], ["pulmonary", "ORGAN", 53, 62], ["Sin Nombre virus", "ORGANISM", 106, 122], ["Sin Nombre virus", "SPECIES", 106, 122], ["The hantavirus", "PROBLEM", 0, 14], ["severe pulmonary disease", "PROBLEM", 46, 70], ["hantavirus", "OBSERVATION", 4, 14], ["outbreak", "OBSERVATION_MODIFIER", 34, 42], ["severe", "OBSERVATION_MODIFIER", 46, 52], ["pulmonary", "ANATOMY", 53, 62], ["disease", "OBSERVATION", 63, 70], ["roughly", "OBSERVATION_MODIFIER", 127, 134], ["spherical", "OBSERVATION_MODIFIER", 135, 144], ["mean diameter", "OBSERVATION_MODIFIER", 153, 166], ["112 nm", "OBSERVATION_MODIFIER", 170, 176]]], ["The virions contain a dense envelope, surrounded by fine surface projections.", [["virions", "ANATOMY", 4, 11], ["surface", "ANATOMY", 57, 64], ["surface projections", "CELLULAR_COMPONENT", 57, 76], ["a dense envelope", "PROBLEM", 20, 36], ["virions", "OBSERVATION", 4, 11], ["dense", "OBSERVATION_MODIFIER", 22, 27], ["envelope", "OBSERVATION_MODIFIER", 28, 36], ["fine", "OBSERVATION_MODIFIER", 52, 56], ["surface", "OBSERVATION_MODIFIER", 57, 64]]], ["Filamentous nucleocapsids are present within the virions.", [["nucleocapsids", "ANATOMY", 12, 25], ["virions", "ANATOMY", 49, 56], ["virions", "CELLULAR_COMPONENT", 49, 56], ["Filamentous nucleocapsids", "PROBLEM", 0, 25], ["nucleocapsids", "OBSERVATION", 12, 25], ["virions", "ANATOMY", 49, 56]]], ["The genome consists of negativesense single-stranded RNA arranged in three physically discrete gene segments.", [["negativesense single-stranded RNA", "RNA", 23, 56], ["physically discrete gene segments", "DNA", 75, 108], ["negativesense single-stranded RNA", "PROBLEM", 23, 56], ["segments", "ANATOMY_MODIFIER", 100, 108]]], ["The smallest segment (S) encodes the nucleoprotein, the middle-sized segment (M), the two envelope glycoproteins, G1 and G2, and the largest (L), the putative polymerase protein.", [["nucleoprotein", "PROTEIN", 37, 50], ["middle-sized segment", "PROTEIN", 56, 76], ["envelope glycoproteins", "PROTEIN", 90, 112], ["G1", "PROTEIN", 114, 116], ["G2", "PROTEIN", 121, 123], ["largest (L)", "PROTEIN", 133, 144], ["putative polymerase protein", "PROTEIN", 150, 177], ["the nucleoprotein", "TEST", 33, 50], ["the putative polymerase protein", "TEST", 146, 177], ["smallest", "OBSERVATION_MODIFIER", 4, 12], ["segment", "ANATOMY_MODIFIER", 13, 20], ["middle", "ANATOMY_MODIFIER", 56, 62], ["sized", "OBSERVATION_MODIFIER", 63, 68], ["segment", "ANATOMY_MODIFIER", 69, 76], ["envelope glycoproteins", "OBSERVATION", 90, 112], ["largest", "OBSERVATION_MODIFIER", 133, 140]]], ["84 Viral entry into the cell is mediated by a variety of cell surface integrins, 85 which may be related to the patterns of pathogenicity of the virus.", [["cell", "ANATOMY", 24, 28], ["cell surface", "ANATOMY", 57, 69], ["cell", "CELL", 24, 28], ["cell", "CELL", 57, 61], ["integrins", "GENE_OR_GENE_PRODUCT", 70, 79], ["cell surface integrins", "PROTEIN", 57, 79], ["85", "PROTEIN", 81, 83], ["cell surface integrins", "TREATMENT", 57, 79], ["the virus", "PROBLEM", 141, 150], ["cell", "OBSERVATION", 24, 28], ["variety", "OBSERVATION_MODIFIER", 46, 53], ["may be related to", "UNCERTAINTY", 90, 107], ["virus", "OBSERVATION", 145, 150]]], ["The genome is segmented, and genetic reassortments in dually infected cells are common.", [["cells", "ANATOMY", 70, 75], ["cells", "CELL", 70, 75], ["dually infected cells", "CELL_TYPE", 54, 75], ["genome", "OBSERVATION", 4, 10], ["segmented", "OBSERVATION_MODIFIER", 14, 23], ["infected cells", "OBSERVATION", 61, 75]]], ["It is believed that new pathogenic strains arise by this mechanism.Epidemiology and TransmissionThe hantavirus pulmonary syndrome (HPS) is a zoonosis in which humans experience severe, often fatal disease.", [["hantavirus pulmonary syndrome", "DISEASE", 100, 129], ["HPS", "DISEASE", 131, 134], ["zoonosis", "DISEASE", 141, 149], ["pulmonary", "ORGAN", 111, 120], ["humans", "ORGANISM", 159, 165], ["humans", "SPECIES", 159, 165], ["humans", "SPECIES", 159, 165], ["new pathogenic strains", "PROBLEM", 20, 42], ["The hantavirus pulmonary syndrome", "PROBLEM", 96, 129], ["often fatal disease", "PROBLEM", 185, 204], ["new", "OBSERVATION_MODIFIER", 20, 23], ["pathogenic", "OBSERVATION_MODIFIER", 24, 34], ["strains", "OBSERVATION", 35, 42], ["hantavirus", "OBSERVATION", 100, 110], ["pulmonary", "ANATOMY", 111, 120], ["syndrome", "OBSERVATION", 121, 129], ["fatal", "OBSERVATION_MODIFIER", 191, 196], ["disease", "OBSERVATION", 197, 204]]], ["Each of the individual hantavirus strains appears to be associated with a specific rodent host (e.g., Sin Nombre virus with the deer mouse, Bayou virus with the rice rat, Black Creek a transient and vulnerable period of \"immunoparalysis,\" making reactivation and not exogenous infection of CMV more likely.", [["immunoparalysis", "DISEASE", 221, 236], ["infection", "DISEASE", 277, 286], ["hantavirus", "ORGANISM", 23, 33], ["Sin Nombre virus", "ORGANISM", 102, 118], ["deer", "ORGANISM", 128, 132], ["mouse", "ORGANISM", 133, 138], ["Bayou virus", "ORGANISM", 140, 151], ["rice rat", "ORGANISM", 161, 169], ["CMV", "ORGANISM", 290, 293], ["rodent", "SPECIES", 83, 89], ["deer", "SPECIES", 128, 132], ["mouse", "SPECIES", 133, 138], ["rice", "SPECIES", 161, 165], ["rat", "SPECIES", 166, 169], ["Sin Nombre virus", "SPECIES", 102, 118], ["mouse", "SPECIES", 133, 138], ["Bayou virus", "SPECIES", 140, 151], ["rice", "SPECIES", 161, 165], ["CMV", "SPECIES", 290, 293], ["the individual hantavirus strains", "PROBLEM", 8, 41], ["Sin Nombre virus", "PROBLEM", 102, 118], ["\"immunoparalysis", "PROBLEM", 220, 236], ["reactivation", "PROBLEM", 246, 258], ["exogenous infection of CMV", "PROBLEM", 267, 293], ["hantavirus", "OBSERVATION", 23, 33], ["infection", "OBSERVATION", 277, 286], ["CMV", "OBSERVATION", 290, 293]]], ["In these patients, CMV viremia was found in 33% and was associated with prolonged hospitalization and death.", [["viremia", "DISEASE", 23, 30], ["death", "DISEASE", 102, 107], ["patients", "ORGANISM", 9, 17], ["CMV", "ORGANISM", 19, 22], ["patients", "SPECIES", 9, 17], ["CMV", "SPECIES", 19, 22], ["CMV viremia", "PROBLEM", 19, 30], ["death", "PROBLEM", 102, 107], ["CMV viremia", "OBSERVATION", 19, 30]]], ["75 It is currently unclear whether CMV prophylaxis would be beneficial in this setting.DiagnosisCytomegalovirus pneumonia should be in the differential diagnosis for any immunosuppressed patient with unexplained lower respiratory complaints or pulmonary opacities.", [["respiratory", "ANATOMY", 218, 229], ["pulmonary", "ANATOMY", 244, 253], ["pneumonia", "DISEASE", 112, 121], ["lower respiratory complaints", "DISEASE", 212, 240], ["pulmonary opacities", "DISEASE", 244, 263], ["CMV", "ORGANISM", 35, 38], ["patient", "ORGANISM", 187, 194], ["pulmonary", "ORGAN", 244, 253], ["patient", "SPECIES", 187, 194], ["CMV", "SPECIES", 35, 38], ["CMV prophylaxis", "TREATMENT", 35, 50], ["DiagnosisCytomegalovirus pneumonia", "PROBLEM", 87, 121], ["unexplained lower respiratory complaints", "PROBLEM", 200, 240], ["pulmonary opacities", "PROBLEM", 244, 263], ["CMV", "OBSERVATION", 35, 38], ["pneumonia", "OBSERVATION", 112, 121], ["lower", "ANATOMY_MODIFIER", 212, 217], ["respiratory", "ANATOMY", 218, 229], ["pulmonary", "ANATOMY", 244, 253], ["opacities", "OBSERVATION", 254, 263]]], ["However, the clinical assessment of patients with suspected CMV pneumonia is complicated because there are often simultaneous pulmonary infections with other microbes 76, 77 and because the clinical features and radiographic appearance of CMV pneumonia are not sufficiently characteristic to permit an accurate etiologic diagnosis.", [["pulmonary", "ANATOMY", 126, 135], ["CMV pneumonia", "DISEASE", 60, 73], ["pulmonary infections", "DISEASE", 126, 146], ["pneumonia", "DISEASE", 243, 252], ["patients", "ORGANISM", 36, 44], ["CMV", "ORGANISM", 60, 63], ["pulmonary", "ORGAN", 126, 135], ["CMV", "ORGANISM", 239, 242], ["patients", "SPECIES", 36, 44], ["CMV", "SPECIES", 60, 63], ["CMV", "SPECIES", 239, 242], ["the clinical assessment", "TEST", 9, 32], ["suspected CMV pneumonia", "PROBLEM", 50, 73], ["simultaneous pulmonary infections", "PROBLEM", 113, 146], ["other microbes", "TEST", 152, 166], ["CMV pneumonia", "PROBLEM", 239, 252], ["CMV pneumonia", "OBSERVATION", 60, 73], ["simultaneous", "OBSERVATION_MODIFIER", 113, 125], ["pulmonary", "ANATOMY", 126, 135], ["infections", "OBSERVATION", 136, 146], ["CMV pneumonia", "OBSERVATION", 239, 252]]], ["In addition, noninfectious pulmonary conditions are also common in the population at risk for CMV pneumonitis, including pulmonary malignancy or hemorrhage and posttransplant lymphoproliferative disorder (see eFigs.", [["pulmonary", "ANATOMY", 27, 36], ["pulmonary malignancy", "ANATOMY", 121, 141], ["noninfectious pulmonary conditions", "DISEASE", 13, 47], ["pneumonitis", "DISEASE", 98, 109], ["pulmonary malignancy", "DISEASE", 121, 141], ["hemorrhage", "DISEASE", 145, 155], ["lymphoproliferative disorder", "DISEASE", 175, 203], ["pulmonary", "ORGAN", 27, 36], ["CMV", "ORGANISM", 94, 97], ["pulmonary", "ORGAN", 121, 130], ["CMV", "SPECIES", 94, 97], ["noninfectious pulmonary conditions", "PROBLEM", 13, 47], ["CMV pneumonitis", "PROBLEM", 94, 109], ["pulmonary malignancy", "PROBLEM", 121, 141], ["hemorrhage", "PROBLEM", 145, 155], ["posttransplant lymphoproliferative disorder", "PROBLEM", 160, 203], ["noninfectious", "OBSERVATION_MODIFIER", 13, 26], ["pulmonary", "ANATOMY", 27, 36], ["conditions", "OBSERVATION", 37, 47], ["CMV pneumonitis", "OBSERVATION", 94, 109], ["pulmonary", "ANATOMY", 121, 130], ["malignancy", "OBSERVATION", 131, 141], ["hemorrhage", "OBSERVATION", 145, 155], ["posttransplant lymphoproliferative", "OBSERVATION", 160, 194]]], ["91-16 and 91-17) .DiagnosisChest radiographic changes (see eFig.", [["DiagnosisChest radiographic changes", "PROBLEM", 18, 53]]], ["91-5A) are usually bilateral, with diffuse or focal haziness involving the mid and lower lung fields.", [["lower lung", "ANATOMY", 83, 93], ["lung", "ORGAN", 89, 93], ["diffuse or focal haziness involving the mid and lower lung fields", "PROBLEM", 35, 100], ["bilateral", "ANATOMY_MODIFIER", 19, 28], ["diffuse", "OBSERVATION_MODIFIER", 35, 42], ["focal", "OBSERVATION_MODIFIER", 46, 51], ["haziness", "OBSERVATION", 52, 60], ["mid", "ANATOMY_MODIFIER", 75, 78], ["lower", "ANATOMY_MODIFIER", 83, 88], ["lung", "ANATOMY", 89, 93], ["fields", "ANATOMY_MODIFIER", 94, 100]]], ["Both miliary and interstitial radiographic patterns have been described.", [["interstitial", "ANATOMY", 17, 29], ["miliary", "DISEASE", 5, 12], ["Both miliary and interstitial radiographic patterns", "PROBLEM", 0, 51], ["miliary", "OBSERVATION", 5, 12], ["interstitial", "ANATOMY_MODIFIER", 17, 29], ["radiographic patterns", "OBSERVATION", 30, 51]]], ["Patients with a miliary pattern may have a sudden onset of tachypnea, severe respiratory distress, and hypoxemia resulting in a rapidly fatal course, 78 whereas patients with an interstitial pattern of disease often have an insidious onset of pneumonia with slowly progressive hypoxemia.", [["respiratory", "ANATOMY", 77, 88], ["interstitial", "ANATOMY", 178, 190], ["tachypnea", "DISEASE", 59, 68], ["respiratory distress", "DISEASE", 77, 97], ["hypoxemia", "DISEASE", 103, 112], ["pneumonia", "DISEASE", 243, 252], ["hypoxemia", "DISEASE", 277, 286], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 161, 169], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 161, 169], ["a miliary pattern", "PROBLEM", 14, 31], ["tachypnea", "PROBLEM", 59, 68], ["severe respiratory distress", "PROBLEM", 70, 97], ["hypoxemia", "PROBLEM", 103, 112], ["an interstitial pattern of disease", "PROBLEM", 175, 209], ["pneumonia", "PROBLEM", 243, 252], ["slowly progressive hypoxemia", "PROBLEM", 258, 286], ["tachypnea", "OBSERVATION", 59, 68], ["severe", "OBSERVATION_MODIFIER", 70, 76], ["respiratory distress", "OBSERVATION", 77, 97], ["hypoxemia", "OBSERVATION", 103, 112], ["interstitial", "OBSERVATION", 178, 190], ["disease", "OBSERVATION", 202, 209], ["insidious", "OBSERVATION_MODIFIER", 224, 233], ["pneumonia", "OBSERVATION", 243, 252], ["slowly", "OBSERVATION_MODIFIER", 258, 264], ["progressive", "OBSERVATION_MODIFIER", 265, 276], ["hypoxemia", "OBSERVATION", 277, 286]]], ["In these patients, pulmonary opacities may be initially localized, with bilateral spread over days or weeks.", [["pulmonary opacities", "ANATOMY", 19, 38], ["pulmonary opacities", "DISEASE", 19, 38], ["patients", "ORGANISM", 9, 17], ["pulmonary", "ORGAN", 19, 28], ["patients", "SPECIES", 9, 17], ["pulmonary opacities", "PROBLEM", 19, 38], ["pulmonary", "ANATOMY", 19, 28], ["opacities", "OBSERVATION", 29, 38], ["bilateral", "ANATOMY_MODIFIER", 72, 81], ["spread", "OBSERVATION_MODIFIER", 82, 88]]], ["Often the perihilar distribution of the opacity is suggestive of pulmonary edema.", [["perihilar", "ANATOMY", 10, 19], ["pulmonary", "ANATOMY", 65, 74], ["opacity", "DISEASE", 40, 47], ["pulmonary edema", "DISEASE", 65, 80], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 65, 80], ["the opacity", "PROBLEM", 36, 47], ["pulmonary edema", "PROBLEM", 65, 80], ["perihilar", "ANATOMY_MODIFIER", 10, 19], ["opacity", "OBSERVATION", 40, 47], ["suggestive of", "UNCERTAINTY", 51, 64], ["pulmonary", "ANATOMY", 65, 74], ["edema", "OBSERVATION", 75, 80]]], ["74 Common chest CT scan findings include small nodules (see eFigs.", [["nodules", "ANATOMY", 47, 54], ["nodules", "CANCER", 47, 54], ["Common chest CT scan findings", "TEST", 3, 32], ["small nodules", "PROBLEM", 41, 54], ["eFigs", "TEST", 60, 65], ["chest", "ANATOMY", 10, 15], ["small", "OBSERVATION_MODIFIER", 41, 46], ["nodules", "OBSERVATION", 47, 54]]], ["91-3B, 91-4, 91-5), consolidation (see eFig. , and ground-glass attenuation (see eFigs.", [["consolidation", "PROBLEM", 20, 33], ["ground-glass attenuation", "PROBLEM", 51, 75], ["consolidation", "OBSERVATION", 20, 33], ["ground", "OBSERVATION_MODIFIER", 51, 57], ["glass attenuation", "OBSERVATION", 58, 75]]], ["79 In patients with possible CMV pneumonia, the preferred approach to diagnosis is quantitative PCR in serum or bronchoalveolar lavage (BAL) fluid.", [["serum", "ANATOMY", 103, 108], ["bronchoalveolar lavage (BAL) fluid", "ANATOMY", 112, 146], ["CMV pneumonia", "DISEASE", 29, 42], ["patients", "ORGANISM", 6, 14], ["CMV", "ORGANISM", 29, 32], ["serum", "ORGANISM_SUBSTANCE", 103, 108], ["bronchoalveolar lavage", "ORGANISM_SUBSTANCE", 112, 134], ["fluid", "ORGANISM_SUBSTANCE", 141, 146], ["patients", "SPECIES", 6, 14], ["CMV", "SPECIES", 29, 32], ["CMV pneumonia", "PROBLEM", 29, 42], ["quantitative PCR", "TEST", 83, 99], ["serum", "TEST", 103, 108], ["bronchoalveolar lavage (BAL) fluid", "TEST", 112, 146], ["possible", "UNCERTAINTY", 20, 28], ["CMV", "OBSERVATION_MODIFIER", 29, 32], ["pneumonia", "OBSERVATION", 33, 42], ["bronchoalveolar lavage", "OBSERVATION", 112, 134]]], ["80 Culture and pathologic examination of specimens obtained by BAL and transbronchial biopsy may also be diagnostic, although these specimens are less suitable for making management decisions in acutely ill patients.", [["specimens", "ANATOMY", 41, 50], ["BAL", "ANATOMY", 63, 66], ["specimens", "ANATOMY", 132, 141], ["acutely ill", "DISEASE", 195, 206], ["specimens", "CANCER", 41, 50], ["BAL", "CELL", 63, 66], ["transbronchial biopsy", "MULTI-TISSUE_STRUCTURE", 71, 92], ["specimens", "CANCER", 132, 141], ["patients", "ORGANISM", 207, 215], ["patients", "SPECIES", 207, 215], ["Culture", "TEST", 3, 10], ["pathologic examination of specimens", "TEST", 15, 50], ["BAL", "TEST", 63, 66], ["transbronchial biopsy", "TEST", 71, 92], ["these specimens", "TEST", 126, 141], ["transbronchial", "ANATOMY", 71, 85]]], ["The detection of virus in respiratory secretions, urine, or blood does not establish with certainty that CMV is responsible for a particular clinical syndrome.", [["respiratory secretions", "ANATOMY", 26, 48], ["urine", "ANATOMY", 50, 55], ["blood", "ANATOMY", 60, 65], ["secretions", "ORGANISM_SUBSTANCE", 38, 48], ["urine", "ORGANISM_SUBSTANCE", 50, 55], ["blood", "ORGANISM_SUBSTANCE", 60, 65], ["CMV", "ORGANISM", 105, 108], ["CMV", "SPECIES", 105, 108], ["virus in respiratory secretions", "PROBLEM", 17, 48], ["blood", "PROBLEM", 60, 65], ["CMV", "PROBLEM", 105, 108], ["a particular clinical syndrome", "PROBLEM", 128, 158], ["virus", "OBSERVATION", 17, 22], ["respiratory secretions", "OBSERVATION", 26, 48], ["CMV", "OBSERVATION", 105, 108]]], ["This is particularly true in patients with AIDS, in whom detection of CMV in BAL is often not associated with pulmonary pathology.", [["BAL", "ANATOMY", 77, 80], ["pulmonary", "ANATOMY", 110, 119], ["AIDS", "DISEASE", 43, 47], ["patients", "ORGANISM", 29, 37], ["CMV", "ORGANISM", 70, 73], ["BAL", "MULTI-TISSUE_STRUCTURE", 77, 80], ["pulmonary", "ORGAN", 110, 119], ["patients", "SPECIES", 29, 37], ["CMV", "SPECIES", 70, 73], ["AIDS", "PROBLEM", 43, 47], ["CMV in BAL", "PROBLEM", 70, 80], ["pulmonary pathology", "PROBLEM", 110, 129], ["CMV", "OBSERVATION", 70, 73], ["often not associated with", "UNCERTAINTY", 84, 109], ["pulmonary", "ANATOMY", 110, 119], ["pathology", "OBSERVATION", 120, 129]]], ["However, in transplant recipients, the presence of CMV in blood does increase the risk of subsequent development of CMV pneumonia and is used in guiding preemptive therapy.", [["blood", "ANATOMY", 58, 63], ["CMV pneumonia", "DISEASE", 116, 129], ["recipients", "ORGANISM", 23, 33], ["CMV", "ORGANISM", 51, 54], ["blood", "ORGANISM_SUBSTANCE", 58, 63], ["CMV", "ORGANISM", 116, 119], ["CMV", "SPECIES", 51, 54], ["CMV", "SPECIES", 116, 119], ["CMV in blood", "PROBLEM", 51, 63], ["CMV pneumonia", "PROBLEM", 116, 129], ["preemptive therapy", "TREATMENT", 153, 171], ["CMV", "OBSERVATION", 51, 54], ["CMV pneumonia", "OBSERVATION", 116, 129]]], ["Serologic testing has no role in diagnosis of acute infection and is used only to determine the serologic status of donors and recipients before transplantation.Treatment and PreventionOnce CMV pneumonitis is established, particularly in allogeneic bone marrow transplant patients, poor outcomes are common.", [["bone marrow", "ANATOMY", 249, 260], ["acute infection", "DISEASE", 46, 61], ["pneumonitis", "DISEASE", 194, 205], ["donors", "ORGANISM", 116, 122], ["recipients", "ORGANISM", 127, 137], ["CMV", "ORGANISM", 190, 193], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 249, 260], ["patients", "ORGANISM", 272, 280], ["patients", "SPECIES", 272, 280], ["CMV", "SPECIES", 190, 193], ["Serologic testing", "TEST", 0, 17], ["acute infection", "PROBLEM", 46, 61], ["transplantation", "TREATMENT", 145, 160], ["Treatment", "TREATMENT", 161, 170], ["PreventionOnce CMV pneumonitis", "PROBLEM", 175, 205], ["allogeneic bone marrow transplant", "TREATMENT", 238, 271], ["no role", "UNCERTAINTY", 22, 29], ["acute", "OBSERVATION_MODIFIER", 46, 51], ["infection", "OBSERVATION", 52, 61], ["CMV pneumonitis", "OBSERVATION", 190, 205]]], ["Ganciclovir is highly active against CMV in vitro, but monotherapy is not effective in pneumonitis in bone period of several days, the patient presents with a mild, nonproductive cough and progressive dyspnea resulting from leakage of high-protein edema fluid into the alveoli.", [["bone", "ANATOMY", 102, 106], ["alveoli", "ANATOMY", 269, 276], ["Ganciclovir", "CHEMICAL", 0, 11], ["pneumonitis", "DISEASE", 87, 98], ["cough", "DISEASE", 179, 184], ["dyspnea", "DISEASE", 201, 208], ["edema", "DISEASE", 248, 253], ["Ganciclovir", "CHEMICAL", 0, 11], ["Ganciclovir", "SIMPLE_CHEMICAL", 0, 11], ["CMV", "ORGANISM", 37, 40], ["bone", "TISSUE", 102, 106], ["patient", "ORGANISM", 135, 142], ["alveoli", "MULTI-TISSUE_STRUCTURE", 269, 276], ["patient", "SPECIES", 135, 142], ["CMV", "SPECIES", 37, 40], ["Ganciclovir", "TREATMENT", 0, 11], ["CMV in vitro", "TREATMENT", 37, 49], ["monotherapy", "TREATMENT", 55, 66], ["pneumonitis", "PROBLEM", 87, 98], ["a mild, nonproductive cough", "PROBLEM", 157, 184], ["progressive dyspnea", "PROBLEM", 189, 208], ["leakage of high-protein edema fluid into the alveoli", "PROBLEM", 224, 276], ["active", "OBSERVATION_MODIFIER", 22, 28], ["not effective", "UNCERTAINTY", 70, 83], ["pneumonitis", "OBSERVATION", 87, 98], ["bone", "ANATOMY", 102, 106], ["mild", "OBSERVATION_MODIFIER", 159, 163], ["nonproductive", "OBSERVATION_MODIFIER", 165, 178], ["cough", "OBSERVATION", 179, 184], ["progressive", "OBSERVATION_MODIFIER", 189, 200], ["dyspnea", "OBSERVATION", 201, 208], ["leakage", "OBSERVATION_MODIFIER", 224, 231], ["high-protein", "OBSERVATION", 235, 247], ["edema fluid", "OBSERVATION", 248, 259], ["alveoli", "ANATOMY", 269, 276]]], ["On physical examination patients are febrile, with tachypnea and tachycardia with mild hypotension.", [["febrile", "DISEASE", 37, 44], ["tachypnea", "DISEASE", 51, 60], ["tachycardia", "DISEASE", 65, 76], ["hypotension", "DISEASE", 87, 98], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["physical examination", "TEST", 3, 23], ["febrile", "PROBLEM", 37, 44], ["tachypnea", "PROBLEM", 51, 60], ["tachycardia", "PROBLEM", 65, 76], ["mild hypotension", "PROBLEM", 82, 98], ["febrile", "OBSERVATION", 37, 44], ["mild", "OBSERVATION_MODIFIER", 82, 86], ["hypotension", "OBSERVATION", 87, 98]]], ["Examination of the chest may reveal fine crackles but is otherwise unremarkable.Treatment and PreventionLaboratory studies generally reveal hemoconcentration, mild thrombocytopenia, and mildly elevated liver function tests.", [["chest", "ANATOMY", 19, 24], ["liver", "ANATOMY", 202, 207], ["hemoconcentration", "DISEASE", 140, 157], ["thrombocytopenia", "DISEASE", 164, 180], ["elevated liver function", "DISEASE", 193, 216], ["chest", "ORGAN", 19, 24], ["liver", "ORGAN", 202, 207], ["Examination of the chest", "TEST", 0, 24], ["fine crackles", "PROBLEM", 36, 49], ["Treatment", "TREATMENT", 80, 89], ["PreventionLaboratory studies", "TEST", 94, 122], ["hemoconcentration", "PROBLEM", 140, 157], ["mild thrombocytopenia", "PROBLEM", 159, 180], ["mildly elevated liver function tests", "PROBLEM", 186, 222], ["chest", "ANATOMY", 19, 24], ["fine", "OBSERVATION_MODIFIER", 36, 40], ["crackles", "OBSERVATION", 41, 49], ["otherwise", "OBSERVATION_MODIFIER", 57, 66], ["unremarkable", "OBSERVATION", 67, 79], ["hemoconcentration", "OBSERVATION", 140, 157], ["mild", "OBSERVATION_MODIFIER", 159, 163], ["thrombocytopenia", "OBSERVATION", 164, 180], ["mildly", "OBSERVATION_MODIFIER", 186, 192], ["elevated", "OBSERVATION", 193, 201], ["liver", "ANATOMY", 202, 207]]], ["The triad of thrombocytopenia, left shift with circulating myeloblasts, and circulating immunoblasts is highly suggestive of HPS.", [["myeloblasts", "ANATOMY", 59, 70], ["immunoblasts", "ANATOMY", 88, 100], ["thrombocytopenia", "DISEASE", 13, 29], ["HPS", "DISEASE", 125, 128], ["myeloblasts", "CELL", 59, 70], ["circulating myeloblasts", "CELL_TYPE", 47, 70], ["thrombocytopenia", "PROBLEM", 13, 29], ["left shift", "PROBLEM", 31, 41], ["circulating myeloblasts", "PROBLEM", 47, 70], ["circulating immunoblasts", "PROBLEM", 76, 100], ["HPS", "PROBLEM", 125, 128], ["thrombocytopenia", "OBSERVATION", 13, 29], ["left", "ANATOMY_MODIFIER", 31, 35], ["circulating myeloblasts", "OBSERVATION", 47, 70], ["circulating immunoblasts", "OBSERVATION", 76, 100], ["highly suggestive of", "UNCERTAINTY", 104, 124], ["HPS", "OBSERVATION", 125, 128]]], ["101 Multivariate analysis has identified dizziness, nausea, and the absence of cough as clinical symptoms predictive of HPS, as well as thrombocytopenia, elevated hematocrit, and decreased serum bicarbonate as features that help distinguish HPS from other causes of acute respiratory distress such as pneumococcal pneumonia and influenza.", [["serum", "ANATOMY", 189, 194], ["respiratory", "ANATOMY", 272, 283], ["dizziness", "DISEASE", 41, 50], ["nausea", "DISEASE", 52, 58], ["cough", "DISEASE", 79, 84], ["HPS", "DISEASE", 120, 123], ["thrombocytopenia", "DISEASE", 136, 152], ["bicarbonate", "CHEMICAL", 195, 206], ["HPS", "DISEASE", 241, 244], ["respiratory distress", "DISEASE", 272, 292], ["pneumococcal pneumonia", "DISEASE", 301, 323], ["influenza", "DISEASE", 328, 337], ["bicarbonate", "CHEMICAL", 195, 206], ["serum", "ORGANISM_SUBSTANCE", 189, 194], ["bicarbonate", "SIMPLE_CHEMICAL", 195, 206], ["pneumococcal", "SPECIES", 301, 313], ["Multivariate analysis", "TEST", 4, 25], ["dizziness", "PROBLEM", 41, 50], ["nausea", "PROBLEM", 52, 58], ["cough", "PROBLEM", 79, 84], ["clinical symptoms", "PROBLEM", 88, 105], ["HPS", "PROBLEM", 120, 123], ["thrombocytopenia", "PROBLEM", 136, 152], ["elevated hematocrit", "PROBLEM", 154, 173], ["decreased serum bicarbonate", "PROBLEM", 179, 206], ["HPS", "PROBLEM", 241, 244], ["acute respiratory distress", "PROBLEM", 266, 292], ["pneumococcal pneumonia", "PROBLEM", 301, 323], ["influenza", "PROBLEM", 328, 337], ["dizziness", "OBSERVATION", 41, 50], ["thrombocytopenia", "OBSERVATION", 136, 152], ["elevated", "OBSERVATION_MODIFIER", 154, 162], ["hematocrit", "OBSERVATION_MODIFIER", 163, 173], ["acute", "OBSERVATION_MODIFIER", 266, 271], ["respiratory distress", "OBSERVATION", 272, 292], ["pneumococcal", "OBSERVATION_MODIFIER", 301, 313], ["pneumonia", "OBSERVATION", 314, 323], ["influenza", "OBSERVATION", 328, 337]]], ["102 Mild renal abnormalities may be detected but, unlike the situation with another hantaviral illness, hemorrhagic fever with renal syndrome, do not progress to renal failure.", [["renal", "ANATOMY", 9, 14], ["renal", "ANATOMY", 127, 132], ["renal", "ANATOMY", 162, 167], ["renal abnormalities", "DISEASE", 9, 28], ["hantaviral illness", "DISEASE", 84, 102], ["hemorrhagic fever", "DISEASE", 104, 121], ["renal syndrome", "DISEASE", 127, 141], ["renal failure", "DISEASE", 162, 175], ["renal", "ORGAN", 9, 14], ["renal", "ORGAN", 127, 132], ["renal", "ORGAN", 162, 167], ["Mild renal abnormalities", "PROBLEM", 4, 28], ["another hantaviral illness", "PROBLEM", 76, 102], ["hemorrhagic fever", "PROBLEM", 104, 121], ["renal syndrome", "PROBLEM", 127, 141], ["renal failure", "PROBLEM", 162, 175], ["renal", "ANATOMY", 9, 14], ["abnormalities", "OBSERVATION", 15, 28], ["hemorrhagic", "OBSERVATION_MODIFIER", 104, 115], ["fever", "OBSERVATION", 116, 121], ["renal", "ANATOMY", 127, 132], ["syndrome", "OBSERVATION", 133, 141], ["renal", "ANATOMY", 162, 167], ["failure", "OBSERVATION", 168, 175]]], ["Renal dysfunction may be more common in HPS associated with the Bayou hantavirus.", [["Renal", "ANATOMY", 0, 5], ["Renal dysfunction", "DISEASE", 0, 17], ["HPS", "DISEASE", 40, 43], ["hantavirus", "DISEASE", 70, 80], ["Renal", "ORGAN", 0, 5], ["Bayou hantavirus", "SPECIES", 64, 80], ["Renal dysfunction", "PROBLEM", 0, 17], ["HPS", "PROBLEM", 40, 43], ["the Bayou hantavirus", "PROBLEM", 60, 80], ["dysfunction", "OBSERVATION", 6, 17], ["may be", "UNCERTAINTY", 18, 24], ["more common", "OBSERVATION_MODIFIER", 25, 36], ["hantavirus", "OBSERVATION", 70, 80]]], ["103 Pleural effusions are present in most cases.", [["Pleural effusions", "ANATOMY", 4, 21], ["Pleural effusions", "DISEASE", 4, 21], ["Pleural effusions", "CANCER", 4, 21], ["Pleural effusions", "PROBLEM", 4, 21], ["Pleural", "ANATOMY", 4, 11], ["effusions", "OBSERVATION", 12, 21]]], ["Early in the course of HPS, these effusions are transudative, while later they develop higher fluid protein content and in severe cases have the protein characteristics of plasma.", [["effusions", "ANATOMY", 34, 43], ["fluid", "ANATOMY", 94, 99], ["plasma", "ANATOMY", 172, 178], ["HPS", "DISEASE", 23, 26], ["effusions", "DISEASE", 34, 43], ["plasma", "ORGANISM_SUBSTANCE", 172, 178], ["HPS", "PROBLEM", 23, 26], ["these effusions", "PROBLEM", 28, 43], ["transudative", "PROBLEM", 48, 60], ["higher fluid protein content", "PROBLEM", 87, 115], ["effusions", "OBSERVATION", 34, 43], ["transudative", "OBSERVATION", 48, 60], ["higher", "OBSERVATION_MODIFIER", 87, 93], ["fluid protein content", "OBSERVATION", 94, 115], ["severe", "OBSERVATION_MODIFIER", 123, 129]]], ["104 Cardiopulmonary manifestations in severe cases include a shock state with low cardiac index, low stroke volume index, and high systemic vascular resistance.", [["Cardiopulmonary", "ANATOMY", 4, 19], ["cardiac", "ANATOMY", 82, 89], ["vascular", "ANATOMY", 140, 148], ["shock", "DISEASE", 61, 66], ["low cardiac index", "DISEASE", 78, 95], ["stroke", "DISEASE", 101, 107], ["cardiac", "ORGAN", 82, 89], ["vascular", "MULTI-TISSUE_STRUCTURE", 140, 148], ["Cardiopulmonary manifestations in severe cases", "PROBLEM", 4, 50], ["a shock state", "PROBLEM", 59, 72], ["low cardiac index", "PROBLEM", 78, 95], ["low stroke volume index", "PROBLEM", 97, 120], ["high systemic vascular resistance", "PROBLEM", 126, 159], ["severe", "OBSERVATION_MODIFIER", 38, 44], ["shock", "OBSERVATION", 61, 66], ["low stroke", "OBSERVATION", 97, 107], ["volume index", "OBSERVATION", 108, 120], ["high", "OBSERVATION_MODIFIER", 126, 130], ["systemic vascular resistance", "OBSERVATION", 131, 159]]], ["104 Progression is associated with worsening cardiac dysfunction and development of lactic acidosis.", [["cardiac", "ANATOMY", 45, 52], ["cardiac dysfunction", "DISEASE", 45, 64], ["lactic acidosis", "DISEASE", 84, 99], ["cardiac", "ORGAN", 45, 52], ["worsening cardiac dysfunction", "PROBLEM", 35, 64], ["lactic acidosis", "PROBLEM", 84, 99], ["associated with", "UNCERTAINTY", 19, 34], ["worsening", "OBSERVATION_MODIFIER", 35, 44], ["cardiac", "ANATOMY", 45, 52], ["dysfunction", "OBSERVATION", 53, 64], ["lactic acidosis", "OBSERVATION", 84, 99]]], ["In those patients who survive, exertional dyspnea and reduced expiratory flow are common in early convalescence and resolve in most patients.", [["dyspnea", "DISEASE", 42, 49], ["patients", "ORGANISM", 9, 17], ["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 9, 17], ["patients", "SPECIES", 132, 140], ["exertional dyspnea", "PROBLEM", 31, 49], ["reduced expiratory flow", "PROBLEM", 54, 77], ["exertional", "OBSERVATION_MODIFIER", 31, 41], ["dyspnea", "OBSERVATION", 42, 49], ["reduced", "OBSERVATION_MODIFIER", 54, 61], ["expiratory flow", "OBSERVATION", 62, 77], ["early", "OBSERVATION_MODIFIER", 92, 97], ["convalescence", "OBSERVATION", 98, 111]]], ["105 However, some patients have manifested long-term pulmonary and cognitive dysfunction.", [["pulmonary", "ANATOMY", 53, 62], ["pulmonary and cognitive dysfunction", "DISEASE", 53, 88], ["patients", "ORGANISM", 18, 26], ["pulmonary", "ORGAN", 53, 62], ["patients", "SPECIES", 18, 26], ["long-term pulmonary and cognitive dysfunction", "PROBLEM", 43, 88], ["long-term", "OBSERVATION_MODIFIER", 43, 52], ["pulmonary", "ANATOMY", 53, 62], ["cognitive dysfunction", "OBSERVATION", 67, 88]]], ["106DiagnosisChest radiographs are typical of pulmonary edema, without consolidation.", [["pulmonary", "ANATOMY", 45, 54], ["pulmonary edema", "DISEASE", 45, 60], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 45, 60], ["Chest radiographs", "TEST", 12, 29], ["pulmonary edema", "PROBLEM", 45, 60], ["consolidation", "PROBLEM", 70, 83], ["typical of", "UNCERTAINTY", 34, 44], ["pulmonary", "ANATOMY", 45, 54], ["edema", "OBSERVATION", 55, 60], ["without", "UNCERTAINTY", 62, 69], ["consolidation", "OBSERVATION", 70, 83]]], ["In the absence of immunodeficiency, patients universally have detectable serum immunoglobulin M (IgM) and IgG antibody at the time of admission, and serologic techniques are the mainstay of diagnosis.", [["serum", "ANATOMY", 73, 78], ["immunodeficiency", "DISEASE", 18, 34], ["patients", "ORGANISM", 36, 44], ["serum", "ORGANISM_SUBSTANCE", 73, 78], ["immunoglobulin M", "GENE_OR_GENE_PRODUCT", 79, 95], ["IgM", "GENE_OR_GENE_PRODUCT", 97, 100], ["IgG antibody", "GENE_OR_GENE_PRODUCT", 106, 118], ["serum immunoglobulin M", "PROTEIN", 73, 95], ["IgM", "PROTEIN", 97, 100], ["IgG antibody", "PROTEIN", 106, 118], ["patients", "SPECIES", 36, 44], ["immunodeficiency", "PROBLEM", 18, 34], ["serum immunoglobulin M", "TEST", 73, 95], ["IgM", "TEST", 97, 100], ["IgG antibody", "TEST", 106, 118], ["serologic techniques", "TEST", 149, 169], ["immunodeficiency", "OBSERVATION", 18, 34]]], ["In low-prevalence areas, a positive IgM is diagnostic.", [["IgM", "GENE_OR_GENE_PRODUCT", 36, 39], ["IgM", "PROTEIN", 36, 39], ["low", "OBSERVATION_MODIFIER", 3, 6], ["-prevalence", "OBSERVATION_MODIFIER", 6, 17], ["IgM", "OBSERVATION", 36, 39]]], ["107 Virus can also be detected in blood by reverse transcriptase polymerase chain reaction (RT-PCR) during the first 10 days of illness.", [["blood", "ANATOMY", 34, 39], ["Virus", "ORGANISM", 4, 9], ["blood", "ORGANISM_SUBSTANCE", 34, 39], ["reverse transcriptase", "PROTEIN", 43, 64], ["Virus", "PROBLEM", 4, 9], ["blood", "TEST", 34, 39], ["reverse transcriptase polymerase chain reaction", "PROBLEM", 43, 90], ["RT-PCR", "TEST", 92, 98], ["illness", "PROBLEM", 128, 135], ["Virus", "OBSERVATION", 4, 9]]], ["108 In contrast, hantaviruses are difficult to isolate from clinical material in cell culture and grow slowly.", [["cell culture", "ANATOMY", 81, 93], ["cell", "CELL", 81, 85], ["hantaviruses", "PROBLEM", 17, 29], ["clinical material in cell culture", "TEST", 60, 93], ["hantaviruses", "OBSERVATION", 17, 29]]], ["Isolation of virus from tissue is laborious and time consuming and must be undertaken in suitable containment facilities, so it is not useful for diagnosis.Treatment and PreventionTreatment is supportive and requires careful management of fluid status to maintain perfusion without exacerbating pulmonary edema.", [["tissue", "ANATOMY", 24, 30], ["fluid", "ANATOMY", 239, 244], ["pulmonary", "ANATOMY", 295, 304], ["pulmonary edema", "DISEASE", 295, 310], ["tissue", "TISSUE", 24, 30], ["fluid", "ORGANISM_SUBSTANCE", 239, 244], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 295, 310], ["virus", "PROBLEM", 13, 18], ["Treatment", "TREATMENT", 156, 165], ["careful management", "TREATMENT", 217, 235], ["fluid status", "TEST", 239, 251], ["exacerbating pulmonary edema", "PROBLEM", 282, 310], ["virus", "OBSERVATION", 13, 18], ["without", "UNCERTAINTY", 274, 281], ["exacerbating", "OBSERVATION_MODIFIER", 282, 294], ["pulmonary", "ANATOMY", 295, 304], ["edema", "OBSERVATION", 305, 310]]], ["It has been suggested that high-dose steroid therapy may be useful 96 because of the pathogenesis of the disease and potential utility of steroids in systemic capillary leak syndrome.", [["capillary", "ANATOMY", 159, 168], ["steroid", "CHEMICAL", 37, 44], ["steroids", "CHEMICAL", 138, 146], ["capillary leak syndrome", "DISEASE", 159, 182], ["steroid", "CHEMICAL", 37, 44], ["steroids", "CHEMICAL", 138, 146], ["steroid", "SIMPLE_CHEMICAL", 37, 44], ["steroids", "SIMPLE_CHEMICAL", 138, 146], ["capillary", "PATHOLOGICAL_FORMATION", 159, 168], ["high-dose steroid therapy", "TREATMENT", 27, 52], ["the disease", "PROBLEM", 101, 112], ["steroids", "TREATMENT", 138, 146], ["systemic capillary leak syndrome", "PROBLEM", 150, 182], ["disease", "OBSERVATION", 105, 112], ["systemic", "OBSERVATION_MODIFIER", 150, 158], ["capillary leak", "OBSERVATION", 159, 173], ["syndrome", "OBSERVATION", 174, 182]]], ["In severe cases, extracorporeal membrane oxygenation may be beneficial.", [["extracorporeal membrane", "ANATOMY", 17, 40], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 17, 40], ["extracorporeal membrane oxygenation", "TREATMENT", 17, 52], ["severe", "OBSERVATION_MODIFIER", 3, 9], ["extracorporeal membrane oxygenation", "OBSERVATION", 17, 52]]], ["109, 110 The broad-spectrum antiviral agent ribavirin is active against hantavirus in vitro and was demonstrated to be effective against hantavirus-induced hemorrhagic fever with renal Canal virus (BCCV) with the cotton rat, and New York virus with the white-footed mouse).", [["renal", "ANATOMY", 179, 184], ["ribavirin", "CHEMICAL", 44, 53], ["hantavirus", "DISEASE", 72, 82], ["hantavirus-induced hemorrhagic fever", "DISEASE", 137, 173], ["ribavirin", "CHEMICAL", 44, 53], ["ribavirin", "SIMPLE_CHEMICAL", 44, 53], ["hantavirus", "ORGANISM", 72, 82], ["hantavirus", "ORGANISM", 137, 147], ["renal Canal virus", "ORGANISM", 179, 196], ["BCCV", "ORGANISM", 198, 202], ["rat", "ORGANISM", 220, 223], ["New York virus", "ORGANISM", 229, 243], ["mouse", "ORGANISM", 266, 271], ["rat", "SPECIES", 220, 223], ["mouse", "SPECIES", 266, 271], ["hantavirus", "SPECIES", 72, 82], ["hantavirus-induced hemorrhagic fever with renal Canal virus", "SPECIES", 137, 196], ["BCCV", "SPECIES", 198, 202], ["cotton rat", "SPECIES", 213, 223], ["New York virus", "SPECIES", 229, 243], ["white-footed mouse", "SPECIES", 253, 271], ["The broad-spectrum antiviral agent ribavirin", "TREATMENT", 9, 53], ["hantavirus", "PROBLEM", 72, 82], ["hantavirus", "PROBLEM", 137, 147], ["hemorrhagic fever", "PROBLEM", 156, 173], ["renal Canal virus", "PROBLEM", 179, 196], ["the cotton rat", "PROBLEM", 209, 223], ["New York virus", "PROBLEM", 229, 243], ["broad", "OBSERVATION_MODIFIER", 13, 18], ["antiviral agent ribavirin", "OBSERVATION", 28, 53], ["hemorrhagic", "OBSERVATION_MODIFIER", 156, 167], ["fever", "OBSERVATION", 168, 173], ["renal Canal", "ANATOMY", 179, 190]]], ["The rodent hosts experience prolonged asymptomatic infection, but the features that are associated with maintenance of these viruses in rodent populations and with rodent-to-rodent transmission are unclear.", [["infection", "DISEASE", 51, 60], ["rodent", "SPECIES", 4, 10], ["rodent", "SPECIES", 136, 142], ["rodent", "SPECIES", 164, 170], ["prolonged asymptomatic infection", "PROBLEM", 28, 60], ["these viruses in rodent populations", "PROBLEM", 119, 154], ["prolonged", "OBSERVATION_MODIFIER", 28, 37], ["asymptomatic", "OBSERVATION_MODIFIER", 38, 50], ["infection", "OBSERVATION", 51, 60], ["viruses", "OBSERVATION", 125, 132]]], ["Serologic studies suggest that hantaviral infection of feral rodents is widespread throughout North America.", [["hantaviral infection", "DISEASE", 31, 51], ["feral rodents", "ORGANISM", 55, 68], ["feral", "SPECIES", 55, 60], ["Serologic studies", "TEST", 0, 17], ["hantaviral infection of feral rodents", "PROBLEM", 31, 68], ["hantaviral", "OBSERVATION_MODIFIER", 31, 41], ["infection", "OBSERVATION", 42, 51], ["feral rodents", "OBSERVATION", 55, 68], ["widespread", "OBSERVATION_MODIFIER", 72, 82]]], ["86 Transmission to humans is presumed to result from contact with infected rodent excreta.", [["humans", "ORGANISM", 19, 25], ["rodent", "ORGANISM", 75, 81], ["excreta", "ORGANISM_SUBDIVISION", 82, 89], ["humans", "SPECIES", 19, 25], ["rodent", "SPECIES", 75, 81], ["humans", "SPECIES", 19, 25], ["infected rodent excreta", "PROBLEM", 66, 89]]], ["Hantaviruses are stable and can persist in the environment for 10 to 15 days without loss of viability.", [["Hantaviruses", "PROBLEM", 0, 12], ["loss of viability", "PROBLEM", 85, 102], ["stable", "OBSERVATION_MODIFIER", 17, 23]]], ["87 Risk factors for acquisition of HPS include high densities of rodents in the household, cleaning of contaminated environments, agricultural activities, and other forms of occupational exposure to rodent droppings.", [["HPS", "DISEASE", 35, 38], ["HPS", "PROBLEM", 35, 38], ["high densities of rodents", "PROBLEM", 47, 72], ["occupational exposure", "PROBLEM", 174, 195], ["high densities", "OBSERVATION_MODIFIER", 47, 61]]], ["In the Four Corners region of the southwestern United States, El Ni\u00f1o-southern oscillation events have been linked to increased rainfall, high rodent population densities, and increased numbers of cases of HPS.", [["HPS", "DISEASE", 206, 209], ["increased rainfall", "PROBLEM", 118, 136], ["high rodent population densities", "PROBLEM", 138, 170], ["HPS", "PROBLEM", 206, 209], ["increased", "OBSERVATION_MODIFIER", 118, 127], ["rainfall", "OBSERVATION_MODIFIER", 128, 136], ["high rodent", "OBSERVATION_MODIFIER", 138, 149], ["increased", "OBSERVATION_MODIFIER", 176, 185], ["numbers", "OBSERVATION_MODIFIER", 186, 193]]], ["88 Person-to-person transmission was not seen in the North American outbreaks.", [["person", "SPECIES", 13, 19]]], ["89 In contrast, a recent outbreak of HPS in South America has suggested that, under certain circumstances, person-to-person transmission can take place.", [["HPS", "DISEASE", 37, 40], ["person", "SPECIES", 107, 113], ["person", "SPECIES", 117, 123], ["HPS", "OBSERVATION", 37, 40]]], ["90 This feature appears to be unique to the particular hantavirus implicated in that outbreak (Andes virus) and has not been a major component of other outbreaks.", [["hantavirus", "DISEASE", 55, 65], ["Andes virus", "ORGANISM", 95, 106], ["Andes virus", "SPECIES", 95, 106], ["the particular hantavirus", "PROBLEM", 40, 65], ["appears to be", "UNCERTAINTY", 16, 29], ["hantavirus", "OBSERVATION", 55, 65], ["major", "OBSERVATION_MODIFIER", 127, 132], ["component", "OBSERVATION_MODIFIER", 133, 142], ["outbreaks", "OBSERVATION", 152, 161]]], ["Currently, approximately 11 to 48 cases of HPS per year are reported in the United States, 91 with a case fatality rate of 35%.PathogenesisInfection with Sin Nombre virus or other agents of HPS have relatively long incubation periods (median 14 to 17 days; range 1 to 51 days), 92 and antibody and cellular responses in humans are usually detectable at the time of presentation.", [["cellular", "ANATOMY", 298, 306], ["HPS", "DISEASE", 43, 46], ["PathogenesisInfection", "DISEASE", 127, 148], ["HPS", "DISEASE", 190, 193], ["Sin Nombre virus", "ORGANISM", 154, 170], ["cellular", "CELL", 298, 306], ["humans", "ORGANISM", 320, 326], ["humans", "SPECIES", 320, 326], ["Sin Nombre virus", "SPECIES", 154, 170], ["humans", "SPECIES", 320, 326], ["a case fatality rate", "TEST", 99, 119], ["PathogenesisInfection", "PROBLEM", 127, 148], ["Sin Nombre virus", "TREATMENT", 154, 170], ["HPS", "PROBLEM", 190, 193], ["antibody", "TEST", 285, 293], ["cellular responses", "OBSERVATION", 298, 316]]], ["93 Neutralizing antibody is directed against the surface glycoproteins G1 and G2, and lower titers on presentation correlate with greater disease severity.", [["surface", "ANATOMY", 49, 56], ["surface glycoproteins", "PROTEIN", 49, 70], ["G2", "PROTEIN", 78, 80], ["Neutralizing antibody", "TEST", 3, 24], ["lower titers", "PROBLEM", 86, 98], ["greater disease severity", "PROBLEM", 130, 154], ["lower titers", "OBSERVATION_MODIFIER", 86, 98], ["greater", "OBSERVATION_MODIFIER", 130, 137], ["disease", "OBSERVATION", 138, 145]]], ["94 Viremia is detectable at presentation and declines promptly after resolution of fever.PathogenesisPathologic findings in fatal cases include pleural effusions, alveolar edema and fibrin, and interstitial mononuclear cell infiltrate 95 with little necrosis or neutrophil infiltration.", [["pleural effusions", "ANATOMY", 144, 161], ["alveolar", "ANATOMY", 163, 171], ["interstitial mononuclear cell", "ANATOMY", 194, 223], ["neutrophil", "ANATOMY", 262, 272], ["fever", "DISEASE", 83, 88], ["pleural effusions", "DISEASE", 144, 161], ["alveolar edema", "DISEASE", 163, 177], ["necrosis", "DISEASE", 250, 258], ["pleural effusions", "PATHOLOGICAL_FORMATION", 144, 161], ["alveolar edema", "PATHOLOGICAL_FORMATION", 163, 177], ["fibrin", "GENE_OR_GENE_PRODUCT", 182, 188], ["interstitial mononuclear cell", "CELL", 194, 223], ["neutrophil", "CELL", 262, 272], ["Viremia", "PROBLEM", 3, 10], ["fever", "PROBLEM", 83, 88], ["PathogenesisPathologic findings in fatal cases", "PROBLEM", 89, 135], ["pleural effusions", "PROBLEM", 144, 161], ["alveolar edema", "PROBLEM", 163, 177], ["fibrin", "PROBLEM", 182, 188], ["interstitial mononuclear cell infiltrate", "PROBLEM", 194, 234], ["little necrosis", "PROBLEM", 243, 258], ["neutrophil infiltration", "PROBLEM", 262, 285], ["Viremia", "OBSERVATION", 3, 10], ["fever", "OBSERVATION", 83, 88], ["fatal", "OBSERVATION_MODIFIER", 124, 129], ["pleural", "ANATOMY", 144, 151], ["effusions", "OBSERVATION", 152, 161], ["alveolar", "ANATOMY_MODIFIER", 163, 171], ["edema", "OBSERVATION", 172, 177], ["fibrin", "OBSERVATION_MODIFIER", 182, 188], ["interstitial", "ANATOMY_MODIFIER", 194, 206], ["mononuclear cell infiltrate", "OBSERVATION", 207, 234], ["little", "OBSERVATION_MODIFIER", 243, 249], ["necrosis", "OBSERVATION", 250, 258], ["neutrophil infiltration", "OBSERVATION", 262, 285]]], ["These findings are felt to be most consistent with a capillary leak syndrome with subsequent noncardiogenic pulmonary edema.", [["capillary", "ANATOMY", 53, 62], ["pulmonary", "ANATOMY", 108, 117], ["noncardiogenic pulmonary edema", "DISEASE", 93, 123], ["capillary", "TISSUE", 53, 62], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 108, 123], ["a capillary leak syndrome", "PROBLEM", 51, 76], ["subsequent noncardiogenic pulmonary edema", "PROBLEM", 82, 123], ["felt to be most consistent with", "UNCERTAINTY", 19, 50], ["capillary leak", "OBSERVATION", 53, 67], ["syndrome", "OBSERVATION", 68, 76], ["noncardiogenic", "OBSERVATION_MODIFIER", 93, 107], ["pulmonary", "ANATOMY", 108, 117], ["edema", "OBSERVATION", 118, 123]]], ["Immunopathologic responses play a major role in HPS.", [["HPS", "DISEASE", 48, 51]]], ["96 Infection of humans with Sin Nombre virus and other hantaviruses results in widespread expression of viral antigens in endothelial cells of pulmonary and cardiac tissues, 97 and CD8 T cell responses peak at the time of maximal clinical symptoms, implicating these responses in the pathogenesis of disease.", [["endothelial cells", "ANATOMY", 122, 139], ["pulmonary", "ANATOMY", 143, 152], ["cardiac tissues", "ANATOMY", 157, 172], ["CD8", "ANATOMY", 181, 184], ["T cell", "ANATOMY", 185, 191], ["hantaviruses", "DISEASE", 55, 67], ["humans", "ORGANISM", 16, 22], ["Sin Nombre virus", "ORGANISM", 28, 44], ["endothelial cells", "CELL", 122, 139], ["pulmonary", "ORGAN", 143, 152], ["cardiac tissues", "TISSUE", 157, 172], ["CD8", "GENE_OR_GENE_PRODUCT", 181, 184], ["T cell", "CELL", 185, 191], ["viral antigens", "PROTEIN", 104, 118], ["endothelial cells", "CELL_TYPE", 122, 139], ["humans", "SPECIES", 16, 22], ["Sin Nombre virus", "SPECIES", 28, 44], ["humans", "SPECIES", 16, 22], ["Sin Nombre virus", "SPECIES", 28, 44], ["Infection of humans", "PROBLEM", 3, 22], ["Sin Nombre virus", "TREATMENT", 28, 44], ["other hantaviruses", "PROBLEM", 49, 67], ["viral antigens", "PROBLEM", 104, 118], ["T cell responses", "TEST", 185, 201], ["maximal clinical symptoms", "PROBLEM", 222, 247], ["disease", "PROBLEM", 300, 307], ["Infection", "OBSERVATION", 3, 12], ["viral antigens", "OBSERVATION", 104, 118], ["endothelial cells", "OBSERVATION", 122, 139], ["pulmonary", "ANATOMY", 143, 152], ["cardiac tissues", "ANATOMY", 157, 172], ["peak", "OBSERVATION_MODIFIER", 202, 206], ["disease", "OBSERVATION", 300, 307]]], ["98 Myocardial depression has also been ascribed to induction of nitric oxide and locally secreted cytokines in response to infection.", [["Myocardial", "ANATOMY", 3, 13], ["Myocardial depression", "DISEASE", 3, 24], ["nitric oxide", "CHEMICAL", 64, 76], ["infection", "DISEASE", 123, 132], ["nitric oxide", "CHEMICAL", 64, 76], ["Myocardial", "MULTI-TISSUE_STRUCTURE", 3, 13], ["nitric oxide", "SIMPLE_CHEMICAL", 64, 76], ["cytokines", "PROTEIN", 98, 107], ["Myocardial depression", "PROBLEM", 3, 24], ["nitric oxide", "TREATMENT", 64, 76], ["locally secreted cytokines", "PROBLEM", 81, 107], ["infection", "PROBLEM", 123, 132], ["Myocardial", "ANATOMY", 3, 13], ["depression", "OBSERVATION", 14, 24], ["infection", "OBSERVATION", 123, 132]]], ["99 Another pathogenic mechanism may be antagonism of the host innate immune response by the hantavirus G1 tail.", [["hantavirus G1 tail", "PROTEIN", 92, 110], ["may be", "UNCERTAINTY", 32, 38]]], ["100Clinical FeaturesPresentation of HPS begins with a prodrome of fever, chills, and myalgias, occasionally accompanied by abdominal discomfort and GI symptoms, and generalized malaise.", [["abdominal", "ANATOMY", 123, 132], ["GI", "ANATOMY", 148, 150], ["HPS", "DISEASE", 36, 39], ["fever", "DISEASE", 66, 71], ["chills", "DISEASE", 73, 79], ["myalgias", "DISEASE", 85, 93], ["abdominal discomfort", "DISEASE", 123, 143], ["GI symptoms", "DISEASE", 148, 159], ["abdominal", "ORGANISM_SUBDIVISION", 123, 132], ["HPS", "PROBLEM", 36, 39], ["fever", "PROBLEM", 66, 71], ["chills", "PROBLEM", 73, 79], ["myalgias", "PROBLEM", 85, 93], ["abdominal discomfort", "PROBLEM", 123, 143], ["GI symptoms", "PROBLEM", 148, 159], ["generalized malaise", "PROBLEM", 165, 184], ["fever", "OBSERVATION", 66, 71], ["chills", "OBSERVATION", 73, 79], ["myalgias", "OBSERVATION", 85, 93], ["abdominal", "ANATOMY", 123, 132], ["discomfort", "OBSERVATION", 133, 143], ["GI", "ANATOMY", 148, 150], ["generalized", "OBSERVATION_MODIFIER", 165, 176], ["malaise", "OBSERVATION", 177, 184]]], ["Upper respiratory symptoms are usually absent.", [["respiratory", "ANATOMY", 6, 17], ["Upper respiratory symptoms", "PROBLEM", 0, 26], ["respiratory", "ANATOMY", 6, 17], ["symptoms", "OBSERVATION", 18, 26]]], ["After a variable Latent infection is established in sensory nerve ganglia and is followed by life-long recurrences of virus shedding and often lesions on skin and mucous membranes of the involved dermatomes.", [["sensory nerve ganglia", "ANATOMY", 52, 73], ["lesions", "ANATOMY", 143, 150], ["skin", "ANATOMY", 154, 158], ["mucous membranes", "ANATOMY", 163, 179], ["dermatomes", "ANATOMY", 196, 206], ["Latent infection", "DISEASE", 17, 33], ["sensory nerve ganglia", "MULTI-TISSUE_STRUCTURE", 52, 73], ["lesions", "PATHOLOGICAL_FORMATION", 143, 150], ["skin", "ORGAN", 154, 158], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 163, 179], ["dermatomes", "ORGAN", 196, 206], ["a variable Latent infection", "PROBLEM", 6, 33], ["sensory nerve ganglia", "PROBLEM", 52, 73], ["virus shedding", "PROBLEM", 118, 132], ["often lesions on skin and mucous membranes", "PROBLEM", 137, 179], ["variable", "OBSERVATION_MODIFIER", 8, 16], ["Latent", "OBSERVATION_MODIFIER", 17, 23], ["infection", "OBSERVATION", 24, 33], ["sensory", "ANATOMY_MODIFIER", 52, 59], ["nerve ganglia", "ANATOMY", 60, 73], ["virus", "OBSERVATION", 118, 123], ["lesions", "OBSERVATION", 143, 150], ["skin", "ANATOMY", 154, 158], ["mucous membranes", "ANATOMY", 163, 179]]], ["Cellular immunity is of primary importance in controlling HSV infection; studies in patients with AIDS and severe mucocutaneous HSV indicate that both CD4 and CD8 T cells contribute to control of viral replication and spread.", [["Cellular", "ANATOMY", 0, 8], ["CD4", "ANATOMY", 151, 154], ["CD8 T cells", "ANATOMY", 159, 170], ["HSV infection", "DISEASE", 58, 71], ["AIDS", "DISEASE", 98, 102], ["Cellular", "CELL", 0, 8], ["HSV", "ORGANISM", 58, 61], ["patients", "ORGANISM", 84, 92], ["HSV", "ORGANISM", 128, 131], ["CD4", "GENE_OR_GENE_PRODUCT", 151, 154], ["CD8", "GENE_OR_GENE_PRODUCT", 159, 162], ["CD4 and CD8 T cells", "CELL_TYPE", 151, 170], ["patients", "SPECIES", 84, 92], ["HSV", "SPECIES", 58, 61], ["HSV", "SPECIES", 128, 131], ["HSV infection", "PROBLEM", 58, 71], ["AIDS", "PROBLEM", 98, 102], ["severe mucocutaneous HSV", "PROBLEM", 107, 131], ["CD8 T cells", "PROBLEM", 159, 170], ["viral replication", "PROBLEM", 196, 213], ["infection", "OBSERVATION", 62, 71], ["severe", "OBSERVATION_MODIFIER", 107, 113], ["mucocutaneous", "OBSERVATION", 114, 127], ["viral replication", "OBSERVATION", 196, 213]]], ["115Clinical IllnessAcute Gingivostomatitis and Pharyngitis.", [["IllnessAcute Gingivostomatitis", "DISEASE", 12, 42], ["Pharyngitis", "DISEASE", 47, 58], ["Clinical IllnessAcute Gingivostomatitis", "PROBLEM", 3, 42], ["Pharyngitis", "PROBLEM", 47, 58], ["IllnessAcute Gingivostomatitis", "OBSERVATION", 12, 42], ["Pharyngitis", "OBSERVATION", 47, 58]]], ["Herpetic disease of the oral cavity and pharynx is the most common overt manifestation of primary infection with HSV-1.", [["oral cavity", "ANATOMY", 24, 35], ["pharynx", "ANATOMY", 40, 47], ["Herpetic disease of the oral cavity", "DISEASE", 0, 35], ["primary infection", "DISEASE", 90, 107], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 24, 35], ["pharynx", "ORGAN", 40, 47], ["HSV-1", "ORGANISM", 113, 118], ["HSV-1", "SPECIES", 113, 118], ["Herpetic disease of the oral cavity and pharynx", "PROBLEM", 0, 47], ["primary infection", "PROBLEM", 90, 107], ["HSV", "PROBLEM", 113, 116], ["oral cavity", "ANATOMY", 24, 35], ["pharynx", "ANATOMY", 40, 47], ["most common", "OBSERVATION_MODIFIER", 55, 66], ["primary", "OBSERVATION_MODIFIER", 90, 97], ["infection", "OBSERVATION", 98, 107]]], ["Scattered or clustered vesicles and ulcers of various sizes (3 to 7 mm) are located on the buccal mucosa, tongue, gingiva, or floor of the mouth.", [["vesicles", "ANATOMY", 23, 31], ["ulcers", "ANATOMY", 36, 42], ["buccal mucosa", "ANATOMY", 91, 104], ["tongue", "ANATOMY", 106, 112], ["gingiva", "ANATOMY", 114, 121], ["floor", "ANATOMY", 126, 131], ["mouth", "ANATOMY", 139, 144], ["ulcers", "DISEASE", 36, 42], ["vesicles", "CELLULAR_COMPONENT", 23, 31], ["ulcers", "PATHOLOGICAL_FORMATION", 36, 42], ["buccal mucosa", "MULTI-TISSUE_STRUCTURE", 91, 104], ["tongue", "ORGAN", 106, 112], ["gingiva", "MULTI-TISSUE_STRUCTURE", 114, 121], ["mouth", "ORGANISM_SUBDIVISION", 139, 144], ["Scattered or clustered vesicles", "PROBLEM", 0, 31], ["ulcers of various sizes", "PROBLEM", 36, 59], ["clustered", "OBSERVATION_MODIFIER", 13, 22], ["vesicles", "OBSERVATION_MODIFIER", 23, 31], ["ulcers", "OBSERVATION", 36, 42], ["various", "OBSERVATION_MODIFIER", 46, 53], ["sizes", "OBSERVATION_MODIFIER", 54, 59], ["3 to 7 mm", "OBSERVATION_MODIFIER", 61, 70], ["buccal mucosa", "ANATOMY", 91, 104], ["tongue", "ANATOMY", 106, 112], ["gingiva", "ANATOMY", 114, 121], ["mouth", "ANATOMY", 139, 144]]], ["Individual lesions usually appear as a shallow, white-based ulcer surrounded by a thin rim of erythema.", [["lesions", "ANATOMY", 11, 18], ["ulcer", "ANATOMY", 60, 65], ["erythema", "ANATOMY", 94, 102], ["ulcer", "DISEASE", 60, 65], ["erythema", "DISEASE", 94, 102], ["lesions", "CANCER", 11, 18], ["ulcer", "PATHOLOGICAL_FORMATION", 60, 65], ["erythema", "PATHOLOGICAL_FORMATION", 94, 102], ["Individual lesions", "PROBLEM", 0, 18], ["a shallow, white-based ulcer", "PROBLEM", 37, 65], ["a thin rim of erythema", "PROBLEM", 80, 102], ["lesions", "OBSERVATION", 11, 18], ["shallow", "OBSERVATION_MODIFIER", 39, 46], ["white", "OBSERVATION_MODIFIER", 48, 53], ["ulcer", "OBSERVATION", 60, 65], ["thin rim", "OBSERVATION_MODIFIER", 82, 90], ["erythema", "OBSERVATION", 94, 102]]], ["Pain is prominent in involved areas of the mouth and pharynx, and regional nodes are tender and enlarged, particularly with the pharyngitis.", [["mouth", "ANATOMY", 43, 48], ["pharynx", "ANATOMY", 53, 60], ["nodes", "ANATOMY", 75, 80], ["Pain", "DISEASE", 0, 4], ["pharyngitis", "DISEASE", 128, 139], ["mouth", "ORGAN", 43, 48], ["pharynx", "ORGAN", 53, 60], ["regional nodes", "MULTI-TISSUE_STRUCTURE", 66, 80], ["Pain", "PROBLEM", 0, 4], ["tender", "PROBLEM", 85, 91], ["enlarged", "PROBLEM", 96, 104], ["the pharyngitis", "PROBLEM", 124, 139], ["prominent", "OBSERVATION_MODIFIER", 8, 17], ["mouth", "ANATOMY", 43, 48], ["pharynx", "ANATOMY", 53, 60], ["regional nodes", "ANATOMY", 66, 80], ["tender", "OBSERVATION_MODIFIER", 85, 91], ["enlarged", "OBSERVATION_MODIFIER", 96, 104], ["pharyngitis", "OBSERVATION", 128, 139]]], ["Fever, malaise, and reduced oral intake may add to the overall severity of these illnesses, which last up to 2 weeks.Clinical IllnessChronic Ulcerative Pharyngitis and Laryngotracheitis.", [["oral", "ANATOMY", 28, 32], ["Fever", "DISEASE", 0, 5], ["Ulcerative Pharyngitis", "DISEASE", 141, 163], ["Laryngotracheitis", "DISEASE", 168, 185], ["oral", "ORGANISM_SUBDIVISION", 28, 32], ["Fever", "PROBLEM", 0, 5], ["malaise", "PROBLEM", 7, 14], ["reduced oral intake", "PROBLEM", 20, 39], ["these illnesses", "PROBLEM", 75, 90], ["Clinical IllnessChronic Ulcerative Pharyngitis", "PROBLEM", 117, 163], ["Laryngotracheitis", "PROBLEM", 168, 185], ["malaise", "OBSERVATION", 7, 14], ["illnesses", "OBSERVATION", 81, 90], ["Chronic", "OBSERVATION_MODIFIER", 133, 140], ["Ulcerative", "OBSERVATION_MODIFIER", 141, 151], ["Pharyngitis", "OBSERVATION", 152, 163], ["Laryngotracheitis", "OBSERVATION", 168, 185]]], ["In immunocompromised patients, including those with AIDS, both primary and recurrent HSV infection may manifest as a chronic erosive process of the mucous membranes of the oral cavity and upper airway.", [["mucous membranes", "ANATOMY", 148, 164], ["oral cavity", "ANATOMY", 172, 183], ["upper airway", "ANATOMY", 188, 200], ["AIDS", "DISEASE", 52, 56], ["HSV infection", "DISEASE", 85, 98], ["patients", "ORGANISM", 21, 29], ["HSV", "ORGANISM", 85, 88], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 148, 164], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 172, 183], ["upper airway", "ORGANISM_SUBDIVISION", 188, 200], ["patients", "SPECIES", 21, 29], ["HSV", "SPECIES", 85, 88], ["AIDS", "PROBLEM", 52, 56], ["recurrent HSV infection", "PROBLEM", 75, 98], ["a chronic erosive process of the mucous membranes of the oral cavity and upper airway", "PROBLEM", 115, 200], ["immunocompromised", "OBSERVATION", 3, 20], ["recurrent", "OBSERVATION_MODIFIER", 75, 84], ["HSV infection", "OBSERVATION", 85, 98], ["chronic", "OBSERVATION_MODIFIER", 117, 124], ["erosive", "OBSERVATION", 125, 132], ["mucous membranes", "ANATOMY", 148, 164], ["oral cavity", "ANATOMY", 172, 183], ["upper", "ANATOMY_MODIFIER", 188, 193], ["airway", "ANATOMY", 194, 200]]], ["Characteristically, the lesions appear as large (5 to 15 mm) individual ulcerations that are slowly progressive and may coalesce when present in adjacent sites.", [["lesions", "ANATOMY", 24, 31], ["ulcerations", "ANATOMY", 72, 83], ["sites", "ANATOMY", 154, 159], ["ulcerations", "DISEASE", 72, 83], ["lesions", "PATHOLOGICAL_FORMATION", 24, 31], ["ulcerations", "PATHOLOGICAL_FORMATION", 72, 83], ["the lesions", "PROBLEM", 20, 31], ["individual ulcerations", "PROBLEM", 61, 83], ["lesions", "OBSERVATION", 24, 31], ["large", "OBSERVATION_MODIFIER", 42, 47], ["5 to 15 mm", "OBSERVATION_MODIFIER", 49, 59], ["ulcerations", "OBSERVATION", 72, 83], ["slowly", "OBSERVATION_MODIFIER", 93, 99], ["progressive", "OBSERVATION_MODIFIER", 100, 111], ["coalesce", "OBSERVATION_MODIFIER", 120, 128]]], ["The base of the ulcer is white or gray.", [["ulcer", "ANATOMY", 16, 21], ["ulcer", "DISEASE", 16, 21], ["ulcer", "PATHOLOGICAL_FORMATION", 16, 21], ["the ulcer", "PROBLEM", 12, 21], ["base", "ANATOMY_MODIFIER", 4, 8], ["ulcer", "OBSERVATION", 16, 21], ["white", "OBSERVATION_MODIFIER", 25, 30]]], ["Although shallow, the lesions are usually painful and may reduce oral intake.", [["lesions", "ANATOMY", 22, 29], ["oral", "ANATOMY", 65, 69], ["lesions", "PATHOLOGICAL_FORMATION", 22, 29], ["oral", "ORGANISM_SUBDIVISION", 65, 69], ["the lesions", "PROBLEM", 18, 29], ["painful", "PROBLEM", 42, 49], ["shallow", "OBSERVATION_MODIFIER", 9, 16], ["lesions", "OBSERVATION", 22, 29]]], ["Herpetic lesions are sometimes present on the lip and skin of the face.", [["lesions", "ANATOMY", 9, 16], ["lip", "ANATOMY", 46, 49], ["skin", "ANATOMY", 54, 58], ["Herpetic lesions", "CANCER", 0, 16], ["lip", "ORGAN", 46, 49], ["skin", "ORGAN", 54, 58], ["Herpetic lesions", "PROBLEM", 0, 16], ["lesions", "OBSERVATION", 9, 16], ["lip", "ANATOMY", 46, 49], ["skin", "ANATOMY", 54, 58], ["face", "ANATOMY", 66, 70]]], ["Infection may spread to the esophagus and lower airway, possibly facilitated by instrumentation such as orotracheal intubation or bronchoscopy, resulting in the development of similar lesions at these sites.", [["esophagus", "ANATOMY", 28, 37], ["lower airway", "ANATOMY", 42, 54], ["orotracheal", "ANATOMY", 104, 115], ["lesions", "ANATOMY", 184, 191], ["esophagus", "ORGAN", 28, 37], ["lower airway", "ORGANISM_SUBDIVISION", 42, 54], ["lesions", "PATHOLOGICAL_FORMATION", 184, 191], ["Infection", "PROBLEM", 0, 9], ["instrumentation", "TREATMENT", 80, 95], ["orotracheal intubation", "TREATMENT", 104, 126], ["bronchoscopy", "TREATMENT", 130, 142], ["similar lesions at these sites", "PROBLEM", 176, 206], ["esophagus", "ANATOMY", 28, 37], ["lower", "ANATOMY_MODIFIER", 42, 47], ["airway", "ANATOMY", 48, 54], ["instrumentation", "OBSERVATION", 80, 95], ["similar", "OBSERVATION_MODIFIER", 176, 183], ["lesions", "OBSERVATION", 184, 191]]], ["Clinical features of herpetic tracheobronchitis include dyspnea, cough, fever, chills, diaphoresis, chest pain, wheezes, hypotension, and hypoxemia.", [["chest", "ANATOMY", 100, 105], ["herpetic tracheobronchitis", "DISEASE", 21, 47], ["dyspnea", "DISEASE", 56, 63], ["cough", "DISEASE", 65, 70], ["fever", "DISEASE", 72, 77], ["chills", "DISEASE", 79, 85], ["diaphoresis", "DISEASE", 87, 98], ["chest pain", "DISEASE", 100, 110], ["wheezes", "DISEASE", 112, 119], ["hypotension", "DISEASE", 121, 132], ["hypoxemia", "DISEASE", 138, 147], ["herpetic tracheobronchitis", "PROBLEM", 21, 47], ["dyspnea", "PROBLEM", 56, 63], ["cough", "PROBLEM", 65, 70], ["fever", "PROBLEM", 72, 77], ["chills", "PROBLEM", 79, 85], ["diaphoresis", "PROBLEM", 87, 98], ["chest pain", "PROBLEM", 100, 110], ["wheezes", "PROBLEM", 112, 119], ["hypotension", "PROBLEM", 121, 132], ["hypoxemia", "PROBLEM", 138, 147], ["herpetic", "OBSERVATION_MODIFIER", 21, 29], ["tracheobronchitis", "OBSERVATION", 30, 47], ["cough", "OBSERVATION", 65, 70], ["chest", "ANATOMY", 100, 105], ["wheezes", "OBSERVATION", 112, 119], ["hypotension", "OBSERVATION", 121, 132], ["hypoxemia", "OBSERVATION", 138, 147]]], ["116 Herpetic tracheobronchitis has also been reported in elderly patients presenting with bronchospasm who did not have histories of chronic lung disease or of immunosuppression.", [["lung", "ANATOMY", 141, 145], ["tracheobronchitis", "DISEASE", 13, 30], ["bronchospasm", "DISEASE", 90, 102], ["chronic lung disease", "DISEASE", 133, 153], ["patients", "ORGANISM", 65, 73], ["lung", "ORGAN", 141, 145], ["patients", "SPECIES", 65, 73], ["Herpetic tracheobronchitis", "PROBLEM", 4, 30], ["bronchospasm", "PROBLEM", 90, 102], ["chronic lung disease", "PROBLEM", 133, 153], ["immunosuppression", "TREATMENT", 160, 177], ["Herpetic", "OBSERVATION_MODIFIER", 4, 12], ["tracheobronchitis", "OBSERVATION", 13, 30], ["bronchospasm", "OBSERVATION", 90, 102], ["chronic", "OBSERVATION_MODIFIER", 133, 140], ["lung", "ANATOMY", 141, 145], ["disease", "OBSERVATION", 146, 153], ["immunosuppression", "OBSERVATION", 160, 177]]], ["117Clinical IllnessPneumonia.", [["117Clinical IllnessPneumonia", "PROBLEM", 0, 28], ["IllnessPneumonia", "OBSERVATION", 12, 28]]], ["Herpes simplex virus causes pneumonia in neonates with congenital and peripartum infections and in patients with malignancy, burns, organ transplantation, and other conditions associated with impaired immunity.", [["organ", "ANATOMY", 132, 137], ["Herpes simplex virus", "DISEASE", 0, 20], ["pneumonia", "DISEASE", 28, 37], ["congenital and peripartum infections", "DISEASE", 55, 91], ["malignancy", "DISEASE", 113, 123], ["burns", "DISEASE", 125, 130], ["impaired immunity", "DISEASE", 192, 209], ["Herpes simplex virus", "ORGANISM", 0, 20], ["patients", "ORGANISM", 99, 107], ["organ", "ORGAN", 132, 137], ["Herpes simplex virus", "SPECIES", 0, 20], ["patients", "SPECIES", 99, 107], ["Herpes simplex virus", "SPECIES", 0, 20], ["Herpes simplex virus", "PROBLEM", 0, 20], ["pneumonia in neonates", "PROBLEM", 28, 49], ["congenital and peripartum infections", "PROBLEM", 55, 91], ["malignancy", "PROBLEM", 113, 123], ["burns", "PROBLEM", 125, 130], ["organ transplantation", "TREATMENT", 132, 153], ["other conditions", "PROBLEM", 159, 175], ["impaired immunity", "PROBLEM", 192, 209], ["simplex virus", "OBSERVATION", 7, 20], ["pneumonia", "OBSERVATION", 28, 37], ["congenital", "OBSERVATION_MODIFIER", 55, 65], ["peripartum", "OBSERVATION_MODIFIER", 70, 80], ["infections", "OBSERVATION", 81, 91], ["malignancy", "OBSERVATION", 113, 123], ["burns", "OBSERVATION", 125, 130], ["organ", "ANATOMY", 132, 137], ["transplantation", "OBSERVATION", 138, 153]]], ["Herpes simplex pneumonia has been reported in neonates between the third and 14th days of life and to be associated with prominent hila and central interstitial opacity on chest radiography.", [["hila", "ANATOMY", 131, 135], ["interstitial", "ANATOMY", 148, 160], ["chest", "ANATOMY", 172, 177], ["Herpes simplex pneumonia", "DISEASE", 0, 24], ["interstitial opacity", "DISEASE", 148, 168], ["Herpes simplex", "ORGANISM", 0, 14], ["neonates", "ORGANISM", 46, 54], ["hila", "CANCER", 131, 135], ["interstitial opacity", "PATHOLOGICAL_FORMATION", 148, 168], ["chest", "ORGAN", 172, 177], ["Herpes simplex", "SPECIES", 0, 14], ["Herpes simplex pneumonia", "PROBLEM", 0, 24], ["prominent hila", "PROBLEM", 121, 135], ["central interstitial opacity", "PROBLEM", 140, 168], ["chest radiography", "TEST", 172, 189], ["simplex", "OBSERVATION_MODIFIER", 7, 14], ["pneumonia", "OBSERVATION", 15, 24], ["prominent", "OBSERVATION_MODIFIER", 121, 130], ["hila", "ANATOMY", 131, 135], ["central", "ANATOMY_MODIFIER", 140, 147], ["interstitial", "ANATOMY_MODIFIER", 148, 160], ["opacity", "OBSERVATION", 161, 168], ["chest", "ANATOMY", 172, 177]]], ["118 Other associated findings include thrombocytopenia, disseminated intravascular coagulation, abnormalities in liver function, vesicular skin lesions, and deterioration during antimicrobial treatment.", [["intravascular", "ANATOMY", 69, 82], ["liver", "ANATOMY", 113, 118], ["vesicular skin lesions", "ANATOMY", 129, 151], ["thrombocytopenia", "DISEASE", 38, 54], ["disseminated intravascular coagulation", "DISEASE", 56, 94], ["abnormalities in liver function", "DISEASE", 96, 127], ["vesicular skin lesions", "DISEASE", 129, 151], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 69, 82], ["liver", "ORGAN", 113, 118], ["vesicular skin lesions", "PATHOLOGICAL_FORMATION", 129, 151], ["thrombocytopenia", "PROBLEM", 38, 54], ["disseminated intravascular coagulation", "PROBLEM", 56, 94], ["abnormalities in liver function", "PROBLEM", 96, 127], ["vesicular skin lesions", "PROBLEM", 129, 151], ["deterioration", "PROBLEM", 157, 170], ["antimicrobial treatment", "TREATMENT", 178, 201], ["thrombocytopenia", "OBSERVATION", 38, 54], ["disseminated", "OBSERVATION_MODIFIER", 56, 68], ["intravascular coagulation", "OBSERVATION", 69, 94], ["liver", "ANATOMY", 113, 118], ["vesicular", "ANATOMY_MODIFIER", 129, 138], ["skin", "ANATOMY", 139, 143], ["lesions", "OBSERVATION", 144, 151], ["deterioration", "OBSERVATION_MODIFIER", 157, 170], ["antimicrobial treatment", "OBSERVATION", 178, 201]]], ["The pathologic findings in infants, children, and adults suggest that the disease may be the result of direct extension of infection from the tracheobronchial tree to the lung or as the result of hematogenous dissemination of virus from mucocutaneous lesions of the upper airway or genitourinary tract.", [["tracheobronchial tree", "ANATOMY", 142, 163], ["lung", "ANATOMY", 171, 175], ["mucocutaneous lesions", "ANATOMY", 237, 258], ["upper airway", "ANATOMY", 266, 278], ["genitourinary tract", "ANATOMY", 282, 301], ["infection", "DISEASE", 123, 132], ["mucocutaneous lesions of the upper airway or genitourinary tract", "DISEASE", 237, 301], ["infants", "ORGANISM", 27, 34], ["children", "ORGANISM", 36, 44], ["tracheobronchial tree", "MULTI-TISSUE_STRUCTURE", 142, 163], ["lung", "ORGAN", 171, 175], ["mucocutaneous lesions", "PATHOLOGICAL_FORMATION", 237, 258], ["upper airway", "ORGAN", 266, 278], ["genitourinary tract", "ORGANISM_SUBDIVISION", 282, 301], ["infants", "SPECIES", 27, 34], ["children", "SPECIES", 36, 44], ["the disease", "PROBLEM", 70, 81], ["infection", "PROBLEM", 123, 132], ["hematogenous dissemination of virus", "PROBLEM", 196, 231], ["mucocutaneous lesions of the upper airway or genitourinary tract", "PROBLEM", 237, 301], ["pathologic", "OBSERVATION", 4, 14], ["disease", "OBSERVATION", 74, 81], ["infection", "OBSERVATION", 123, 132], ["tracheobronchial", "ANATOMY", 142, 158], ["tree", "ANATOMY_MODIFIER", 159, 163], ["lung", "ANATOMY", 171, 175], ["hematogenous", "OBSERVATION_MODIFIER", 196, 208], ["dissemination", "OBSERVATION", 209, 222], ["mucocutaneous", "OBSERVATION_MODIFIER", 237, 250], ["lesions", "OBSERVATION", 251, 258], ["upper", "ANATOMY_MODIFIER", 266, 271], ["airway", "ANATOMY", 272, 278], ["genitourinary tract", "ANATOMY", 282, 301]]], ["CT scan findings include multifocal segmental and subsegmental ground-glass opacities but are not syndrome in Korea.", [["CT scan", "TEST", 0, 7], ["multifocal segmental and subsegmental ground-glass opacities", "PROBLEM", 25, 85], ["syndrome", "PROBLEM", 98, 106], ["multifocal", "OBSERVATION_MODIFIER", 25, 35], ["segmental", "ANATOMY_MODIFIER", 36, 45], ["subsegmental", "ANATOMY_MODIFIER", 50, 62], ["ground-glass opacities", "OBSERVATION", 63, 85], ["not", "UNCERTAINTY", 94, 97], ["syndrome", "OBSERVATION", 98, 106]]], ["111 However, trials of ribavirin in HPS have not shown efficacy.", [["ribavirin", "CHEMICAL", 23, 32], ["HPS", "DISEASE", 36, 39], ["ribavirin", "CHEMICAL", 23, 32], ["ribavirin", "SIMPLE_CHEMICAL", 23, 32], ["ribavirin", "TREATMENT", 23, 32], ["HPS", "TREATMENT", 36, 39]]], ["112HERPES SIMPLEX VIRUSBoth herpes simplex virus (HSV) types 1 and 2 belong to the alphaherpesvirus subfamily of herpesviruses and share the same basic structural features.", [["herpes simplex", "DISEASE", 28, 42], ["VIRUSBoth herpes simplex virus (HSV) types 1", "ORGANISM", 18, 62], ["2", "GENE_OR_GENE_PRODUCT", 67, 68], ["alphaherpesvirus", "GENE_OR_GENE_PRODUCT", 83, 99], ["herpesviruses", "ORGANISM", 113, 126], ["alphaherpesvirus subfamily", "PROTEIN", 83, 109], ["herpes simplex virus", "SPECIES", 28, 48], ["herpes simplex virus", "SPECIES", 28, 48], ["HSV", "SPECIES", 50, 53], ["SIMPLEX VIRUSBoth herpes simplex virus (HSV) types 1", "PROBLEM", 10, 62], ["simplex virus", "OBSERVATION", 35, 48], ["alphaherpesvirus", "ANATOMY", 83, 99], ["structural features", "OBSERVATION", 152, 171]]], ["HSV-1 is most commonly associated with respiratory infection, whereas HSV-2 is more commonly associated with genital infection.", [["respiratory", "ANATOMY", 39, 50], ["genital", "ANATOMY", 109, 116], ["respiratory infection", "DISEASE", 39, 60], ["genital infection", "DISEASE", 109, 126], ["HSV-1", "ORGANISM", 0, 5], ["HSV-2", "ORGANISM", 70, 75], ["genital", "ORGANISM_SUBDIVISION", 109, 116], ["HSV-1", "SPECIES", 0, 5], ["HSV-1", "SPECIES", 0, 5], ["HSV-2", "SPECIES", 70, 75], ["HSV", "TEST", 0, 3], ["respiratory infection", "PROBLEM", 39, 60], ["HSV", "TEST", 70, 73], ["genital infection", "PROBLEM", 109, 126], ["most commonly", "OBSERVATION_MODIFIER", 9, 22], ["respiratory", "ANATOMY", 39, 50], ["infection", "OBSERVATION", 51, 60], ["genital", "ANATOMY", 109, 116], ["infection", "OBSERVATION", 117, 126]]], ["The two HSV types were originally differentiated by neutralization assay and have been found to differ in a number of biologic and biochemical properties as well.", [["HSV", "ORGANISM", 8, 11], ["HSV", "SPECIES", 8, 11], ["neutralization assay", "TEST", 52, 72], ["two", "OBSERVATION_MODIFIER", 4, 7], ["HSV", "OBSERVATION", 8, 11], ["biochemical properties", "OBSERVATION", 131, 153]]], ["Infection with either type results in production of both type-specific and crossreactive antibodies, with higher concentrations of antibodies being produced against the homologous type.Epidemiology and TransmissionHumans are the reservoir for HSV-1 and HSV-2 viruses.", [["HSV-1", "ORGANISM", 243, 248], ["HSV-2 viruses", "ORGANISM", 253, 266], ["crossreactive antibodies", "PROTEIN", 75, 99], ["antibodies", "PROTEIN", 131, 141], ["HSV-1", "SPECIES", 243, 248], ["HSV-2", "SPECIES", 253, 258], ["HSV-1", "SPECIES", 243, 248], ["HSV-2 viruses", "SPECIES", 253, 266], ["Infection", "PROBLEM", 0, 9], ["both type-specific and crossreactive antibodies", "PROBLEM", 52, 99], ["higher concentrations of antibodies", "PROBLEM", 106, 141], ["HSV", "TEST", 243, 246], ["HSV", "PROBLEM", 253, 256], ["crossreactive antibodies", "OBSERVATION", 75, 99]]], ["With primary infection, infectious virus is produced in the skin and mucous membranes, being present in vesicle fluid and cellular debris from herpetic ulcers.", [["skin", "ANATOMY", 60, 64], ["mucous membranes", "ANATOMY", 69, 85], ["vesicle fluid", "ANATOMY", 104, 117], ["cellular debris", "ANATOMY", 122, 137], ["herpetic ulcers", "ANATOMY", 143, 158], ["primary infection", "DISEASE", 5, 22], ["herpetic ulcers", "DISEASE", 143, 158], ["skin", "ORGAN", 60, 64], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 69, 85], ["vesicle fluid", "ORGANISM_SUBSTANCE", 104, 117], ["cellular debris", "CELLULAR_COMPONENT", 122, 137], ["herpetic ulcers", "PATHOLOGICAL_FORMATION", 143, 158], ["primary infection", "PROBLEM", 5, 22], ["infectious virus", "PROBLEM", 24, 40], ["mucous membranes", "PROBLEM", 69, 85], ["vesicle fluid", "PROBLEM", 104, 117], ["cellular debris", "PROBLEM", 122, 137], ["herpetic ulcers", "PROBLEM", 143, 158], ["primary", "OBSERVATION_MODIFIER", 5, 12], ["infection", "OBSERVATION", 13, 22], ["infectious virus", "OBSERVATION", 24, 40], ["skin", "ANATOMY", 60, 64], ["mucous membranes", "ANATOMY", 69, 85], ["vesicle", "ANATOMY", 104, 111], ["fluid", "OBSERVATION", 112, 117], ["cellular debris", "OBSERVATION", 122, 137], ["herpetic ulcers", "OBSERVATION", 143, 158]]], ["After establishment of latency in nerve ganglia, virus is intermittently shed in respiratory, vaginal, and urethral secretions in the absence of clinical disease.", [["nerve ganglia", "ANATOMY", 34, 47], ["respiratory", "ANATOMY", 81, 92], ["vaginal", "ANATOMY", 94, 101], ["urethral secretions", "ANATOMY", 107, 126], ["nerve ganglia", "MULTI-TISSUE_STRUCTURE", 34, 47], ["vaginal", "ORGANISM_SUBDIVISION", 94, 101], ["urethral secretions", "ORGAN", 107, 126], ["latency in nerve ganglia", "PROBLEM", 23, 47], ["virus", "PROBLEM", 49, 54], ["respiratory, vaginal, and urethral secretions", "PROBLEM", 81, 126], ["clinical disease", "PROBLEM", 145, 161], ["latency", "OBSERVATION_MODIFIER", 23, 30], ["nerve ganglia", "ANATOMY", 34, 47], ["respiratory", "ANATOMY", 81, 92], ["vaginal", "ANATOMY", 94, 101], ["urethral", "ANATOMY", 107, 115], ["secretions", "OBSERVATION", 116, 126]]], ["Asymptomatic respiratory tract shedding can be detected in about 1% to 2% of seropositive children and adults.Epidemiology and TransmissionHSV-1 spreads by means of transfer of virus-containing respiratory secretions, vesicle fluid, and cell debris under conditions of close personal contact.", [["respiratory tract", "ANATOMY", 13, 30], ["respiratory secretions", "ANATOMY", 194, 216], ["vesicle fluid", "ANATOMY", 218, 231], ["cell", "ANATOMY", 237, 241], ["respiratory tract shedding", "DISEASE", 13, 39], ["tract", "ORGANISM_SUBDIVISION", 25, 30], ["children", "ORGANISM", 90, 98], ["vesicle fluid", "ORGANISM_SUBSTANCE", 218, 231], ["cell debris", "CELLULAR_COMPONENT", 237, 248], ["children", "SPECIES", 90, 98], ["Asymptomatic respiratory tract shedding", "PROBLEM", 0, 39], ["TransmissionHSV", "TEST", 127, 142], ["virus", "TREATMENT", 177, 182], ["respiratory secretions", "PROBLEM", 194, 216], ["vesicle fluid", "PROBLEM", 218, 231], ["cell debris", "PROBLEM", 237, 248], ["respiratory tract", "ANATOMY", 13, 30], ["respiratory", "ANATOMY", 194, 205], ["secretions", "OBSERVATION", 206, 216], ["vesicle fluid", "OBSERVATION", 218, 231], ["cell debris", "OBSERVATION", 237, 248]]], ["The portals of entry for primary infection are the mucous membranes of the oropharynx and possibly the eye.", [["mucous membranes", "ANATOMY", 51, 67], ["oropharynx", "ANATOMY", 75, 85], ["eye", "ANATOMY", 103, 106], ["primary infection", "DISEASE", 25, 42], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 51, 67], ["oropharynx", "ORGAN", 75, 85], ["eye", "ORGAN", 103, 106], ["primary infection", "PROBLEM", 25, 42], ["the mucous membranes of the oropharynx and possibly the eye", "PROBLEM", 47, 106], ["primary", "OBSERVATION_MODIFIER", 25, 32], ["infection", "OBSERVATION", 33, 42], ["mucous membranes", "OBSERVATION", 51, 67], ["oropharynx", "ANATOMY", 75, 85], ["eye", "ANATOMY", 103, 106]]], ["Virus deposited onto areas of burned or abraded skin, and exogenous inoculation or autoinoculation of virus, also lead to clinical lesions.", [["skin", "ANATOMY", 48, 52], ["lesions", "ANATOMY", 131, 138], ["Virus", "ORGANISM", 0, 5], ["skin", "ORGAN", 48, 52], ["lesions", "PATHOLOGICAL_FORMATION", 131, 138], ["Virus", "PROBLEM", 0, 5], ["burned or abraded skin", "PROBLEM", 30, 52], ["exogenous inoculation", "PROBLEM", 58, 79], ["autoinoculation of virus", "PROBLEM", 83, 107], ["clinical lesions", "PROBLEM", 122, 138], ["burned", "OBSERVATION", 30, 36], ["abraded", "OBSERVATION_MODIFIER", 40, 47], ["skin", "ANATOMY", 48, 52], ["exogenous", "OBSERVATION_MODIFIER", 58, 67], ["inoculation", "OBSERVATION", 68, 79], ["virus", "OBSERVATION", 102, 107], ["lesions", "OBSERVATION", 131, 138]]], ["Cases of HSV-1 arise sporadically throughout the year, occasionally in small clusters.", [["HSV-1", "ORGANISM", 9, 14], ["HSV-1", "SPECIES", 9, 14], ["HSV-1", "SPECIES", 9, 14], ["HSV", "TEST", 9, 12], ["HSV", "OBSERVATION", 9, 12], ["small clusters", "OBSERVATION", 71, 85]]], ["HSV-1 infection is usually acquired in childhood or adolescence, with epidemiologic surveys showing a prevalence of antibody to HSV-1 in 30% to 100% in adults.PathogenesisPrimary HSV infection has a mean incubation period of approximately 1 week.", [["HSV-1 infection", "DISEASE", 0, 15], ["HSV infection", "DISEASE", 179, 192], ["HSV-1", "ORGANISM", 0, 5], ["HSV-1", "ORGANISM", 128, 133], ["HSV", "ORGANISM", 179, 182], ["HSV-1", "SPECIES", 0, 5], ["HSV-1", "SPECIES", 128, 133], ["HSV-1", "SPECIES", 0, 5], ["HSV-1", "SPECIES", 128, 133], ["HSV", "SPECIES", 179, 182], ["HSV", "PROBLEM", 0, 3], ["1 infection", "PROBLEM", 4, 15], ["epidemiologic surveys", "TEST", 70, 91], ["antibody", "TEST", 116, 124], ["HSV", "TEST", 128, 131], ["PathogenesisPrimary HSV infection", "PROBLEM", 159, 192], ["infection", "OBSERVATION", 6, 15], ["infection", "OBSERVATION", 183, 192], ["mean incubation", "OBSERVATION_MODIFIER", 199, 214]]], ["Primary infection begins at a local site, with viral replication in parabasal and intermediate epithelial cells and resultant cell destruction and initiation of host inflammatory responses.", [["parabasal", "ANATOMY", 68, 77], ["epithelial cells", "ANATOMY", 95, 111], ["cell", "ANATOMY", 126, 130], ["infection", "DISEASE", 8, 17], ["parabasal", "CELL", 68, 77], ["intermediate epithelial cells", "CELL", 82, 111], ["cell", "CELL", 126, 130], ["parabasal and intermediate epithelial cells", "CELL_TYPE", 68, 111], ["Primary infection", "PROBLEM", 0, 17], ["viral replication in parabasal and intermediate epithelial cells", "PROBLEM", 47, 111], ["resultant cell destruction", "PROBLEM", 116, 142], ["host inflammatory responses", "PROBLEM", 161, 188], ["infection", "OBSERVATION", 8, 17], ["viral replication", "OBSERVATION", 47, 64], ["parabasal", "ANATOMY_MODIFIER", 68, 77], ["intermediate epithelial cells", "OBSERVATION", 82, 111], ["resultant cell destruction", "OBSERVATION", 116, 142], ["host", "OBSERVATION_MODIFIER", 161, 165], ["inflammatory", "OBSERVATION_MODIFIER", 166, 178]]], ["Cells containing characteristic nuclear inclusions and sometimes multinucleation may be observed in lesions.", [["Cells", "ANATOMY", 0, 5], ["nuclear inclusions", "ANATOMY", 32, 50], ["lesions", "ANATOMY", 100, 107], ["Cells", "CELL", 0, 5], ["nuclear", "CELLULAR_COMPONENT", 32, 39], ["lesions", "PATHOLOGICAL_FORMATION", 100, 107], ["characteristic nuclear inclusions", "PROBLEM", 17, 50], ["multinucleation", "PROBLEM", 65, 80], ["lesions", "PROBLEM", 100, 107], ["characteristic", "OBSERVATION_MODIFIER", 17, 31], ["nuclear inclusions", "OBSERVATION", 32, 50], ["multinucleation", "OBSERVATION_MODIFIER", 65, 80], ["may be observed", "UNCERTAINTY", 81, 96], ["lesions", "OBSERVATION", 100, 107]]], ["In immunocompetent individuals, regional lymph nodes may be involved during primary infection, but the disease is usually contained at the primary site by innate antiviral responses.", [["lymph nodes", "ANATOMY", 41, 52], ["primary site", "ANATOMY", 139, 151], ["primary infection", "DISEASE", 76, 93], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 41, 52], ["regional lymph nodes", "PROBLEM", 32, 52], ["primary infection", "PROBLEM", 76, 93], ["the disease", "PROBLEM", 99, 110], ["immunocompetent", "OBSERVATION_MODIFIER", 3, 18], ["regional", "OBSERVATION_MODIFIER", 32, 40], ["lymph nodes", "OBSERVATION", 41, 52], ["primary", "OBSERVATION_MODIFIER", 76, 83], ["infection", "OBSERVATION", 84, 93], ["disease", "OBSERVATION", 103, 110], ["antiviral responses", "OBSERVATION", 162, 181]]], ["In neonates and others with deficient or impaired immune systems, local infection may be followed by viremic spread to multiple organs, including skin, liver, brain, adrenals, and lungs.", [["organs", "ANATOMY", 128, 134], ["skin", "ANATOMY", 146, 150], ["liver", "ANATOMY", 152, 157], ["brain", "ANATOMY", 159, 164], ["adrenals", "ANATOMY", 166, 174], ["lungs", "ANATOMY", 180, 185], ["impaired immune systems", "DISEASE", 41, 64], ["infection", "DISEASE", 72, 81], ["neonates", "ORGANISM", 3, 11], ["organs", "ORGAN", 128, 134], ["skin", "ORGAN", 146, 150], ["liver", "ORGAN", 152, 157], ["brain", "ORGAN", 159, 164], ["adrenals", "ORGAN", 166, 174], ["lungs", "ORGAN", 180, 185], ["deficient or impaired immune systems", "PROBLEM", 28, 64], ["local infection", "PROBLEM", 66, 81], ["skin, liver, brain, adrenals, and lungs", "PROBLEM", 146, 185], ["impaired", "OBSERVATION_MODIFIER", 41, 49], ["immune systems", "OBSERVATION", 50, 64], ["infection", "OBSERVATION", 72, 81], ["skin", "ANATOMY", 146, 150], ["liver", "ANATOMY", 152, 157], ["brain", "ANATOMY", 159, 164], ["adrenals", "ANATOMY", 166, 174], ["lungs", "ANATOMY", 180, 185]]], ["Disease may also disseminate in such individuals following reactivation of latent infection.", [["infection", "DISEASE", 82, 91], ["Disease", "PROBLEM", 0, 7], ["latent infection", "PROBLEM", 75, 91], ["latent", "OBSERVATION_MODIFIER", 75, 81], ["infection", "OBSERVATION", 82, 91]]], ["Visceral infection is characterized by a highly destructive coagulation necrosis of involved sites.", [["Visceral", "ANATOMY", 0, 8], ["sites", "ANATOMY", 93, 98], ["Visceral infection", "DISEASE", 0, 18], ["necrosis", "DISEASE", 72, 80], ["Visceral infection", "PROBLEM", 0, 18], ["a highly destructive coagulation necrosis", "PROBLEM", 39, 80], ["infection", "OBSERVATION", 9, 18], ["highly", "OBSERVATION_MODIFIER", 41, 47], ["destructive", "OBSERVATION_MODIFIER", 48, 59], ["coagulation", "OBSERVATION_MODIFIER", 60, 71], ["necrosis", "OBSERVATION", 72, 80]]], ["113 In a series of fatal cases of HSV pneumonia, inflammatory infiltrates, parenchymal necrosis, and hemorrhage were found at autopsy.", [["parenchymal", "ANATOMY", 75, 86], ["HSV pneumonia", "DISEASE", 34, 47], ["parenchymal necrosis", "DISEASE", 75, 95], ["hemorrhage", "DISEASE", 101, 111], ["HSV", "ORGANISM", 34, 37], ["HSV", "SPECIES", 34, 37], ["HSV pneumonia", "PROBLEM", 34, 47], ["inflammatory infiltrates", "PROBLEM", 49, 73], ["parenchymal necrosis", "PROBLEM", 75, 95], ["hemorrhage", "PROBLEM", 101, 111], ["fatal", "OBSERVATION_MODIFIER", 19, 24], ["HSV", "OBSERVATION_MODIFIER", 34, 37], ["pneumonia", "OBSERVATION", 38, 47], ["inflammatory", "OBSERVATION_MODIFIER", 49, 61], ["infiltrates", "OBSERVATION", 62, 73], ["parenchymal", "ANATOMY_MODIFIER", 75, 86], ["necrosis", "OBSERVATION", 87, 95], ["hemorrhage", "OBSERVATION", 101, 111]]], ["114 Patients with associated herpetic laryngotracheitis have necrotizing lesions in these areas.PathogenesisHSV pneumonia depends on obtaining a sample of involved lung for viral culture and testing for HSV antigen or nucleic acid.", [["necrotizing lesions", "ANATOMY", 61, 80], ["lung", "ANATOMY", 164, 168], ["herpetic laryngotracheitis", "DISEASE", 29, 55], ["necrotizing lesions", "DISEASE", 61, 80], ["pneumonia", "DISEASE", 112, 121], ["nucleic acid", "CHEMICAL", 218, 230], ["Patients", "ORGANISM", 4, 12], ["necrotizing lesions", "PATHOLOGICAL_FORMATION", 61, 80], ["lung", "ORGAN", 164, 168], ["HSV", "ORGANISM", 203, 206], ["antigen", "GENE_OR_GENE_PRODUCT", 207, 214], ["nucleic acid", "SIMPLE_CHEMICAL", 218, 230], ["HSV antigen", "PROTEIN", 203, 214], ["Patients", "SPECIES", 4, 12], ["HSV", "SPECIES", 203, 206], ["herpetic laryngotracheitis", "PROBLEM", 29, 55], ["necrotizing lesions in these areas", "PROBLEM", 61, 95], ["PathogenesisHSV pneumonia", "PROBLEM", 96, 121], ["a sample", "TEST", 143, 151], ["viral culture", "TEST", 173, 186], ["testing", "TEST", 191, 198], ["HSV antigen", "TEST", 203, 214], ["nucleic acid", "PROBLEM", 218, 230], ["herpetic", "OBSERVATION_MODIFIER", 29, 37], ["laryngotracheitis", "OBSERVATION", 38, 55], ["necrotizing", "OBSERVATION_MODIFIER", 61, 72], ["lesions", "OBSERVATION", 73, 80], ["areas", "ANATOMY_MODIFIER", 90, 95], ["pneumonia", "OBSERVATION", 112, 121], ["lung", "ANATOMY", 164, 168]]], ["Limited experience with lung biopsy in patients with HSV pneumonia suggests that obtaining adequate samples for culture and histologic examination may be a problem 114 and that, when possible, generous biopsy specimens should be obtained.Treatment and PreventionNo vaccines of proven value are currently available.", [["lung", "ANATOMY", 24, 28], ["samples", "ANATOMY", 100, 107], ["biopsy specimens", "ANATOMY", 202, 218], ["HSV pneumonia", "DISEASE", 53, 66], ["lung biopsy", "MULTI-TISSUE_STRUCTURE", 24, 35], ["patients", "ORGANISM", 39, 47], ["HSV", "ORGANISM", 53, 56], ["biopsy specimens", "CANCER", 202, 218], ["patients", "SPECIES", 39, 47], ["HSV", "SPECIES", 53, 56], ["lung biopsy", "TEST", 24, 35], ["HSV pneumonia", "PROBLEM", 53, 66], ["culture", "TEST", 112, 119], ["histologic examination", "TEST", 124, 146], ["generous biopsy specimens", "TEST", 193, 218], ["Treatment", "TREATMENT", 238, 247], ["PreventionNo vaccines", "TREATMENT", 252, 273], ["lung", "ANATOMY", 24, 28], ["biopsy", "OBSERVATION", 29, 35], ["pneumonia", "OBSERVATION", 57, 66]]], ["Primary HSV gingivostomatitis in immunocompetent persons responds to oral acyclovir treatment.", [["oral", "ANATOMY", 69, 73], ["HSV gingivostomatitis", "DISEASE", 8, 29], ["acyclovir", "CHEMICAL", 74, 83], ["acyclovir", "CHEMICAL", 74, 83], ["HSV", "ORGANISM", 8, 11], ["persons", "ORGANISM", 49, 56], ["oral", "ORGANISM_SUBDIVISION", 69, 73], ["acyclovir", "SIMPLE_CHEMICAL", 74, 83], ["persons", "SPECIES", 49, 56], ["HSV", "SPECIES", 8, 11], ["Primary HSV gingivostomatitis", "PROBLEM", 0, 29], ["oral acyclovir treatment", "TREATMENT", 69, 93], ["HSV gingivostomatitis", "OBSERVATION", 8, 29], ["immunocompetent", "OBSERVATION", 33, 48]]], ["Specific therapy of herpes simplex pneumonia has not been evaluated in controlled trials, but most clinicians would use intravenous acyclovir.", [["intravenous", "ANATOMY", 120, 131], ["herpes simplex pneumonia", "DISEASE", 20, 44], ["acyclovir", "CHEMICAL", 132, 141], ["acyclovir", "CHEMICAL", 132, 141], ["herpes simplex", "ORGANISM", 20, 34], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 120, 131], ["acyclovir", "SIMPLE_CHEMICAL", 132, 141], ["herpes simplex", "SPECIES", 20, 34], ["Specific therapy", "TREATMENT", 0, 16], ["herpes simplex pneumonia", "PROBLEM", 20, 44], ["intravenous acyclovir", "TREATMENT", 120, 141], ["herpes", "OBSERVATION_MODIFIER", 20, 26], ["simplex pneumonia", "OBSERVATION", 27, 44]]], ["In immunosuppressed patients with chronic mucocutaneous HSV infection, including pharyngitis and laryngotracheitis, prompt treatment with acyclovir is recommended to control the local infection and prevent possible dissemination to the lung.", [["lung", "ANATOMY", 236, 240], ["mucocutaneous HSV infection", "DISEASE", 42, 69], ["pharyngitis", "DISEASE", 81, 92], ["laryngotracheitis", "DISEASE", 97, 114], ["acyclovir", "CHEMICAL", 138, 147], ["infection", "DISEASE", 184, 193], ["acyclovir", "CHEMICAL", 138, 147], ["patients", "ORGANISM", 20, 28], ["HSV", "ORGANISM", 56, 59], ["acyclovir", "SIMPLE_CHEMICAL", 138, 147], ["lung", "ORGAN", 236, 240], ["patients", "SPECIES", 20, 28], ["HSV", "SPECIES", 56, 59], ["chronic mucocutaneous HSV infection", "PROBLEM", 34, 69], ["pharyngitis", "PROBLEM", 81, 92], ["laryngotracheitis", "PROBLEM", 97, 114], ["acyclovir", "TREATMENT", 138, 147], ["the local infection", "PROBLEM", 174, 193], ["dissemination to the lung", "PROBLEM", 215, 240], ["immunosuppressed", "OBSERVATION_MODIFIER", 3, 19], ["chronic", "OBSERVATION_MODIFIER", 34, 41], ["mucocutaneous HSV infection", "OBSERVATION", 42, 69], ["pharyngitis", "OBSERVATION", 81, 92], ["laryngotracheitis", "OBSERVATION", 97, 114], ["infection", "OBSERVATION", 184, 193], ["possible", "UNCERTAINTY", 206, 214], ["dissemination", "OBSERVATION", 215, 228], ["lung", "ANATOMY", 236, 240]]], ["Valacyclovir, the valine ester prodrug of acyclovir, and famciclovir, the prodrug of penciclovir, are orally administered drugs that are also effective for mucocutaneous HSV.Treatment and PreventionAntiviral susceptibility testing should be considered in patients with serious HSV infection who do not respond to initial treatment with oral valacyclovir or intravenous acyclovir.", [["oral", "ANATOMY", 336, 340], ["intravenous", "ANATOMY", 357, 368], ["Valacyclovir", "CHEMICAL", 0, 12], ["valine ester", "CHEMICAL", 18, 30], ["acyclovir", "CHEMICAL", 42, 51], ["famciclovir", "CHEMICAL", 57, 68], ["penciclovir", "CHEMICAL", 85, 96], ["HSV infection", "DISEASE", 277, 290], ["valacyclovir", "CHEMICAL", 341, 353], ["acyclovir", "CHEMICAL", 369, 378], ["Valacyclovir", "CHEMICAL", 0, 12], ["valine ester", "CHEMICAL", 18, 30], ["acyclovir", "CHEMICAL", 42, 51], ["famciclovir", "CHEMICAL", 57, 68], ["penciclovir", "CHEMICAL", 85, 96], ["valacyclovir", "CHEMICAL", 341, 353], ["acyclovir", "CHEMICAL", 369, 378], ["Valacyclovir", "SIMPLE_CHEMICAL", 0, 12], ["valine ester", "SIMPLE_CHEMICAL", 18, 30], ["acyclovir", "SIMPLE_CHEMICAL", 42, 51], ["famciclovir", "SIMPLE_CHEMICAL", 57, 68], ["penciclovir", "SIMPLE_CHEMICAL", 85, 96], ["HSV", "ORGANISM", 170, 173], ["patients", "ORGANISM", 255, 263], ["HSV", "ORGANISM", 277, 280], ["oral", "ORGANISM_SUBDIVISION", 336, 340], ["valacyclovir", "SIMPLE_CHEMICAL", 341, 353], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 357, 368], ["acyclovir", "SIMPLE_CHEMICAL", 369, 378], ["patients", "SPECIES", 255, 263], ["HSV", "SPECIES", 170, 173], ["HSV", "SPECIES", 277, 280], ["Valacyclovir", "TREATMENT", 0, 12], ["the valine ester prodrug", "TREATMENT", 14, 38], ["acyclovir", "TREATMENT", 42, 51], ["famciclovir", "TREATMENT", 57, 68], ["penciclovir", "TREATMENT", 85, 96], ["orally administered drugs", "TREATMENT", 102, 127], ["mucocutaneous HSV", "PROBLEM", 156, 173], ["Treatment", "TREATMENT", 174, 183], ["PreventionAntiviral susceptibility testing", "TEST", 188, 230], ["serious HSV infection", "PROBLEM", 269, 290], ["initial treatment", "TREATMENT", 313, 330], ["oral valacyclovir", "TREATMENT", 336, 353], ["intravenous acyclovir", "TREATMENT", 357, 378], ["infection", "OBSERVATION", 281, 290]]], ["Foscarnet is probably the best available alternative therapy.", [["Foscarnet", "CHEMICAL", 0, 9], ["Foscarnet", "CHEMICAL", 0, 9], ["Foscarnet", "SIMPLE_CHEMICAL", 0, 9], ["Foscarnet", "TREATMENT", 0, 9], ["alternative therapy", "TREATMENT", 41, 60]]], ["Prophylactic intravenous and oral acyclovir regimens have been shown to be effective in preventing recurrences of mucocutaneous HSV infection in seropositive patients undergoing intense periods of immunosuppression, such as bone marrow transplant recipients or patients receiving combination chemotherapy for leukemia.INFLUENZA VIRUSInfluenza viruses belong to the family Orthomyxoviridae and are classified into three distinct types: influenza A, influenza B, and influenza C virus.", [["intravenous", "ANATOMY", 13, 24], ["oral", "ANATOMY", 29, 33], ["bone marrow", "ANATOMY", 224, 235], ["leukemia", "ANATOMY", 309, 317], ["acyclovir", "CHEMICAL", 34, 43], ["HSV infection", "DISEASE", 128, 141], ["leukemia", "DISEASE", 309, 317], ["influenza A", "DISEASE", 435, 446], ["influenza B", "DISEASE", 448, 459], ["influenza C virus", "DISEASE", 465, 482], ["acyclovir", "CHEMICAL", 34, 43], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 13, 24], ["oral", "ORGANISM_SUBDIVISION", 29, 33], ["acyclovir", "SIMPLE_CHEMICAL", 34, 43], ["HSV", "ORGANISM", 128, 131], ["patients", "ORGANISM", 158, 166], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 224, 235], ["recipients", "ORGANISM", 247, 257], ["patients", "ORGANISM", 261, 269], ["leukemia", "CANCER", 309, 317], ["Orthomyxoviridae", "GENE_OR_GENE_PRODUCT", 372, 388], ["influenza A", "ORGANISM", 435, 446], ["influenza B", "ORGANISM", 448, 459], ["influenza C virus", "ORGANISM", 465, 482], ["patients", "SPECIES", 158, 166], ["patients", "SPECIES", 261, 269], ["influenza C virus", "SPECIES", 465, 482], ["HSV", "SPECIES", 128, 131], ["influenza C virus", "SPECIES", 465, 482], ["Prophylactic intravenous", "TREATMENT", 0, 24], ["oral acyclovir regimens", "TREATMENT", 29, 52], ["mucocutaneous HSV infection", "PROBLEM", 114, 141], ["immunosuppression", "TREATMENT", 197, 214], ["bone marrow transplant recipients", "TREATMENT", 224, 257], ["combination chemotherapy", "TREATMENT", 280, 304], ["leukemia", "PROBLEM", 309, 317], ["INFLUENZA VIRUSInfluenza viruses", "PROBLEM", 318, 350], ["influenza A", "PROBLEM", 435, 446], ["influenza B", "PROBLEM", 448, 459], ["influenza C virus", "PROBLEM", 465, 482], ["mucocutaneous HSV infection", "OBSERVATION", 114, 141], ["immunosuppression", "OBSERVATION", 197, 214], ["bone", "ANATOMY", 224, 228], ["leukemia", "OBSERVATION", 309, 317], ["influenza", "OBSERVATION", 435, 444]]], ["All three viruses share the presence of a host cell-derived envelope, envelope glycoproteins important for entry and egress from cells, and a segmented negative-sense, single-stranded RNA genome.", [["cell", "ANATOMY", 47, 51], ["cells", "ANATOMY", 129, 134], ["cell", "CELL", 47, 51], ["cells", "CELL", 129, 134], ["envelope glycoproteins", "PROTEIN", 70, 92], ["single-stranded RNA genome", "DNA", 168, 194], ["a host cell", "PROBLEM", 40, 51], ["envelope glycoproteins", "TREATMENT", 70, 92], ["entry and egress from cells", "PROBLEM", 107, 134], ["viruses", "OBSERVATION", 10, 17], ["host cell", "OBSERVATION", 42, 51], ["RNA genome", "OBSERVATION", 184, 194]]], ["The standard nomenclature for influenza viruses includes the influenza type, place of initial isolation, strain designation, and year of isolation.", [["influenza viruses", "DISEASE", 30, 47], ["influenza", "DISEASE", 61, 70], ["influenza viruses", "ORGANISM", 30, 47], ["influenza viruses", "PROBLEM", 30, 47], ["the influenza type", "PROBLEM", 57, 75]]], ["For example, an influenza A virus isolated from a patient in Puerto Rico in 1934 is given the strain designation A/Puerto Rico/8/34.INFLUENZA VIRUSThe envelope glycoproteins are the hemagglutinin (HA) and neuraminidase (NA).", [["influenza A virus", "DISEASE", 16, 33], ["influenza A virus", "ORGANISM", 16, 33], ["patient", "ORGANISM", 50, 57], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 182, 195], ["HA", "GENE_OR_GENE_PRODUCT", 197, 199], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 205, 218], ["envelope glycoproteins", "PROTEIN", 151, 173], ["hemagglutinin", "PROTEIN", 182, 195], ["HA", "PROTEIN", 197, 199], ["neuraminidase", "PROTEIN", 205, 218], ["NA", "PROTEIN", 220, 222], ["influenza A virus", "SPECIES", 16, 33], ["patient", "SPECIES", 50, 57], ["influenza A virus", "SPECIES", 16, 33], ["A/Puerto Rico/8/34", "SPECIES", 113, 131], ["an influenza A virus", "PROBLEM", 13, 33], ["INFLUENZA VIRUSThe envelope glycoproteins", "TREATMENT", 132, 173], ["the hemagglutinin (HA)", "TREATMENT", 178, 200], ["neuraminidase (NA)", "TREATMENT", 205, 223], ["influenza", "OBSERVATION", 16, 25]]], ["HA mediates binding of the virus to sialic (also known as neuraminic) acid residues on host cell glycoproteins and glycolipids and is essential for viral entry.", [["cell", "ANATOMY", 92, 96], ["HA", "CHEMICAL", 0, 2], ["neuraminic) acid", "CHEMICAL", 58, 74], ["neuraminic) acid", "CHEMICAL", 58, 74], ["HA", "GENE_OR_GENE_PRODUCT", 0, 2], ["neuraminic) acid", "SIMPLE_CHEMICAL", 58, 74], ["host cell", "CELL", 87, 96], ["HA mediates binding", "PROBLEM", 0, 19], ["the virus", "PROBLEM", 23, 32], ["neuraminic) acid residues", "PROBLEM", 58, 83], ["host cell glycoproteins", "TREATMENT", 87, 110], ["glycolipids", "TREATMENT", 115, 126], ["viral entry", "PROBLEM", 148, 159], ["essential for", "UNCERTAINTY", 134, 147], ["viral entry", "OBSERVATION", 148, 159]]], ["NA cleaves terminal sialic acid (neuraminic acid) residues from host cell molecules, thereby releasing new viral particles from the cell in which they replicated.", [["cell molecules", "ANATOMY", 69, 83], ["cell", "ANATOMY", 132, 136], ["NA", "CHEMICAL", 0, 2], ["sialic acid", "CHEMICAL", 20, 31], ["neuraminic acid", "CHEMICAL", 33, 48], ["sialic acid", "CHEMICAL", 20, 31], ["neuraminic acid", "CHEMICAL", 33, 48], ["NA", "SIMPLE_CHEMICAL", 0, 2], ["sialic acid", "AMINO_ACID", 20, 31], ["neuraminic acid", "SIMPLE_CHEMICAL", 33, 48], ["cell", "CELL", 132, 136], ["NA", "TEST", 0, 2], ["terminal sialic acid (neuraminic acid)", "TREATMENT", 11, 49], ["host cell molecules", "PROBLEM", 64, 83], ["releasing new viral particles", "PROBLEM", 93, 122], ["terminal", "OBSERVATION_MODIFIER", 11, 19], ["sialic acid", "OBSERVATION", 20, 31], ["host cell molecules", "OBSERVATION", 64, 83], ["new", "OBSERVATION_MODIFIER", 103, 106], ["viral particles", "OBSERVATION", 107, 122]]], ["At least 16 highly divergent, antigenically distinct HAs (H1 to H16), and at least 9 distinct NAs (N1 to N9), have been described in influenza A viruses.", [["influenza A viruses", "DISEASE", 133, 152], ["H1 to H16", "GENE_OR_GENE_PRODUCT", 58, 67], ["influenza A viruses", "ORGANISM", 133, 152], ["H16", "PROTEIN", 64, 67], ["influenza A viruses", "SPECIES", 133, 152], ["influenza A viruses", "PROBLEM", 133, 152], ["highly divergent", "OBSERVATION_MODIFIER", 12, 28], ["influenza", "OBSERVATION", 133, 142]]], ["Influenza A viruses are therefore further divided into subtypes on the basis of the hemagglutinin (H) and neuraminidase (N) (e.g., H1N1 or H3N2).", [["Influenza A viruses", "ORGANISM", 0, 19], ["hemagglutinin (H)", "GENE_OR_GENE_PRODUCT", 84, 101], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 106, 119], ["Influenza A viruses", "SPECIES", 0, 19], ["Influenza A viruses", "PROBLEM", 0, 19], ["the hemagglutinin", "TREATMENT", 80, 97], ["neuraminidase", "PROBLEM", 106, 119], ["H1N1", "PROBLEM", 131, 135], ["H3N2", "PROBLEM", 139, 143], ["viruses", "OBSERVATION", 12, 19]]], ["Infection with influenza virus results in long-lived resistance to reinfection with the homologous virus.", [["influenza virus", "DISEASE", 15, 30], ["influenza virus", "ORGANISM", 15, 30], ["influenza virus", "SPECIES", 15, 30], ["Infection", "PROBLEM", 0, 9], ["influenza virus", "PROBLEM", 15, 30], ["reinfection", "PROBLEM", 67, 78], ["the homologous virus", "PROBLEM", 84, 104], ["influenza virus", "OBSERVATION", 15, 30]]], ["Infection induces both systemic and local antibodies, as well as cellular distinctive.", [["cellular", "ANATOMY", 65, 73], ["cellular", "CELL", 65, 73], ["Infection", "PROBLEM", 0, 9], ["both systemic and local antibodies", "PROBLEM", 18, 52], ["both", "OBSERVATION_MODIFIER", 18, 22], ["systemic", "OBSERVATION_MODIFIER", 23, 31], ["local antibodies", "OBSERVATION", 36, 52], ["cellular", "OBSERVATION_MODIFIER", 65, 73], ["distinctive", "OBSERVATION_MODIFIER", 74, 85]]], ["119 In one study, more than one half of the patients had concomitant pulmonary infection with other microorganisms, including bacterial, candidal, and Aspergillus species and cytomegalovirus.", [["pulmonary", "ANATOMY", 69, 78], ["candidal", "ANATOMY", 137, 145], ["pulmonary infection", "DISEASE", 69, 88], ["candidal", "DISEASE", 137, 145], ["Aspergillus species", "DISEASE", 151, 170], ["patients", "ORGANISM", 44, 52], ["pulmonary", "ORGAN", 69, 78], ["candidal", "PATHOLOGICAL_FORMATION", 137, 145], ["Aspergillus species", "ORGANISM", 151, 170], ["cytomegalovirus", "ORGANISM", 175, 190], ["patients", "SPECIES", 44, 52], ["one study", "TEST", 7, 16], ["concomitant pulmonary infection", "PROBLEM", 57, 88], ["other microorganisms", "PROBLEM", 94, 114], ["bacterial, candidal", "PROBLEM", 126, 145], ["Aspergillus species", "PROBLEM", 151, 170], ["cytomegalovirus", "PROBLEM", 175, 190], ["pulmonary", "ANATOMY", 69, 78], ["infection", "OBSERVATION", 79, 88], ["bacterial", "OBSERVATION_MODIFIER", 126, 135], ["candidal", "OBSERVATION", 137, 145], ["Aspergillus species", "OBSERVATION", 151, 170], ["cytomegalovirus", "OBSERVATION", 175, 190]]], ["114 Histologic evidence of herpetic esophagitis was present in 10 of 16 patients with herpes pneumonia in whom esophageal examination was performed.", [["esophageal", "ANATOMY", 111, 121], ["herpetic esophagitis", "DISEASE", 27, 47], ["herpes pneumonia", "DISEASE", 86, 102], ["herpetic esophagitis", "PATHOLOGICAL_FORMATION", 27, 47], ["patients", "ORGANISM", 72, 80], ["herpes", "ORGANISM", 86, 92], ["esophageal", "ORGAN", 111, 121], ["patients", "SPECIES", 72, 80], ["herpetic esophagitis", "PROBLEM", 27, 47], ["herpes pneumonia", "PROBLEM", 86, 102], ["esophageal examination", "TEST", 111, 133], ["evidence of", "UNCERTAINTY", 15, 26], ["herpetic esophagitis", "OBSERVATION", 27, 47], ["pneumonia", "OBSERVATION", 93, 102], ["esophageal", "ANATOMY", 111, 121]]], ["120 Herpes simplex virus infection of the lower airway has also been found in association with ARDS.", [["lower airway", "ANATOMY", 42, 54], ["Herpes simplex virus infection", "DISEASE", 4, 34], ["ARDS", "DISEASE", 95, 99], ["120", "ORGANISM", 0, 3], ["Herpes simplex virus", "ORGANISM", 4, 24], ["lower airway", "ORGAN", 42, 54], ["Herpes simplex virus", "SPECIES", 4, 24], ["Herpes simplex virus", "SPECIES", 4, 24], ["Herpes simplex virus infection of the lower airway", "PROBLEM", 4, 54], ["ARDS", "PROBLEM", 95, 99], ["simplex virus", "OBSERVATION", 11, 24], ["lower", "ANATOMY_MODIFIER", 42, 47], ["airway", "ANATOMY", 48, 54], ["ARDS", "OBSERVATION", 95, 99]]], ["The relationship of HSV infection to ARDS is unclear, but the presence of HSV in the lower respiratory tract was associated with the need for prolonged respiratory support and an increased late mortality.", [["lower respiratory tract", "ANATOMY", 85, 108], ["respiratory", "ANATOMY", 152, 163], ["HSV infection", "DISEASE", 20, 33], ["ARDS", "DISEASE", 37, 41], ["HSV in the lower respiratory tract", "DISEASE", 74, 108], ["HSV", "ORGANISM", 20, 23], ["HSV", "ORGANISM", 74, 77], ["lower", "ORGANISM_SUBDIVISION", 85, 90], ["respiratory tract", "ORGANISM_SUBDIVISION", 91, 108], ["HSV", "SPECIES", 20, 23], ["HSV", "SPECIES", 74, 77], ["HSV infection", "PROBLEM", 20, 33], ["ARDS", "PROBLEM", 37, 41], ["HSV in the lower respiratory tract", "PROBLEM", 74, 108], ["prolonged respiratory support", "TREATMENT", 142, 171], ["an increased late mortality", "PROBLEM", 176, 203], ["HSV", "OBSERVATION_MODIFIER", 20, 23], ["infection", "OBSERVATION", 24, 33], ["ARDS", "OBSERVATION", 37, 41], ["HSV", "OBSERVATION", 74, 77], ["lower", "ANATOMY_MODIFIER", 85, 90], ["respiratory tract", "ANATOMY", 91, 108], ["increased", "OBSERVATION_MODIFIER", 179, 188], ["late", "OBSERVATION_MODIFIER", 189, 193], ["mortality", "OBSERVATION", 194, 203]]], ["Isolation of HSV from lower respiratory tract secretions has also been common in mechanically ventilated patients and may be associated with a poor outcome, 121, 122 although it is unclear whether this represents reactivation as a consequence of severe illness or whether the virus plays a direct role in mortality.", [["lower respiratory tract secretions", "ANATOMY", 22, 56], ["HSV", "ORGANISM", 13, 16], ["lower", "ORGANISM_SUBDIVISION", 22, 27], ["respiratory tract", "ORGANISM_SUBDIVISION", 28, 45], ["secretions", "ORGANISM_SUBSTANCE", 46, 56], ["patients", "ORGANISM", 105, 113], ["patients", "SPECIES", 105, 113], ["HSV", "SPECIES", 13, 16], ["HSV", "PROBLEM", 13, 16], ["lower respiratory tract secretions", "PROBLEM", 22, 56], ["severe illness", "PROBLEM", 246, 260], ["the virus", "PROBLEM", 272, 281], ["HSV", "OBSERVATION", 13, 16], ["lower", "ANATOMY_MODIFIER", 22, 27], ["respiratory tract", "ANATOMY", 28, 45], ["reactivation", "OBSERVATION", 213, 225]]], ["123, 124DiagnosisThe clinical features of herpetic gingivostomatitis are sufficiently characteristic to permit accurate diagnosis in most cases.", [["herpetic gingivostomatitis", "DISEASE", 42, 68], ["herpetic gingivostomatitis", "PROBLEM", 42, 68], ["herpetic gingivostomatitis", "OBSERVATION", 42, 68]]], ["Other conditions with similar oral lesions are limited and include herpangina, aphthous stomatitis, Steven-Johnson syndrome, and other enanthems resulting from infection and drug sensitivities.", [["oral lesions", "ANATOMY", 30, 42], ["herpangina", "DISEASE", 67, 77], ["aphthous stomatitis", "DISEASE", 79, 98], ["Steven-Johnson syndrome", "DISEASE", 100, 123], ["infection", "DISEASE", 160, 169], ["oral lesions", "PATHOLOGICAL_FORMATION", 30, 42], ["similar oral lesions", "PROBLEM", 22, 42], ["herpangina", "PROBLEM", 67, 77], ["aphthous stomatitis", "PROBLEM", 79, 98], ["Johnson syndrome", "PROBLEM", 107, 123], ["other enanthems", "PROBLEM", 129, 144], ["infection", "PROBLEM", 160, 169], ["drug sensitivities", "PROBLEM", 174, 192], ["lesions", "OBSERVATION", 35, 42], ["aphthous stomatitis", "OBSERVATION", 79, 98], ["infection", "OBSERVATION", 160, 169]]], ["In herpangina, the lesions are smaller (1 to 3 mm), more often vesicular, and usually localized to the soft palate.", [["herpangina", "ANATOMY", 3, 13], ["lesions", "ANATOMY", 19, 26], ["vesicular", "ANATOMY", 63, 72], ["soft palate", "ANATOMY", 103, 114], ["herpangina", "DISEASE", 3, 13], ["herpangina", "CANCER", 3, 13], ["lesions", "PATHOLOGICAL_FORMATION", 19, 26], ["palate", "ORGAN", 108, 114], ["the lesions", "PROBLEM", 15, 26], ["lesions", "OBSERVATION", 19, 26], ["smaller", "OBSERVATION_MODIFIER", 31, 38], ["1 to 3 mm", "OBSERVATION_MODIFIER", 40, 49], ["often", "OBSERVATION_MODIFIER", 57, 62], ["vesicular", "OBSERVATION_MODIFIER", 63, 72], ["soft palate", "ANATOMY", 103, 114]]], ["The ulcers in aphthous stomatitis are few, relatively deep, and circumscribed.", [["ulcers", "ANATOMY", 4, 10], ["ulcers", "DISEASE", 4, 10], ["aphthous stomatitis", "DISEASE", 14, 33], ["ulcers", "PATHOLOGICAL_FORMATION", 4, 10], ["The ulcers in aphthous stomatitis", "PROBLEM", 0, 33], ["ulcers", "OBSERVATION", 4, 10], ["aphthous stomatitis", "OBSERVATION", 14, 33], ["few", "OBSERVATION_MODIFIER", 38, 41], ["relatively", "OBSERVATION_MODIFIER", 43, 53], ["deep", "OBSERVATION_MODIFIER", 54, 58], ["circumscribed", "OBSERVATION_MODIFIER", 64, 77]]], ["Aphthosis is characterized by periodic recurrence, whereas acute herpetic gingivostomatitis and pharyngitis are limited to a single occurrence.", [["Aphthosis", "DISEASE", 0, 9], ["gingivostomatitis", "DISEASE", 74, 91], ["pharyngitis", "DISEASE", 96, 107], ["Aphthosis", "PROBLEM", 0, 9], ["periodic recurrence", "PROBLEM", 30, 49], ["acute herpetic gingivostomatitis", "PROBLEM", 59, 91], ["pharyngitis", "PROBLEM", 96, 107], ["periodic", "OBSERVATION_MODIFIER", 30, 38], ["recurrence", "OBSERVATION", 39, 49], ["acute", "OBSERVATION_MODIFIER", 59, 64], ["herpetic gingivostomatitis", "OBSERVATION", 65, 91], ["pharyngitis", "OBSERVATION", 96, 107]]], ["Herpetic pharyngitis, when exudative, must be distinguished from pharyngitis due to Streptococcus pyogenes, adenovirus, Epstein-Barr virus, and diphtheria.", [["pharyngitis", "DISEASE", 9, 20], ["pharyngitis", "DISEASE", 65, 76], ["Streptococcus pyogenes", "DISEASE", 84, 106], ["Epstein-Barr virus", "DISEASE", 120, 138], ["diphtheria", "DISEASE", 144, 154], ["Streptococcus pyogenes", "ORGANISM", 84, 106], ["adenovirus", "ORGANISM", 108, 118], ["Epstein-Barr virus", "ORGANISM", 120, 138], ["Streptococcus pyogenes", "SPECIES", 84, 106], ["Streptococcus pyogenes", "SPECIES", 84, 106], ["Epstein-Barr virus", "SPECIES", 120, 138], ["Herpetic pharyngitis", "PROBLEM", 0, 20], ["exudative", "PROBLEM", 27, 36], ["pharyngitis", "PROBLEM", 65, 76], ["Streptococcus pyogenes", "PROBLEM", 84, 106], ["adenovirus", "PROBLEM", 108, 118], ["Epstein-Barr virus", "PROBLEM", 120, 138], ["diphtheria", "PROBLEM", 144, 154], ["pharyngitis", "OBSERVATION", 9, 20], ["pharyngitis", "OBSERVATION", 65, 76], ["Streptococcus pyogenes", "OBSERVATION", 84, 106], ["Barr virus", "OBSERVATION", 128, 138]]], ["The diagnosis of acute herpetic disease of the oropharynx can be confirmed by examination of Giemsa-or Wrightstained smears of scrapings from the base of a fresh lesion (Tzanck test) and by culture of scrapings or swab specimens.", [["oropharynx", "ANATOMY", 47, 57], ["scrapings", "ANATOMY", 127, 136], ["lesion", "ANATOMY", 162, 168], ["scrapings", "ANATOMY", 201, 210], ["swab specimens", "ANATOMY", 214, 228], ["herpetic disease of the oropharynx", "DISEASE", 23, 57], ["oropharynx", "ORGAN", 47, 57], ["scrapings", "TISSUE", 127, 136], ["scrapings", "TISSUE", 201, 210], ["swab specimens", "CANCER", 214, 228], ["acute herpetic disease of the oropharynx", "PROBLEM", 17, 57], ["examination", "TEST", 78, 89], ["Giemsa", "TEST", 93, 99], ["Wrightstained smears of scrapings", "PROBLEM", 103, 136], ["a fresh lesion", "PROBLEM", 154, 168], ["Tzanck test", "TEST", 170, 181], ["scrapings", "TEST", 201, 210], ["swab specimens", "TEST", 214, 228], ["acute", "OBSERVATION_MODIFIER", 17, 22], ["herpetic", "OBSERVATION", 23, 31], ["oropharynx", "ANATOMY", 47, 57], ["fresh", "OBSERVATION_MODIFIER", 156, 161], ["lesion", "OBSERVATION", 162, 168]]], ["Techniques for the rapid detection of viral antigens or DNA are widely available.DiagnosisChronic ulcerative pharyngitis due to HSV has a characteristic clinical appearance that is highly suggestive of the diagnosis.", [["ulcerative pharyngitis", "DISEASE", 98, 120], ["HSV", "DISEASE", 128, 131], ["DNA", "CELLULAR_COMPONENT", 56, 59], ["HSV", "ORGANISM", 128, 131], ["viral antigens", "PROTEIN", 38, 52], ["HSV", "SPECIES", 128, 131], ["the rapid detection", "TEST", 15, 34], ["viral antigens", "PROBLEM", 38, 52], ["DNA", "PROBLEM", 56, 59], ["Chronic ulcerative pharyngitis", "PROBLEM", 90, 120], ["HSV", "PROBLEM", 128, 131], ["viral", "OBSERVATION", 38, 43], ["Chronic", "OBSERVATION_MODIFIER", 90, 97], ["ulcerative", "OBSERVATION_MODIFIER", 98, 108], ["pharyngitis", "OBSERVATION", 109, 120], ["HSV", "OBSERVATION", 128, 131], ["highly suggestive of", "UNCERTAINTY", 181, 201]]], ["The white color of the lesions may lead to confusion with candidiasis, but the lesion of thrush is an easily removable plaque, not an ulcer.", [["lesions", "ANATOMY", 23, 30], ["lesion", "ANATOMY", 79, 85], ["plaque", "ANATOMY", 119, 125], ["ulcer", "ANATOMY", 134, 139], ["confusion", "DISEASE", 43, 52], ["candidiasis", "DISEASE", 58, 69], ["thrush", "DISEASE", 89, 95], ["plaque", "DISEASE", 119, 125], ["ulcer", "DISEASE", 134, 139], ["lesions", "PATHOLOGICAL_FORMATION", 23, 30], ["candidiasis", "PATHOLOGICAL_FORMATION", 58, 69], ["plaque", "PATHOLOGICAL_FORMATION", 119, 125], ["ulcer", "PATHOLOGICAL_FORMATION", 134, 139], ["the lesions", "PROBLEM", 19, 30], ["confusion", "PROBLEM", 43, 52], ["candidiasis", "PROBLEM", 58, 69], ["the lesion of thrush", "PROBLEM", 75, 95], ["an easily removable plaque", "PROBLEM", 99, 125], ["an ulcer", "PROBLEM", 131, 139], ["white", "OBSERVATION_MODIFIER", 4, 9], ["lesions", "OBSERVATION", 23, 30], ["may lead to", "UNCERTAINTY", 31, 42], ["candidiasis", "OBSERVATION", 58, 69], ["lesion", "OBSERVATION", 79, 85], ["thrush", "OBSERVATION", 89, 95], ["easily", "OBSERVATION_MODIFIER", 102, 108], ["removable", "OBSERVATION_MODIFIER", 109, 118], ["plaque", "OBSERVATION", 119, 125], ["ulcer", "OBSERVATION", 134, 139]]], ["Thrush and chronic herpetic pharyngitis may coexist in the same patient.", [["herpetic pharyngitis", "DISEASE", 19, 39], ["patient", "ORGANISM", 64, 71], ["patient", "SPECIES", 64, 71], ["Thrush", "PROBLEM", 0, 6], ["chronic herpetic pharyngitis", "PROBLEM", 11, 39], ["chronic", "OBSERVATION_MODIFIER", 11, 18], ["herpetic", "OBSERVATION_MODIFIER", 19, 27], ["pharyngitis", "OBSERVATION", 28, 39]]], ["The lesions of aphthous stomatitis are not characteristically found in the back of the oropharynx and are relatively small (2 to 5 mm) with a fixed diameter.DiagnosisThe diagnosis of herpetic laryngotracheitis may be difficult because of the inaccessibility of the lesions.", [["lesions", "ANATOMY", 4, 11], ["back", "ANATOMY", 75, 79], ["oropharynx", "ANATOMY", 87, 97], ["herpetic laryngotracheitis", "ANATOMY", 183, 209], ["lesions", "ANATOMY", 265, 272], ["aphthous stomatitis", "DISEASE", 15, 34], ["herpetic laryngotracheitis", "DISEASE", 183, 209], ["lesions", "PATHOLOGICAL_FORMATION", 4, 11], ["aphthous stomatitis", "ORGANISM", 15, 34], ["oropharynx", "ORGAN", 87, 97], ["lesions", "PATHOLOGICAL_FORMATION", 265, 272], ["aphthous stomatitis", "PROBLEM", 15, 34], ["herpetic laryngotracheitis", "PROBLEM", 183, 209], ["the lesions", "PROBLEM", 261, 272], ["lesions", "OBSERVATION", 4, 11], ["aphthous stomatitis", "OBSERVATION", 15, 34], ["back", "ANATOMY_MODIFIER", 75, 79], ["oropharynx", "ANATOMY", 87, 97], ["relatively", "OBSERVATION_MODIFIER", 106, 116], ["small", "OBSERVATION_MODIFIER", 117, 122], ["2 to 5 mm", "OBSERVATION_MODIFIER", 124, 133], ["fixed", "OBSERVATION_MODIFIER", 142, 147], ["diameter", "OBSERVATION_MODIFIER", 148, 156], ["herpetic laryngotracheitis", "OBSERVATION", 183, 209], ["lesions", "OBSERVATION", 265, 272]]], ["The disease should be suspected in any immunocompromised patient with herpetic lesions of the mouth, upper airway, or skin of the face, especially if endotracheal intubation has been performed.", [["herpetic lesions", "ANATOMY", 70, 86], ["mouth", "ANATOMY", 94, 99], ["upper airway", "ANATOMY", 101, 113], ["skin", "ANATOMY", 118, 122], ["endotracheal", "ANATOMY", 150, 162], ["herpetic lesions of the mouth", "DISEASE", 70, 99], ["patient", "ORGANISM", 57, 64], ["herpetic lesions", "PATHOLOGICAL_FORMATION", 70, 86], ["mouth", "ORGANISM_SUBDIVISION", 94, 99], ["upper airway", "ORGANISM_SUBDIVISION", 101, 113], ["skin", "ORGAN", 118, 122], ["patient", "SPECIES", 57, 64], ["The disease", "PROBLEM", 0, 11], ["herpetic lesions of the mouth, upper airway, or skin of the face", "PROBLEM", 70, 134], ["endotracheal intubation", "TREATMENT", 150, 173], ["disease", "OBSERVATION", 4, 11], ["should be suspected", "UNCERTAINTY", 12, 31], ["herpetic", "OBSERVATION_MODIFIER", 70, 78], ["lesions", "OBSERVATION", 79, 86], ["mouth", "ANATOMY", 94, 99], ["upper", "ANATOMY_MODIFIER", 101, 106], ["airway", "ANATOMY", 107, 113], ["skin", "ANATOMY", 118, 122], ["face", "ANATOMY", 130, 134]]], ["In such patients, bronchoscopic examination is indicated for sampling of suspected areas for cytology and viral culture.DiagnosisThe diagnosis of HSV pneumonia should be suspected in any immunocompromised patient with unexplained pulmonary opacities, especially in the presence of herpetic laryngotracheitis or herpetic lesions of other mucocutaneous sites, including the genital area.", [["pulmonary", "ANATOMY", 230, 239], ["herpetic lesions", "ANATOMY", 311, 327], ["mucocutaneous sites", "ANATOMY", 337, 356], ["genital area", "ANATOMY", 372, 384], ["HSV pneumonia", "DISEASE", 146, 159], ["pulmonary opacities", "DISEASE", 230, 249], ["herpetic laryngotracheitis", "DISEASE", 281, 307], ["patients", "ORGANISM", 8, 16], ["HSV", "ORGANISM", 146, 149], ["patient", "ORGANISM", 205, 212], ["pulmonary", "ORGAN", 230, 239], ["herpetic lesions", "PATHOLOGICAL_FORMATION", 311, 327], ["mucocutaneous sites", "MULTI-TISSUE_STRUCTURE", 337, 356], ["genital", "ORGANISM_SUBDIVISION", 372, 379], ["patients", "SPECIES", 8, 16], ["patient", "SPECIES", 205, 212], ["HSV", "SPECIES", 146, 149], ["bronchoscopic examination", "TEST", 18, 43], ["cytology", "TEST", 93, 101], ["viral culture", "TEST", 106, 119], ["HSV pneumonia", "PROBLEM", 146, 159], ["unexplained pulmonary opacities", "PROBLEM", 218, 249], ["herpetic laryngotracheitis", "PROBLEM", 281, 307], ["herpetic lesions of other mucocutaneous sites", "PROBLEM", 311, 356], ["the genital area", "PROBLEM", 368, 384], ["HSV", "OBSERVATION_MODIFIER", 146, 149], ["pneumonia", "OBSERVATION", 150, 159], ["pulmonary", "ANATOMY", 230, 239], ["opacities", "OBSERVATION", 240, 249], ["herpetic", "OBSERVATION_MODIFIER", 281, 289], ["laryngotracheitis", "OBSERVATION", 290, 307], ["herpetic", "OBSERVATION_MODIFIER", 311, 319], ["lesions", "OBSERVATION", 320, 327], ["mucocutaneous sites", "OBSERVATION", 337, 356], ["genital", "ANATOMY", 372, 379], ["area", "ANATOMY_MODIFIER", 380, 384]]], ["Perhaps for this reason, older adults were relatively spared, and the pandemic disease affected mainly children, adolescents, and adults younger than 50.DiagnosisAlthough the circulation of multiple antigenic subtypes is confined to influenza A viruses, influenza B viruses undergo significant antigenic variation as well.", [["influenza A viruses", "DISEASE", 233, 252], ["influenza B", "DISEASE", 254, 265], ["adults", "ORGANISM", 31, 37], ["children", "ORGANISM", 103, 111], ["influenza A viruses", "ORGANISM", 233, 252], ["influenza B viruses", "ORGANISM", 254, 273], ["children", "SPECIES", 103, 111], ["adolescents", "SPECIES", 113, 124], ["influenza A viruses", "SPECIES", 233, 252], ["influenza B viruses", "SPECIES", 254, 273], ["the pandemic disease", "PROBLEM", 66, 86], ["multiple antigenic subtypes", "PROBLEM", 190, 217], ["influenza A viruses", "PROBLEM", 233, 252], ["influenza B viruses", "PROBLEM", 254, 273], ["significant antigenic variation", "PROBLEM", 282, 313], ["multiple", "OBSERVATION_MODIFIER", 190, 198], ["antigenic subtypes", "OBSERVATION", 199, 217], ["influenza", "OBSERVATION", 233, 242], ["significant", "OBSERVATION_MODIFIER", 282, 293], ["antigenic variation", "OBSERVATION", 294, 313]]], ["Currently, two antigenically distinct lineages of influenza B have co-circulated, designated the \"Yamagata\" and the \"Victoria\" lineages.", [["influenza B", "DISEASE", 50, 61], ["influenza B", "ORGANISM", 50, 61], ["influenza B", "PROBLEM", 50, 61], ["antigenically", "OBSERVATION_MODIFIER", 15, 28], ["distinct", "OBSERVATION_MODIFIER", 29, 37], ["lineages", "OBSERVATION_MODIFIER", 38, 46], ["influenza", "OBSERVATION", 50, 59]]], ["Because antibodies to viruses in one lineage do not provide substantial protection against the other, recent influenza vaccines have included examples of both (see later).PathogenesisInfection with influenza virus in humans is generally limited to the respiratory tract.", [["respiratory tract", "ANATOMY", 252, 269], ["PathogenesisInfection", "DISEASE", 171, 192], ["influenza virus", "DISEASE", 198, 213], ["influenza virus", "ORGANISM", 198, 213], ["humans", "ORGANISM", 217, 223], ["respiratory tract", "ORGANISM_SUBDIVISION", 252, 269], ["antibodies", "PROTEIN", 8, 18], ["influenza virus", "SPECIES", 198, 213], ["humans", "SPECIES", 217, 223], ["humans", "SPECIES", 217, 223], ["antibodies to viruses", "PROBLEM", 8, 29], ["recent influenza vaccines", "TREATMENT", 102, 127], ["PathogenesisInfection", "PROBLEM", 171, 192], ["influenza virus in humans", "PROBLEM", 198, 223], ["influenza virus", "OBSERVATION", 198, 213], ["respiratory tract", "ANATOMY", 252, 269]]], ["After inoculation, the incubation period is thought to be from 18 to 72 hours depending in part on the inoculum dose.", [["inoculation", "TREATMENT", 6, 17], ["the inoculum dose", "TREATMENT", 99, 116], ["thought to be", "UNCERTAINTY", 44, 57]]], ["Virus shedding is maximal at the onset of illness and may continue for 5 to 7 days or longer in children.", [["illness", "DISEASE", 42, 49], ["Virus", "ORGANISM", 0, 5], ["children", "ORGANISM", 96, 104], ["children", "SPECIES", 96, 104], ["Virus shedding", "PROBLEM", 0, 14], ["illness", "PROBLEM", 42, 49]]], ["In immunocompromised patients, especially recipients of solid organ or hematopoietic stem cell transplants, viral shedding can be prolonged for weeks to months.", [["solid organ", "ANATOMY", 56, 67], ["hematopoietic stem cell", "ANATOMY", 71, 94], ["patients", "ORGANISM", 21, 29], ["recipients", "ORGANISM", 42, 52], ["organ", "ORGAN", 62, 67], ["hematopoietic stem cell", "CELL", 71, 94], ["patients", "SPECIES", 21, 29], ["solid organ", "PROBLEM", 56, 67], ["hematopoietic stem cell transplants", "TREATMENT", 71, 106], ["viral shedding", "PROBLEM", 108, 122], ["immunocompromised", "OBSERVATION", 3, 20], ["solid organ", "ANATOMY", 56, 67], ["hematopoietic stem cell transplants", "OBSERVATION", 71, 106]]], ["132 Bronchoscopy of individuals with influenza typically reveals diffuse inflammation of the larynx, trachea, and bronchi, as well as a range of histologic findings, from vacuolization of columnar cells with cell loss, to extensive desquamation of the ciliated columnar epithelium down to the basal layer of cells.", [["larynx", "ANATOMY", 93, 99], ["trachea", "ANATOMY", 101, 108], ["bronchi", "ANATOMY", 114, 121], ["columnar cells", "ANATOMY", 188, 202], ["cell", "ANATOMY", 208, 212], ["columnar epithelium", "ANATOMY", 261, 280], ["basal layer", "ANATOMY", 293, 304], ["cells", "ANATOMY", 308, 313], ["influenza", "DISEASE", 37, 46], ["individuals", "ORGANISM", 20, 31], ["larynx", "ORGAN", 93, 99], ["trachea", "MULTI-TISSUE_STRUCTURE", 101, 108], ["bronchi", "MULTI-TISSUE_STRUCTURE", 114, 121], ["columnar cells", "CELL", 188, 202], ["cell", "CELL", 208, 212], ["ciliated columnar epithelium", "TISSUE", 252, 280], ["basal layer", "CELLULAR_COMPONENT", 293, 304], ["cells", "CELL", 308, 313], ["columnar cells", "CELL_TYPE", 188, 202], ["Bronchoscopy of individuals", "TEST", 4, 31], ["influenza", "PROBLEM", 37, 46], ["diffuse inflammation of the larynx, trachea, and bronchi", "PROBLEM", 65, 121], ["vacuolization of columnar cells", "PROBLEM", 171, 202], ["cell loss", "PROBLEM", 208, 217], ["extensive desquamation of the ciliated columnar epithelium", "PROBLEM", 222, 280], ["diffuse", "OBSERVATION_MODIFIER", 65, 72], ["inflammation", "OBSERVATION", 73, 85], ["larynx", "ANATOMY", 93, 99], ["trachea", "ANATOMY", 101, 108], ["bronchi", "ANATOMY", 114, 121], ["vacuolization", "OBSERVATION_MODIFIER", 171, 184], ["columnar cells", "OBSERVATION", 188, 202], ["cell loss", "OBSERVATION", 208, 217], ["extensive", "OBSERVATION_MODIFIER", 222, 231], ["desquamation", "OBSERVATION", 232, 244], ["ciliated", "ANATOMY_MODIFIER", 252, 260], ["columnar", "ANATOMY_MODIFIER", 261, 269], ["epithelium", "ANATOMY_MODIFIER", 270, 280], ["basal", "ANATOMY_MODIFIER", 293, 298], ["layer", "ANATOMY_MODIFIER", 299, 304], ["cells", "ANATOMY", 308, 313]]], ["133, 134 Generally, the tissue response becomes more prominent as one moves distally in the airway.", [["tissue", "ANATOMY", 24, 30], ["airway", "ANATOMY", 92, 98], ["tissue", "TISSUE", 24, 30], ["airway", "MULTI-TISSUE_STRUCTURE", 92, 98], ["tissue", "OBSERVATION", 24, 30], ["more prominent", "OBSERVATION_MODIFIER", 48, 62], ["airway", "ANATOMY", 92, 98]]], ["Recovery is associated with rapid regeneration of the epithelial cell layer and pseudometaplasia.", [["epithelial cell layer", "ANATOMY", 54, 75], ["pseudometaplasia", "ANATOMY", 80, 96], ["pseudometaplasia", "DISEASE", 80, 96], ["epithelial cell layer", "TISSUE", 54, 75], ["the epithelial cell layer", "PROBLEM", 50, 75], ["pseudometaplasia", "PROBLEM", 80, 96], ["associated with", "UNCERTAINTY", 12, 27], ["rapid", "OBSERVATION_MODIFIER", 28, 33], ["regeneration", "OBSERVATION", 34, 46], ["epithelial cell", "OBSERVATION", 54, 69], ["layer", "OBSERVATION_MODIFIER", 70, 75], ["pseudometaplasia", "OBSERVATION", 80, 96]]], ["Fatal influenza pneumonia exhibits diffuse alveolar damage with hyaline membranes lining the alveoli, and the alveolar air spaces contain edema fluid, strands of fibrin, desquamated epithelial cells, and inflammatory cells (Fig. 32-8A-D) .PathogenesisAbnormalities of pulmonary function are frequently demonstrated in otherwise healthy, nonasthmatic young adults with uncomplicated (non-pneumonic) acute influenza.", [["alveolar", "ANATOMY", 43, 51], ["hyaline membranes", "ANATOMY", 64, 81], ["alveoli", "ANATOMY", 93, 100], ["alveolar air spaces", "ANATOMY", 110, 129], ["edema fluid", "ANATOMY", 138, 149], ["fibrin", "ANATOMY", 162, 168], ["desquamated epithelial cells", "ANATOMY", 170, 198], ["inflammatory cells", "ANATOMY", 204, 222], ["pulmonary", "ANATOMY", 268, 277], ["pneumonia", "DISEASE", 16, 25], ["alveolar damage", "DISEASE", 43, 58], ["edema", "DISEASE", 138, 143], ["influenza", "DISEASE", 404, 413], ["alveolar", "TISSUE", 43, 51], ["hyaline membranes", "CELLULAR_COMPONENT", 64, 81], ["alveoli", "MULTI-TISSUE_STRUCTURE", 93, 100], ["alveolar air", "TISSUE", 110, 122], ["edema fluid", "PATHOLOGICAL_FORMATION", 138, 149], ["fibrin", "GENE_OR_GENE_PRODUCT", 162, 168], ["epithelial cells", "CELL", 182, 198], ["inflammatory cells", "CELL", 204, 222], ["pulmonary", "ORGAN", 268, 277], ["fibrin", "PROTEIN", 162, 168], ["desquamated epithelial cells", "CELL_TYPE", 170, 198], ["inflammatory cells", "CELL_TYPE", 204, 222], ["Fatal influenza pneumonia", "PROBLEM", 0, 25], ["diffuse alveolar damage", "PROBLEM", 35, 58], ["hyaline membranes lining the alveoli", "PROBLEM", 64, 100], ["the alveolar air spaces", "PROBLEM", 106, 129], ["edema fluid", "PROBLEM", 138, 149], ["strands of fibrin", "PROBLEM", 151, 168], ["desquamated epithelial cells", "PROBLEM", 170, 198], ["inflammatory cells", "PROBLEM", 204, 222], ["Fig.", "TEST", 224, 228], ["PathogenesisAbnormalities of pulmonary function", "PROBLEM", 239, 286], ["uncomplicated (non-pneumonic) acute influenza", "PROBLEM", 368, 413], ["pneumonia", "OBSERVATION", 16, 25], ["diffuse", "OBSERVATION_MODIFIER", 35, 42], ["alveolar", "ANATOMY_MODIFIER", 43, 51], ["damage", "OBSERVATION", 52, 58], ["hyaline membranes", "OBSERVATION", 64, 81], ["alveoli", "ANATOMY_MODIFIER", 93, 100], ["alveolar", "ANATOMY_MODIFIER", 110, 118], ["air spaces", "OBSERVATION", 119, 129], ["edema", "OBSERVATION", 138, 143], ["fluid", "OBSERVATION_MODIFIER", 144, 149], ["strands", "OBSERVATION_MODIFIER", 151, 158], ["fibrin", "OBSERVATION_MODIFIER", 162, 168], ["epithelial cells", "OBSERVATION", 182, 198], ["inflammatory cells", "OBSERVATION", 204, 222], ["pulmonary", "ANATOMY", 268, 277], ["acute", "OBSERVATION_MODIFIER", 398, 403], ["influenza", "OBSERVATION", 404, 413]]], ["Demonstrated defects include diminished forced expiratory flow rates, increased total pulmonary resistance, and decreased density-dependent forced expiratory flow rates consistent with generalized increased resistance in airways less than 2 mm in diameter, 135, 136 as well as increased responses to bronchoprovocation.", [["pulmonary", "ANATOMY", 86, 95], ["airways", "ANATOMY", 221, 228], ["bronchoprovocation", "DISEASE", 300, 318], ["pulmonary", "ORGAN", 86, 95], ["airways", "MULTI-TISSUE_STRUCTURE", 221, 228], ["defects", "PROBLEM", 13, 20], ["diminished forced expiratory flow rates", "PROBLEM", 29, 68], ["increased total pulmonary resistance", "PROBLEM", 70, 106], ["decreased density-dependent forced expiratory flow rates", "PROBLEM", 112, 168], ["generalized increased resistance in airways", "PROBLEM", 185, 228], ["bronchoprovocation", "TEST", 300, 318], ["defects", "OBSERVATION", 13, 20], ["diminished", "OBSERVATION_MODIFIER", 29, 39], ["forced", "OBSERVATION_MODIFIER", 40, 46], ["expiratory flow", "OBSERVATION", 47, 62], ["increased", "OBSERVATION_MODIFIER", 70, 79], ["total", "OBSERVATION_MODIFIER", 80, 85], ["pulmonary resistance", "OBSERVATION", 86, 106], ["decreased", "OBSERVATION_MODIFIER", 112, 121], ["density", "OBSERVATION", 122, 129], ["dependent", "OBSERVATION_MODIFIER", 130, 139], ["forced", "OBSERVATION_MODIFIER", 140, 146], ["expiratory flow", "OBSERVATION", 147, 162], ["consistent with", "UNCERTAINTY", 169, 184], ["generalized", "OBSERVATION_MODIFIER", 185, 196], ["increased", "OBSERVATION_MODIFIER", 197, 206], ["resistance", "OBSERVATION", 207, 217], ["airways", "ANATOMY", 221, 228], ["less than 2 mm", "OBSERVATION_MODIFIER", 229, 243], ["increased", "OBSERVATION_MODIFIER", 277, 286]]], ["135 In addition, abnormalities have been seen in the carbon monoxide diffusing capacity 137 and the alveolar-arterial oxygen difference.", [["alveolar", "ANATOMY", 100, 108], ["arterial", "ANATOMY", 109, 117], ["carbon monoxide", "CHEMICAL", 53, 68], ["oxygen", "CHEMICAL", 118, 124], ["carbon monoxide", "CHEMICAL", 53, 68], ["oxygen", "CHEMICAL", 118, 124], ["carbon monoxide", "SIMPLE_CHEMICAL", 53, 68], ["alveolar-arterial", "MULTI-TISSUE_STRUCTURE", 100, 117], ["oxygen", "SIMPLE_CHEMICAL", 118, 124], ["abnormalities", "PROBLEM", 17, 30], ["the carbon monoxide diffusing capacity", "TEST", 49, 87], ["the alveolar-arterial oxygen difference", "PROBLEM", 96, 135], ["alveolar", "ANATOMY_MODIFIER", 100, 108], ["arterial", "ANATOMY", 109, 117], ["oxygen difference", "OBSERVATION", 118, 135]]], ["138 Pulmonary function defects can persist for weeks after clinical recovery.", [["Pulmonary", "ANATOMY", 4, 13], ["Pulmonary function defects", "DISEASE", 4, 30], ["Pulmonary function defects", "PROBLEM", 4, 30], ["Pulmonary", "ANATOMY", 4, 13], ["defects", "OBSERVATION", 23, 30]]], ["Influenza in asthmatics or patients with chronic obstructive disease with influenza may result in acute declines in forced vital capacity or FEV 1 .", [["Influenza", "DISEASE", 0, 9], ["chronic obstructive disease", "DISEASE", 41, 68], ["influenza", "DISEASE", 74, 83], ["asthmatics", "ORGANISM", 13, 23], ["patients", "ORGANISM", 27, 35], ["FEV 1", "GENE_OR_GENE_PRODUCT", 141, 146], ["Influenza", "SPECIES", 0, 9], ["patients", "SPECIES", 27, 35], ["Influenza", "PROBLEM", 0, 9], ["asthmatics", "PROBLEM", 13, 23], ["chronic obstructive disease", "PROBLEM", 41, 68], ["influenza", "PROBLEM", 74, 83], ["acute declines", "PROBLEM", 98, 112], ["forced vital capacity", "TEST", 116, 137], ["chronic", "OBSERVATION_MODIFIER", 41, 48], ["obstructive", "OBSERVATION", 49, 60], ["acute", "OBSERVATION_MODIFIER", 98, 103], ["declines", "OBSERVATION", 104, 112]]], ["Individuals with acute influenza may be more susceptible to bronchoconstriction from air pollutants such as nitrates.", [["influenza", "DISEASE", 23, 32], ["bronchoconstriction", "DISEASE", 60, 79], ["nitrates", "CHEMICAL", 108, 116], ["nitrates", "CHEMICAL", 108, 116], ["nitrates", "SIMPLE_CHEMICAL", 108, 116], ["acute influenza", "PROBLEM", 17, 32], ["bronchoconstriction", "PROBLEM", 60, 79], ["air pollutants", "PROBLEM", 85, 99], ["nitrates", "TREATMENT", 108, 116], ["acute", "OBSERVATION_MODIFIER", 17, 22], ["influenza", "OBSERVATION", 23, 32], ["air pollutants", "OBSERVATION", 85, 99]]], ["139Clinical IllnessTypical uncomplicated influenza often begins with an abrupt onset of symptoms after an incubation period of 1 to 2 days.", [["influenza", "DISEASE", 41, 50], ["Typical uncomplicated influenza", "PROBLEM", 19, 50], ["symptoms", "PROBLEM", 88, 96], ["uncomplicated", "OBSERVATION_MODIFIER", 27, 40], ["influenza", "OBSERVATION", 41, 50], ["abrupt", "OBSERVATION_MODIFIER", 72, 78]]], ["Systemic symptoms include feverishness, chilliness, or frank shaking chills, headaches, myalgia, malaise, and anorexia.", [["feverishness", "DISEASE", 26, 38], ["chilliness", "DISEASE", 40, 50], ["chills", "DISEASE", 69, 75], ["headaches", "DISEASE", 77, 86], ["myalgia", "DISEASE", 88, 95], ["malaise", "DISEASE", 97, 104], ["anorexia", "DISEASE", 110, 118], ["Systemic symptoms", "PROBLEM", 0, 17], ["feverishness", "PROBLEM", 26, 38], ["chilliness", "PROBLEM", 40, 50], ["frank shaking chills", "PROBLEM", 55, 75], ["headaches", "PROBLEM", 77, 86], ["myalgia", "PROBLEM", 88, 95], ["malaise", "PROBLEM", 97, 104], ["anorexia", "PROBLEM", 110, 118], ["myalgia", "ANATOMY", 88, 95], ["malaise", "OBSERVATION", 97, 104], ["anorexia", "OBSERVATION", 110, 118]]], ["Typical respiratory symptoms include dry cough, severe pharyngeal pain, and nasal obstruction and discharge.", [["respiratory", "ANATOMY", 8, 19], ["pharyngeal", "ANATOMY", 55, 65], ["nasal", "ANATOMY", 76, 81], ["respiratory symptoms", "DISEASE", 8, 28], ["dry cough", "DISEASE", 37, 46], ["pharyngeal pain", "DISEASE", 55, 70], ["nasal obstruction", "DISEASE", 76, 93], ["pharyngeal", "ORGANISM_SUBDIVISION", 55, 65], ["nasal", "ORGANISM_SUBDIVISION", 76, 81], ["Typical respiratory symptoms", "PROBLEM", 0, 28], ["dry cough", "PROBLEM", 37, 46], ["severe pharyngeal pain", "PROBLEM", 48, 70], ["nasal obstruction", "PROBLEM", 76, 93], ["dry", "OBSERVATION_MODIFIER", 37, 40], ["cough", "OBSERVATION", 41, 46], ["severe", "OBSERVATION_MODIFIER", 48, 54], ["pharyngeal", "ANATOMY", 55, 65], ["pain", "OBSERVATION", 66, 70], ["nasal", "ANATOMY", 76, 81], ["obstruction", "OBSERVATION", 82, 93]]], ["Elderly individuals may simply present with responses, each of which plays a role in recovery from infection and resistance to reinfection.Epidemiology and TransmissionInfluenza virus infection is acquired by transfer of viruscontaining respiratory secretions.", [["respiratory secretions", "ANATOMY", 237, 259], ["infection", "DISEASE", 99, 108], ["reinfection", "DISEASE", 127, 138], ["Influenza virus infection", "DISEASE", 168, 193], ["individuals", "ORGANISM", 8, 19], ["Influenza virus", "ORGANISM", 168, 183], ["Influenza virus", "SPECIES", 168, 183], ["TransmissionInfluenza virus", "SPECIES", 156, 183], ["infection", "PROBLEM", 99, 108], ["reinfection", "PROBLEM", 127, 138], ["TransmissionInfluenza virus infection", "PROBLEM", 156, 193], ["viruscontaining respiratory secretions", "PROBLEM", 221, 259], ["infection", "OBSERVATION", 99, 108], ["reinfection", "OBSERVATION", 127, 138], ["Influenza virus", "OBSERVATION", 168, 183], ["respiratory secretions", "OBSERVATION", 237, 259]]], ["Both small particle aerosols and droplets probably play a role in this transmission, but for infection control purposes influenza is generally considered to be transmitted by droplets.", [["infection", "DISEASE", 93, 102], ["influenza", "DISEASE", 120, 129], ["Both small particle aerosols", "TREATMENT", 0, 28], ["infection", "PROBLEM", 93, 102], ["influenza", "PROBLEM", 120, 129], ["small", "OBSERVATION_MODIFIER", 5, 10], ["particle aerosols", "OBSERVATION", 11, 28]]], ["In temperate climates in either hemisphere, epidemics are seen almost exclusively in the winter months (generally October to April in the Northern hemisphere and May to September in the Southern hemisphere), whereas in the tropics, influenza may be seen throughout the year.Epidemiology and TransmissionInfluenza epidemics are regularly associated with morbidity and mortality, usually expressed in the form of excess rates of pneumonia and influenza-associated hospitalizations and deaths, with as many as 51,000 deaths annually in the United States.", [["influenza", "DISEASE", 232, 241], ["Influenza epidemics", "DISEASE", 303, 322], ["pneumonia", "DISEASE", 427, 436], ["influenza", "DISEASE", 441, 450], ["deaths", "DISEASE", 483, 489], ["deaths", "DISEASE", 514, 520], ["epidemics", "PROBLEM", 44, 53], ["influenza", "PROBLEM", 232, 241], ["TransmissionInfluenza epidemics", "PROBLEM", 291, 322], ["morbidity", "PROBLEM", 353, 362], ["pneumonia", "PROBLEM", 427, 436], ["influenza-associated hospitalizations", "PROBLEM", 441, 478], ["temperate", "OBSERVATION_MODIFIER", 3, 12], ["climates", "OBSERVATION", 13, 21], ["hemisphere", "ANATOMY_MODIFIER", 32, 42], ["pneumonia", "OBSERVATION", 427, 436]]], ["125 Attack rates are generally highest in the young, whereas mortality is generally highest in the elderly.", [["Attack rates", "TEST", 4, 16], ["highest", "OBSERVATION_MODIFIER", 31, 38], ["highest", "OBSERVATION_MODIFIER", 84, 91]]], ["Excess morbidity and mortality are particularly high in those with medical conditions including pulmonary conditions such as asthma or COPD.", [["pulmonary", "ANATOMY", 96, 105], ["asthma", "DISEASE", 125, 131], ["COPD", "DISEASE", 135, 139], ["pulmonary", "ORGAN", 96, 105], ["Excess morbidity", "PROBLEM", 0, 16], ["mortality", "PROBLEM", 21, 30], ["medical conditions", "PROBLEM", 67, 85], ["pulmonary conditions", "PROBLEM", 96, 116], ["asthma", "PROBLEM", 125, 131], ["COPD", "PROBLEM", 135, 139], ["morbidity", "OBSERVATION", 7, 16], ["high", "OBSERVATION_MODIFIER", 48, 52], ["pulmonary", "ANATOMY", 96, 105], ["asthma", "OBSERVATION", 125, 131], ["COPD", "OBSERVATION", 135, 139]]], ["Rates of influenzarelated hospitalizations are particularly high in healthy children younger than 2, where rates approach those of older children with high-risk conditions.", [["children", "ORGANISM", 76, 84], ["children", "ORGANISM", 137, 145], ["children", "SPECIES", 76, 84], ["children", "SPECIES", 137, 145], ["high-risk conditions", "PROBLEM", 151, 171]]], ["126, 127 A high frequency of antigenic variation is a unique feature of influenza virus that helps explain why this virus continues to cause epidemic disease.", [["influenza virus", "DISEASE", 72, 87], ["influenza virus", "ORGANISM", 72, 87], ["influenza virus", "SPECIES", 72, 87], ["influenza virus", "SPECIES", 72, 87], ["antigenic variation", "PROBLEM", 29, 48], ["influenza virus", "PROBLEM", 72, 87], ["this virus", "PROBLEM", 111, 121], ["epidemic disease", "PROBLEM", 141, 157], ["high", "OBSERVATION_MODIFIER", 11, 15], ["antigenic variation", "OBSERVATION", 29, 48], ["influenza virus", "OBSERVATION", 72, 87]]], ["Antigenic variation principally involves the two external glycoproteins of the virus, the HA and NA, and is referred to as antigenic drift or antigenic shift, depending on whether the variation is small or great.", [["NA", "CHEMICAL", 97, 99], ["HA", "GENE_OR_GENE_PRODUCT", 90, 92], ["Antigenic variation", "PROBLEM", 0, 19], ["the virus", "PROBLEM", 75, 84], ["the HA and NA", "PROBLEM", 86, 99], ["antigenic shift", "PROBLEM", 142, 157], ["virus", "OBSERVATION", 79, 84], ["small", "OBSERVATION_MODIFIER", 197, 202]]], ["Antigenic drift refers to relatively minor antigenic changes that result from amino acid changes in one or more of the five identified major antigenic sites on the HA molecule.", [["amino acid", "CHEMICAL", 78, 88], ["amino acid", "CHEMICAL", 78, 88], ["amino acid", "AMINO_ACID", 78, 88], ["HA molecule", "PROTEIN", 164, 175], ["Antigenic drift", "PROBLEM", 0, 15], ["relatively minor antigenic changes", "PROBLEM", 26, 60], ["amino acid changes", "PROBLEM", 78, 96], ["drift", "OBSERVATION", 10, 15], ["amino acid", "OBSERVATION", 78, 88], ["major", "OBSERVATION_MODIFIER", 135, 140], ["antigenic sites", "OBSERVATION", 141, 156]]], ["128 Antigenic shift refers to the complete replacement of the HA or NA with a novel HA or NA.", [["NA", "CHEMICAL", 68, 70], ["NA", "CHEMICAL", 90, 92], ["the HA", "PROBLEM", 58, 64], ["a novel HA", "PROBLEM", 76, 86]]], ["These viruses are \"new\" viruses to which the population has no specific immunity.", [["These viruses", "PROBLEM", 0, 13], ["new\" viruses", "PROBLEM", 19, 31], ["viruses", "OBSERVATION", 6, 13], ["new", "OBSERVATION_MODIFIER", 19, 22], ["no", "UNCERTAINTY", 60, 62]]], ["When such a new virus is introduced into a population, a severe, worldwide epidemic, or pandemic, of influenza can result.", [["influenza", "DISEASE", 101, 110], ["a new virus", "PROBLEM", 10, 21], ["a severe, worldwide epidemic", "PROBLEM", 55, 83], ["pandemic", "PROBLEM", 88, 96], ["influenza", "PROBLEM", 101, 110], ["severe", "OBSERVATION_MODIFIER", 57, 63]]], ["Influenza pandemics in the 20th century include the H1N1 pandemic of 1918, the H2N2 pandemic of 1957, and the H3N2 pandemic of 1968.", [["Influenza pandemics", "DISEASE", 0, 19], ["Influenza", "SPECIES", 0, 9], ["Influenza pandemics", "PROBLEM", 0, 19]]], ["Extensive surveillance and sequence information suggests that these new HA and NA genes are introduced into viruses circulating in humans from resident populations of influenza A viruses in birds.", [["influenza A viruses", "DISEASE", 167, 186], ["HA", "GENE_OR_GENE_PRODUCT", 72, 74], ["humans", "ORGANISM", 131, 137], ["influenza A viruses", "ORGANISM", 167, 186], ["birds", "ORGANISM", 190, 195], ["HA and NA genes", "DNA", 72, 87], ["humans", "SPECIES", 131, 137], ["humans", "SPECIES", 131, 137], ["influenza A viruses", "SPECIES", 167, 186], ["Extensive surveillance and sequence information", "TEST", 0, 47], ["these new HA and NA genes", "PROBLEM", 62, 87], ["influenza", "PROBLEM", 167, 176], ["new", "OBSERVATION_MODIFIER", 68, 71], ["influenza", "OBSERVATION", 167, 176]]], ["129 Since 1997, sporadic outbreaks of influenza in humans caused by direct transmission of avian viruses from bird to human have been reported.", [["influenza", "DISEASE", 38, 47], ["avian viruses", "DISEASE", 91, 104], ["humans", "ORGANISM", 51, 57], ["avian viruses", "ORGANISM", 91, 104], ["human", "ORGANISM", 118, 123], ["humans", "SPECIES", 51, 57], ["human", "SPECIES", 118, 123], ["humans", "SPECIES", 51, 57], ["human", "SPECIES", 118, 123], ["influenza", "PROBLEM", 38, 47], ["avian viruses", "PROBLEM", 91, 104], ["influenza", "OBSERVATION", 38, 47]]], ["Although sustained human-tohuman transmission has not been seen, avian subtypes such as H5N1 130 and H7N9 131 continue to pose a potential pandemic threat.", [["H5N1 130 and H7N9 131", "CHEMICAL", 88, 109], ["human", "ORGANISM", 19, 24], ["tohuman", "CELL", 25, 32], ["H5N1 130", "ORGANISM", 88, 96], ["H7N9 131", "ORGANISM", 101, 109], ["human", "SPECIES", 19, 24], ["human", "SPECIES", 19, 24], ["H5N1", "PROBLEM", 88, 92], ["H7N9", "PROBLEM", 101, 105]]], ["In the spring of 2009, a novel H1N1 virus containing genes from viruses of swine, avian, and human origin emerged.", [["H1N1 virus", "ORGANISM", 31, 41], ["swine", "ORGANISM", 75, 80], ["avian", "ORGANISM", 82, 87], ["human", "ORGANISM", 93, 98], ["H1N1 virus", "SPECIES", 31, 41], ["swine", "SPECIES", 75, 80], ["avian", "SPECIES", 82, 87], ["human", "SPECIES", 93, 98], ["H1N1 virus", "SPECIES", 31, 41], ["swine", "SPECIES", 75, 80], ["human", "SPECIES", 93, 98], ["a novel H1N1 virus", "PROBLEM", 23, 41]]], ["Importantly, the HA gene of this virus was derived from swine influenza virus.", [["influenza virus", "DISEASE", 62, 77], ["HA", "GENE_OR_GENE_PRODUCT", 17, 19], ["swine influenza virus", "ORGANISM", 56, 77], ["HA gene", "DNA", 17, 24], ["swine influenza virus", "SPECIES", 56, 77], ["swine influenza virus", "SPECIES", 56, 77], ["this virus", "PROBLEM", 28, 38], ["swine influenza virus", "PROBLEM", 56, 77], ["influenza virus", "OBSERVATION", 62, 77]]], ["Although still an H1N1 virus, the novel, or pandemic H1N1 (pH1N1) was antigenically distinct from the human H1N1 viruses in circulation since 1977.", [["H1N1", "DISEASE", 53, 57], ["H1N1 virus", "ORGANISM", 18, 28], ["pandemic H1N1 (pH1N1", "ORGANISM", 44, 64], ["human H1N1 viruses", "ORGANISM", 102, 120], ["pandemic H1N1", "SPECIES", 44, 57], ["human", "SPECIES", 102, 107], ["H1N1 virus", "SPECIES", 18, 28], ["pandemic H1N1 (pH1N1", "SPECIES", 44, 64], ["human H1N1 viruses", "SPECIES", 102, 120], ["an H1N1 virus", "PROBLEM", 15, 28], ["pandemic H1N1", "PROBLEM", 44, 57], ["H1N1", "PROBLEM", 60, 64], ["the human H1N1 viruses", "PROBLEM", 98, 120], ["H1N1", "OBSERVATION", 18, 22], ["H1N1", "OBSERVATION", 108, 112]]], ["Instead, the HA was closely related to human H1 viruses from the early 20th century that had been introduced into pigs in approximately 1918 and had not undergone significant antigenic evolution in these animals since bilateral abnormalities (Fig. 32-9 , eFigs.", [["HA", "GENE_OR_GENE_PRODUCT", 13, 15], ["human H1 viruses", "ORGANISM", 39, 55], ["pigs", "ORGANISM", 114, 118], ["human", "SPECIES", 39, 44], ["pigs", "SPECIES", 114, 118], ["human H1 viruses", "SPECIES", 39, 55], ["pigs", "SPECIES", 114, 118], ["the HA", "PROBLEM", 9, 15], ["human H1 viruses", "PROBLEM", 39, 55], ["bilateral abnormalities", "PROBLEM", 218, 241], ["Fig.", "TEST", 243, 247], ["eFigs", "TEST", 255, 260], ["significant", "OBSERVATION_MODIFIER", 163, 174], ["antigenic", "OBSERVATION", 175, 184], ["bilateral", "ANATOMY_MODIFIER", 218, 227], ["abnormalities", "OBSERVATION", 228, 241]]], ["32-6 and 32-7), sometimes suggestive of an acute lung injury pattern or ARDS (eFig.", [["lung", "ANATOMY", 49, 53], ["acute lung injury", "DISEASE", 43, 60], ["ARDS", "DISEASE", 72, 76], ["lung", "ORGAN", 49, 53], ["an acute lung injury pattern", "PROBLEM", 40, 68], ["ARDS (eFig", "PROBLEM", 72, 82], ["suggestive of", "UNCERTAINTY", 26, 39], ["acute", "OBSERVATION_MODIFIER", 43, 48], ["lung", "ANATOMY", 49, 53], ["injury", "OBSERVATION", 54, 60], ["ARDS", "OBSERVATION", 72, 76]]], ["H1N1 (\"swine-origin\") influenza infection has a relatively nonspecific appearance, ranging from normal or nearly normal chest radiography at presentation to multifocal bilateral opacities resembling multifocal pneumonia (eFig.", [["chest", "ANATOMY", 120, 125], ["H1N1", "DISEASE", 0, 4], ["influenza infection", "DISEASE", 22, 41], ["opacities", "DISEASE", 178, 187], ["pneumonia", "DISEASE", 210, 219], ["H1N1", "ORGANISM", 0, 4], ["chest", "ORGAN", 120, 125], ["swine", "SPECIES", 7, 12], ["H1N1", "PROBLEM", 0, 4], ["influenza infection", "PROBLEM", 22, 41], ["multifocal bilateral opacities", "PROBLEM", 157, 187], ["multifocal pneumonia (eFig", "PROBLEM", 199, 225], ["infection", "OBSERVATION", 32, 41], ["nonspecific", "OBSERVATION_MODIFIER", 59, 70], ["chest", "ANATOMY", 120, 125], ["multifocal", "OBSERVATION_MODIFIER", 157, 167], ["bilateral", "ANATOMY_MODIFIER", 168, 177], ["opacities", "OBSERVATION", 178, 187], ["multifocal", "OBSERVATION_MODIFIER", 199, 209], ["pneumonia", "OBSERVATION", 210, 219]]], ["32-9) or a noninfectious acute lung injury pattern.", [["lung", "ANATOMY", 31, 35], ["32-9", "CHEMICAL", 0, 4], ["acute lung injury", "DISEASE", 25, 42], ["lung", "ORGAN", 31, 35], ["a noninfectious acute lung injury pattern", "PROBLEM", 9, 50], ["noninfectious", "OBSERVATION_MODIFIER", 11, 24], ["acute", "OBSERVATION_MODIFIER", 25, 30], ["lung", "ANATOMY", 31, 35], ["injury", "OBSERVATION", 36, 42]]], ["Chest CT often shows multifocal areas of ground-glass opacity and consolidation, which may show a peripheral distribution, resembling organizing pneumonia fever, lassitude, and confusion without any of the characteristic respiratory complaints.", [["respiratory", "ANATOMY", 221, 232], ["pneumonia", "DISEASE", 145, 154], ["fever", "DISEASE", 155, 160], ["lassitude", "DISEASE", 162, 171], ["confusion", "DISEASE", 177, 186], ["respiratory complaints", "DISEASE", 221, 243], ["Chest CT", "TEST", 0, 8], ["ground-glass opacity", "PROBLEM", 41, 61], ["consolidation", "PROBLEM", 66, 79], ["a peripheral distribution", "PROBLEM", 96, 121], ["organizing pneumonia fever", "PROBLEM", 134, 160], ["lassitude", "PROBLEM", 162, 171], ["confusion", "PROBLEM", 177, 186], ["the characteristic respiratory complaints", "PROBLEM", 202, 243], ["multifocal", "OBSERVATION_MODIFIER", 21, 31], ["ground-glass opacity", "OBSERVATION", 41, 61], ["consolidation", "OBSERVATION", 66, 79], ["peripheral", "ANATOMY_MODIFIER", 98, 108], ["distribution", "OBSERVATION_MODIFIER", 109, 121], ["organizing", "OBSERVATION_MODIFIER", 134, 144], ["pneumonia", "OBSERVATION", 145, 154], ["respiratory complaints", "OBSERVATION", 221, 243]]], ["There may be a wide range of symptoms, but the presence of fever plus either sore throat or cough is predictive of positive culture results for influenza in adults.Epidemiology and TransmissionThe syndrome of primary influenza viral pneumonia was first well documented in the 1957-1958 outbreak.", [["fever", "DISEASE", 59, 64], ["sore throat", "DISEASE", 77, 88], ["cough", "DISEASE", 92, 97], ["influenza", "DISEASE", 144, 153], ["influenza viral pneumonia", "DISEASE", 217, 242], ["influenza viral pneumonia", "SPECIES", 217, 242], ["a wide range of symptoms", "PROBLEM", 13, 37], ["fever", "PROBLEM", 59, 64], ["sore throat", "PROBLEM", 77, 88], ["cough", "PROBLEM", 92, 97], ["positive culture results", "PROBLEM", 115, 139], ["influenza", "PROBLEM", 144, 153], ["primary influenza viral pneumonia", "PROBLEM", 209, 242], ["may be", "UNCERTAINTY", 6, 12], ["wide", "OBSERVATION_MODIFIER", 15, 19], ["fever", "OBSERVATION", 59, 64], ["primary", "OBSERVATION_MODIFIER", 209, 216], ["influenza", "OBSERVATION", 217, 226], ["pneumonia", "OBSERVATION", 233, 242]]], ["The illness begins with a typical onset of influenza, followed by a rapid progression of fever, cough, dyspnea, and cyanosis.", [["illness", "DISEASE", 4, 11], ["influenza", "DISEASE", 43, 52], ["fever", "DISEASE", 89, 94], ["cough", "DISEASE", 96, 101], ["dyspnea", "DISEASE", 103, 110], ["cyanosis", "DISEASE", 116, 124], ["influenza", "PROBLEM", 43, 52], ["fever", "PROBLEM", 89, 94], ["cough", "PROBLEM", 96, 101], ["dyspnea", "PROBLEM", 103, 110], ["cyanosis", "PROBLEM", 116, 124], ["illness", "OBSERVATION", 4, 11], ["influenza", "OBSERVATION", 43, 52], ["fever", "OBSERVATION", 89, 94], ["cyanosis", "OBSERVATION", 116, 124]]], ["Physical examination and thoracic imaging studies reveal Fig 1) .Epidemiology and Transmission17).", [["thoracic", "ANATOMY", 25, 33], ["Physical examination", "TEST", 0, 20], ["thoracic imaging studies", "TEST", 25, 49], ["thoracic", "ANATOMY", 25, 33]]], ["The reported sensitivities of each test in comparison to cell culture or nucleic acid amplification varies between 40% and 80% and depends on the nature of the samples tested and the viral strain.", [["cell", "ANATOMY", 57, 61], ["samples", "ANATOMY", 160, 167], ["nucleic acid", "CHEMICAL", 73, 85], ["cell", "CELL", 57, 61], ["nucleic acid", "SIMPLE_CHEMICAL", 73, 85], ["each test", "TEST", 30, 39], ["cell culture", "TEST", 57, 69], ["nucleic acid amplification", "TEST", 73, 99], ["the samples", "TEST", 156, 167], ["the viral strain", "PROBLEM", 179, 195], ["viral strain", "OBSERVATION", 183, 195]]], ["In general, sensitivities in adults and elderly patients tend to be lower than those reported in young children, who shed much larger quantities of virus and higher concentrations of antigen in their samples.", [["samples", "ANATOMY", 200, 207], ["adults", "ORGANISM", 29, 35], ["patients", "ORGANISM", 48, 56], ["children", "ORGANISM", 103, 111], ["patients", "SPECIES", 48, 56], ["children", "SPECIES", 103, 111]]], ["148 Similarly, sensitivity is likely to be higher early in the course of illness, when viral shedding is maximal.", [["illness", "DISEASE", 73, 80], ["sensitivity", "TEST", 15, 26], ["illness", "PROBLEM", 73, 80], ["viral shedding", "PROBLEM", 87, 101], ["likely to be", "UNCERTAINTY", 30, 42], ["higher", "OBSERVATION_MODIFIER", 43, 49]]], ["Real-time RT-PCR methods have been developed and licensed and are discussed in greater detail in Chapter 17.", [["RT-PCR methods", "TEST", 10, 24]]], ["Many of these tests are designed to detect multiple respiratory pathogens simultaneously and are leading to a growing recognition of the role of respiratory viruses and coinfection in diverse respiratory infections.", [["respiratory", "ANATOMY", 192, 203], ["respiratory viruses", "DISEASE", 145, 164], ["coinfection", "DISEASE", 169, 180], ["respiratory infections", "DISEASE", 192, 214], ["these tests", "TEST", 8, 19], ["multiple respiratory pathogens", "PROBLEM", 43, 73], ["respiratory viruses", "PROBLEM", 145, 164], ["coinfection", "PROBLEM", 169, 180], ["diverse respiratory infections", "PROBLEM", 184, 214], ["multiple", "OBSERVATION_MODIFIER", 43, 51], ["respiratory pathogens", "OBSERVATION", 52, 73], ["respiratory viruses", "OBSERVATION", 145, 164], ["diverse", "OBSERVATION_MODIFIER", 184, 191], ["respiratory infections", "OBSERVATION", 192, 214]]], ["148a Most cases of influenza, in otherwise healthy individuals with typical symptoms during the course of a recognized influenza epidemic, do not need specific viral confirmation.", [["influenza", "DISEASE", 19, 28], ["influenza", "DISEASE", 119, 128], ["influenza", "PROBLEM", 19, 28], ["typical symptoms", "PROBLEM", 68, 84], ["a recognized influenza epidemic", "PROBLEM", 106, 137], ["specific viral confirmation", "TEST", 151, 178], ["influenza", "OBSERVATION", 19, 28]]], ["However, diagnostic testing should be used if the results of the test will influence subsequent clinical management, such as the use of antiviral agents, the need for antibacterial drugs, and the use of infection control.", [["infection", "DISEASE", 203, 212], ["diagnostic testing", "TEST", 9, 27], ["the test", "TEST", 61, 69], ["clinical management", "TREATMENT", 96, 115], ["antiviral agents", "TREATMENT", 136, 152], ["antibacterial drugs", "TREATMENT", 167, 186], ["infection control", "TREATMENT", 203, 220], ["infection", "OBSERVATION", 203, 212]]], ["149 Virus can also be isolated readily from nasal swab specimens, nasal aspirates, combined nose and throat swabs, sputum, or endotracheal aspirate specimens.", [["nasal swab specimens", "ANATOMY", 44, 64], ["nasal aspirates", "ANATOMY", 66, 81], ["nose", "ANATOMY", 92, 96], ["throat swabs", "ANATOMY", 101, 113], ["sputum", "ANATOMY", 115, 121], ["endotracheal aspirate specimens", "ANATOMY", 126, 157], ["Virus", "ORGANISM", 4, 9], ["nasal swab specimens", "ORGANISM_SUBSTANCE", 44, 64], ["nasal aspirates", "MULTI-TISSUE_STRUCTURE", 66, 81], ["nose", "ORGANISM_SUBDIVISION", 92, 96], ["Virus", "PROBLEM", 4, 9], ["nasal swab specimens", "TEST", 44, 64], ["nasal aspirates", "TEST", 66, 81], ["combined nose and throat swabs, sputum", "TEST", 83, 121], ["endotracheal aspirate specimens", "TEST", 126, 157], ["nasal", "ANATOMY", 66, 71], ["aspirates", "OBSERVATION", 72, 81], ["throat", "ANATOMY", 101, 107], ["endotracheal", "ANATOMY", 126, 138]]], ["More than 90% of positive influenza cultures can be detected within 3 days of inoculation.", [["influenza", "DISEASE", 26, 35], ["positive influenza cultures", "PROBLEM", 17, 44], ["inoculation", "PROBLEM", 78, 89], ["influenza", "OBSERVATION", 26, 35]]], ["32-9B-E), although other patterns, including small nodules (eFigs.", [["nodules", "ANATOMY", 51, 58], ["nodules", "PATHOLOGICAL_FORMATION", 51, 58], ["small nodules (eFigs", "PROBLEM", 45, 65], ["small", "OBSERVATION_MODIFIER", 45, 50], ["nodules", "OBSERVATION", 51, 58]]], ["32-10A and B), ground-glass opacity associated with linear and reticular abnormalities without a clear zonal distribution (eFig.", [["reticular", "ANATOMY", 63, 72], ["B", "GENE_OR_GENE_PRODUCT", 11, 12], ["ground-glass opacity", "PROBLEM", 15, 35], ["linear and reticular abnormalities", "PROBLEM", 52, 86], ["a clear zonal distribution (eFig", "PROBLEM", 95, 127], ["ground", "OBSERVATION", 15, 21], ["glass opacity", "OBSERVATION", 22, 35], ["linear", "OBSERVATION_MODIFIER", 52, 58], ["reticular", "ANATOMY_MODIFIER", 63, 72], ["abnormalities", "OBSERVATION", 73, 86], ["without", "UNCERTAINTY", 87, 94], ["clear", "OBSERVATION_MODIFIER", 97, 102], ["zonal", "OBSERVATION_MODIFIER", 103, 108], ["distribution", "OBSERVATION_MODIFIER", 109, 121]]], ["32-10C), and lobar consolidation (eFig.", [["lobar", "ANATOMY", 13, 18], ["lobar consolidation (eFig", "PROBLEM", 13, 38], ["lobar", "ANATOMY", 13, 18], ["consolidation", "OBSERVATION", 19, 32]]], ["Gram stain of the sputum fails to reveal significant bacteria, and bacterial culture yields sparse growth of normal flora, whereas viral cultures yield high titers of influenza A virus.", [["sputum", "ANATOMY", 18, 24], ["flora", "ANATOMY", 116, 121], ["influenza A virus", "DISEASE", 167, 184], ["sputum", "ORGANISM_SUBSTANCE", 18, 24], ["influenza A virus", "ORGANISM", 167, 184], ["influenza A virus", "SPECIES", 167, 184], ["influenza A virus", "SPECIES", 167, 184], ["Gram stain", "TEST", 0, 10], ["the sputum", "TEST", 14, 24], ["significant bacteria", "PROBLEM", 41, 61], ["bacterial culture", "TEST", 67, 84], ["sparse growth of normal flora", "PROBLEM", 92, 121], ["viral cultures", "TEST", 131, 145], ["influenza A virus", "PROBLEM", 167, 184], ["significant", "OBSERVATION_MODIFIER", 41, 52], ["bacteria", "OBSERVATION", 53, 61], ["normal flora", "OBSERVATION", 109, 121]]], ["Such patients do not respond to antibacterial drugs and the mortality is high.Epidemiology and TransmissionSecondary bacterial pneumonia is an important complication of influenza ( Fig. 32-8C ) (eFig. .", [["bacterial pneumonia", "DISEASE", 117, 136], ["influenza", "DISEASE", 169, 178], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["antibacterial drugs", "TREATMENT", 32, 51], ["bacterial pneumonia", "PROBLEM", 117, 136], ["influenza", "PROBLEM", 169, 178], ["bacterial", "OBSERVATION_MODIFIER", 117, 126], ["pneumonia", "OBSERVATION", 127, 136], ["influenza", "OBSERVATION", 169, 178]]], ["The classic description is of an influenza illness followed by a period of improvement, usually lasting 4 to 14 days.", [["influenza illness", "DISEASE", 33, 50], ["an influenza illness", "PROBLEM", 30, 50], ["influenza", "OBSERVATION", 33, 42]]], ["Recrudescence of fever is associated with symptoms and signs of bacterial pneumonia such as cough, sputum production, and an area of consolidation detected on physical examination and chest radiography.", [["sputum", "ANATOMY", 99, 105], ["Recrudescence", "DISEASE", 0, 13], ["fever", "DISEASE", 17, 22], ["pneumonia", "DISEASE", 74, 83], ["cough", "DISEASE", 92, 97], ["fever", "PROBLEM", 17, 22], ["symptoms", "PROBLEM", 42, 50], ["bacterial pneumonia", "PROBLEM", 64, 83], ["cough", "PROBLEM", 92, 97], ["sputum production", "PROBLEM", 99, 116], ["consolidation", "PROBLEM", 133, 146], ["physical examination", "TEST", 159, 179], ["chest radiography", "TEST", 184, 201], ["fever", "OBSERVATION", 17, 22], ["bacterial", "OBSERVATION_MODIFIER", 64, 73], ["pneumonia", "OBSERVATION", 74, 83], ["cough", "OBSERVATION", 92, 97], ["area", "OBSERVATION_MODIFIER", 125, 129], ["consolidation", "OBSERVATION", 133, 146], ["chest", "ANATOMY", 184, 189]]], ["The most common bacteria implicated are Streptococcus pneumoniae, with a significantly increased frequency of Staphylococcus aureus, 140, 141 including methicillin-resistant staphylococcus (MRSA).", [["Streptococcus pneumoniae", "DISEASE", 40, 64], ["Staphylococcus aureus", "DISEASE", 110, 131], [", 140, 141", "CHEMICAL", 131, 141], ["methicillin", "CHEMICAL", 152, 163], ["MRSA", "DISEASE", 190, 194], ["methicillin", "CHEMICAL", 152, 163], ["Streptococcus pneumoniae", "ORGANISM", 40, 64], ["Staphylococcus aureus", "ORGANISM", 110, 131], ["methicillin-resistant staphylococcus", "ORGANISM", 152, 188], ["MRSA", "CANCER", 190, 194], ["Streptococcus pneumoniae", "SPECIES", 40, 64], ["Staphylococcus aureus", "SPECIES", 110, 131], ["MRSA", "SPECIES", 190, 194], ["Streptococcus pneumoniae", "SPECIES", 40, 64], ["Staphylococcus aureus", "SPECIES", 110, 131], ["MRSA", "SPECIES", 190, 194], ["The most common bacteria", "PROBLEM", 0, 24], ["Streptococcus pneumoniae", "PROBLEM", 40, 64], ["Staphylococcus aureus", "PROBLEM", 110, 131], ["methicillin-resistant staphylococcus (MRSA", "PROBLEM", 152, 194], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["Streptococcus pneumoniae", "OBSERVATION", 40, 64], ["significantly", "OBSERVATION_MODIFIER", 73, 86], ["increased", "OBSERVATION_MODIFIER", 87, 96], ["Staphylococcus aureus", "OBSERVATION", 110, 131]]], ["Patients may present with mixed viral and bacterial pneumonia.", [["pneumonia", "DISEASE", 52, 61], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["mixed viral and bacterial pneumonia", "PROBLEM", 26, 61], ["mixed", "OBSERVATION_MODIFIER", 26, 31], ["viral", "OBSERVATION", 32, 37], ["bacterial", "OBSERVATION_MODIFIER", 42, 51], ["pneumonia", "OBSERVATION", 52, 61]]], ["Bacterial superinfections of influenza have been postulated as a major cause of death during the pandemic of 1918.", [["influenza", "DISEASE", 29, 38], ["death", "DISEASE", 80, 85], ["Bacterial superinfections", "PROBLEM", 0, 25], ["influenza", "PROBLEM", 29, 38], ["death", "PROBLEM", 80, 85], ["superinfections", "OBSERVATION", 10, 25], ["influenza", "OBSERVATION", 29, 38]]], ["142 Patients with a wide range of preexisting conditions are well recognized to be at higher risk for the development of pneumonia and other complications of influenza leading to hospitalization or death (Table 32-4 ).", [["pneumonia", "DISEASE", 121, 130], ["influenza", "DISEASE", 158, 167], ["death", "DISEASE", 198, 203], ["Patients", "ORGANISM", 4, 12], ["Patients", "SPECIES", 4, 12], ["preexisting conditions", "PROBLEM", 34, 56], ["pneumonia", "PROBLEM", 121, 130], ["influenza", "PROBLEM", 158, 167], ["death", "PROBLEM", 198, 203], ["pneumonia", "OBSERVATION", 121, 130], ["influenza", "OBSERVATION", 158, 167]]], ["In recent years, new conditions leading to increased risk have been recognized, including the presence of neuromuscular conditions that compromise respiration 143 and, in the 2009 pandemic, the presence of obesity.", [["neuromuscular", "ANATOMY", 106, 119], ["obesity", "DISEASE", 206, 213], ["new conditions", "PROBLEM", 17, 31], ["increased risk", "PROBLEM", 43, 57], ["neuromuscular conditions", "PROBLEM", 106, 130], ["obesity", "PROBLEM", 206, 213], ["obesity", "OBSERVATION", 206, 213]]], ["144, 145 In addition, the 2009 pandemic reemphasized the known increased risk of hospitalization or death in women in all stages of pregnancy or in the immediate postpartum period.", [["death", "DISEASE", 100, 105], ["women", "ORGANISM", 109, 114], ["women", "SPECIES", 109, 114], ["death", "PROBLEM", 100, 105], ["pregnancy", "PROBLEM", 132, 141], ["increased", "OBSERVATION_MODIFIER", 63, 72]]], ["146, 147 Diagnosis Immunologic detection of influenza antigens in respiratory samples can be used for rapid diagnosis, and a large number of such tests are commercially available 147a (see Chapter Although vaccine virus can be recovered from vaccinated individuals, particularly children, for several days following vaccine, transmission is extremely unusual.", [["respiratory samples", "ANATOMY", 66, 85], ["children", "ORGANISM", 279, 287], ["influenza antigens", "PROTEIN", 44, 62], ["children", "SPECIES", 279, 287], ["Immunologic detection", "TEST", 19, 40], ["influenza antigens in respiratory samples", "PROBLEM", 44, 85], ["such tests", "TEST", 141, 151], ["vaccine virus", "PROBLEM", 206, 219], ["vaccine", "TREATMENT", 316, 323], ["large", "OBSERVATION_MODIFIER", 125, 130]]], ["159 Live vaccine can be administered safely to health care workers except for those caring for immunosuppressed individuals requiring barrier precautions.Epidemiology and TransmissionRandomized controlled comparisons of the efficacy of inactivated and live attenuated vaccine in children have consistently shown that live vaccine provides superior efficacy in this population, with an approximately 50% lower cumulative incidence of influenza in those receiving live vaccine.", [["influenza", "DISEASE", 433, 442], ["children", "ORGANISM", 279, 287], ["children", "SPECIES", 279, 287], ["Live vaccine", "TREATMENT", 4, 16], ["immunosuppressed individuals", "TREATMENT", 95, 123], ["barrier precautions", "TREATMENT", 134, 153], ["live attenuated vaccine", "TREATMENT", 252, 275], ["live vaccine", "TREATMENT", 317, 329], ["influenza", "PROBLEM", 433, 442], ["live vaccine", "TREATMENT", 462, 474], ["influenza", "OBSERVATION", 433, 442]]], ["160 Similar comparisons in adults have suggested slightly superior efficacy of inactivated vaccine, 161 and large cohort studies are also consistent with the interpretation that inactivated vaccine has slightly better efficacy than live vaccine in adults, particularly in those who have received vaccines in previous years.", [["adults", "ORGANISM", 27, 33], ["adults", "ORGANISM", 248, 254], ["inactivated vaccine", "TREATMENT", 79, 98], ["large cohort studies", "TEST", 108, 128], ["inactivated vaccine", "TREATMENT", 178, 197], ["vaccines", "TREATMENT", 296, 304], ["consistent with", "UNCERTAINTY", 138, 153]]], ["162 Previous strategies for prevention of influenza in the United States and other countries have focused on targeting vaccines to persons at higher risk for influenza-related complications (see Table 32 -4) and on individuals in close contact with these high-risk individuals.", [["influenza", "DISEASE", 42, 51], ["influenza", "DISEASE", 158, 167], ["persons", "ORGANISM", 131, 138], ["persons", "SPECIES", 131, 138], ["Previous strategies", "TREATMENT", 4, 23], ["influenza", "PROBLEM", 42, 51], ["targeting vaccines", "TREATMENT", 109, 127], ["influenza", "PROBLEM", 158, 167], ["related complications", "PROBLEM", 168, 189], ["influenza", "OBSERVATION", 42, 51]]], ["In addition, it was recognized that more universal vaccination strategies, particularly of children, might be able to impact the spread of influenza in the community.", [["influenza", "DISEASE", 139, 148], ["children", "ORGANISM", 91, 99], ["children", "SPECIES", 91, 99], ["universal vaccination strategies", "TREATMENT", 41, 73], ["influenza", "PROBLEM", 139, 148], ["influenza", "OBSERVATION", 139, 148]]], ["Currently, the United States and many other countries have adopted a universal vaccination strategy with annual vaccination of all members of the population.", [["a universal vaccination strategy", "TREATMENT", 67, 99]]], ["This, of course, includes health care providers, and most institutions have adopted a policy of mandatory vaccination of individuals in contact with patients.Epidemiology and TransmissionAntibody responses to influenza A virus, whether induced by vaccination or natural infection, are predominantly directed at the \"globular head\" domain of the HA protein, which is involved in binding host cells.", [["head", "ANATOMY", 325, 329], ["cells", "ANATOMY", 391, 396], ["influenza A virus", "DISEASE", 209, 226], ["infection", "DISEASE", 270, 279], ["individuals", "ORGANISM", 121, 132], ["patients", "ORGANISM", 149, 157], ["influenza A virus", "ORGANISM", 209, 226], ["HA", "GENE_OR_GENE_PRODUCT", 345, 347], ["host cells", "CELL", 386, 396], ["globular head\" domain", "PROTEIN", 316, 337], ["HA protein", "PROTEIN", 345, 355], ["binding host cells", "CELL_TYPE", 378, 396], ["patients", "SPECIES", 149, 157], ["influenza A virus", "SPECIES", 209, 226], ["influenza A virus", "SPECIES", 209, 226], ["TransmissionAntibody responses", "TEST", 175, 205], ["influenza A virus", "PROBLEM", 209, 226], ["natural infection", "PROBLEM", 262, 279], ["the HA protein", "PROBLEM", 341, 355], ["infection", "OBSERVATION", 270, 279], ["host cells", "OBSERVATION", 386, 396]]], ["This domain of HA mutates frequently, and amino acid substitutions in this domain allow the new viral variant to escape recognition by antibodies that developed in response to the original virus.", [["amino acid", "CHEMICAL", 42, 52], ["amino acid", "CHEMICAL", 42, 52], ["HA", "GENE_OR_GENE_PRODUCT", 15, 17], ["amino acid", "AMINO_ACID", 42, 52], ["HA", "PROTEIN", 15, 17], ["antibodies", "PROTEIN", 135, 145], ["HA mutates", "PROBLEM", 15, 25], ["amino acid substitutions", "PROBLEM", 42, 66], ["this domain", "PROBLEM", 70, 81], ["the new viral variant", "PROBLEM", 88, 109], ["escape recognition", "PROBLEM", 113, 131], ["the original virus", "PROBLEM", 176, 194], ["acid substitutions", "OBSERVATION", 48, 66], ["new", "OBSERVATION_MODIFIER", 92, 95], ["viral variant", "OBSERVATION", 96, 109]]], ["Thus, new antigenic variant viruses emerge regularly, and this necessitates development and administration of new influenza vaccines each year.", [["new antigenic variant viruses", "PROBLEM", 6, 35], ["new influenza vaccines", "TREATMENT", 110, 132], ["new", "OBSERVATION_MODIFIER", 6, 9], ["antigenic variant viruses", "OBSERVATION", 10, 35]]], ["The costly and logistically complex requirement for a distinct influenza vaccine each year has stimulated efforts to develop a vaccine that targets conserved domains of the influenza virus hemagglutinin, rather than the variable globular head domain.", [["head", "ANATOMY", 238, 242], ["influenza", "DISEASE", 63, 72], ["influenza virus hemagglutinin", "ORGANISM", 173, 202], ["variable globular head domain", "PROTEIN", 220, 249], ["influenza virus hemagglutinin", "SPECIES", 173, 202], ["The costly and logistically complex requirement", "PROBLEM", 0, 47], ["a distinct influenza vaccine", "TREATMENT", 52, 80], ["a vaccine", "TREATMENT", 125, 134], ["the influenza virus hemagglutinin", "PROBLEM", 169, 202], ["the variable globular head domain", "PROBLEM", 216, 249], ["influenza virus", "OBSERVATION", 173, 188], ["globular", "ANATOMY_MODIFIER", 229, 237], ["head", "ANATOMY", 238, 242]]], ["Although these efforts have revealed evidence for broadly neutralizing antibodies produced by certain subjects, a clear strategy for production of a vaccine that induces broadly neutralizing antibodies has not yet emerged.", [["neutralizing antibodies", "PROTEIN", 58, 81], ["neutralizing antibodies", "PROTEIN", 178, 201], ["broadly neutralizing antibodies", "PROBLEM", 50, 81], ["a vaccine", "TREATMENT", 147, 156], ["broadly neutralizing antibodies", "PROBLEM", 170, 201], ["evidence for", "UNCERTAINTY", 37, 49], ["broadly", "OBSERVATION_MODIFIER", 50, 57], ["neutralizing", "OBSERVATION", 58, 70]]], ["[163] [164] [165] Antivirals.", [["[163] [164] [165] Antivirals", "SIMPLE_CHEMICAL", 0, 28], ["Antivirals", "TREATMENT", 18, 28]]], ["Two classes of antiviral agents are currently available for the treatment and prevention of influenza: the M2 inhibitors (M2Is) amantadine and rimantadine (adamantanes) and the neuraminidase inhibitors (NAIs) oseltamivir and zanamivir.", [["influenza", "DISEASE", 92, 101], ["amantadine", "CHEMICAL", 128, 138], ["rimantadine", "CHEMICAL", 143, 154], ["adamantanes", "CHEMICAL", 156, 167], ["oseltamivir", "CHEMICAL", 209, 220], ["zanamivir", "CHEMICAL", 225, 234], ["amantadine", "CHEMICAL", 128, 138], ["rimantadine", "CHEMICAL", 143, 154], ["adamantanes", "CHEMICAL", 156, 167], ["oseltamivir", "CHEMICAL", 209, 220], ["zanamivir", "CHEMICAL", 225, 234], ["M2Is", "SIMPLE_CHEMICAL", 122, 126], ["amantadine", "SIMPLE_CHEMICAL", 128, 138], ["rimantadine", "SIMPLE_CHEMICAL", 143, 154], ["adamantanes", "SIMPLE_CHEMICAL", 156, 167], ["neuraminidase inhibitors", "SIMPLE_CHEMICAL", 177, 201], ["NAIs", "SIMPLE_CHEMICAL", 203, 207], ["oseltamivir", "SIMPLE_CHEMICAL", 209, 220], ["zanamivir", "SIMPLE_CHEMICAL", 225, 234], ["antiviral agents", "TREATMENT", 15, 31], ["the treatment", "TREATMENT", 60, 73], ["influenza", "PROBLEM", 92, 101], ["the M2 inhibitors", "TREATMENT", 103, 120], ["M2Is", "TREATMENT", 122, 126], ["amantadine", "TREATMENT", 128, 138], ["rimantadine (adamantanes)", "TREATMENT", 143, 168], ["the neuraminidase inhibitors", "TREATMENT", 173, 201], ["NAIs", "TREATMENT", 203, 207], ["oseltamivir", "TREATMENT", 209, 220], ["zanamivir", "TREATMENT", 225, 234], ["antiviral agents", "OBSERVATION", 15, 31]]], ["The M2 protein is located in the viral envelope, where it functions as a proton channel and is essential for viral escape into the host cell cytoplasm, where viral replication takes place.", [["cell cytoplasm", "ANATOMY", 136, 150], ["M2", "GENE_OR_GENE_PRODUCT", 4, 6], ["cell", "CELLULAR_COMPONENT", 136, 140], ["cytoplasm", "ORGANISM_SUBSTANCE", 141, 150], ["M2 protein", "PROTEIN", 4, 14], ["proton channel", "PROTEIN", 73, 87], ["The M2 protein", "TEST", 0, 14], ["the viral envelope", "PROBLEM", 29, 47], ["a proton channel", "TREATMENT", 71, 87], ["viral escape into the host cell cytoplasm", "PROBLEM", 109, 150], ["viral replication", "TREATMENT", 158, 175], ["M2", "OBSERVATION_MODIFIER", 4, 6], ["viral envelope", "OBSERVATION", 33, 47], ["host cell cytoplasm", "OBSERVATION", 131, 150], ["viral replication", "OBSERVATION", 158, 175]]], ["The M2-inhibiting adamantanes specifically block the ion channel function of the influenza A M2 protein and are not active against influenzaTreatment and PreventionVaccines.", [["adamantanes", "CHEMICAL", 18, 29], ["adamantanes", "CHEMICAL", 18, 29], ["M2", "GENE_OR_GENE_PRODUCT", 4, 6], ["adamantanes", "SIMPLE_CHEMICAL", 18, 29], ["influenza A M2", "GENE_OR_GENE_PRODUCT", 81, 95], ["M2", "PROTEIN", 4, 6], ["influenza A M2 protein", "PROTEIN", 81, 103], ["influenzaTreatment", "TREATMENT", 131, 149], ["PreventionVaccines", "TREATMENT", 154, 172], ["M2", "OBSERVATION_MODIFIER", 4, 6], ["ion channel", "OBSERVATION_MODIFIER", 53, 64]]], ["Two types of vaccine are available for prevention of influenza.", [["influenza", "DISEASE", 53, 62], ["vaccine", "TREATMENT", 13, 20], ["influenza", "PROBLEM", 53, 62], ["influenza", "OBSERVATION", 53, 62]]], ["Inactivated vaccines consist of partially purified HA and NA preparations derived from virions produced in eggs or in cell culture or, in one case, purified recombinant HA produced in insect cells.", [["virions", "ANATOMY", 87, 94], ["eggs", "ANATOMY", 107, 111], ["cell culture", "ANATOMY", 118, 130], ["cells", "ANATOMY", 191, 196], ["NA", "CHEMICAL", 58, 60], ["cell culture", "CELL", 118, 130], ["HA", "GENE_OR_GENE_PRODUCT", 169, 171], ["insect cells", "CELL", 184, 196], ["purified recombinant HA", "PROTEIN", 148, 171], ["insect cells", "CELL_TYPE", 184, 196], ["Inactivated vaccines", "TREATMENT", 0, 20], ["partially purified HA", "PROBLEM", 32, 53], ["NA preparations", "TREATMENT", 58, 73], ["virions", "PROBLEM", 87, 94], ["cell culture", "TEST", 118, 130], ["purified recombinant HA", "PROBLEM", 148, 171], ["insect cells", "OBSERVATION", 184, 196]]], ["Current vaccines contain one example of H1N1, one example of H3N2, and either one or both lineages of influenza B. Inactivated vaccines are administered intramuscularly or intradermally and are primarily designed to induce systemic antibody, although they also induce cellular immune responses that may be associated with protection.", [["intradermally", "ANATOMY", 172, 185], ["cellular", "ANATOMY", 268, 276], ["H3N2", "DISEASE", 61, 65], ["influenza", "DISEASE", 102, 111], ["H3N2", "ORGANISM", 61, 65], ["influenza B.", "ORGANISM", 102, 114], ["cellular", "CELL", 268, 276], ["systemic antibody", "PROTEIN", 223, 240], ["Current vaccines", "TREATMENT", 0, 16], ["H1N1", "PROBLEM", 40, 44], ["H3N2", "PROBLEM", 61, 65], ["influenza B.", "TREATMENT", 102, 114], ["Inactivated vaccines", "TREATMENT", 115, 135], ["systemic antibody", "TEST", 223, 240], ["may be associated with", "UNCERTAINTY", 299, 321]]], ["Inactivated vaccines are well tolerated in all age groups, although hypersensitivity to hens' eggs is a relative contraindication to use of eggproduced vaccines.", [["hypersensitivity", "DISEASE", 68, 84], ["hens", "ORGANISM", 88, 92], ["Inactivated vaccines", "TREATMENT", 0, 20], ["hypersensitivity", "PROBLEM", 68, 84], ["eggproduced vaccines", "TREATMENT", 140, 160]]], ["Generally, if persons can eat eggs or egg-containing products, vaccination is safe.", [["persons", "ORGANISM", 14, 21], ["egg", "ORGANISM_SUBDIVISION", 38, 41], ["persons", "SPECIES", 14, 21], ["vaccination", "TREATMENT", 63, 74]]], ["If necessary, individuals with anaphylaxis can be desensitized and safely vaccinated, 151 or vaccines free of egg products can be used.Treatment and PreventionIncreases in hemagglutination-inhibition antibody are seen in about 90% of healthy adult recipients of vaccine.", [["egg", "ANATOMY", 110, 113], ["anaphylaxis", "DISEASE", 31, 42], ["individuals", "ORGANISM", 14, 25], ["egg", "ORGANISM", 110, 113], ["recipients", "ORGANISM", 248, 258], ["hemagglutination-inhibition antibody", "PROTEIN", 172, 208], ["anaphylaxis", "PROBLEM", 31, 42], ["vaccines", "TREATMENT", 93, 101], ["egg products", "TREATMENT", 110, 122], ["Treatment", "TREATMENT", 135, 144], ["PreventionIncreases", "TEST", 149, 168], ["hemagglutination", "TEST", 172, 188], ["inhibition antibody", "TEST", 189, 208], ["vaccine", "TREATMENT", 262, 269]]], ["Only a single dose of vaccine is required in individuals who have been previously vaccinated or who have experienced prior infection with a related subtype, but a two-dose schedule is required in unprimed individuals.", [["infection", "DISEASE", 123, 132], ["individuals", "ORGANISM", 45, 56], ["a single dose of vaccine", "TREATMENT", 5, 29], ["prior infection", "PROBLEM", 117, 132], ["a two-dose schedule", "TREATMENT", 161, 180], ["infection", "OBSERVATION", 123, 132]]], ["This includes children up to age 9 who have not previously been vaccinated or who were vaccinated for the first time with only a single dose in the previous season.", [["children", "ORGANISM", 14, 22], ["children", "SPECIES", 14, 22]]], ["152 Diminished responses and diminished efficacy are seen in elderly and immunocompromised populations.Treatment and PreventionThe protective efficacy of inactivated influenza vaccine is estimated to be in the range of 70% to 90% in healthy adults when there is a good antigenic match between vaccine and epidemic viruses.", [["influenza", "DISEASE", 166, 175], ["Diminished responses", "PROBLEM", 4, 24], ["diminished efficacy", "PROBLEM", 29, 48], ["immunocompromised populations", "PROBLEM", 73, 102], ["Treatment", "TREATMENT", 103, 112], ["The protective efficacy", "TREATMENT", 127, 150], ["inactivated influenza vaccine", "TREATMENT", 154, 183], ["vaccine", "TREATMENT", 293, 300], ["epidemic viruses", "PROBLEM", 305, 321], ["Diminished", "OBSERVATION_MODIFIER", 4, 14], ["diminished", "OBSERVATION_MODIFIER", 29, 39], ["efficacy", "OBSERVATION_MODIFIER", 40, 48], ["immunocompromised", "OBSERVATION", 73, 90]]], ["153, 154 Few prospective trials of protective efficacy have been conducted in high-risk populations.", [["protective efficacy", "TREATMENT", 35, 54]]], ["In one placebo-controlled prospective trial, inactivated vaccine was approximately 58% effective in preventing influenza among adults older than 60 and 29% in those older than 70.", [["influenza", "DISEASE", 111, 120], ["one placebo-controlled prospective trial", "TREATMENT", 3, 43], ["inactivated vaccine", "TREATMENT", 45, 64], ["influenza", "PROBLEM", 111, 120]]], ["155 However, this study used a serologic definition of influenza infection, possibly biasing results in favor of vaccine efficacy.Treatment and PreventionObservational studies have suggested that in practice the effectiveness of inactivated vaccine in prevention of acute respiratory illness due to influenza ranges between 40% and 60%, with even lower effectiveness in older adults and in seasons with antigenic mismatch.", [["respiratory", "ANATOMY", 272, 283], ["influenza infection", "DISEASE", 55, 74], ["acute respiratory illness", "DISEASE", 266, 291], ["influenza", "DISEASE", 299, 308], ["this study", "TEST", 13, 23], ["influenza infection", "PROBLEM", 55, 74], ["vaccine efficacy", "TREATMENT", 113, 129], ["Treatment", "TREATMENT", 130, 139], ["PreventionObservational studies", "TEST", 144, 175], ["inactivated vaccine", "TREATMENT", 229, 248], ["acute respiratory illness", "PROBLEM", 266, 291], ["influenza", "PROBLEM", 299, 308], ["antigenic mismatch", "PROBLEM", 403, 421], ["influenza", "OBSERVATION", 55, 64], ["acute", "OBSERVATION_MODIFIER", 266, 271], ["respiratory illness", "OBSERVATION", 272, 291], ["antigenic mismatch", "OBSERVATION", 403, 421]]], ["Attempts to improve the effectiveness of inactivated vaccines have included the use of higher doses and adjuvants.Treatment and PreventionThe live attenuated vaccine, administered intranasally, induces a limited, asymptomatic infection of the upper respiratory tract and induces a variety of immune responses designed to mimic the protective immunity induced by natural infection.", [["intranasally", "ANATOMY", 180, 192], ["upper respiratory tract", "ANATOMY", 243, 266], ["infection of the upper respiratory tract", "DISEASE", 226, 266], ["natural infection", "DISEASE", 362, 379], ["upper respiratory", "ORGANISM_SUBDIVISION", 243, 260], ["tract", "ORGANISM_SUBDIVISION", 261, 266], ["inactivated vaccines", "TREATMENT", 41, 61], ["higher doses and adjuvants", "TREATMENT", 87, 113], ["Treatment", "TREATMENT", 114, 123], ["The live attenuated vaccine", "TREATMENT", 138, 165], ["asymptomatic infection of the upper respiratory tract", "PROBLEM", 213, 266], ["immune responses", "PROBLEM", 292, 308], ["natural infection", "PROBLEM", 362, 379], ["infection", "OBSERVATION", 226, 235], ["upper", "ANATOMY_MODIFIER", 243, 248], ["respiratory tract", "ANATOMY", 249, 266], ["natural", "OBSERVATION_MODIFIER", 362, 369], ["infection", "OBSERVATION", 370, 379]]], ["156, 157 The vaccine is well tolerated and highly effective in children but is associated with an increased frequency of wheezing in children younger than 2 years of age.", [["wheezing", "DISEASE", 121, 129], ["children", "ORGANISM", 63, 71], ["children", "ORGANISM", 133, 141], ["children", "SPECIES", 63, 71], ["children", "SPECIES", 133, 141], ["The vaccine", "TREATMENT", 9, 20], ["wheezing", "PROBLEM", 121, 129], ["increased", "OBSERVATION_MODIFIER", 98, 107], ["wheezing", "OBSERVATION", 121, 129]]], ["Live vaccine is protective in adults as well, resulting in decreased laboratory-confirmed influenza in challenge studies and reduced frequencies of influenza-like illness in the field.", [["influenza", "DISEASE", 90, 99], ["influenza-like illness", "DISEASE", 148, 170], ["Live vaccine", "TREATMENT", 0, 12], ["decreased laboratory", "PROBLEM", 59, 79], ["influenza", "PROBLEM", 90, 99], ["challenge studies", "TEST", 103, 120], ["influenza", "PROBLEM", 148, 157]]], ["158 Although the vaccine is well tolerated in the elderly and in those with chronic lung disease, immune responses are less frequent in older recipients and the vaccine is not licensed for use in those older than 49. related complications, with reductions in the use of antibacterials and in hospitalization.", [["lung", "ANATOMY", 84, 88], ["chronic lung disease", "DISEASE", 76, 96], ["lung", "ORGAN", 84, 88], ["recipients", "ORGANISM", 142, 152], ["the vaccine", "TREATMENT", 13, 24], ["chronic lung disease", "PROBLEM", 76, 96], ["immune responses", "PROBLEM", 98, 114], ["the vaccine", "TREATMENT", 157, 168], ["complications", "PROBLEM", 225, 238], ["antibacterials", "TREATMENT", 270, 284], ["chronic", "OBSERVATION_MODIFIER", 76, 83], ["lung", "ANATOMY", 84, 88], ["disease", "OBSERVATION", 89, 96], ["complications", "OBSERVATION", 225, 238], ["reductions", "OBSERVATION_MODIFIER", 245, 255]]], ["170 Only oseltamivir is currently licensed for use in children younger than 5 years of age.", [["oseltamivir", "CHEMICAL", 9, 20], ["oseltamivir", "CHEMICAL", 9, 20], ["oseltamivir", "SIMPLE_CHEMICAL", 9, 20], ["children", "ORGANISM", 54, 62], ["children", "SPECIES", 54, 62], ["oseltamivir", "TREATMENT", 9, 20], ["oseltamivir", "OBSERVATION", 9, 20]]], ["Administration of oseltamivir liquid at a dose of 3 mg/kg in children 0 to 8 months of age, and 3.5 mg/kg in children 9 to 11 months of age, twice daily for 5 days reached target ranges.", [["oseltamivir", "CHEMICAL", 18, 29], ["oseltamivir", "CHEMICAL", 18, 29], ["oseltamivir", "SIMPLE_CHEMICAL", 18, 29], ["children", "ORGANISM", 61, 69], ["children", "ORGANISM", 109, 117], ["children", "SPECIES", 61, 69], ["children", "SPECIES", 109, 117], ["oseltamivir liquid", "TREATMENT", 18, 36]]], ["Earlier studies showed that they were well tolerated and resulted in a 36-hour reduction in the duration of symptoms in children with influenza A. 170a,171 NAIs have also been used successfully for seasonal or contact prophylaxis.Treatment and PreventionInitial placebo-controlled trials of NAI therapy conducted primarily in otherwise healthy adults did not capture substantial numbers of influenza complications.", [["influenza", "DISEASE", 134, 143], ["NAI", "CHEMICAL", 291, 294], ["influenza", "DISEASE", 390, 399], ["children", "ORGANISM", 120, 128], ["children", "SPECIES", 120, 128], ["Earlier studies", "TEST", 0, 15], ["a 36-hour reduction", "TREATMENT", 69, 88], ["symptoms", "PROBLEM", 108, 116], ["influenza A.", "PROBLEM", 134, 146], ["seasonal or contact prophylaxis", "TREATMENT", 198, 229], ["Treatment", "TREATMENT", 230, 239], ["PreventionInitial placebo", "TREATMENT", 244, 269], ["NAI therapy", "TREATMENT", 291, 302], ["influenza complications", "PROBLEM", 390, 413], ["influenza", "OBSERVATION", 390, 399]]], ["However, pooled analyses of these studies of early therapy with zanamivir 172 and oseltamivir 170,173 demonstrated a significant reduction in the rate of influenza complications in treated individuals.", [["zanamivir 172", "CHEMICAL", 64, 77], ["oseltamivir 170,173", "CHEMICAL", 82, 101], ["influenza complications", "DISEASE", 154, 177], ["zanamivir 172", "CHEMICAL", 64, 77], ["oseltamivir 170,173", "CHEMICAL", 82, 101], ["zanamivir 172", "SIMPLE_CHEMICAL", 64, 77], ["oseltamivir 170,173", "SIMPLE_CHEMICAL", 82, 101], ["these studies", "TEST", 28, 41], ["early therapy", "TREATMENT", 45, 58], ["zanamivir", "TREATMENT", 64, 73], ["oseltamivir", "TREATMENT", 82, 93], ["a significant reduction", "PROBLEM", 115, 138], ["influenza complications", "PROBLEM", 154, 177], ["significant", "OBSERVATION_MODIFIER", 117, 128], ["reduction", "OBSERVATION_MODIFIER", 129, 138], ["influenza", "OBSERVATION", 154, 163]]], ["Subsequent experience in the emerging epidemic of pH1N1 virus has also suggested a beneficial effect of early therapy on complications.", [["pH1N1", "DISEASE", 50, 55], ["pH1N1 virus", "ORGANISM", 50, 61], ["pH1N1 virus", "SPECIES", 50, 61], ["pH1N1 virus", "PROBLEM", 50, 61], ["early therapy", "TREATMENT", 104, 117], ["complications", "PROBLEM", 121, 134]]], ["These include observations in hospitalized patients 174, 175 and surveillance data suggesting that therapy as late as 5 days improved survival of hospitalized patients.", [["patients", "ORGANISM", 43, 51], ["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 43, 51], ["patients", "SPECIES", 159, 167], ["surveillance data", "TEST", 65, 82], ["therapy", "TREATMENT", 99, 106]]], ["176 Surveillance data have also suggested that treated children had lower rates of complications.", [["children", "ORGANISM", 55, 63], ["children", "SPECIES", 55, 63], ["Surveillance data", "TEST", 4, 21], ["lower rates of complications", "PROBLEM", 68, 96], ["complications", "OBSERVATION", 83, 96]]], ["177 Mutations within the catalytic framework of the NA that abolish binding of the drugs have been described.", [["NA", "CHEMICAL", 52, 54]]], ["178, 179 Depending on the location of the mutation, these viruses may be specifically resistant to only one of the inhibitors.", [["the mutation", "PROBLEM", 38, 50], ["these viruses", "PROBLEM", 52, 65], ["the inhibitors", "TREATMENT", 111, 125]]], ["180 Resistance mutations in the NA may also be associated with altered characteristics of the enzyme with significantly reduced activity.", [["NA", "CHEMICAL", 32, 34], ["Resistance mutations", "PROBLEM", 4, 24], ["the enzyme", "TEST", 90, 100], ["significantly reduced activity", "PROBLEM", 106, 136], ["reduced", "OBSERVATION_MODIFIER", 120, 127], ["activity", "OBSERVATION_MODIFIER", 128, 136]]], ["181, 182 Drug-resistant viruses are most commonly isolated from treated children.", [["children", "ORGANISM", 72, 80], ["children", "SPECIES", 72, 80], ["resistant viruses", "PROBLEM", 14, 31], ["viruses", "OBSERVATION", 24, 31]]], ["183 Viral fitness appears to be less compromised by oseltamivir resistance mutations in the N1 neuraminidase, 184 and resistance was common among seasonal H1N1 viruses before the pH1N1 pandemic.", [["oseltamivir", "CHEMICAL", 52, 63], ["N1 neuraminidase, 184", "CHEMICAL", 92, 113], ["oseltamivir", "CHEMICAL", 52, 63], ["Viral", "ORGANISM", 4, 9], ["oseltamivir", "SIMPLE_CHEMICAL", 52, 63], ["seasonal H1N1 viruses", "ORGANISM", 146, 167], ["seasonal H1N1 viruses", "SPECIES", 146, 167], ["Viral fitness", "PROBLEM", 4, 17], ["oseltamivir resistance mutations", "PROBLEM", 52, 84], ["the N1 neuraminidase", "TEST", 88, 108], ["seasonal H1N1 viruses", "PROBLEM", 146, 167], ["the pH1N1 pandemic", "PROBLEM", 175, 193], ["Viral fitness", "OBSERVATION", 4, 17], ["appears to be", "UNCERTAINTY", 18, 31]]], ["Currently, the majority of seasonal influenza viruses are susceptible to both drugs, but N1 resistance is being sporadically reported and it is important to continue to monitor susceptibility patterns.Treatment and PreventionAlthough the benefits of antiviral therapy were initially demonstrated as a shortening of illness duration in healthy adults with uncomplicated influenza, this is generally not considered the priority target group for antiviral therapy.", [["influenza viruses", "DISEASE", 36, 53], ["illness", "DISEASE", 315, 322], ["influenza", "DISEASE", 369, 378], ["seasonal influenza viruses", "ORGANISM", 27, 53], ["seasonal influenza viruses", "SPECIES", 27, 53], ["seasonal influenza viruses", "PROBLEM", 27, 53], ["both drugs", "TREATMENT", 73, 83], ["Treatment", "TREATMENT", 201, 210], ["antiviral therapy", "TREATMENT", 250, 267], ["uncomplicated influenza", "PROBLEM", 355, 378], ["antiviral therapy", "TREATMENT", 443, 460], ["influenza viruses", "OBSERVATION", 36, 53], ["influenza", "OBSERVATION", 369, 378], ["antiviral therapy", "OBSERVATION", 443, 460]]], ["Current recommendations include the use of antivirals in individuals at risk for more severe influenza, or in individuals with severe disease or requiring hospitalization.", [["influenza", "DISEASE", 93, 102], ["antivirals", "TREATMENT", 43, 53], ["more severe influenza", "PROBLEM", 81, 102], ["severe disease", "PROBLEM", 127, 141], ["severe", "OBSERVATION_MODIFIER", 86, 92], ["influenza", "OBSERVATION", 93, 102], ["severe", "OBSERVATION_MODIFIER", 127, 133], ["disease", "OBSERVATION", 134, 141]]], ["149 Treatment should be started as early as possible, but even delayed therapy can be of benefit in hospitalized patients.Treatment and PreventionTreatment of patients requiring mechanical ventilation can be challenging.", [["patients", "ORGANISM", 113, 121], ["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 113, 121], ["patients", "SPECIES", 159, 167], ["Treatment", "TREATMENT", 4, 13], ["Treatment", "TREATMENT", 122, 131], ["PreventionTreatment", "TREATMENT", 136, 155], ["mechanical ventilation", "TREATMENT", 178, 200]]], ["Administration of oseltamivir by nasogastric tube is effective, and intravenous preparations of zanamivir and the experimental NAI peramivir are available under compassionate use protocols.MEASLES VIRUSMeasles virus is classified in the Morbillivirus genus of the Paramyxoviridae family and is structurally similar to parainfluenza virus and RSV.", [["nasogastric tube", "ANATOMY", 33, 49], ["intravenous", "ANATOMY", 68, 79], ["oseltamivir", "CHEMICAL", 18, 29], ["zanamivir", "CHEMICAL", 96, 105], ["peramivir", "CHEMICAL", 131, 140], ["parainfluenza virus", "DISEASE", 318, 337], ["RSV", "DISEASE", 342, 345], ["oseltamivir", "CHEMICAL", 18, 29], ["zanamivir", "CHEMICAL", 96, 105], ["peramivir", "CHEMICAL", 131, 140], ["oseltamivir", "SIMPLE_CHEMICAL", 18, 29], ["nasogastric tube", "MULTI-TISSUE_STRUCTURE", 33, 49], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 68, 79], ["zanamivir", "SIMPLE_CHEMICAL", 96, 105], ["peramivir", "SIMPLE_CHEMICAL", 131, 140], ["VIRUSMeasles virus", "ORGANISM", 197, 215], ["Morbillivirus genus", "ORGANISM", 237, 256], ["Paramyxoviridae", "GENE_OR_GENE_PRODUCT", 264, 279], ["parainfluenza virus", "ORGANISM", 318, 337], ["RSV", "ORGANISM", 342, 345], ["parainfluenza virus", "SPECIES", 318, 337], ["RSV", "SPECIES", 342, 345], ["parainfluenza virus", "SPECIES", 318, 337], ["RSV", "SPECIES", 342, 345], ["oseltamivir", "TREATMENT", 18, 29], ["nasogastric tube", "TREATMENT", 33, 49], ["intravenous preparations", "TREATMENT", 68, 92], ["zanamivir", "TREATMENT", 96, 105], ["the experimental NAI peramivir", "TREATMENT", 110, 140], ["MEASLES VIRUSMeasles virus", "PROBLEM", 189, 215], ["parainfluenza virus", "PROBLEM", 318, 337], ["RSV", "PROBLEM", 342, 345], ["nasogastric tube", "OBSERVATION", 33, 49], ["parainfluenza virus", "OBSERVATION", 318, 337]]], ["Its surface glycoproteins include a hemagglutinin responsible for attachment to cells, a fusion (F) protein responsible for cell membrane fusion and virus B viruses.", [["surface", "ANATOMY", 4, 11], ["cells", "ANATOMY", 80, 85], ["cell membrane", "ANATOMY", 124, 137], ["cells", "CELL", 80, 85], ["cell membrane", "CELLULAR_COMPONENT", 124, 137], ["virus B viruses", "ORGANISM", 149, 164], ["surface glycoproteins", "PROTEIN", 4, 25], ["hemagglutinin", "PROTEIN", 36, 49], ["fusion (F) protein", "PROTEIN", 89, 107], ["Its surface glycoproteins", "TREATMENT", 0, 25], ["a hemagglutinin", "TREATMENT", 34, 49], ["attachment to cells", "PROBLEM", 66, 85], ["a fusion (F) protein", "TREATMENT", 87, 107], ["cell membrane fusion", "TREATMENT", 124, 144], ["virus B viruses", "PROBLEM", 149, 164], ["cell membrane fusion", "OBSERVATION", 124, 144]]], ["Resistance to these drugs emerges readily in treated individuals, particularly children, 166 and there may be prolonged shedding of resistant viruses in immunocompromised patients even after therapy is terminated.", [["children", "ORGANISM", 79, 87], ["patients", "ORGANISM", 171, 179], ["children", "SPECIES", 79, 87], ["patients", "SPECIES", 171, 179], ["these drugs", "TREATMENT", 14, 25], ["prolonged shedding of resistant viruses", "PROBLEM", 110, 149], ["therapy", "TREATMENT", 191, 198], ["may be", "UNCERTAINTY", 103, 109], ["resistant", "OBSERVATION_MODIFIER", 132, 141], ["viruses", "OBSERVATION", 142, 149]]], ["167 For reasons that remain unclear, the first decade of this century has seen the emergence and spread of adamantaneresistant influenza A (H3N2) viruses, 168 and pH1N1 viruses are also uniformly resistant.", [["influenza A (H3N2) viruses", "DISEASE", 127, 153], ["adamantaneresistant influenza A (H3N2) viruses", "ORGANISM", 107, 153], ["pH1N1 viruses", "ORGANISM", 163, 176], ["influenza A (H3N2", "SPECIES", 127, 144], ["adamantaneresistant influenza A (H3N2) viruses", "SPECIES", 107, 153], ["pH1N1 viruses", "SPECIES", 163, 176], ["adamantaneresistant influenza A (H3N2) viruses", "PROBLEM", 107, 153], ["pH1N1 viruses", "PROBLEM", 163, 176], ["resistant", "OBSERVATION_MODIFIER", 196, 205]]], ["Therefore, the adamantane M2I drugs do not have utility against current influenza viruses but might be used if susceptible strains emerge in the future.MEASLES VIRUSNAIs are potent inhibitors of influenza virus in vitro and in vivo because neuraminidase activity is essential for viral release, a necessary step for viral spread to other cells.", [["cells", "ANATOMY", 338, 343], ["adamantane", "CHEMICAL", 15, 25], ["influenza viruses", "DISEASE", 72, 89], ["influenza virus", "DISEASE", 195, 210], ["adamantane", "CHEMICAL", 15, 25], ["adamantane M2I", "SIMPLE_CHEMICAL", 15, 29], ["influenza viruses", "ORGANISM", 72, 89], ["influenza virus", "ORGANISM", 195, 210], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 240, 253], ["cells", "CELL", 338, 343], ["neuraminidase", "PROTEIN", 240, 253], ["influenza virus", "SPECIES", 195, 210], ["the adamantane M2I drugs", "TREATMENT", 11, 35], ["current influenza viruses", "PROBLEM", 64, 89], ["susceptible strains", "PROBLEM", 111, 130], ["MEASLES VIRUSNAIs", "PROBLEM", 152, 169], ["potent inhibitors", "TREATMENT", 174, 191], ["influenza virus", "PROBLEM", 195, 210], ["vitro", "TREATMENT", 214, 219], ["neuraminidase activity", "PROBLEM", 240, 262], ["viral release", "PROBLEM", 280, 293], ["viral spread to other cells", "PROBLEM", 316, 343], ["influenza virus", "OBSERVATION", 195, 210]]], ["Influenza B viruses are somewhat less sensitive than influenza A viruses but are well within clinically achievable concentrations.", [["Influenza B", "DISEASE", 0, 11], ["Influenza B viruses", "ORGANISM", 0, 19], ["influenza A viruses", "ORGANISM", 53, 72], ["Influenza B viruses", "SPECIES", 0, 19], ["Influenza B viruses", "SPECIES", 0, 19], ["influenza A viruses", "SPECIES", 53, 72], ["Influenza B viruses", "PROBLEM", 0, 19], ["influenza A viruses", "PROBLEM", 53, 72], ["viruses", "OBSERVATION", 12, 19], ["less sensitive", "OBSERVATION_MODIFIER", 33, 47]]], ["Avian viruses with all nine known neuraminidase subtypes are also sensitive.", [["Avian viruses", "ORGANISM", 0, 13], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 34, 47], ["Avian", "SPECIES", 0, 5], ["Avian viruses", "PROBLEM", 0, 13], ["all nine known neuraminidase subtypes", "PROBLEM", 19, 56], ["viruses", "OBSERVATION", 6, 13], ["neuraminidase subtypes", "OBSERVATION", 34, 56]]], ["Although zanamivir and oseltamivir have an identical mechanism of action and similar profile of antiviral activity, they have differing pharmacologic properties.", [["zanamivir", "CHEMICAL", 9, 18], ["oseltamivir", "CHEMICAL", 23, 34], ["zanamivir", "CHEMICAL", 9, 18], ["oseltamivir", "CHEMICAL", 23, 34], ["zanamivir", "SIMPLE_CHEMICAL", 9, 18], ["oseltamivir", "SIMPLE_CHEMICAL", 23, 34], ["zanamivir", "TREATMENT", 9, 18], ["oseltamivir", "TREATMENT", 23, 34], ["antiviral activity", "TREATMENT", 96, 114], ["antiviral activity", "OBSERVATION", 96, 114]]], ["Zanamivir is not orally bioavailable and is administered as a dry powder for oral inhalation, using the so-called \"diskhaler\" device.", [["oral", "ANATOMY", 77, 81], ["Zanamivir", "CHEMICAL", 0, 9], ["Zanamivir", "CHEMICAL", 0, 9], ["Zanamivir", "SIMPLE_CHEMICAL", 0, 9], ["oral", "ORGANISM_SUBDIVISION", 77, 81], ["Zanamivir", "TREATMENT", 0, 9], ["a dry powder", "TREATMENT", 60, 72], ["oral inhalation", "TREATMENT", 77, 92], ["the so-called \"diskhaler\" device", "TREATMENT", 100, 132]]], ["Oseltamivir phosphate is an orally bioavailable ethyl ester prodrug that is rapidly absorbed from the GI tract and converted in the liver by hepatic esterases to the active metabolite, oseltamivir carboxylate.", [["GI tract", "ANATOMY", 102, 110], ["liver", "ANATOMY", 132, 137], ["hepatic", "ANATOMY", 141, 148], ["Oseltamivir phosphate", "CHEMICAL", 0, 21], ["ethyl ester", "CHEMICAL", 48, 59], ["oseltamivir carboxylate", "CHEMICAL", 185, 208], ["Oseltamivir phosphate", "CHEMICAL", 0, 21], ["ethyl ester", "CHEMICAL", 48, 59], ["oseltamivir carboxylate", "CHEMICAL", 185, 208], ["Oseltamivir phosphate", "SIMPLE_CHEMICAL", 0, 21], ["ethyl ester prodrug", "SIMPLE_CHEMICAL", 48, 67], ["GI tract", "ORGANISM_SUBDIVISION", 102, 110], ["liver", "ORGAN", 132, 137], ["hepatic", "ORGAN", 141, 148], ["oseltamivir carboxylate", "SIMPLE_CHEMICAL", 185, 208], ["Oseltamivir phosphate", "TREATMENT", 0, 21], ["an orally bioavailable ethyl ester prodrug", "TREATMENT", 25, 67], ["oseltamivir carboxylate", "TREATMENT", 185, 208], ["GI tract", "ANATOMY", 102, 110], ["liver", "ANATOMY", 132, 137], ["hepatic", "ANATOMY", 141, 148], ["active metabolite", "OBSERVATION", 166, 183]]], ["The metabolite is excreted unchanged in the urine by tubular secretion, with a serum half-life of 6 to 10 hours.MEASLES VIRUSThe major adverse effects reported for oseltamivir have been GI upset in about 10% to 15% of recipients, probably due to irritation caused by rapid release of the drug in the stomach.", [["urine", "ANATOMY", 44, 49], ["tubular", "ANATOMY", 53, 60], ["serum", "ANATOMY", 79, 84], ["stomach", "ANATOMY", 300, 307], ["oseltamivir", "CHEMICAL", 164, 175], ["irritation", "DISEASE", 246, 256], ["oseltamivir", "CHEMICAL", 164, 175], ["urine", "ORGANISM_SUBSTANCE", 44, 49], ["tubular", "MULTI-TISSUE_STRUCTURE", 53, 60], ["serum", "ORGANISM_SUBSTANCE", 79, 84], ["oseltamivir", "SIMPLE_CHEMICAL", 164, 175], ["GI", "ORGANISM_SUBDIVISION", 186, 188], ["recipients", "ORGANISM", 218, 228], ["stomach", "ORGAN", 300, 307], ["the urine", "TEST", 40, 49], ["oseltamivir", "TREATMENT", 164, 175], ["GI upset", "PROBLEM", 186, 194], ["irritation", "PROBLEM", 246, 256], ["metabolite", "OBSERVATION_MODIFIER", 4, 14], ["excreted", "OBSERVATION_MODIFIER", 18, 26], ["unchanged", "OBSERVATION_MODIFIER", 27, 36], ["tubular secretion", "OBSERVATION", 53, 70], ["probably due to", "UNCERTAINTY", 230, 245], ["irritation", "OBSERVATION", 246, 256], ["stomach", "ANATOMY", 300, 307]]], ["Rates of nausea can be substantially reduced if the drug is taken with food.", [["nausea", "DISEASE", 9, 15], ["nausea", "PROBLEM", 9, 15], ["nausea", "OBSERVATION", 9, 15], ["reduced", "OBSERVATION_MODIFIER", 37, 44]]], ["Adverse effects reported for zanamivir have been at essentially the same rate as in placebo recipients.", [["zanamivir", "CHEMICAL", 29, 38], ["zanamivir", "CHEMICAL", 29, 38], ["zanamivir", "SIMPLE_CHEMICAL", 29, 38], ["Adverse effects", "PROBLEM", 0, 15], ["zanamivir", "TREATMENT", 29, 38], ["placebo recipients", "TREATMENT", 84, 102]]], ["However, postmarketing surveillance has found that inhaled zanamivir may be uncommonly associated with bronchospasm in influenza patients, particularly those with underlying airways disease; this acute bronchospasm has sometimes been severe or fatal.MEASLES VIRUSThe dose of oseltamivir should be reduced to 75 mg once daily in individuals with renal impairment (i.e., with creatinine clearance 15-30 mL/min and 75 mg every other day in prophylactic treatment).", [["airways", "ANATOMY", 174, 181], ["renal", "ANATOMY", 345, 350], ["zanamivir", "CHEMICAL", 59, 68], ["bronchospasm", "DISEASE", 103, 115], ["influenza", "DISEASE", 119, 128], ["airways disease", "DISEASE", 174, 189], ["bronchospasm", "DISEASE", 202, 214], ["oseltamivir", "CHEMICAL", 275, 286], ["renal impairment", "DISEASE", 345, 361], ["creatinine", "CHEMICAL", 374, 384], ["zanamivir", "CHEMICAL", 59, 68], ["oseltamivir", "CHEMICAL", 275, 286], ["creatinine", "CHEMICAL", 374, 384], ["zanamivir", "SIMPLE_CHEMICAL", 59, 68], ["patients", "ORGANISM", 129, 137], ["airways", "MULTI-TISSUE_STRUCTURE", 174, 181], ["oseltamivir", "SIMPLE_CHEMICAL", 275, 286], ["renal", "ORGAN", 345, 350], ["creatinine", "SIMPLE_CHEMICAL", 374, 384], ["patients", "SPECIES", 129, 137], ["postmarketing surveillance", "TEST", 9, 35], ["inhaled zanamivir", "TREATMENT", 51, 68], ["bronchospasm", "PROBLEM", 103, 115], ["influenza", "PROBLEM", 119, 128], ["underlying airways disease", "PROBLEM", 163, 189], ["this acute bronchospasm", "PROBLEM", 191, 214], ["oseltamivir", "TREATMENT", 275, 286], ["renal impairment", "PROBLEM", 345, 361], ["creatinine clearance", "TREATMENT", 374, 394], ["prophylactic treatment", "TREATMENT", 437, 459], ["bronchospasm", "OBSERVATION", 103, 115], ["airways", "ANATOMY", 174, 181], ["disease", "OBSERVATION", 182, 189], ["acute", "OBSERVATION_MODIFIER", 196, 201], ["bronchospasm", "OBSERVATION", 202, 214], ["severe", "OBSERVATION_MODIFIER", 234, 240], ["fatal", "OBSERVATION_MODIFIER", 244, 249], ["renal", "ANATOMY", 345, 350], ["impairment", "OBSERVATION", 351, 361]]], ["No data are available regarding the use of the drug in individuals with more significant levels of renal impairment.", [["renal", "ANATOMY", 99, 104], ["renal impairment", "DISEASE", 99, 115], ["renal", "ORGAN", 99, 104], ["renal impairment", "PROBLEM", 99, 115], ["renal", "ANATOMY", 99, 104], ["impairment", "OBSERVATION", 105, 115]]], ["Likewise, no information is available regarding the use of oseltamivir in individuals with hepatic impairment.", [["hepatic", "ANATOMY", 91, 98], ["oseltamivir", "CHEMICAL", 59, 70], ["hepatic impairment", "DISEASE", 91, 109], ["oseltamivir", "CHEMICAL", 59, 70], ["oseltamivir", "SIMPLE_CHEMICAL", 59, 70], ["hepatic", "ORGAN", 91, 98], ["oseltamivir", "TREATMENT", 59, 70], ["hepatic impairment", "PROBLEM", 91, 109], ["hepatic", "ANATOMY", 91, 98], ["impairment", "OBSERVATION", 99, 109]]], ["Clinically significant drug interactions have not been reported.", [["significant", "OBSERVATION_MODIFIER", 11, 22], ["drug", "OBSERVATION", 23, 27]]], ["Because the drug is eliminated by tubular secretion, probenecid increases serum levels of the active metabolite approximately twofold.", [["tubular", "ANATOMY", 34, 41], ["serum", "ANATOMY", 74, 79], ["probenecid", "CHEMICAL", 53, 63], ["probenecid", "CHEMICAL", 53, 63], ["tubular", "MULTI-TISSUE_STRUCTURE", 34, 41], ["probenecid", "SIMPLE_CHEMICAL", 53, 63], ["serum", "ORGANISM_SUBSTANCE", 74, 79], ["tubular secretion", "PROBLEM", 34, 51], ["probenecid", "TREATMENT", 53, 63], ["serum levels", "TEST", 74, 86], ["tubular secretion", "OBSERVATION", 34, 51], ["active", "OBSERVATION_MODIFIER", 94, 100], ["metabolite approximately", "OBSERVATION", 101, 125]]], ["However, dosage adjustments are not necessary in individuals taking probenecid.", [["probenecid", "CHEMICAL", 68, 78], ["probenecid", "CHEMICAL", 68, 78], ["probenecid", "SIMPLE_CHEMICAL", 68, 78], ["dosage adjustments", "TREATMENT", 9, 27], ["probenecid", "TREATMENT", 68, 78]]], ["Coadministration of cimetidine, amoxicillin, or acetaminophen has no effect on serum levels of oseltamivir or oseltamivir carboxylate.", [["serum", "ANATOMY", 79, 84], ["cimetidine", "CHEMICAL", 20, 30], ["amoxicillin", "CHEMICAL", 32, 43], ["acetaminophen", "CHEMICAL", 48, 61], ["oseltamivir", "CHEMICAL", 95, 106], ["oseltamivir carboxylate", "CHEMICAL", 110, 133], ["cimetidine", "CHEMICAL", 20, 30], ["amoxicillin", "CHEMICAL", 32, 43], ["acetaminophen", "CHEMICAL", 48, 61], ["oseltamivir", "CHEMICAL", 95, 106], ["oseltamivir carboxylate", "CHEMICAL", 110, 133], ["cimetidine", "SIMPLE_CHEMICAL", 20, 30], ["amoxicillin", "SIMPLE_CHEMICAL", 32, 43], ["acetaminophen", "SIMPLE_CHEMICAL", 48, 61], ["serum", "ORGANISM_SUBSTANCE", 79, 84], ["oseltamivir", "SIMPLE_CHEMICAL", 95, 106], ["oseltamivir carboxylate", "SIMPLE_CHEMICAL", 110, 133], ["Coadministration", "TREATMENT", 0, 16], ["cimetidine", "TREATMENT", 20, 30], ["amoxicillin", "TREATMENT", 32, 43], ["acetaminophen", "TREATMENT", 48, 61], ["serum levels", "TEST", 79, 91], ["oseltamivir", "TREATMENT", 95, 106], ["oseltamivir carboxylate", "TREATMENT", 110, 133]]], ["169 Because zanamivir has no significant systemic absorption, there are no recommended dosage reductions.MEASLES VIRUSBoth NAIs are effective in the treatment of influenza due to either influenza A or B virus if administered within the first 48 hours of symptom onset, with reduced duration of illness and earlier return to work or normal activities.", [["zanamivir", "CHEMICAL", 12, 21], ["influenza", "DISEASE", 162, 171], ["influenza A or B", "DISEASE", 186, 202], ["zanamivir", "CHEMICAL", 12, 21], ["zanamivir", "SIMPLE_CHEMICAL", 12, 21], ["influenza A or B virus", "ORGANISM", 186, 208], ["influenza A or B virus", "SPECIES", 186, 208], ["zanamivir", "TREATMENT", 12, 21], ["significant systemic absorption", "PROBLEM", 29, 60], ["dosage reductions", "TREATMENT", 87, 104], ["MEASLES VIRUSBoth NAIs", "PROBLEM", 105, 127], ["influenza", "PROBLEM", 162, 171], ["influenza A", "PROBLEM", 186, 197], ["B virus", "PROBLEM", 201, 208], ["symptom", "PROBLEM", 254, 261], ["illness", "PROBLEM", 294, 301], ["no", "UNCERTAINTY", 26, 28], ["significant", "OBSERVATION_MODIFIER", 29, 40], ["systemic absorption", "OBSERVATION", 41, 60]]], ["Metaanalysis of results of these trials has also suggested that early treatment may reduce the frequency of influenza-The onset of the rash correlates temporally with the development of host immune responses and subsequent termination of virus shedding.", [["influenza", "DISEASE", 108, 117], ["rash", "DISEASE", 135, 139], ["early treatment", "TREATMENT", 64, 79], ["influenza", "PROBLEM", 108, 117], ["the rash", "PROBLEM", 131, 139], ["host immune responses", "PROBLEM", 186, 207], ["virus shedding", "PROBLEM", 238, 252], ["influenza", "OBSERVATION", 108, 117], ["rash", "OBSERVATION", 135, 139]]], ["Skin rash develops in agammaglobulinemic patients with measles, whereas progressive giant cell (measles virus) pneumonia without rash may develop in those with deficient cell-mediated immune function.", [["Skin", "ANATOMY", 0, 4], ["giant cell", "ANATOMY", 84, 94], ["cell", "ANATOMY", 170, 174], ["Skin rash", "DISEASE", 0, 9], ["agammaglobulinemic", "DISEASE", 22, 40], ["measles", "DISEASE", 55, 62], ["giant cell (measles virus) pneumonia", "DISEASE", 84, 120], ["rash", "DISEASE", 129, 133], ["Skin", "ORGAN", 0, 4], ["patients", "ORGANISM", 41, 49], ["giant cell", "CANCER", 84, 94], ["measles virus", "ORGANISM", 96, 109], ["cell", "CELL", 170, 174], ["patients", "SPECIES", 41, 49], ["measles virus", "SPECIES", 96, 109], ["Skin rash", "PROBLEM", 0, 9], ["measles", "PROBLEM", 55, 62], ["progressive giant cell (measles virus", "PROBLEM", 72, 109], ["pneumonia", "PROBLEM", 111, 120], ["rash", "PROBLEM", 129, 133], ["deficient cell", "PROBLEM", 160, 174], ["rash", "OBSERVATION", 5, 9], ["progressive", "OBSERVATION_MODIFIER", 72, 83], ["giant cell", "OBSERVATION", 84, 94], ["pneumonia", "OBSERVATION", 111, 120], ["immune function", "OBSERVATION", 184, 199]]], ["The pathologic changes in involved organs include lymphoid hyperplasia, mononuclear cell infiltration, and the presence of multinucleated giant cells.", [["organs", "ANATOMY", 35, 41], ["lymphoid hyperplasia", "ANATOMY", 50, 70], ["mononuclear cell", "ANATOMY", 72, 88], ["multinucleated giant cells", "ANATOMY", 123, 149], ["lymphoid hyperplasia", "DISEASE", 50, 70], ["organs", "ORGAN", 35, 41], ["lymphoid", "CELL", 50, 58], ["mononuclear cell", "CELL", 72, 88], ["multinucleated giant cells", "CELL", 123, 149], ["multinucleated giant cells", "CELL_TYPE", 123, 149], ["The pathologic changes in involved organs", "PROBLEM", 0, 41], ["lymphoid hyperplasia", "PROBLEM", 50, 70], ["mononuclear cell infiltration", "PROBLEM", 72, 101], ["multinucleated giant cells", "PROBLEM", 123, 149], ["pathologic", "OBSERVATION", 4, 14], ["organs", "ANATOMY", 35, 41], ["lymphoid hyperplasia", "OBSERVATION", 50, 70], ["mononuclear cell infiltration", "OBSERVATION", 72, 101], ["multinucleated", "OBSERVATION_MODIFIER", 123, 137], ["giant cells", "OBSERVATION", 138, 149]]], ["Lower respiratory tract involvement may be associated with the destruction of ciliated respiratory epithelium, interstitial pneumonia, epithelial cell hyperplasia, and syncytial cell formation.Clinical IllnessTypical Measles.", [["Lower respiratory tract", "ANATOMY", 0, 23], ["respiratory epithelium", "ANATOMY", 87, 109], ["interstitial", "ANATOMY", 111, 123], ["epithelial cell", "ANATOMY", 135, 150], ["syncytial cell", "ANATOMY", 168, 182], ["Lower respiratory tract involvement", "DISEASE", 0, 35], ["pneumonia", "DISEASE", 124, 133], ["epithelial cell hyperplasia", "DISEASE", 135, 162], ["Measles", "DISEASE", 217, 224], ["respiratory tract", "ORGANISM_SUBDIVISION", 6, 23], ["respiratory epithelium", "TISSUE", 87, 109], ["interstitial pneumonia", "PATHOLOGICAL_FORMATION", 111, 133], ["epithelial cell", "CELL", 135, 150], ["syncytial cell", "CELL", 168, 182], ["Lower respiratory tract involvement", "PROBLEM", 0, 35], ["ciliated respiratory epithelium", "PROBLEM", 78, 109], ["interstitial pneumonia", "PROBLEM", 111, 133], ["epithelial cell hyperplasia", "PROBLEM", 135, 162], ["syncytial cell formation", "PROBLEM", 168, 192], ["Clinical IllnessTypical Measles", "PROBLEM", 193, 224], ["respiratory tract", "ANATOMY", 6, 23], ["may be associated with", "UNCERTAINTY", 36, 58], ["destruction", "OBSERVATION", 63, 74], ["ciliated", "ANATOMY_MODIFIER", 78, 86], ["respiratory epithelium", "ANATOMY", 87, 109], ["interstitial", "ANATOMY_MODIFIER", 111, 123], ["pneumonia", "OBSERVATION", 124, 133], ["epithelial cell hyperplasia", "OBSERVATION", 135, 162], ["syncytial cell formation", "OBSERVATION", 168, 192], ["Measles", "OBSERVATION", 217, 224]]], ["The typical prodrome of measles lasts 2 to 8 days and is characterized by fever, malaise, anorexia, cough, coryza, and conjunctivitis.", [["measles", "DISEASE", 24, 31], ["fever", "DISEASE", 74, 79], ["anorexia", "DISEASE", 90, 98], ["cough", "DISEASE", 100, 105], ["coryza", "DISEASE", 107, 113], ["conjunctivitis", "DISEASE", 119, 133], ["measles", "PROBLEM", 24, 31], ["fever", "PROBLEM", 74, 79], ["malaise", "PROBLEM", 81, 88], ["anorexia", "PROBLEM", 90, 98], ["cough", "PROBLEM", 100, 105], ["coryza", "PROBLEM", 107, 113], ["conjunctivitis", "PROBLEM", 119, 133], ["typical", "OBSERVATION_MODIFIER", 4, 11], ["prodrome", "OBSERVATION", 12, 20], ["fever", "OBSERVATION", 74, 79], ["malaise", "OBSERVATION", 81, 88], ["anorexia", "OBSERVATION", 90, 98], ["cough", "OBSERVATION", 100, 105], ["coryza", "ANATOMY", 107, 113], ["conjunctivitis", "OBSERVATION", 119, 133]]], ["Koplik spots, which are erythematous macular lesions with central white-yellow or gray puncta, appear on the buccal or labial mucous membranes toward the end of the prodromal period.", [["erythematous macular lesions", "ANATOMY", 24, 52], ["gray puncta", "ANATOMY", 82, 93], ["buccal", "ANATOMY", 109, 115], ["labial mucous membranes", "ANATOMY", 119, 142], ["macular lesions", "PATHOLOGICAL_FORMATION", 37, 52], ["buccal", "ORGAN", 109, 115], ["labial mucous membranes", "MULTI-TISSUE_STRUCTURE", 119, 142], ["Koplik spots", "PROBLEM", 0, 12], ["erythematous macular lesions", "PROBLEM", 24, 52], ["central white-yellow or gray puncta", "PROBLEM", 58, 93], ["erythematous", "OBSERVATION_MODIFIER", 24, 36], ["macular", "OBSERVATION_MODIFIER", 37, 44], ["lesions", "OBSERVATION", 45, 52], ["central", "OBSERVATION_MODIFIER", 58, 65], ["white", "OBSERVATION_MODIFIER", 66, 71], ["yellow", "OBSERVATION_MODIFIER", 72, 78], ["gray puncta", "OBSERVATION", 82, 93], ["buccal", "ANATOMY_MODIFIER", 109, 115], ["labial", "ANATOMY_MODIFIER", 119, 125], ["mucous membranes", "ANATOMY", 126, 142]]], ["The maculopapular, erythematous eruption begins about the face and neck and progresses to involve the upper body, trunk, and extremities.", [["maculopapular", "ANATOMY", 4, 17], ["face", "ANATOMY", 58, 62], ["neck", "ANATOMY", 67, 71], ["upper body", "ANATOMY", 102, 112], ["trunk", "ANATOMY", 114, 119], ["extremities", "ANATOMY", 125, 136], ["maculopapular", "DISEASE", 4, 17], ["neck", "ORGAN", 67, 71], ["upper body", "ORGANISM_SUBDIVISION", 102, 112], ["trunk", "ORGANISM_SUBDIVISION", 114, 119], ["extremities", "ORGANISM_SUBDIVISION", 125, 136], ["The maculopapular", "PROBLEM", 0, 17], ["erythematous eruption", "PROBLEM", 19, 40], ["maculopapular", "OBSERVATION_MODIFIER", 4, 17], ["erythematous", "OBSERVATION_MODIFIER", 19, 31], ["eruption", "OBSERVATION", 32, 40], ["face", "ANATOMY", 58, 62], ["neck", "ANATOMY", 67, 71], ["upper", "ANATOMY_MODIFIER", 102, 107], ["body", "ANATOMY", 108, 112], ["trunk", "ANATOMY", 114, 119], ["extremities", "ANATOMY", 125, 136]]], ["The rash typically resolves after 5 to 6 days in the order in which it appeared.", [["rash", "DISEASE", 4, 8], ["The rash", "PROBLEM", 0, 8], ["rash", "OBSERVATION", 4, 8]]], ["The fever abates and symptoms improve several days after the appearance of the rash, although persistent cough is common.", [["fever", "DISEASE", 4, 9], ["rash", "DISEASE", 79, 83], ["cough", "DISEASE", 105, 110], ["The fever abates", "PROBLEM", 0, 16], ["symptoms", "PROBLEM", 21, 29], ["the rash", "PROBLEM", 75, 83], ["persistent cough", "PROBLEM", 94, 110], ["fever", "OBSERVATION", 4, 9], ["rash", "OBSERVATION", 79, 83], ["persistent", "OBSERVATION_MODIFIER", 94, 104], ["cough", "OBSERVATION", 105, 110]]], ["Leukopenia is common during the prodromal and early exanthematous stages of measles.", [["Leukopenia", "DISEASE", 0, 10], ["measles", "DISEASE", 76, 83], ["Leukopenia", "PROBLEM", 0, 10], ["the prodromal and early exanthematous stages of measles", "PROBLEM", 28, 83], ["early", "OBSERVATION_MODIFIER", 46, 51], ["exanthematous", "OBSERVATION_MODIFIER", 52, 65], ["measles", "OBSERVATION", 76, 83]]], ["Pronounced leukopenia (<2000 cells/\u00b5L) is associated with a poor prognosis.", [["cells", "ANATOMY", 29, 34], ["leukopenia", "DISEASE", 11, 21], ["Pronounced leukopenia", "PROBLEM", 0, 21], ["a poor prognosis", "PROBLEM", 58, 74], ["leukopenia", "OBSERVATION", 11, 21]]], ["The development of neutrophilic leukocytosis suggests the possibility of bacterial superinfection or other complications.Clinical IllnessLower respiratory tract complications develop in 4% to 50% of patients.", [["respiratory tract", "ANATOMY", 143, 160], ["neutrophilic leukocytosis", "DISEASE", 19, 44], ["superinfection", "DISEASE", 83, 97], ["IllnessLower respiratory tract complications", "DISEASE", 130, 174], ["tract", "ORGANISM_SUBDIVISION", 155, 160], ["patients", "ORGANISM", 199, 207], ["patients", "SPECIES", 199, 207], ["neutrophilic leukocytosis", "PROBLEM", 19, 44], ["bacterial superinfection", "PROBLEM", 73, 97], ["other complications", "PROBLEM", 101, 120], ["Clinical IllnessLower respiratory tract complications", "PROBLEM", 121, 174], ["neutrophilic", "OBSERVATION_MODIFIER", 19, 31], ["leukocytosis", "OBSERVATION", 32, 44], ["suggests the possibility of", "UNCERTAINTY", 45, 72], ["bacterial", "OBSERVATION_MODIFIER", 73, 82], ["superinfection", "OBSERVATION", 83, 97], ["complications", "OBSERVATION", 107, 120], ["respiratory tract", "ANATOMY", 143, 160]]], ["These include bronchitis, pneumonia, and, less often, croup or bronchiolitis.", [["bronchitis", "DISEASE", 14, 24], ["pneumonia", "DISEASE", 26, 35], ["croup", "DISEASE", 54, 59], ["bronchiolitis", "DISEASE", 63, 76], ["bronchitis", "PROBLEM", 14, 24], ["pneumonia", "PROBLEM", 26, 35], ["croup", "PROBLEM", 54, 59], ["bronchiolitis", "PROBLEM", 63, 76], ["bronchitis", "OBSERVATION", 14, 24], ["pneumonia", "OBSERVATION", 26, 35], ["less often", "OBSERVATION_MODIFIER", 42, 52], ["bronchiolitis", "OBSERVATION", 63, 76]]], ["In young adults, a multilobar reticulonodular opacity is the most common radiographic abnormality (see eFig. .", [["reticulonodular opacity", "DISEASE", 30, 53], ["a multilobar reticulonodular opacity", "PROBLEM", 17, 53], ["the most common radiographic abnormality", "PROBLEM", 57, 97], ["multilobar", "OBSERVATION_MODIFIER", 19, 29], ["reticulonodular", "OBSERVATION_MODIFIER", 30, 45], ["opacity", "OBSERVATION", 46, 53], ["most common", "OBSERVATION_MODIFIER", 61, 72]]], ["191 In the absence of bacterial superinfection or atypical measles, pleural effusion or lobar consolidation is uncommon.", [["pleural effusion", "ANATOMY", 68, 84], ["lobar", "ANATOMY", 88, 93], ["superinfection", "DISEASE", 32, 46], ["measles", "DISEASE", 59, 66], ["pleural effusion", "DISEASE", 68, 84], ["pleural", "ORGAN", 68, 75], ["bacterial superinfection", "PROBLEM", 22, 46], ["atypical measles", "PROBLEM", 50, 66], ["pleural effusion", "PROBLEM", 68, 84], ["lobar consolidation", "PROBLEM", 88, 107], ["absence of", "UNCERTAINTY", 11, 21], ["bacterial", "OBSERVATION_MODIFIER", 22, 31], ["superinfection", "OBSERVATION", 32, 46], ["atypical", "OBSERVATION_MODIFIER", 50, 58], ["measles", "OBSERVATION", 59, 66], ["pleural", "ANATOMY", 68, 75], ["effusion", "OBSERVATION", 76, 84], ["lobar", "OBSERVATION_MODIFIER", 88, 93], ["consolidation", "OBSERVATION", 94, 107]]], ["In patients with altered cell-mediated immune function, and rarely in apparently normal persons, infection by wild measles virus can cause a lethal giant cell pneumonia with or without rash.", [["cell", "ANATOMY", 25, 29], ["giant cell", "ANATOMY", 148, 158], ["infection", "DISEASE", 97, 106], ["measles virus", "DISEASE", 115, 128], ["giant cell pneumonia", "DISEASE", 148, 168], ["rash", "DISEASE", 185, 189], ["patients", "ORGANISM", 3, 11], ["cell", "CELL", 25, 29], ["persons", "ORGANISM", 88, 95], ["wild measles virus", "ORGANISM", 110, 128], ["giant cell", "CELL", 148, 158], ["patients", "SPECIES", 3, 11], ["persons", "SPECIES", 88, 95], ["wild measles virus", "SPECIES", 110, 128], ["measles virus", "SPECIES", 115, 128], ["altered cell-mediated immune function", "PROBLEM", 17, 54], ["infection", "PROBLEM", 97, 106], ["wild measles virus", "PROBLEM", 110, 128], ["a lethal giant cell pneumonia", "PROBLEM", 139, 168], ["rash", "PROBLEM", 185, 189], ["immune function", "OBSERVATION", 39, 54], ["lethal", "OBSERVATION_MODIFIER", 141, 147], ["giant cell pneumonia", "OBSERVATION", 148, 168], ["without", "UNCERTAINTY", 177, 184]]], ["192 Severe virus-induced pneumonia has been recognized during measles in pregnant women 193 and in those infected with HIV.", [["pneumonia", "DISEASE", 25, 34], ["measles", "DISEASE", 62, 69], ["HIV", "DISEASE", 119, 122], ["women", "ORGANISM", 82, 87], ["HIV", "ORGANISM", 119, 122], ["women", "SPECIES", 82, 87], ["HIV", "SPECIES", 119, 122], ["HIV", "SPECIES", 119, 122], ["Severe virus-induced pneumonia", "PROBLEM", 4, 34], ["HIV", "PROBLEM", 119, 122], ["virus", "OBSERVATION", 11, 16], ["pneumonia", "OBSERVATION", 25, 34]]], ["194 In hospitalized patients, mortality rates are approximately 70% in oncology patients and 40% in HIVinfected patients.", [["patients", "ORGANISM", 20, 28], ["patients", "ORGANISM", 80, 88], ["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 20, 28], ["patients", "SPECIES", 80, 88], ["patients", "SPECIES", 112, 120], ["mortality rates", "TEST", 30, 45]]], ["192 Secondary bacterial infection has been found in 30% to 50% of young adults with measles-related pneumonia.", [["bacterial infection", "DISEASE", 14, 33], ["measles", "DISEASE", 84, 91], ["pneumonia", "DISEASE", 100, 109], ["Secondary bacterial infection", "PROBLEM", 4, 33], ["measles", "PROBLEM", 84, 91], ["pneumonia", "PROBLEM", 100, 109], ["bacterial", "OBSERVATION_MODIFIER", 14, 23], ["infection", "OBSERVATION", 24, 33], ["measles", "OBSERVATION", 84, 91], ["pneumonia", "OBSERVATION", 100, 109]]], ["Symptoms and signs indicative of bacterial infection usually begin 5 to 10 days after onset of the rash.", [["bacterial infection", "DISEASE", 33, 52], ["rash", "DISEASE", 99, 103], ["Symptoms", "PROBLEM", 0, 8], ["bacterial infection", "PROBLEM", 33, 52], ["the rash", "PROBLEM", 95, 103], ["signs indicative of", "UNCERTAINTY", 13, 32], ["bacterial", "OBSERVATION_MODIFIER", 33, 42], ["infection", "OBSERVATION", 43, 52], ["rash", "OBSERVATION", 99, 103]]], ["One study employing transtracheal aspiration found a range of bacterial pathogens in adults, most commonly Haemophilus influenzae, Neisseria meningitidis, and S. pneumoniae.", [["Haemophilus influenzae", "DISEASE", 107, 129], ["Neisseria meningitidis", "DISEASE", 131, 153], ["Haemophilus influenzae", "ORGANISM", 107, 129], ["Neisseria meningitidis", "ORGANISM", 131, 153], ["S. pneumoniae", "ORGANISM", 159, 172], ["Haemophilus influenzae", "SPECIES", 107, 129], ["Neisseria meningitidis", "SPECIES", 131, 153], ["S. pneumoniae", "SPECIES", 159, 172], ["Haemophilus influenzae", "SPECIES", 107, 129], ["Neisseria meningitidis", "SPECIES", 131, 153], ["S. pneumoniae", "SPECIES", 159, 172], ["One study", "TEST", 0, 9], ["transtracheal aspiration", "TEST", 20, 44], ["bacterial pathogens in adults", "PROBLEM", 62, 91], ["Haemophilus influenzae", "PROBLEM", 107, 129], ["Neisseria meningitidis", "PROBLEM", 131, 153], ["S. pneumoniae", "PROBLEM", 159, 172], ["bacterial", "OBSERVATION_MODIFIER", 62, 71], ["pathogens", "OBSERVATION", 72, 81], ["pneumoniae", "OBSERVATION", 162, 172]]], ["191 Up to 30% of cases are complicated by otitis media or sinusitis.", [["otitis media", "DISEASE", 42, 54], ["sinusitis", "DISEASE", 58, 67], ["otitis media", "PROBLEM", 42, 54], ["sinusitis", "PROBLEM", 58, 67], ["otitis", "OBSERVATION", 42, 48], ["sinusitis", "OBSERVATION", 58, 67]]], ["Acute nonrespiratory complications include hepatitis, encephalitis, keratitis, mesenteric adenitis, as well as a high rate of severe diarrheal disease in children in developed countries.", [["nonrespiratory", "ANATOMY", 6, 20], ["mesenteric", "ANATOMY", 79, 89], ["hepatitis", "DISEASE", 43, 52], ["encephalitis", "DISEASE", 54, 66], ["keratitis", "DISEASE", 68, 77], ["mesenteric adenitis", "DISEASE", 79, 98], ["diarrheal disease", "DISEASE", 133, 150], ["mesenteric", "ORGAN", 79, 89], ["children", "ORGANISM", 154, 162], ["children", "SPECIES", 154, 162], ["Acute nonrespiratory complications", "PROBLEM", 0, 34], ["hepatitis", "PROBLEM", 43, 52], ["encephalitis", "PROBLEM", 54, 66], ["keratitis", "PROBLEM", 68, 77], ["mesenteric adenitis", "PROBLEM", 79, 98], ["severe diarrheal disease", "PROBLEM", 126, 150], ["nonrespiratory complications", "OBSERVATION", 6, 34], ["hepatitis", "OBSERVATION", 43, 52], ["encephalitis", "OBSERVATION", 54, 66], ["keratitis", "OBSERVATION", 68, 77], ["mesenteric", "ANATOMY", 79, 89], ["adenitis", "OBSERVATION", 90, 98], ["high", "OBSERVATION_MODIFIER", 113, 117], ["severe", "OBSERVATION_MODIFIER", 126, 132], ["diarrheal disease", "OBSERVATION", 133, 150]]], ["Measles infection or vaccination may be accompanied by conversion of the tuberculin skin reaction from positive to negative for weeks.", [["skin", "ANATOMY", 84, 88], ["Measles infection", "DISEASE", 0, 17], ["skin", "ORGAN", 84, 88], ["Measles infection", "PROBLEM", 0, 17], ["vaccination", "PROBLEM", 21, 32], ["the tuberculin skin reaction", "PROBLEM", 69, 97], ["infection", "OBSERVATION", 8, 17], ["tuberculin", "OBSERVATION", 73, 83], ["skin", "ANATOMY", 84, 88]]], ["Measles may exacerbate active penetration of cells, but no neuraminidase.", [["cells", "ANATOMY", 45, 50], ["Measles", "DISEASE", 0, 7], ["cells", "CELL", 45, 50], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 59, 72], ["neuraminidase", "PROTEIN", 59, 72], ["active penetration of cells", "PROBLEM", 23, 50], ["neuraminidase", "PROBLEM", 59, 72]]], ["The cell surface molecule SLAM (Signaling Lymphocyte Activation Molecule) serves as a receptor for entry of the virus into susceptible cells.", [["cell surface", "ANATOMY", 4, 16], ["cells", "ANATOMY", 135, 140], ["cell", "CELL", 4, 8], ["SLAM", "GENE_OR_GENE_PRODUCT", 26, 30], ["Signaling Lymphocyte Activation Molecule", "GENE_OR_GENE_PRODUCT", 32, 72], ["cells", "CELL", 135, 140], ["cell surface molecule", "PROTEIN", 4, 25], ["SLAM", "PROTEIN", 26, 30], ["Signaling Lymphocyte Activation Molecule", "PROTEIN", 32, 72], ["susceptible cells", "CELL_TYPE", 123, 140], ["The cell surface molecule SLAM", "TEST", 0, 30], ["Signaling Lymphocyte Activation Molecule)", "TREATMENT", 32, 73], ["a receptor", "TREATMENT", 84, 94], ["the virus into susceptible cells", "PROBLEM", 108, 140], ["cell", "OBSERVATION_MODIFIER", 4, 8], ["surface", "OBSERVATION_MODIFIER", 9, 16], ["molecule SLAM", "OBSERVATION", 17, 30], ["susceptible cells", "OBSERVATION", 123, 140]]], ["185 In addition, the complement regulatory protein CD46 can also serve as a receptor, particularly for the vaccine strain.", [["CD46", "GENE_OR_GENE_PRODUCT", 51, 55], ["complement regulatory protein", "PROTEIN", 21, 50], ["CD46", "PROTEIN", 51, 55], ["the complement regulatory protein CD46", "TREATMENT", 17, 55], ["a receptor", "TREATMENT", 74, 84], ["the vaccine strain", "PROBLEM", 103, 121]]], ["186 Only one serotype of wild measles virus is recognized, although minor antigenic differences are detectable by monoclonal antibodies.", [["measles virus", "DISEASE", 30, 43], ["wild", "ORGANISM", 25, 29], ["measles virus", "ORGANISM", 30, 43], ["monoclonal antibodies", "PROTEIN", 114, 135], ["wild measles virus", "SPECIES", 25, 43], ["measles virus", "SPECIES", 30, 43], ["wild measles virus", "PROBLEM", 25, 43], ["minor antigenic differences", "PROBLEM", 68, 95], ["monoclonal antibodies", "TEST", 114, 135], ["one serotype", "OBSERVATION_MODIFIER", 9, 21], ["monoclonal antibodies", "OBSERVATION", 114, 135]]], ["The human is the sole natural host for measles virus.Epidemiology and TransmissionMeasles is found worldwide, but epidemic patterns vary depending on population density and levels of acquired immunity.", [["measles virus", "DISEASE", 39, 52], ["Measles", "DISEASE", 82, 89], ["human", "ORGANISM", 4, 9], ["measles virus", "ORGANISM", 39, 52], ["human", "SPECIES", 4, 9], ["measles virus", "SPECIES", 39, 52], ["human", "SPECIES", 4, 9], ["measles virus", "SPECIES", 39, 52], ["measles virus", "PROBLEM", 39, 52], ["epidemic patterns", "PROBLEM", 114, 131]]], ["Before vaccine use, measles arose in epidemics of 3 to 4 months in duration every 2 to 5 years in temperate regions.", [["measles", "DISEASE", 20, 27], ["vaccine", "TREATMENT", 7, 14], ["measles", "PROBLEM", 20, 27]]], ["187 Except in isolated areas, most people experienced infection by 20 years of age, and 90% of reported cases were seen in those younger than 10.", [["infection", "DISEASE", 54, 63], ["people", "ORGANISM", 35, 41], ["people", "SPECIES", 35, 41], ["infection", "PROBLEM", 54, 63], ["isolated", "OBSERVATION_MODIFIER", 14, 22], ["areas", "OBSERVATION_MODIFIER", 23, 28], ["most people", "OBSERVATION_MODIFIER", 30, 41], ["infection", "OBSERVATION", 54, 63]]], ["Infection confers lifelong protection against measles, although asymptomatic reinfections may develop.Epidemiology and TransmissionMeasles virus infection is highly contagious and can spread despite high levels of acquired immunity in the population.", [["measles", "DISEASE", 46, 53], ["reinfections", "DISEASE", 77, 89], ["Measles virus infection", "DISEASE", 131, 154], ["Measles virus", "ORGANISM", 131, 144], ["measles", "SPECIES", 46, 53], ["Measles virus", "SPECIES", 131, 144], ["Infection", "PROBLEM", 0, 9], ["measles", "PROBLEM", 46, 53], ["asymptomatic reinfections", "PROBLEM", 64, 89], ["TransmissionMeasles virus infection", "PROBLEM", 119, 154]]], ["Airborne transmission via small-particle aerosols and possible spread by fomites appear to account for its high communicability.", [["small-particle aerosols", "TREATMENT", 26, 49], ["its high communicability", "PROBLEM", 103, 127], ["small", "OBSERVATION_MODIFIER", 26, 31], ["particle aerosols", "OBSERVATION", 32, 49], ["possible", "UNCERTAINTY", 54, 62], ["spread", "OBSERVATION_MODIFIER", 63, 69]]], ["The virus remains infectious in smallparticle aerosols for several hours at low relative humidity and has caused secondary infections in the absence of faceto-face contact with an index case.", [["infections", "DISEASE", 123, 133], ["The virus", "PROBLEM", 0, 9], ["infectious", "PROBLEM", 18, 28], ["secondary infections", "PROBLEM", 113, 133], ["virus", "OBSERVATION", 4, 9], ["infectious", "OBSERVATION", 18, 28], ["secondary", "OBSERVATION_MODIFIER", 113, 122], ["infections", "OBSERVATION", 123, 133]]], ["Patients are most infectious during the late prodrome, when respiratory involvement contributes to creation of infectious aerosols.", [["respiratory", "ANATOMY", 60, 71], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["the late prodrome", "PROBLEM", 36, 53], ["respiratory involvement", "PROBLEM", 60, 83], ["infectious aerosols", "TREATMENT", 111, 130], ["most", "OBSERVATION_MODIFIER", 13, 17], ["infectious", "OBSERVATION_MODIFIER", 18, 28], ["infectious", "OBSERVATION", 111, 121]]], ["The virus may be shed for several days after the onset of rash in normal hosts.Epidemiology and TransmissionMeasles-associated mortality in developed countries is usually 0.1% or less but approaches 2% of cases in the developing world.", [["rash", "DISEASE", 58, 62], ["Measles", "DISEASE", 108, 115], ["The virus", "PROBLEM", 0, 9], ["rash", "PROBLEM", 58, 62], ["virus", "OBSERVATION", 4, 9], ["rash", "OBSERVATION", 58, 62], ["normal hosts", "OBSERVATION", 66, 78]]], ["Case fatality rates have been as high as 25% in some areas.", [["Case fatality rates", "TEST", 0, 19], ["high", "OBSERVATION_MODIFIER", 33, 37]]], ["Most deaths result from respiratory tract involvement, neurologic complications, or both, and are related to various combinations of malnutrition, young age, and complications of the immunosuppression induced by measles virus infection itself.PathogenesisThe respiratory tract and possibly the conjunctival epithelium are the portals of entry and initial sites of replication of measles virus, as well as subsequent target organs of disease expression.", [["respiratory tract", "ANATOMY", 24, 41], ["neurologic", "ANATOMY", 55, 65], ["respiratory tract", "ANATOMY", 259, 276], ["conjunctival epithelium", "ANATOMY", 294, 317], ["sites", "ANATOMY", 355, 360], ["organs", "ANATOMY", 423, 429], ["deaths", "DISEASE", 5, 11], ["respiratory tract involvement", "DISEASE", 24, 53], ["neurologic complications", "DISEASE", 55, 79], ["malnutrition", "DISEASE", 133, 145], ["measles virus infection", "DISEASE", 212, 235], ["measles", "DISEASE", 379, 386], ["respiratory tract", "ORGANISM_SUBDIVISION", 24, 41], ["measles virus", "ORGANISM", 212, 225], ["tract", "ORGANISM_SUBDIVISION", 271, 276], ["conjunctival epithelium", "TISSUE", 294, 317], ["measles virus", "ORGANISM", 379, 392], ["organs", "ORGAN", 423, 429], ["measles virus", "SPECIES", 212, 225], ["measles virus", "SPECIES", 379, 392], ["respiratory tract involvement", "PROBLEM", 24, 53], ["neurologic complications", "PROBLEM", 55, 79], ["malnutrition", "PROBLEM", 133, 145], ["the immunosuppression", "TREATMENT", 179, 200], ["measles virus infection", "PROBLEM", 212, 235], ["PathogenesisThe respiratory tract", "PROBLEM", 243, 276], ["the conjunctival epithelium", "PROBLEM", 290, 317], ["measles virus", "PROBLEM", 379, 392], ["disease expression", "PROBLEM", 433, 451], ["respiratory tract", "ANATOMY", 24, 41], ["malnutrition", "OBSERVATION", 133, 145], ["respiratory tract", "ANATOMY", 259, 276], ["conjunctival epithelium", "OBSERVATION", 294, 317], ["replication", "OBSERVATION_MODIFIER", 364, 375], ["measles virus", "OBSERVATION", 379, 392], ["disease", "OBSERVATION", 433, 440]]], ["An initial viremic phase leads to infection of mononuclear phagocytes including dendritic cells, and a second phase of viremia, corresponding to the prodromal stage of illness, results in dissemination of virus to the epithelial cells of the skin, respiratory tract, gut, bile duct, and bladder and to lymphoid organs.PathogenesisMeasles virus-induced giant cells may be present in the tonsils, appendix, other lymphoid organs, and various epithelial surfaces, including those of the respiratory tract.", [["mononuclear phagocytes", "ANATOMY", 47, 69], ["dendritic cells", "ANATOMY", 80, 95], ["epithelial cells", "ANATOMY", 218, 234], ["skin", "ANATOMY", 242, 246], ["respiratory tract", "ANATOMY", 248, 265], ["gut", "ANATOMY", 267, 270], ["bile duct", "ANATOMY", 272, 281], ["bladder", "ANATOMY", 287, 294], ["lymphoid organs", "ANATOMY", 302, 317], ["giant cells", "ANATOMY", 352, 363], ["tonsils", "ANATOMY", 386, 393], ["appendix", "ANATOMY", 395, 403], ["lymphoid organs", "ANATOMY", 411, 426], ["epithelial surfaces", "ANATOMY", 440, 459], ["respiratory tract", "ANATOMY", 484, 501], ["infection", "DISEASE", 34, 43], ["viremia", "DISEASE", 119, 126], ["illness", "DISEASE", 168, 175], ["mononuclear phagocytes", "CELL", 47, 69], ["dendritic cells", "CELL", 80, 95], ["epithelial cells", "CELL", 218, 234], ["skin", "ORGAN", 242, 246], ["respiratory tract", "ORGANISM_SUBDIVISION", 248, 265], ["gut", "ORGANISM_SUBDIVISION", 267, 270], ["bile duct", "MULTI-TISSUE_STRUCTURE", 272, 281], ["bladder", "ORGAN", 287, 294], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 302, 317], ["Measles virus", "ORGANISM", 330, 343], ["giant cells", "CELL", 352, 363], ["tonsils", "ORGAN", 386, 393], ["appendix", "ORGAN", 395, 403], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 411, 426], ["epithelial surfaces", "TISSUE", 440, 459], ["respiratory tract", "ORGANISM_SUBDIVISION", 484, 501], ["mononuclear phagocytes", "CELL_TYPE", 47, 69], ["dendritic cells", "CELL_TYPE", 80, 95], ["epithelial cells", "CELL_TYPE", 218, 234], ["giant cells", "CELL_TYPE", 352, 363], ["Measles virus", "SPECIES", 330, 343], ["An initial viremic phase", "TEST", 0, 24], ["infection of mononuclear phagocytes", "PROBLEM", 34, 69], ["dendritic cells", "PROBLEM", 80, 95], ["viremia", "PROBLEM", 119, 126], ["the prodromal stage of illness", "PROBLEM", 145, 175], ["dissemination of virus", "PROBLEM", 188, 210], ["respiratory tract, gut, bile duct, and bladder and to lymphoid organs", "PROBLEM", 248, 317], ["PathogenesisMeasles virus", "PROBLEM", 318, 343], ["induced giant cells", "PROBLEM", 344, 363], ["various epithelial surfaces", "PROBLEM", 432, 459], ["viremic phase", "OBSERVATION", 11, 24], ["mononuclear phagocytes", "OBSERVATION", 47, 69], ["dendritic cells", "OBSERVATION", 80, 95], ["viremia", "OBSERVATION", 119, 126], ["epithelial cells", "OBSERVATION", 218, 234], ["skin", "ANATOMY", 242, 246], ["respiratory tract", "ANATOMY", 248, 265], ["gut", "ANATOMY", 267, 270], ["bile duct", "ANATOMY", 272, 281], ["bladder", "ANATOMY", 287, 294], ["lymphoid organs", "OBSERVATION", 302, 317], ["giant cells", "OBSERVATION", 352, 363], ["tonsils", "ANATOMY", 386, 393], ["appendix", "ANATOMY", 395, 403], ["lymphoid organs", "OBSERVATION", 411, 426], ["various", "OBSERVATION_MODIFIER", 432, 439], ["epithelial surfaces", "OBSERVATION", 440, 459], ["respiratory tract", "ANATOMY", 484, 501]]], ["The effects of infection on the lymphoid system include leukopenia and immune suppression manifested by cutaneous anergy and depressed natural killer cell activity 189 for weeks after rash onset.", [["lymphoid system", "ANATOMY", 32, 47], ["cutaneous", "ANATOMY", 104, 113], ["natural killer cell", "ANATOMY", 135, 154], ["infection", "DISEASE", 15, 24], ["leukopenia", "DISEASE", 56, 66], ["depressed", "DISEASE", 125, 134], ["rash", "DISEASE", 184, 188], ["lymphoid system", "MULTI-TISSUE_STRUCTURE", 32, 47], ["natural killer cell", "CELL", 135, 154], ["infection on the lymphoid system", "PROBLEM", 15, 47], ["leukopenia", "PROBLEM", 56, 66], ["immune suppression", "PROBLEM", 71, 89], ["cutaneous anergy", "PROBLEM", 104, 120], ["depressed natural killer cell activity", "PROBLEM", 125, 163], ["rash onset", "PROBLEM", 184, 194], ["infection", "OBSERVATION", 15, 24], ["lymphoid system", "OBSERVATION", 32, 47], ["leukopenia", "OBSERVATION", 56, 66], ["immune suppression", "OBSERVATION", 71, 89], ["cutaneous anergy", "OBSERVATION", 104, 120], ["depressed", "OBSERVATION_MODIFIER", 125, 134], ["natural killer cell activity", "OBSERVATION", 135, 163]]], ["The mechanisms by which measles induces immunosuppression are incompletely understood, but infection of dendritic cells and suppression of IL-12 production are thought to play an important role.", [["dendritic cells", "ANATOMY", 104, 119], ["measles", "DISEASE", 24, 31], ["infection", "DISEASE", 91, 100], ["measles", "ORGANISM", 24, 31], ["dendritic cells", "CELL", 104, 119], ["IL-12", "GENE_OR_GENE_PRODUCT", 139, 144], ["dendritic cells", "CELL_TYPE", 104, 119], ["immunosuppression", "TREATMENT", 40, 57], ["infection of dendritic cells", "PROBLEM", 91, 119], ["suppression of IL", "TREATMENT", 124, 141], ["dendritic cells", "OBSERVATION", 104, 119]]], ["199, 200 The vaccine is safe, and it has been conclusively shown to have no association with autism.", [["autism", "DISEASE", 93, 99], ["The vaccine", "TREATMENT", 9, 20], ["autism", "PROBLEM", 93, 99]]], ["201, 202 There have been recent outbreaks of measles in undervaccinated communities in the United States, often introduced by an imported case in an immigrant or traveler.", [["measles", "DISEASE", 45, 52], ["outbreaks", "OBSERVATION_MODIFIER", 32, 41]]], ["202aMETAPNEUMOVIRUSESThe human metapneumoviruses (hMPVs) are pleomorphic particles with short envelope projections, resembling other paramyxoviruses.", [["hMPVs", "ANATOMY", 50, 55], ["pleomorphic particles", "ANATOMY", 61, 82], ["human", "ORGANISM", 25, 30], ["metapneumoviruses", "GENE_OR_GENE_PRODUCT", 31, 48], ["hMPVs", "CANCER", 50, 55], ["pleomorphic particles", "CANCER", 61, 82], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 25, 30], ["202aMETAPNEUMOVIRUSESThe human metapneumoviruses (hMPVs)", "TREATMENT", 0, 56], ["pleomorphic particles", "TREATMENT", 61, 82], ["short envelope projections", "TREATMENT", 88, 114], ["other paramyxoviruses", "PROBLEM", 127, 148], ["paramyxoviruses", "OBSERVATION", 133, 148]]], ["203 These viruses are closely related to the pneumoviruses (of which RSV is the human example), differing only by the absence of two nonstructural proteins and a slightly different arrangement of gene order on the negative-sense, single-stranded RNA genome.", [["pneumoviruses", "CANCER", 45, 58], ["RSV", "ORGANISM", 69, 72], ["human", "ORGANISM", 80, 85], ["nonstructural proteins", "PROTEIN", 133, 155], ["negative-sense, single-stranded RNA genome", "DNA", 214, 256], ["human", "SPECIES", 80, 85], ["RSV", "SPECIES", 69, 72], ["human", "SPECIES", 80, 85], ["These viruses", "PROBLEM", 4, 17], ["the pneumoviruses", "PROBLEM", 41, 58], ["two nonstructural proteins", "PROBLEM", 129, 155], ["viruses", "OBSERVATION", 10, 17], ["RNA genome", "OBSERVATION", 246, 256]]], ["The basic virology of these viruses closely resembles that of RSV.", [["RSV", "DISEASE", 62, 65], ["RSV", "ORGANISM", 62, 65], ["RSV", "SPECIES", 62, 65], ["these viruses", "PROBLEM", 22, 35], ["RSV", "PROBLEM", 62, 65], ["viruses", "OBSERVATION", 28, 35], ["RSV", "OBSERVATION", 62, 65]]], ["Envelope glycoproteins include the SH (sulfhydryl), F (fusion), and G (attachment), although there is little sequence homology in these genes between RSV and hMPV.", [["sulfhydryl", "CHEMICAL", 39, 49], ["hMPV", "DISEASE", 158, 162], ["sulfhydryl", "CHEMICAL", 39, 49], ["SH (sulfhydryl)", "GENE_OR_GENE_PRODUCT", 35, 50], ["F", "GENE_OR_GENE_PRODUCT", 52, 53], ["G", "GENE_OR_GENE_PRODUCT", 68, 69], ["RSV", "ORGANISM", 150, 153], ["hMPV", "ORGANISM", 158, 162], ["Envelope glycoproteins", "PROTEIN", 0, 22], ["SH", "PROTEIN", 35, 37], ["F", "PROTEIN", 52, 53], ["G", "PROTEIN", 68, 69], ["RSV", "SPECIES", 150, 153], ["hMPV", "SPECIES", 158, 162], ["Envelope glycoproteins", "TREATMENT", 0, 22], ["the SH (sulfhydryl)", "TREATMENT", 31, 50], ["F (fusion)", "TREATMENT", 52, 62], ["little sequence homology", "PROBLEM", 102, 126], ["RSV", "PROBLEM", 150, 153], ["hMPV", "PROBLEM", 158, 162], ["hMPV", "OBSERVATION", 158, 162]]], ["204 By analogy, it is expected that antibody to the F and G proteins of hMPV would play a role in protection against reinfection.", [["F", "GENE_OR_GENE_PRODUCT", 52, 53], ["G proteins", "GENE_OR_GENE_PRODUCT", 58, 68], ["hMPV", "ORGANISM", 72, 76], ["F and G proteins", "PROTEIN", 52, 68], ["hMPV", "SPECIES", 72, 76], ["hMPV", "PROBLEM", 72, 76], ["reinfection", "PROBLEM", 117, 128]]], ["At least two major genetic groups have been identified, roughly corresponding to subgroups A and B of RSV.", [["RSV", "DISEASE", 102, 105], ["RSV", "ORGANISM", 102, 105], ["RSV", "SPECIES", 102, 105], ["RSV", "PROBLEM", 102, 105], ["two", "OBSERVATION_MODIFIER", 9, 12], ["major", "OBSERVATION_MODIFIER", 13, 18], ["genetic groups", "OBSERVATION", 19, 33], ["RSV", "OBSERVATION", 102, 105]]], ["205 Sequential infections of the same individual tend to involve different genogroups.", [["infections", "DISEASE", 15, 25], ["Sequential infections", "PROBLEM", 4, 25], ["infections", "OBSERVATION", 15, 25]]], ["The role of cell-mediated immunity in this infection is largely unexplored.Epidemiology and TransmissionhMPV infections are distributed worldwide and have been documented in both the outpatient 206 and inpatient setting.", [["cell", "ANATOMY", 12, 16], ["infection", "DISEASE", 43, 52], ["TransmissionhMPV infections", "DISEASE", 92, 119], ["cell", "CELL", 12, 16], ["cell-mediated immunity", "TREATMENT", 12, 34], ["this infection", "PROBLEM", 38, 52], ["TransmissionhMPV infections", "PROBLEM", 92, 119], ["infection", "OBSERVATION", 43, 52], ["infections", "OBSERVATION", 109, 119]]], ["207 Recent estimates of disease burden based on PCR diagnostics suggest that hMPV results in 1 to 1.2 hospitalizations, 13 emergency department visits, and 55 outpatient visits per 1000 children younger than 5.", [["hMPV", "ORGANISM", 77, 81], ["children", "SPECIES", 186, 194], ["hMPV", "SPECIES", 77, 81], ["disease burden", "PROBLEM", 24, 38], ["PCR diagnostics", "TEST", 48, 63], ["hMPV", "PROBLEM", 77, 81], ["disease", "OBSERVATION", 24, 31]]], ["As with many other respiratory viruses, infection is linked to day care attendance.", [["respiratory viruses", "DISEASE", 19, 38], ["infection", "DISEASE", 40, 49], ["many other respiratory viruses", "PROBLEM", 8, 38], ["infection", "PROBLEM", 40, 49], ["respiratory", "ANATOMY", 19, 30], ["viruses", "OBSERVATION", 31, 38], ["infection", "OBSERVATION", 40, 49]]], ["210 Serologic studies suggest that essentially all children have been infected by age 5.", [["children", "ORGANISM", 51, 59], ["children", "SPECIES", 51, 59], ["Serologic studies", "TEST", 4, 21], ["infected", "OBSERVATION", 70, 78]]], ["203 Similar to the case with RSV, disease has also been documented in adults and in the elderly, 211 although asymptomatic infection is also common in adults.", [["RSV, disease", "DISEASE", 29, 41], ["infection", "DISEASE", 123, 132], ["RSV", "ORGANISM", 29, 32], ["RSV", "SPECIES", 29, 32], ["RSV", "PROBLEM", 29, 32], ["disease", "PROBLEM", 34, 41], ["asymptomatic infection", "PROBLEM", 110, 132], ["RSV", "OBSERVATION", 29, 32], ["disease", "OBSERVATION", 34, 41], ["asymptomatic", "OBSERVATION_MODIFIER", 110, 122], ["infection", "OBSERVATION", 123, 132]]], ["Outbreaks of severe disease have been documented in residential care facilities in older adults.", [["severe disease", "PROBLEM", 13, 27], ["severe", "OBSERVATION_MODIFIER", 13, 19], ["disease", "OBSERVATION", 20, 27]]], ["212, 213 Severe disease may also be seen in immunocompromised subjects such as hematopoietic stem cell transplant recipients (see eFig. .", [["hematopoietic stem cell", "ANATOMY", 79, 102], ["hematopoietic stem cell", "CELL", 79, 102], ["recipients", "ORGANISM", 114, 124], ["Severe disease", "PROBLEM", 9, 23], ["immunocompromised subjects", "PROBLEM", 44, 70], ["hematopoietic stem cell transplant recipients", "TREATMENT", 79, 124], ["disease", "OBSERVATION", 16, 23], ["may also be seen", "UNCERTAINTY", 24, 40], ["immunocompromised", "OBSERVATION", 44, 61], ["hematopoietic stem cell transplant", "OBSERVATION", 79, 113]]], ["214, 215 The mode of transmission has not been documented but is likely to be via droplet spread as with RSV.", [["RSV", "ORGANISM", 105, 108], ["RSV", "SPECIES", 105, 108], ["droplet spread", "PROBLEM", 82, 96], ["RSV", "PROBLEM", 105, 108], ["likely to be", "UNCERTAINTY", 65, 77], ["droplet", "OBSERVATION", 82, 89]]], ["There is a clear seasonal variation in incidence, with the majority of cases appearing during the winter months.", [["clear", "OBSERVATION_MODIFIER", 11, 16], ["seasonal variation", "OBSERVATION", 17, 35]]], ["206 An interesting feature of the epidemiology of these viruses is that children with hMPV are often coinfected with other respiratory viral pathogens, especially RSV.", [["hMPV", "DISEASE", 86, 90], ["respiratory viral pathogens", "DISEASE", 123, 150], ["RSV", "DISEASE", 163, 166], ["children", "ORGANISM", 72, 80], ["hMPV", "ORGANISM", 86, 90], ["RSV", "ORGANISM", 163, 166], ["children", "SPECIES", 72, 80], ["hMPV", "SPECIES", 86, 90], ["RSV", "SPECIES", 163, 166], ["hMPV", "PROBLEM", 86, 90], ["other respiratory viral pathogens", "PROBLEM", 117, 150], ["RSV", "PROBLEM", 163, 166], ["viruses", "OBSERVATION", 56, 63], ["viral pathogens", "OBSERVATION", 135, 150]]], ["216 Dual infections with both viruses may result in more intense bronchiolitis in some infants.", [["infections", "DISEASE", 9, 19], ["bronchiolitis", "DISEASE", 65, 78], ["infants", "ORGANISM", 87, 94], ["infants", "SPECIES", 87, 94], ["Dual infections", "PROBLEM", 4, 19], ["both viruses", "PROBLEM", 25, 37], ["intense bronchiolitis in some infants", "PROBLEM", 57, 94], ["viruses", "OBSERVATION", 30, 37], ["more", "OBSERVATION_MODIFIER", 52, 56], ["intense", "OBSERVATION_MODIFIER", 57, 64], ["bronchiolitis", "OBSERVATION", 65, 78]]], ["217 hMPV was also detected in many cases of SARS but did not appear to exacerbate this illness.", [["SARS", "DISEASE", 44, 48], ["hMPV", "ORGANISM", 4, 8], ["hMPV", "SPECIES", 4, 8], ["hMPV", "PROBLEM", 4, 8], ["SARS", "PROBLEM", 44, 48], ["this illness", "PROBLEM", 82, 94]]], ["218Clinical FeaturesHuman metapneumoviruses appear to be responsible for a spectrum of acute respiratory illnesses ranging from mild or asymptomatic infection to severe bronchiolitis and pneumonitis.", [["respiratory", "ANATOMY", 93, 104], ["respiratory illnesses", "DISEASE", 93, 114], ["infection", "DISEASE", 149, 158], ["bronchiolitis", "DISEASE", 169, 182], ["pneumonitis", "DISEASE", 187, 198], ["Human", "ORGANISM", 20, 25], ["Human", "SPECIES", 20, 25], ["acute respiratory illnesses", "PROBLEM", 87, 114], ["mild or asymptomatic infection", "PROBLEM", 128, 158], ["severe bronchiolitis", "PROBLEM", 162, 182], ["pneumonitis", "PROBLEM", 187, 198], ["acute", "OBSERVATION_MODIFIER", 87, 92], ["respiratory", "ANATOMY", 93, 104], ["illnesses", "OBSERVATION", 105, 114], ["mild", "OBSERVATION_MODIFIER", 128, 132], ["asymptomatic", "OBSERVATION_MODIFIER", 136, 148], ["infection", "OBSERVATION", 149, 158], ["severe", "OBSERVATION_MODIFIER", 162, 168], ["bronchiolitis", "OBSERVATION", 169, 182], ["pneumonitis", "OBSERVATION", 187, 198]]], ["The clinical picture most closely resembles that tuberculosis, but whether measles reactivates dormant tuberculosis is unresolved.", [["tuberculosis", "DISEASE", 49, 61], ["measles", "DISEASE", 75, 82], ["tuberculosis", "DISEASE", 103, 115], ["tuberculosis", "PROBLEM", 49, 61], ["measles reactivates dormant tuberculosis", "PROBLEM", 75, 115], ["tuberculosis", "OBSERVATION", 49, 61], ["tuberculosis", "OBSERVATION", 103, 115]]], ["195 Atypical Measles.", [["Measles", "DISEASE", 13, 20], ["Atypical Measles", "PROBLEM", 4, 20], ["Atypical", "OBSERVATION_MODIFIER", 4, 12], ["Measles", "OBSERVATION", 13, 20]]], ["An unusual clinical syndrome has been recognized in adolescents and young adults who received the inactivated measles vaccine between 1963 and 1968 and who were subsequently re-exposed to the wild virus.", [["adults", "ORGANISM", 74, 80], ["adolescents", "SPECIES", 52, 63], ["An unusual clinical syndrome", "PROBLEM", 0, 28], ["the inactivated measles vaccine", "TREATMENT", 94, 125], ["the wild virus", "PROBLEM", 188, 202], ["unusual", "OBSERVATION_MODIFIER", 3, 10], ["clinical syndrome", "OBSERVATION", 11, 28]]], ["The illness begins abruptly, with high fever, headache, myalgia, vomiting, abdominal pain, and nonproductive cough.", [["abdominal", "ANATOMY", 75, 84], ["illness", "DISEASE", 4, 11], ["fever", "DISEASE", 39, 44], ["headache", "DISEASE", 46, 54], ["myalgia", "DISEASE", 56, 63], ["vomiting", "DISEASE", 65, 73], ["abdominal pain", "DISEASE", 75, 89], ["cough", "DISEASE", 109, 114], ["abdominal", "ORGANISM_SUBDIVISION", 75, 84], ["The illness", "PROBLEM", 0, 11], ["high fever", "PROBLEM", 34, 44], ["headache", "PROBLEM", 46, 54], ["myalgia", "PROBLEM", 56, 63], ["vomiting", "PROBLEM", 65, 73], ["abdominal pain", "PROBLEM", 75, 89], ["nonproductive cough", "PROBLEM", 95, 114], ["illness", "OBSERVATION", 4, 11], ["myalgia", "OBSERVATION", 56, 63], ["abdominal", "ANATOMY", 75, 84], ["pain", "OBSERVATION", 85, 89], ["nonproductive", "OBSERVATION_MODIFIER", 95, 108], ["cough", "OBSERVATION", 109, 114]]], ["Respiratory symptoms, including dyspnea, coryza, sore throat, and pleuritic chest pain, are common.", [["Respiratory", "ANATOMY", 0, 11], ["chest", "ANATOMY", 76, 81], ["Respiratory symptoms", "DISEASE", 0, 20], ["dyspnea", "DISEASE", 32, 39], ["coryza", "DISEASE", 41, 47], ["sore throat", "DISEASE", 49, 60], ["chest pain", "DISEASE", 76, 86], ["chest", "ORGANISM_SUBDIVISION", 76, 81], ["Respiratory symptoms", "PROBLEM", 0, 20], ["dyspnea", "PROBLEM", 32, 39], ["coryza", "PROBLEM", 41, 47], ["sore throat", "PROBLEM", 49, 60], ["pleuritic chest pain", "PROBLEM", 66, 86], ["coryza", "ANATOMY", 41, 47], ["sore throat", "ANATOMY", 49, 60], ["pleuritic", "OBSERVATION_MODIFIER", 66, 75], ["chest", "ANATOMY", 76, 81], ["pain", "OBSERVATION", 82, 86]]], ["A polymorphous eruption, which may include vesicles, petechiae, purpura, and urticarial lesions, begins typically on the distal extremities and spreads proximally over 3 to 5 days.", [["vesicles", "ANATOMY", 43, 51], ["petechiae", "ANATOMY", 53, 62], ["urticarial lesions", "ANATOMY", 77, 95], ["distal extremities", "ANATOMY", 121, 139], ["petechiae", "DISEASE", 53, 62], ["purpura", "DISEASE", 64, 71], ["urticarial lesions", "DISEASE", 77, 95], ["vesicles", "CELLULAR_COMPONENT", 43, 51], ["petechiae", "PATHOLOGICAL_FORMATION", 53, 62], ["urticarial lesions", "PATHOLOGICAL_FORMATION", 77, 95], ["extremities", "ORGANISM_SUBDIVISION", 128, 139], ["A polymorphous eruption", "PROBLEM", 0, 23], ["vesicles", "PROBLEM", 43, 51], ["petechiae", "PROBLEM", 53, 62], ["purpura", "PROBLEM", 64, 71], ["urticarial lesions", "PROBLEM", 77, 95], ["polymorphous", "OBSERVATION_MODIFIER", 2, 14], ["eruption", "OBSERVATION", 15, 23], ["may include", "UNCERTAINTY", 31, 42], ["vesicles", "ANATOMY", 43, 51], ["petechiae", "OBSERVATION", 53, 62], ["purpura", "OBSERVATION", 64, 71], ["urticarial", "OBSERVATION_MODIFIER", 77, 87], ["lesions", "OBSERVATION", 88, 95], ["distal", "ANATOMY_MODIFIER", 121, 127], ["extremities", "ANATOMY", 128, 139], ["spreads", "OBSERVATION_MODIFIER", 144, 151], ["proximally", "OBSERVATION_MODIFIER", 152, 162]]], ["Although Koplik spots are absent, conjunctivitis and glossitis with strawberry tongue have been described.Clinical FeaturesPulmonary abnormalities are found in most cases, and acute respiratory failure has been described.", [["tongue", "ANATOMY", 79, 85], ["Pulmonary", "ANATOMY", 123, 132], ["respiratory", "ANATOMY", 182, 193], ["conjunctivitis", "DISEASE", 34, 48], ["glossitis", "DISEASE", 53, 62], ["strawberry tongue", "DISEASE", 68, 85], ["Pulmonary abnormalities", "DISEASE", 123, 146], ["respiratory failure", "DISEASE", 182, 201], ["Koplik", "GENE_OR_GENE_PRODUCT", 9, 15], ["tongue", "ORGAN", 79, 85], ["Pulmonary", "ORGAN", 123, 132], ["Koplik spots", "PROBLEM", 9, 21], ["conjunctivitis", "PROBLEM", 34, 48], ["glossitis", "PROBLEM", 53, 62], ["strawberry tongue", "PROBLEM", 68, 85], ["Clinical FeaturesPulmonary abnormalities", "PROBLEM", 106, 146], ["acute respiratory failure", "PROBLEM", 176, 201], ["Koplik spots", "OBSERVATION", 9, 21], ["conjunctivitis", "OBSERVATION", 34, 48], ["glossitis", "OBSERVATION", 53, 62], ["strawberry tongue", "ANATOMY", 68, 85], ["Pulmonary", "ANATOMY", 123, 132], ["abnormalities", "OBSERVATION", 133, 146], ["acute", "OBSERVATION_MODIFIER", 176, 181], ["respiratory failure", "OBSERVATION", 182, 201]]], ["Chest radiographic changes include patchy, diffuse, or dense lobar opacities, pleural effusions, and hilar lymphadenopathy.", [["lobar", "ANATOMY", 61, 66], ["pleural effusions", "ANATOMY", 78, 95], ["hilar lymphadenopathy", "ANATOMY", 101, 122], ["opacities", "DISEASE", 67, 76], ["pleural effusions", "DISEASE", 78, 95], ["lymphadenopathy", "DISEASE", 107, 122], ["pleural effusions", "CANCER", 78, 95], ["hilar lymphadenopathy", "CANCER", 101, 122], ["Chest radiographic changes", "TEST", 0, 26], ["patchy, diffuse, or dense lobar opacities", "PROBLEM", 35, 76], ["pleural effusions", "PROBLEM", 78, 95], ["hilar lymphadenopathy", "PROBLEM", 101, 122], ["patchy", "OBSERVATION_MODIFIER", 35, 41], ["diffuse", "OBSERVATION_MODIFIER", 43, 50], ["dense", "OBSERVATION_MODIFIER", 55, 60], ["lobar", "ANATOMY_MODIFIER", 61, 66], ["opacities", "OBSERVATION", 67, 76], ["pleural", "ANATOMY", 78, 85], ["effusions", "OBSERVATION", 86, 95], ["hilar", "ANATOMY", 101, 106], ["lymphadenopathy", "OBSERVATION", 107, 122]]], ["196 Residual nodular pulmonary opacities may persist for years and lead to diagnostic confusion.", [["nodular pulmonary opacities", "ANATOMY", 13, 40], ["pulmonary opacities", "DISEASE", 21, 40], ["confusion", "DISEASE", 86, 95], ["pulmonary", "ORGAN", 21, 30], ["Residual nodular pulmonary opacities", "PROBLEM", 4, 40], ["diagnostic confusion", "PROBLEM", 75, 95], ["Residual", "OBSERVATION_MODIFIER", 4, 12], ["nodular", "OBSERVATION_MODIFIER", 13, 20], ["pulmonary", "ANATOMY", 21, 30], ["opacities", "OBSERVATION", 31, 40]]], ["The fever and other symptoms usually resolve in 1 to 3 weeks.", [["fever", "DISEASE", 4, 9], ["The fever", "PROBLEM", 0, 9], ["other symptoms", "PROBLEM", 14, 28], ["fever", "OBSERVATION", 4, 9]]], ["The pulmonary function changes in atypical measles include transient hypoxemia and significantly reduced lung volumes.DiagnosisThe diagnosis of measles is most readily confirmed in immunocompetent patients by detecting measles virusspecific IgM by ELISA.", [["pulmonary", "ANATOMY", 4, 13], ["lung", "ANATOMY", 105, 109], ["measles", "DISEASE", 43, 50], ["hypoxemia", "DISEASE", 69, 78], ["measles", "DISEASE", 144, 151], ["pulmonary", "ORGAN", 4, 13], ["lung", "ORGAN", 105, 109], ["measles", "ORGANISM", 144, 151], ["patients", "ORGANISM", 197, 205], ["IgM", "GENE_OR_GENE_PRODUCT", 241, 244], ["measles virusspecific IgM", "PROTEIN", 219, 244], ["patients", "SPECIES", 197, 205], ["measles", "SPECIES", 219, 226], ["The pulmonary function changes in atypical measles", "PROBLEM", 0, 50], ["transient hypoxemia", "PROBLEM", 59, 78], ["significantly reduced lung volumes", "PROBLEM", 83, 117], ["measles", "PROBLEM", 144, 151], ["pulmonary", "ANATOMY", 4, 13], ["atypical", "OBSERVATION_MODIFIER", 34, 42], ["transient", "OBSERVATION_MODIFIER", 59, 68], ["hypoxemia", "OBSERVATION", 69, 78], ["significantly", "OBSERVATION_MODIFIER", 83, 96], ["reduced", "OBSERVATION_MODIFIER", 97, 104], ["lung", "ANATOMY", 105, 109], ["volumes", "OBSERVATION_MODIFIER", 110, 117], ["measles", "OBSERVATION", 144, 151]]], ["In immunodeficient patients, detection of measles virus by nucleic acid amplification of urine or of samples obtained by throat or nasopharyngeal swab is sensitive and specific; samples can be sent to the U.S. Centers for Disease Control (http://www.cdc.gov/measles/ lab-tools/rt-pcr.html).", [["urine", "ANATOMY", 89, 94], ["samples", "ANATOMY", 101, 108], ["throat", "ANATOMY", 121, 127], ["nasopharyngeal swab", "ANATOMY", 131, 150], ["nucleic acid", "CHEMICAL", 59, 71], ["patients", "ORGANISM", 19, 27], ["measles virus", "ORGANISM", 42, 55], ["urine", "ORGANISM_SUBSTANCE", 89, 94], ["throat", "ORGANISM_SUBDIVISION", 121, 127], ["nasopharyngeal swab", "MULTI-TISSUE_STRUCTURE", 131, 150], ["patients", "SPECIES", 19, 27], ["measles virus", "SPECIES", 42, 55], ["measles virus", "PROBLEM", 42, 55], ["nucleic acid amplification of urine", "TEST", 59, 94], ["throat or nasopharyngeal swab", "TEST", 121, 150], ["Disease Control (http://www.cdc.gov/measles", "PROBLEM", 222, 265], ["throat", "ANATOMY", 121, 127], ["nasopharyngeal", "ANATOMY", 131, 145]]], ["Measles virus may also be isolated from the blood, urine, or respiratory secretions during the prodrome and up to several days after the exanthem appears.", [["blood", "ANATOMY", 44, 49], ["urine", "ANATOMY", 51, 56], ["respiratory secretions", "ANATOMY", 61, 83], ["Measles virus", "ORGANISM", 0, 13], ["blood", "ORGANISM_SUBSTANCE", 44, 49], ["urine", "ORGANISM_SUBSTANCE", 51, 56], ["secretions", "ORGANISM_SUBSTANCE", 73, 83], ["Measles virus", "SPECIES", 0, 13], ["Measles virus", "SPECIES", 0, 13], ["Measles virus", "PROBLEM", 0, 13], ["the blood, urine", "TEST", 40, 56], ["respiratory secretions", "PROBLEM", 61, 83], ["the prodrome", "PROBLEM", 91, 103], ["the exanthem", "PROBLEM", 133, 145], ["may also be", "UNCERTAINTY", 14, 25], ["respiratory", "ANATOMY", 61, 72], ["secretions", "OBSERVATION", 73, 83]]], ["Isolation of virus from clinical specimens has been performed in several types of human and monkey cell cultures but is slow and inefficient.", [["specimens", "ANATOMY", 33, 42], ["cell cultures", "ANATOMY", 99, 112], ["human", "ORGANISM", 82, 87], ["monkey", "ORGANISM", 92, 98], ["cell cultures", "CELL", 99, 112], ["human and monkey cell cultures", "CELL_LINE", 82, 112], ["human", "SPECIES", 82, 87], ["human", "SPECIES", 82, 87], ["Isolation of virus", "PROBLEM", 0, 18], ["clinical specimens", "TEST", 24, 42], ["monkey cell cultures", "TEST", 92, 112], ["virus", "OBSERVATION", 13, 18]]], ["Respiratory and conjunctival secretions or urine sediment stained by various techniques reveals multinucleated giant cells in most cases.", [["Respiratory", "ANATOMY", 0, 11], ["conjunctival secretions", "ANATOMY", 16, 39], ["urine sediment", "ANATOMY", 43, 57], ["multinucleated giant cells", "ANATOMY", 96, 122], ["conjunctival secretions", "ORGANISM_SUBSTANCE", 16, 39], ["urine", "ORGANISM_SUBSTANCE", 43, 48], ["multinucleated giant cells", "CELL", 96, 122], ["multinucleated giant cells", "CELL_TYPE", 96, 122], ["Respiratory and conjunctival secretions", "TEST", 0, 39], ["urine sediment", "TEST", 43, 57], ["various techniques", "TEST", 69, 87], ["multinucleated giant cells", "PROBLEM", 96, 122], ["conjunctival", "ANATOMY", 16, 28], ["secretions", "OBSERVATION", 29, 39], ["urine sediment", "OBSERVATION", 43, 57], ["multinucleated", "OBSERVATION_MODIFIER", 96, 110], ["giant cells", "OBSERVATION", 111, 122]]], ["Immunofluorescent staining of skin biopsy specimens, cells from combined nasopharyngeal and throat swab samples, and, less often, exfoliated cells in the urine demonstrates measles virus antigens early in the disease.Treatment and PreventionThe treatment of measles involves supportive care and specific therapy for bacterial complications.", [["skin biopsy specimens", "ANATOMY", 30, 51], ["cells", "ANATOMY", 53, 58], ["nasopharyngeal", "ANATOMY", 73, 87], ["throat swab samples", "ANATOMY", 92, 111], ["exfoliated cells", "ANATOMY", 130, 146], ["urine", "ANATOMY", 154, 159], ["measles", "DISEASE", 258, 265], ["skin biopsy", "TISSUE", 30, 41], ["cells", "CELL", 53, 58], ["nasopharyngeal", "CANCER", 73, 87], ["exfoliated cells", "CELL", 130, 146], ["urine", "ORGANISM_SUBSTANCE", 154, 159], ["exfoliated cells", "CELL_TYPE", 130, 146], ["measles virus antigens", "PROTEIN", 173, 195], ["measles virus", "SPECIES", 173, 186], ["Immunofluorescent staining", "TEST", 0, 26], ["skin biopsy specimens", "TEST", 30, 51], ["cells", "TEST", 53, 58], ["combined nasopharyngeal and throat swab samples", "TEST", 64, 111], ["exfoliated cells", "PROBLEM", 130, 146], ["the urine", "TEST", 150, 159], ["measles virus antigens", "PROBLEM", 173, 195], ["the disease", "PROBLEM", 205, 216], ["Treatment", "TREATMENT", 217, 226], ["The treatment of measles", "TREATMENT", 241, 265], ["supportive care", "TREATMENT", 275, 290], ["specific therapy", "TREATMENT", 295, 311], ["bacterial complications", "PROBLEM", 316, 339], ["skin", "ANATOMY", 30, 34], ["nasopharyngeal", "ANATOMY", 73, 87], ["throat", "ANATOMY", 92, 98], ["exfoliated cells", "OBSERVATION", 130, 146], ["urine", "ANATOMY", 154, 159], ["measles virus", "OBSERVATION", 173, 186]]], ["No antiviral agents have proven clinical value, but aerosol and intravenous ribavirin and immunoglobulin have been used in treating measles pneumonia.", [["intravenous", "ANATOMY", 64, 75], ["ribavirin", "CHEMICAL", 76, 85], ["measles pneumonia", "DISEASE", 132, 149], ["ribavirin", "CHEMICAL", 76, 85], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 64, 75], ["ribavirin", "SIMPLE_CHEMICAL", 76, 85], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 90, 104], ["immunoglobulin", "PROTEIN", 90, 104], ["antiviral agents", "TREATMENT", 3, 19], ["aerosol", "TREATMENT", 52, 59], ["intravenous ribavirin", "TREATMENT", 64, 85], ["immunoglobulin", "TREATMENT", 90, 104], ["measles pneumonia", "PROBLEM", 132, 149], ["antiviral agents", "OBSERVATION", 3, 19], ["pneumonia", "OBSERVATION", 140, 149]]], ["193, 197 Vitamin A therapy reduces morbidity and mortality in severe measles in children.", [["Vitamin", "CHEMICAL", 9, 16], ["measles", "DISEASE", 69, 76], ["Vitamin", "CHEMICAL", 9, 16], ["Vitamin", "SIMPLE_CHEMICAL", 9, 16], ["children", "ORGANISM", 80, 88], ["children", "SPECIES", 80, 88], ["Vitamin", "TREATMENT", 9, 16], ["A therapy", "TREATMENT", 17, 26], ["morbidity", "PROBLEM", 35, 44], ["severe", "OBSERVATION_MODIFIER", 62, 68], ["measles", "OBSERVATION", 69, 76]]], ["198 Patients suspected of having measles should be placed in respiratory isolation.Treatment and PreventionThe live attenuated measles vaccine currently used in the United States provides durable immunity in more than 90% of recipients.", [["respiratory", "ANATOMY", 61, 72], ["measles", "DISEASE", 33, 40], ["Patients", "ORGANISM", 4, 12], ["recipients", "ORGANISM", 225, 235], ["Patients", "SPECIES", 4, 12], ["measles", "PROBLEM", 33, 40], ["respiratory isolation", "TREATMENT", 61, 82], ["Treatment", "TREATMENT", 83, 92], ["The live attenuated measles vaccine", "TREATMENT", 107, 142], ["respiratory isolation", "OBSERVATION", 61, 82]]], ["Recent outbreaks have seen cases in adolescent and adult recipients of two doses of measles vaccine, but the illness has been mild and not associated with trans-infected cells after viral replication.", [["cells", "ANATOMY", 170, 175], ["cells", "CELL", 170, 175], ["trans-infected cells", "CELL_TYPE", 155, 175], ["measles vaccine", "TREATMENT", 84, 99], ["the illness", "PROBLEM", 105, 116], ["infected cells", "PROBLEM", 161, 175], ["viral replication", "TREATMENT", 182, 199], ["mild", "OBSERVATION_MODIFIER", 126, 130]]], ["The F glycoprotein has membrane-fusing activity and is responsible for viral penetration into cells and for the formation of multinucleated syncytial cells.", [["membrane", "ANATOMY", 23, 31], ["cells", "ANATOMY", 94, 99], ["multinucleated syncytial cells", "ANATOMY", 125, 155], ["F glycoprotein", "GENE_OR_GENE_PRODUCT", 4, 18], ["membrane", "CELLULAR_COMPONENT", 23, 31], ["cells", "CELL", 94, 99], ["multinucleated syncytial cells", "CELL", 125, 155], ["F glycoprotein", "PROTEIN", 4, 18], ["multinucleated syncytial cells", "CELL_TYPE", 125, 155], ["viral penetration into cells", "PROBLEM", 71, 99], ["multinucleated syncytial cells", "PROBLEM", 125, 155], ["multinucleated syncytial cells", "OBSERVATION", 125, 155]]], ["Antibodies against the HN and F are involved in protective immunity.Epidemiology and TransmissionParainfluenza viruses have a worldwide distribution, and almost all persons are infected initially during childhood.", [["Parainfluenza viruses", "DISEASE", 97, 118], ["HN", "GENE_OR_GENE_PRODUCT", 23, 25], ["F", "GENE_OR_GENE_PRODUCT", 30, 31], ["Parainfluenza viruses", "ORGANISM", 97, 118], ["persons", "ORGANISM", 165, 172], ["HN and F", "PROTEIN", 23, 31], ["persons", "SPECIES", 165, 172], ["TransmissionParainfluenza viruses", "SPECIES", 85, 118], ["TransmissionParainfluenza viruses", "PROBLEM", 85, 118], ["Parainfluenza viruses", "OBSERVATION", 97, 118], ["infected", "OBSERVATION", 177, 185]]], ["Parainfluenza type 3 virus may cause infection in infancy, whereas infections by type 1 and 2 viruses appear to be prevented by maternal antibody and usually arise later.", [["infection", "DISEASE", 37, 46], ["infections", "DISEASE", 67, 77], ["Parainfluenza type 3 virus", "ORGANISM", 0, 26], ["type 1", "ORGANISM", 81, 87], ["maternal antibody", "PROTEIN", 128, 145], ["Parainfluenza type 3 virus", "SPECIES", 0, 26], ["Parainfluenza type 3 virus", "PROBLEM", 0, 26], ["infection in infancy", "PROBLEM", 37, 57], ["type 1 and 2 viruses", "PROBLEM", 81, 101], ["maternal antibody", "PROBLEM", 128, 145], ["may cause", "UNCERTAINTY", 27, 36], ["infection", "OBSERVATION", 37, 46]]], ["National surveillance has demonstrated distinct seasonality for type 1 viruses, with biennial outbreaks in the fall of oddnumbered years.", [["type 1 viruses", "DISEASE", 64, 78], ["type 1 viruses", "SPECIES", 64, 78], ["National surveillance", "TEST", 0, 21], ["type 1 viruses", "PROBLEM", 64, 78], ["biennial outbreaks", "PROBLEM", 85, 103], ["distinct", "OBSERVATION_MODIFIER", 39, 47], ["seasonality", "OBSERVATION", 48, 59], ["viruses", "OBSERVATION", 71, 78]]], ["In contrast, yearly outbreaks of type 3 virus take place in the spring, with smaller autumn outbreaks in those years without type 1 outbreaks.", [["type 3 virus", "ORGANISM", 33, 45], ["type 3 virus", "SPECIES", 33, 45], ["type 3 virus", "PROBLEM", 33, 45], ["type 1 outbreaks", "PROBLEM", 125, 141], ["smaller", "OBSERVATION_MODIFIER", 77, 84], ["autumn", "OBSERVATION_MODIFIER", 85, 91], ["outbreaks", "OBSERVATION", 92, 101]]], ["Type 2 viruses are detected much less frequently but appear to be more prevalent in the autumn; type 4 does not exhibit notable seasonality.", [["Type 2 viruses", "SPECIES", 0, 14], ["Type 2 viruses", "PROBLEM", 0, 14], ["viruses", "OBSERVATION", 7, 14], ["more prevalent", "OBSERVATION_MODIFIER", 66, 80], ["autumn", "OBSERVATION", 88, 94], ["notable", "OBSERVATION_MODIFIER", 120, 127], ["seasonality", "OBSERVATION", 128, 139]]], ["227 Parainfluenza viruses appear to be transmitted from person to person by direct contact with infectious respiratory secretions or by large-particle aerosols.", [["respiratory", "ANATOMY", 107, 118], ["infectious respiratory secretions", "DISEASE", 96, 129], ["Parainfluenza viruses", "ORGANISM", 4, 25], ["person", "SPECIES", 56, 62], ["person", "SPECIES", 66, 72], ["Parainfluenza viruses", "PROBLEM", 4, 25], ["infectious respiratory secretions", "PROBLEM", 96, 129]]], ["Virus is transmitted readily in families.", [["Virus", "ORGANISM", 0, 5], ["Virus", "PROBLEM", 0, 5]]], ["Outbreaks of infection have been seen in closed populations, such as nurseries, day care centers, and hospitals, in which susceptible populations have high attack rates (40% to 80%).Epidemiology and TransmissionParainfluenza virus infections, most commonly type 1 virus, are associated with approximately 40% of croup cases and up to 75% of those with a documented viral cause, with smaller proportions of pneumonia or bronchiolitis cases in children.", [["infection", "DISEASE", 13, 22], ["Parainfluenza virus infections", "DISEASE", 211, 241], ["croup", "DISEASE", 312, 317], ["pneumonia", "DISEASE", 406, 415], ["bronchiolitis", "DISEASE", 419, 432], ["Parainfluenza virus", "ORGANISM", 211, 230], ["children", "ORGANISM", 442, 450], ["children", "SPECIES", 442, 450], ["TransmissionParainfluenza virus", "SPECIES", 199, 230], ["type 1 virus", "SPECIES", 257, 269], ["infection", "PROBLEM", 13, 22], ["high attack rates", "PROBLEM", 151, 168], ["TransmissionParainfluenza virus infections", "PROBLEM", 199, 241], ["type 1 virus", "PROBLEM", 257, 269], ["croup cases", "TEST", 312, 323], ["a documented viral cause", "PROBLEM", 352, 376], ["pneumonia", "PROBLEM", 406, 415], ["bronchiolitis cases in children", "PROBLEM", 419, 450], ["infection", "OBSERVATION", 13, 22], ["closed", "OBSERVATION_MODIFIER", 41, 47], ["populations", "OBSERVATION", 48, 59], ["Parainfluenza virus", "OBSERVATION", 211, 230], ["viral", "OBSERVATION", 365, 370], ["smaller", "OBSERVATION_MODIFIER", 383, 390], ["pneumonia", "OBSERVATION", 406, 415], ["bronchiolitis", "OBSERVATION", 419, 432]]], ["The incidence of croup and lower respiratory tract disease due to type 1 or 2 infections is highest between 6 months and 3 years of age, whereas parainfluenza type 3 is an important cause of bronchiolitis or pneumonia in infants younger than 6 months.", [["lower respiratory tract", "ANATOMY", 27, 50], ["croup", "DISEASE", 17, 22], ["lower respiratory tract disease", "DISEASE", 27, 58], ["infections", "DISEASE", 78, 88], ["parainfluenza type 3", "DISEASE", 145, 165], ["bronchiolitis", "DISEASE", 191, 204], ["pneumonia", "DISEASE", 208, 217], ["tract", "ORGANISM_SUBDIVISION", 45, 50], ["parainfluenza type 3", "ORGANISM", 145, 165], ["infants", "ORGANISM", 221, 228], ["parainfluenza", "SPECIES", 145, 158], ["infants", "SPECIES", 221, 228], ["croup and lower respiratory tract disease", "PROBLEM", 17, 58], ["type 1 or 2 infections", "PROBLEM", 66, 88], ["parainfluenza type 3", "PROBLEM", 145, 165], ["bronchiolitis", "PROBLEM", 191, 204], ["pneumonia", "PROBLEM", 208, 217], ["croup", "OBSERVATION", 17, 22], ["lower", "ANATOMY_MODIFIER", 27, 32], ["respiratory tract disease", "OBSERVATION", 33, 58], ["infections", "OBSERVATION", 78, 88], ["important cause of", "UNCERTAINTY", 172, 190], ["bronchiolitis", "OBSERVATION", 191, 204], ["pneumonia", "OBSERVATION", 208, 217]]], ["Reinfections with parainfluenza viruses are common and, in young children, may arise within several months of each other.", [["Reinfections", "DISEASE", 0, 12], ["parainfluenza viruses", "DISEASE", 18, 39], ["parainfluenza viruses", "ORGANISM", 18, 39], ["children", "ORGANISM", 65, 73], ["parainfluenza", "SPECIES", 18, 31], ["children", "SPECIES", 65, 73], ["parainfluenza viruses", "PROBLEM", 18, 39], ["parainfluenza viruses", "OBSERVATION", 18, 39]]], ["Recent population-based disease burden estimates suggest that 1 in 1000 children younger than 5 experience parainfluenza virus-related hospitalization, and that about 6.8% of hospitalizations for fever or respiratory illness in this age group can be attributed to parainfluenza virus.", [["respiratory", "ANATOMY", 205, 216], ["parainfluenza virus", "DISEASE", 107, 126], ["fever", "DISEASE", 196, 201], ["respiratory illness", "DISEASE", 205, 224], ["parainfluenza", "DISEASE", 264, 277], ["children", "ORGANISM", 72, 80], ["parainfluenza virus", "ORGANISM", 107, 126], ["parainfluenza virus", "ORGANISM", 264, 283], ["children", "SPECIES", 72, 80], ["parainfluenza virus", "SPECIES", 107, 126], ["parainfluenza", "SPECIES", 264, 277], ["parainfluenza virus", "SPECIES", 264, 283], ["Recent population-based disease burden", "PROBLEM", 0, 38], ["parainfluenza virus", "PROBLEM", 107, 126], ["fever", "PROBLEM", 196, 201], ["respiratory illness", "PROBLEM", 205, 224], ["parainfluenza virus", "PROBLEM", 264, 283], ["population", "OBSERVATION", 7, 17], ["disease", "OBSERVATION", 24, 31], ["parainfluenza virus", "OBSERVATION", 264, 283]]], ["228PathogenesisAlthough viremia has been described, replication of the virus is generally restricted to the respiratory tract mucosa.", [["respiratory tract mucosa", "ANATOMY", 108, 132], ["viremia", "DISEASE", 24, 31], ["respiratory tract mucosa", "MULTI-TISSUE_STRUCTURE", 108, 132], ["viremia", "PROBLEM", 24, 31], ["the virus", "PROBLEM", 67, 76], ["viremia", "OBSERVATION", 24, 31], ["virus", "OBSERVATION", 71, 76], ["respiratory tract", "ANATOMY", 108, 125]]], ["The quantity of virus shed in respiratory secretions tends to parallel the severity of illness.", [["respiratory secretions", "ANATOMY", 30, 52], ["illness", "DISEASE", 87, 94], ["virus", "PROBLEM", 16, 21], ["respiratory secretions", "PROBLEM", 30, 52], ["illness", "PROBLEM", 87, 94], ["quantity", "OBSERVATION_MODIFIER", 4, 12], ["virus", "OBSERVATION", 16, 21], ["respiratory secretions", "OBSERVATION", 30, 52]]], ["229 Virus shedding commonly continues for periods of 8 to 10 days in initial infections but may last for 3 weeks or longer.", [["infections", "DISEASE", 77, 87], ["Virus", "ORGANISM", 4, 9], ["Virus shedding", "PROBLEM", 4, 18], ["initial infections", "PROBLEM", 69, 87], ["infections", "OBSERVATION", 77, 87]]], ["Prolonged shedding (months) of parainfluenza virus type 1 or 3 has been reported in apparently normal hosts, 230 as well as in immunodeficient children.", [["parainfluenza virus", "DISEASE", 31, 50], ["parainfluenza virus type 1", "ORGANISM", 31, 57], ["3", "GENE_OR_GENE_PRODUCT", 61, 62], ["children", "ORGANISM", 143, 151], ["parainfluenza virus type 1", "SPECIES", 31, 57], ["children", "SPECIES", 143, 151], ["parainfluenza virus type 1", "SPECIES", 31, 57], ["Prolonged shedding", "PROBLEM", 0, 18], ["parainfluenza virus type 1", "PROBLEM", 31, 57], ["parainfluenza virus", "OBSERVATION", 31, 50]]], ["231 The pathologic findings in fatal cases are typical of other viral pneumonias and include peribronchiolar and alveolar lymphocytic infiltration.", [["peribronchiolar", "ANATOMY", 93, 108], ["alveolar lymphocytic", "ANATOMY", 113, 133], ["pneumonias", "DISEASE", 70, 80], ["alveolar lymphocytic infiltration", "DISEASE", 113, 146], ["peribronchiolar", "CANCER", 93, 108], ["alveolar lymphocytic", "PATHOLOGICAL_FORMATION", 113, 133], ["other viral pneumonias", "PROBLEM", 58, 80], ["peribronchiolar and alveolar lymphocytic infiltration", "PROBLEM", 93, 146], ["pathologic", "OBSERVATION", 8, 18], ["fatal", "OBSERVATION_MODIFIER", 31, 36], ["typical of", "UNCERTAINTY", 47, 57], ["viral", "OBSERVATION_MODIFIER", 64, 69], ["pneumonias", "OBSERVATION", 70, 80], ["peribronchiolar", "ANATOMY_MODIFIER", 93, 108], ["alveolar", "ANATOMY_MODIFIER", 113, 121], ["lymphocytic infiltration", "OBSERVATION", 122, 146]]], ["232 Infection of the tracheal epithelium with localized edema and fibrinous exudate contributes to airway narrowing in croup.", [["tracheal epithelium", "ANATOMY", 21, 40], ["edema", "ANATOMY", 56, 61], ["fibrinous exudate", "ANATOMY", 66, 83], ["airway", "ANATOMY", 99, 105], ["edema", "DISEASE", 56, 61], ["croup", "DISEASE", 119, 124], ["tracheal epithelium", "TISSUE", 21, 40], ["edema", "PATHOLOGICAL_FORMATION", 56, 61], ["fibrinous exudate", "PATHOLOGICAL_FORMATION", 66, 83], ["airway", "MULTI-TISSUE_STRUCTURE", 99, 105], ["Infection of the tracheal epithelium", "PROBLEM", 4, 40], ["localized edema", "PROBLEM", 46, 61], ["fibrinous exudate", "PROBLEM", 66, 83], ["airway narrowing in croup", "PROBLEM", 99, 124], ["Infection", "OBSERVATION", 4, 13], ["tracheal", "ANATOMY", 21, 29], ["epithelium", "ANATOMY_MODIFIER", 30, 40], ["localized", "OBSERVATION_MODIFIER", 46, 55], ["edema", "OBSERVATION", 56, 61], ["fibrinous", "OBSERVATION_MODIFIER", 66, 75], ["exudate", "OBSERVATION", 76, 83], ["airway", "ANATOMY", 99, 105], ["narrowing", "OBSERVATION", 106, 115], ["croup", "OBSERVATION", 119, 124]]], ["The mechanisms that account for the laryngotracheal localization of parainfluenza virus-induced disease are unresolved.", [["laryngotracheal", "ANATOMY", 36, 51], ["parainfluenza virus-induced disease", "DISEASE", 68, 103], ["laryngotracheal", "MULTI-TISSUE_STRUCTURE", 36, 51], ["parainfluenza virus", "ORGANISM", 68, 87], ["parainfluenza virus", "SPECIES", 68, 87], ["parainfluenza virus", "PROBLEM", 68, 87], ["induced disease", "PROBLEM", 88, 103], ["laryngotracheal", "ANATOMY", 36, 51], ["parainfluenza virus", "OBSERVATION", 68, 87]]], ["Virus-host cell of RSV, and bronchiolitis is the major manifestation in children.", [["cell", "ANATOMY", 11, 15], ["bronchiolitis", "DISEASE", 28, 41], ["Virus", "ORGANISM", 0, 5], ["host cell", "CELL", 6, 15], ["RSV", "ORGANISM", 19, 22], ["children", "ORGANISM", 72, 80], ["children", "SPECIES", 72, 80], ["RSV", "SPECIES", 19, 22], ["Virus", "PROBLEM", 0, 5], ["RSV", "PROBLEM", 19, 22], ["bronchiolitis", "PROBLEM", 28, 41], ["host cell", "OBSERVATION", 6, 15], ["RSV", "OBSERVATION", 19, 22], ["bronchiolitis", "OBSERVATION", 28, 41]]], ["206, 219 Clinical features in hospitalized children include wheezing and hypoxia.", [["wheezing", "DISEASE", 60, 68], ["hypoxia", "DISEASE", 73, 80], ["children", "ORGANISM", 43, 51], ["children", "SPECIES", 43, 51], ["wheezing", "PROBLEM", 60, 68], ["hypoxia", "PROBLEM", 73, 80], ["wheezing", "OBSERVATION", 60, 68], ["hypoxia", "OBSERVATION", 73, 80]]], ["220 A variety of other lower and upper respiratory tract syndromes are also associated with hMPV infection, including croup and pneumonitis.", [["upper respiratory tract", "ANATOMY", 33, 56], ["respiratory tract syndromes", "DISEASE", 39, 66], ["hMPV infection", "DISEASE", 92, 106], ["croup", "DISEASE", 118, 123], ["pneumonitis", "DISEASE", 128, 139], ["upper", "ORGANISM_SUBDIVISION", 33, 38], ["respiratory tract", "ORGANISM_SUBDIVISION", 39, 56], ["hMPV", "ORGANISM", 92, 96], ["hMPV", "SPECIES", 92, 96], ["A variety of other lower and upper respiratory tract syndromes", "PROBLEM", 4, 66], ["hMPV infection", "PROBLEM", 92, 106], ["croup", "PROBLEM", 118, 123], ["pneumonitis", "PROBLEM", 128, 139], ["variety", "OBSERVATION_MODIFIER", 6, 13], ["lower", "ANATOMY_MODIFIER", 23, 28], ["upper", "ANATOMY_MODIFIER", 33, 38], ["respiratory tract", "ANATOMY", 39, 56], ["associated with", "UNCERTAINTY", 76, 91], ["hMPV", "OBSERVATION_MODIFIER", 92, 96], ["infection", "OBSERVATION", 97, 106], ["pneumonitis", "OBSERVATION", 128, 139]]], ["206, 207 There are no clinical features that can distinguish between disease caused by hMPV and RSV, although RSV may be more severe.PathogenesisSymptomatic infection in adults and in the elderly has also been described.", [["hMPV", "DISEASE", 87, 91], ["RSV", "DISEASE", 96, 99], ["RSV", "DISEASE", 110, 113], ["PathogenesisSymptomatic infection", "DISEASE", 133, 166], ["hMPV", "ORGANISM", 87, 91], ["RSV", "ORGANISM", 96, 99], ["RSV", "ORGANISM", 110, 113], ["hMPV", "SPECIES", 87, 91], ["RSV", "SPECIES", 96, 99], ["RSV", "SPECIES", 110, 113], ["clinical features", "PROBLEM", 22, 39], ["disease", "PROBLEM", 69, 76], ["hMPV", "PROBLEM", 87, 91], ["RSV", "PROBLEM", 96, 99], ["RSV", "PROBLEM", 110, 113], ["PathogenesisSymptomatic infection", "PROBLEM", 133, 166], ["no", "UNCERTAINTY", 19, 21], ["hMPV", "OBSERVATION", 87, 91], ["RSV", "OBSERVATION", 96, 99], ["may be", "UNCERTAINTY", 114, 120], ["more severe", "OBSERVATION_MODIFIER", 121, 132], ["infection", "OBSERVATION", 157, 166]]], ["211 hMPV infections of young adults had features of the common cold, with nasal congestion, rhinorrhea, cough, and hoarseness predominating.", [["nasal", "ANATOMY", 74, 79], ["hMPV infections", "DISEASE", 4, 19], ["nasal congestion", "DISEASE", 74, 90], ["rhinorrhea", "DISEASE", 92, 102], ["cough", "DISEASE", 104, 109], ["hoarseness", "DISEASE", 115, 125], ["hMPV", "ORGANISM", 4, 8], ["adults", "ORGANISM", 29, 35], ["nasal", "ORGANISM_SUBDIVISION", 74, 79], ["the common cold", "PROBLEM", 52, 67], ["nasal congestion", "PROBLEM", 74, 90], ["rhinorrhea", "PROBLEM", 92, 102], ["cough", "PROBLEM", 104, 109], ["hoarseness", "PROBLEM", 115, 125], ["common cold", "ANATOMY", 56, 67], ["nasal", "ANATOMY", 74, 79], ["congestion", "OBSERVATION", 80, 90], ["rhinorrhea", "OBSERVATION", 92, 102], ["cough", "OBSERVATION", 104, 109], ["hoarseness", "OBSERVATION", 115, 125]]], ["Frail elderly and high-risk adults had lower rates of hMPV infection but more severe clinical symptoms, with significantly higher frequencies of dyspnea and wheezing, and more prolonged illness.", [["hMPV infection", "DISEASE", 54, 68], ["dyspnea", "DISEASE", 145, 152], ["wheezing", "DISEASE", 157, 165], ["prolonged illness", "DISEASE", 176, 193], ["adults", "ORGANISM", 28, 34], ["hMPV", "ORGANISM", 54, 58], ["hMPV", "SPECIES", 54, 58], ["hMPV infection", "PROBLEM", 54, 68], ["more severe clinical symptoms", "PROBLEM", 73, 102], ["dyspnea", "PROBLEM", 145, 152], ["wheezing", "PROBLEM", 157, 165], ["more prolonged illness", "PROBLEM", 171, 193], ["hMPV infection", "OBSERVATION", 54, 68], ["wheezing", "OBSERVATION", 157, 165]]], ["211 Elderly patients with hMPV infection were hospitalized with diagnoses of COPD, bronchitis, and pneumonia. hMPV appears to be a leading cause of respiratory tract infection in lung transplantation patients.", [["respiratory tract", "ANATOMY", 148, 165], ["lung", "ANATOMY", 179, 183], ["hMPV infection", "DISEASE", 26, 40], ["COPD", "DISEASE", 77, 81], ["bronchitis", "DISEASE", 83, 93], ["pneumonia", "DISEASE", 99, 108], ["hMPV", "DISEASE", 110, 114], ["respiratory tract infection", "DISEASE", 148, 175], ["patients", "ORGANISM", 12, 20], ["hMPV", "ORGANISM", 26, 30], ["hMPV", "ORGANISM", 110, 114], ["respiratory tract", "ORGANISM_SUBDIVISION", 148, 165], ["lung", "ORGAN", 179, 183], ["patients", "ORGANISM", 200, 208], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 200, 208], ["hMPV", "SPECIES", 26, 30], ["hMPV", "SPECIES", 110, 114], ["hMPV infection", "PROBLEM", 26, 40], ["COPD", "PROBLEM", 77, 81], ["bronchitis", "PROBLEM", 83, 93], ["pneumonia", "PROBLEM", 99, 108], ["hMPV", "PROBLEM", 110, 114], ["respiratory tract infection", "PROBLEM", 148, 175], ["lung transplantation", "TREATMENT", 179, 199], ["infection", "OBSERVATION", 31, 40], ["COPD", "OBSERVATION", 77, 81], ["bronchitis", "OBSERVATION", 83, 93], ["pneumonia", "OBSERVATION", 99, 108], ["respiratory tract", "ANATOMY", 148, 165], ["infection", "OBSERVATION", 166, 175], ["lung", "ANATOMY", 179, 183], ["transplantation", "OBSERVATION", 184, 199]]], ["221 In one study, hMPV was the most commonly detected RNA virus in BAL samples from immunocompromised patients.", [["BAL samples", "ANATOMY", 67, 78], ["hMPV", "ORGANISM", 18, 22], ["BAL samples", "CANCER", 67, 78], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["hMPV", "SPECIES", 18, 22], ["one study", "TEST", 7, 16], ["hMPV", "PROBLEM", 18, 22], ["RNA virus", "PROBLEM", 54, 63], ["BAL samples", "TEST", 67, 78], ["hMPV", "OBSERVATION", 18, 22]]], ["222PathogenesisRelatively little is known regarding the pathogenesis of this disease.", [["222Pathogenesis", "CHEMICAL", 0, 15], ["this disease", "PROBLEM", 72, 84], ["disease", "OBSERVATION", 77, 84]]], ["In hospitalized children with hMPV, levels of nasal secretion RANTES have been reported to be suppressed, while levels of nasal IL-8 were increased.", [["nasal", "ANATOMY", 46, 51], ["hMPV", "DISEASE", 30, 34], ["children", "ORGANISM", 16, 24], ["hMPV", "ORGANISM", 30, 34], ["nasal", "ORGAN", 46, 51], ["RANTES", "GENE_OR_GENE_PRODUCT", 62, 68], ["IL-8", "GENE_OR_GENE_PRODUCT", 128, 132], ["RANTES", "PROTEIN", 62, 68], ["nasal IL-8", "PROTEIN", 122, 132], ["children", "SPECIES", 16, 24], ["hMPV", "SPECIES", 30, 34], ["hMPV", "PROBLEM", 30, 34], ["nasal secretion RANTES", "PROBLEM", 46, 68], ["nasal IL", "TREATMENT", 122, 130], ["nasal", "ANATOMY", 46, 51]]], ["223 The immune responses elicited by hMPV are similar to those of RSV but often not as vigorous.", [["hMPV", "ORGANISM", 37, 41], ["RSV", "ORGANISM", 66, 69], ["hMPV", "SPECIES", 37, 41], ["RSV", "SPECIES", 66, 69], ["hMPV", "PROBLEM", 37, 41], ["RSV", "PROBLEM", 66, 69], ["hMPV", "OBSERVATION", 37, 41], ["RSV", "OBSERVATION", 66, 69], ["vigorous", "OBSERVATION", 87, 95]]], ["224DiagnosisViral culture is slow and has low sensitivity.", [["224DiagnosisViral culture", "TEST", 0, 25], ["low sensitivity", "PROBLEM", 42, 57], ["low sensitivity", "OBSERVATION_MODIFIER", 42, 57]]], ["Most infections have been detected by nucleic acid amplification techniques, which are available in panels to detect and identify respiratory viruses 224a-d (see Chapter 17) .Prevention and TreatmentTreatment is supportive.", [["infections", "DISEASE", 5, 15], ["nucleic acid", "CHEMICAL", 38, 50], ["Most infections", "PROBLEM", 0, 15], ["nucleic acid amplification techniques", "TEST", 38, 75], ["respiratory viruses", "PROBLEM", 130, 149], ["infections", "OBSERVATION", 5, 15]]], ["No antiviral agents or vaccines are currently licensed for treatment or prevention of hMPV infections, and this is unlikely to change in the near future.", [["hMPV infections", "DISEASE", 86, 101], ["hMPV", "ORGANISM", 86, 90], ["hMPV", "SPECIES", 86, 90], ["antiviral agents", "TREATMENT", 3, 19], ["vaccines", "TREATMENT", 23, 31], ["treatment", "TREATMENT", 59, 68], ["hMPV infections", "PROBLEM", 86, 101], ["antiviral agents", "OBSERVATION", 3, 19], ["hMPV infections", "OBSERVATION", 86, 101]]], ["Ribavirin is as active in vitro against hMPV as it is against hRSV, 225 but there are no data to support the therapeutic efficacy of this drug.", [["Ribavirin", "CHEMICAL", 0, 9], ["Ribavirin", "CHEMICAL", 0, 9], ["Ribavirin", "SIMPLE_CHEMICAL", 0, 9], ["hMPV", "ORGANISM", 40, 44], ["hMPV", "SPECIES", 40, 44], ["hRSV", "SPECIES", 62, 66], ["Ribavirin", "TREATMENT", 0, 9], ["hMPV", "PROBLEM", 40, 44], ["hRSV", "PROBLEM", 62, 66], ["this drug", "TREATMENT", 133, 142], ["active", "OBSERVATION_MODIFIER", 16, 22]]], ["There are no specific monoclonal antibodies available for clinical use, although intravenous immunoglobulin has been suggested as a possible therapeutic agent in immunocompromised hosts.", [["intravenous", "ANATOMY", 81, 92], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 81, 92], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 93, 107], ["monoclonal antibodies", "PROTEIN", 22, 43], ["intravenous immunoglobulin", "PROTEIN", 81, 107], ["specific monoclonal antibodies", "TEST", 13, 43], ["intravenous immunoglobulin", "TREATMENT", 81, 107], ["therapeutic agent", "TREATMENT", 141, 158], ["immunocompromised hosts", "PROBLEM", 162, 185], ["no", "UNCERTAINTY", 10, 12], ["monoclonal antibodies", "OBSERVATION", 22, 43]]], ["226PARAINFLUENZA VIRUSESParainfluenza viruses belong to the Paramyxovirus genus of the Paramyxoviridae family, which includes mumps virus and important veterinary pathogens.", [["mumps virus", "DISEASE", 126, 137], ["mumps virus", "ORGANISM", 126, 137], ["mumps virus", "SPECIES", 126, 137], ["PARAINFLUENZA VIRUSESParainfluenza viruses", "PROBLEM", 3, 45], ["mumps virus", "PROBLEM", 126, 137], ["important veterinary pathogens", "PROBLEM", 142, 172]]], ["This group of medium-sized (150 to 200 nm), pleomorphic, enveloped viruses has a nonsegmented, single-stranded RNA genome contained in a helical nucleocapsid.", [["nonsegmented, single-stranded RNA genome", "DNA", 81, 121], ["helical nucleocapsid", "PROTEIN", 137, 157], ["pleomorphic, enveloped viruses", "PROBLEM", 44, 74], ["a nonsegmented, single-stranded RNA genome", "PROBLEM", 79, 121], ["a helical nucleocapsid", "PROBLEM", 135, 157], ["medium", "OBSERVATION_MODIFIER", 14, 20], ["sized", "OBSERVATION_MODIFIER", 21, 26], ["enveloped viruses", "OBSERVATION", 57, 74], ["RNA genome", "OBSERVATION", 111, 121], ["helical nucleocapsid", "OBSERVATION_MODIFIER", 137, 157]]], ["The human parainfluenza viruses are separated into types 1 to 4, and type 4 is further divided into subtypes A and B, on the basis of antigenic differences.", [["parainfluenza viruses", "DISEASE", 10, 31], ["human", "ORGANISM", 4, 9], ["parainfluenza viruses", "ORGANISM", 10, 31], ["B", "CELL", 115, 116], ["human", "SPECIES", 4, 9], ["parainfluenza", "SPECIES", 10, 23], ["human parainfluenza viruses", "SPECIES", 4, 31], ["The human parainfluenza viruses", "PROBLEM", 0, 31], ["parainfluenza viruses", "OBSERVATION", 10, 31]]], ["One envelope glycoprotein (HN) has both hemagglutinin and neuraminidase activity and mediates adsorption of virus to host cell receptors for entry into host cells, as well as subsequent release of new virions from not associated with improved survival in bone marrow transplant recipients.", [["cell", "ANATOMY", 122, 126], ["cells", "ANATOMY", 157, 162], ["virions", "ANATOMY", 201, 208], ["bone marrow", "ANATOMY", 255, 266], ["HN", "GENE_OR_GENE_PRODUCT", 27, 29], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 58, 71], ["host cell", "CELL", 117, 126], ["host cells", "CELL", 152, 162], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 255, 266], ["envelope glycoprotein", "PROTEIN", 4, 25], ["HN", "PROTEIN", 27, 29], ["hemagglutinin", "PROTEIN", 40, 53], ["neuraminidase", "PROTEIN", 58, 71], ["host cell receptors", "PROTEIN", 117, 136], ["host cells", "CELL_TYPE", 152, 162], ["One envelope glycoprotein (HN)", "TREATMENT", 0, 30], ["both hemagglutinin", "TREATMENT", 35, 53], ["neuraminidase activity", "TREATMENT", 58, 80], ["virus to host cell receptors", "TREATMENT", 108, 136], ["new virions", "PROBLEM", 197, 208], ["bone marrow transplant recipients", "TREATMENT", 255, 288], ["glycoprotein", "OBSERVATION", 13, 25], ["host cells", "OBSERVATION", 152, 162], ["bone", "ANATOMY", 255, 259], ["marrow transplant", "OBSERVATION", 260, 277]]], ["238 The combination of aerosolized ribavirin and intravenous immunoglobulin is frequently used in immunocompromised patients, 239 but there is no direct evidence of efficacy.", [["intravenous", "ANATOMY", 49, 60], ["ribavirin", "CHEMICAL", 35, 44], ["ribavirin", "CHEMICAL", 35, 44], ["ribavirin", "SIMPLE_CHEMICAL", 35, 44], ["intravenous immunoglobulin", "SIMPLE_CHEMICAL", 49, 75], ["patients", "ORGANISM", 116, 124], ["intravenous immunoglobulin", "PROTEIN", 49, 75], ["patients", "SPECIES", 116, 124], ["aerosolized ribavirin", "TREATMENT", 23, 44], ["intravenous immunoglobulin", "TREATMENT", 49, 75], ["direct evidence of efficacy", "PROBLEM", 146, 173], ["aerosolized ribavirin", "OBSERVATION", 23, 44], ["no direct evidence of", "UNCERTAINTY", 143, 164], ["efficacy", "OBSERVATION", 165, 173]]], ["The sialidase DAS-181 is active in vitro and in small clinical studies 240,240a but is not currently available for clinical use.PARAINFLUENZA VIRUSESInitial attempts to develop vaccines for the prevention of parainfluenza viruses involved use of formalin-inactivated virus.", [["DAS-181", "CHEMICAL", 14, 21], ["parainfluenza viruses", "DISEASE", 208, 229], ["formalin", "CHEMICAL", 246, 254], ["formalin", "CHEMICAL", 246, 254], ["parainfluenza viruses", "ORGANISM", 208, 229], ["formalin-inactivated virus", "ORGANISM", 246, 272], ["parainfluenza", "SPECIES", 208, 221], ["The sialidase DAS", "TEST", 0, 17], ["small clinical studies", "TEST", 48, 70], ["PARAINFLUENZA", "PROBLEM", 128, 141], ["vaccines", "TREATMENT", 177, 185], ["parainfluenza viruses", "PROBLEM", 208, 229], ["formalin", "TREATMENT", 246, 254], ["inactivated virus", "PROBLEM", 255, 272], ["active", "OBSERVATION_MODIFIER", 25, 31], ["parainfluenza viruses", "OBSERVATION", 208, 229]]], ["However, these vaccines failed to provide protection in field trials carried out in the 1960s, despite being modestly immunogenic.", [["these vaccines", "TREATMENT", 9, 23], ["immunogenic", "OBSERVATION", 118, 129]]], ["In contrast to RSV vaccines, the use of formalin-inactivated parainfluenza vaccine was not associated with enhanced disease on subsequent infection.", [["formalin", "CHEMICAL", 40, 48], ["parainfluenza", "DISEASE", 61, 74], ["infection", "DISEASE", 138, 147], ["formalin", "CHEMICAL", 40, 48], ["RSV", "ORGANISM", 15, 18], ["formalin", "SIMPLE_CHEMICAL", 40, 48], ["parainfluenza", "ORGANISM", 61, 74], ["parainfluenza", "SPECIES", 61, 74], ["RSV", "SPECIES", 15, 18], ["RSV vaccines", "TREATMENT", 15, 27], ["formalin-inactivated parainfluenza vaccine", "TREATMENT", 40, 82], ["enhanced disease", "PROBLEM", 107, 123], ["subsequent infection", "PROBLEM", 127, 147], ["RSV vaccines", "OBSERVATION", 15, 27], ["infection", "OBSERVATION", 138, 147]]], ["Several approaches have been explored subsequently, including use of live attenuated viruses and recombinant subunit vaccines.", [["live attenuated viruses", "TREATMENT", 69, 92], ["recombinant subunit vaccines", "TREATMENT", 97, 125]]], ["Clinical trials of these are ongoing.RESPIRATORY SYNCYTIAL VIRUSRSV is classified in the Pneumovirus genus of the Paramyxoviridae family.", [["RESPIRATORY SYNCYTIAL VIRUSRSV", "PROBLEM", 37, 67], ["SYNCYTIAL VIRUSRSV", "OBSERVATION", 49, 67]]], ["Similar in structure to parainfluenza viruses, RSV is a pleomorphic (150 to 300 nm), enveloped virus with a single-stranded, nonsegmented RNA genome.", [["parainfluenza viruses", "DISEASE", 24, 45], ["RSV", "DISEASE", 47, 50], ["parainfluenza viruses", "ORGANISM", 24, 45], ["RSV", "ORGANISM", 47, 50], ["nonsegmented RNA genome", "DNA", 125, 148], ["parainfluenza", "SPECIES", 24, 37], ["parainfluenza viruses", "SPECIES", 24, 45], ["RSV", "SPECIES", 47, 50], ["parainfluenza viruses", "PROBLEM", 24, 45], ["RSV", "PROBLEM", 47, 50], ["enveloped virus", "PROBLEM", 85, 100], ["a single-stranded, nonsegmented RNA genome", "PROBLEM", 106, 148], ["parainfluenza viruses", "OBSERVATION", 24, 45], ["pleomorphic", "OBSERVATION_MODIFIER", 56, 67], ["virus", "OBSERVATION", 95, 100], ["RNA genome", "OBSERVATION", 138, 148]]], ["The surface proteins include the F protein responsible for fusion of the viral envelope with the host cell membranes and formation of syncytium, and the G protein, a heavily glycosylated protein responsible for attachment to cells.", [["surface", "ANATOMY", 4, 11], ["cell membranes", "ANATOMY", 102, 116], ["syncytium", "ANATOMY", 134, 143], ["cells", "ANATOMY", 225, 230], ["F protein", "GENE_OR_GENE_PRODUCT", 33, 42], ["cell membranes", "CELLULAR_COMPONENT", 102, 116], ["syncytium", "CELLULAR_COMPONENT", 134, 143], ["G protein", "GENE_OR_GENE_PRODUCT", 153, 162], ["cells", "CELL", 225, 230], ["surface proteins", "PROTEIN", 4, 20], ["F protein", "PROTEIN", 33, 42], ["G protein", "PROTEIN", 153, 162], ["heavily glycosylated protein", "PROTEIN", 166, 194], ["The surface proteins", "TEST", 0, 20], ["the F protein", "TEST", 29, 42], ["fusion", "TREATMENT", 59, 65], ["the viral envelope", "PROBLEM", 69, 87], ["the host cell membranes", "TREATMENT", 93, 116], ["syncytium", "PROBLEM", 134, 143], ["the G protein", "TEST", 149, 162], ["a heavily glycosylated protein", "PROBLEM", 164, 194], ["viral envelope", "OBSERVATION", 73, 87], ["host cell membranes", "OBSERVATION", 97, 116]]], ["Antibodies against the F and G protein neutralize RSV in vitro, but antibodies against the G do not prevent syncytium formation.", [["syncytium", "ANATOMY", 108, 117], ["F", "GENE_OR_GENE_PRODUCT", 23, 24], ["G protein", "GENE_OR_GENE_PRODUCT", 29, 38], ["RSV", "ORGANISM", 50, 53], ["syncytium", "CELL", 108, 117], ["F and G protein", "PROTEIN", 23, 38], ["antibodies", "PROTEIN", 68, 78], ["RSV", "SPECIES", 50, 53], ["Antibodies", "TEST", 0, 10], ["the F and G protein", "TREATMENT", 19, 38], ["antibodies", "TREATMENT", 68, 78], ["the G", "TREATMENT", 87, 92], ["syncytium formation", "PROBLEM", 108, 127]]], ["Two major antigenic groups (designated A and B) 241 are distinguished primarily by differences in the G glycoprotein.", [["G glycoprotein", "GENE_OR_GENE_PRODUCT", 102, 116], ["G glycoprotein", "PROTEIN", 102, 116]]], ["The clinical and epidemiologic importance of strain variation are under study, but infections by group A strains appear to be more severe.", [["infections", "DISEASE", 83, 93], ["strain variation", "PROBLEM", 45, 61], ["infections", "PROBLEM", 83, 93], ["group A strains", "PROBLEM", 97, 112]]], ["242 Further antigenic subgroups and genomic heterogeneity are recognized among circulating RSV strains.Epidemiology and TransmissionRSV is worldwide in distribution and, in temperate climates, causes annual outbreaks of infection in the late fall, winter, or spring.", [["infection", "DISEASE", 220, 229], ["RSV", "ORGANISM", 91, 94], ["RSV", "SPECIES", 91, 94], ["Further antigenic subgroups", "PROBLEM", 4, 31], ["genomic heterogeneity", "PROBLEM", 36, 57], ["circulating RSV strains", "PROBLEM", 79, 102], ["infection", "PROBLEM", 220, 229], ["antigenic subgroups", "OBSERVATION_MODIFIER", 12, 31], ["genomic heterogeneity", "OBSERVATION", 36, 57], ["RSV strains", "OBSERVATION", 91, 102], ["worldwide", "OBSERVATION_MODIFIER", 139, 148], ["infection", "OBSERVATION", 220, 229]]], ["Epidemics are associated with increases in pediatric hospitalizations and deaths due to lower respiratory tract illness in infants and young children.", [["lower respiratory tract", "ANATOMY", 88, 111], ["deaths", "DISEASE", 74, 80], ["lower respiratory tract illness", "DISEASE", 88, 119], ["lower", "ORGANISM_SUBDIVISION", 88, 93], ["respiratory tract", "ORGANISM_SUBDIVISION", 94, 111], ["infants", "ORGANISM", 123, 130], ["children", "ORGANISM", 141, 149], ["infants", "SPECIES", 123, 130], ["children", "SPECIES", 141, 149], ["Epidemics", "PROBLEM", 0, 9], ["lower respiratory tract illness", "PROBLEM", 88, 119], ["increases", "OBSERVATION_MODIFIER", 30, 39], ["lower", "ANATOMY_MODIFIER", 88, 93], ["respiratory tract", "ANATOMY", 94, 111]]], ["243 Nearly 50% of children are infected within the first year of life, and almost all have been infected by 3 years of age.", [["children", "ORGANISM", 18, 26], ["children", "SPECIES", 18, 26], ["infected", "OBSERVATION", 31, 39], ["infected", "OBSERVATION", 96, 104]]], ["Reinfections in children and adults are quite common even with the same strain, 244 suggesting immunity is only partial.", [["Reinfections", "DISEASE", 0, 12], ["children", "ORGANISM", 16, 24], ["children", "SPECIES", 16, 24]]], ["Epidemiologic factors related to serious illness in infected infants include low socioeconomic status, crowding, maternal smoking, lack of breast feeding, day care center attendance, and history of allergic disease.", [["breast", "ANATOMY", 139, 145], ["breast feeding", "DISEASE", 139, 153], ["allergic disease", "DISEASE", 198, 214], ["infants", "ORGANISM", 61, 68], ["breast", "ORGANISM_SUBDIVISION", 139, 145], ["infants", "SPECIES", 61, 68], ["Epidemiologic factors", "PROBLEM", 0, 21], ["serious illness in infected infants", "PROBLEM", 33, 68], ["low socioeconomic status", "PROBLEM", 77, 101], ["allergic disease", "PROBLEM", 198, 214], ["serious", "OBSERVATION_MODIFIER", 33, 40], ["breast", "ANATOMY", 139, 145], ["allergic disease", "OBSERVATION", 198, 214]]], ["RSV is also recognized as a cause of severe disease in older adults 245 and may result in a greater total burden of mortality in the elderly than in infants.", [["RSV", "DISEASE", 0, 3], ["RSV", "ORGANISM", 0, 3], ["infants", "ORGANISM", 149, 156], ["infants", "SPECIES", 149, 156], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3], ["severe disease", "PROBLEM", 37, 51], ["severe", "OBSERVATION_MODIFIER", 37, 43], ["disease", "OBSERVATION", 44, 51], ["greater", "OBSERVATION_MODIFIER", 92, 99]]], ["125 RSV spreads by large-particle aerosols during close personal contact and by hand contamination with infectious secretions and subsequent self-inoculation of the eye or nose.", [["hand", "ANATOMY", 80, 84], ["secretions", "ANATOMY", 115, 125], ["eye", "ANATOMY", 165, 168], ["nose", "ANATOMY", 172, 176], ["RSV", "ORGANISM", 4, 7], ["hand", "ORGANISM_SUBDIVISION", 80, 84], ["eye", "ORGAN", 165, 168], ["nose", "ORGANISM_SUBDIVISION", 172, 176], ["RSV", "SPECIES", 4, 7], ["infectious secretions", "PROBLEM", 104, 125], ["subsequent self-inoculation of the eye or nose", "PROBLEM", 130, 176], ["large", "OBSERVATION_MODIFIER", 19, 24], ["-particle", "OBSERVATION_MODIFIER", 24, 33], ["infectious", "OBSERVATION", 104, 114], ["eye", "ANATOMY", 165, 168], ["nose", "ANATOMY", 172, 176]]], ["RSV is a major nosocomial pathogen on pediatric wards, and there can be high attack rates during outbreaks in hospitals, transplantation units, day care centers, and geriatric homes.", [["RSV", "DISEASE", 0, 3], ["RSV", "ORGANISM", 0, 3], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3]]], ["Attack rates in children have approached interactions (specifically cleavage of the F protein) and other host factors, including the nature of the immune response, are postulated to play contributory roles in the pathogenesis of croup.", [["croup", "DISEASE", 229, 234], ["children", "ORGANISM", 16, 24], ["F protein", "GENE_OR_GENE_PRODUCT", 84, 93], ["F protein", "PROTEIN", 84, 93], ["host factors", "PROTEIN", 105, 117], ["children", "SPECIES", 16, 24], ["croup", "PROBLEM", 229, 234]]], ["The nasopharyngeal secretion concentrations of parainfluenza virus-specific IgE and of histamine and leukotriene C4, as well as cellular responses to viral antigen, are higher in patients with wheezing than in those with upper respiratory tract illness alone.", [["nasopharyngeal", "ANATOMY", 4, 18], ["cellular", "ANATOMY", 128, 136], ["upper respiratory tract", "ANATOMY", 221, 244], ["histamine", "CHEMICAL", 87, 96], ["leukotriene", "CHEMICAL", 101, 112], ["wheezing", "DISEASE", 193, 201], ["upper respiratory tract illness", "DISEASE", 221, 252], ["histamine", "CHEMICAL", 87, 96], ["nasopharyngeal", "ORGAN", 4, 18], ["parainfluenza virus", "ORGANISM", 47, 66], ["IgE", "GENE_OR_GENE_PRODUCT", 76, 79], ["histamine", "SIMPLE_CHEMICAL", 87, 96], ["leukotriene C4", "GENE_OR_GENE_PRODUCT", 101, 115], ["cellular", "CELL", 128, 136], ["patients", "ORGANISM", 179, 187], ["tract", "ORGANISM_SUBDIVISION", 239, 244], ["IgE", "PROTEIN", 76, 79], ["leukotriene C4", "PROTEIN", 101, 115], ["viral antigen", "PROTEIN", 150, 163], ["parainfluenza virus", "SPECIES", 47, 66], ["patients", "SPECIES", 179, 187], ["parainfluenza virus", "SPECIES", 47, 66], ["The nasopharyngeal secretion concentrations", "PROBLEM", 0, 43], ["parainfluenza virus", "PROBLEM", 47, 66], ["histamine and leukotriene C4", "TREATMENT", 87, 115], ["viral antigen", "TEST", 150, 163], ["wheezing", "PROBLEM", 193, 201], ["upper respiratory tract illness", "PROBLEM", 221, 252], ["nasopharyngeal", "ANATOMY", 4, 18], ["secretion concentrations", "OBSERVATION", 19, 43], ["parainfluenza virus", "OBSERVATION", 47, 66], ["viral antigen", "OBSERVATION", 150, 163], ["higher", "OBSERVATION_MODIFIER", 169, 175], ["upper", "ANATOMY_MODIFIER", 221, 226], ["respiratory tract", "ANATOMY", 227, 244]]], ["233Clinical IllnessPrimary infections are usually symptomatic and are associated with the most severe forms of illness.", [["Primary infections", "DISEASE", 19, 37], ["illness", "DISEASE", 111, 118], ["Primary infections", "PROBLEM", 19, 37], ["symptomatic", "PROBLEM", 50, 61], ["illness", "PROBLEM", 111, 118], ["infections", "OBSERVATION", 27, 37]]], ["Initial infections with parainfluenza virus types 1 to 3 cause febrile rhinitis, pharyngitis, laryngitis, and bronchitis in children.", [["infections", "DISEASE", 8, 18], ["parainfluenza virus", "DISEASE", 24, 43], ["febrile rhinitis", "DISEASE", 63, 79], ["pharyngitis", "DISEASE", 81, 92], ["laryngitis", "DISEASE", 94, 104], ["bronchitis", "DISEASE", 110, 120], ["parainfluenza virus", "ORGANISM", 24, 43], ["children", "ORGANISM", 124, 132], ["parainfluenza virus", "SPECIES", 24, 43], ["children", "SPECIES", 124, 132], ["Initial infections", "PROBLEM", 0, 18], ["parainfluenza virus types", "PROBLEM", 24, 49], ["febrile rhinitis", "PROBLEM", 63, 79], ["pharyngitis", "PROBLEM", 81, 92], ["laryngitis", "PROBLEM", 94, 104], ["bronchitis", "PROBLEM", 110, 120], ["infections", "OBSERVATION", 8, 18], ["parainfluenza virus", "OBSERVATION", 24, 43], ["febrile", "OBSERVATION_MODIFIER", 63, 70], ["rhinitis", "OBSERVATION", 71, 79], ["pharyngitis", "OBSERVATION", 81, 92], ["laryngitis", "OBSERVATION", 94, 104], ["bronchitis", "OBSERVATION", 110, 120]]], ["Depending on the serotype causing infection, 50% to 80% of primary infections are associated with fever, and up to one third of children have evidence of lower respiratory tract involvement.", [["lower respiratory tract", "ANATOMY", 154, 177], ["infection", "DISEASE", 34, 43], ["primary infections", "DISEASE", 59, 77], ["fever", "DISEASE", 98, 103], ["lower respiratory tract involvement", "DISEASE", 154, 189], ["children", "ORGANISM", 128, 136], ["lower", "ORGANISM_SUBDIVISION", 154, 159], ["respiratory tract", "ORGANISM_SUBDIVISION", 160, 177], ["children", "SPECIES", 128, 136], ["the serotype causing infection", "PROBLEM", 13, 43], ["primary infections", "PROBLEM", 59, 77], ["fever", "PROBLEM", 98, 103], ["lower respiratory tract involvement", "PROBLEM", 154, 189], ["infection", "OBSERVATION", 34, 43], ["infections", "OBSERVATION", 67, 77], ["lower", "ANATOMY_MODIFIER", 154, 159], ["respiratory tract", "ANATOMY", 160, 177]]], ["In parainfluenza virus type 1 and 2 infections, lower respiratory disease is principally manifested as croup, whereas type 3 infection has been associated with croup, bronchiolitis, and pneumonia.Clinical IllnessIn adults and older children, reinfections are frequently asymptomatic.", [["respiratory", "ANATOMY", 54, 65], ["parainfluenza virus type 1 and 2 infections", "DISEASE", 3, 46], ["respiratory disease", "DISEASE", 54, 73], ["croup", "DISEASE", 103, 108], ["infection", "DISEASE", 125, 134], ["croup", "DISEASE", 160, 165], ["bronchiolitis", "DISEASE", 167, 180], ["pneumonia", "DISEASE", 186, 195], ["reinfections", "DISEASE", 242, 254], ["parainfluenza virus type 1", "ORGANISM", 3, 29], ["children", "ORGANISM", 232, 240], ["parainfluenza virus", "SPECIES", 3, 22], ["children", "SPECIES", 232, 240], ["parainfluenza virus type 1", "SPECIES", 3, 29], ["parainfluenza virus type 1", "PROBLEM", 3, 29], ["2 infections", "PROBLEM", 34, 46], ["lower respiratory disease", "PROBLEM", 48, 73], ["croup", "PROBLEM", 103, 108], ["type 3 infection", "PROBLEM", 118, 134], ["croup", "PROBLEM", 160, 165], ["bronchiolitis", "PROBLEM", 167, 180], ["pneumonia", "PROBLEM", 186, 195], ["reinfections", "PROBLEM", 242, 254], ["parainfluenza virus", "OBSERVATION", 3, 22], ["lower", "OBSERVATION_MODIFIER", 48, 53], ["respiratory disease", "OBSERVATION", 54, 73], ["infection", "OBSERVATION", 125, 134], ["associated with", "UNCERTAINTY", 144, 159], ["bronchiolitis", "OBSERVATION", 167, 180], ["pneumonia", "OBSERVATION", 186, 195]]], ["Symptomatic infections are manifested as common colds, usually without fever, and less often pharyngitis, tracheobronchitis, or influenza-like illness.", [["infections", "DISEASE", 12, 22], ["colds", "DISEASE", 48, 53], ["fever", "DISEASE", 71, 76], ["pharyngitis", "DISEASE", 93, 104], ["tracheobronchitis", "DISEASE", 106, 123], ["influenza-like illness", "DISEASE", 128, 150], ["Symptomatic infections", "PROBLEM", 0, 22], ["common colds", "PROBLEM", 41, 53], ["fever", "PROBLEM", 71, 76], ["less often pharyngitis", "PROBLEM", 82, 104], ["tracheobronchitis", "PROBLEM", 106, 123], ["influenza", "PROBLEM", 128, 137], ["infections", "OBSERVATION", 12, 22], ["common", "OBSERVATION_MODIFIER", 41, 47], ["colds", "OBSERVATION", 48, 53], ["less", "OBSERVATION_MODIFIER", 82, 86], ["often", "OBSERVATION_MODIFIER", 87, 92], ["pharyngitis", "OBSERVATION", 93, 104], ["tracheobronchitis", "OBSERVATION", 106, 123], ["influenza", "OBSERVATION", 128, 137]]], ["Pneumonia and exacerbations of chronic airway disease have been described following parainfluenza virus infection in adults and in the elderly.", [["airway", "ANATOMY", 39, 45], ["Pneumonia", "DISEASE", 0, 9], ["chronic airway disease", "DISEASE", 31, 53], ["parainfluenza virus infection", "DISEASE", 84, 113], ["airway", "ORGAN", 39, 45], ["parainfluenza virus", "ORGANISM", 84, 103], ["parainfluenza virus", "SPECIES", 84, 103], ["parainfluenza virus", "SPECIES", 84, 103], ["Pneumonia", "PROBLEM", 0, 9], ["exacerbations", "PROBLEM", 14, 27], ["chronic airway disease", "PROBLEM", 31, 53], ["parainfluenza virus infection", "PROBLEM", 84, 113], ["exacerbations", "OBSERVATION_MODIFIER", 14, 27], ["chronic", "OBSERVATION_MODIFIER", 31, 38], ["airway disease", "OBSERVATION", 39, 53], ["parainfluenza virus infection", "OBSERVATION", 84, 113]]], ["234 Although uncommon, parainfluenza viruses can cause serious lower respiratory tract disease, including fatal pneumonia with or without giant cells, in children with immunodeficiency or leukemia, and in pediatric and adult stem cell transplant recipients.", [["lower respiratory tract", "ANATOMY", 63, 86], ["giant cells", "ANATOMY", 138, 149], ["leukemia", "ANATOMY", 188, 196], ["stem cell", "ANATOMY", 225, 234], ["parainfluenza viruses", "DISEASE", 23, 44], ["lower respiratory tract disease", "DISEASE", 63, 94], ["pneumonia", "DISEASE", 112, 121], ["immunodeficiency or leukemia", "DISEASE", 168, 196], ["parainfluenza viruses", "ORGANISM", 23, 44], ["lower", "ORGANISM_SUBDIVISION", 63, 68], ["respiratory tract", "ORGANISM_SUBDIVISION", 69, 86], ["giant cells", "CELL", 138, 149], ["children", "ORGANISM", 154, 162], ["leukemia", "CANCER", 188, 196], ["stem cell", "CELL", 225, 234], ["recipients", "ORGANISM", 246, 256], ["giant cells", "CELL_TYPE", 138, 149], ["parainfluenza", "SPECIES", 23, 36], ["children", "SPECIES", 154, 162], ["parainfluenza viruses", "PROBLEM", 23, 44], ["serious lower respiratory tract disease", "PROBLEM", 55, 94], ["fatal pneumonia", "PROBLEM", 106, 121], ["giant cells", "PROBLEM", 138, 149], ["immunodeficiency", "PROBLEM", 168, 184], ["leukemia", "PROBLEM", 188, 196], ["adult stem cell transplant recipients", "TREATMENT", 219, 256], ["parainfluenza viruses", "OBSERVATION", 23, 44], ["respiratory tract disease", "OBSERVATION", 69, 94], ["fatal", "OBSERVATION_MODIFIER", 106, 111], ["pneumonia", "OBSERVATION", 112, 121], ["without", "UNCERTAINTY", 130, 137], ["giant cells", "OBSERVATION", 138, 149], ["leukemia", "OBSERVATION", 188, 196], ["stem cell transplant recipients", "OBSERVATION", 225, 256]]], ["235 Nosocomial outbreaks in immunosuppressed patients have been reported.", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53]]], ["236 Because upper respiratory illness may be absent and nasopharyngeal cultures negative, BAL is often required for diagnosis.DiagnosisRapid diagnosis of parainfluenza infection can be made by detection of viral antigen or RNA in respiratory secretions obtained using throat or nasopharyngeal swabs.", [["respiratory", "ANATOMY", 18, 29], ["nasopharyngeal cultures", "ANATOMY", 56, 79], ["BAL", "ANATOMY", 90, 93], ["respiratory secretions", "ANATOMY", 230, 252], ["throat", "ANATOMY", 268, 274], ["nasopharyngeal swabs", "ANATOMY", 278, 298], ["respiratory illness", "DISEASE", 18, 37], ["parainfluenza infection", "DISEASE", 154, 177], ["nasopharyngeal cultures", "CELL", 56, 79], ["BAL", "ORGANISM_SUBSTANCE", 90, 93], ["parainfluenza", "ORGANISM", 154, 167], ["viral antigen", "GENE_OR_GENE_PRODUCT", 206, 219], ["throat", "ORGANISM_SUBDIVISION", 268, 274], ["nasopharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 278, 298], ["viral antigen", "PROTEIN", 206, 219], ["parainfluenza", "SPECIES", 154, 167], ["upper respiratory illness", "PROBLEM", 12, 37], ["nasopharyngeal cultures", "TEST", 56, 79], ["BAL", "TEST", 90, 93], ["parainfluenza infection", "PROBLEM", 154, 177], ["viral antigen", "PROBLEM", 206, 219], ["RNA in respiratory secretions", "PROBLEM", 223, 252], ["throat or nasopharyngeal swabs", "PROBLEM", 268, 298], ["upper", "ANATOMY_MODIFIER", 12, 17], ["respiratory", "ANATOMY", 18, 29], ["illness", "OBSERVATION", 30, 37], ["nasopharyngeal", "ANATOMY", 56, 70], ["parainfluenza infection", "OBSERVATION", 154, 177], ["respiratory secretions", "OBSERVATION", 230, 252], ["nasopharyngeal", "ANATOMY", 278, 292]]], ["Detection of parainfluenza RNA is performed in multiplex nucleic acid amplification panels for respiratory viruses 224a-d (see Chapter 17) , which may be more readily available than rapid antigen detection assays.", [["nucleic acid", "CHEMICAL", 57, 69], ["parainfluenza", "ORGANISM", 13, 26], ["parainfluenza RNA", "RNA", 13, 30], ["parainfluenza", "SPECIES", 13, 26], ["parainfluenza RNA", "PROBLEM", 13, 30], ["multiplex nucleic acid amplification panels", "TEST", 47, 90], ["respiratory viruses", "TEST", 95, 114], ["rapid antigen detection assays", "TEST", 182, 212], ["parainfluenza RNA", "OBSERVATION", 13, 30]]], ["Respiratory secretions contain the virus at the time of symptom onset.", [["Respiratory secretions", "ANATOMY", 0, 22], ["Respiratory secretions", "PROBLEM", 0, 22], ["the virus", "PROBLEM", 31, 40], ["symptom onset", "PROBLEM", 56, 69], ["secretions", "OBSERVATION", 12, 22]]], ["Viral culture is also sensitive, and parainfluenza viruses can be isolated as early as 3 days and usually within 10 days after inoculation of cell culture with specimens from infants and children.", [["cell", "ANATOMY", 142, 146], ["specimens", "ANATOMY", 160, 169], ["parainfluenza viruses", "DISEASE", 37, 58], ["parainfluenza viruses", "ORGANISM", 37, 58], ["cell", "CELL", 142, 146], ["infants", "ORGANISM", 175, 182], ["children", "ORGANISM", 187, 195], ["parainfluenza", "SPECIES", 37, 50], ["infants", "SPECIES", 175, 182], ["children", "SPECIES", 187, 195], ["parainfluenza viruses", "SPECIES", 37, 58], ["Viral culture", "TEST", 0, 13], ["parainfluenza viruses", "PROBLEM", 37, 58], ["cell culture", "TEST", 142, 154], ["parainfluenza viruses", "OBSERVATION", 37, 58]]], ["Virus replication in cell culture is usually detected by hemadsorption of guinea pig erythrocytes or immunofluorescence.Treatment and PreventionThere are currently no available antiviral agents of proven effectiveness against parainfluenza virus.", [["cell culture", "ANATOMY", 21, 33], ["erythrocytes", "ANATOMY", 85, 97], ["parainfluenza virus", "DISEASE", 226, 245], ["Virus", "ORGANISM", 0, 5], ["cell", "CELL", 21, 25], ["guinea", "ORGANISM", 74, 80], ["pig", "ORGANISM", 81, 84], ["erythrocytes", "CELL", 85, 97], ["parainfluenza virus", "ORGANISM", 226, 245], ["guinea pig erythrocytes", "CELL_TYPE", 74, 97], ["guinea pig", "SPECIES", 74, 84], ["parainfluenza", "SPECIES", 226, 239], ["guinea pig", "SPECIES", 74, 84], ["parainfluenza virus", "SPECIES", 226, 245], ["Virus replication", "TREATMENT", 0, 17], ["cell culture", "TEST", 21, 33], ["guinea pig erythrocytes", "PROBLEM", 74, 97], ["immunofluorescence", "TEST", 101, 119], ["Treatment", "TREATMENT", 120, 129], ["available antiviral agents", "TREATMENT", 167, 193], ["parainfluenza virus", "PROBLEM", 226, 245], ["cell culture", "OBSERVATION", 21, 33], ["pig erythrocytes", "OBSERVATION", 81, 97]]], ["Ribavirin is active against parainfluenza viruses in vitro and would theoretically be expected to be active in vivo as well.", [["Ribavirin", "CHEMICAL", 0, 9], ["parainfluenza viruses", "DISEASE", 28, 49], ["Ribavirin", "CHEMICAL", 0, 9], ["Ribavirin", "SIMPLE_CHEMICAL", 0, 9], ["parainfluenza viruses", "ORGANISM", 28, 49], ["parainfluenza", "SPECIES", 28, 41], ["Ribavirin", "TREATMENT", 0, 9], ["parainfluenza viruses", "PROBLEM", 28, 49], ["active", "OBSERVATION_MODIFIER", 13, 19], ["against", "OBSERVATION_MODIFIER", 20, 27], ["parainfluenza viruses", "OBSERVATION", 28, 49], ["active", "OBSERVATION", 101, 107]]], ["Anecdotal reports in immunodeficient children with severe parainfluenza virus infections suggest that aerosolized ribavirin may be associated with antiviral effects and clinical benefit, 237 although delayed treatment with aerosol ribavirin was infants born prematurely are also at risk for severe disease, perhaps because they lack maternal antibody.", [["parainfluenza virus infections", "DISEASE", 58, 88], ["ribavirin", "CHEMICAL", 114, 123], ["ribavirin", "CHEMICAL", 231, 240], ["ribavirin", "CHEMICAL", 114, 123], ["ribavirin", "CHEMICAL", 231, 240], ["immunodeficient", "ORGANISM", 21, 36], ["children", "ORGANISM", 37, 45], ["parainfluenza virus", "ORGANISM", 58, 77], ["ribavirin", "SIMPLE_CHEMICAL", 114, 123], ["maternal antibody", "PROTEIN", 333, 350], ["children", "SPECIES", 37, 45], ["parainfluenza", "SPECIES", 58, 71], ["infants", "SPECIES", 245, 252], ["parainfluenza virus", "SPECIES", 58, 77], ["severe parainfluenza virus infections", "PROBLEM", 51, 88], ["aerosolized ribavirin", "TREATMENT", 102, 123], ["antiviral effects", "PROBLEM", 147, 164], ["delayed treatment", "TREATMENT", 200, 217], ["aerosol ribavirin", "TREATMENT", 223, 240], ["severe disease", "PROBLEM", 291, 305], ["maternal antibody", "PROBLEM", 333, 350], ["severe", "OBSERVATION_MODIFIER", 51, 57], ["parainfluenza virus", "OBSERVATION", 58, 77], ["aerosolized ribavirin", "OBSERVATION", 102, 123], ["severe", "OBSERVATION_MODIFIER", 291, 297], ["disease", "OBSERVATION", 298, 305]]], ["Mortality is usually 0.5% to 1.5% in previously healthy infants hospitalized with RSV disease but is 15% to 40% in those with primary immunodeficiency, cancer chemotherapy, or pulmonary and heart disease.", [["cancer", "ANATOMY", 152, 158], ["pulmonary", "ANATOMY", 176, 185], ["heart", "ANATOMY", 190, 195], ["RSV disease", "DISEASE", 82, 93], ["primary immunodeficiency", "DISEASE", 126, 150], ["cancer", "DISEASE", 152, 158], ["pulmonary and heart disease", "DISEASE", 176, 203], ["infants", "ORGANISM", 56, 63], ["RSV", "ORGANISM", 82, 85], ["cancer", "CANCER", 152, 158], ["pulmonary", "ORGAN", 176, 185], ["heart", "ORGAN", 190, 195], ["infants", "SPECIES", 56, 63], ["RSV", "SPECIES", 82, 85], ["RSV disease", "PROBLEM", 82, 93], ["primary immunodeficiency", "PROBLEM", 126, 150], ["cancer chemotherapy", "TREATMENT", 152, 171], ["pulmonary and heart disease", "PROBLEM", 176, 203], ["RSV disease", "OBSERVATION", 82, 93], ["immunodeficiency", "OBSERVATION", 134, 150], ["cancer chemotherapy", "OBSERVATION", 152, 171], ["pulmonary", "ANATOMY", 176, 185], ["heart", "ANATOMY", 190, 195], ["disease", "OBSERVATION", 196, 203]]], ["Pulmonary hypertension is associated with a particularly high frequency of poor outcomes.", [["Pulmonary", "ANATOMY", 0, 9], ["Pulmonary hypertension", "DISEASE", 0, 22], ["Pulmonary", "ORGAN", 0, 9], ["Pulmonary hypertension", "PROBLEM", 0, 22], ["hypertension", "OBSERVATION", 10, 22]]], ["Severe disease has also been associated in children with a family history of asthma and those exposed to cigarette smoke in the household.", [["asthma", "DISEASE", 77, 83], ["children", "ORGANISM", 43, 51], ["cigarette", "ORGANISM", 105, 114], ["children", "SPECIES", 43, 51], ["Severe disease", "PROBLEM", 0, 14], ["asthma", "PROBLEM", 77, 83], ["disease", "OBSERVATION", 7, 14], ["asthma", "OBSERVATION", 77, 83]]], ["253 However, it is important to recognize that the majority of those hospitalized with RSV are previously healthy young children.", [["RSV", "DISEASE", 87, 90], ["RSV", "ORGANISM", 87, 90], ["children", "ORGANISM", 120, 128], ["children", "SPECIES", 120, 128], ["RSV", "SPECIES", 87, 90]]], ["243 Chest radiographic findings in lower respiratory tract disease include bronchial wall thickening, peribronchial shadowing, air-trapping (eFig.", [["lower respiratory tract", "ANATOMY", 35, 58], ["bronchial wall", "ANATOMY", 75, 89], ["peribronchial", "ANATOMY", 102, 115], ["lower respiratory tract disease", "DISEASE", 35, 66], ["lower", "ORGANISM_SUBDIVISION", 35, 40], ["respiratory tract", "ORGANISM_SUBDIVISION", 41, 58], ["bronchial wall", "MULTI-TISSUE_STRUCTURE", 75, 89], ["Chest radiographic", "TEST", 4, 22], ["lower respiratory tract disease", "PROBLEM", 35, 66], ["bronchial wall thickening", "PROBLEM", 75, 100], ["peribronchial shadowing", "PROBLEM", 102, 125], ["air-trapping", "PROBLEM", 127, 139], ["eFig", "TEST", 141, 145], ["lower", "ANATOMY_MODIFIER", 35, 40], ["respiratory tract", "ANATOMY", 41, 58], ["bronchial", "ANATOMY", 75, 84], ["wall", "ANATOMY_MODIFIER", 85, 89], ["thickening", "OBSERVATION", 90, 100], ["peribronchial", "ANATOMY_MODIFIER", 102, 115], ["shadowing", "OBSERVATION", 116, 125]]], ["32-12A), and, in pneumonia, multilobar patchy shadowing or poorly defined nodularity ( Fig. 32-3 , eFig.", [["pneumonia", "DISEASE", 17, 26], ["pneumonia", "PROBLEM", 17, 26], ["multilobar patchy shadowing", "PROBLEM", 28, 55], ["poorly defined nodularity", "PROBLEM", 59, 84], ["Fig.", "TEST", 87, 91], ["eFig", "TEST", 99, 103], ["pneumonia", "OBSERVATION", 17, 26], ["multilobar", "OBSERVATION_MODIFIER", 28, 38], ["patchy", "OBSERVATION_MODIFIER", 39, 45], ["shadowing", "OBSERVATION_MODIFIER", 46, 55], ["poorly defined", "OBSERVATION_MODIFIER", 59, 73], ["nodularity", "OBSERVATION", 74, 84]]], ["Although no radiographic pattern is specific, air trapping, alone or with other abnormalities, is highly associated with RSV infection in hospitalized children.", [["RSV infection", "DISEASE", 121, 134], ["RSV", "ORGANISM", 121, 124], ["children", "ORGANISM", 151, 159], ["children", "SPECIES", 151, 159], ["RSV", "SPECIES", 121, 124], ["radiographic pattern", "TEST", 12, 32], ["air trapping", "PROBLEM", 46, 58], ["other abnormalities", "PROBLEM", 74, 93], ["RSV infection", "PROBLEM", 121, 134], ["no", "UNCERTAINTY", 9, 11], ["air trapping", "OBSERVATION", 46, 58], ["highly associated with", "UNCERTAINTY", 98, 120], ["RSV", "OBSERVATION_MODIFIER", 121, 124], ["infection", "OBSERVATION", 125, 134]]], ["254 Chest CT findings (eFig.", [["Chest CT findings", "TEST", 4, 21], ["eFig", "TEST", 23, 27], ["Chest", "ANATOMY", 4, 9]]], ["32-13) are relatively nonspecific, often resembling other viral pulmonary infections, including multifocal areas of ground-glass opacity, consolidation, and small nodules, which may show branching configurations (\"tree-in-bud\" opacity).Treatment and PreventionThe most common physiologic abnormality is hypoxemia that may persist for weeks after apparent recovery.", [["pulmonary", "ANATOMY", 64, 73], ["nodules", "ANATOMY", 163, 170], ["bud", "ANATOMY", 222, 225], ["viral pulmonary infections", "DISEASE", 58, 84], ["opacity", "DISEASE", 227, 234], ["hypoxemia", "DISEASE", 303, 312], ["pulmonary", "ORGAN", 64, 73], ["nodules", "PATHOLOGICAL_FORMATION", 163, 170], ["bud", "TISSUE", 222, 225], ["other viral pulmonary infections", "PROBLEM", 52, 84], ["ground-glass opacity", "PROBLEM", 116, 136], ["consolidation", "PROBLEM", 138, 151], ["small nodules", "PROBLEM", 157, 170], ["branching configurations", "PROBLEM", 187, 211], ["bud\" opacity", "PROBLEM", 222, 234], ["Treatment", "TREATMENT", 236, 245], ["The most common physiologic abnormality", "PROBLEM", 260, 299], ["hypoxemia", "PROBLEM", 303, 312], ["relatively", "OBSERVATION_MODIFIER", 11, 21], ["nonspecific", "OBSERVATION", 22, 33], ["viral", "OBSERVATION_MODIFIER", 58, 63], ["pulmonary", "ANATOMY", 64, 73], ["infections", "OBSERVATION", 74, 84], ["multifocal", "OBSERVATION_MODIFIER", 96, 106], ["areas", "OBSERVATION_MODIFIER", 107, 112], ["ground-glass opacity", "OBSERVATION", 116, 136], ["consolidation", "OBSERVATION", 138, 151], ["small", "OBSERVATION_MODIFIER", 157, 162], ["nodules", "OBSERVATION", 163, 170], ["may show", "UNCERTAINTY", 178, 186], ["branching", "OBSERVATION_MODIFIER", 187, 196], ["configurations", "OBSERVATION_MODIFIER", 197, 211], ["tree", "OBSERVATION_MODIFIER", 214, 218], ["bud", "OBSERVATION_MODIFIER", 222, 225], ["\"", "OBSERVATION_MODIFIER", 225, 226], ["opacity", "OBSERVATION", 227, 234], ["abnormality", "OBSERVATION", 288, 299], ["hypoxemia", "OBSERVATION", 303, 312]]], ["255 Prolonged pulmonary function abnormalities, including increased airway resistance, peripheral airway obstruction, and decreased arterial oxygen saturation, have been detected in children years after bouts of bronchiolitis.", [["pulmonary", "ANATOMY", 14, 23], ["airway", "ANATOMY", 68, 74], ["peripheral airway", "ANATOMY", 87, 104], ["arterial", "ANATOMY", 132, 140], ["pulmonary function abnormalities", "DISEASE", 14, 46], ["peripheral airway obstruction", "DISEASE", 87, 116], ["oxygen", "CHEMICAL", 141, 147], ["bronchiolitis", "DISEASE", 212, 225], ["oxygen", "CHEMICAL", 141, 147], ["pulmonary", "ORGAN", 14, 23], ["airway", "MULTI-TISSUE_STRUCTURE", 68, 74], ["peripheral airway", "MULTI-TISSUE_STRUCTURE", 87, 104], ["arterial", "MULTI-TISSUE_STRUCTURE", 132, 140], ["oxygen", "SIMPLE_CHEMICAL", 141, 147], ["children", "ORGANISM", 182, 190], ["children", "SPECIES", 182, 190], ["Prolonged pulmonary function abnormalities", "PROBLEM", 4, 46], ["increased airway resistance", "PROBLEM", 58, 85], ["peripheral airway obstruction", "PROBLEM", 87, 116], ["decreased arterial oxygen saturation", "PROBLEM", 122, 158], ["bronchiolitis", "PROBLEM", 212, 225], ["pulmonary", "ANATOMY", 14, 23], ["function abnormalities", "OBSERVATION", 24, 46], ["increased", "OBSERVATION_MODIFIER", 58, 67], ["airway resistance", "OBSERVATION", 68, 85], ["peripheral", "ANATOMY_MODIFIER", 87, 97], ["airway", "ANATOMY", 98, 104], ["obstruction", "OBSERVATION", 105, 116], ["decreased", "OBSERVATION_MODIFIER", 122, 131], ["arterial", "OBSERVATION_MODIFIER", 132, 140], ["oxygen saturation", "OBSERVATION", 141, 158], ["bronchiolitis", "OBSERVATION", 212, 225]]], ["256 Bronchiolitis in infancy has also been associated with an increased risk of subsequent recurrent wheezing and cough and airway hyperreactivity.Treatment and PreventionIn adults, one half or more of recurrent infections are associated with upper respiratory tract illness.", [["airway", "ANATOMY", 124, 130], ["upper respiratory tract", "ANATOMY", 243, 266], ["Bronchiolitis", "DISEASE", 4, 17], ["wheezing", "DISEASE", 101, 109], ["cough", "DISEASE", 114, 119], ["airway hyperreactivity", "DISEASE", 124, 146], ["infections", "DISEASE", 212, 222], ["upper respiratory tract illness", "DISEASE", 243, 274], ["airway", "MULTI-TISSUE_STRUCTURE", 124, 130], ["upper respiratory", "ORGANISM_SUBDIVISION", 243, 260], ["tract", "ORGANISM_SUBDIVISION", 261, 266], ["Bronchiolitis", "PROBLEM", 4, 17], ["subsequent recurrent wheezing", "PROBLEM", 80, 109], ["cough", "PROBLEM", 114, 119], ["airway hyperreactivity", "PROBLEM", 124, 146], ["Treatment", "TREATMENT", 147, 156], ["PreventionIn adults", "TREATMENT", 161, 180], ["recurrent infections", "PROBLEM", 202, 222], ["upper respiratory tract illness", "PROBLEM", 243, 274], ["Bronchiolitis", "OBSERVATION", 4, 17], ["increased", "OBSERVATION_MODIFIER", 62, 71], ["recurrent", "OBSERVATION_MODIFIER", 91, 100], ["wheezing", "OBSERVATION", 101, 109], ["cough", "OBSERVATION", 114, 119], ["airway", "ANATOMY", 124, 130], ["hyperreactivity", "OBSERVATION", 131, 146], ["infections", "OBSERVATION", 212, 222], ["upper", "ANATOMY_MODIFIER", 243, 248], ["respiratory tract", "ANATOMY", 249, 266]]], ["Adults typically experience coryza, pharyngitis, and cough, sometimes accompanied by low-grade fever.", [["pharyngitis", "DISEASE", 36, 47], ["cough", "DISEASE", 53, 58], ["low-grade fever", "DISEASE", 85, 100], ["Adults", "ORGANISM", 0, 6], ["Adults", "SPECIES", 0, 6], ["coryza", "PROBLEM", 28, 34], ["pharyngitis", "PROBLEM", 36, 47], ["cough", "PROBLEM", 53, 58], ["low-grade fever", "PROBLEM", 85, 100], ["coryza", "OBSERVATION", 28, 34], ["pharyngitis", "OBSERVATION", 36, 47], ["cough", "OBSERVATION", 53, 58], ["low-grade", "OBSERVATION_MODIFIER", 85, 94], ["fever", "OBSERVATION", 95, 100]]], ["Bronchitis, influenza-like illness, pneumonia, and exacerbations of asthma and chronic bronchitis have also been described in adults with RSV infection.", [["Bronchitis", "DISEASE", 0, 10], ["influenza-like illness", "DISEASE", 12, 34], ["pneumonia", "DISEASE", 36, 45], ["asthma", "DISEASE", 68, 74], ["chronic bronchitis", "DISEASE", 79, 97], ["RSV infection", "DISEASE", 138, 151], ["adults", "ORGANISM", 126, 132], ["RSV", "ORGANISM", 138, 141], ["RSV", "SPECIES", 138, 141], ["Bronchitis", "PROBLEM", 0, 10], ["influenza", "PROBLEM", 12, 21], ["illness", "PROBLEM", 27, 34], ["pneumonia", "PROBLEM", 36, 45], ["exacerbations", "PROBLEM", 51, 64], ["asthma", "PROBLEM", 68, 74], ["chronic bronchitis", "PROBLEM", 79, 97], ["RSV infection", "PROBLEM", 138, 151], ["influenza", "OBSERVATION", 12, 21], ["pneumonia", "OBSERVATION", 36, 45], ["exacerbations", "OBSERVATION_MODIFIER", 51, 64], ["asthma", "OBSERVATION", 68, 74], ["chronic", "OBSERVATION_MODIFIER", 79, 86], ["bronchitis", "OBSERVATION", 87, 97], ["RSV", "OBSERVATION_MODIFIER", 138, 141], ["infection", "OBSERVATION", 142, 151]]], ["In the United States, approximately 170,000 hospitalizations and more than 10,000 deaths are associated with RSV annually in adults older than 65.", [["deaths", "DISEASE", 82, 88], ["RSV", "DISEASE", 109, 112], ["RSV", "ORGANISM", 109, 112], ["RSV", "SPECIES", 109, 112], ["RSV", "PROBLEM", 109, 112]]], ["125 In elderly adults, the clinical features of RSV infection can mimic those of influenza, although fever is less frequent and wheezing is more frequent.", [["RSV infection", "DISEASE", 48, 61], ["influenza", "DISEASE", 81, 90], ["fever", "DISEASE", 101, 106], ["wheezing", "DISEASE", 128, 136], ["RSV", "ORGANISM", 48, 51], ["RSV", "SPECIES", 48, 51], ["RSV infection", "PROBLEM", 48, 61], ["influenza", "PROBLEM", 81, 90], ["fever", "PROBLEM", 101, 106], ["wheezing", "PROBLEM", 128, 136], ["RSV infection", "OBSERVATION", 48, 61], ["influenza", "OBSERVATION", 81, 90]]], ["257 In one study, RSV infection was seen in 3% to 7% of healthy elderly and 4% to 10% of high-risk adults annually.", [["RSV infection", "DISEASE", 18, 31], ["RSV", "ORGANISM", 18, 21], ["adults", "ORGANISM", 99, 105], ["RSV", "SPECIES", 18, 21], ["one study", "TEST", 7, 16], ["RSV infection", "PROBLEM", 18, 31], ["RSV", "OBSERVATION_MODIFIER", 18, 21], ["infection", "OBSERVATION", 22, 31]]], ["Compared with influenza, ICU admissions were higher, and mortality was similar, at 7% to 8%.", [["influenza", "DISEASE", 14, 23], ["influenza", "PROBLEM", 14, 23]]], ["245 RSV also contributes to 5% to 10% of COPD exacerbations.", [["COPD", "DISEASE", 41, 45], ["RSV", "ORGANISM", 4, 7], ["RSV", "SPECIES", 4, 7], ["RSV", "PROBLEM", 4, 7], ["COPD exacerbations", "PROBLEM", 41, 59], ["RSV", "OBSERVATION", 4, 7], ["COPD", "OBSERVATION", 41, 45]]], ["258 Older patients with severe RSV infection had a longer period of viral shedding, higher levels of mucosal IL-6, and a higher frequency of circulating activated T cells compared with young patients with mild disease, 259 suggesting viral loads and inflammation may play a role in disease severity.Treatment and PreventionIn immunosuppressed children and adults, RSV, often nosocomially acquired, causes severe lower respiratory tract disease.", [["mucosal", "ANATOMY", 101, 108], ["T cells", "ANATOMY", 163, 170], ["lower respiratory tract", "ANATOMY", 412, 435], ["RSV infection", "DISEASE", 31, 44], ["inflammation", "DISEASE", 250, 262], ["RSV", "DISEASE", 364, 367], ["lower respiratory tract disease", "DISEASE", 412, 443], ["patients", "ORGANISM", 10, 18], ["RSV", "ORGANISM", 31, 34], ["IL-6", "GENE_OR_GENE_PRODUCT", 109, 113], ["T cells", "CELL", 163, 170], ["patients", "ORGANISM", 191, 199], ["children", "ORGANISM", 343, 351], ["adults", "ORGANISM", 356, 362], ["RSV", "ORGANISM", 364, 367], ["tract", "ORGANISM_SUBDIVISION", 430, 435], ["mucosal IL-6", "PROTEIN", 101, 113], ["circulating activated T cells", "CELL_TYPE", 141, 170], ["patients", "SPECIES", 10, 18], ["patients", "SPECIES", 191, 199], ["children", "SPECIES", 343, 351], ["RSV", "SPECIES", 31, 34], ["RSV", "SPECIES", 364, 367], ["severe RSV infection", "PROBLEM", 24, 44], ["viral shedding", "PROBLEM", 68, 82], ["mucosal IL", "TEST", 101, 111], ["circulating activated T cells", "PROBLEM", 141, 170], ["mild disease", "PROBLEM", 205, 217], ["viral loads", "PROBLEM", 234, 245], ["inflammation", "PROBLEM", 250, 262], ["disease severity", "PROBLEM", 282, 298], ["Treatment", "TREATMENT", 299, 308], ["RSV", "PROBLEM", 364, 367], ["severe lower respiratory tract disease", "PROBLEM", 405, 443], ["severe", "OBSERVATION_MODIFIER", 24, 30], ["RSV", "OBSERVATION_MODIFIER", 31, 34], ["infection", "OBSERVATION", 35, 44], ["mucosal IL", "ANATOMY", 101, 111], ["mild", "OBSERVATION_MODIFIER", 205, 209], ["disease", "OBSERVATION", 210, 217], ["viral loads", "OBSERVATION", 234, 245], ["inflammation", "OBSERVATION", 250, 262], ["severe", "OBSERVATION_MODIFIER", 405, 411], ["lower", "ANATOMY_MODIFIER", 412, 417], ["respiratory tract", "ANATOMY", 418, 435], ["disease", "OBSERVATION", 436, 443]]], ["Upper respiratory tract illness usually precedes the development of pneumonia, and complicating sinusitis and otitis media are common.", [["Upper respiratory tract", "ANATOMY", 0, 23], ["respiratory tract illness", "DISEASE", 6, 31], ["pneumonia", "DISEASE", 68, 77], ["sinusitis", "DISEASE", 96, 105], ["otitis", "DISEASE", 110, 116], ["tract", "ORGANISM_SUBDIVISION", 18, 23], ["Upper respiratory tract illness", "PROBLEM", 0, 31], ["pneumonia", "PROBLEM", 68, 77], ["sinusitis", "PROBLEM", 96, 105], ["otitis media", "PROBLEM", 110, 122], ["respiratory tract", "ANATOMY", 6, 23], ["pneumonia", "OBSERVATION", 68, 77], ["complicating", "UNCERTAINTY", 83, 95], ["sinusitis", "OBSERVATION", 96, 105], ["otitis", "OBSERVATION", 110, 116]]], ["Two thirds or more of the bone marrow transplant recipients that develop RSV pneumonia will die of the infection.Treatment and Prevention100% during outbreaks in day care centers and are commonly 20% to 50% in hospital staff and patients during epidemic periods.", [["bone marrow", "ANATOMY", 26, 37], ["RSV pneumonia", "DISEASE", 73, 86], ["infection", "DISEASE", 103, 112], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 26, 37], ["recipients", "ORGANISM", 49, 59], ["RSV", "ORGANISM", 73, 76], ["patients", "ORGANISM", 229, 237], ["patients", "SPECIES", 229, 237], ["RSV", "SPECIES", 73, 76], ["the bone marrow transplant recipients", "TREATMENT", 22, 59], ["RSV pneumonia", "PROBLEM", 73, 86], ["the infection", "PROBLEM", 99, 112], ["Treatment", "TREATMENT", 113, 122], ["Prevention", "TREATMENT", 127, 137], ["bone", "ANATOMY", 26, 30], ["marrow transplant", "OBSERVATION", 31, 48], ["RSV", "OBSERVATION_MODIFIER", 73, 76], ["pneumonia", "OBSERVATION", 77, 86], ["infection", "OBSERVATION", 103, 112]]], ["In the family setting, secondary infection develops in approximately one half of infants and up to one third of adult contacts after introduction of virus by an older sibling.", [["infection", "DISEASE", 33, 42], ["infants", "ORGANISM", 81, 88], ["infants", "SPECIES", 81, 88], ["secondary infection", "PROBLEM", 23, 42], ["introduction of virus", "TREATMENT", 133, 154], ["secondary", "OBSERVATION_MODIFIER", 23, 32], ["infection", "OBSERVATION", 33, 42]]], ["246 Pathogenesis Viral replication generally begins in the upper respiratory tract with gradual (4-to 5-day) progression to involve the lower respiratory tract.", [["upper respiratory tract", "ANATOMY", 59, 82], ["lower respiratory tract", "ANATOMY", 136, 159], ["upper respiratory", "ORGANISM_SUBDIVISION", 59, 76], ["tract", "ORGANISM_SUBDIVISION", 77, 82], ["lower", "ORGANISM_SUBDIVISION", 136, 141], ["respiratory tract", "ORGANISM_SUBDIVISION", 142, 159], ["Pathogenesis Viral replication", "PROBLEM", 4, 34], ["progression to involve the lower respiratory tract", "PROBLEM", 109, 159], ["Viral replication", "OBSERVATION", 17, 34], ["upper", "ANATOMY_MODIFIER", 59, 64], ["respiratory tract", "ANATOMY", 65, 82], ["gradual", "OBSERVATION_MODIFIER", 88, 95], ["lower", "ANATOMY_MODIFIER", 136, 141], ["respiratory tract", "ANATOMY", 142, 159]]], ["In children with normal immunity, the duration of viral shedding ranges from 1 to 3 weeks.", [["children", "ORGANISM", 3, 11], ["children", "SPECIES", 3, 11], ["normal immunity", "OBSERVATION_MODIFIER", 17, 32]]], ["Clinical signs of bronchiolitis include airway trapping and wheezing.", [["airway", "ANATOMY", 40, 46], ["bronchiolitis", "DISEASE", 18, 31], ["wheezing", "DISEASE", 60, 68], ["airway", "MULTI-TISSUE_STRUCTURE", 40, 46], ["bronchiolitis", "PROBLEM", 18, 31], ["airway trapping", "PROBLEM", 40, 55], ["wheezing", "PROBLEM", 60, 68], ["bronchiolitis", "OBSERVATION", 18, 31], ["airway trapping", "OBSERVATION", 40, 55], ["wheezing", "OBSERVATION", 60, 68]]], ["Pathologic findings in RSV bronchiolitis include necrosis of bronchiolar epithelium, loss of ciliated epithelial cells, and marked peribronchiolar mononuclear inflammation.", [["bronchiolar epithelium", "ANATOMY", 61, 83], ["ciliated epithelial cells", "ANATOMY", 93, 118], ["peribronchiolar mononuclear", "ANATOMY", 131, 158], ["bronchiolitis", "DISEASE", 27, 40], ["necrosis", "DISEASE", 49, 57], ["mononuclear inflammation", "DISEASE", 147, 171], ["RSV", "ORGANISM", 23, 26], ["bronchiolar epithelium", "TISSUE", 61, 83], ["ciliated epithelial cells", "CELL", 93, 118], ["peribronchiolar mononuclear", "CELL", 131, 158], ["ciliated epithelial cells", "CELL_TYPE", 93, 118], ["RSV", "SPECIES", 23, 26], ["Pathologic findings", "TEST", 0, 19], ["RSV bronchiolitis", "PROBLEM", 23, 40], ["necrosis", "PROBLEM", 49, 57], ["bronchiolar epithelium", "PROBLEM", 61, 83], ["loss of ciliated epithelial cells", "PROBLEM", 85, 118], ["marked peribronchiolar mononuclear inflammation", "PROBLEM", 124, 171], ["RSV bronchiolitis", "OBSERVATION", 23, 40], ["necrosis", "OBSERVATION", 49, 57], ["bronchiolar epithelium", "OBSERVATION", 61, 83], ["loss", "OBSERVATION_MODIFIER", 85, 89], ["ciliated", "ANATOMY_MODIFIER", 93, 101], ["epithelial cells", "OBSERVATION", 102, 118], ["marked", "OBSERVATION_MODIFIER", 124, 130], ["peribronchiolar mononuclear inflammation", "OBSERVATION", 131, 171]]], ["247 Virus-induced cytopathology and associated submucosal edema lead to obstruction of smaller bronchioles, particularly in infants, with distal collapse or air trapping.Treatment and PreventionBoth serum and mucosal antibody responses are seen but are associated with limited protection.", [["submucosal edema", "ANATOMY", 47, 63], ["bronchioles", "ANATOMY", 95, 106], ["serum", "ANATOMY", 199, 204], ["mucosal", "ANATOMY", 209, 216], ["submucosal edema", "DISEASE", 47, 63], ["Virus", "ORGANISM", 4, 9], ["submucosal edema", "PATHOLOGICAL_FORMATION", 47, 63], ["bronchioles", "MULTI-TISSUE_STRUCTURE", 95, 106], ["infants", "ORGANISM", 124, 131], ["serum", "ORGANISM_SUBSTANCE", 199, 204], ["mucosal", "ORGAN", 209, 216], ["infants", "SPECIES", 124, 131], ["Virus", "PROBLEM", 4, 9], ["submucosal edema", "PROBLEM", 47, 63], ["obstruction of smaller bronchioles", "PROBLEM", 72, 106], ["distal collapse", "PROBLEM", 138, 153], ["air trapping", "PROBLEM", 157, 169], ["Treatment", "TREATMENT", 170, 179], ["PreventionBoth serum", "TEST", 184, 204], ["mucosal antibody responses", "TEST", 209, 235], ["submucosal", "ANATOMY_MODIFIER", 47, 57], ["edema", "OBSERVATION", 58, 63], ["obstruction", "OBSERVATION", 72, 83], ["smaller", "OBSERVATION_MODIFIER", 87, 94], ["bronchioles", "ANATOMY", 95, 106], ["distal", "OBSERVATION_MODIFIER", 138, 144], ["collapse", "OBSERVATION", 145, 153], ["air trapping", "OBSERVATION", 157, 169], ["mucosal antibody", "ANATOMY", 209, 225]]], ["The magnitude of the antibody response is related to the age at primary infection, with infants younger than 8 months having approximately 10-fold lower antibody levels than older ones.", [["primary infection", "DISEASE", 64, 81], ["infants", "ORGANISM", 88, 95], ["infants", "SPECIES", 88, 95], ["the antibody response", "PROBLEM", 17, 38], ["primary infection", "PROBLEM", 64, 81], ["magnitude", "OBSERVATION_MODIFIER", 4, 13], ["antibody response", "OBSERVATION", 21, 38], ["infection", "OBSERVATION", 72, 81]]], ["248 Reinfection may take place within weeks after primary infection.", [["primary infection", "DISEASE", 50, 67], ["Reinfection", "PROBLEM", 4, 15], ["primary infection", "PROBLEM", 50, 67], ["Reinfection", "OBSERVATION", 4, 15], ["infection", "OBSERVATION", 58, 67]]], ["244 Circulating and mucosal antibody levels increase with each successive infection and appear to be associated with milder illness.", [["mucosal", "ANATOMY", 20, 27], ["infection", "DISEASE", 74, 83], ["mucosal antibody", "GENE_OR_GENE_PRODUCT", 20, 36], ["Circulating and mucosal antibody levels", "TEST", 4, 43], ["each successive infection", "PROBLEM", 58, 83], ["milder illness", "PROBLEM", 117, 131], ["mucosal", "ANATOMY", 20, 27], ["antibody levels", "OBSERVATION", 28, 43], ["infection", "OBSERVATION", 74, 83], ["appear to be associated with", "UNCERTAINTY", 88, 116], ["milder", "OBSERVATION_MODIFIER", 117, 123], ["illness", "OBSERVATION", 124, 131]]], ["High titers of serum neutralizing antibody are generally associated with a lower risk of severe illness in infants and children.", [["serum", "ANATOMY", 15, 20], ["illness", "DISEASE", 96, 103], ["serum", "ORGANISM_SUBSTANCE", 15, 20], ["infants", "ORGANISM", 107, 114], ["children", "ORGANISM", 119, 127], ["serum neutralizing antibody", "PROTEIN", 15, 42], ["infants", "SPECIES", 107, 114], ["children", "SPECIES", 119, 127], ["High titers of serum neutralizing antibody", "PROBLEM", 0, 42], ["severe illness", "PROBLEM", 89, 103], ["neutralizing antibody", "OBSERVATION", 21, 42], ["severe", "OBSERVATION_MODIFIER", 89, 95], ["illness", "OBSERVATION", 96, 103]]], ["249 Cell-mediated immunity appears to be important in viral clearance and may also be involved in pathogenesis.", [["Cell", "ANATOMY", 4, 8], ["Cell", "CELL", 4, 8]]], ["For example, adult bone marrow transplant patients are at high risk of severe lower respiratory disease from RSV which is likely due to prolonged periods of decreased cellular immunity.", [["bone marrow", "ANATOMY", 19, 30], ["respiratory", "ANATOMY", 84, 95], ["cellular", "ANATOMY", 167, 175], ["lower respiratory disease", "DISEASE", 78, 103], ["RSV", "DISEASE", 109, 112], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 19, 30], ["patients", "ORGANISM", 42, 50], ["RSV", "ORGANISM", 109, 112], ["cellular", "CELL", 167, 175], ["patients", "SPECIES", 42, 50], ["RSV", "SPECIES", 109, 112], ["adult bone marrow transplant", "TREATMENT", 13, 41], ["severe lower respiratory disease", "PROBLEM", 71, 103], ["RSV", "PROBLEM", 109, 112], ["decreased cellular immunity", "PROBLEM", 157, 184], ["bone", "ANATOMY", 19, 23], ["marrow transplant", "OBSERVATION", 24, 41], ["severe", "OBSERVATION_MODIFIER", 71, 77], ["lower", "ANATOMY_MODIFIER", 78, 83], ["respiratory", "ANATOMY", 84, 95], ["disease", "OBSERVATION", 96, 103], ["RSV", "OBSERVATION", 109, 112], ["likely due to", "UNCERTAINTY", 122, 135], ["decreased cellular immunity", "OBSERVATION", 157, 184]]], ["250, 251 In contrast, AIDS patients with decreased cellular immunity may suffer only mild disease, but viral shedding can continue for up to 6 months.", [["cellular", "ANATOMY", 51, 59], ["AIDS", "DISEASE", 22, 26], ["patients", "ORGANISM", 27, 35], ["cellular", "CELL", 51, 59], ["patients", "SPECIES", 27, 35], ["decreased cellular immunity", "PROBLEM", 41, 68], ["mild disease", "PROBLEM", 85, 97], ["viral shedding", "PROBLEM", 103, 117], ["mild", "OBSERVATION_MODIFIER", 85, 89], ["disease", "OBSERVATION", 90, 97]]], ["252 Studies investigating the association of severe RSV disease in infants with genetic polymorphisms have implicated several candidate innate and adaptive immune genes including surfactants, TLR4, and several cytokine and chemokine genes as modulating the severity of RSV disease.Clinical IllnessThe clinical manifestations of infection depend on both the age and immunologic state of the host.", [["RSV disease", "DISEASE", 52, 63], ["RSV disease", "DISEASE", 269, 280], ["infection", "DISEASE", 328, 337], ["RSV", "ORGANISM", 52, 55], ["infants", "ORGANISM", 67, 74], ["TLR4", "GENE_OR_GENE_PRODUCT", 192, 196], ["RSV", "ORGANISM", 269, 272], ["immune genes", "DNA", 156, 168], ["TLR4", "DNA", 192, 196], ["cytokine and chemokine genes", "DNA", 210, 238], ["infants", "SPECIES", 67, 74], ["RSV", "SPECIES", 52, 55], ["RSV", "SPECIES", 269, 272], ["severe RSV disease", "PROBLEM", 45, 63], ["genetic polymorphisms", "PROBLEM", 80, 101], ["adaptive immune genes", "TREATMENT", 147, 168], ["surfactants", "TREATMENT", 179, 190], ["TLR4", "TREATMENT", 192, 196], ["several cytokine and chemokine genes", "TREATMENT", 202, 238], ["RSV disease", "PROBLEM", 269, 280], ["Clinical Illness", "PROBLEM", 281, 297], ["infection", "PROBLEM", 328, 337], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["RSV disease", "OBSERVATION", 52, 63], ["RSV disease", "OBSERVATION", 269, 280], ["infection", "OBSERVATION", 328, 337]]], ["In infants and young children, upper respiratory illness accompanied by fever and otitis media is common.", [["respiratory", "ANATOMY", 37, 48], ["respiratory illness", "DISEASE", 37, 56], ["fever", "DISEASE", 72, 77], ["otitis media", "DISEASE", 82, 94], ["infants", "ORGANISM", 3, 10], ["children", "ORGANISM", 21, 29], ["infants", "SPECIES", 3, 10], ["children", "SPECIES", 21, 29], ["upper respiratory illness", "PROBLEM", 31, 56], ["fever", "PROBLEM", 72, 77], ["otitis media", "PROBLEM", 82, 94], ["upper", "ANATOMY_MODIFIER", 31, 36], ["respiratory", "ANATOMY", 37, 48], ["illness", "OBSERVATION", 49, 56], ["fever", "OBSERVATION", 72, 77], ["otitis", "OBSERVATION", 82, 88]]], ["RSV is the major cause of lower respiratory tract illness in infants and young children and accounts for 45% to 90% of bronchiolitis, up to 40% of pneumonia, and smaller proportions of croup and bronchitis cases in this age group.", [["lower respiratory tract", "ANATOMY", 26, 49], ["RSV", "DISEASE", 0, 3], ["lower respiratory tract illness", "DISEASE", 26, 57], ["bronchiolitis", "DISEASE", 119, 132], ["pneumonia", "DISEASE", 147, 156], ["croup", "DISEASE", 185, 190], ["bronchitis", "DISEASE", 195, 205], ["RSV", "ORGANISM", 0, 3], ["lower", "ORGANISM_SUBDIVISION", 26, 31], ["respiratory tract", "ORGANISM_SUBDIVISION", 32, 49], ["infants", "ORGANISM", 61, 68], ["children", "ORGANISM", 79, 87], ["infants", "SPECIES", 61, 68], ["children", "SPECIES", 79, 87], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3], ["lower respiratory tract illness", "PROBLEM", 26, 57], ["bronchiolitis", "PROBLEM", 119, 132], ["pneumonia", "PROBLEM", 147, 156], ["croup and bronchitis cases", "PROBLEM", 185, 211], ["lower", "ANATOMY_MODIFIER", 26, 31], ["respiratory tract", "ANATOMY", 32, 49], ["bronchiolitis", "OBSERVATION", 119, 132], ["pneumonia", "OBSERVATION", 147, 156], ["smaller", "OBSERVATION_MODIFIER", 162, 169], ["proportions", "OBSERVATION_MODIFIER", 170, 181], ["croup", "OBSERVATION", 185, 190], ["bronchitis", "OBSERVATION", 195, 205]]], ["Most severe infections are seen in infants younger than 6 months, and almost all primary infections are symptomatic, with 40% or more associated with bronchiolitis or pneumonia.", [["infections", "DISEASE", 12, 22], ["primary infections", "DISEASE", 81, 99], ["bronchiolitis", "DISEASE", 150, 163], ["pneumonia", "DISEASE", 167, 176], ["infants", "ORGANISM", 35, 42], ["infants", "SPECIES", 35, 42], ["Most severe infections", "PROBLEM", 0, 22], ["all primary infections", "PROBLEM", 77, 99], ["symptomatic", "PROBLEM", 104, 115], ["bronchiolitis", "PROBLEM", 150, 163], ["pneumonia", "PROBLEM", 167, 176], ["severe", "OBSERVATION_MODIFIER", 5, 11], ["infections", "OBSERVATION", 12, 22], ["primary", "OBSERVATION_MODIFIER", 81, 88], ["infections", "OBSERVATION", 89, 99], ["symptomatic", "OBSERVATION_MODIFIER", 104, 115], ["bronchiolitis", "OBSERVATION", 150, 163], ["pneumonia", "OBSERVATION", 167, 176]]], ["Approximately 1% to 2% of infections result in hospitalization, and about one in ten hospitalized infants require mechanical ventilatory support.Clinical IllnessThe risk of hospitalization and severe bronchiolitis is particularly high in infants with congenital heart disease, chronic lung disease, or immunodeficiency.", [["heart", "ANATOMY", 262, 267], ["lung", "ANATOMY", 285, 289], ["infections", "DISEASE", 26, 36], ["bronchiolitis", "DISEASE", 200, 213], ["congenital heart disease", "DISEASE", 251, 275], ["chronic lung disease", "DISEASE", 277, 297], ["immunodeficiency", "DISEASE", 302, 318], ["infants", "ORGANISM", 98, 105], ["infants", "ORGANISM", 238, 245], ["heart", "ORGAN", 262, 267], ["lung", "ORGAN", 285, 289], ["infants", "SPECIES", 98, 105], ["infants", "SPECIES", 238, 245], ["infections", "PROBLEM", 26, 36], ["mechanical ventilatory support", "TREATMENT", 114, 144], ["severe bronchiolitis", "PROBLEM", 193, 213], ["congenital heart disease", "PROBLEM", 251, 275], ["chronic lung disease", "PROBLEM", 277, 297], ["immunodeficiency", "PROBLEM", 302, 318], ["infections", "OBSERVATION", 26, 36], ["mechanical ventilatory support", "OBSERVATION", 114, 144], ["severe", "OBSERVATION_MODIFIER", 193, 199], ["bronchiolitis", "OBSERVATION", 200, 213], ["high", "OBSERVATION_MODIFIER", 230, 234], ["heart", "ANATOMY", 262, 267], ["disease", "OBSERVATION", 268, 275], ["chronic", "OBSERVATION_MODIFIER", 277, 284], ["lung", "ANATOMY", 285, 289], ["disease", "OBSERVATION", 290, 297], ["immunodeficiency", "OBSERVATION", 302, 318]]], ["In addition, In contrast to the earlier vaccine experience, passive transfer of antibody to the RSV F protein has been shown to be a highly effective means to prevent RSV morbidity in high-risk children.", [["RSV", "ORGANISM", 96, 99], ["F", "GENE_OR_GENE_PRODUCT", 100, 101], ["RSV", "ORGANISM", 167, 170], ["children", "ORGANISM", 194, 202], ["RSV F protein", "PROTEIN", 96, 109], ["children", "SPECIES", 194, 202], ["RSV", "SPECIES", 96, 99], ["RSV", "SPECIES", 167, 170], ["passive transfer of antibody", "TREATMENT", 60, 88], ["RSV morbidity", "PROBLEM", 167, 180]]], ["The currently commercially available product, palivizumab, is a humanized monoclonal antibody to the F protein.", [["palivizumab", "CHEMICAL", 46, 57], ["palivizumab", "CHEMICAL", 46, 57], ["palivizumab", "SIMPLE_CHEMICAL", 46, 57], ["F protein", "GENE_OR_GENE_PRODUCT", 101, 110], ["humanized monoclonal antibody", "PROTEIN", 64, 93], ["F protein", "PROTEIN", 101, 110], ["palivizumab", "TREATMENT", 46, 57], ["a humanized monoclonal antibody", "TREATMENT", 62, 93]]], ["272 Administration of palivizumab to infants with prematurity or bronchopulmonary dysplasia resulted in a 55% reduction in RSV-related hospitalizations and a lower incidence of ICU admissions.", [["bronchopulmonary dysplasia", "ANATOMY", 65, 91], ["palivizumab", "CHEMICAL", 22, 33], ["prematurity", "DISEASE", 50, 61], ["bronchopulmonary dysplasia", "DISEASE", 65, 91], ["RSV", "DISEASE", 123, 126], ["palivizumab", "ORGANISM", 22, 33], ["infants", "ORGANISM", 37, 44], ["bronchopulmonary dysplasia", "PATHOLOGICAL_FORMATION", 65, 91], ["RSV", "ORGANISM", 123, 126], ["infants", "SPECIES", 37, 44], ["RSV", "SPECIES", 123, 126], ["palivizumab", "TREATMENT", 22, 33], ["prematurity", "PROBLEM", 50, 61], ["bronchopulmonary dysplasia", "PROBLEM", 65, 91], ["a 55% reduction", "TREATMENT", 104, 119], ["RSV", "PROBLEM", 123, 126], ["bronchopulmonary", "ANATOMY", 65, 81], ["dysplasia", "OBSERVATION", 82, 91], ["RSV", "OBSERVATION", 123, 126]]], ["273 In a second trial, administration of palivizumab to infants and children with hemodynamically significant congenital heart disease was well tolerated and resulted in a 45% decrease in RSVassociated hospitalizations.", [["heart", "ANATOMY", 121, 126], ["palivizumab", "CHEMICAL", 41, 52], ["congenital heart disease", "DISEASE", 110, 134], ["palivizumab", "ORGANISM", 41, 52], ["infants", "ORGANISM", 56, 63], ["children", "ORGANISM", 68, 76], ["heart", "ORGAN", 121, 126], ["infants", "SPECIES", 56, 63], ["children", "SPECIES", 68, 76], ["palivizumab", "TREATMENT", 41, 52], ["hemodynamically significant congenital heart disease", "PROBLEM", 82, 134], ["a 45% decrease in RSVassociated hospitalizations", "PROBLEM", 170, 218], ["significant", "OBSERVATION_MODIFIER", 98, 109], ["congenital", "OBSERVATION", 110, 120], ["heart", "ANATOMY", 121, 126], ["disease", "OBSERVATION", 127, 134]]], ["274 Prophylaxis with palivizumab should be considered for infants younger than 24 months with chronic lung disease severe enough to require medical therapy within 6 months of the anticipated start of the RSV season.", [["lung", "ANATOMY", 102, 106], ["palivizumab", "CHEMICAL", 21, 32], ["chronic lung disease", "DISEASE", 94, 114], ["palivizumab", "ORGANISM", 21, 32], ["infants", "ORGANISM", 58, 65], ["lung", "ORGAN", 102, 106], ["RSV", "ORGANISM", 204, 207], ["infants", "SPECIES", 58, 65], ["RSV", "SPECIES", 204, 207], ["Prophylaxis", "TREATMENT", 4, 15], ["palivizumab", "TREATMENT", 21, 32], ["chronic lung disease", "PROBLEM", 94, 114], ["medical therapy", "TREATMENT", 140, 155], ["lung", "ANATOMY", 102, 106], ["disease", "OBSERVATION", 107, 114]]], ["275 Prophylaxis with palivizumab (and not RSV-IVIG) should be given to infants with hemodynamically significant congenital heart disease and infants born before 32 weeks of gestation.", [["heart", "ANATOMY", 123, 128], ["palivizumab", "CHEMICAL", 21, 32], ["congenital heart disease", "DISEASE", 112, 136], ["palivizumab", "ORGANISM", 21, 32], ["RSV", "ORGANISM", 42, 45], ["infants", "ORGANISM", 71, 78], ["heart", "ORGAN", 123, 128], ["infants", "ORGANISM", 141, 148], ["infants", "SPECIES", 71, 78], ["infants", "SPECIES", 141, 148], ["RSV", "SPECIES", 42, 45], ["Prophylaxis", "TREATMENT", 4, 15], ["palivizumab", "TREATMENT", 21, 32], ["RSV", "TREATMENT", 42, 45], ["IVIG", "TREATMENT", 46, 50], ["hemodynamically significant congenital heart disease", "PROBLEM", 84, 136], ["significant", "OBSERVATION_MODIFIER", 100, 111], ["congenital", "OBSERVATION", 112, 122], ["heart", "ANATOMY", 123, 128], ["disease", "OBSERVATION", 129, 136]]], ["Prophylaxis for infants between 32 and 35 weeks of gestation depends on the presence of other RSV risk factors, such as exposure to tobacco smoke, attendance at day care, schoolaged siblings in the household, and congenital airway abnormalities.", [["airway", "ANATOMY", 224, 230], ["smoke", "CHEMICAL", 140, 145], ["congenital airway abnormalities", "DISEASE", 213, 244], ["infants", "ORGANISM", 16, 23], ["RSV", "ORGANISM", 94, 97], ["tobacco", "ORGANISM", 132, 139], ["airway", "MULTI-TISSUE_STRUCTURE", 224, 230], ["infants", "SPECIES", 16, 23], ["RSV", "SPECIES", 94, 97], ["tobacco", "SPECIES", 132, 139], ["Prophylaxis", "TREATMENT", 0, 11], ["gestation depends", "PROBLEM", 51, 68], ["other RSV risk factors", "PROBLEM", 88, 110], ["congenital airway abnormalities", "PROBLEM", 213, 244], ["congenital", "OBSERVATION", 213, 223], ["airway", "ANATOMY", 224, 230], ["abnormalities", "OBSERVATION", 231, 244]]], ["Palivizumab has not been shown to be effective in the therapy of established RSV disease.Clinical IllnessRecommendations for interruption of nosocomial transmission include handwashing, decontamination of surfaces and inanimate objects, and isolation of infected patients.", [["Palivizumab", "CHEMICAL", 0, 11], ["RSV disease", "DISEASE", 77, 88], ["nosocomial transmission", "DISEASE", 141, 164], ["Palivizumab", "CHEMICAL", 0, 11], ["Palivizumab", "SIMPLE_CHEMICAL", 0, 11], ["RSV", "ORGANISM", 77, 80], ["patients", "ORGANISM", 263, 271], ["patients", "SPECIES", 263, 271], ["RSV", "SPECIES", 77, 80], ["Palivizumab", "TREATMENT", 0, 11], ["established RSV disease", "PROBLEM", 65, 88], ["nosocomial transmission", "TREATMENT", 141, 164], ["handwashing", "TREATMENT", 173, 184], ["decontamination of surfaces", "TREATMENT", 186, 213], ["RSV", "OBSERVATION", 77, 80], ["inanimate objects", "OBSERVATION", 218, 235], ["infected", "OBSERVATION_MODIFIER", 254, 262]]], ["Use of disposable eye-nose goggles by pediatric staff reduces the risk of nosocomial RSV infection in both staff and patients.", [["RSV infection", "DISEASE", 85, 98], ["RSV", "ORGANISM", 85, 88], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["RSV", "SPECIES", 85, 88], ["disposable eye-nose goggles", "TREATMENT", 7, 34], ["nosocomial RSV infection", "PROBLEM", 74, 98], ["nosocomial RSV infection", "OBSERVATION", 74, 98]]], ["276 Regular use of gowns, gloves, and possibly masks by hospital staff caring for infected children may also reduce the risk of nosocomial RSV spread.", [["RSV", "DISEASE", 139, 142], ["children", "ORGANISM", 91, 99], ["RSV", "ORGANISM", 139, 142], ["children", "SPECIES", 91, 99], ["RSV", "SPECIES", 139, 142], ["gowns", "TREATMENT", 19, 24], ["gloves", "TREATMENT", 26, 32], ["nosocomial RSV spread", "PROBLEM", 128, 149], ["nosocomial RSV spread", "OBSERVATION", 128, 149]]], ["Protective isolation of high-risk infants or deferring their elective admission has been recommended during institutional outbreaks of RSV.RHINOVIRUSRhinoviruses (RVs) are species in the Enterovirus genus in the Picornaviridae family.", [["RSV", "DISEASE", 135, 138], ["infants", "ORGANISM", 34, 41], ["RSV", "ORGANISM", 135, 138], ["Enterovirus genus", "ORGANISM", 187, 204], ["infants", "SPECIES", 34, 41], ["RSV", "SPECIES", 135, 138], ["Protective isolation", "TREATMENT", 0, 20], ["RSV", "PROBLEM", 135, 138], ["RHINOVIRUSRhinoviruses (RVs)", "PROBLEM", 139, 167], ["species", "PROBLEM", 172, 179], ["the Enterovirus genus", "PROBLEM", 183, 204], ["high", "OBSERVATION_MODIFIER", 24, 28], ["Enterovirus genus", "OBSERVATION", 187, 204]]], ["The RV virion is a nonenveloped particle 30 nm in diameter with four major structural proteins.", [["structural proteins", "PROTEIN", 75, 94], ["RV virion", "ANATOMY", 4, 13], ["nonenveloped", "OBSERVATION_MODIFIER", 19, 31], ["particle", "OBSERVATION_MODIFIER", 32, 40], ["30 nm", "OBSERVATION_MODIFIER", 41, 46], ["major", "OBSERVATION_MODIFIER", 69, 74], ["structural proteins", "OBSERVATION", 75, 94]]], ["The genome of RV consists of single-stranded RNA of approximately 2.5 \u00d7 10 6 daltons and codes for a 240 kD protein that is cleaved into the structural units of the virion.", [["virion", "ANATOMY", 165, 171], ["virion", "CELLULAR_COMPONENT", 165, 171], ["RV", "DNA", 14, 16], ["single-stranded RNA", "RNA", 29, 48], ["240 kD protein", "PROTEIN", 101, 115], ["a 240 kD protein", "TREATMENT", 99, 115], ["RV", "ANATOMY", 14, 16], ["stranded RNA", "OBSERVATION_MODIFIER", 36, 48], ["virion", "ANATOMY", 165, 171]]], ["RV genomes have been found to have 45% to 62% homology with poliovirus genomes.", [["RV genomes", "DNA", 0, 10], ["poliovirus genomes", "DNA", 60, 78], ["poliovirus genomes", "PROBLEM", 60, 78], ["poliovirus genomes", "OBSERVATION", 60, 78]]], ["Poliovirus and RV differ, however, in the construction of their protein shells: that of RV being loosely packed with a resultant sensitivity to inactivation at low pH and that of poliovirus being tightly packed, providing the virion with resistance to acid inactivation.", [["Poliovirus", "ORGANISM", 0, 10], ["Poliovirus", "SPECIES", 0, 10], ["poliovirus", "SPECIES", 179, 189], ["Poliovirus", "PROBLEM", 0, 10], ["RV", "PROBLEM", 88, 90], ["a resultant sensitivity", "PROBLEM", 117, 140], ["low pH", "PROBLEM", 160, 166], ["poliovirus", "PROBLEM", 179, 189], ["the virion", "TREATMENT", 222, 232], ["acid inactivation", "TREATMENT", 252, 269], ["RV", "ANATOMY", 15, 17], ["RV", "ANATOMY", 88, 90], ["poliovirus", "OBSERVATION", 179, 189]]], ["The acid sensitivity of RV and its optimum growth at 32\u00b0 C to 34\u00b0 C are thought to account for its replication in the nasal passages (and possibly large airways) but not in the GI tract.RHINOVIRUSOn the basis of sequence data, rhinovirus are grouped into three genogroups: A, B, and C. 277 In addition, three of the four proteins in the RV shell (VP1, VP2, and VP3) react with neutralizing antibody, forming the basis on which more than 100 antigenic types have been numbered.", [["nasal passages", "ANATOMY", 118, 132], ["airways", "ANATOMY", 153, 160], ["GI tract", "ANATOMY", 177, 185], ["C", "GENE_OR_GENE_PRODUCT", 66, 67], ["airways", "MULTI-TISSUE_STRUCTURE", 153, 160], ["GI tract", "ORGANISM_SUBDIVISION", 177, 185], ["rhinovirus", "ORGANISM", 227, 237], ["B", "CELL", 276, 277], ["VP1", "GENE_OR_GENE_PRODUCT", 347, 350], ["VP2", "GENE_OR_GENE_PRODUCT", 352, 355], ["VP3", "GENE_OR_GENE_PRODUCT", 361, 364], ["RV shell", "PROTEIN", 337, 345], ["VP1", "PROTEIN", 347, 350], ["VP2", "PROTEIN", 352, 355], ["VP3", "PROTEIN", 361, 364], ["neutralizing antibody", "PROTEIN", 377, 398], ["The acid sensitivity", "TEST", 0, 20], ["RV", "TEST", 24, 26], ["its replication in the nasal passages", "PROBLEM", 95, 132], ["large airways)", "PROBLEM", 147, 161], ["sequence data", "TEST", 212, 225], ["rhinovirus", "PROBLEM", 227, 237], ["VP1", "TEST", 347, 350], ["VP2", "TEST", 352, 355], ["neutralizing antibody", "TEST", 377, 398], ["RV", "ANATOMY", 24, 26], ["thought to account for", "UNCERTAINTY", 72, 94], ["replication", "OBSERVATION", 99, 110], ["nasal passages", "ANATOMY", 118, 132], ["possibly", "UNCERTAINTY", 138, 146], ["large", "OBSERVATION_MODIFIER", 147, 152], ["airways", "ANATOMY", 153, 160], ["GI tract", "ANATOMY", 177, 185], ["RV", "ANATOMY", 337, 339], ["shell", "ANATOMY_MODIFIER", 340, 345], ["neutralizing antibody", "OBSERVATION", 377, 398]]], ["The presence of neutralizing antibody in serum and nasalDiagnosisThe most rapidly and readily available approach to establishing RSV infection is by rapid antigen detection.", [["serum", "ANATOMY", 41, 46], ["nasal", "ANATOMY", 51, 56], ["RSV infection", "DISEASE", 129, 142], ["serum", "ORGANISM_SUBSTANCE", 41, 46], ["nasal", "ORGAN", 51, 56], ["RSV", "ORGANISM", 129, 132], ["neutralizing antibody", "PROTEIN", 16, 37], ["RSV", "SPECIES", 129, 132], ["neutralizing antibody in serum and nasalDiagnosis", "PROBLEM", 16, 65], ["RSV infection", "PROBLEM", 129, 142], ["rapid antigen detection", "TEST", 149, 172], ["neutralizing", "OBSERVATION_MODIFIER", 16, 28], ["antibody", "OBSERVATION", 29, 37], ["nasal", "ANATOMY", 51, 56], ["RSV", "OBSERVATION", 129, 132]]], ["The sensitivity of such techniques is dependent on the quality of the nasopharyngeal specimen, with nasopharyngeal aspirates superior to brushings or swabs.", [["nasopharyngeal specimen", "ANATOMY", 70, 93], ["nasopharyngeal aspirates", "ANATOMY", 100, 124], ["brushings", "ANATOMY", 137, 146], ["swabs", "ANATOMY", 150, 155], ["nasopharyngeal specimen", "CANCER", 70, 93], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 100, 124], ["such techniques", "TEST", 19, 34], ["the nasopharyngeal specimen", "TEST", 66, 93], ["nasopharyngeal aspirates", "PROBLEM", 100, 124], ["brushings", "TEST", 137, 146], ["swabs", "TEST", 150, 155], ["nasopharyngeal", "ANATOMY", 70, 84], ["nasopharyngeal", "ANATOMY", 100, 114]]], ["260 In addition, sensitivity is related to the amount of antigen being shed, so it is generally greater in children than adults.", [["children", "ORGANISM", 107, 115], ["children", "SPECIES", 107, 115], ["greater", "OBSERVATION_MODIFIER", 96, 103]]], ["In transplant patients with suspected RSV pneumonia, samples of the lower respiratory tract by BAL are more sensitive than throat swabs for detection of RSV antigens.", [["samples", "ANATOMY", 53, 60], ["lower respiratory tract", "ANATOMY", 68, 91], ["BAL", "ANATOMY", 95, 98], ["throat swabs", "ANATOMY", 123, 135], ["RSV pneumonia", "DISEASE", 38, 51], ["patients", "ORGANISM", 14, 22], ["RSV", "ORGANISM", 38, 41], ["lower", "ORGANISM_SUBDIVISION", 68, 73], ["respiratory tract", "ORGANISM_SUBDIVISION", 74, 91], ["BAL", "ORGANISM_SUBSTANCE", 95, 98], ["RSV", "ORGANISM", 153, 156], ["RSV antigens", "PROTEIN", 153, 165], ["patients", "SPECIES", 14, 22], ["RSV", "SPECIES", 38, 41], ["RSV", "SPECIES", 153, 156], ["suspected RSV pneumonia", "PROBLEM", 28, 51], ["the lower respiratory tract", "PROBLEM", 64, 91], ["BAL", "TEST", 95, 98], ["throat swabs", "TEST", 123, 135], ["RSV antigens", "PROBLEM", 153, 165], ["suspected", "UNCERTAINTY", 28, 37], ["RSV", "OBSERVATION_MODIFIER", 38, 41], ["pneumonia", "OBSERVATION", 42, 51], ["lower", "ANATOMY_MODIFIER", 68, 73], ["respiratory tract", "ANATOMY", 74, 91]]], ["261 PCR-based respiratory viral multiplex assays for detection of RSV and other respiratory viruses have also been approved by the U.S. Food and Drug Administration and are becoming widely available 224a-d (see Chapter 17) .", [["respiratory viruses", "DISEASE", 80, 99], ["RSV", "ORGANISM", 66, 69], ["RSV", "SPECIES", 66, 69], ["PCR", "TEST", 4, 7], ["respiratory viral multiplex assays", "TEST", 14, 48], ["RSV", "PROBLEM", 66, 69], ["other respiratory viruses", "PROBLEM", 74, 99], ["RSV", "OBSERVATION", 66, 69], ["respiratory viruses", "OBSERVATION", 80, 99]]], ["RSV grows well in several human cell lines, in which it causes formation of characteristic syncytia.", [["cell lines", "ANATOMY", 32, 42], ["syncytia", "ANATOMY", 91, 99], ["RSV", "ORGANISM", 0, 3], ["human", "ORGANISM", 26, 31], ["cell lines", "CELL", 32, 42], ["syncytia", "CELL", 91, 99], ["human cell lines", "CELL_LINE", 26, 42], ["human", "SPECIES", 26, 31], ["RSV", "SPECIES", 0, 3], ["human", "SPECIES", 26, 31], ["RSV", "PROBLEM", 0, 3], ["several human cell lines", "TREATMENT", 18, 42], ["characteristic syncytia", "PROBLEM", 76, 99], ["several human", "OBSERVATION_MODIFIER", 18, 31], ["cell lines", "OBSERVATION", 32, 42], ["characteristic", "OBSERVATION_MODIFIER", 76, 90], ["syncytia", "OBSERVATION", 91, 99]]], ["Virus can be detected as early as 2 days and usually within 7 days on primary isolation from specimens collected from children.Treatment and PreventionCorrection of hypoxemia is the most important aspect of managing RSV lower respiratory tract disease.", [["specimens", "ANATOMY", 93, 102], ["lower respiratory tract", "ANATOMY", 220, 243], ["hypoxemia", "DISEASE", 165, 174], ["RSV lower respiratory tract disease", "DISEASE", 216, 251], ["Virus", "ORGANISM", 0, 5], ["specimens", "CANCER", 93, 102], ["children", "ORGANISM", 118, 126], ["RSV", "ORGANISM", 216, 219], ["tract", "ORGANISM_SUBDIVISION", 238, 243], ["children", "SPECIES", 118, 126], ["RSV", "SPECIES", 216, 219], ["Virus", "PROBLEM", 0, 5], ["primary isolation", "TREATMENT", 70, 87], ["Treatment", "TREATMENT", 127, 136], ["hypoxemia", "PROBLEM", 165, 174], ["managing RSV lower respiratory tract disease", "PROBLEM", 207, 251], ["hypoxemia", "OBSERVATION", 165, 174], ["respiratory tract disease", "OBSERVATION", 226, 251]]], ["Ribavirin is highly active against RSV in vitro, and aerosolized ribavirin has been shown to reduce viral shedding and shorten the course of illness in some but not all studies.", [["Ribavirin", "CHEMICAL", 0, 9], ["ribavirin", "CHEMICAL", 65, 74], ["illness", "DISEASE", 141, 148], ["Ribavirin", "CHEMICAL", 0, 9], ["ribavirin", "CHEMICAL", 65, 74], ["Ribavirin", "SIMPLE_CHEMICAL", 0, 9], ["RSV", "ORGANISM", 35, 38], ["ribavirin", "SIMPLE_CHEMICAL", 65, 74], ["RSV", "SPECIES", 35, 38], ["Ribavirin", "TREATMENT", 0, 9], ["RSV", "PROBLEM", 35, 38], ["aerosolized ribavirin", "TREATMENT", 53, 74], ["viral shedding", "PROBLEM", 100, 114], ["illness", "PROBLEM", 141, 148], ["active", "OBSERVATION_MODIFIER", 20, 26]]], ["Aerosolized ribavirin is currently recommended for use only in selected infants and young children who are at high risk for serious RSV disease.", [["ribavirin", "CHEMICAL", 12, 21], ["RSV disease", "DISEASE", 132, 143], ["ribavirin", "CHEMICAL", 12, 21], ["ribavirin", "SIMPLE_CHEMICAL", 12, 21], ["infants", "ORGANISM", 72, 79], ["children", "ORGANISM", 90, 98], ["RSV", "ORGANISM", 132, 135], ["infants", "SPECIES", 72, 79], ["children", "SPECIES", 90, 98], ["RSV", "SPECIES", 132, 135], ["Aerosolized ribavirin", "TREATMENT", 0, 21], ["serious RSV disease", "PROBLEM", 124, 143], ["ribavirin", "OBSERVATION", 12, 21], ["serious", "OBSERVATION_MODIFIER", 124, 131], ["RSV disease", "OBSERVATION", 132, 143]]], ["262 In immunosuppressed patients, particularly hematopoietic stem cell transplant recipients, both aerosolized ribavirin and high-dose oral ribavirin have been used for early treatment to prevent progression to pneumonia.", [["hematopoietic stem cell", "ANATOMY", 47, 70], ["oral", "ANATOMY", 135, 139], ["ribavirin", "CHEMICAL", 111, 120], ["ribavirin", "CHEMICAL", 140, 149], ["pneumonia", "DISEASE", 211, 220], ["ribavirin", "CHEMICAL", 111, 120], ["ribavirin", "CHEMICAL", 140, 149], ["patients", "ORGANISM", 24, 32], ["hematopoietic stem cell", "CELL", 47, 70], ["ribavirin", "SIMPLE_CHEMICAL", 111, 120], ["oral", "ORGANISM_SUBDIVISION", 135, 139], ["ribavirin", "SIMPLE_CHEMICAL", 140, 149], ["patients", "SPECIES", 24, 32], ["hematopoietic stem cell transplant recipients", "TREATMENT", 47, 92], ["both aerosolized ribavirin", "TREATMENT", 94, 120], ["high-dose oral ribavirin", "TREATMENT", 125, 149], ["early treatment", "TREATMENT", 169, 184], ["pneumonia", "PROBLEM", 211, 220], ["immunosuppressed", "OBSERVATION", 7, 23], ["hematopoietic stem cell transplant", "OBSERVATION", 47, 81], ["aerosolized", "OBSERVATION_MODIFIER", 99, 110], ["ribavirin", "OBSERVATION", 111, 120], ["pneumonia", "OBSERVATION", 211, 220]]], ["263 Recent studies suggest that intermittent aerosolized ribavirin is as effective as continuous aerosolized ribavirin in these patients.", [["ribavirin", "CHEMICAL", 57, 66], ["ribavirin", "CHEMICAL", 109, 118], ["ribavirin", "CHEMICAL", 57, 66], ["ribavirin", "CHEMICAL", 109, 118], ["ribavirin", "SIMPLE_CHEMICAL", 57, 66], ["ribavirin", "SIMPLE_CHEMICAL", 109, 118], ["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 128, 136], ["Recent studies", "TEST", 4, 18], ["intermittent aerosolized ribavirin", "TREATMENT", 32, 66], ["continuous aerosolized ribavirin", "TREATMENT", 86, 118], ["intermittent", "OBSERVATION_MODIFIER", 32, 44], ["aerosolized ribavirin", "OBSERVATION", 45, 66]]], ["264 Once RSV pneumonia has developed, intravenous ribavirin alone is ineffective but, if treatment is initiated before the onset of respiratory failure, combinations of aerosolized ribavirin with intravenous immunoglobulin, and particularly paluvizumab (see later) may be beneficial.", [["intravenous", "ANATOMY", 38, 49], ["respiratory", "ANATOMY", 132, 143], ["intravenous", "ANATOMY", 196, 207], ["RSV pneumonia", "DISEASE", 9, 22], ["ribavirin", "CHEMICAL", 50, 59], ["respiratory failure", "DISEASE", 132, 151], ["ribavirin", "CHEMICAL", 181, 190], ["paluvizumab", "CHEMICAL", 241, 252], ["ribavirin", "CHEMICAL", 50, 59], ["ribavirin", "CHEMICAL", 181, 190], ["paluvizumab", "CHEMICAL", 241, 252], ["RSV", "ORGANISM", 9, 12], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 38, 49], ["ribavirin", "SIMPLE_CHEMICAL", 50, 59], ["ribavirin", "SIMPLE_CHEMICAL", 181, 190], ["intravenous immunoglobulin", "SIMPLE_CHEMICAL", 196, 222], ["paluvizumab", "SIMPLE_CHEMICAL", 241, 252], ["intravenous immunoglobulin", "PROTEIN", 196, 222], ["RSV", "SPECIES", 9, 12], ["RSV pneumonia", "PROBLEM", 9, 22], ["intravenous ribavirin", "TREATMENT", 38, 59], ["treatment", "TREATMENT", 89, 98], ["respiratory failure", "PROBLEM", 132, 151], ["aerosolized ribavirin", "TREATMENT", 169, 190], ["intravenous immunoglobulin", "TREATMENT", 196, 222], ["RSV", "OBSERVATION_MODIFIER", 9, 12], ["pneumonia", "OBSERVATION", 13, 22], ["respiratory failure", "OBSERVATION", 132, 151]]], ["265, 266 In adults, short courses of systemic corticosteroids for RSV-related wheezing did not affect viral loads or shedding and only mildly diminished antibody responses.", [["corticosteroids", "CHEMICAL", 46, 61], ["RSV", "DISEASE", 66, 69], ["wheezing", "DISEASE", 78, 86], ["corticosteroids", "CHEMICAL", 46, 61], ["RSV", "ORGANISM", 66, 69], ["RSV", "SPECIES", 66, 69], ["systemic corticosteroids", "TREATMENT", 37, 61], ["RSV", "PROBLEM", 66, 69], ["wheezing", "PROBLEM", 78, 86], ["viral loads", "PROBLEM", 102, 113], ["shedding", "PROBLEM", 117, 125], ["mildly diminished antibody responses", "PROBLEM", 135, 171], ["mildly", "OBSERVATION_MODIFIER", 135, 141], ["diminished", "OBSERVATION", 142, 152]]], ["267 An effective vaccine for prevention of RSV has not yet been developed.", [["RSV", "DISEASE", 43, 46], ["RSV", "ORGANISM", 43, 46], ["RSV", "SPECIES", 43, 46], ["An effective vaccine", "TREATMENT", 4, 24], ["RSV", "PROBLEM", 43, 46], ["RSV", "OBSERVATION", 43, 46]]], ["In a study of formalin-inactivated RSV vaccine conducted in the 1960s, vaccinated infants developed more severe disease compared with unvaccinated children.", [["formalin", "CHEMICAL", 14, 22], ["formalin", "CHEMICAL", 14, 22], ["formalin", "SIMPLE_CHEMICAL", 14, 22], ["RSV", "ORGANISM", 35, 38], ["infants", "ORGANISM", 82, 89], ["children", "ORGANISM", 147, 155], ["infants", "SPECIES", 82, 89], ["children", "SPECIES", 147, 155], ["RSV", "SPECIES", 35, 38], ["a study of formalin", "TEST", 3, 22], ["RSV vaccine", "TREATMENT", 35, 46], ["more severe disease", "PROBLEM", 100, 119], ["severe", "OBSERVATION_MODIFIER", 105, 111], ["disease", "OBSERVATION", 112, 119]]], ["268 The mechanisms of this enhancement remain uncertain, although studies in those vaccine recipients and in rodent models have implicated low levels or low affinity of the antibodies induced by the formalin-inactivated vaccine, which permitted excessive cytolytic T-cell responses to develop and cause tissue damage.", [["T-cell", "ANATOMY", 265, 271], ["tissue", "ANATOMY", 303, 309], ["formalin", "CHEMICAL", 199, 207], ["tissue damage", "DISEASE", 303, 316], ["formalin", "CHEMICAL", 199, 207], ["recipients", "ORGANISM", 91, 101], ["formalin", "SIMPLE_CHEMICAL", 199, 207], ["T-cell", "CELL", 265, 271], ["tissue", "TISSUE", 303, 309], ["antibodies", "PROTEIN", 173, 183], ["this enhancement", "PROBLEM", 22, 38], ["those vaccine recipients", "TREATMENT", 77, 101], ["low levels", "PROBLEM", 139, 149], ["low affinity of the antibodies", "PROBLEM", 153, 183], ["the formalin-inactivated vaccine", "TREATMENT", 195, 227], ["tissue damage", "PROBLEM", 303, 316], ["low levels", "OBSERVATION_MODIFIER", 139, 149], ["low affinity", "OBSERVATION_MODIFIER", 153, 165], ["damage", "OBSERVATION", 310, 316]]], ["Low-affinity antibodies may also have contributed to immune complex formation and deposition, leading to local inflammation.", [["inflammation", "DISEASE", 111, 123], ["Low-affinity antibodies", "PROTEIN", 0, 23], ["Low-affinity antibodies", "PROBLEM", 0, 23], ["immune complex formation", "PROBLEM", 53, 77], ["local inflammation", "PROBLEM", 105, 123], ["local", "OBSERVATION_MODIFIER", 105, 110], ["inflammation", "OBSERVATION", 111, 123]]], ["269, 270 Formalin-inactivated RSV also primes a T helper 2 response, with high levels of interleukin 4 and interleukin 5, which can promote inflammation of small airways.", [["airways", "ANATOMY", 162, 169], ["inflammation", "DISEASE", 140, 152], ["RSV", "ORGANISM", 30, 33], ["T helper 2", "GENE_OR_GENE_PRODUCT", 48, 58], ["interleukin 4", "GENE_OR_GENE_PRODUCT", 89, 102], ["interleukin 5", "GENE_OR_GENE_PRODUCT", 107, 120], ["airways", "MULTI-TISSUE_STRUCTURE", 162, 169], ["interleukin 4", "PROTEIN", 89, 102], ["interleukin 5", "PROTEIN", 107, 120], ["RSV", "SPECIES", 30, 33], ["Formalin", "TEST", 9, 17], ["RSV", "PROBLEM", 30, 33], ["interleukin 4 and interleukin 5", "TREATMENT", 89, 120], ["inflammation of small airways", "PROBLEM", 140, 169], ["inflammation", "OBSERVATION", 140, 152], ["small", "OBSERVATION_MODIFIER", 156, 161], ["airways", "ANATOMY", 162, 169]]], ["271 Although this adverse experience has prompted extra caution, current RSV vaccine development efforts are ongoing and focus on live attenuated and recombinant subunit vaccines.Treatment and Preventionintroduce it into their homes, infecting other family members.", [["RSV", "ORGANISM", 73, 76], ["RSV", "SPECIES", 73, 76], ["extra caution", "TREATMENT", 50, 63], ["current RSV vaccine", "TREATMENT", 65, 84], ["recombinant subunit vaccines", "TREATMENT", 150, 178], ["Treatment", "TREATMENT", 179, 188]]], ["Studies of experimental RV colds in volunteers have shown that RV is most efficiently spread by contaminated fingers accidentally depositing virus into the nose or eye.", [["nose", "ANATOMY", 156, 160], ["eye", "ANATOMY", 164, 167], ["RV colds", "DISEASE", 24, 32], ["volunteers", "ORGANISM", 36, 46], ["fingers", "ORGANISM_SUBDIVISION", 109, 116], ["nose", "ORGAN", 156, 160], ["eye", "ORGAN", 164, 167], ["experimental RV colds in volunteers", "PROBLEM", 11, 46], ["RV", "PROBLEM", 63, 65], ["RV", "ANATOMY", 24, 26], ["colds", "OBSERVATION", 27, 32], ["RV", "ANATOMY", 63, 65], ["nose", "ANATOMY", 156, 160], ["eye", "ANATOMY", 164, 167]]], ["Experimental RV transmission has also been achieved by the airborne route, presumably by large-particle aerosol.", [["Experimental RV transmission", "TREATMENT", 0, 28], ["RV", "ANATOMY", 13, 15], ["large", "OBSERVATION_MODIFIER", 89, 94]]], ["The relative importance of these two routes of RV transmission under natural conditions has not been determined.PathogenesisApproximately two thirds of both natural and experimental RV infections result in overt illness.", [["RV infections", "DISEASE", 182, 195], ["RV", "MULTI-TISSUE_STRUCTURE", 47, 49], ["RV", "SPECIES", 182, 184], ["RV transmission", "TREATMENT", 47, 62], ["experimental RV infections", "PROBLEM", 169, 195], ["overt illness", "PROBLEM", 206, 219], ["thirds", "OBSERVATION_MODIFIER", 142, 148], ["both", "OBSERVATION_MODIFIER", 152, 156], ["natural", "OBSERVATION_MODIFIER", 157, 164], ["RV", "ANATOMY", 182, 184], ["infections", "OBSERVATION", 185, 195], ["overt", "OBSERVATION_MODIFIER", 206, 211], ["illness", "OBSERVATION", 212, 219]]], ["The incubation period of RV colds is usually 2 days but may be up to a week.", [["colds", "DISEASE", 28, 33], ["RV colds", "PROBLEM", 25, 33], ["RV", "ANATOMY", 25, 27], ["colds", "OBSERVATION", 28, 33]]], ["Symptoms begin within 1 day following experimental infection.", [["infection", "DISEASE", 51, 60], ["Symptoms", "PROBLEM", 0, 8], ["experimental infection", "PROBLEM", 38, 60], ["infection", "OBSERVATION", 51, 60]]], ["Small doses of RV instilled into the nose or eye of susceptible volunteers regularly lead to infection, indicating that mucociliary clearance is not effective against the virus.", [["RV", "ANATOMY", 15, 17], ["nose", "ANATOMY", 37, 41], ["eye", "ANATOMY", 45, 48], ["mucociliary", "ANATOMY", 120, 131], ["infection", "DISEASE", 93, 102], ["RV", "MULTI-TISSUE_STRUCTURE", 15, 17], ["nose", "ORGAN", 37, 41], ["eye", "ORGAN", 45, 48], ["volunteers", "ORGANISM", 64, 74], ["mucociliary", "ORGAN", 120, 131], ["RV instilled", "TREATMENT", 15, 27], ["susceptible volunteers", "PROBLEM", 52, 74], ["infection", "PROBLEM", 93, 102], ["mucociliary clearance", "PROBLEM", 120, 141], ["the virus", "PROBLEM", 167, 176], ["RV", "ANATOMY", 15, 17], ["instilled", "OBSERVATION", 18, 27], ["nose", "ANATOMY", 37, 41], ["eye", "ANATOMY", 45, 48], ["infection", "OBSERVATION", 93, 102]]], ["During the period of illness, sloughed ciliated epithelial cells containing viral antigen are present in nasal secretions.", [["epithelial cells", "ANATOMY", 48, 64], ["nasal secretions", "ANATOMY", 105, 121], ["ciliated epithelial cells", "CELL", 39, 64], ["viral antigen", "GENE_OR_GENE_PRODUCT", 76, 89], ["nasal secretions", "ORGANISM_SUBSTANCE", 105, 121], ["sloughed ciliated epithelial cells", "CELL_TYPE", 30, 64], ["viral antigen", "PROTEIN", 76, 89], ["illness", "PROBLEM", 21, 28], ["sloughed ciliated epithelial cells", "PROBLEM", 30, 64], ["viral antigen", "PROBLEM", 76, 89], ["nasal secretions", "PROBLEM", 105, 121], ["sloughed", "OBSERVATION_MODIFIER", 30, 38], ["ciliated epithelial cells", "OBSERVATION", 39, 64], ["viral antigen", "OBSERVATION", 76, 89], ["nasal", "ANATOMY", 105, 110], ["secretions", "OBSERVATION", 111, 121]]], ["281 In general, the number of RV-infected cells in the nasopharynx appears to be limited, 282 and infection does not lead to detectable damage to the epithelium of the nasal passages.", [["cells", "ANATOMY", 42, 47], ["nasopharynx", "ANATOMY", 55, 66], ["epithelium", "ANATOMY", 150, 160], ["nasal passages", "ANATOMY", 168, 182], ["infection", "DISEASE", 98, 107], ["RV", "CELL", 30, 32], ["cells", "CELL", 42, 47], ["nasopharynx", "ORGAN", 55, 66], ["epithelium", "TISSUE", 150, 160], ["nasal", "ORGAN", 168, 173], ["RV-infected cells", "CELL_TYPE", 30, 47], ["infected cells in the nasopharynx", "PROBLEM", 33, 66], ["infection", "PROBLEM", 98, 107], ["detectable damage to the epithelium of the nasal passages", "PROBLEM", 125, 182], ["RV", "ANATOMY", 30, 32], ["infected cells", "OBSERVATION", 33, 47], ["nasopharynx", "ANATOMY", 55, 66], ["appears to be", "UNCERTAINTY", 67, 80], ["infection", "OBSERVATION", 98, 107], ["damage", "OBSERVATION", 136, 142], ["epithelium", "ANATOMY_MODIFIER", 150, 160], ["nasal", "ANATOMY", 168, 173], ["passages", "OBSERVATION", 174, 182]]], ["These results have suggested that virus-induced cellular injury is not the direct cause of symptoms in RV colds and that inflammatory mediators play an important role.", [["cellular", "ANATOMY", 48, 56], ["cellular injury", "DISEASE", 48, 63], ["colds", "DISEASE", 106, 111], ["cellular", "CELL", 48, 56], ["inflammatory mediators", "PROTEIN", 121, 143], ["RV", "SPECIES", 103, 105], ["virus", "PROBLEM", 34, 39], ["cellular injury", "PROBLEM", 48, 63], ["symptoms", "PROBLEM", 91, 99], ["RV colds", "PROBLEM", 103, 111], ["inflammatory mediators", "PROBLEM", 121, 143], ["cellular injury", "OBSERVATION", 48, 63], ["RV", "ANATOMY", 103, 105], ["colds", "OBSERVATION", 106, 111], ["inflammatory", "OBSERVATION", 121, 133]]], ["Nasal secretions during the initial response to RV infection are predominantly the result of increased vascular permeability, as demonstrated by elevated levels of plasma proteins in nasal secretions.", [["Nasal secretions", "ANATOMY", 0, 16], ["vascular", "ANATOMY", 103, 111], ["plasma", "ANATOMY", 164, 170], ["nasal secretions", "ANATOMY", 183, 199], ["RV infection", "DISEASE", 48, 60], ["Nasal secretions", "MULTI-TISSUE_STRUCTURE", 0, 16], ["vascular", "MULTI-TISSUE_STRUCTURE", 103, 111], ["plasma", "ORGANISM_SUBSTANCE", 164, 170], ["nasal secretions", "ORGANISM_SUBSTANCE", 183, 199], ["plasma proteins", "PROTEIN", 164, 179], ["Nasal secretions", "PROBLEM", 0, 16], ["RV infection", "PROBLEM", 48, 60], ["increased vascular permeability", "PROBLEM", 93, 124], ["elevated levels of plasma proteins in nasal secretions", "PROBLEM", 145, 199], ["secretions", "OBSERVATION", 6, 16], ["RV", "ANATOMY", 48, 50], ["infection", "OBSERVATION", 51, 60], ["increased", "OBSERVATION_MODIFIER", 93, 102], ["vascular permeability", "OBSERVATION", 103, 124], ["elevated", "OBSERVATION_MODIFIER", 145, 153], ["nasal", "ANATOMY", 183, 188], ["secretions", "OBSERVATION", 189, 199]]], ["283 Glandular secretions (lactoferrin, lysozyme, and secretory IgA) predominate late in colds.", [["Glandular secretions", "ANATOMY", 4, 24], ["colds", "DISEASE", 88, 93], ["lactoferrin", "GENE_OR_GENE_PRODUCT", 26, 37], ["lysozyme", "GENE_OR_GENE_PRODUCT", 39, 47], ["IgA", "GENE_OR_GENE_PRODUCT", 63, 66], ["lactoferrin", "PROTEIN", 26, 37], ["lysozyme", "PROTEIN", 39, 47], ["secretory IgA", "PROTEIN", 53, 66], ["lactoferrin, lysozyme", "TREATMENT", 26, 47], ["secretory IgA)", "TREATMENT", 53, 67], ["secretions", "OBSERVATION", 14, 24]]], ["283 In contrast to the situation in allergic rhinitis, histamine does not appear to play a role in the induction of symptoms in colds.", [["allergic rhinitis", "DISEASE", 36, 53], ["histamine", "CHEMICAL", 55, 64], ["colds", "DISEASE", 128, 133], ["histamine", "CHEMICAL", 55, 64], ["histamine", "SIMPLE_CHEMICAL", 55, 64], ["allergic rhinitis", "PROBLEM", 36, 53], ["histamine", "TREATMENT", 55, 64], ["symptoms", "PROBLEM", 116, 124], ["colds", "PROBLEM", 128, 133], ["allergic rhinitis", "OBSERVATION", 36, 53]]], ["Nasal secretion kinin levels correlate with symptoms in natural and experimental colds, and intranasal administration of bradykinin causes increased nasal vascular permeability, rhinitis, and sore throat.", [["Nasal", "ANATOMY", 0, 5], ["nasal vascular", "ANATOMY", 149, 163], ["sore throat", "ANATOMY", 192, 203], ["colds", "DISEASE", 81, 86], ["bradykinin", "CHEMICAL", 121, 131], ["rhinitis", "DISEASE", 178, 186], ["sore throat", "DISEASE", 192, 203], ["bradykinin", "CHEMICAL", 121, 131], ["Nasal", "MULTI-TISSUE_STRUCTURE", 0, 5], ["kinin", "GENE_OR_GENE_PRODUCT", 16, 21], ["bradykinin", "SIMPLE_CHEMICAL", 121, 131], ["nasal vascular", "MULTI-TISSUE_STRUCTURE", 149, 163], ["throat", "ORGANISM_SUBDIVISION", 197, 203], ["Nasal secretion kinin levels", "TEST", 0, 28], ["symptoms", "PROBLEM", 44, 52], ["natural and experimental colds", "PROBLEM", 56, 86], ["intranasal administration", "TREATMENT", 92, 117], ["bradykinin", "TREATMENT", 121, 131], ["increased nasal vascular permeability", "PROBLEM", 139, 176], ["rhinitis", "PROBLEM", 178, 186], ["sore throat", "PROBLEM", 192, 203], ["increased", "OBSERVATION_MODIFIER", 139, 148], ["nasal vascular", "ANATOMY", 149, 163], ["permeability", "OBSERVATION", 164, 176], ["rhinitis", "OBSERVATION", 178, 186], ["sore throat", "ANATOMY", 192, 203]]], ["284 Interleukin (IL)-1, IL-6, and IL-8 concentrations also increase in experimental RV colds and correlate well with symptom severity.", [["colds", "DISEASE", 87, 92], ["Interleukin (IL)-1", "GENE_OR_GENE_PRODUCT", 4, 22], ["IL-6", "GENE_OR_GENE_PRODUCT", 24, 28], ["IL-8", "GENE_OR_GENE_PRODUCT", 34, 38], ["Interleukin (IL)", "TREATMENT", 4, 20], ["IL", "TREATMENT", 34, 36], ["experimental RV colds", "TREATMENT", 71, 92], ["symptom severity", "PROBLEM", 117, 133], ["increase", "OBSERVATION_MODIFIER", 59, 67], ["RV", "ANATOMY", 84, 86], ["colds", "OBSERVATION", 87, 92]]], ["285 Enhanced synthesis of proinflammatory cytokines and cell adhesion molecules in the middle ear may also contribute to the pathogenesis of otitis media associated with colds.", [["cell", "ANATOMY", 56, 60], ["middle ear", "ANATOMY", 87, 97], ["otitis media", "DISEASE", 141, 153], ["colds", "DISEASE", 170, 175], ["cell", "CELL", 56, 60], ["ear", "ORGAN", 94, 97], ["proinflammatory cytokines", "PROTEIN", 26, 51], ["cell adhesion molecules", "PROTEIN", 56, 79], ["proinflammatory cytokines", "TREATMENT", 26, 51], ["cell adhesion molecules", "TREATMENT", 56, 79], ["otitis media", "PROBLEM", 141, 153], ["colds", "PROBLEM", 170, 175], ["proinflammatory cytokines", "OBSERVATION", 26, 51], ["cell", "OBSERVATION", 56, 60], ["adhesion molecules", "OBSERVATION", 61, 79], ["middle ear", "ANATOMY", 87, 97], ["may also contribute to", "UNCERTAINTY", 98, 120], ["otitis", "OBSERVATION", 141, 147]]], ["286 Polymorphisms in the IL-6 gene affect the symptomatic response to experimental RV challenge in adults.", [["IL-6", "GENE_OR_GENE_PRODUCT", 25, 29], ["adults", "ORGANISM", 99, 105], ["IL-6 gene", "DNA", 25, 34], ["Polymorphisms in the IL", "TREATMENT", 4, 27], ["the symptomatic response", "PROBLEM", 42, 66], ["experimental RV challenge", "TREATMENT", 70, 95], ["RV", "ANATOMY", 83, 85]]], ["287Clinical IllnessRV colds vary in severity from mild episodes characterized by 1 to 2 days of coryza or scratchy throat to full-blown illnesses with profuse and prolonged rhinorrhea, pharyngitis, and bronchitis.", [["throat", "ANATOMY", 115, 121], ["colds", "DISEASE", 22, 27], ["rhinorrhea", "DISEASE", 173, 183], ["pharyngitis", "DISEASE", 185, 196], ["bronchitis", "DISEASE", 202, 212], ["throat", "ORGANISM_SUBDIVISION", 115, 121], ["IllnessRV colds", "PROBLEM", 12, 27], ["mild episodes", "PROBLEM", 50, 63], ["coryza", "PROBLEM", 96, 102], ["scratchy throat", "PROBLEM", 106, 121], ["full-blown illnesses", "PROBLEM", 125, 145], ["profuse and prolonged rhinorrhea", "PROBLEM", 151, 183], ["pharyngitis", "PROBLEM", 185, 196], ["bronchitis", "PROBLEM", 202, 212], ["mild", "OBSERVATION_MODIFIER", 50, 54], ["throat", "ANATOMY", 115, 121], ["blown illnesses", "OBSERVATION", 130, 145], ["profuse", "OBSERVATION_MODIFIER", 151, 158], ["prolonged", "OBSERVATION_MODIFIER", 163, 172], ["rhinorrhea", "OBSERVATION", 173, 183], ["pharyngitis", "OBSERVATION", 185, 196], ["bronchitis", "OBSERVATION", 202, 212]]], ["The profile of a typical RV cold, based on composite results from young adults with natural infection, is shown in Figure 32 -1.", [["natural infection", "DISEASE", 84, 101], ["a typical RV cold", "PROBLEM", 15, 32], ["natural infection", "PROBLEM", 84, 101], ["RV", "ANATOMY", 25, 27], ["cold", "OBSERVATION", 28, 32], ["infection", "OBSERVATION", 92, 101]]], ["The median length of illness is 1 week, with symptoms lasting up to 2 weeks in one quarter of cases.", [["illness", "DISEASE", 21, 28], ["symptoms", "PROBLEM", 45, 53], ["median", "OBSERVATION_MODIFIER", 4, 10], ["length", "OBSERVATION_MODIFIER", 11, 17], ["illness", "OBSERVATION", 21, 28]]], ["Peak symptoms are usually seen on the second and third days of illness.", [["Peak symptoms", "PROBLEM", 0, 13], ["illness", "PROBLEM", 63, 70]]], ["The characteristics of RV illness are not distinctive enough to permit their differentiation from colds due to other respiratory viruses.", [["RV illness", "DISEASE", 23, 33], ["colds", "DISEASE", 98, 103], ["respiratory viruses", "DISEASE", 117, 136], ["RV", "ORGAN", 23, 25], ["RV illness", "PROBLEM", 23, 33], ["colds", "PROBLEM", 98, 103], ["other respiratory viruses", "PROBLEM", 111, 136], ["RV", "ANATOMY", 23, 25], ["illness", "OBSERVATION", 26, 33], ["respiratory", "ANATOMY", 117, 128], ["viruses", "OBSERVATION", 129, 136]]], ["RV is among the respiratory viruses implicated in the development of acute sinusitis and represents about half of all viruses recovered from middle ear effusions in children with acute otitis media.", [["middle ear effusions", "ANATOMY", 141, 161], ["respiratory viruses", "DISEASE", 16, 35], ["sinusitis", "DISEASE", 75, 84], ["ear effusions", "DISEASE", 148, 161], ["otitis", "DISEASE", 185, 191], ["RV", "MULTI-TISSUE_STRUCTURE", 0, 2], ["ear", "ORGAN", 148, 151], ["children", "ORGANISM", 165, 173], ["children", "SPECIES", 165, 173], ["the respiratory viruses", "PROBLEM", 12, 35], ["acute sinusitis", "PROBLEM", 69, 84], ["all viruses", "PROBLEM", 114, 125], ["middle ear effusions", "PROBLEM", 141, 161], ["acute otitis media", "PROBLEM", 179, 197], ["respiratory viruses", "OBSERVATION", 16, 35], ["acute", "OBSERVATION_MODIFIER", 69, 74], ["sinusitis", "OBSERVATION", 75, 84], ["viruses", "OBSERVATION", 118, 125], ["middle", "ANATOMY_MODIFIER", 141, 147], ["ear", "ANATOMY", 148, 151], ["effusions", "OBSERVATION", 152, 161], ["acute", "OBSERVATION_MODIFIER", 179, 184], ["otitis", "OBSERVATION", 185, 191]]], ["288 Recently, a clinical presentation indistinguishable from that of influenza has also been reported in healthy adults.", [["influenza", "DISEASE", 69, 78], ["influenza", "PROBLEM", 69, 78], ["influenza", "OBSERVATION", 69, 78]]], ["289 secretions correlates with protection from infection.", [["secretions", "ANATOMY", 4, 14], ["infection", "DISEASE", 47, 56], ["infection", "PROBLEM", 47, 56], ["infection", "OBSERVATION", 47, 56]]], ["X-ray diffraction studies of RV have disclosed the presence of a large depression on the surface of the virus shell at a junction between the plateaus of the three proteins ( Fig. 32-10) .", [["surface", "ANATOMY", 89, 96], ["depression", "DISEASE", 71, 81], ["surface", "CELLULAR_COMPONENT", 89, 96], ["Fig. 32-10", "PROTEIN", 175, 185], ["X-ray diffraction studies", "TEST", 0, 25], ["RV", "TEST", 29, 31], ["a large depression", "PROBLEM", 63, 81], ["the virus shell", "PROBLEM", 100, 115], ["RV", "ANATOMY", 29, 31], ["large", "OBSERVATION_MODIFIER", 65, 70], ["depression", "OBSERVATION", 71, 81], ["surface", "OBSERVATION_MODIFIER", 89, 96], ["virus shell", "OBSERVATION", 104, 115], ["plateaus", "ANATOMY_MODIFIER", 142, 150]]], ["278 This depression contains the recognition site for the host cell receptor, intercellular adhesion molecule-1 (ICAM-1), which binds 91 of the 102 known rhinovirus serotypes.", [["cell", "ANATOMY", 63, 67], ["depression", "DISEASE", 9, 19], ["host cell receptor", "GENE_OR_GENE_PRODUCT", 58, 76], ["intercellular adhesion molecule-1", "GENE_OR_GENE_PRODUCT", 78, 111], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 113, 119], ["rhinovirus", "ORGANISM", 154, 164], ["host cell receptor", "PROTEIN", 58, 76], ["intercellular adhesion molecule-1", "PROTEIN", 78, 111], ["ICAM", "PROTEIN", 113, 117], ["This depression", "PROBLEM", 4, 19], ["intercellular adhesion molecule", "TEST", 78, 109], ["ICAM", "TEST", 113, 117], ["known rhinovirus serotypes", "PROBLEM", 148, 174], ["depression", "OBSERVATION", 9, 19], ["host cell", "OBSERVATION", 58, 67], ["rhinovirus serotypes", "OBSERVATION", 154, 174]]], ["279 RV serotypes that do not bind to ICAM-1 are referred to as the minor receptor group viruses and appear to utilize the low-density lipoprotein receptor.", [["ICAM-1", "GENE_OR_GENE_PRODUCT", 37, 43], ["low-density lipoprotein receptor", "GENE_OR_GENE_PRODUCT", 122, 154], ["ICAM-1", "PROTEIN", 37, 43], ["low-density lipoprotein receptor", "PROTEIN", 122, 154], ["RV serotypes", "PROBLEM", 4, 16], ["the low-density lipoprotein receptor", "TREATMENT", 118, 154], ["serotypes", "OBSERVATION", 7, 16]]], ["280 Manipulation of these receptor proteins has been explored as a potential control measure for rhinovirus infection.Epidemiology and TransmissionRVs are worldwide in distribution.", [["rhinovirus infection", "DISEASE", 97, 117], ["rhinovirus", "ORGANISM", 97, 107], ["receptor proteins", "PROTEIN", 26, 43], ["these receptor proteins", "TREATMENT", 20, 43], ["rhinovirus infection", "PROBLEM", 97, 117], ["rhinovirus", "OBSERVATION", 97, 107], ["worldwide", "OBSERVATION_MODIFIER", 155, 164]]], ["In the United States, RV has been observed to cause 0.74 to 0.77 infections per person per year in adults.", [["infections", "DISEASE", 65, 75], ["person", "SPECIES", 80, 86], ["RV", "ANATOMY", 22, 24], ["infections", "OBSERVATION", 65, 75]]], ["RV is believed to produce even higher infection rates in children, leading to acquisition of antibody to the different RV types throughout childhood and adolescence, with peak antibody prevalence in young adults.", [["RV", "ANATOMY", 119, 121], ["infection", "DISEASE", 38, 47], ["RV", "MULTI-TISSUE_STRUCTURE", 0, 2], ["children", "ORGANISM", 57, 65], ["children", "SPECIES", 57, 65], ["higher infection rates", "PROBLEM", 31, 53], ["antibody", "TREATMENT", 93, 101], ["peak antibody prevalence", "PROBLEM", 171, 195], ["higher", "OBSERVATION_MODIFIER", 31, 37], ["infection", "OBSERVATION", 38, 47], ["different RV", "ANATOMY", 109, 121]]], ["Immunity to RV is type specific and confers longlived protection following infection, although there may be second infections with the same virus type.", [["infection", "DISEASE", 75, 84], ["infections", "DISEASE", 115, 125], ["infection", "PROBLEM", 75, 84], ["second infections", "PROBLEM", 108, 125], ["the same virus type", "PROBLEM", 131, 150], ["infection", "OBSERVATION", 75, 84], ["may be", "UNCERTAINTY", 101, 107], ["second", "OBSERVATION_MODIFIER", 108, 114], ["infections", "OBSERVATION", 115, 125]]], ["The different immunotypes circulate in a given population in an apparently random manner.", [["different", "OBSERVATION_MODIFIER", 4, 13], ["immunotypes", "OBSERVATION_MODIFIER", 14, 25], ["circulate", "OBSERVATION_MODIFIER", 26, 35]]], ["In the United States, RV infections are most prevalent in the early fall and late spring.Epidemiology and TransmissionThe major reservoir for RV is school children, who transmit RV infection among their peers in the classroom and a highly contagious, childhood disease that typically causes community outbreaks in late winter and early spring months in temperate regions.", [["RV infections", "DISEASE", 22, 35], ["RV infection", "DISEASE", 178, 190], ["children", "ORGANISM", 155, 163], ["children", "SPECIES", 155, 163], ["RV", "SPECIES", 142, 144], ["RV infections", "PROBLEM", 22, 35], ["RV infection", "PROBLEM", 178, 190], ["childhood disease", "PROBLEM", 251, 268], ["RV", "ANATOMY", 22, 24], ["infections", "OBSERVATION", 25, 35], ["early", "OBSERVATION_MODIFIER", 62, 67], ["fall", "OBSERVATION", 68, 72], ["RV", "ANATOMY", 178, 180], ["infection", "OBSERVATION", 181, 190], ["contagious", "OBSERVATION_MODIFIER", 239, 249], ["community", "OBSERVATION_MODIFIER", 291, 300]]], ["Varicella spreads rapidly to household contacts, with an attack rate of nearly 90% within 2 weeks.", [["Varicella", "DISEASE", 0, 9], ["Varicella", "PROBLEM", 0, 9], ["an attack rate", "TEST", 54, 68]]], ["Consequently, most adults in temperate areas have experienced infection during childhood, but a high proportion of adults in semitropical and tropical areas remain susceptible to primary infection.", [["infection", "DISEASE", 62, 71], ["primary infection", "DISEASE", 179, 196], ["infection", "PROBLEM", 62, 71], ["adults in semitropical and tropical areas", "PROBLEM", 115, 156], ["primary infection", "PROBLEM", 179, 196], ["infection", "OBSERVATION", 62, 71], ["tropical", "OBSERVATION_MODIFIER", 142, 150], ["primary", "OBSERVATION_MODIFIER", 179, 186], ["infection", "OBSERVATION", 187, 196]]], ["300 Herpes zoster is nonseasonal and is seen in persons of all ages, although its incidence increases almost linearly after 30 years of age.", [["Herpes zoster", "DISEASE", 4, 17], ["Herpes zoster", "ORGANISM", 4, 17], ["persons", "ORGANISM", 48, 55], ["Herpes zoster", "SPECIES", 4, 17], ["persons", "SPECIES", 48, 55], ["Herpes zoster", "PROBLEM", 4, 17]]], ["About 10% to 20% of adults experience zoster, typically as a single episode after the fifth decade of life.", [["zoster", "DISEASE", 38, 44], ["adults", "ORGANISM", 20, 26], ["zoster", "ORGANISM", 38, 44], ["zoster", "PROBLEM", 38, 44], ["zoster", "OBSERVATION", 38, 44]]], ["Clinically apparent reinfections can be seen with VZV.Epidemiology and TransmissionAlthough the virus has been infrequently recovered from respiratory secretions of varicella patients, epidemiologic evidence indicates that the virus is spread from person to person through airborne transmission.", [["respiratory secretions", "ANATOMY", 139, 161], ["varicella", "DISEASE", 165, 174], ["VZV", "ORGANISM", 50, 53], ["patients", "ORGANISM", 175, 183], ["patients", "SPECIES", 175, 183], ["person", "SPECIES", 248, 254], ["person", "SPECIES", 258, 264], ["VZV", "SPECIES", 50, 53], ["Clinically apparent reinfections", "PROBLEM", 0, 32], ["VZV", "PROBLEM", 50, 53], ["the virus", "PROBLEM", 92, 101], ["respiratory secretions of varicella patients", "PROBLEM", 139, 183], ["the virus", "PROBLEM", 223, 232], ["reinfections", "OBSERVATION", 20, 32], ["VZV", "OBSERVATION", 50, 53], ["respiratory secretions", "OBSERVATION", 139, 161], ["virus", "OBSERVATION", 227, 232]]], ["Cutaneous lesions may also be the source of infectious virus.", [["Cutaneous lesions", "ANATOMY", 0, 17], ["Cutaneous lesions", "PATHOLOGICAL_FORMATION", 0, 17], ["Cutaneous lesions", "PROBLEM", 0, 17], ["infectious virus", "PROBLEM", 44, 60], ["lesions", "OBSERVATION", 10, 17], ["may also be the source of", "UNCERTAINTY", 18, 43], ["infectious", "OBSERVATION_MODIFIER", 44, 54], ["virus", "OBSERVATION", 55, 60]]], ["Susceptible persons have been infected after contact with patients with varicella, or, less often, with herpes zoster.", [["varicella", "DISEASE", 72, 81], ["herpes zoster", "DISEASE", 104, 117], ["persons", "ORGANISM", 12, 19], ["patients", "ORGANISM", 58, 66], ["herpes zoster", "ORGANISM", 104, 117], ["persons", "SPECIES", 12, 19], ["patients", "SPECIES", 58, 66], ["herpes zoster", "SPECIES", 104, 117], ["varicella", "PROBLEM", 72, 81], ["herpes zoster", "PROBLEM", 104, 117], ["infected", "OBSERVATION_MODIFIER", 30, 38]]], ["Before the implementation of vaccination, VZV was an important cause of nosocomial outbreaks on pediatric wards, with spread by small-particle aerosols.PathogenesisThe incubation period of varicella averages 2 weeks, and almost all cases of varicella develop within 11 to 20 days after exposure.", [["VZV", "DISEASE", 42, 45], ["varicella", "DISEASE", 189, 198], ["varicella", "DISEASE", 241, 250], ["VZV", "ORGANISM", 42, 45], ["VZV", "SPECIES", 42, 45], ["vaccination", "TREATMENT", 29, 40], ["VZV", "PROBLEM", 42, 45], ["nosocomial outbreaks", "PROBLEM", 72, 92], ["varicella averages", "PROBLEM", 189, 207], ["varicella develop", "PROBLEM", 241, 258], ["nosocomial", "OBSERVATION", 72, 82], ["small", "OBSERVATION_MODIFIER", 128, 133], ["particle aerosols", "OBSERVATION", 134, 151], ["varicella", "OBSERVATION", 189, 198], ["varicella", "OBSERVATION", 241, 250]]], ["The initial portal of infection is the respiratory tract, with viremic dissemination leading to the extensive cutaneous and mucous membrane lesions.", [["respiratory tract", "ANATOMY", 39, 56], ["cutaneous", "ANATOMY", 110, 119], ["mucous membrane lesions", "ANATOMY", 124, 147], ["infection", "DISEASE", 22, 31], ["respiratory tract", "ORGANISM_SUBDIVISION", 39, 56], ["cutaneous", "PATHOLOGICAL_FORMATION", 110, 119], ["mucous membrane lesions", "PATHOLOGICAL_FORMATION", 124, 147], ["infection", "PROBLEM", 22, 31], ["the respiratory tract", "PROBLEM", 35, 56], ["viremic dissemination", "PROBLEM", 63, 84], ["the extensive cutaneous and mucous membrane lesions", "PROBLEM", 96, 147], ["portal", "ANATOMY", 12, 18], ["infection", "OBSERVATION", 22, 31], ["respiratory tract", "ANATOMY", 39, 56], ["viremic dissemination", "OBSERVATION", 63, 84], ["extensive", "OBSERVATION_MODIFIER", 100, 109], ["cutaneous", "ANATOMY", 110, 119], ["mucous membrane lesions", "OBSERVATION", 124, 147]]], ["Following infection, VZV establishes latency in the posterior dorsal root ganglia.", [["dorsal root ganglia", "ANATOMY", 62, 81], ["infection", "DISEASE", 10, 19], ["VZV", "ORGANISM", 21, 24], ["posterior dorsal root ganglia", "MULTI-TISSUE_STRUCTURE", 52, 81], ["VZV", "SPECIES", 21, 24], ["infection", "PROBLEM", 10, 19], ["VZV", "PROBLEM", 21, 24], ["infection", "OBSERVATION", 10, 19], ["VZV", "OBSERVATION", 21, 24], ["latency", "OBSERVATION_MODIFIER", 37, 44], ["posterior", "ANATOMY_MODIFIER", 52, 61], ["dorsal", "ANATOMY_MODIFIER", 62, 68], ["root ganglia", "ANATOMY", 69, 81]]], ["Reactivation of virus replication and centrifugal spread along sensory nerves lead to the unique dermatomal distribution of shingles (zoster).", [["sensory nerves", "ANATOMY", 63, 77], ["dermatomal", "ANATOMY", 97, 107], ["shingles", "DISEASE", 124, 132], ["zoster", "DISEASE", 134, 140], ["sensory nerves", "MULTI-TISSUE_STRUCTURE", 63, 77], ["zoster", "ORGANISM", 134, 140], ["virus replication", "PROBLEM", 16, 33], ["centrifugal spread along sensory nerves", "PROBLEM", 38, 77], ["shingles (zoster)", "PROBLEM", 124, 141], ["virus replication", "OBSERVATION", 16, 33], ["centrifugal", "OBSERVATION_MODIFIER", 38, 49], ["spread", "OBSERVATION_MODIFIER", 50, 56], ["sensory nerves", "ANATOMY", 63, 77], ["dermatomal", "OBSERVATION_MODIFIER", 97, 107], ["distribution", "OBSERVATION_MODIFIER", 108, 120], ["shingles", "OBSERVATION", 124, 132], ["zoster", "OBSERVATION", 134, 140]]], ["In immunocompromised hosts with zoster, virus may disseminate to other sites.Clinical IllnessVaricella.", [["zoster", "DISEASE", 32, 38], ["IllnessVaricella", "DISEASE", 86, 102], ["zoster", "ORGANISM", 32, 38], ["immunocompromised hosts", "PROBLEM", 3, 26], ["zoster", "PROBLEM", 32, 38], ["virus", "PROBLEM", 40, 45], ["Clinical IllnessVaricella", "PROBLEM", 77, 102], ["immunocompromised hosts", "OBSERVATION", 3, 26], ["zoster", "OBSERVATION", 32, 38]]], ["In children with normal immunity, varicella is usually not associated with significant systemic or respiratory manifestations.", [["respiratory", "ANATOMY", 99, 110], ["varicella", "DISEASE", 34, 43], ["children", "ORGANISM", 3, 11], ["children", "SPECIES", 3, 11], ["varicella", "PROBLEM", 34, 43], ["significant systemic or respiratory manifestations", "PROBLEM", 75, 125], ["normal immunity", "OBSERVATION_MODIFIER", 17, 32], ["varicella", "OBSERVATION", 34, 43], ["respiratory manifestations", "OBSERVATION", 99, 125]]], ["The exanthem typically begins around the scalp and head, with subsequent involvement of the trunk and extremities.", [["scalp", "ANATOMY", 41, 46], ["head", "ANATOMY", 51, 55], ["trunk", "ANATOMY", 92, 97], ["extremities", "ANATOMY", 102, 113], ["exanthem", "DISEASE", 4, 12], ["exanthem", "CANCER", 4, 12], ["scalp", "ORGAN", 41, 46], ["head", "ORGAN", 51, 55], ["trunk", "ORGANISM_SUBDIVISION", 92, 97], ["extremities", "ORGANISM_SUBDIVISION", 102, 113], ["The exanthem", "PROBLEM", 0, 12], ["subsequent involvement of the trunk and extremities", "PROBLEM", 62, 113], ["exanthem", "OBSERVATION", 4, 12], ["scalp", "ANATOMY", 41, 46], ["head", "ANATOMY", 51, 55], ["involvement", "OBSERVATION", 73, 84], ["trunk", "ANATOMY", 92, 97], ["extremities", "ANATOMY", 102, 113]]], ["Lesions progress through various stages (erythematous macules, vesicles, pustules, crusts), so an area will have lesions in different stages of evolution.", [["macules", "ANATOMY", 54, 61], ["vesicles", "ANATOMY", 63, 71], ["pustules", "ANATOMY", 73, 81], ["crusts", "ANATOMY", 83, 89], ["lesions", "ANATOMY", 113, 120], ["macules", "DISEASE", 54, 61], ["pustules", "DISEASE", 73, 81], ["erythematous macules", "PATHOLOGICAL_FORMATION", 41, 61], ["pustules", "PATHOLOGICAL_FORMATION", 73, 81], ["lesions", "PATHOLOGICAL_FORMATION", 113, 120], ["Lesions", "PROBLEM", 0, 7], ["erythematous macules", "PROBLEM", 41, 61], ["vesicles", "PROBLEM", 63, 71], ["pustules", "PROBLEM", 73, 81], ["crusts", "PROBLEM", 83, 89], ["lesions", "PROBLEM", 113, 120], ["various stages", "OBSERVATION_MODIFIER", 25, 39], ["erythematous", "OBSERVATION_MODIFIER", 41, 53], ["macules", "OBSERVATION", 54, 61], ["vesicles", "ANATOMY", 63, 71], ["pustules", "OBSERVATION", 73, 81], ["crusts", "OBSERVATION_MODIFIER", 83, 89], ["lesions", "OBSERVATION", 113, 120], ["different stages", "OBSERVATION_MODIFIER", 124, 140], ["evolution", "OBSERVATION_MODIFIER", 144, 153]]], ["In contrast, in smallpox, a disease with which varicella was often confused, lesions begin on the face and spread outwardly to the extremities, and adjacent lesions are at the same stage of development.Clinical IllnessIn children and susceptible adults who are immunocompromised, particularly those with defects in cell mediated immunity, including HIV infection, 301 varicella follows a more severe course.", [["lesions", "ANATOMY", 77, 84], ["face", "ANATOMY", 98, 102], ["extremities", "ANATOMY", 131, 142], ["lesions", "ANATOMY", 157, 164], ["cell", "ANATOMY", 315, 319], ["smallpox", "DISEASE", 16, 24], ["varicella", "DISEASE", 47, 56], ["HIV infection", "DISEASE", 349, 362], ["varicella", "DISEASE", 368, 377], ["lesions", "PATHOLOGICAL_FORMATION", 77, 84], ["extremities", "ORGANISM_SUBDIVISION", 131, 142], ["lesions", "CANCER", 157, 164], ["children", "ORGANISM", 221, 229], ["adults", "ORGANISM", 246, 252], ["cell", "CELL", 315, 319], ["HIV", "ORGANISM", 349, 352], ["children", "SPECIES", 221, 229], ["HIV", "SPECIES", 349, 352], ["HIV", "SPECIES", 349, 352], ["a disease with which varicella", "PROBLEM", 26, 56], ["confused", "PROBLEM", 67, 75], ["lesions", "PROBLEM", 77, 84], ["adjacent lesions", "PROBLEM", 148, 164], ["immunocompromised", "PROBLEM", 261, 278], ["defects in cell mediated immunity", "PROBLEM", 304, 337], ["HIV infection", "PROBLEM", 349, 362], ["varicella", "PROBLEM", 368, 377], ["disease", "OBSERVATION", 28, 35], ["varicella", "OBSERVATION", 47, 56], ["lesions", "OBSERVATION", 77, 84], ["face", "ANATOMY", 98, 102], ["extremities", "ANATOMY", 131, 142], ["lesions", "OBSERVATION", 157, 164], ["immunocompromised", "OBSERVATION", 261, 278]]], ["Continued lesion development, particularly involving the extremities; high fever; and visceral involvement with pneumonia, meningoencephalitis, and hepatitis are common.", [["lesion", "ANATOMY", 10, 16], ["extremities", "ANATOMY", 57, 68], ["visceral", "ANATOMY", 86, 94], ["fever", "DISEASE", 75, 80], ["pneumonia", "DISEASE", 112, 121], ["meningoencephalitis", "DISEASE", 123, 142], ["hepatitis", "DISEASE", 148, 157], ["extremities", "ORGANISM_SUBDIVISION", 57, 68], ["visceral", "ORGANISM_SUBDIVISION", 86, 94], ["Continued lesion development", "PROBLEM", 0, 28], ["high fever", "PROBLEM", 70, 80], ["visceral involvement", "PROBLEM", 86, 106], ["pneumonia", "PROBLEM", 112, 121], ["meningoencephalitis", "PROBLEM", 123, 142], ["hepatitis", "PROBLEM", 148, 157], ["lesion", "OBSERVATION", 10, 16], ["extremities", "ANATOMY", 57, 68], ["high", "OBSERVATION_MODIFIER", 70, 74], ["fever", "OBSERVATION", 75, 80], ["visceral", "ANATOMY", 86, 94], ["pneumonia", "OBSERVATION", 112, 121], ["meningoencephalitis", "OBSERVATION", 123, 142], ["hepatitis", "OBSERVATION", 148, 157]]], ["During pregnancy, severe pneumonia can develop in approximately 10% of varicella cases.", [["pneumonia", "DISEASE", 25, 34], ["varicella", "DISEASE", 71, 80], ["severe pneumonia", "PROBLEM", 18, 34], ["varicella cases", "PROBLEM", 71, 86], ["severe", "OBSERVATION_MODIFIER", 18, 24], ["pneumonia", "OBSERVATION", 25, 34], ["varicella cases", "OBSERVATION", 71, 86]]], ["Viral pneumonia is the major complication of varicella in normal adults, in whom the frequency is estimated to be 25-fold higher than in children.", [["Viral pneumonia", "DISEASE", 0, 15], ["varicella", "DISEASE", 45, 54], ["children", "ORGANISM", 137, 145], ["children", "SPECIES", 137, 145], ["Viral pneumonia", "PROBLEM", 0, 15], ["varicella", "PROBLEM", 45, 54], ["pneumonia", "OBSERVATION", 6, 15], ["major", "OBSERVATION_MODIFIER", 23, 28], ["complication", "OBSERVATION_MODIFIER", 29, 41], ["varicella", "OBSERVATION", 45, 54], ["normal adults", "OBSERVATION_MODIFIER", 58, 71]]], ["Pneumonia associated with varicella is usually apparent 1 to 6 days after the onset of rash.", [["Pneumonia", "DISEASE", 0, 9], ["varicella", "DISEASE", 26, 35], ["rash", "DISEASE", 87, 91], ["Pneumonia", "PROBLEM", 0, 9], ["varicella", "PROBLEM", 26, 35], ["rash", "PROBLEM", 87, 91], ["varicella", "OBSERVATION", 26, 35], ["usually apparent 1 to 6", "OBSERVATION_MODIFIER", 39, 62], ["rash", "OBSERVATION", 87, 91]]], ["Symptoms RV alone or in combination with bacteria has been recovered from aspirates obtained by direct puncture of the maxillary sinuses of patients with acute sinusitis.", [["aspirates", "ANATOMY", 74, 83], ["maxillary sinuses", "ANATOMY", 119, 136], ["sinusitis", "DISEASE", 160, 169], ["aspirates", "TISSUE", 74, 83], ["maxillary sinuses", "MULTI-TISSUE_STRUCTURE", 119, 136], ["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 140, 148], ["Symptoms", "PROBLEM", 0, 8], ["bacteria", "PROBLEM", 41, 49], ["aspirates", "TEST", 74, 83], ["direct puncture", "TEST", 96, 111], ["acute sinusitis", "PROBLEM", 154, 169], ["aspirates", "OBSERVATION", 74, 83], ["maxillary sinuses", "ANATOMY", 119, 136], ["acute", "OBSERVATION_MODIFIER", 154, 159], ["sinusitis", "OBSERVATION", 160, 169]]], ["290 Mucosal thickening and/or sinus exudates have been observed in up to 77% of subjects with acute colds.", [["Mucosal", "ANATOMY", 4, 11], ["sinus exudates", "ANATOMY", 30, 44], ["colds", "DISEASE", 100, 105], ["sinus exudates", "MULTI-TISSUE_STRUCTURE", 30, 44], ["Mucosal thickening", "PROBLEM", 4, 22], ["sinus exudates", "PROBLEM", 30, 44], ["acute colds", "PROBLEM", 94, 105], ["Mucosal", "ANATOMY", 4, 11], ["thickening", "OBSERVATION", 12, 22], ["sinus", "ANATOMY", 30, 35], ["exudates", "OBSERVATION", 36, 44], ["acute", "OBSERVATION_MODIFIER", 94, 99], ["colds", "OBSERVATION", 100, 105]]], ["291 These abnormalities are transient, and in uncomplicated cases they resolve within 21 days.", [["These abnormalities", "PROBLEM", 4, 23], ["abnormalities", "OBSERVATION", 10, 23], ["transient", "OBSERVATION_MODIFIER", 28, 37]]], ["However, clinically manifest acute bacterial sinusitis is seen in a small (0.5% to 5%) proportion of individuals with naturally occurring colds.", [["sinusitis", "DISEASE", 45, 54], ["colds", "DISEASE", 138, 143], ["acute bacterial sinusitis", "PROBLEM", 29, 54], ["naturally occurring colds", "PROBLEM", 118, 143], ["acute", "OBSERVATION_MODIFIER", 29, 34], ["bacterial", "OBSERVATION_MODIFIER", 35, 44], ["sinusitis", "OBSERVATION", 45, 54], ["small", "OBSERVATION_MODIFIER", 68, 73]]], ["It is presumed that the RV infection impairs mucociliary clearance and other local defenses in the sinus cavity, allowing secondary bacterial invasion.Clinical IllnessThere is increasing evidence for an important role of rhinoviruses in lower respiratory tract disease in adults and children.", [["RV", "ANATOMY", 24, 26], ["mucociliary", "ANATOMY", 45, 56], ["sinus cavity", "ANATOMY", 99, 111], ["lower respiratory tract", "ANATOMY", 237, 260], ["RV infection", "DISEASE", 24, 36], ["lower respiratory tract disease", "DISEASE", 237, 268], ["mucociliary", "ORGAN", 45, 56], ["sinus cavity", "MULTI-TISSUE_STRUCTURE", 99, 111], ["rhinoviruses", "ORGANISM", 221, 233], ["lower", "ORGANISM_SUBDIVISION", 237, 242], ["respiratory tract", "ORGANISM_SUBDIVISION", 243, 260], ["children", "ORGANISM", 283, 291], ["children", "SPECIES", 283, 291], ["the RV infection", "PROBLEM", 20, 36], ["mucociliary clearance", "PROBLEM", 45, 66], ["other local defenses in the sinus cavity", "PROBLEM", 71, 111], ["secondary bacterial invasion", "PROBLEM", 122, 150], ["rhinoviruses", "PROBLEM", 221, 233], ["lower respiratory tract disease", "PROBLEM", 237, 268], ["presumed that", "UNCERTAINTY", 6, 19], ["RV", "ANATOMY", 24, 26], ["infection", "OBSERVATION", 27, 36], ["mucociliary clearance", "OBSERVATION", 45, 66], ["local defenses", "OBSERVATION", 77, 91], ["sinus cavity", "ANATOMY", 99, 111], ["secondary", "OBSERVATION_MODIFIER", 122, 131], ["bacterial invasion", "OBSERVATION", 132, 150], ["rhinoviruses", "OBSERVATION", 221, 233], ["lower", "ANATOMY_MODIFIER", 237, 242], ["respiratory tract", "ANATOMY", 243, 260]]], ["292 RV is the second most frequently recognized agent associated with pneumonia and bronchiolitis in infants and young children and commonly causes exacerbations of preexisting airways disease in those with COPD or cystic fibrosis.", [["airways", "ANATOMY", 177, 184], ["cystic", "ANATOMY", 215, 221], ["pneumonia", "DISEASE", 70, 79], ["bronchiolitis", "DISEASE", 84, 97], ["airways disease", "DISEASE", 177, 192], ["COPD", "DISEASE", 207, 211], ["cystic fibrosis", "DISEASE", 215, 230], ["infants", "ORGANISM", 101, 108], ["children", "ORGANISM", 119, 127], ["airways", "MULTI-TISSUE_STRUCTURE", 177, 184], ["infants", "SPECIES", 101, 108], ["children", "SPECIES", 119, 127], ["pneumonia", "PROBLEM", 70, 79], ["bronchiolitis", "PROBLEM", 84, 97], ["preexisting airways disease", "PROBLEM", 165, 192], ["COPD", "PROBLEM", 207, 211], ["cystic fibrosis", "PROBLEM", 215, 230], ["associated with", "UNCERTAINTY", 54, 69], ["pneumonia", "OBSERVATION", 70, 79], ["bronchiolitis", "OBSERVATION", 84, 97], ["airways disease", "OBSERVATION", 177, 192], ["COPD", "OBSERVATION", 207, 211], ["cystic", "OBSERVATION_MODIFIER", 215, 221], ["fibrosis", "OBSERVATION", 222, 230]]], ["293 Colds are generally more severe in atopic individuals and rhinoviruses are major causes of asthma exacerbation.", [["atopic", "DISEASE", 39, 45], ["rhinoviruses", "DISEASE", 62, 74], ["asthma", "DISEASE", 95, 101], ["rhinoviruses", "ORGANISM", 62, 74], ["Colds", "PROBLEM", 4, 9], ["atopic individuals", "PROBLEM", 39, 57], ["rhinoviruses", "PROBLEM", 62, 74], ["asthma exacerbation", "PROBLEM", 95, 114], ["generally more", "OBSERVATION_MODIFIER", 14, 28], ["severe", "OBSERVATION_MODIFIER", 29, 35], ["atopic individuals", "OBSERVATION", 39, 57], ["rhinoviruses", "OBSERVATION", 62, 74], ["asthma", "OBSERVATION", 95, 101]]], ["294 Children with a history of wheezing/ asthma had significantly more RV-associated hospitalizations than those without a history.", [["wheezing", "DISEASE", 31, 39], ["asthma", "DISEASE", 41, 47], ["Children", "ORGANISM", 4, 12], ["Children", "SPECIES", 4, 12], ["wheezing", "PROBLEM", 31, 39], ["asthma", "PROBLEM", 41, 47], ["asthma", "OBSERVATION", 41, 47]]], ["295 RV infections may also be associated with severe lower respiratory tract disease in transplant patients 296 and in some cases can be associated with prolonged shedding.", [["lower respiratory tract", "ANATOMY", 53, 76], ["RV infections", "DISEASE", 4, 17], ["lower respiratory tract disease", "DISEASE", 53, 84], ["lower", "ORGANISM_SUBDIVISION", 53, 58], ["respiratory tract", "ORGANISM_SUBDIVISION", 59, 76], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["RV infections", "PROBLEM", 4, 17], ["severe lower respiratory tract disease", "PROBLEM", 46, 84], ["prolonged shedding", "PROBLEM", 153, 171], ["infections", "OBSERVATION", 7, 17], ["may also be associated with", "UNCERTAINTY", 18, 45], ["severe", "OBSERVATION_MODIFIER", 46, 52], ["lower", "ANATOMY_MODIFIER", 53, 58], ["respiratory tract", "ANATOMY", 59, 76]]], ["297 These viruses can also be detected in lower respiratory tract disease in individuals with hematologic malignancy, often in conjunction with other pathogens.", [["lower respiratory tract", "ANATOMY", 42, 65], ["hematologic malignancy", "ANATOMY", 94, 116], ["respiratory tract disease", "DISEASE", 48, 73], ["hematologic malignancy", "DISEASE", 94, 116], ["lower", "ORGANISM_SUBDIVISION", 42, 47], ["respiratory tract", "ORGANISM_SUBDIVISION", 48, 65], ["hematologic malignancy", "CANCER", 94, 116], ["These viruses", "PROBLEM", 4, 17], ["lower respiratory tract disease", "PROBLEM", 42, 73], ["hematologic malignancy", "PROBLEM", 94, 116], ["other pathogens", "PROBLEM", 144, 159], ["viruses", "OBSERVATION", 10, 17], ["lower", "ANATOMY_MODIFIER", 42, 47], ["respiratory tract", "ANATOMY", 48, 65], ["malignancy", "OBSERVATION", 106, 116], ["pathogens", "OBSERVATION", 150, 159]]], ["298DiagnosisRapid tests for detecting RV nucleic acid are available in respiratory virus panels (see Chapter 17); they generally do not distinguish rhinoviruses from other enteroviruses.", [["nucleic acid", "CHEMICAL", 41, 53], ["rhinoviruses", "DISEASE", 148, 160], ["enteroviruses", "DISEASE", 172, 185], ["rhinoviruses", "ORGANISM", 148, 160], ["enteroviruses", "ORGANISM", 172, 185], ["298DiagnosisRapid tests", "TEST", 0, 23], ["RV nucleic acid", "TEST", 38, 53], ["respiratory virus panels", "TEST", 71, 95], ["rhinoviruses", "PROBLEM", 148, 160], ["other enteroviruses", "PROBLEM", 166, 185], ["rhinoviruses", "OBSERVATION", 148, 160], ["enteroviruses", "OBSERVATION", 172, 185]]], ["RVs can be isolated in cell culture, usually within 2 to 7 days after inoculation.", [["cell culture", "ANATOMY", 23, 35], ["cell culture", "CELL", 23, 35], ["RVs", "PROBLEM", 0, 3], ["cell culture", "TEST", 23, 35], ["inoculation", "PROBLEM", 70, 81], ["cell culture", "OBSERVATION", 23, 35]]], ["Virus is present in nasopharyngeal secretions in highest concentrations during the first and second days of illness but may be shed for as long as 3 weeks.", [["nasopharyngeal secretions", "ANATOMY", 20, 45], ["illness", "DISEASE", 108, 115], ["Virus", "ORGANISM", 0, 5], ["nasopharyngeal secretions", "ORGAN", 20, 45], ["Virus", "PROBLEM", 0, 5], ["nasopharyngeal secretions", "PROBLEM", 20, 45], ["illness", "PROBLEM", 108, 115], ["nasopharyngeal", "ANATOMY", 20, 34], ["secretions", "OBSERVATION", 35, 45], ["highest", "OBSERVATION_MODIFIER", 49, 56], ["concentrations", "OBSERVATION_MODIFIER", 57, 71]]], ["When indicated, identification of the specific serotype of a rhinovirus isolate is made by neutralization test.Treatment and PreventionThe only effective therapy for RV colds currently available is symptomatic treatment of individual complaints.", [["RV colds", "DISEASE", 166, 174], ["rhinovirus", "ORGANISM", 61, 71], ["a rhinovirus isolate", "TREATMENT", 59, 79], ["neutralization test", "TEST", 91, 110], ["Treatment", "TREATMENT", 111, 120], ["Prevention", "TREATMENT", 125, 135], ["effective therapy", "TREATMENT", 144, 161], ["RV colds", "PROBLEM", 166, 174], ["symptomatic treatment", "TREATMENT", 198, 219], ["individual complaints", "PROBLEM", 223, 244]]], ["Remedies recommended for such treatment are described in the section on common cold in this chapter.", [["Remedies", "TREATMENT", 0, 8], ["such treatment", "TREATMENT", 25, 39]]], ["Although hand washing is undoubtedly important in preventing transmission, a recent study could show no benefit to routine hand disinfection in the prevention of RV colds.", [["hand", "ANATOMY", 9, 13], ["hand", "ANATOMY", 123, 127], ["RV colds", "DISEASE", 162, 170], ["hand", "ORGANISM_SUBDIVISION", 9, 13], ["hand", "ORGANISM_SUBDIVISION", 123, 127], ["RV", "SPECIES", 162, 164], ["hand washing", "TREATMENT", 9, 21], ["a recent study", "TEST", 75, 89], ["routine hand disinfection", "TREATMENT", 115, 140], ["RV colds", "PROBLEM", 162, 170], ["washing", "OBSERVATION", 14, 21], ["disinfection", "OBSERVATION", 128, 140], ["RV", "ANATOMY", 162, 164], ["colds", "OBSERVATION", 165, 170]]], ["299 As mentioned earlier, the plethora of rhinovirus serotypes suggests that an effective vaccine will not be forthcoming in the foreseeable future.", [["rhinovirus", "ORGANISM", 42, 52], ["rhinovirus serotypes", "PROBLEM", 42, 62], ["an effective vaccine", "TREATMENT", 77, 97], ["rhinovirus", "OBSERVATION", 42, 52]]], ["Advances in understanding of the structural and molecular biology of the rhinoviruses has led to development of a number of strategies for antiviral intervention, including receptor blockade and capsid-binding agents.", [["rhinoviruses", "DISEASE", 73, 85], ["rhinoviruses", "ORGANISM", 73, 85], ["capsid-binding agents", "SIMPLE_CHEMICAL", 195, 216], ["the rhinoviruses", "PROBLEM", 69, 85], ["antiviral intervention", "TREATMENT", 139, 161], ["receptor blockade", "TREATMENT", 173, 190], ["capsid-binding agents", "TREATMENT", 195, 216], ["rhinoviruses", "OBSERVATION", 73, 85]]], ["However, none of these agents has reached approval for clinical use.VARICELLA-ZOSTER VIRUSVaricella-zoster virus (VZV) is an enveloped double-stranded DNA virus with a large genome (\u2248125,000 bp).", [["VARICELLA-ZOSTER VIRUSVaricella-zoster virus", "ORGANISM", 68, 112], ["VZV", "ORGANISM", 114, 117], ["DNA", "CELLULAR_COMPONENT", 151, 154], ["VIRUSVaricella-zoster virus", "SPECIES", 85, 112], ["VIRUSVaricella-zoster virus", "SPECIES", 85, 112], ["VZV", "SPECIES", 114, 117], ["VARICELLA", "TEST", 68, 77], ["ZOSTER VIRUSVaricella-zoster virus", "PROBLEM", 78, 112], ["an enveloped double-stranded DNA virus", "PROBLEM", 122, 160], ["bp", "TEST", 191, 193], ["ZOSTER", "OBSERVATION", 78, 84], ["large", "OBSERVATION_MODIFIER", 168, 173], ["genome", "OBSERVATION", 174, 180]]], ["Varicella is affected.", [["Varicella", "DISEASE", 0, 9], ["Varicella", "PROBLEM", 0, 9], ["affected", "OBSERVATION", 13, 21]]], ["Mortality depends on the degree of immunosuppression and ranges from zero to 10%.DiagnosisA rapid diagnosis of herpes group infection can be established by cytologic examination of lesion scrapings (Tzank smear and others), which has a sensitivity of 70% to 85% when lesions are in the vesicular stage.", [["lesion scrapings", "ANATOMY", 181, 197], ["lesions", "ANATOMY", 267, 274], ["vesicular", "ANATOMY", 286, 295], ["herpes group infection", "DISEASE", 111, 133], ["herpes", "ORGANISM", 111, 117], ["lesion scrapings", "TISSUE", 181, 197], ["lesions", "PATHOLOGICAL_FORMATION", 267, 274], ["immunosuppression", "TREATMENT", 35, 52], ["herpes group infection", "PROBLEM", 111, 133], ["cytologic examination", "TEST", 156, 177], ["lesion scrapings", "PROBLEM", 181, 197], ["Tzank smear", "TEST", 199, 210], ["a sensitivity", "TEST", 234, 247], ["lesions", "PROBLEM", 267, 274], ["immunosuppression", "OBSERVATION", 35, 52], ["herpes", "OBSERVATION", 111, 117], ["lesion", "OBSERVATION", 181, 187], ["lesions", "OBSERVATION", 267, 274], ["vesicular stage", "OBSERVATION", 286, 301]]], ["Direct immunofluorescence for VZV antigen in lesions is the most sensitive rapid laboratory test.", [["lesions", "ANATOMY", 45, 52], ["VZV", "ORGANISM", 30, 33], ["antigen", "GENE_OR_GENE_PRODUCT", 34, 41], ["lesions", "PATHOLOGICAL_FORMATION", 45, 52], ["VZV antigen", "PROTEIN", 30, 41], ["VZV", "SPECIES", 30, 33], ["Direct immunofluorescence", "TEST", 0, 25], ["VZV antigen in lesions", "PROBLEM", 30, 52], ["lesions", "OBSERVATION", 45, 52]]], ["The virus is labile but can be isolated from vesicular fluid during the first 3 days of varicella in normal hosts and for up to 10 days in immunocompromised hosts or patients with disseminated zoster.", [["vesicular fluid", "ANATOMY", 45, 60], ["varicella", "DISEASE", 88, 97], ["disseminated zoster", "DISEASE", 180, 199], ["vesicular fluid", "ORGANISM_SUBSTANCE", 45, 60], ["patients", "ORGANISM", 166, 174], ["zoster", "ORGANISM", 193, 199], ["patients", "SPECIES", 166, 174], ["The virus", "PROBLEM", 0, 9], ["labile", "PROBLEM", 13, 19], ["vesicular fluid", "PROBLEM", 45, 60], ["varicella", "PROBLEM", 88, 97], ["immunocompromised hosts", "PROBLEM", 139, 162], ["disseminated zoster", "PROBLEM", 180, 199], ["virus", "OBSERVATION", 4, 9], ["labile", "OBSERVATION_MODIFIER", 13, 19], ["vesicular", "OBSERVATION_MODIFIER", 45, 54], ["fluid", "OBSERVATION", 55, 60], ["normal hosts", "OBSERVATION_MODIFIER", 101, 113], ["disseminated", "OBSERVATION_MODIFIER", 180, 192], ["zoster", "OBSERVATION", 193, 199]]], ["Direct inoculation of vesicular fluid onto monolayers of cell culture (human embryonic lung fibroblasts) at the bedside increases the likelihood of isolation.Treatment and PreventionLive, attenuated varicella vaccine generates neutralizing antibody in more than 95% of recipients and also generates long-lived CD8 + cytotoxic T-cell responses against varicella virus.", [["vesicular fluid", "ANATOMY", 22, 37], ["monolayers", "ANATOMY", 43, 53], ["cell culture", "ANATOMY", 57, 69], ["embryonic lung fibroblasts", "ANATOMY", 77, 103], ["CD8 + cytotoxic T-cell", "ANATOMY", 310, 332], ["varicella", "DISEASE", 199, 208], ["varicella virus", "DISEASE", 351, 366], ["vesicular fluid", "ORGANISM_SUBSTANCE", 22, 37], ["monolayers", "CELL", 43, 53], ["cell culture", "CELL", 57, 69], ["human", "ORGANISM", 71, 76], ["embryonic lung fibroblasts", "CELL", 77, 103], ["varicella", "ORGANISM", 199, 208], ["recipients", "ORGANISM", 269, 279], ["CD8", "GENE_OR_GENE_PRODUCT", 310, 313], ["varicella virus", "ORGANISM", 351, 366], ["cell culture", "CELL_LINE", 57, 69], ["human embryonic lung fibroblasts", "CELL_TYPE", 71, 103], ["neutralizing antibody", "PROTEIN", 227, 248], ["CD8", "PROTEIN", 310, 313], ["human", "SPECIES", 71, 76], ["varicella virus", "SPECIES", 351, 366], ["human", "SPECIES", 71, 76], ["varicella virus", "SPECIES", 351, 366], ["Direct inoculation of vesicular fluid", "PROBLEM", 0, 37], ["cell culture", "TEST", 57, 69], ["human embryonic lung fibroblasts", "PROBLEM", 71, 103], ["Treatment", "TREATMENT", 158, 167], ["PreventionLive", "TREATMENT", 172, 186], ["attenuated varicella vaccine", "TREATMENT", 188, 216], ["neutralizing antibody", "TEST", 227, 248], ["varicella virus", "PROBLEM", 351, 366], ["vesicular fluid", "OBSERVATION", 22, 37], ["cell culture", "OBSERVATION", 57, 69], ["lung", "ANATOMY", 87, 91], ["fibroblasts", "OBSERVATION", 92, 103], ["isolation", "OBSERVATION", 148, 157], ["varicella virus", "OBSERVATION", 351, 366]]], ["304 Vaccination of immunosuppressed children, including those with leukemia, is safe, although a small proportion of children will experience a mild, varicella-like clinical syndrome approximately 1 month after vaccination.", [["leukemia", "ANATOMY", 67, 75], ["leukemia", "DISEASE", 67, 75], ["varicella", "DISEASE", 150, 159], ["children", "ORGANISM", 36, 44], ["leukemia", "CANCER", 67, 75], ["children", "ORGANISM", 117, 125], ["children", "SPECIES", 36, 44], ["children", "SPECIES", 117, 125], ["leukemia", "PROBLEM", 67, 75], ["a mild, varicella-like clinical syndrome", "PROBLEM", 142, 182], ["vaccination", "TREATMENT", 211, 222], ["leukemia", "OBSERVATION", 67, 75], ["mild", "OBSERVATION_MODIFIER", 144, 148]]], ["305 In both healthy and immunosuppressed children, the vaccine is highly effective at preventing varicella, with efficacy rates of 50% to 90%.", [["varicella", "DISEASE", 97, 106], ["children", "ORGANISM", 41, 49], ["children", "SPECIES", 41, 49], ["the vaccine", "TREATMENT", 51, 62], ["varicella", "PROBLEM", 97, 106], ["efficacy rates", "TEST", 113, 127], ["varicella", "OBSERVATION", 97, 106]]], ["Two doses of varicella vaccine administered subcutaneously are recommended for children 12 months and older, adolescents, and adults without evidence of prior immunity.", [["subcutaneously", "ANATOMY", 44, 58], ["varicella", "ORGANISM", 13, 22], ["children", "ORGANISM", 79, 87], ["children", "SPECIES", 79, 87], ["adolescents", "SPECIES", 109, 120], ["varicella vaccine", "TREATMENT", 13, 30], ["without evidence of", "UNCERTAINTY", 133, 152]]], ["306 Second-dose catch-up vaccination is recommended for those who previously received only a single dose of vaccine.Treatment and PreventionA higher-dose live vaccine effectively re-stimulates virusspecific cellular immunity in adults and can reduce the frequency of reactivation, as well as the clinical severity of zoster.", [["cellular", "ANATOMY", 207, 215], ["zoster", "DISEASE", 317, 323], ["cellular", "CELL", 207, 215], ["adults", "ORGANISM", 228, 234], ["zoster", "ORGANISM", 317, 323], ["Second-dose catch-up vaccination", "TREATMENT", 4, 36], ["a single dose of vaccine", "TREATMENT", 91, 115], ["Treatment", "TREATMENT", 116, 125], ["PreventionA higher-dose live vaccine", "TREATMENT", 130, 166], ["reactivation", "PROBLEM", 267, 279], ["zoster", "PROBLEM", 317, 323], ["reactivation", "OBSERVATION", 267, 279], ["zoster", "OBSERVATION", 317, 323]]], ["307 The high-dose live vaccine is recommended as a single dose in all healthy individuals 60 and older.", [["The high-dose live vaccine", "TREATMENT", 4, 30]]], ["308 Although uncomplicated varicella in children usually requires no specific treatment, oral acyclovir initiated within 24 hours of rash onset reduces the number of lesions, duration of fever, and healing time compared with placebo in children, adolescents, and adults.", [["oral", "ANATOMY", 89, 93], ["lesions", "ANATOMY", 166, 173], ["varicella", "DISEASE", 27, 36], ["acyclovir", "CHEMICAL", 94, 103], ["rash", "DISEASE", 133, 137], ["fever", "DISEASE", 187, 192], ["acyclovir", "CHEMICAL", 94, 103], ["children", "ORGANISM", 40, 48], ["oral", "ORGANISM_SUBDIVISION", 89, 93], ["acyclovir", "SIMPLE_CHEMICAL", 94, 103], ["lesions", "PATHOLOGICAL_FORMATION", 166, 173], ["children", "ORGANISM", 236, 244], ["children", "SPECIES", 40, 48], ["children", "SPECIES", 236, 244], ["adolescents", "SPECIES", 246, 257], ["uncomplicated varicella in children", "PROBLEM", 13, 48], ["specific treatment", "TREATMENT", 69, 87], ["oral acyclovir", "TREATMENT", 89, 103], ["rash onset", "PROBLEM", 133, 143], ["lesions", "PROBLEM", 166, 173], ["fever", "PROBLEM", 187, 192], ["uncomplicated", "OBSERVATION_MODIFIER", 13, 26], ["varicella", "OBSERVATION", 27, 36], ["number", "OBSERVATION_MODIFIER", 156, 162], ["lesions", "OBSERVATION", 166, 173]]], ["309 Sequential intravenous and oral acyclovir has been used in therapy of varicella in immunocompromised children.", [["intravenous", "ANATOMY", 15, 26], ["oral", "ANATOMY", 31, 35], ["acyclovir", "CHEMICAL", 36, 45], ["varicella", "DISEASE", 74, 83], ["acyclovir", "CHEMICAL", 36, 45], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 15, 26], ["oral", "ORGANISM_SUBDIVISION", 31, 35], ["acyclovir", "SIMPLE_CHEMICAL", 36, 45], ["children", "ORGANISM", 105, 113], ["children", "SPECIES", 105, 113], ["Sequential intravenous", "TREATMENT", 4, 26], ["oral acyclovir", "TREATMENT", 31, 45], ["varicella", "PROBLEM", 74, 83], ["immunocompromised children", "OBSERVATION", 87, 113]]], ["310 In immunocompromised patients with localized zoster, intravenous acyclovir has been found to halt dissemination.", [["intravenous", "ANATOMY", 57, 68], ["zoster", "DISEASE", 49, 55], ["acyclovir", "CHEMICAL", 69, 78], ["acyclovir", "CHEMICAL", 69, 78], ["patients", "ORGANISM", 25, 33], ["zoster", "ORGANISM", 49, 55], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 57, 68], ["acyclovir", "SIMPLE_CHEMICAL", 69, 78], ["patients", "SPECIES", 25, 33], ["localized zoster", "PROBLEM", 39, 55], ["intravenous acyclovir", "TREATMENT", 57, 78], ["immunocompromised", "OBSERVATION", 7, 24], ["localized", "OBSERVATION_MODIFIER", 39, 48], ["zoster", "OBSERVATION", 49, 55], ["halt", "OBSERVATION_MODIFIER", 97, 101], ["dissemination", "OBSERVATION", 102, 115]]], ["In addition, oral acyclovir, valacyclovir, and famciclovir are effective for the treatment of zoster and may reduce the duration of postherpetic neuralgia in healthy adults.", [["oral", "ANATOMY", 13, 17], ["acyclovir", "CHEMICAL", 18, 27], ["valacyclovir", "CHEMICAL", 29, 41], ["famciclovir", "CHEMICAL", 47, 58], ["zoster", "DISEASE", 94, 100], ["postherpetic neuralgia", "DISEASE", 132, 154], ["acyclovir", "CHEMICAL", 18, 27], ["valacyclovir", "CHEMICAL", 29, 41], ["famciclovir", "CHEMICAL", 47, 58], ["oral", "ORGANISM_SUBDIVISION", 13, 17], ["acyclovir", "SIMPLE_CHEMICAL", 18, 27], ["valacyclovir", "SIMPLE_CHEMICAL", 29, 41], ["famciclovir", "SIMPLE_CHEMICAL", 47, 58], ["zoster", "ORGANISM", 94, 100], ["oral acyclovir", "TREATMENT", 13, 27], ["valacyclovir", "TREATMENT", 29, 41], ["famciclovir", "TREATMENT", 47, 58], ["zoster", "PROBLEM", 94, 100], ["postherpetic neuralgia", "PROBLEM", 132, 154], ["zoster", "OBSERVATION", 94, 100], ["postherpetic", "OBSERVATION_MODIFIER", 132, 144], ["neuralgia", "OBSERVATION", 145, 154]]], ["311 Intravenous acyclovir (10 mg/kg every 8 hours for 5 to 7 days) appears efficacious in varicella pneumonia in previously healthy adults if started early.", [["acyclovir", "CHEMICAL", 16, 25], ["varicella pneumonia", "DISEASE", 90, 109], ["acyclovir", "CHEMICAL", 16, 25], ["acyclovir", "SIMPLE_CHEMICAL", 16, 25], ["Intravenous acyclovir", "TREATMENT", 4, 25], ["varicella pneumonia", "PROBLEM", 90, 109], ["varicella", "OBSERVATION_MODIFIER", 90, 99], ["pneumonia", "OBSERVATION", 100, 109]]], ["312Key Points\u25a0 Viral infections, important causes of disease of the respiratory tract, are associated with substantial morbidity and mortality in all age groups. \u25a0 Clinical syndromes such as the common cold, pharyngitis, acute bronchitis, influenza-like illness, croup, include cough, dyspnea, pleuritic chest pain, and hemoptysis.", [["respiratory tract", "ANATOMY", 68, 85], ["chest", "ANATOMY", 304, 309], ["Viral infections", "DISEASE", 15, 31], ["disease of the respiratory tract", "DISEASE", 53, 85], ["pharyngitis", "DISEASE", 208, 219], ["acute bronchitis", "DISEASE", 221, 237], ["influenza-like illness", "DISEASE", 239, 261], ["croup", "DISEASE", 263, 268], ["cough", "DISEASE", 278, 283], ["dyspnea", "DISEASE", 285, 292], ["pleuritic chest pain", "DISEASE", 294, 314], ["hemoptysis", "DISEASE", 320, 330], ["respiratory tract", "ORGANISM_SUBDIVISION", 68, 85], ["Viral infections", "PROBLEM", 15, 31], ["disease of the respiratory tract", "PROBLEM", 53, 85], ["substantial morbidity", "PROBLEM", 107, 128], ["Clinical syndromes", "PROBLEM", 164, 182], ["the common cold", "PROBLEM", 191, 206], ["pharyngitis", "PROBLEM", 208, 219], ["acute bronchitis", "PROBLEM", 221, 237], ["influenza", "PROBLEM", 239, 248], ["croup", "PROBLEM", 263, 268], ["cough", "PROBLEM", 278, 283], ["dyspnea", "PROBLEM", 285, 292], ["pleuritic chest pain", "PROBLEM", 294, 314], ["hemoptysis", "PROBLEM", 320, 330], ["Viral infections", "OBSERVATION", 15, 31], ["disease", "OBSERVATION", 53, 60], ["respiratory tract", "ANATOMY", 68, 85], ["substantial", "OBSERVATION_MODIFIER", 107, 118], ["morbidity", "OBSERVATION", 119, 128], ["pharyngitis", "OBSERVATION", 208, 219], ["acute", "OBSERVATION_MODIFIER", 221, 226], ["bronchitis", "OBSERVATION", 227, 237], ["pleuritic", "ANATOMY", 294, 303], ["chest", "ANATOMY", 304, 309], ["hemoptysis", "OBSERVATION", 320, 330]]], ["Physical findings other than fever and tachypnea are often modest.", [["fever", "DISEASE", 29, 34], ["tachypnea", "DISEASE", 39, 48], ["fever", "PROBLEM", 29, 34], ["tachypnea", "PROBLEM", 39, 48], ["tachypnea", "OBSERVATION", 39, 48], ["modest", "OBSERVATION_MODIFIER", 59, 65]]], ["The intensity of the rash does not necessarily correlate with the severity of pneumonia.", [["rash", "DISEASE", 21, 25], ["pneumonia", "DISEASE", 78, 87], ["the rash", "PROBLEM", 17, 25], ["pneumonia", "PROBLEM", 78, 87], ["intensity", "OBSERVATION_MODIFIER", 4, 13], ["rash", "OBSERVATION", 21, 25], ["pneumonia", "OBSERVATION", 78, 87]]], ["The characteristic chest radiographic pattern is that of diffuse nodular (1 to 10 mm) opacities ( Fig. 32-11 , eFig. , which may resolve with miliary calcified nodules (eFig. .", [["chest", "ANATOMY", 19, 24], ["miliary calcified nodules", "ANATOMY", 142, 167], ["opacities", "DISEASE", 86, 95], ["chest", "ORGAN", 19, 24], ["miliary calcified nodules", "CANCER", 142, 167], ["The characteristic chest radiographic pattern", "TEST", 0, 45], ["diffuse nodular (1 to 10 mm) opacities", "PROBLEM", 57, 95], ["Fig.", "TEST", 98, 102], ["eFig", "TEST", 111, 115], ["miliary calcified nodules", "PROBLEM", 142, 167], ["chest", "ANATOMY", 19, 24], ["diffuse", "OBSERVATION_MODIFIER", 57, 64], ["nodular", "OBSERVATION_MODIFIER", 65, 72], ["1 to 10 mm", "OBSERVATION_MODIFIER", 74, 84], ["opacities", "OBSERVATION", 86, 95], ["may resolve with", "UNCERTAINTY", 125, 141], ["miliary", "OBSERVATION_MODIFIER", 142, 149], ["calcified", "OBSERVATION_MODIFIER", 150, 159], ["nodules", "OBSERVATION", 160, 167]]], ["303 Hilar lymphadenopathy, pleural effusions, and peribronchial opacities are frequently present.", [["Hilar lymphadenopathy", "ANATOMY", 4, 25], ["pleural effusions", "ANATOMY", 27, 44], ["peribronchial opacities", "ANATOMY", 50, 73], ["lymphadenopathy", "DISEASE", 10, 25], ["pleural effusions", "DISEASE", 27, 44], ["peribronchial opacities", "DISEASE", 50, 73], ["pleural effusions", "CANCER", 27, 44], ["peribronchial opacities", "CANCER", 50, 73], ["Hilar lymphadenopathy", "PROBLEM", 4, 25], ["pleural effusions", "PROBLEM", 27, 44], ["peribronchial opacities", "PROBLEM", 50, 73], ["Hilar", "ANATOMY", 4, 9], ["lymphadenopathy", "OBSERVATION", 10, 25], ["pleural", "ANATOMY", 27, 34], ["effusions", "OBSERVATION", 35, 44], ["peribronchial", "ANATOMY", 50, 63], ["opacities", "OBSERVATION", 64, 73]]], ["Pulmonary infarction may complicate the clinical picture.", [["Pulmonary", "ANATOMY", 0, 9], ["Pulmonary infarction", "DISEASE", 0, 20], ["Pulmonary", "ORGAN", 0, 9], ["Pulmonary infarction", "PROBLEM", 0, 20], ["the clinical picture", "PROBLEM", 36, 56], ["infarction", "OBSERVATION", 10, 20]]], ["Chest CT in patients with varicella pneumonia typically shows multifocal or diffuse, variably sized nodules (1 to 10 mm), which may be circumscribed or poorly defined (eFig. .", [["nodules", "ANATOMY", 100, 107], ["varicella pneumonia", "DISEASE", 26, 45], ["patients", "ORGANISM", 12, 20], ["nodules", "CANCER", 100, 107], ["patients", "SPECIES", 12, 20], ["Chest CT", "TEST", 0, 8], ["varicella pneumonia", "PROBLEM", 26, 45], ["multifocal or diffuse, variably sized nodules", "PROBLEM", 62, 107], ["eFig", "TEST", 168, 172], ["varicella", "ANATOMY", 26, 35], ["pneumonia", "OBSERVATION", 36, 45], ["multifocal", "OBSERVATION_MODIFIER", 62, 72], ["diffuse", "OBSERVATION_MODIFIER", 76, 83], ["variably", "OBSERVATION_MODIFIER", 85, 93], ["sized", "OBSERVATION_MODIFIER", 94, 99], ["nodules", "OBSERVATION", 100, 107], ["1 to 10 mm", "OBSERVATION_MODIFIER", 109, 119], ["may be", "UNCERTAINTY", 128, 134], ["circumscribed", "OBSERVATION_MODIFIER", 135, 148], ["poorly defined", "OBSERVATION_MODIFIER", 152, 166]]], ["Ground-glass opacity halos may be seen around some of the nodules.", [["nodules", "ANATOMY", 58, 65], ["nodules", "CANCER", 58, 65], ["Ground-glass opacity halos", "PROBLEM", 0, 26], ["the nodules", "PROBLEM", 54, 65], ["-", "OBSERVATION_MODIFIER", 6, 7], ["glass opacity", "OBSERVATION", 7, 20], ["halos", "OBSERVATION", 21, 26], ["may be seen", "UNCERTAINTY", 27, 38], ["nodules", "OBSERVATION", 58, 65]]], ["Pulmonary function studies have found normal expiratory flow values but decreased carbon monoxide diffusing capacity, which may persist for months.", [["Pulmonary", "ANATOMY", 0, 9], ["carbon monoxide", "CHEMICAL", 82, 97], ["carbon monoxide", "CHEMICAL", 82, 97], ["Pulmonary", "ORGAN", 0, 9], ["carbon monoxide", "SIMPLE_CHEMICAL", 82, 97], ["Pulmonary function studies", "TEST", 0, 26], ["decreased carbon monoxide diffusing capacity", "PROBLEM", 72, 116], ["normal", "OBSERVATION", 38, 44], ["expiratory flow", "OBSERVATION", 45, 60], ["decreased", "OBSERVATION_MODIFIER", 72, 81], ["carbon monoxide", "OBSERVATION", 82, 97]]], ["However, many individuals with radiographic changes are relatively asymptomatic.Key PointsHerpes Zoster.", [["radiographic changes", "PROBLEM", 31, 51], ["Key PointsHerpes Zoster", "PROBLEM", 80, 103], ["Zoster", "OBSERVATION", 97, 103]]], ["Zoster represents reactivation of latent virus along one to three dermatomes and, in adults, is usually associated with pain.", [["Zoster", "CHEMICAL", 0, 6], ["pain", "DISEASE", 120, 124], ["Zoster", "PROBLEM", 0, 6], ["latent virus", "PROBLEM", 34, 46], ["pain", "PROBLEM", 120, 124], ["latent", "OBSERVATION_MODIFIER", 34, 40], ["virus", "OBSERVATION", 41, 46]]], ["The thoracic dermatomes are involved in about one half of cases.", [["thoracic dermatomes", "ANATOMY", 4, 23], ["thoracic dermatomes", "MULTI-TISSUE_STRUCTURE", 4, 23], ["thoracic dermatomes", "ANATOMY", 4, 23]]], ["Prolonged severe pain, or postherpetic neuralgia, can be a serious complication, with increased frequency in those older than 50.Key PointsZoster presents more often in those receiving immunosuppressive therapy or chemotherapy for malignancies and at anatomic sites irradiated for treatment of malignancies.", [["malignancies", "ANATOMY", 231, 243], ["sites", "ANATOMY", 260, 265], ["malignancies", "ANATOMY", 294, 306], ["pain", "DISEASE", 17, 21], ["postherpetic neuralgia", "DISEASE", 26, 48], ["malignancies", "DISEASE", 231, 243], ["malignancies", "DISEASE", 294, 306], ["malignancies", "CANCER", 231, 243], ["malignancies", "CANCER", 294, 306], ["Prolonged severe pain", "PROBLEM", 0, 21], ["postherpetic neuralgia", "PROBLEM", 26, 48], ["a serious complication", "PROBLEM", 57, 79], ["immunosuppressive therapy", "TREATMENT", 185, 210], ["chemotherapy", "TREATMENT", 214, 226], ["malignancies", "PROBLEM", 231, 243], ["malignancies", "PROBLEM", 294, 306], ["severe", "OBSERVATION_MODIFIER", 10, 16], ["pain", "OBSERVATION", 17, 21], ["postherpetic", "OBSERVATION_MODIFIER", 26, 38], ["neuralgia", "OBSERVATION", 39, 48], ["more often", "OBSERVATION_MODIFIER", 155, 165], ["malignancies", "OBSERVATION", 294, 306]]], ["Depending on the degree of immunosuppression, herpes zoster may develop in 30% or more of patients.", [["herpes zoster", "DISEASE", 46, 59], ["herpes zoster", "ORGANISM", 46, 59], ["patients", "ORGANISM", 90, 98], ["herpes zoster", "SPECIES", 46, 59], ["patients", "SPECIES", 90, 98], ["immunosuppression", "TREATMENT", 27, 44], ["herpes zoster", "PROBLEM", 46, 59], ["immunosuppression", "OBSERVATION", 27, 44]]], ["Cutaneous dissemination (defined as more than 20 lesions outside the primary dermatome) develops in 25% to 50% of immunosuppressed patients and in up to 2% of apparently normal patients with zoster.", [["Cutaneous", "ANATOMY", 0, 9], ["lesions", "ANATOMY", 49, 56], ["primary dermatome", "ANATOMY", 69, 86], ["immunosuppressed", "DISEASE", 114, 130], ["zoster", "DISEASE", 191, 197], ["lesions", "CANCER", 49, 56], ["dermatome", "ORGAN", 77, 86], ["patients", "ORGANISM", 131, 139], ["patients", "ORGANISM", 177, 185], ["zoster", "ORGANISM", 191, 197], ["patients", "SPECIES", 131, 139], ["patients", "SPECIES", 177, 185], ["Cutaneous dissemination", "PROBLEM", 0, 23], ["20 lesions", "PROBLEM", 46, 56], ["zoster", "PROBLEM", 191, 197], ["dissemination", "OBSERVATION", 10, 23], ["normal", "OBSERVATION", 170, 176], ["zoster", "OBSERVATION", 191, 197]]], ["It is associated with visceral involvement including pneumonitis, as well as hepatitis, meningoencephalitis, and uveitis in approximately one half of those bronchiolitis, and pneumonia-may be caused by several different viruses, and most of the major respiratory viruses may cause more than one clinical syndrome. \u25a0 There is increasing recognition of the role of respiratory viruses in lower respiratory tract disease in immunocompromised individuals; the growing availability of molecular diagnostic tests will lead to many more viral diagnoses. \u25a0 Effective vaccines are available for the prevention of disease due to some viral pathogens, including influenza, measles, mumps, rubella, and varicella virus, and antiviral agents are available for some, including influenza, herpes viruses, cytomegalovirus, and varicella-zoster virus.", [["visceral", "ANATOMY", 22, 30], ["lower respiratory tract", "ANATOMY", 386, 409], ["pneumonitis", "DISEASE", 53, 64], ["hepatitis", "DISEASE", 77, 86], ["meningoencephalitis", "DISEASE", 88, 107], ["uveitis", "DISEASE", 113, 120], ["bronchiolitis", "DISEASE", 156, 169], ["pneumonia", "DISEASE", 175, 184], ["respiratory viruses", "DISEASE", 251, 270], ["respiratory viruses", "DISEASE", 363, 382], ["respiratory tract disease", "DISEASE", 392, 417], ["influenza", "DISEASE", 651, 660], ["measles, mumps, rubella, and varicella virus", "DISEASE", 662, 706], ["influenza, herpes viruses", "DISEASE", 763, 788], ["cytomegalovirus", "DISEASE", 790, 805], ["varicella-zoster virus", "DISEASE", 811, 833], ["visceral", "ORGANISM_SUBDIVISION", 22, 30], ["respiratory viruses", "ORGANISM", 363, 382], ["lower", "ORGANISM_SUBDIVISION", 386, 391], ["respiratory tract", "ORGANISM_SUBDIVISION", 392, 409], ["varicella virus", "ORGANISM", 691, 706], ["herpes viruses", "ORGANISM", 774, 788], ["cytomegalovirus", "ORGANISM", 790, 805], ["varicella-zoster virus", "ORGANISM", 811, 833], ["mumps, rubella", "SPECIES", 671, 685], ["varicella virus", "SPECIES", 691, 706], ["varicella-zoster virus", "SPECIES", 811, 833], ["varicella virus", "SPECIES", 691, 706], ["varicella-zoster virus", "SPECIES", 811, 833], ["visceral involvement", "PROBLEM", 22, 42], ["pneumonitis", "PROBLEM", 53, 64], ["hepatitis", "PROBLEM", 77, 86], ["meningoencephalitis", "PROBLEM", 88, 107], ["uveitis", "PROBLEM", 113, 120], ["those bronchiolitis", "PROBLEM", 150, 169], ["pneumonia", "PROBLEM", 175, 184], ["several different viruses", "PROBLEM", 202, 227], ["the major respiratory viruses", "PROBLEM", 241, 270], ["one clinical syndrome", "PROBLEM", 291, 312], ["respiratory viruses", "PROBLEM", 363, 382], ["lower respiratory tract disease", "PROBLEM", 386, 417], ["immunocompromised individuals", "PROBLEM", 421, 450], ["molecular diagnostic tests", "TEST", 480, 506], ["Effective vaccines", "TREATMENT", 549, 567], ["disease", "PROBLEM", 604, 611], ["some viral pathogens", "PROBLEM", 619, 639], ["influenza", "PROBLEM", 651, 660], ["measles", "PROBLEM", 662, 669], ["mumps", "PROBLEM", 671, 676], ["rubella", "PROBLEM", 678, 685], ["varicella virus", "PROBLEM", 691, 706], ["antiviral agents", "TREATMENT", 712, 728], ["influenza", "PROBLEM", 763, 772], ["herpes viruses", "PROBLEM", 774, 788], ["cytomegalovirus", "PROBLEM", 790, 805], ["varicella", "PROBLEM", 811, 820], ["zoster virus", "PROBLEM", 821, 833], ["associated with", "UNCERTAINTY", 6, 21], ["visceral", "ANATOMY", 22, 30], ["involvement", "OBSERVATION", 31, 42], ["pneumonitis", "OBSERVATION", 53, 64], ["hepatitis", "OBSERVATION", 77, 86], ["meningoencephalitis", "OBSERVATION", 88, 107], ["uveitis", "OBSERVATION", 113, 120], ["approximately", "OBSERVATION_MODIFIER", 124, 137], ["one half", "OBSERVATION_MODIFIER", 138, 146], ["bronchiolitis", "OBSERVATION", 156, 169], ["pneumonia", "OBSERVATION", 175, 184], ["may be caused", "UNCERTAINTY", 185, 198], ["several", "OBSERVATION_MODIFIER", 202, 209], ["different", "OBSERVATION_MODIFIER", 210, 219], ["viruses", "OBSERVATION", 220, 227], ["respiratory viruses", "OBSERVATION", 251, 270], ["increasing", "OBSERVATION_MODIFIER", 325, 335], ["respiratory viruses", "OBSERVATION", 363, 382], ["lower", "ANATOMY_MODIFIER", 386, 391], ["respiratory tract", "ANATOMY", 392, 409], ["immunocompromised individuals", "OBSERVATION", 421, 450], ["varicella virus", "OBSERVATION", 691, 706], ["zoster virus", "OBSERVATION", 821, 833]]], ["For most respiratory viral pathogens, neither vaccines nor antivirals are currently available. \u25a0 New respiratory viruses are continually emerging at the interface between human and animal species.", [["respiratory viral pathogens", "DISEASE", 9, 36], ["respiratory viruses", "DISEASE", 101, 120], ["human", "ORGANISM", 171, 176], ["human", "SPECIES", 171, 176], ["human", "SPECIES", 171, 176], ["most respiratory viral pathogens", "PROBLEM", 4, 36], ["neither vaccines", "TREATMENT", 38, 54], ["antivirals", "TREATMENT", 59, 69], ["New respiratory viruses", "PROBLEM", 97, 120], ["respiratory viruses", "OBSERVATION", 101, 120], ["animal species", "OBSERVATION", 181, 195]]], ["Recent examples include avian and swine influenza viruses, severe acute respiratory syndrome, Middle East respiratory syndrome, and hantavirus pulmonary syndrome.", [["pulmonary", "ANATOMY", 143, 152], ["avian and swine influenza viruses", "DISEASE", 24, 57], ["acute respiratory syndrome", "DISEASE", 66, 92], ["Middle East respiratory syndrome", "DISEASE", 94, 126], ["hantavirus pulmonary syndrome", "DISEASE", 132, 161], ["avian", "ORGANISM", 24, 29], ["swine influenza viruses", "ORGANISM", 34, 57], ["pulmonary", "ORGAN", 143, 152], ["swine influenza viruses", "SPECIES", 34, 57], ["swine influenza viruses", "SPECIES", 34, 57], ["avian and swine influenza viruses", "PROBLEM", 24, 57], ["severe acute respiratory syndrome", "PROBLEM", 59, 92], ["Middle East respiratory syndrome", "PROBLEM", 94, 126], ["hantavirus pulmonary syndrome", "PROBLEM", 132, 161], ["influenza viruses", "OBSERVATION", 40, 57], ["severe", "OBSERVATION_MODIFIER", 59, 65], ["acute", "OBSERVATION_MODIFIER", 66, 71], ["respiratory syndrome", "OBSERVATION", 72, 92], ["Middle", "ANATOMY_MODIFIER", 94, 100], ["respiratory syndrome", "OBSERVATION", 106, 126], ["hantavirus", "OBSERVATION", 132, 142], ["pulmonary", "ANATOMY", 143, 152], ["syndrome", "OBSERVATION", 153, 161]]], ["Continued surveillance for new agents is critical in controlling pandemics.Key ReadingsAssiri year-old woman with no significant previous medical history presenting to the emergency department with fever, cough, and nasal congestion shows multifocal, perihilar predominantly linear opacity and bronchovascular thickening and hazy opacities.", [["nasal", "ANATOMY", 216, 221], ["perihilar", "ANATOMY", 251, 260], ["bronchovascular", "ANATOMY", 294, 309], ["fever", "DISEASE", 198, 203], ["cough", "DISEASE", 205, 210], ["nasal congestion", "DISEASE", 216, 232], ["opacities", "DISEASE", 330, 339], ["woman", "ORGANISM", 103, 108], ["woman", "SPECIES", 103, 108], ["new agents", "TREATMENT", 27, 37], ["fever", "PROBLEM", 198, 203], ["cough", "PROBLEM", 205, 210], ["nasal congestion", "PROBLEM", 216, 232], ["multifocal, perihilar predominantly linear opacity", "PROBLEM", 239, 289], ["bronchovascular thickening", "PROBLEM", 294, 320], ["hazy opacities", "PROBLEM", 325, 339], ["fever", "OBSERVATION", 198, 203], ["cough", "OBSERVATION", 205, 210], ["nasal", "ANATOMY", 216, 221], ["congestion", "OBSERVATION", 222, 232], ["multifocal", "OBSERVATION_MODIFIER", 239, 249], ["perihilar", "ANATOMY_MODIFIER", 251, 260], ["predominantly", "OBSERVATION_MODIFIER", 261, 274], ["linear", "OBSERVATION_MODIFIER", 275, 281], ["opacity", "OBSERVATION", 282, 289], ["bronchovascular", "ANATOMY_MODIFIER", 294, 309], ["thickening", "OBSERVATION", 310, 320], ["hazy", "OBSERVATION_MODIFIER", 325, 329], ["opacities", "OBSERVATION", 330, 339]]], ["The patient had been seen as an outpatient and treated with several broad-spectrum antibiotics with no improvement.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["several broad-spectrum antibiotics", "TREATMENT", 60, 94]]], ["At the time the chest radiograph was performed, the patient was mildly leukopenic with an oxygen saturation of 82% on room air.", [["chest", "ANATOMY", 16, 21], ["oxygen", "CHEMICAL", 90, 96], ["oxygen", "CHEMICAL", 90, 96], ["patient", "ORGANISM", 52, 59], ["oxygen", "SIMPLE_CHEMICAL", 90, 96], ["patient", "SPECIES", 52, 59], ["the chest radiograph", "TEST", 12, 32], ["mildly leukopenic", "PROBLEM", 64, 81], ["an oxygen saturation", "TEST", 87, 107], ["chest", "ANATOMY", 16, 21], ["mildly", "OBSERVATION_MODIFIER", 64, 70], ["leukopenic", "OBSERVATION", 71, 81], ["oxygen saturation", "OBSERVATION", 90, 107]]], ["B-E, Axial chest CT displayed in lung windows shows multifocal, bilateral, nonsegmental areas of ground-glass opacity, in some areas peripherally and peribronchially distributed, associated with intralobular interstitial thickening, mild interlobular septal thickening, and a few areas of consolidation.", [["chest", "ANATOMY", 11, 16], ["lung", "ANATOMY", 33, 37], ["intralobular interstitial", "ANATOMY", 195, 220], ["interlobular septal", "ANATOMY", 238, 257], ["B-E", "GENE_OR_GENE_PRODUCT", 0, 3], ["lung", "ORGAN", 33, 37], ["intralobular interstitial", "TISSUE", 195, 220], ["interlobular septal", "PATHOLOGICAL_FORMATION", 238, 257], ["Axial chest CT", "TEST", 5, 19], ["lung windows", "TEST", 33, 45], ["multifocal, bilateral, nonsegmental areas of ground-glass opacity", "PROBLEM", 52, 117], ["intralobular interstitial thickening", "PROBLEM", 195, 231], ["mild interlobular septal thickening", "PROBLEM", 233, 268], ["consolidation", "PROBLEM", 289, 302], ["chest", "ANATOMY", 11, 16], ["lung", "ANATOMY", 33, 37], ["multifocal", "OBSERVATION_MODIFIER", 52, 62], ["bilateral", "ANATOMY_MODIFIER", 64, 73], ["nonsegmental", "OBSERVATION_MODIFIER", 75, 87], ["areas", "OBSERVATION_MODIFIER", 88, 93], ["ground-glass opacity", "OBSERVATION", 97, 117], ["some", "OBSERVATION_MODIFIER", 122, 126], ["areas", "OBSERVATION_MODIFIER", 127, 132], ["peripherally", "ANATOMY_MODIFIER", 133, 145], ["intralobular", "ANATOMY_MODIFIER", 195, 207], ["interstitial", "ANATOMY_MODIFIER", 208, 220], ["thickening", "OBSERVATION", 221, 231], ["mild", "OBSERVATION_MODIFIER", 233, 237], ["interlobular", "ANATOMY_MODIFIER", 238, 250], ["septal", "ANATOMY_MODIFIER", 251, 257], ["thickening", "OBSERVATION", 258, 268], ["few", "OBSERVATION_MODIFIER", 276, 279], ["areas", "OBSERVATION_MODIFIER", 280, 285], ["consolidation", "OBSERVATION", 289, 302]]], ["The imaging findings are nonspecific and can be seen with numerous causes of noninfectious acute lung injury and other pulmonary infections including severe acute respiratory syndrome (SARS).", [["lung", "ANATOMY", 97, 101], ["pulmonary", "ANATOMY", 119, 128], ["acute lung injury", "DISEASE", 91, 108], ["pulmonary infections", "DISEASE", 119, 139], ["acute respiratory syndrome", "DISEASE", 157, 183], ["SARS", "DISEASE", 185, 189], ["lung", "ORGAN", 97, 101], ["pulmonary", "ORGAN", 119, 128], ["The imaging", "TEST", 0, 11], ["noninfectious acute lung injury", "PROBLEM", 77, 108], ["other pulmonary infections", "PROBLEM", 113, 139], ["severe acute respiratory syndrome", "PROBLEM", 150, 183], ["nonspecific", "OBSERVATION_MODIFIER", 25, 36], ["noninfectious", "OBSERVATION_MODIFIER", 77, 90], ["acute", "OBSERVATION_MODIFIER", 91, 96], ["lung", "ANATOMY", 97, 101], ["injury", "OBSERVATION", 102, 108], ["pulmonary", "ANATOMY", 119, 128], ["infections", "OBSERVATION", 129, 139], ["severe", "OBSERVATION_MODIFIER", 150, 156], ["acute", "OBSERVATION_MODIFIER", 157, 162], ["respiratory syndrome", "OBSERVATION", 163, 183]]], ["Surgical lung biopsy showed diffuse alveolar damage with some intrabronchiolar and alveolar inflammatory cells suggesting the possibility of an infectious insult, and bronchoscopy before the surgical biopsy recovered influenza A. The patient suffered hypoxic respiratory failure requiring mechanical ventilation but subsequently recovered.", [["lung", "ANATOMY", 9, 13], ["alveolar", "ANATOMY", 36, 44], ["intrabronchiolar", "ANATOMY", 62, 78], ["alveolar inflammatory cells", "ANATOMY", 83, 110], ["respiratory", "ANATOMY", 259, 270], ["alveolar damage", "DISEASE", 36, 51], ["infectious insult", "DISEASE", 144, 161], ["respiratory failure", "DISEASE", 259, 278], ["lung biopsy", "MULTI-TISSUE_STRUCTURE", 9, 20], ["alveolar", "TISSUE", 36, 44], ["alveolar inflammatory cells", "CELL", 83, 110], ["patient", "ORGANISM", 234, 241], ["intrabronchiolar and alveolar inflammatory cells", "CELL_TYPE", 62, 110], ["patient", "SPECIES", 234, 241], ["Surgical lung biopsy", "TEST", 0, 20], ["diffuse alveolar damage", "PROBLEM", 28, 51], ["some intrabronchiolar and alveolar inflammatory cells", "PROBLEM", 57, 110], ["an infectious insult", "PROBLEM", 141, 161], ["bronchoscopy", "TEST", 167, 179], ["the surgical biopsy", "TEST", 187, 206], ["influenza A.", "PROBLEM", 217, 229], ["hypoxic respiratory failure", "PROBLEM", 251, 278], ["mechanical ventilation", "TREATMENT", 289, 311], ["lung", "ANATOMY", 9, 13], ["biopsy", "OBSERVATION", 14, 20], ["diffuse", "OBSERVATION_MODIFIER", 28, 35], ["alveolar damage", "OBSERVATION", 36, 51], ["some", "OBSERVATION_MODIFIER", 57, 61], ["intrabronchiolar", "OBSERVATION_MODIFIER", 62, 78], ["alveolar", "ANATOMY_MODIFIER", 83, 91], ["inflammatory cells", "OBSERVATION", 92, 110], ["suggesting the possibility of", "UNCERTAINTY", 111, 140], ["infectious", "OBSERVATION_MODIFIER", 144, 154], ["insult", "OBSERVATION", 155, 161], ["hypoxic", "OBSERVATION_MODIFIER", 251, 258], ["respiratory failure", "OBSERVATION", 259, 278], ["mechanical ventilation", "OBSERVATION", 289, 311]]]], "1689eb004e24a579f4b0a41b4847106be337edec": [["CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8]]]], "PMC7131212": [], "81dca255b6a8ee974209757ba48e9e672783f51d": [["Dear Editors,The rapidly expanding COVID-19 pandemic and associated global health crisis have impacted all areas of daily life, including medical treatment.", [["global health crisis", "PROBLEM", 68, 88], ["medical treatment", "TREATMENT", 138, 155], ["global", "OBSERVATION_MODIFIER", 68, 74], ["health crisis", "OBSERVATION", 75, 88]]], ["Some groups of patients are considered to be facing more serious complications from SARS-CoV-2, including cancer patients [1] .", [["cancer", "ANATOMY", 106, 112], ["SARS", "DISEASE", 84, 88], ["cancer", "DISEASE", 106, 112], ["patients", "ORGANISM", 15, 23], ["cancer", "CANCER", 106, 112], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 15, 23], ["patients", "SPECIES", 113, 121], ["SARS", "PROBLEM", 84, 88]]], ["Data are limited but suggest that the likelihood of a severe illness from COVID-19 is higher among adult patients with cancer, especially for those with active disease [2] .", [["cancer", "ANATOMY", 119, 125], ["illness", "DISEASE", 61, 68], ["cancer", "DISEASE", 119, 125], ["patients", "ORGANISM", 105, 113], ["cancer", "CANCER", 119, 125], ["patients", "SPECIES", 105, 113], ["a severe illness", "PROBLEM", 52, 68], ["COVID", "TEST", 74, 79], ["cancer", "PROBLEM", 119, 125], ["active disease", "PROBLEM", 153, 167], ["severe", "OBSERVATION_MODIFIER", 54, 60], ["illness", "OBSERVATION", 61, 68], ["cancer", "OBSERVATION", 119, 125]]], ["Thus, when performing thyroid surgery, surgeons must adopt a decisionmaking approach in response to the COVID-19 pandemic in order to balance the risks of postponing thyroid interventions versus the risks of COVID-19 exposure and possible complications.Dear Editors,The World Health Organization declared the outbreak a Public Health Emergency of International Concern on January 30, 2020, and a pandemic on March 11.", [["thyroid", "ANATOMY", 22, 29], ["thyroid", "ANATOMY", 166, 173], ["COVID-19", "CHEMICAL", 208, 216], ["COVID-19", "CHEMICAL", 208, 216], ["thyroid", "ORGAN", 22, 29], ["thyroid", "ORGAN", 166, 173], ["thyroid surgery", "TREATMENT", 22, 37], ["the COVID", "TEST", 100, 109], ["postponing thyroid interventions", "TREATMENT", 155, 187], ["COVID-19 exposure", "TREATMENT", 208, 225], ["complications", "PROBLEM", 239, 252], ["thyroid", "ANATOMY", 22, 29], ["thyroid", "ANATOMY", 166, 173]]], ["More than 532,000 people have died of COVID-19 [2] .Dear Editors,In Vietnam, a developing country with a population of more than 97 million, the first case of SARS-CoV-2 was found on January 23, 2020.", [["SARS", "DISEASE", 159, 163], ["COVID-19", "CHEMICAL", 38, 46], ["people", "ORGANISM", 18, 24], ["people", "SPECIES", 18, 24], ["SARS-CoV", "SPECIES", 159, 167], ["COVID", "TEST", 38, 43], ["SARS", "PROBLEM", 159, 163]]], ["Of these cases, 340 have recovered and no deaths have been reported [2] .", [["deaths", "DISEASE", 42, 48]]], ["The COVID-19 epidemic in Vietnam could be divided in three phases [3] .Dear Editors,The first phase lasted from January 23 to February 13, 2020, and was characterized by detecting and treating 16 cases related to Wuhan in China.", [["The COVID", "TEST", 0, 9]]], ["All of these cases recovered and the last patient was discharged on February 25, 2020, thus freeing Vietnam temporarily from the COVID-19 pandemic for 20 days [3] .Dear Editors,The second phase was from March 6 to April 16 and was characterized by the emergence of a further epidemic involving 253 new cases detected in the country.", [["patient", "ORGANISM", 42, 49], ["patient", "SPECIES", 42, 49]]], ["The other patients with Covid-19 came from cluster transmission in high population density areas.", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["Covid", "TEST", 24, 29], ["high population density areas", "PROBLEM", 67, 96], ["high population", "OBSERVATION_MODIFIER", 67, 82], ["density", "OBSERVATION", 83, 90]]], ["All confirmed cases came from other countries and were detected while people were in 14-day quarantine after entry to Vietnam.", [["people", "ORGANISM", 70, 76], ["people", "SPECIES", 70, 76]]], ["There have been no cases detected of cluster transmission [3] .Dear Editors,From March 31 to April 22, Vietnam implemented societal interventions, such as social distancing measures, stay at home orders, borders closure and nationwide lockdowns.Dear Editors,Vietnam's Minister of Health issued recommendations to postpone or cancel most thyroid surgery.", [["thyroid", "ANATOMY", 337, 344], ["thyroid", "ORGAN", 337, 344], ["societal interventions", "TREATMENT", 123, 145], ["borders closure", "TREATMENT", 204, 219], ["thyroid surgery", "TREATMENT", 337, 352], ["no", "UNCERTAINTY", 16, 18], ["thyroid", "ANATOMY", 337, 344], ["surgery", "OBSERVATION", 345, 352]]], ["Obviously, however, some patients require urgent or active intervention in a timely fashion:Dear Editors,\u2022 Life-threatening or severely symptomatic Graves' disease that cannot be controlled medically.Dear Editors,\u2022 Goiter causing airway compromise.Dear Editors,\u2022 Thyroid cancers that imminently threatening the life or health of the patient, such as those with short doubling time or aggressive recurrence.Dear Editors,\u2022 Open biopsy to confirm a suspected diagnosis of anaplastic thyroid cancer or thyroid lymphoma in order to direct appropriate treatment.Dear Editors,Other types of thyroid surgery can be postponed for 2 to 3 months:Dear Editors,\u2022 Differentiated thyroid cancer (both in children and in pregnant women).Dear Editors,\u2022 Medullary thyroid cancer.Dear Editors,\u2022 Recurrent thyroid carcinoma.Dear Editors,\u2022 Thyroid goiter (very rarely acutely symptomatic).Dear Editors,\u2022 Indeterminate thyroid nodules without documented progression.Dear Editors,\u2022 Large indeterminate thyroid nodules (particularly suspected malignancies) with documented progression.Dear Editors,\u2022 Medically controlled Grave's disease.Dear Editors,\u2022 Primary hyperparathyroidism.Dear Editors,These restrictions were eased along with societal restrictions on April 23, and Vietnam's Minister of Health recommended that all planned surgery could go ahead.", [["airway", "ANATOMY", 230, 236], ["Thyroid cancers", "ANATOMY", 263, 278], ["anaplastic thyroid cancer", "ANATOMY", 469, 494], ["thyroid lymphoma", "ANATOMY", 498, 514], ["thyroid", "ANATOMY", 584, 591], ["thyroid cancer", "ANATOMY", 665, 679], ["Medullary thyroid cancer", "ANATOMY", 736, 760], ["thyroid carcinoma", "ANATOMY", 786, 803], ["Thyroid goiter", "ANATOMY", 819, 833], ["thyroid nodules", "ANATOMY", 897, 912], ["thyroid nodules", "ANATOMY", 979, 994], ["malignancies", "ANATOMY", 1019, 1031], ["Graves' disease", "DISEASE", 148, 163], ["Thyroid cancers", "DISEASE", 263, 278], ["anaplastic thyroid cancer", "DISEASE", 469, 494], ["thyroid lymphoma", "DISEASE", 498, 514], ["thyroid cancer", "DISEASE", 665, 679], ["Medullary thyroid cancer", "DISEASE", 736, 760], ["thyroid carcinoma", "DISEASE", 786, 803], ["Thyroid goiter", "DISEASE", 819, 833], ["thyroid nodules", "DISEASE", 979, 994], ["malignancies", "DISEASE", 1019, 1031], ["Grave's disease", "DISEASE", 1097, 1112], ["hyperparathyroidism", "DISEASE", 1136, 1155], ["patients", "ORGANISM", 25, 33], ["airway", "MULTI-TISSUE_STRUCTURE", 230, 236], ["Thyroid cancers", "CANCER", 263, 278], ["patient", "ORGANISM", 333, 340], ["anaplastic thyroid cancer", "CANCER", 469, 494], ["thyroid lymphoma", "CANCER", 498, 514], ["thyroid", "ORGAN", 584, 591], ["Differentiated thyroid cancer", "CANCER", 650, 679], ["children", "ORGANISM", 689, 697], ["women", "ORGANISM", 714, 719], ["Medullary thyroid cancer", "CANCER", 736, 760], ["thyroid carcinoma", "CANCER", 786, 803], ["Thyroid", "ORGAN", 819, 826], ["thyroid nodules", "CANCER", 897, 912], ["thyroid nodules", "CANCER", 979, 994], ["malignancies", "CANCER", 1019, 1031], ["patients", "SPECIES", 25, 33], ["patient", "SPECIES", 333, 340], ["children", "SPECIES", 689, 697], ["women", "SPECIES", 714, 719], ["urgent or active intervention", "TREATMENT", 42, 71], ["severely symptomatic Graves' disease", "PROBLEM", 127, 163], ["Goiter", "PROBLEM", 215, 221], ["airway compromise", "PROBLEM", 230, 247], ["Thyroid cancers", "PROBLEM", 263, 278], ["aggressive recurrence", "PROBLEM", 384, 405], ["Open biopsy", "TEST", 421, 432], ["anaplastic thyroid cancer", "PROBLEM", 469, 494], ["thyroid lymphoma", "PROBLEM", 498, 514], ["appropriate treatment", "TREATMENT", 534, 555], ["thyroid surgery", "TREATMENT", 584, 599], ["Differentiated thyroid cancer", "PROBLEM", 650, 679], ["Medullary thyroid cancer", "PROBLEM", 736, 760], ["Recurrent thyroid carcinoma", "PROBLEM", 776, 803], ["Thyroid goiter", "PROBLEM", 819, 833], ["Indeterminate thyroid nodules", "PROBLEM", 883, 912], ["Large indeterminate thyroid nodules", "PROBLEM", 959, 994], ["suspected malignancies", "PROBLEM", 1009, 1031], ["Grave's disease", "PROBLEM", 1097, 1112], ["Primary hyperparathyroidism", "PROBLEM", 1128, 1155], ["all planned surgery", "TREATMENT", 1295, 1314], ["severely", "OBSERVATION_MODIFIER", 127, 135], ["symptomatic", "OBSERVATION_MODIFIER", 136, 147], ["Graves", "OBSERVATION", 148, 154], ["Goiter", "OBSERVATION", 215, 221], ["airway", "ANATOMY", 230, 236], ["compromise", "OBSERVATION", 237, 247], ["Thyroid", "ANATOMY", 263, 270], ["cancers", "OBSERVATION", 271, 278], ["biopsy", "OBSERVATION", 426, 432], ["anaplastic", "OBSERVATION_MODIFIER", 469, 479], ["thyroid", "ANATOMY", 480, 487], ["cancer", "OBSERVATION", 488, 494], ["thyroid", "ANATOMY", 498, 505], ["lymphoma", "OBSERVATION", 506, 514], ["thyroid", "ANATOMY", 584, 591], ["surgery", "OBSERVATION", 592, 599], ["thyroid", "ANATOMY", 665, 672], ["cancer", "OBSERVATION", 673, 679], ["Medullary", "ANATOMY_MODIFIER", 736, 745], ["thyroid", "ANATOMY", 746, 753], ["cancer", "OBSERVATION", 754, 760], ["Recurrent", "OBSERVATION_MODIFIER", 776, 785], ["thyroid", "ANATOMY", 786, 793], ["carcinoma", "OBSERVATION", 794, 803], ["Thyroid", "ANATOMY", 819, 826], ["goiter", "OBSERVATION", 827, 833], ["Indeterminate", "OBSERVATION_MODIFIER", 883, 896], ["thyroid", "ANATOMY", 897, 904], ["nodules", "OBSERVATION", 905, 912], ["without", "UNCERTAINTY", 913, 920], ["progression", "OBSERVATION_MODIFIER", 932, 943], ["Large", "OBSERVATION_MODIFIER", 959, 964], ["indeterminate", "OBSERVATION_MODIFIER", 965, 978], ["thyroid", "ANATOMY", 979, 986], ["nodules", "OBSERVATION", 987, 994], ["malignancies", "OBSERVATION", 1019, 1031], ["progression", "OBSERVATION_MODIFIER", 1049, 1060], ["Primary", "OBSERVATION_MODIFIER", 1128, 1135], ["hyperparathyroidism", "OBSERVATION", 1136, 1155]]], ["As a result, most thyroid surgery patients in Vietnam have not been affected by the COVID-19 pandemic because most thyroid tumors grow slowly.", [["thyroid", "ANATOMY", 18, 25], ["thyroid tumors", "ANATOMY", 115, 129], ["thyroid tumors", "DISEASE", 115, 129], ["thyroid", "ORGAN", 18, 25], ["patients", "ORGANISM", 34, 42], ["thyroid tumors", "CANCER", 115, 129], ["patients", "SPECIES", 34, 42], ["most thyroid surgery", "TREATMENT", 13, 33], ["the COVID", "TEST", 80, 89], ["most thyroid tumors", "PROBLEM", 110, 129], ["thyroid", "ANATOMY", 18, 25], ["thyroid", "ANATOMY", 115, 122], ["tumors", "OBSERVATION", 123, 129]]], ["In summary, the success of the Vietnamese approach in handling of the COVID-19 pandemic meant that thyroid interventions were not affected.", [["thyroid", "ANATOMY", 99, 106], ["thyroid", "ORGAN", 99, 106], ["the Vietnamese approach", "TREATMENT", 27, 50], ["the COVID", "TREATMENT", 66, 75], ["thyroid interventions", "TREATMENT", 99, 120], ["thyroid", "ANATOMY", 99, 106]]], ["As a result, most Vietnamese patients with thyroid disease have been treated normally, without any influence on their treatment.", [["thyroid", "ANATOMY", 43, 50], ["thyroid disease", "DISEASE", 43, 58], ["patients", "ORGANISM", 29, 37], ["thyroid", "ORGAN", 43, 50], ["patients", "SPECIES", 29, 37], ["thyroid disease", "PROBLEM", 43, 58], ["their treatment", "TREATMENT", 112, 127], ["thyroid", "ANATOMY", 43, 50], ["disease", "OBSERVATION", 51, 58]]], ["Thus, the successful control of the COVID-19 pandemic is key to treating thyroid disease in any nation.Conflict of interestNo author has any conflict of interest.Financial disclosersNone.", [["thyroid", "ANATOMY", 73, 80], ["thyroid disease", "DISEASE", 73, 88], ["thyroid", "ORGAN", 73, 80], ["the COVID", "TREATMENT", 32, 41], ["thyroid disease", "PROBLEM", 73, 88], ["thyroid", "ANATOMY", 73, 80], ["disease", "OBSERVATION", 81, 88]]]]}